<SEC-DOCUMENT>0001193125-21-047064.txt : 20210218
<SEC-HEADER>0001193125-21-047064.hdr.sgml : 20210218
<ACCEPTANCE-DATETIME>20210218070058
ACCESSION NUMBER:		0001193125-21-047064
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210218
DATE AS OF CHANGE:		20210218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		21647633

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d51794d10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:md="http://www.mednax.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2020To12_31_2020">false</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="hidden18208864" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="hidden18208865" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden18208866" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden18208867" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden18209306" contextRef="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden18209307" contextRef="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden18209308" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden18209309" contextRef="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="hidden18209310" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">P1Y</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2020To12_31_2020">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2020To12_31_2020">0000893949</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2020To12_31_2020">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="hidden18210623" contextRef="P01_01_2020To12_31_2020">FL</ix:nonNumeric><ix:footnote id="FN_65625" xml:lang="en-US">Presented within retained (deficit) earnings as the balance is immaterial.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20201231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_12_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_UnsecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:UnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >md:PhysicianAndHospitalAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >md:OtherTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis" >us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis" >us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >md:RestrictedAndDeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >md:PhysicianAndHospitalAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >md:OtherTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis" >us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis" >us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PhysicianGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:AlternateBaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_FederalFundsEffectiveSwapRateMemberusgaapVariableRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:AlternateBaseRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:ApplicableMarginRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:ApplicableMarginRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapCollateralAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CollateralAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:PediatricCardiologyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:MaternalFetalMedicineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:BuildingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >md:DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodSixAndThereafterMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >md:DebtInstrumentRedemptionPeriodSixAndThereafterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFiveMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFourMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >md:DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherOwnershipInterestsByNameAxis" >md:ChangeInControlMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherOwnershipInterestsByNameAxis" >md:ChangeInControlMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >md:RestrictedAndDeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis" >md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:EarliestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapCollateralAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CollateralAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:PediatricCardiologyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:MaternalFetalMedicineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PhysicianGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LatestTaxYearMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:LatestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:PediatricCardiologyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:MaternalFetalMedicineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis" >md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForThirdQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForThirdQuarterOf2021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis" >md:RuralAreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_15_2020To12_15_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-15</xbrli:startDate> <xbrli:endDate>2020-12-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis" >md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ScenarioForecastMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2019_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Number" > <xbrli:measure>md:Number</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_18209834" toRefs="FN_65625"/><ix:relationship fromRefs="Fact_18209835" toRefs="FN_65625"/><ix:relationship fromRefs="Fact_18210161" toRefs="FN_65625"/><ix:relationship fromRefs="Fact_18210162" toRefs="FN_65625"/><ix:relationship fromRefs="Fact_18210163" toRefs="FN_65625"/><ix:relationship fromRefs="Fact_18210164" toRefs="FN_65625"/></ix:resources></ix:header></div><div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em; line-height: 12pt;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES&#160;&#160;&#160;&#160; </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To12_31_2020">10-K</ix:nonNumeric></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To12_31_2020">2020</ix:nonNumeric></ix:nonNumeric> </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission file number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To12_31_2020">001-12111</ix:nonNumeric></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To12_31_2020">MEDNAX, INC.</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden18210623">FLORIDA</span></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2020To12_31_2020">26-3667538</ix:nonNumeric></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To12_31_2020">1301 Concord Terrace</ix:nonNumeric>,</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To12_31_2020">Sunrise</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To12_31_2020">33323</ix:nonNumeric></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To12_31_2020">954</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To12_31_2020">384-0175</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of Each Class</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Each Exchange on Which Registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To12_31_2020">Common Stock</ix:nonNumeric>,&#160;par&#160;value&#160;$.01&#160;per&#160;share</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To12_31_2020">MD</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: None </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15 (d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2020To12_31_2020">No</ix:nonNumeric>&#160;&#160;&#9746; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 59%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Non-accelerated filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9746;</ix:nonNumeric> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">The aggregate market value of shares of Common Stock of the registrant held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> of the registrant on June&#160;30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,251,965,108</ix:nonFraction> based on a $17.10 closing price per share as reported on the New York Stock Exchange composite transactions list on such date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of Common Stock of the registrant outstanding on February&#160;12, 2021 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn02_12_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">85,631,836</ix:nonFraction>.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">DOCUMENTS INCORPORATED BY REFERENCE: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">The registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, with respect to the 2021 Annual Meeting of Shareholders is incorporated by reference in Part III of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> to the extent stated herein. Except with respect to information specifically incorporated by reference in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> each document incorporated by reference herein is deemed not to be filed as part hereof.&#160;&#160;&#160;&#160; </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mednax, Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT ON FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Year Ended December&#160;31, 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 86%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#toc51794_1">PART I</a></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_2">Item&#160;1. Business</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_3">Item&#160;1A. Risk Factors</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">27</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_4">Item&#160;1B. Unresolved Staff Comments</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_5">Item&#160;2. Properties</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_6">Item&#160;3. Legal Proceedings</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_7">Item&#160;4. Mine Safety Disclosures</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_8">PART II</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_9">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_10">Item&#160;6. Selected Financial Data</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">52</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_11">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">54</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_12">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_13">Item&#160;8. Financial Statements and Supplementary Data</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">74</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_14">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">107</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_15">Item&#160;9A. Controls and Procedures.</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">107</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_16">Item&#160;9B. Other Information</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">107</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_17">PART&#160;III</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_18">Item&#160;10. Directors, Executive Officers and Corporate Governance</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_19">Item&#160;11. Executive Compensation</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_20">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_21">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_22">Item&#160;14. Principal Accountant Fees and Services</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">110</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_23">PART IV</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_24">Item&#160;15. Exhibits, Financial Statement Schedule</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">111</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="text-indent: -3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><a href="#toc51794_25">Item&#160;16. Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> Summary</a></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">115</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FORWARD-LOOKING STATEMENTS </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Certain information included or incorporated by reference in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> may be deemed to be &#8220;forward-looking statements&#8221; which may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including the risks set forth under &#8220;Risk Factors&#8221; in Item 1A. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As used in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> unless the context otherwise requires, the terms &#8220;Mednax,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, Mednax, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;MDX&#8221;), together with MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc51794_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_2" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OVERVIEW </div></div></div> </div> </div> </div> </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mednax is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 39 states and Puerto Rico. At December&#160;31, 2020, our national network comprised over 2,300 affiliated physicians, including 1,320 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#8220;NICUs&#8221;), to babies born prematurely or with medical complications. We have over 425 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including over 245 physicians providing pediatric intensive care, 100 physicians providing pediatric cardiology care, 175 physicians providing hospital-based pediatric care, 35 physicians providing pediatric surgical care and urology services, 10 physicians providing pediatric ear, nose and throat services, and five physicians providing pediatric ophthalmology. Mednax divested its anesthesiology services medical group on May&#160;6, 2020 and its radiology services medical group on December&#160;15, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Mednax, Inc. was incorporated in Florida in 2007 and is the successor to Pediatrix Medical Group, Inc., which was incorporated in Florida in 1979. Our principal executive offices are located at 1301 Concord Terrace, Sunrise, Florida 33323 and our telephone number is (954) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">384-0175.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OUR PHYSICIAN SPECIALTIES AND SERVICES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion describes our physician specialties and the care that we provide: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neonatal Care </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We provide clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through our network of affiliated neonatal physician subspecialists (&#8220;neonatologists&#8221;), neonatal nurse practitioners and other pediatric clinicians who staff and manage clinical activities at over 380 NICUs in 36 states and Puerto Rico. Neonatologists are board-certified, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eligible-to-apply-for-certification,</div></div></div></div> physicians who have extensive education and training for the care of babies born prematurely or with complications that require complex medical treatment. Neonatal nurse practitioners are registered nurses who have advanced training and education in assessing and treating the healthcare needs of newborns and infants as well as managing the needs of their families. </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We partner with our hospital clients in an effort to enhance the quality of care delivered to premature and sick babies. Some of the nation&#8217;s largest and most prestigious hospitals, including both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-profit</div> institutions, retain us to staff and manage their NICUs. Our affiliated neonatologists generally provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hours-a-day,</div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-days-a-week</div></div> coverage in NICUs, support the local referring physician community and are available for consultation in other hospital departments. Our hospital partners benefit from our experience in managing complex intensive care units. Our neonatal physicians interact with colleagues across the country </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through an internal communications system to draw upon their collective expertise in managing challenging patient-care issues. Our neonatal physicians also work collaboratively with maternal-fetal medicine subspecialists to coordinate the care of mothers experiencing complicated pregnancies and their fetuses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maternal-Fetal Care </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We provide inpatient and office-based clinical care to expectant mothers and their unborn babies through our affiliated maternal-fetal medicine subspecialists as well as obstetricians and other clinicians, such as maternal-fetal nurse practitioners, certified nurse <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-wives,</div> ultrasonographers and genetic counselors. Maternal-fetal medicine subspecialists are board-certified, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eligible-to-apply-for-certification,</div></div></div></div> obstetricians who have extensive education and training for the treatment of high-risk expectant mothers and their fetuses. Our affiliated maternal-fetal medicine subspecialists practice primarily in metropolitan areas where we have affiliated neonatologists to provide coordinated care for women with complicated pregnancies whose babies are often admitted to a NICU upon delivery.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We believe continuity of treatment from mother and developing fetus during the pregnancy to the newborn upon delivery has improved the clinical outcomes of our patients. </div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric Cardiology Care </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We provide inpatient and office-based pediatric cardiology care of the fetus, infant, child and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through our affiliated pediatric cardiologist subspecialists and other related clinical professionals such as pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists. Pediatric cardiologists are board-certified, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eligible-to-apply</div></div> for certification, pediatricians who have additional education and training in congenital heart defects and pediatric acquired heart disorders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide specialized cardiac care to the fetus, neonatal and pediatric patients with congenital and acquired heart disorders, as well as adults with congenital heart defects, through scheduled office visits, hospital rounds and immediate consultation in emergency situations. Our affiliated pediatric cardiologists work collaboratively with neonatologists and maternal-fetal medicine subspecialists to provide a coordinated continuum of care. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Pediatric Subspecialty Care </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our network includes other pediatric subspecialists such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, pediatric ophthalmologists and pediatric ear, nose and throat physicians. In addition, our affiliated physicians seek to provide support services in other areas of hospitals, particularly in the pediatric emergency room, labor and delivery area, and nursery and pediatric departments, where immediate accessibility to specialized care may be critical. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Intensive Care</div></div></div></div>. Pediatric intensivists are hospital-based pediatricians with additional education and training in caring for critically ill or injured children and adolescents. Our affiliated physicians who provide this clinical care staff and manage pediatric intensive care units (&#8220;PICUs&#8221;) at over 70 hospitals. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Hospitalists</div></div></div></div>. Pediatric hospitalists are hospital-based pediatricians specializing in inpatient care and management of acutely ill children. Our affiliated hospital-based physicians provide this inpatient pediatric and newborn care in PICUs, NICUs and pediatric emergency rooms at approximately 55 hospitals. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Surgery</div></div></div></div>. Pediatric surgeons provide specialized care for patients ranging from newborns to adolescents, for all problems or conditions that require surgical intervention, and often have particular expertise in the areas of neonatal, prenatal, trauma, and pediatric oncology. Our affiliated physicians in this subspecialty include pediatric urologists, pediatric plastic and craniofacial surgeons and general and thoracic pediatric surgeons. Areas of particular expertise include management of neonatal and congenital anomalies, prenatal counseling, trauma management, pediatric oncology, gastrointestinal surgery, as well as common pediatric surgical conditions. <br/></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Urology. </div></div></div></div>Pediatric urologists are specialized pediatric surgeons who diagnose, treat and manage children&#8217;s urinary and genital problems. Our affiliated physicians provide consults for all pediatric and fetal genitourinary disorders; bladder, kidney and genitalia reconstructive and corrective surgery; cystoscopy; circumcision; ultrasound; and urinalysis services to children. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Ear, Nose and Throat (&#8220;ENT&#8221;). </div></div></div></div>Pediatric ENT physicians treat conditions that affect a child&#8217;s ear, nose, throat and neck. Our affiliated physicians in this subspecialty provide all aspects of ear, nose and throat medical, audiology and surgical services, including ear tubes, tonsillectomies and sinus surgery. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Ophthalmology. </div></div></div></div>Pediatric ophthalmologists focus on the development of the visual system and various diseases that disrupt visual development in children. Our affiliated physicians in this subspecialty specialize in retinopathy of prematurity screening and visual care consulting services. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Newborn and Pediatric Care</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>Because our affiliated physicians and advanced nurse practitioners generally provide hospital-based coverage, they are situated to provide highly specialized care to address medical needs that may arise during a baby&#8217;s hospitalization. For example, as part of our ongoing efforts to support and partner with hospitals and the local referring physician community, our affiliated neonatologists, pediatric hospitalists and advanced nurse practitioners provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-hospital</div> nursery care to newborns through our newborn nursery program. This program is made available for babies during their hospital stay, which in the case of healthy babies typically consists of evaluation and observation, following which they are referred, and their hospital records are provided, to their pediatricians or family practitioners for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> care. </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Newborn Hearing Screening Program</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>Our affiliated physicians also oversee our newborn hearing screening program. Since we launched this program in 1994, we believe that we have become the largest provider of newborn hearing screening services in the United States. In 2020, we screened over 965,000 babies for potential hearing loss at 465 hospitals across the nation. Over 40 states either require newborns to be screened for potential hearing loss before being discharged from the hospital or require that parents be offered the opportunity to submit their newborns to hearing screens. We contract or coordinate with hospitals to provide newborn hearing screening services. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical Research, Education, Quality and Safety </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our ongoing commitment to improving patient care through evidence-based medicine, we also conduct clinical research, monitor clinical outcomes and implement clinical quality initiatives with a view to improving patient outcomes, shortening the length of hospital stays and reducing long-term health system costs. Our physician-centric approach to clinical research and continuous quality improvement has demonstrated improvements in clinical outcomes, while reducing the costs of care associated with complications as well as variability in protocols. We provide extensive continuing medical education and continuing nursing education to our affiliated clinicians in an effort to ensure that they have access to current treatment methodologies, national best practices and evidence-based guidelines. We believe that referring and collaborating physicians, hospitals, third-party payors and patients all benefit from our clinical research, education, quality and safety initiatives. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DEMAND FOR OUR SERVICES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hospital-Based Care. </div></div></div></div>Hospitals generally must provide cost-effective, quality care in order to enhance their reputations within their communities and desirability to patients, referring and collaborating physicians and third-party payors. In an effort to improve outcomes and manage costs, hospitals typically employ or contract with physician specialists to provide specialized care in many hospital-based units or settings. Hospitals traditionally staff these units or settings through affiliations with local physician groups or independent practitioners. However, management of these units and settings presents significant operational challenges, including variable admissions rates, increased operating costs, complex reimbursement systems and other administrative burdens. As a result, some hospitals choose to contract with physician organizations that have the clinical quality </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiatives, information and reimbursement systems and management expertise required to effectively and efficiently operate these units and settings in the current healthcare environment. With continuing shifts to value-based reimbursement models, we anticipate that hospitals will continue to seek out experienced organizations with documented success in improving quality indicators and reducing costs. Demand for hospital-based physician services, including neonatology, is determined by a national market in which qualified physicians with advanced training compete for hospital contracts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Neonatal Medicine</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Of the just under 4&#160;million births in the United States annually, we estimate that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14%-15%</div> require NICU admission. Numerous institutions conduct research to identify potential causes of premature birth and medical complications that often require NICU admission. Some common contributing factors include the presence of hypertension or diabetes in the mother, lack of prenatal care, complications during pregnancy, drug and alcohol abuse and smoking or poor nutritional habits during pregnancy. Babies admitted to NICUs typically have an illness or condition that requires the care of a neonatologist. Babies who are born prematurely or have a low birth weight often require neonatal intensive care services because of an increased risk for medical complications. We believe obstetricians generally prefer to perform deliveries at hospitals that provide a full complement of labor and delivery services, including a NICU staffed by board-certified, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eligible-to-apply-for-certification,</div></div></div></div> neonatologists. Because obstetrics is a significant source of hospital admissions, hospital administrators have responded to these demands by establishing NICUs and contracting with independent neonatology group practices, such as our affiliated professional contractors, to staff and manage these units. As a result, NICUs within the United States tend to be concentrated in hospitals with higher volumes of births. There are approximately 6,000 board-certified neonatologists in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maternal-Fetal Medicine</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Expectant mothers with pregnancy complications often seek or are referred by their obstetricians to maternal-fetal medicine subspecialists. These subspecialists provide inpatient and office-based care to women with conditions such as diabetes, heart disease, hypertension, multiple gestation, recurrent miscarriage, family history of genetic diseases, suspected fetal birth defects and other complications during their pregnancies. We believe that improved maternal-fetal care has a positive impact on neonatal outcomes. Data on neonatal outcomes demonstrates that, in general, the likelihood of mortality or an adverse condition or outcome (referred to as &#8220;morbidity&#8221;) is reduced the longer a baby remains in the womb. There are approximately 2,500 board-certified maternal-fetal medicine subspecialists in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Cardiology Medicine</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">. </div></div>Pediatric cardiologists provide inpatient and office-based cardiology care of the fetus, infant, child, and adolescent with congenital heart defects and acquired heart disease, as well as providing care to adults with congenital heart defects. We estimate that approximately one in every 125 babies is born with some form of heart defect. With advancements in care, there are approximately 1.4&#160;million adults in the United States today living with congenital heart disease. There are approximately 3,000 board-certified pediatric cardiologists in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Pediatric Subspecialty Medicine</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Other areas of pediatric subspecialty medicine are closely associated with maternal-fetal-newborn medical care. For example, pediatric intensivists are subspecialists who care for critically ill or injured children and adolescents in PICUs. There are approximately 2,500 board-certified pediatric intensivists in the United States. As another example, pediatric hospitalists are pediatricians who provide care in many hospital areas, including labor and delivery and the newborn nursery. In addition, pediatric surgeons provide specialized care for patients ranging from newborns to adolescents, for all problems or conditions affecting children that require surgical intervention, and often have particular expertise in the areas of neonatal, prenatal, trauma, and pediatric oncology. There are approximately 1,100 board-certified pediatric surgeons in the United States. Pediatric urologists are specialized pediatric surgeons who diagnose, treat and manage children&#8217;s urinary and genital problems. There are approximately 400 board-certified pediatric urologists in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Physician Practice Administration. </div></div></div></div>Administrative demands and cost containment pressures from a number of sources, principally commercial and government payors, make it increasingly difficult for physicians to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">effectively manage patient care, remain current on the latest procedures and efficiently administer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> activities. As a result, we believe that physicians remain receptive to being affiliated with larger organizations that reduce administrative burdens, achieve economies of scale and provide value-added clinical research, education and quality initiatives. By relieving many of the burdens associated with the management of a subspecialty group practice, we believe that our practice administration services permit our affiliated physicians to focus on providing quality patient care and thereby contribute to improving patient outcomes, ensuring appropriate length of hospital stays and reducing long-term health system costs. In addition, our national network of affiliated physician practices, modeled around a traditional group practice structure, is managed by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> professional management team with proven abilities to achieve significant operating efficiencies in providing administrative support systems, interacting with physicians, hospitals and third-party payors, managing information systems and technologies, and complying with applicable laws, rules and regulations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OUR BUSINESS STRATEGY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business objective is to enhance our position as a leading provider of physician and other complementary healthcare services. The key elements of our strategy to achieve this objective are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Build upon core competencies</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> We have developed significant administrative expertise relating to our practice physician services. We have also facilitated the development of a clinical approach to the practice of medicine among our affiliated physicians through clinical data warehouses that include research, education and quality initiatives intended to advance the practice of medicine and care, improve the quality of care provided to our patients and reduce long-term health system costs. Analysis of the data within our clinical data warehouses across our neonatology and other pediatric subspecialty services allows us to provide feedback to our physicians and hospital partners and to develop and implement best practices, all with the goal of improving outcomes, creating efficiencies and ensuring patient satisfaction. As healthcare organizations are expected to increasingly be held accountable for the quality and cost of the care they provide, we believe that our ability to capture this data within our clinical data warehouses adds value to our patients and our hospital and physician partners. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Utilize enhanced technology solutions.</div></div></div></div> We are introducing several technology-enabled solutions that we believe will improve the efficiency of the work our affiliated physicians do each day. These include a more streamlined charge capture system, a cloud-based image access and storage solution, continued development of our cloud-based neonatology-specific notes system and upgrades to our office-based practices electronic health record system that are designed to be better for our physicians and improve the patient-facing portal for our patients and their families. We plan to continue to find ways to supply real time data to our affiliated physician practices so that they can see, and more importantly manage, patient volumes. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promote same-unit and organic growth</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> We seek opportunities for increasing revenue from our hospital- and office-based operations. For example, our affiliated hospital-based neonatal, maternal-fetal and other pediatric physicians are well situated to, and, in some cases, provide physician services in other departments, such as pediatric emergency rooms, newborn nurseries, or in situations where immediate accessibility to specialized obstetric and pediatric care may be critical. Our hospital-based and office-based physicians continue to pursue an organic growth strategy that involves working with our hospital partners to develop integrated service programs for which we become a provider of solutions across the maternal-fetal, newborn, pediatric continuum of care. An integrated program results in a broader offering of care across our specialties and permits the extension of our service lines in our markets. We have successfully executed this organic growth strategy and market partnership in many metropolitan areas and intend to continue this growth initiative in the future. In addition, we market our capabilities to obstetricians, pediatricians and family physicians to attract referrals to our hospital-based units and our office-based practices. We also market the services of our affiliated physicians to other hospitals to attract maternal, neonatal and pediatric transport admissions. In addition, we may pursue new contractual arrangements with hospitals, including possibly through joint ventures, either where we currently provide or do not currently provide physician services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, with the goal of further expanding our organic growth strategy, our national sales team pursues opportunities across our service lines by employing a targeting strategy with a specific focus and prioritization. This sales team works with existing hospital and other healthcare partners and also focuses on building new relationships with hospitals and other service providers to which we do not currently provide services in order to offer clinical and other solutions and respond to requests for proposals. Our growth teams are managed under one collaborative group that addresses acquisition and organic growth opportunities with the shared goal of Mednax being viewed by hospitals and other partners as a multi-specialty health solutions partner across all of its women&#8217;s health and pediatrics service lines. The growth team partners with the operational leadership across each of our medical groups to execute our overall growth strategy. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adaptation and Expansion of Telehealth. </div></div></div></div>Our robust telehealth programs offer the latest in telemedicine, which is the use of telecommunication and information technology in order to provide clinical healthcare at a distance. Even before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we had focused on expanding our services in telemedicine as we have long expected that many pediatric subspecialties, as well as maternal-fetal medicine, will benefit in the future from having a robust platform in telemedicine. Telemedicine services are well documented as high quality, safe and efficient means of expanding physician services into metropolitan and rural communities. We have expanded our services to provide these remote programs to our hospital partners. We believe telehealth reduces overall healthcare spending, improves access to quality care and facilitates collaboration with specialists while improving patient engagement and satisfaction. As a result of these benefits, we believe these programs enhance the standing of our hospital partners while creating another portal of entry of pediatric patients to our inpatient service lines. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquire physician practice groups. </div></div></div></div>We continue to seek to expand our operations by acquiring established physician practices in our core physician specialties and pursuing complementary pediatric subspecialty physician groups outside of our core specialties when appropriate. During 2020, we added one pediatric subspecialty practice. We currently expect a modest level of acquisition activity during 2021. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Strengthen and broaden relationships with our partners</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> By managing many of the operational challenges associated with physician practices, encouraging clinical research, education, quality, and safety initiatives, and promoting timely intervention by our physicians, we believe that our business model is focused on improving the quality of care delivered to patients, promoting the appropriate length of their hospital stays and optimizing efficient use of health system resources. We believe that referring and collaborating physicians, hospitals, third-party payors and patients all benefit to the extent that we are successful in implementing our business model. In addition, we plan to continue to concentrate efforts in becoming more responsive and proactive in broadening our existing hospital relationships to expand the scope of services that we provide across all specialties. In the fall of 2020, we began focusing our efforts in this area around a market-based approach and in each geographic area where we operate we consider how we can expand our existing hospital and health system relationships and form new ones. We believe this will be critical as hospitals and health systems seek to expand their service offerings and as the broader healthcare market seeks new solutions to operate more efficiently. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also believe one of the greatest predictors of success in our partnerships at the hospital and health system level is a high degree of strategic alignment between our clinical leaders and our partners. This requires our clinicians to hone a skill set beyond just the practice of medicine. To this end, we are relaunching our Clinical Leadership Development Program where our affiliated clinicians from across the organization will participate in a variety of leadership workshops to provide them with the best tools to foster positive productive relationships with our valued partners. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CLINICAL RESEARCH, EDUCATION, QUALITY AND SAFETY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our patient focus and ongoing commitment to improving patient care through evidenced-based medicine, we engage in clinical research, continuous quality improvement, safety and education initiatives. We </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discover, understand and teach healthcare practices that enhance the abilities of clinicians to deliver quality care, thereby contributing to better patient outcomes and reduced long-term health care costs. These initiatives benefit our patients, clinicians, referring and collaborating physicians, hospital partners and third-party payors. We believe that these initiatives help us, among other things, to enhance the value of our services, attract new and retain high-quality clinicians, improve clinical operations and enhance practice communication. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Research.</div></div></div></div> We conduct clinical research to discover ways to improve clinical care for our patients and share our discoveries throughout the medical community through submissions to peer-reviewed literature. To help facilitate and support research efforts, Mednax established a Research Advisory Committee (&#8220;RAC&#8221;). The goal of the RAC is to design, implement and maintain a program for clinical research oversight and support that enables our practices to conduct research that is safe, effective, financially viable and legally compliant, while optimizing research opportunities. The RAC&#8217;s multi-disciplinary approach involves the collaboration of both clinical and business professionals, including finance, legal and compliance, and has ultimately enhanced our research efforts and improved overall process flow. With participating clinicians located throughout the country, the RAC supports a comprehensive scope of research efforts, allowing for a more <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> look at our specialties. This nationwide perspective allows us to better anticipate future needs and opportunities. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quality and Safety. </div></div></div></div>Through the leadership of our affiliated clinicians, we have cultivated a culture of continuous quality improvement and safety, which is the cornerstone of our success and helps us to fulfill our mission. Our team of clinical experts leads and provides oversight for several national quality and safety programs across various specialties and subspecialties. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Continuous Quality Improvement (&#8220;CQI&#8221;)</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> CQI initiatives are important for all our physician specialties. As part of our dedication to improving quality across our affiliated practices, we provide our clinicians with the opportunity to collaborate and share best practices and facilitate access to valuable information, resources and professional development tools. From these collaborations, our affiliated physicians can identify areas for improvement, and then systematically monitor, study, learn, and implement change. There are several complex initiatives that are derived and based on our long-standing CQI efforts, such as our 100,000 Babies and 100,000 Women Campaigns, our value-based care initiatives and several clinical quality collaboratives. Our quality metrics are analyzed to include standard clinical outcome reporting, trend analysis and threshold performance, which are provided to our affiliated physicians. The quality committees and medical directors of the practices manage quality improvement programs and drive best practices that are adapted to the needs of the local care setting. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patient Safety Organization (&#8220;PSO&#8221;). </div></div></div></div>We have a federally-listed PSO, the mission of which is to improve the quality and safety of care rendered by our clinical providers through the collection and analysis of quality data. As a federally-listed PSO, our mission to improve the safety of care rendered is supported by the dissemination of best practices information and implementation of patient safety programs. Our Women&#8217;s and Children&#8217;s National High Reliability Organization program aims to provide &#8220;Just Culture&#8221; training to our clinicians. The complex curriculum has been customized to meet our affiliated physician practices&#8217; needs and is based on principles outlined by the Agency for Healthcare Research and Quality (&#8220;AHRQ&#8221;), Institute for Healthcare Improvement, National Patient Safety Foundation and Team STEPPS, the teamwork system developed by the AHRQ and the Department of Defense. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medical Simulation.</div></div></div></div> Practicing critical decision-making, communication, task and teamwork skills with<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in situ</div></div>&#160;scenarios promotes optimized clinical performance for high-risk, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-volume</div> critical situations. To meet the needs of our health care providers and hospital partners, Mednax offers a variety of customized simulation programs with the aim of instilling competence and confidence with one goal in mind: improved outcomes. Our Simulation Program has provisional accreditation by the Society for&#160;Simulation in&#160;Healthcare, a required first step towards attaining full accreditation, and currently offers highly interactive programs for neonatology and hospital-</div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">based medicine practices. Medical simulation is proven as a performance improvement method and enhances communication and improves patient outcomes. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Education. </div></div></div></div>We provide extensive continuing medical education and continuing nursing education to our affiliated clinicians to ensure that they have access to current treatment methodologies, national best practices and evidence-based guidelines. As an Accreditation Council for Continuing Medical Education accredited provider, we offer a variety of live and online educational credit opportunities that can be accessed on demand by our providers and are in synergy with latest research publications and healthcare industry standards. We are expanding our learning materials to new subspecialties. In addition, each year, hundreds of healthcare providers worldwide take advantage of educational programs hosted by Mednax. We believe that the number of clinicians both nationally and internationally who participate in these activities is evidence of the depth and breadth of our clinical expertise and position as an industry leader. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Innovation. </div></div></div></div>We believe collaborative innovation is a pathway towards excellence in research, education, quality and safety. Because of the critical role innovation plays, our team strives to integrate the latest technological advances, artificial or augmented intelligence, genomics and mobile applications into everyday care. Tele- and mobile health, virtual reality, next generation sequencing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> diagnostics and advanced data analytics are currently shaping the future of medicine. Our team is actively engaged in integrating the latest innovations that can optimize clinical care delivery and augment our clinical research initiatives with the goal of further optimizing patient outcomes. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that these initiatives have been enhanced by our integrated national presence together with our clinical and management information systems, which are an integral component of our clinical research and education activities. See &#8220;Our Information Systems.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OUR INFORMATION SYSTEMS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We maintain several information systems that support our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations, ongoing clinical initiatives and business analysis. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BabySteps</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div></div></div>BabySteps is a clinical electronic documentation system used by our affiliated neonatal physicians and other clinicians to record clinical progress notes and certain laboratory reports and provides a decision tree to assist them in certain situations with the selection of appropriate billing codes. BabySteps is in the process of moving to a cloud-based application known as the Mednax Clinical App (&#8220;MCA&#8221;). The NICU version will be referred to as &#8220;BabySteps 2.0,&#8221; but this advance provides an opportunity to expand use of the application to our other hospital-based specialties. MCA/BabySteps 2.0 is currently being piloted in certain locations with a plan to roll it out across additional NICUs in 2021. The plan for broader use across other hospital-based specialties is under development. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Data Warehouse. </div></div></div></div>BabySteps enables our affiliated practices to capture a consistent set of clinical information about the patients we treat. We <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-identify</div> and transfer data from our electronic health records that reside in BabySteps to our &#8220;clinical data warehouse&#8221; that since inception has accumulated clinical information on more than 1.6&#160;million patients and over 29&#160;million patient days. With comprehensive reporting tools, our physicians are able to use this information to benchmark outcomes, enhance clinical decision-making and advance best practices at the bedside. Using a variety of clinical performance markers, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-identified</div> data warehouse also helps us track medication and procedure interactions, link treatments to outcomes and identify opportunities to enhance patient outcomes. Our clinical data warehouse also helps us to identify which prospective clinical trials are most important and allows us to monitor the impact of our continuous quality improvement initiatives. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nextgen</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> We have licensed the Nextgen Electronic Medical Record (&#8220;EMR&#8221;) and Electronic Patient Management (&#8220;EPM&#8221;) system for our affiliated office-based physicians and other clinicians to record clinical documentation related to their patients and to manage the revenue cycle for our office-based </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">practices. This system has the ability to provide benefits to our office-based practices that are similar to what BabySteps provides to our neonatology practices, including decision trees to assist physicians with the selection of compliant billing codes, promotion of consistent documentation, and data for research and education. We are continuing the process of implementing EMR and EPM throughout our office-based practices. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Charge Capture.</div></div></div></div> Our electronic charge capture system is used to appropriately record and bill for pediatric intensive care clinicians, hospitalist clinicians and other clinical care providers. We also use administrative data derived from this system to drive quality assurance and quality improvement programs. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mednax Learning Center</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div></div></div>In addition to providing continuing education, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">web-based</div> education platforms also function as important educational adjuncts to our affiliated physician groups, providing a rich source of ongoing medical education for our physicians and enabling physicians to discuss cases with one another through various clinical resources. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management information systems are also an integral element of the billing and reimbursement process. We maintain systems that provide for electronic data interchange with payors that accept electronic submissions, including electronic claims submission, insurance benefits verification and claims processing and remittance advice, which enable us to track numerous and diverse third-party payor relationships and payment methods. Our information systems provide scalability and flexibility as payor groups upgrade their payment and reimbursement systems. We continually seek improvements to our systems to expedite the overall process, streamline information gathering from our clinical systems and improve efficiencies in the reimbursement process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain additional information systems designed to improve operating efficiencies of our affiliated practice groups, reduce physicians&#8217; paperwork requirements and facilitate interaction among our affiliated physicians and their colleagues regarding patient care issues. Following the acquisition of a physician practice group, we implement systematic procedures to improve the acquired group&#8217;s operating and financial performance. One of our first steps is to convert a newly acquired group to our broad-based management information system. We also maintain a database management system to assist our business development and recruiting departments to identify potential practice group acquisitions and physician candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PHYSICIAN PRACTICE GROUP ADMINISTRATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide multiple administrative services to support the practice of medicine by our affiliated physicians and strive to improve operating efficiencies of our affiliated practice groups. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unit Management</div></div></div></div>. A senior physician practicing medicine in each physician specialty or subspecialty practice that we manage acts as the medical director for that practice. Each medical director is responsible for the overall management of his or her practice, including staffing and scheduling, quality of care, professional discipline, utilization review, coordinating physician recruitment and monitoring of the financial success within the practice. Medical directors also serve as a liaison with hospital administration, other physicians and the community. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staffing and Scheduling</div></div></div></div>. We assist with staffing and scheduling physicians and advanced practice nurses within the units and practices that we manage. For example, each NICU is staffed by at least one specialist on site or available on call. We are responsible for managing and coordinating the process for the salaries and benefits paid and provided to our affiliated physicians and practitioners. In addition, we employ, compensate and manage all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-medical</div> personnel for our affiliated physician groups. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recruiting and Credentialing</div></div></div></div>. We have significant experience in locating, qualifying, recruiting and retaining experienced physicians. We maintain an extensive nationwide database of neonatologists, maternal-fetal medicine physicians, and other pediatric subspecialty physicians. Our medical directors and physician leaders play a central role in the recruiting and interviewing process before candidates </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are introduced to other practice group physicians and hospital administrators. We verify the credentials, licenses and references of all prospective affiliated physician candidates. In addition to our database of physicians, we recruit nationally through trade advertising, referrals from our affiliated physicians and attendance at conferences. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Billing, Collection and Reimbursement</div></div></div></div>. We assume responsibility for assisting our affiliated physicians with contracting with third-party payors. We are responsible for billing, collection and reimbursement for services rendered by our affiliated physicians. In all instances, however, we do not assume responsibility for charges relating to services provided by hospitals or other physicians with whom we collaborate. Such charges are separately billed and collected by the hospitals or other physicians. We provide our affiliated physicians and other clinicians with a training curriculum that emphasizes detailed documentation of and compliant coding protocols for all procedures performed and services provided, and we provide comprehensive internal auditing processes, all of which are designed to achieve compliant coding, billing and collection of revenue for physician services. Generally, our billing and collection operations are conducted from our business offices located across the United States and in Puerto Rico, as well as our corporate offices. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Management</div></div></div></div>.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We maintain a risk management program focused on reducing risk, including the identification and communication of potential risk areas to our medical affairs staff. We maintain professional liability coverage for our national group of affiliated healthcare professionals. Through our risk management and medical affairs staff, we conduct risk management programs for loss prevention and early intervention in order to prevent or minimize professional liability claims. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compliance</div></div></div></div>. We provide a multi-faceted compliance program that is designed to assist our affiliated practice groups in understanding and complying with the increasingly complex laws, rules and regulations that govern the provision of healthcare services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Services</div></div></div></div>. We also provide management information systems, facilities management, legal support, marketing support and other services to our affiliated physicians and affiliated practice groups. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RELATIONSHIPS WITH OUR PARTNERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business model, which has been influenced by the direct contact and daily interaction that our affiliated physicians have with their patients, emphasizes a patient-focused clinical approach that addresses the needs of our various &#8220;partners,&#8221; including hospitals, third-party payors, referring and collaborating physicians, affiliated physicians and, most importantly, our patients. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospitals and Other Customers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our relationships with our hospital partners and other customers are critical to our operations. Hospitals control access to their units and operating rooms through the awarding of contracts and hospital privileges. We have been retained by approximately 415 hospitals to staff and manage clinical activities within specific hospital-based units and other departments. Our affiliated physicians are important components of obstetric, pediatric and surgical services provided at hospitals. Our hospital-based focus enhances our relationships with hospitals and creates opportunities for our affiliated physicians to provide patient care in other areas of the hospital. For example, our physicians may provide care in emergency rooms, nurseries, intensive care units and other departments where access to specialized obstetric and pediatric care may be critical. Our hospital partners benefit from our expertise in managing critical care units and other settings staffed with physician specialists, including managing variable admission rates, operating costs, complex reimbursement systems and other administrative burdens. We work with our hospital partners to enhance their reputation and market our services to referring physicians within the communities served by those hospitals. In addition, our affiliated physicians work with our hospital partners to develop integrated services programs for solutions within the services we provide. Integrated programs provide our hospital partners and us with incremental growth and result in a broader spectrum of care across our specialties and permit us to extend our patient service lines into our existing markets. Our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relationships with our hospital partners are continually evolving with the goal of being viewed by them as a solutions provider across all of our specialties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under our contracts with hospitals, we have the responsibility to manage, in many cases exclusively, the provision of physician services for hospital-based units, such as NICUs, and other hospital settings. We typically are responsible for billing patients and third-party payors for services rendered by our affiliated physicians separately from other related charges billed by the hospital or other physicians to the same payors. Some of our hospital contracts require hospitals to pay us administrative fees. Some contracts provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that we receive a specified minimum revenue level. We also receive fees from hospitals for administrative services performed by our affiliated physicians providing medical director services at the hospital. Administrative fees accounted for approximately 12.5% of our net revenue during 2020. Some of our contracts with hospitals require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians. Our hospital contracts typically have terms of one to three years which can be terminated without cause by either party upon prior written notice, and renew automatically for additional terms of one to three years unless terminated early by any party. While we have in most cases been able to renew these arrangements, hospitals may cancel or not renew our arrangements, or reduce or eliminate our administrative fees in the future. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-Party Payors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our relationships with government-sponsored or funded healthcare programs (&#8220;GHC Programs&#8221;), including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors are vital to our business. We seek to maintain professional working relationships with our third-party payors, streamline the administrative process of billing and collection, and assist our patients and their families in understanding their health insurance coverage and any balances due for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-insurance,</div> deductibles or benefit limitations. In addition, through our quality initiatives and continuing research and education efforts, we have sought to enhance clinical care provided to patients, which we believe benefits third-party payors by contributing to improved patient outcomes and reduced long-term health system costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We receive compensation for professional services provided by our affiliated physicians to patients based upon rates for specific services provided, principally from third-party payors. Our billed charges are substantially the same for all parties in a particular geographic area, regardless of the party responsible for paying the bill for our services, but the payments we receive vary among payors. A significant portion of our net revenue is received from GHC Programs, principally state Medicaid programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Medicaid programs, which are jointly funded by the federal government and state governments, pay for medical and health-related services for certain categories of individuals and families generally who have low incomes or disabilities. Medicaid programs can be either standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> payment programs or managed care programs in which states have contracted with health insurance companies to run local or state-wide health plans with features similar to health maintenance organizations. Our compensation rates under standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> Medicaid programs are established by state governments and are not negotiated. Although Medicaid rates vary across the states, these rates are generally much lower in comparison to private-sector health plan rates. Rates under Medicaid managed care programs typically are negotiated but are also generally much lower in comparison to private-sector health plan rates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Affordable Care Act (&#8220;ACA&#8221;) allows states to expand their Medicaid programs to enroll more individuals through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historical eligibility levels to 133% of the federal poverty level. As of December&#160;31, 2020, 38&#160;states and the District of Columbia have expanded Medicaid eligibility to cover this additional low income patient population (including states that have adopted but not yet implemented expansion and those that are using an alternative approach to eligibility expansion) and other states are considering such expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">household income is at or below 133% of the federal poverty level, and some states offer expanded coverage, with state eligibility thresholds that may range from 133% to 400% of the federal poverty level based on a combination of federal mandates and voluntary state expansions. In light of changes to the ACA, some of these states may eliminate, reduce or otherwise modify expanded enrollment eligibility. See Item 1A. Risk Factors &#8212; &#8220;State budgetary constraints and the uncertainty over the future Medicaid expansion could have an adverse effect on our reimbursement from Medicaid programs&#8221; and &#8220;Potential healthcare reform efforts may have a significant effect on our business.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Medicare is a health insurance program primarily for individuals 65 years of age and older, younger individuals with certain disabilities and individuals with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-stage</div> renal disease. The program is available without regard to income or assets (with means-tested premiums for beneficiaries with relatively high incomes) and offers beneficiaries different ways to obtain their medical benefits. The most common option selected today by Medicare beneficiaries is the traditional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> payment system. The other options include managed care, preferred provider organizations, private <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> and specialty plans. Medicare compensation rates are generally much lower in comparison to private-sector health plans. In 2020, the majority of the over 65&#160;million people on Medicare were covered by traditional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> Medicare, but approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> were enrolled in Medicare Advantage plans. Enrollment in Medicare Advantage has been increasingly annually over the past decade and is projected to continue such growth. Because we provide services primarily to women and children in our neonatology, maternal-fetal medicine and other pediatric specialties, our reimbursements from Medicare programs are not material. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to participate in government programs, we and our affiliated practices must comply with stringent and often complex standards, including enrollment and reimbursement requirements. Different states also impose varying standards for their Medicaid programs. See &#8220;Government Regulation&#8212;Government Regulatory Requirements.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also receive compensation pursuant to contracts with commercial payors that offer a wide variety of health insurance products, such as health maintenance organizations, preferred provider organizations and exclusive provider organizations that are subject to various state laws and regulations, as well as employer-sponsored coverage subject to federal Employee Retirement Income Security Act (&#8220;ERISA&#8221;) requirements. We seek to secure mutually agreeable contracts with payors that enable our affiliated physicians to be listed as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> participants within the payors&#8217; provider networks. We generally contract with commercial payors through our affiliated professional contractors. Subject to applicable laws, rules and regulations, the terms, conditions and compensation rates of our contracts with commercial third-party payors are negotiated and often vary across markets and among payors. In some cases, we contract with organizations that establish and maintain provider networks and then rent or lease such networks to the actual payor. Our contracts with commercial payors typically provide for discounted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> arrangements. Our contracts with commercial payors typically also grant each party the right to terminate the contracts without cause upon prior written notice and various notice periods. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we do not have a contractual relationship with a health insurance payor, we generally bill the payor our full billed charges. If payment is less than billed charges, we bill the balance to the patient, subject to federal and state laws regulating such billing, which Congress or states may continue to enact. See Item 1A. Risk Factors &#8211; &#8220;Congress or states have, and may continue to, enact laws restricting the amount <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers of services can charge and recover for such services.&#8221; In addition, these contracts generally give commercial payors the right to audit our billings and related reimbursements for professional and other services provided by or through our affiliated physicians. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we maintain standard billing and collections procedures with appropriate discounts for prompt payment, we also provide discounts in certain hardship situations where patients and their families do not have financial resources necessary to pay the amount due for services rendered. Any amounts <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">written-off</div> are based on the specific facts and circumstances related to each individual patient account. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Referring and Collaborating Physicians </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our relationships with our referring and collaborating physicians are critical to our success. Our affiliated physicians seek to establish and maintain professional relationships with referring physicians in the communities where they practice. Because patient volumes in our NICUs are based in part on referrals from other physicians, particularly obstetricians, it is important that we are responsive to the needs of referring physicians in the communities in which we operate. We believe that our community presence, through our hospital coverage and outpatient clinics, assists referring obstetricians, office-based pediatricians and family physicians with their practices. Our affiliated physicians are able to provide comprehensive maternal-fetal, newborn and pediatric subspecialty care to patients using the latest advances in methodologies, supporting the local referring physician community with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hours-a-day,</div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-days-a-week</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-call</div> coverage. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Affiliated Physicians and Practice Groups </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our relationships with our affiliated physicians are important. Our affiliated physicians are organized in traditional practice group structures. In accordance with applicable state laws, our affiliated practice groups are responsible for the provision of medical care to patients. Our affiliated practice groups are separate legal entities organized under state law as business corporations or professional associations, professional corporations, limited liability companies and partnerships, which we sometimes refer to as our &#8220;affiliated professional contractors&#8221;. Each of our affiliated professional contractors is owned by a licensed physician affiliated with the Company through employment or another contractual relationship. Our national infrastructure enables more effective and efficient sharing of new discoveries and clinical outcomes data, including best demonstrated processes, access to our sophisticated information systems, clinical research and education. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our business corporations and affiliated professional contractors employ or contract with physicians to provide clinical services in certain states and Puerto Rico. In most of our affiliated practice groups, each physician has entered into an employment agreement with us or one of our affiliated professional contractors providing for a base salary and incentive bonus eligibility and typically having a term of three to seven years. We are typically responsible for billing patients and third-party payors for services rendered by our affiliated physicians and, with respect to services provided in a hospital, separately from other charges billed by hospitals to the same payors. Each physician must hold a valid license to practice medicine in the state in which he or she provides patient care and must become a member of the medical staff, with appropriate clinical privileges, at each hospital at which he or she practices. Substantially all the physicians employed by us or our affiliated professional contractors have agreed not to compete within a specified geographic area during employment and for a certain period after termination of employment. Although we believe that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> covenants of our affiliated physicians are reasonable in scope and duration and therefore enforceable under applicable state laws, we cannot predict whether a court or arbitration panel would enforce these covenants in any particular case. Our hospital contracts also typically require that we and the physicians performing services maintain minimum levels of professional and general liability insurance. We negotiate those policies and contract and pay the premiums for such insurance on behalf of the physicians. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of our affiliated professional contractors has entered into a comprehensive management agreement with a subsidiary of Mednax as the manager. Under the terms of these management agreements, and subject to state laws and other regulations, the manager is typically paid for its services based on the performance of the applicable practice group. See &#8220;Government Regulation&#8212;Fee Splitting; Corporate Practice of Medicine.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMPETITION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The physician services industry is highly fragmented. Competition in our business is generally based upon a number of factors, including reputation, experience and level of care and our affiliated physicians&#8217; ability to provide cost-effective, quality clinical care. The nature of competition for our hospital-based practices differs significantly from competition for our office-based practices. Our hospital-based practices compete nationally </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with other health services companies and physician groups for hospital contracts and qualified physicians. In some instances, our hospital-based physicians also compete on a regional or local basis. For example, our neonatologists compete for referrals from local physicians and transports from surrounding hospitals. Our office-based practices, such as maternal-fetal medicine and pediatric cardiology, compete for patients with office-based practices in those subspecialties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Hospitals control access to their NICUs and operating rooms by awarding contracts and hospital clinical privileges, and our relationships with our hospital partners are critical to our operations. Because our operations consist primarily of physician services provided within hospital-based units, we compete with others for contracts with hospitals to provide services. We also compete with hospitals themselves to provide such services. Hospitals may employ neonatologists directly or contract with other physician groups to provide services either on an exclusive or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> basis. A hospital not otherwise competing with us may begin to do so by opening a new NICU or operating facility, expanding the capacity of an existing NICU, adding operating room suites or, in the case of neonatal services, upgrading the level of its existing NICU. If the hospital chooses to do so, it may award the contract to operate the relevant facility to a competing group or company from within or outside the surrounding community. Our contracts with hospitals generally provide that they may be terminated without cause upon prior written notice. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is highly competitive. Companies in other segments of the industry as well as healthcare-focused and other private equity firms, some of which have financial and other resources greater than ours, may become competitors in providing neonatal, maternal-fetal and other pediatric subspecialty care. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GOVERNMENT REGULATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is governed by a framework of federal and state laws, rules and regulations that are extensive and complex and for which, in many cases, the industry has the benefit of only limited judicial and regulatory interpretation. The resources and costs required to comply with these laws, rules and regulations are high. If we or one of our affiliated practice groups or service businesses is found to have violated these laws, rules or regulations, our business, financial condition and results of operations could be materially, adversely affected. The ACA made numerous changes that have reshaped the United States healthcare delivery system. Further healthcare reform continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may affect our reimbursement, restrict our existing operations, limit the expansion of our business or impose additional compliance requirements and costs, any of which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. See Item 1A. Risk Factors &#8212; &#8220;Potential healthcare reform efforts may have a significant effect on our business.&#8221; Additional changes at the state level, including changes in Medicaid Program administration, eligibility and coverage, as well as changes in the regulatory framework governing the provision of telemedicine services, and other legal developments, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing and Certification </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each state imposes licensing requirements on individual physicians and clinical professionals, and on facilities operated or utilized by healthcare companies like us. Many states require regulatory approval, including certificates of need, before establishing certain types of healthcare facilities, offering certain services or expending amounts in excess of statutory thresholds for healthcare equipment, facilities or programs. We and our affiliated physicians are also required to meet applicable Medicare supplier requirements under federal laws, rules and regulations and Medicaid provider requirements under federal and state laws, rules and regulations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fee Splitting; Corporate Practice of Medicine </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Many states have laws that prohibit business corporations, such as Mednax, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians, or engaging in certain arrangements, such as fee splitting, with physicians. In light of these restrictions, we operate by maintaining long-term management contracts through our subsidiaries with affiliated professional contractors, which employ or contract with physicians to provide professional medical services. Under these arrangements, our manager subsidiaries perform only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-medical</div> administrative services, do not represent that they offer medical services and do not exercise influence or control over the practice of medicine by the physicians and other licensed health professionals employed by the affiliated professional contractors. In states where fee splitting with a business corporation or manager is prohibited, the fees that are received from the affiliated professional contractors have been established on a basis that we believe complies with applicable laws. Although the relevant laws in these states have been subject to limited judicial and regulatory interpretation, we believe that we are in compliance with applicable state laws in relation to the corporate practice of medicine and fee splitting. However, regulatory authorities or other parties, including our affiliated physicians, may assert that, despite these arrangements, we or our manager subsidiaries are engaged in the corporate practice of medicine or that the contractual arrangements with the affiliated professional contractors constitute unlawful fee splitting, in which case we or our affiliated physicians could be subject to administrative, civil or criminal remedies or penalties, the contracts could be found to be legally invalid and unenforceable, in whole or in part, or we could be required to restructure our contractual arrangements with our affiliated professional contractors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fraud and Abuse Provisions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Existing federal laws, as well as similar state laws, governing Medicare, Medicaid, other GHC Programs and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> arrangements and interactions, impose a variety of fraud and abuse prohibitions on healthcare companies like us. These laws are interpreted broadly and enforced aggressively by multiple government agencies, including the Office of Inspector General of the Department of Health and Human Services (&#8220;OIG&#8221;), the Department of Justice (&#8220;DOJ&#8221;), Centers for Medicare and Medicaid Service (&#8220;CMS&#8221;), and various state agencies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Federal and state fraud and abuse laws apply to and affect our financial relationships and other ordinary and common business interactions with hospitals, referring physicians and other healthcare entities. In particular, the federal anti-kickback statute makes it a crime to knowingly and willfully solicit, receive, offer, or pay any remuneration, in cash or in kind, in return for either referring items or services for which payment may be made in whole or in part by a GHC Program or purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or ordering of any service or item for which payment may be made in whole or in part by a GHC Program. In addition, the federal physician self-referral law, commonly known as the &#8220;Stark Law,&#8221; is a strict liability statute that prohibits a physician from making a referral to an entity for certain &#8220;designated health services&#8221; payable by Medicare if the physician, or an immediate family member of the physician, has a financial relationship with that entity, unless an exception applies. The entity is further prohibited from billing the Medicare program for designated health services furnished pursuant to a prohibited referral. Further, the Stark Law, through the addition of section 1903(s) to the Social Security Act, prohibits the federal government from making federal financial participation payments to state Medicaid programs for designated health services furnished as a result of a referral that would violate the Stark Law if Medicare &#8220;covered the service to the same extent and under the same conditions&#8221; as the state Medicaid Program. The DOJ and several state agencies have successfully argued that Section&#160;1903(s) expands the Stark Law to Medicaid-covered claims, even absent a separate state self-referral law prohibiting the same conduct. These laws have been broadly interpreted by federal courts and agencies, and potentially subject many healthcare business arrangements to government investigation, enforcement and prosecution, which can be costly and time consuming. Additionally, many of the states in which we operate also have similar anti-kickback and self-referral laws that apply to our government and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-government</div> business, including in some cases, to patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-pay</div> services. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Violations of these laws are punishable by substantial penalties and other remedies, including monetary fines, civil penalties, administrative remedies, criminal sanctions (in the case of the federal anti-kickback statute and certain state anti-kickback laws), exclusion from participation in GHC Programs and forfeiture of amounts collected in violation of such laws. The government may also assert that a claim to a GHC Program for covered items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (&#8220;FCA&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a variety of other types of federal and state fraud and abuse laws, including laws authorizing the imposition of criminal, civil and administrative penalties for submitting false or fraudulent claims for reimbursement to GHC Programs. These laws include the federal civil FCA, which prohibits knowingly presenting, or causing to be presented, false claims to GHC Programs, including Medicare, Medicaid, TRICARE (the program for military dependents and retirees), the Federal Employees Health Benefits Program, and insurance plans purchased through the ACA insurance exchanges where payments include federal funds. The FCA also makes the knowing retention of an identified overpayment from a GHC Program a separate basis for FCA liability. Substantial civil fines and treble damages, along with other remedies, including exclusion from GHC Programs, can be imposed for violating the FCA. Furthermore, the FCA does not require that the individual or company that presented or caused to be presented an allegedly false claim have actual knowledge of its falsity. The statute applies where the individual or company acted in &#8220;reckless disregard&#8221; or in &#8220;deliberate ignorance&#8221; of the truth or falsity of the claim. The FCA includes &#8220;whistleblower&#8221; provisions that permit private citizens to sue a claimant on behalf of the government and share in the amounts recovered under the law. In recent years, many cases have been brought against healthcare companies by the government and by &#8220;whistleblowers,&#8221; which have resulted in judgments and settlements involving substantial payments to the government by the companies involved. The cost to defend against allegations, even when the government declines to intervene, can be substantial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Civil Monetary Penalties Law imposes substantial civil monetary penalties against a person or entity that engages in other prohibited activities, such as presenting or causing to be presented a claim to a GHC Program that the person knows or should know is for an item or service that was not provided as claimed or for a claim that is false or fraudulent, or providing remuneration to a GHC Program beneficiary that the person or entity knows or should know is likely to influence the beneficiary&#8217;s selection of a provider or supplier. Regulators also have the authority to exclude individuals and entities from participation in GHC Programs under the Civil Monetary Penalties Law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The civil and administrative false claims statutes are being applied in a broad range of circumstances. For example, claims for services that are medically unnecessary or fail to meet applicable coverage standards may, under certain circumstances, violate these statutes. Claims for services that were induced by kickbacks and Stark Law violations may also form the basis for FCA liability. Many of the laws and regulations referenced above can be used in conjunction with each other. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we or our affiliated professional contractors were excluded from participation in any GHC Programs, not only would we be prohibited from submitting claims for reimbursement under such programs, but we also would be unable to contract with other healthcare providers, such as hospitals, to provide services to them. It could also adversely affect our or our affiliated professional contractors&#8217; ability to contract with, or obtain payment from, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> payors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we intend to conduct our business in compliance with all applicable federal and state fraud and abuse laws, many of the laws, rules and regulations applicable to us, including those relating to billing and those relating to financial relationships with physicians and hospitals, are broadly worded and may be interpreted or applied by prosecutorial, regulatory or judicial authorities in ways that we cannot predict. Accordingly, we cannot assure you that our arrangements or business practices will not be subject to government scrutiny or be alleged or found to violate applicable fraud and abuse laws. If there is a determination by government authorities that we have not complied with any of these laws, rules and regulations, our business, financial condition and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">results of operations could be materially, adversely affected. See &#8220;Government Investigations.&#8221; Additionally, federal and state fraud and abuse laws, rules and regulations are not static and amendments, clarifications, revisions, or other modifications to these laws may occur from time to time. For instance, on December&#160;2, 2020, both CMS and the OIG published final rules substantially modifying the anti-kickback statute, Civil Monetary Penalty Law, and the Stark Law regulations to foster arrangements that would promote care coordination, advance the delivery of value-based care, and protect consumers from harms caused by fraud and abuse. Changes reflected in OIG and CMS&#8217;s final rules could affect our operations and may cause us to modify certain arrangements, transactions, or other financial relationships. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulatory Requirements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to participate in the Medicare program and in the various state Medicaid programs, we and our affiliated physician practices must comply with stringent and often complex regulatory requirements. Moreover, different states impose varying standards for their Medicaid programs. While our compliance program requires that we and our affiliated physician practices adhere to the laws, rules and regulations applicable to the government programs in which we participate, our failure to comply with these laws, rules and regulations could negatively affect our business, financial condition and results of operations. See &#8220;Government Regulation&#8212;Fraud and Abuse Provisions,&#8221; &#8220;Government Regulation&#8212;Compliance Program,&#8221; &#8220;Government Investigations&#8221; and &#8220;Other Legal Proceedings,&#8221; and Item 1A. Risk Factors &#8212; &#8220;Government-funded programs, private insurers or state laws and regulations may limit, reduce or make retroactive adjustments to reimbursement amounts or rates,&#8221; &#8220;We may become subject to billing investigations by federal and state government authorities and private insurers&#8221; and &#8220;The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules or regulations.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, GHC Programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, manual guidance, requirements for utilization review and new governmental funding restrictions, all of which may materially increase or decrease program payments, as well as affect the cost of providing services and the timing of payments to providers. Moreover, because GHC Programs generally provide for reimbursement on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-schedule,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-service</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-discharge</div> basis rather than on a charge-related basis, we generally cannot increase our revenue through increases in the amount we charge for our services. To the extent our costs increase, we may not be able to recover our increased costs from these programs, and cost containment measures and market changes in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> insurance plans have generally restricted our ability to recover or shift these increased costs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> payors. In addition, the health care industry is increasing the use of value-based reimbursement methodologies and accordingly, our reimbursement may be dependent upon our ability to achieve quality targets that change year over year. See Item 1A. Risk Factors &#8211; &#8220;Potential healthcare reform efforts may have a significant effect on our business.&#8221; In attempts to limit federal and state spending, there have been, and we expect that there will continue to be, a number of proposals to limit or reduce Medicare and Medicaid reimbursement for various services. Our business may be significantly and adversely affected by any such changes in reimbursement policies and other legislative initiatives aimed at reducing healthcare costs associated with Medicare, Medicaid and other GHC Programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business also could be adversely affected by reductions in or limitations of funding of GHC Programs or restrictions on or elimination of coverage for certain individuals or treatments under these programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antitrust </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is subject to close antitrust scrutiny. The Federal Trade Commission (&#8220;FTC&#8221;), the Antitrust Division of the DOJ and state Attorneys General all actively review and, in some cases, take enforcement action against business conduct and acquisitions in the healthcare industry. Private parties harmed by alleged anticompetitive conduct can also bring antitrust suits. Violations of antitrust laws may be punishable by substantial penalties, including significant monetary fines, civil penalties, criminal sanctions, consent decrees and injunctions prohibiting certain activities or requiring divestiture or discontinuance of business operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these penalties could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA and Other Privacy, Security and Breach Notification Laws </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerous federal and state laws, rules and regulations govern the collection, dissemination, use, privacy, security and confidentiality of personal information. For example, the federal Health Insurance Portability and Accountability Act of 1996, as amended, and its implementing regulations (collectively, &#8220;HIPAA&#8221;) impose requirements to protect the privacy and security of protected health information (&#8220;PHI&#8221;) and to provide notification in the event of a breach of PHI. Violations of HIPAA are punishable by civil money penalties and, in some cases, criminal penalties and imprisonment. The U.S. Department of Health and Human Services (&#8220;HHS&#8221;) Office for Civil Rights (&#8220;OCR&#8221;), which is responsible for enforcing HIPAA, also may enter into resolution agreements requiring the payment of a civil money penalty and/or the establishment of a corrective action plan to address violations of HIPAA. As part of our business operations, including in connection with medical record keeping, third-party billing, research and other services, we and our affiliated physician practices collect and maintain PHI regarding patients, which subjects us to compliance with HIPAA requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to HIPAA, HHS has adopted privacy regulations, known as the privacy rule, to govern the use and disclosure of PHI (the &#8220;Privacy Rule&#8221;). The Privacy Rule applies to &#8220;Covered Entities,&#8221; which are health plans, health care clearinghouses, and health care providers that engage in standardized transactions under HIPAA, and, as discussed further below, &#8220;Business Associates,&#8221; which are entities that perform functions or services for or on behalf of Covered Entities that involve the use or disclosure of PHI. The term &#8220;Business Associate&#8221; also includes &#8220;Subcontractors,&#8221; which means any entity to which a Business Associate delegates any function, activity or service, other than in the capacity of a member of that Business Associate&#8217;s workforce. PHI is broadly defined as any individually identifiable health information transmitted or maintained in any form, including electronic, paper or oral. As a general rule, a Covered Entity or Business Associate may not use or disclose PHI except as permitted under the Privacy Rule. We have implemented privacy policies and procedures, including training programs, and signed Business Associate Agreements, designed to comply with the requirements set forth in the Privacy Rule, as amended to reflect changes required by HITECH, as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HHS has also adopted data security regulations (the &#8220;Security Rule&#8221;) that require Covered Entities (including health care providers) and Business Associates to implement administrative, physical and technical safeguards to protect the integrity, confidentiality and availability of PHI that is electronically created, received, maintained or transmitted (such as between us and our affiliated practices). We have implemented security policies, procedures and systems, including training programs, designed to comply with the requirements set forth in the Security Rule. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Congress enacted the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act as part of the American Recovery and Reinvestment Act. Among other changes to the laws governing PHI, HITECH required OCR to strengthen and expand HIPAA requirements, increase penalties for violations, give patients new rights to restrict uses and disclosures of their PHI, and impose a number of privacy and security requirements directly on Business Associates. A Covered Entity can also be held liable for violations of HIPAA resulting from the acts or omissions of any Business Associate acting as its agent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under HIPAA, as amended by regulations promulgated pursuant to HITECH, Covered Entities are required to report any unauthorized use or disclosure of PHI that meets the definition of a breach to affected individuals, HHS and, depending on the number of affected individuals, the media for the affected market. In addition, HIPAA requires that Business Associates report breaches to their Covered Entity customers. HITECH further authorizes state Attorneys General to bring civil actions in response to violations of HIPAA that threaten the privacy of state residents. We have adopted breach notification policies and procedures designed to comply with the applicable requirements set forth in HIPAA. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">HIPAA establishes a federal &#8220;floor&#8221; with respect to privacy, security, and breach notification requirements and does not supersede any state laws insofar as they are broader or more stringent than HIPAA. Numerous state and certain other federal laws protect the confidentiality of health information and other personal information, including but not limited to state medical privacy laws, state laws protecting personal information, state data breach notification laws, state genetic privacy laws, human subjects research laws and federal and state consumer protection laws. These additional federal and state privacy and security-related laws may be more restrictive than HIPAA and could impose additional penalties. For example, the Federal Trade Commission uses its consumer protection authority under Section&#160;5 of the Federal Trade Act to initiate enforcement actions in response to alleged privacy violations and data breaches. California recently enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which went into effect on January&#160;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. California recently amended and expanded CCPA through another ballot initiative, the California Privacy Rights Act (&#8220;CPRA&#8221;), passed on November&#160;3, 2020. It remains unclear what, if any, additional modifications will be made to the CPRA by the California legislature or how it will be interpreted. In addition to California, other states have strengthened their data security laws and others are indicated their intention to do so as well. A bill introduced in the New York Senate on October&#160;28, 2020, the &#8220;It&#8217;s Your Data Act&#8221; (IYDA), would modify New York&#8217;s civil rights and general business laws to expand the current right of privacy as well as create a series of consumer rights and business obligations concerning the collection, storage, and use of a consumer&#8217;s personal information. Violations could result in civil and criminal liability. It is expected that additional state legislatures will introduce stronger data privacy protections this year. In addition, industry groups such as the payment card industry have developed self-regulatory guidelines for privacy and data security that are more stringent than HIPAA. In order to accept payments from payment cards, merchants must use payment card processing applications that have been validated under the Payment Application Data Security Standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;PA-DSS&#8221;),</div> and complete a self-assessment questionnaire that complies with the Payment Card Industry Data Security Standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;PCI-DSS&#8221;).</div> Failure to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PA-DSS</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PCI-DSS</div> may result in fines and penalties imposed by payment card brands, and/or termination of the merchant&#8217;s relationship with the bank it relies on to process payment card payments. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These requirements are also subject to change. Compliance with new privacy, security, and breach notification laws, regulations, requirements and self-regulatory guidelines may result in increased operating costs, and may constrain or require us to alter our business model or operations. For example, changes to HIPAA promulgated pursuant to HITECH further restricted our ability to collect, disclose and use PHI and imposed additional compliance requirements on us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently maintain liability insurance coverage intended to cover cyber liability and certain other privacy and security breach-related claims, we cannot ensure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. Liabilities in excess of our insurance coverage, including coverage for cyber liability and certain other privacy and security breach-related claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA Transaction Requirements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to privacy, security, and breach notifications requirements, HIPAA establishes uniform electronic data transmission standards that all healthcare providers must use for electronic healthcare transactions. For example, claims for reimbursement that are transmitted electronically to third-party payors must comply with specific formatting standards, and these standards apply whether the payor is a government or a private entity. We report medical diagnoses under International Classification of Diseases, 10<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">th</div> Edition <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ICD-10&#8221;).</div> If claims are not reported properly under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ICD-10</div> due to technical or coding errors or other implementation issues involving systems, including ours and those of our third-party payors, there can be a delay in the processing and payment of such claims, or a denial of such claims, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Regulations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our healthcare operations generate medical waste that must be disposed of in compliance with federal, state and local environmental laws, rules and regulations. Our office-based operations are subject to compliance with various other environmental laws, rules and regulations. Such compliance does not, and we anticipate that such compliance will not, materially affect our capital expenditures, financial position or results of operations. Some states, such as Florida, require us to be licensed by the state in order to dispose of biomedical waste. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance Program </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain a compliance program that includes the OIG&#8217;s seven established elements of an effective program and which reflects our commitment to complying with all laws, rules and regulations applicable to our business and that meets our ethical obligations in conducting our business (the &#8220;Compliance Program&#8221;). We believe our Compliance Program provides a solid framework to meet this commitment and our obligations as a provider of healthcare services, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Chief Compliance Officer who reports to the Board of Directors on a regular basis; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Compliance Committee consisting of our senior executives; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a formal internal audit function, including a Senior Director of Internal Audit who reports to the Audit Committee on a regular basis; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>, which is applicable to our employees, independent contractors, officers and directors; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Professional Conduct &#8211; Finance</div></div>, which is applicable to our finance personnel, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a disclosure program that includes a mechanism to enable individuals to disclose on a confidential or anonymous basis to the Chief Compliance Officer or any person who is not in the disclosing individual&#8217;s chain of command, issues or questions believed by the individual to be a potential violation of criminal, civil, or administrative laws or of company policies or procedures; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an organizational structure designed to integrate our compliance objectives into our corporate offices, regions and practices; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">education, monitoring and corrective action programs designed to establish methods to promote the understanding of our Compliance Program and adherence to its requirements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The foundation of our Compliance Program is our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>, which is intended to be a comprehensive statement of the ethical and legal standards governing the daily activities of our employees, affiliated professionals, independent contractors, officers and directors. All of our personnel are required to abide by, and are given thorough education regarding, our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>. In addition, all employees and affiliated professionals are expected to report incidents that they believe in good faith may be in violation of our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>. We maintain a toll-free helpline to permit individuals to report compliance concerns on an anonymous or confidential basis, if they elect to do so, and obtain answers to questions about our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>. Our Compliance Program, including our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div>, is administered by our Chief Compliance Officer with oversight by our Chief Executive Officer, Compliance Committee and Board of Directors. Copies of our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct</div></div> and our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Professional Conduct &#8211; Finance</div></div> are available on our website, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.Mednax.com</div>. Our internet website and the information contained therein or connected thereto are not incorporated into or deemed a part of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Any amendments or waivers to our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Professional Conduct &#8211; Finance</div></div> will be promptly disclosed on our website following the date of any such amendment or waiver. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GOVERNMENT INVESTIGATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that audits, inquiries and investigations from government authorities, agencies, contractors and payors will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OTHER LEGAL PROCEEDINGS </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits, including with payors or other counterparties that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> </div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;20, 2019, a derivative action was filed by plaintiff Beverly Jackson on behalf of Mednax, Inc. against Mednax, Inc. and certain of its officers and directors in the Seventeenth Judicial Circuit in and for Broward County, Florida (Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CACE-19-006253).</div></div> The plaintiff purported to bring suit derivatively on behalf of our company against certain of our officers and directors for breach of fiduciary duties and unjust enrichment claiming alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> thereunder, based on statements made by the defendants primarily concerning our former anesthesiology business. The complaint seeks unspecified damages, interest, attorneys&#8217; fees and other costs. We filed a motion to dismiss in December 2019, and on March&#160;16, 2020, an order granting our motion to dismiss without prejudice was issued. On April&#160;6, 2020, the plaintiff filed an amended complaint, and on April&#160;30, 2020, we filed a motion to dismiss the amended complaint. On September&#160;24, 2020, our motion to dismiss was granted, but the plaintiff was granted 20 days to amend their complaint, and on October&#160;14, 2020, the plaintiff filed a second amended complaint. We filed our motion to dismiss the second amended complaint on October&#160;26, 2020. On December&#160;18, 2020 an Order was entered summarily denying our motion to dismiss the second amended complaint, and our answer is due on February&#160;26, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot ensure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. See &#8220;Professional and General Liability Coverage.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PROFESSIONAL AND GENERAL LIABILITY COVERAGE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional and general liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles, self-insured retention limits, policy aggregates, exclusions, and other restrictions, in accordance with standard industry practice. We believe that our insurance coverage is appropriate based upon our claims experience and the nature and risks of our business. However, we cannot predict whether any pending or future claim would be successful or, if successful, would not exceed the limits of available insurance coverage. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business entails an inherent risk of claims of medical malpractice against our affiliated physicians, clinicians and us. We contract and pay premiums for professional liability insurance that indemnifies us and our affiliated healthcare professionals generally on a claims-made basis for losses incurred related to medical malpractice litigation. Professional liability coverage is required in order for our affiliated physicians to maintain </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hospital privileges. Our self-insured retention under our professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. We record estimates in our Consolidated Financial Statements for our liabilities for self-insured retention amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. Because many factors can affect historical and future loss patterns, the determination of an appropriate reserve involves complex, subjective judgment, and actual results may vary significantly from estimates. If the self-insured retention amounts and other amounts that we are actually required to pay materially exceed the estimates that have been reserved, our financial condition, results of operations and cash flows could be materially, adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HUMAN CAPITAL MANAGEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe our affiliated physicians, other clinical professionals and administrative employees are key to our success. As of December&#160;31, 2020, we had more than 2,300 practicing physicians affiliated with us, and we employed or contracted with approximately 2,000 other clinical professionals and approximately 3,600 other full-time and part-time employees. Our affiliated physicians and clinicians provide critical medical care through more than 17 women&#8217;s and children&#8217;s healthcare services across 39 states and Puerto Rico, providing care to the most vulnerable patient population in the country: expecting mothers and their newborns and children. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the success of our mission to &#8220;Take great care of the patient every day and in every way<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div>&#8221; is realized by the engagement and empowerment of our affiliated physicians, other clinicians and administrative employees. Our Chief Human Resources Officer (&#8220;CHRO&#8221;) is responsible for developing and executing our human capital strategy. This includes the attraction, acquisition, development and engagement of talent to deliver on our strategy and the design of employee compensation and benefits programs. Our CHRO reports directly to our Chief Executive Officer and regularly engages with our board of directors and its compensation committee. Our Human Resources department is a core administrative support function of Mednax.&#160;Through its functional experts, our Human Resources team provides support and guidance in the areas of talent acquisition, employee wellness and safety programs, workplace policies and procedures, training and development and rewards strategies that include compensation, benefits and other rewards.&#160;It is the goal of the Human Resources department to support the needs of our organization and our workforce while serving as a trusted strategic partner to our management team. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We work together to make sound decisions for all of our operations teams and medical groups. Physicians spend years of their lives learning and training the science of medicine in order to bring their knowledge and skill to the bedside of a patient. It is an art, honed through repeated patient interactions, that allows any clinician to translate science into compassionate care for our patients. But healthcare is also our business, so we must also take great care of the business. This requires us to work every day to put tools into the hands of our affiliated physicians and other clinical professionals so they can deliver high quality care to our patients. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Training and Leadership Development </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are committed to the continued development of our people and believe in fostering great leaders. Our Training and Development team is committed to providing an environment that fosters both individual and organizational development. Through its various training and educational programs, the training and development team supports the organization&#8217;s commitment to excellence and its mission to &#8220;Take great care of the patient every day and in every way<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div>&#8221;. We make available a catalog of over 5,000 courses to all audiences across subjects including business skills, leadership and management, office productivity, health and wellness and personal development, among others. The courses are designed to develop great people who become great leaders that will ultimately shape a great company. Our training materials were enhanced with additional resources to support remote work environments required due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the greatest predictors of success in our partnerships at the hospital and health system level is a high degree of strategic alignment between our clinical leadership and our partners. This requires that our clinicians </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have a skill set beyond just the practice of medicine. During 2021, our affiliated physicians and advanced practitioners across the organization will participate in our COVID-delayed Clinical Leadership Development Program focused on actively developing and supporting our clinician leaders at Mednax. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compliance Program and Training </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fundamental to our core values are people and a culture of integrity. Our Compliance Department is led by our Chief Compliance Officer. The Compliance Program is supported by a written Compliance Plan, which details the components, organizational structure and operational aspects of the Compliance Program. Although the Compliance Program is supported by numerous operational policies and procedures, there are some key elements that are critical to its success. These include a Compliance Committee; a written Code of Conduct; new hire and periodic compliance training for all employees; compliance reporting mechanisms; and periodic reports to our board of directors. Annual participation in compliance trainings related to ethics, environment, health and safety, and emergency responses are at 100%. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Health and Well-Being </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We care about the health and well-being of our affiliated clinicians, other clinical professionals and our administrative employees and their families and are committed to their health, safety and wellness. We support all of our colleagues in encouraging habits of wellness, increased awareness of factors and resources that contribute to overall well-being and inspire individuals to take responsibility for their own health. When individuals take great care of themselves, we can continue to take great care of our patients and take great care of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We provide all our colleagues access to an Employee Assistance Program (&#8220;EAP&#8221;) that offers free and confidential assessments, short-term counseling, referrals, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> services to employees who have personal and/or work-related problems.&#160;Our EAP addresses a broad and complex body of issues affecting mental and emotional well-being, such as alcohol and other substance abuse, stress, grief, family problems, and psychological disorders.&#160;EAP counselors also work in a consultative role with managers and supervisors to address employee and organizational challenges and needs. The EAP is designed to help our colleagues lead happier and more productive lives at home and at work. Our EAP services are available to all eligible employees, their spouses or domestic partners, dependent children, parents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">parents-in-law.&#160;We</div></div> encourage all of our employees and their family members to make full use of this resource which is designed to help maintain high employee productivity, health, and well-being in all aspects of life.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also partnered with the American Heart Association to provide heart healthy information and programs to our employees and encourage local participation in the AHA annual Heart Walk. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">With the onset of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we worked tirelessly to source and provide personal protective equipment for our patient facing employees. For employees who were and are not in direct clinical care, we pivoted to a remote work arrangement which continues today and will do so until such time that the majority of the population is vaccinated. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diversity and Inclusion </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We strive to make diversity, equality and inclusion a priority. As of February&#160;1, 2021, approximately 80% of our total headcount was female and approximately 40% of our total headcount identified as part of a minority group. Among our affiliated physicians and other clinical professionals, approximately 70% was female and approximately 35% identified as part of a minority group. Among the executive and senior executive level and manager group, approximately 36% was female and approximately 20% identified as part of a minority group. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that a diverse workforce is critical to our success, and we will continue to focus on the hiring, retention and advancement of any underrepresented population to achieve this goal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total Rewards: Compensation and Benefits </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We value our colleagues&#8217; contributions to our success and strive to provide all of our colleagues with a competitive and comprehensive total rewards package. This includes robust compensation and benefits programs to help meet the needs of our affiliated physicians, other clinical professionals and administrative employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We take great care to ensure that our cash-based compensation packages are reflective of the market value for the work that our colleagues perform. We also understand that providing a comprehensive suite of employee benefits is essential to attracting, retaining and engaging world-class employees. Therefore, we regularly evaluate our benefit offerings to be sure we fully support our employees. In addition to base salaries, these offerings may include a combination of annual bonuses, stock-based compensation awards, an Employee Stock Purchase Plan, a 401(k) Plan, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, adoption assistance, employee assistance programs, continuing education, among many others. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GEOGRAPHIC COVERAGE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide physician services across 39 states and Puerto Rico. During 2020, approximately 62% of our net revenue was generated by operations in our five largest states. Our operations in Texas accounted for approximately 29% of our net revenue for the same period. Although we continue to seek to diversify the geographic scope of our operations, we may not be able to implement successfully or realize the expected benefits of any of these initiatives. Adverse changes or conditions affecting states in which our operations are concentrated, such as healthcare reforms, changes in laws, rules and regulations, reduced Medicare or Medicaid reimbursements, an increase in the income level required to qualify for government healthcare programs or government investigations, may have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SERVICE MARKS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have registered with the United States Patent and Trademark Office the service marks &#8220;Mednax National Medical Group and Design,&#8221; &#8220;Pediatrix Medical Group and Design,&#8221; &#8220;Obstetrix Medical Group and Design,&#8221; &#8220;BabySteps,&#8221; the &#8220;Baby Design,&#8221; &#8220;iNewborn,&#8221; and &#8220;NEO Conference and Design,&#8221; among others. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVAILABLE INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our annual proxy statements, annual reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> quarterly reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> current reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> and amendments to those statements and reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 are available free of charge and may be printed out through our internet website, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.Mednax.com</div>, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (&#8220;SEC&#8221;). Our proxy statements and reports may also be obtained directly from the SEC&#8217;s Internet website at <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.sec.gov</div>. Our internet website and the information contained therein or connected thereto are not incorporated into or deemed a part of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_3" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business is subject to a number of factors that could materially affect future developments and performance. In addition to factors affecting our business that have been described elsewhere in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> any of the following risks could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. We may update these risk factors in our periodic and other filings with the SEC. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the principal risk factors described in this section: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our financial condition and results of operations have been and may continue to be materially adversely affected by the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Economic conditions could have an adverse effect on our business. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unfavorable changes or conditions could occur in the states where our operations are concentrated. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has necessitated the delivery of certain healthcare services remotely via telehealth, which is subject to extensive federal and state regulation, as well as temporary waivers tied to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> public health emergency. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;) and potential changes to it may have a significant effect on our business. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;) and potential changes to Medicare reimbursement enacted pursuant to the legislation may have a significant effect on our business. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Transparency in Coverage Final Rule, which requires health plans to, beginning January&#160;1, 2022, report to insureds upon request negotiated rates for all covered items and services and cost sharing obligations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers, could have a material impact on our business. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Congress or states have, and may continue to, enact laws restricting the amount <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers of services can charge and recover for such services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expanding eligibility of GHC Programs could adversely affect our reimbursement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government-funded programs, private insurers, or state laws and regulations may limit, reduce, or make retroactive adjustments to reimbursement amounts or rates. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not find suitable acquisition candidates or successfully integrate our acquisitions. Our acquisitions may expose us to greater business risks and could affect our payor mix. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to successfully execute our same-unit and organic growth strategies. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to manage third-party service providers may adversely affect our ability to maintain the quality of service that we provide. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to litigation risks. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to collect reimbursements for our services from third-party payors. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current indebtedness and any future indebtedness could adversely affect us by reducing our flexibility to respond to changing business and economic conditions and expose us to interest rate risk to the extent of any variable rate debt. In addition, a certain portion of our interest expense may not be deductible. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to successfully recruit, onboard and retain qualified physicians and other clinicians and other personnel, and our compensation expense for existing clinicians and other personnel may increase. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our employees and business partners may not appropriately secure and protect confidential information in their possession. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in federal and state information privacy and security laws could cause us to incur costs to comply, including potential changes to technology systems, legal and consulting services, and potential litigation risk. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Macroeconomic Conditions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Our financial condition and results of operations have been and may continue to be materially adversely affected by the ongoing coronavirus pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19).</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> evolved into a global pandemic that spread to most regions of the world, including virtually all of the United States. The full extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or treat its impact, such as the potential for further shutdown or stay at home orders, and shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, saw a significant elevation of appointment cancellations compared to historical normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> We believe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> either directly or indirectly, has also had an impact on our NICU patient volumes, and there is no assurance that impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not further adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business. Overall, our operating results were significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through December 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The foregoing and other continued disruptions to our business as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could result in a material adverse effect on our business, results of operations, financial condition, prospects and the trading prices of our securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Economic conditions could have an adverse effect on our business. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operations and performance depend significantly on economic conditions.&#160;During the year ended December&#160;31, 2020, the percentage of our patient service revenue being reimbursed under GHC Programs increased as compared to the year ended December&#160;31, 2019. If, however, economic conditions in the United States deteriorate, we could experience shifts toward GHC Programs, and patient volumes could decline. Further, we could experience and have experienced shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services. Adverse economic conditions could also lead to additional increases in the number of unemployed and under-employed workers and a decline in the number of private employers that offer healthcare insurance coverage to their employees. Employers that do offer healthcare coverage may increase the required contributions from employees to pay for their coverage and increase patient responsibility amounts. In addition, certain private payors&#8217; poor experience with the healthcare insurance exchanges and uncertainty around the future of the ACA and healthcare insurance exchanges may result in those payors exiting the healthcare insurance exchange marketplaces or the cessation of the healthcare insurance exchanges. As a consequence, the number of patients who participate in GHC Programs or who are uninsured or underinsured could increase. Payments received from GHC Programs are substantially less than payments received from private healthcare insurance programs (managed care and other third-party payors). Payments under policies issued through the healthcare insurance exchanges may be less than payments from private healthcare insurance programs and in some cases, patients&#8217; responsibility for costs related to healthcare </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">plans obtained through the healthcare insurance exchanges may be high and could increase in the future, and we may experience increased bad debt due to patients&#8217; inability to pay for certain services. A payor mix shift from private healthcare insurance programs to GHC Programs or to healthcare insurance exchanges may result and has resulted in an increase in our estimated provision for contractual adjustments and uncollectibles and a corresponding decrease in our net revenue, as well as a significant reduction in our average reimbursement rates. While we have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, to address some of the effects of changes in economic conditions, there is no assurance that these initiatives will be successful in generating improvements in our general and administrative expenses and our operational infrastructure. If these initiatives are unsuccessful, it could have an adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The birth rate in the United States has declined and may decline further. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Final birth data for 2019 indicate that total births in the United States declined by approximately 1% as compared to 2018. Provisional data for 2020 is not yet available; however, we expect that birth trends at the hospitals where we provide services will continue to be soft in the near future. Future declines in births are possible and could have an adverse effect on our patient volumes, net revenue, results of operations, cash flows, financial condition and the trading price of our common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unfavorable changes or conditions could occur in the states where our operations are concentrated. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A majority of our net revenue in 2020 was generated by our operations in five states. In particular, Texas accounted for approximately 29% of our net revenue in 2020. See Item 1. Business&#8212;&#8220;Geographic Coverage.&#8221; Adverse changes or conditions affecting these particular states, such as healthcare reforms, changes in laws and regulations, reduced Medicaid eligibility or reimbursements and government investigations, economic conditions, weather conditions, and natural disasters may have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The value of our common stock may fluctuate. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There has been significant volatility in the market price of securities of healthcare companies generally that we believe in many cases has been unrelated to operating performance. In addition, we believe that certain factors, such as actual and potential legislative and regulatory developments, including announced regulatory investigations, quarterly fluctuations in our actual or anticipated results of operations, lower revenue or earnings than those anticipated by securities analysts, not meeting publicly announced expectations, general economic and financial market conditions, and the effect of short interest in our common stock could cause the price of our common stock to fluctuate substantially. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Governmental Changes and the Healthcare Regulatory Environment </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential healthcare reform efforts may have a significant effect on our business. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA contains a number of provisions that have affected us and may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA remains subject to continuing legislative and administrative flux and uncertainty. The law has faced many challenges, both legislative and legal, since its inception and may be subject to further modification. We cannot predict what impact, if any, further healthcare reform efforts or ACA changes may have on our business. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2021, the results of the federal and state elections have changed which persons and parties occupy the Office of the President of the United States and control both chambers of Congress and many states&#8217; governors and legislatures. The Biden Administration may propose sweeping changes to the U.S. healthcare system, including further changes to the ACA and further expanding government-funded health insurance options and replacing current healthcare financing mechanisms with systems that would be entirely administered by the federal government. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. Congress and the Administration, in recent years, have sought to convert Medicaid into a block grant or to institute per capita spending caps, among other things. At least one state received approval for a block grant waiver from standard Medicaid requirements. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. Congress also could advance changes that result in more people being covered by Medicaid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many states have recently shifted a majority or all of their Medicaid program beneficiaries into Managed Medicaid Plans. Managed Medicaid Plans have some flexibility to set rates for providers, but many states require minimum provider rates in their contracts with such plans. In July of each year, CMS releases the annual Medicaid Managed Care Rate Development Guide which provides federal baseline rules for setting reimbursement rates in managed care plans. We could be affected by lower reimbursement rates in some or all of the Managed Medicaid Plans with which we participate. We could also be materially impacted if we are dropped from the provider network in one or more of the Managed Medicaid Plans with which we currently participate. In Florida, more than 75% of the Medicaid population participates in a Managed Medicaid Plan, with even higher participation rates for children. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have an adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has necessitated the delivery of certain healthcare services remotely via telehealth, which is subject to extensive federal and state regulation, as well as temporary waivers tied to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> public health emergency. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In an effort to address <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">shelter-in-place,</div></div> quarantine, executive order or related measures to combat the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> as well as the perceived need by individuals to continue such practices to avoid infection and to provide safe access to care for our patients, we have converted certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> visits to telehealth visits. There is significant variation in demand, consumer acceptance, and market adoption of telehealth services, as well as the laws and regulations governing telehealth in the markets in which we operate. The provision of telehealth is largely regulated at the state level and can include, among other things, variations in the definition of telehealth, physician/patient relationship requirements, informed consent for telehealth services, licensure, scope of practice, covered modalities, electronic prescribing, coverage and reimbursement, and privacy and security requirements. Our ability to conduct telehealth services and provide medical services in a particular jurisdiction is directly dependent upon the applicable laws governing remote healthcare, the practice of medicine and healthcare delivery in general in such location, which are subject to changing political, regulatory and other influences. While numerous federal agencies have released waivers to ease regulatory obstacles to the adoption of telehealth, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">these waivers do not override applicable state laws. States have adopted waivers as well but differ in the scope and application of such waivers and also on the time period the waiver is available. Many state waivers in relation to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> have already expired, despite the extension of the federal public health emergency declaration. Evolving interpretations and acceptance of telehealth by medical boards, state attorneys general and other regulatory or administrative bodies require us to monitor our compliance with law in every jurisdiction in which we operate, on an ongoing basis, and we cannot provide assurance that our activities and arrangements, if challenged, will be found to be in compliance with the law. Monitoring regulatory changes at the federal and state levels has and will continue to incur costs for us and may result in making changes to our business operations to ensure continued compliance. Challenges also exist with respect to coverage and reimbursement of telehealth services by both commercial and governmental payors. If telehealth services achieve coverage, there is no guarantee that reimbursement will be equivalent to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> care and may negatively impact our financial condition. Negative publicity in any of our markets concerning our products or services or the telehealth market as a whole could limit market acceptance of our services. Similarly, individual and healthcare industry concerns or negative publicity regarding patient confidentiality and privacy in the context of telehealth could limit market acceptance of our healthcare services when delivered remotely. If any of these events occur, it could have an adverse effect on our business, financial condition, results of operations and the trading price of our securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;) and potential changes to it may have a significant effect on our business. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MACRA contains numerous measures that could affect us, including, requirements that physicians participate in quality measurement programs that differentiate payments to physicians under Medicare based on quality and cost of care, rather than the quantity of procedures performed. MACRA requires physicians to choose to participate in one of two payment formulas, MIPS or Alternative Payment Models (&#8220;APMs&#8221;). Beginning in 2020, MIPS allowed eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians could choose to participate in an Advanced APM, and physicians who were meaningful participants in APMs could receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians will continue to be eligible to receive bonus payments in 2021 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have an adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The Transparency in Coverage Final Rule, which requires health plans to, beginning January&#160;1, 2022, report to insureds upon request negotiated rates for all covered items and services, and cost sharing obligations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers, and could have a material impact on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Beginning January&#160;1, 2022, health plans must begin reporting to their covered beneficiaries certain pricing information for covered items and services as well as the individual&#8217;s cost-sharing obligations for those services. This rule aims to put health pricing information into the hands of consumers and allow them to select their providers based, in part, on cost. Through this final rule, plans and health insurers will be required to disclose on a public website their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> negotiated rates, billed charges and allowed amounts paid for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers, and the negotiated rate and historical net price for prescription drugs. Price reporting will expand to all services by January&#160;1, 2024. We cannot predict how the availability of this health pricing information may </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impact our business operations and patient volumes. If patients choose to use services of less costly providers, we could see a reduction in patient volumes or decide to reduce the prices of our services to compensate, either of which could have an adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">State budgetary constraints and the uncertainty over the future of Medicaid could have an adverse effect on our reimbursement from Medicaid programs</div></div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA allowed states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. As of December&#160;31, 2020, 38 states and the District of Columbia adopted the expansion of Medicaid eligibility. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household incomes are at or below 133% of the federal poverty level. If states that expanded Medicaid reduce or eliminate eligibility for certain individuals, the number of patients who are uninsured could increase. Some states may seek to maintain expanded eligibility and to do so could offset the cost by further reducing payments to providers of services. In some states, we could experience delayed or reduced Medicaid payment for services furnished to program enrollees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Congress and the Biden Administration may also seek substantial reforms to Medicaid law and the ability of states to design Medicaid programs. Any changes, if enacted, could reduce or eliminate eligibility for certain individuals or reduce payments to providers of services. As a result, we could experience an increase in the number of uninsured patients and delayed or reduced Medicaid payment for services furnished to program enrollees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, many states are continuing to collect less tax revenue than they did historically and as a consequence continue to face budget shortfalls and underfunded pension and other obligations. Although shortfalls have been declining in more recent budgetary years, they are still significant by historical standards. The financial condition of the states in which we do business could lead to reduced or delayed funding for Medicaid programs and, in turn, reduced or delayed reimbursement for physician services, which could adversely affect our results of operations, cash flows and financial condition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any changes to Medicaid eligibility, enrollment, financing or reimbursement could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Congress or states have, and may continue to, enact laws restricting the amount <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers of services can charge and recover for such services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In late 2020, Congress enacted legislation intended to protect patients from &#8220;surprise&#8221; medical bills when services are furnished by providers who are not subject to contractual arrangements and payment limitations with the patient&#8217;s insurer. Effective January&#160;1, 2022, patients will be protected from unexpected or &#8220;surprise&#8221; medical bills that could arise from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> emergency care provided at an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> facility or at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> facilities by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> nonemergency care provided at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> facilities without the patient&#8217;s informed consent. Many states have passed similar legislation, but the federal government has been working to enact a ban on surprise billing for quite some time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the &#8220;No Surprises Act,&#8221; patients are only required to pay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> cost-sharing amount, which will be determined through an established formula and will count toward the patient&#8217;s health plan deductible and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> cost-sharing limits. Providers will generally not be permitted to balance bill patients beyond this cost-sharing amount. An <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider will only be permitted to bill a patient more than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> cost-sharing amount for care if the provider gives the patient notice of the provider&#8217;s network status and delivers to the patient or their health plan an estimate of charges within certain specified timeframes, and obtains the patient&#8217;s written consent prior to the delivery of care. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#8217;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Moreover, these measures could affect our ability to contract with certain payors and under historically similar terms and may cause, and the prospect of these changes may have caused, payors to terminate their contracts with us and our affiliated practices. Should any relationships with payors continue on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> basis, the No Surprises Act requires that rate disputes be resolved through binding arbitration, in which both the payor and provider submit a requested rate and the arbitrator selects one submission without hearing or modification of the selected request. These unpredictable results will bind both the provider and payor for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period. We cannot predict the results of such proceedings, and the results could further affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expanding eligibility of GHC Programs could adversely affect our reimbursement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2018, Congress reauthorized the Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) through 2023 and then in February 2018 lengthened this funding extension through 2027. Changes to CHIP or the ACA&#8217;s expansion of Medicaid coverage could cause patients who otherwise would have participated in private healthcare insurance programs to participate in GHC Programs, or vice versa, or cause patients who otherwise would have been covered by CHIP or Medicaid to lose insurance coverage altogether. Additional reform efforts, as well as legislative or administrative amendment or repeal of the ACA, could change the eligibility requirements for Medicaid and for other GHC Programs, including CHIP, and could increase the number of patients who participate in such programs or the number of uninsured patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2021, the results of the federal and state elections have affected which persons and parties occupy the Office of the President of the United States and control both chambers of Congress and many states&#8217; governors and legislatures. President Biden has proposed sweeping changes to the U.S. healthcare system, including expanding government-funded health insurance options and replacing current healthcare financing mechanisms with systems that would be entirely administered by the federal government. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, payments received from GHC Programs are substantially less than payments received from private healthcare insurance programs (managed care and other third-party payors). A shift in the mix of our payors from private healthcare insurance programs to government payors may result in an increase in our estimated provision for contractual adjustments and uncollectibles and a corresponding decrease in our net revenue, as well as a significant reduction in our average reimbursement rates. Additionally, if Congress does not act to extend CHIP beyond 2027, or if Congress extends CHIP but substantially alters the current program, we could be adversely affected if children in states where we do business lose Medicaid coverage or payments for services furnished to these children are delayed or reduced. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government-funded programs, private insurers or state laws and regulations may limit, reduce or make retroactive adjustments to reimbursement amounts or rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our net revenue is derived from payments made by GHC Programs, principally Medicare and Medicaid, including the managed care plans under the Medicare and Medicaid programs. These government-funded programs, as well as private insurers, have been and may continue to be subject to changes, including increased use of managed care organizations, value-based purchasing, and new patient care models to control the cost, eligibility for, use and delivery of healthcare services as a result of budgetary constraints and cost containment pressures due to unfavorable economic conditions, rising healthcare costs and for other reasons, including those described above under Item 1. Business&#8212;&#8220;Government Regulation&#8212;Government Regulatory Requirements.&#8221; Federal and state legislatures or administrators of these government-funded programs and private insurers may attempt other measures to control costs, including bundling of services and denial of, or reduction in, reimbursement for certain services and treatments. In addition, increased consolidation among private insurers is resulting in fewer and larger third-party payors with increased negotiating power. As a result, payments from </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">government programs or private payors may decrease significantly. Also, any adjustment in Medicare reimbursement rates may have a detrimental impact on our reimbursement rates not only for Medicare patients, but also for patients covered under Medicaid and other third-party payors, because a state&#8217;s Medicaid payments cannot exceed the payments it would have made had those patients been enrolled in traditional Medicare, and other third-party payors often base their reimbursement rates on a percentage of Medicare rates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, the federal Medicare agency announced changes in payments for physician services that would increase payment for services typically delivered by primary care providers, but that also would have reduced payment for many other specialty services. The impact of this change varied significantly across specialties, with some specialties potentially facing cuts of as much as 10%. Legislation enacted by Congress in December 2020 moderated the payment reductions for 2021 through 2023, but some of the relief mechanisms will be effective only in 2021, meaning physician service payments will face similar reductions again in 2022, unless Congress or the Medicare agency intervenes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our business may also be materially affected by limitations on, or reductions in, reimbursement amounts or rates or elimination of coverage for certain individuals or treatments. Our business may also be materially affected by changes in medical codes for services that our affiliated clinicians provide if services under a new code are reimbursed at a lower rate. For example, the medical code for certain of our hearing screen services was recently changed by CMS to a code that could provide for lower reimbursement rates. While we have not yet experienced any material decrease in reimbursement rates as a result of this coding change, we are still evaluating the result of this change on our hearing screen contracts and ultimate effect of this coding change is not known at this time. Moreover, because government-funded programs generally provide for reimbursements on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-schedule</div> basis rather than on a charge-related basis, we generally cannot increase our revenue from these programs through increases in the amount we charge for our services. To the extent our costs increase, we may not be able to recover our increased costs from these programs, and cost containment measures and market changes in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-government-funded</div> insurance plans have generally restricted our ability to recover, or shift to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> payors, these increased costs. In addition, funds we receive from third-party payors are subject to audit with respect to the proper billing for physician and ancillary services and, accordingly, our revenue from these programs may be adjusted retroactively. Any retroactive adjustments to our reimbursement amounts could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, our agreements with certain third-party payors are terminable for various reasons. If an agreement with a third-party payor is terminated, we are generally required to seek reimbursement as an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider. In the event we attempt to balance-bill patients, we may be limited in our ability to do so by certain state laws and regulations. As these laws and regulations continue to develop in certain states, it could incentivize, and may have incentivized, certain third-party payors to terminate agreements as a business strategy which could lower overall reimbursement to providers. Any reductions in reimbursement amounts could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, if a federal government shutdown were to occur for a prolonged period of time, federal government payment obligations, including its obligations under Medicaid and Medicare, may be delayed. Similarly, if state government shutdowns were to occur, state payment obligations may be delayed. If the federal or state governments fail to make payments under these programs on a timely basis, our business could suffer, and our financial position, results of operations or cash flows may be materially affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may become subject to billing investigations by federal and state government authorities and private insurers. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal and state laws, rules and regulations impose substantial penalties, including criminal and civil fines, monetary penalties, exclusion from participation in government healthcare programs and imprisonment, on entities or individuals (including any individual corporate officers or individual providers deemed responsible) that fraudulently or wrongfully bill government-funded programs or other third-party payors for healthcare services. CMS requires states to maintain a Medicaid Recovery Audit Contractor (&#8220;RAC&#8221;) program. States are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">required to contract with one or more eligible Medicaid RACs to review Medicaid claims for any overpayments or underpayments, and to recoup overpayments from providers on behalf of the state. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal laws, along with a growing number of state laws, allow a private person to bring a civil action in the name of the government for false billing violations. See Item 1. Business&#8212; &#8220;Government Regulation&#8212;Fraud and Abuse Provisions.&#8221; Further, identified overpayments from Medicare or Medicaid must be refunded to the government within 60 days or the entity could be held liable under the federal FCA, including for treble damages and substantial civil penalties. In addition, our contracts with private insurers often provide such insurers with audit rights over payments made to us and the ability to seek recoupment for overpayments. We believe that audits, inquiries and investigations from government agencies and private insurers will occur from time to time in the ordinary course of our business, which could result in substantial costs to us, legal actions by or against us, and a diversion of management&#8217;s time and attention. New regulations and heightened enforcement activity also could materially affect our cost of doing business and our risk of becoming the subject of an audit or investigation. We cannot predict whether any future audits, inquiries or investigations, or the public disclosure of such matters, likely would have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. See Item 1. Business&#8212;&#8220;Government Investigations.&#8221; </div></div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules or regulations. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry and physicians&#8217; medical practices, including the healthcare and other services that we and our affiliated physicians provide, are subject to extensive and complex federal, state and local laws, rules and regulations, compliance with which imposes substantial costs on us. Of particular importance are the provisions summarized as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal laws (including the federal FCA) that prohibit entities and individuals from knowingly and willfully (or with reckless disregard or deliberate ignorance) presenting or causing to be presented false or fraudulent claims to Medicare, Medicaid and other government-funded programs, or improperly retaining known overpayments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When an entity is determined to have violated the federal FCA, it must pay three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,363 and $23,331 for each separate false claim. Suits filed under the federal FCA can be brought directly by the government or be brought by an individual (known as a &#8220;relator&#8221; or, more commonly, as a &#8220;whistleblower&#8221;) on behalf of the government, known as &#8220;qui tam&#8221; actions. Relators bringing qui tam actions under the federal FCA receive a share of any amounts paid by the entity to the government in fines or settlement. In addition, certain states have enacted laws modeled after the federal FCA. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, even before the validity of the claim is established and even if the government decides not to intervene in the lawsuit. Healthcare entities may decide to agree to large settlements with the government and/or whistleblowers to avoid the cost and negative publicity associated with litigation. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA amended federal law to provide that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil FCA. Criminal prosecution is possible for knowingly making or presenting a false or fictitious or fraudulent claim to the federal government. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a provision of the Social Security Act, commonly referred to as the federal &#8220;anti-kickback&#8221; statute, that prohibits the knowing and willful offer, payment, solicitation or receipt of any remuneration, including a bribe, kickback, rebate, directly or indirectly, in cash or in kind, in return for the referral, arrangement for, or recommendation of patients for, or for the purchasing, leasing, ordering or arranging for, items and services for which payment may be made, in whole or in part, by federal healthcare programs, such as Medicare and Medicaid; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments, and providing anything at less than its fair market value. Due to the broad sweep of the federal anti-kickback statute, Congress established certain exceptions to the definition of remuneration under the statute and also authorized the HHS Office of the Inspector General to issue regulations, commonly known as safe harbors, that remove certain arrangements from the definition of remuneration under the statute, provided that the arrangement satisfies, in their entirety, the provisions of the particular exception or safe harbor. Meeting a statutory exception or regulatory safe harbor under the federal anti-kickback statute will assure parties to the arrangement that they will not be prosecuted under the federal anti-kickback statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor element may result in increased scrutiny by government enforcement authorities or invite litigation by private citizens under state or federal false claims statutes. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our relationships with referral sources, including GHC Program patients, are subject to scrutiny under the federal anti-kickback statute and must be structured in a manner to promote compliance. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The penalties for violating the federal anti-kickback statute include imprisonment for up to ten years, fines of up to $100,000 per violation and possible exclusion from federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items and services reimbursed by any source, not only by the government programs such as Medicare and Medicaid. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a provision of the Social Security Act, the federal Physician Self-Referral Law, commonly referred to as the Stark Law, that, subject to certain exceptions, prohibits physicians from making a referral to an entity for certain &#8220;designated health services&#8221; or &#8220;DHS&#8221; payable by Medicare if the physician, or an immediate family member of the physician, has a direct or indirect financial relationship (including ownership interests and compensation arrangements) with the entity. The Stark Law also prohibits such an entity from presenting or causing to be presented a claim to Medicare for DHS provided pursuant to a prohibited referral, and provides that certain collections related to any such claims must be refunded in a timely manner. Although the Stark Law is drafted to apply only to Medicare claims, the DOJ has taken the position that it applies to Medicaid claims under an extension of the federal FCA and several courts, including courts in Florida and Texas, have agreed. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Stark Law is a strict liability statute and therefore, any referrals for Medicare DHS pursuant to a financial relationship that does not meet an exception will be nonpayable and subject to refund to Medicare. In addition, any Medicare &#8220;overpayment&#8221; (that is, Medicare funds to which a person is not entitled) must be returned within 60 days of identification&#8212;or risk liability under the FCA&#8217;s &#8220;obligation&#8221; provision. Therefore, claims relating to Stark Law violations must be timely refunded to Medicare or we would risk liability under the federal FCA. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our relationships with referring physicians will implicate the Stark Law, including our ownership, physician employment, independent contractor physicians, lease arrangements with physicians, nonmonetary compensation to physicians, and our relationships with hospitals and other entities. Each such financial relationship must satisfy a Stark Law exception. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Because our practices provide DHS within the practice (e.g., outpatient drugs, laboratory services, etc.), an exception to the Stark Law must be met with respect to those referrals. Generally, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Office</div> Ancillary Services (&#8220;IOAS&#8221;) Exception is utilized for referrals of DHS made within a physician&#8217;s group practice. Alternatively, the Physician Services Exception could also be used to shield referrals of physician services within a physician group. In order to utilize both the IOAS Exception and the Physician Services Exception, the group must, among other things, satisfy the </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stark Law&#8217;s definition of a &#8220;group practice.&#8221; The group practice definition also encompasses how a physician practice may compensate its physician shareholders, employees, and independent contractors. For example, group practices are not permitted to distribute profits derived from DHS based directly on the volume or value of referrals. However, there are a number of ways that a group practice can distribute profits, including DHS profits, to its physicians, based indirectly upon referrals, without running afoul of the Stark Law. Our ancillary services revenues must be allocated in a compliant manner to avoid falling outside of the Group Practice definition, which would result in all of our Medicare (and potentially, Medicaid) DHS referral revenues becoming nonpayable and subject to refund. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Violations of the Stark Law result in civil penalties and program exclusions for knowing violations, civil assessment of up to three times the amount claimed. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Another federal law, the Civil Monetary Penalties Law (&#8220;CMPL&#8221;) provides for additional civil monetary penalties against an entity that engages in prohibited activities including but not limited to violations of the Stark or Anti-Kickback laws, knowing submission of a false or fraudulent claim, employment of an excluded individual and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence beneficiary selection of a particular provider for which payment may be made in whole or in part by Medicare or Medicaid; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Remuneration&#8221; is defined under the CMPL as any transfer of items or services for free or for less than fair market value. There are certain exceptions to the definition of remuneration for offerings that meet the Financial Need, Preventative Care, or Promoting Access to Care exceptions. Sanctions for violations of the CMPL include civil monetary penalties and administrative penalties up to and including exclusion from participation in federal healthcare programs. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">similar state law provisions pertaining to anti-kickback, fee splitting, self-referral and false claims, and other fraud and abuse issues which typically are not limited to relationships involving government-funded programs. In some cases these laws prohibit or regulate additional conduct beyond what federal law affects, including applicability to items and services paid by commercial insurers and private pay patients. Penalties for violating these laws can range from fines to criminal sanctions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provisions of 18 U.S.C. &#167;&#160;1347 that prohibit knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing or covering up a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal and state regulations that broadly define provider and supplier affiliation and require providers to disclose to GHC Programs certain disclosable events including, without limitation, current or previous direct or indirect affiliations with providers or suppliers having uncollected debt to GHC Programs, being subject to payment suspension, being excluded from participation in GHC Programs or had such billing privileges denied or revoked, and that permit GHC Programs to deny or revoke provider or supplier enrollment based upon such affiliations upon determining that the affiliations pose an undue risk of fraud, waste, or abuse; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal and state laws related to confidentiality, privacy and security of personal information such as HIPAA, including medical information and records, that limit the manner in which we may use and disclose that information, impose obligations to safeguard that information and require that we notify third parties in the event of a breach; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA violations can result in both civil monetary penalties and criminal sanctions. HIPAA has ranges of increasing minimum penalty amounts tiered according to the entity&#8217;s degree of culpability, with a maximum penalty of $1,500,000 for all violations of an identical provision within a year. Further, HHS has obtained increasingly high dollar settlements from covered entities relating to HIPAA violations over the past several years. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unsecured Breaches of PHI may also result in unexpected costs in the millions of dollars to us through third party litigation, contractual breaches, and breach notification and remediation. In addition, we may experience reputational harms and a negative market perception when it comes to protecting patient data that could influence our future operations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">state laws that prohibit general business corporations from practicing medicine, controlling physicians&#8217; medical decisions or engaging in certain practices, such as splitting fees with physicians; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal and state laws governing participation in GHC Programs could result in denial of our application to become a participating provider or revocation of our participation or billing privileges, which in turn, could cause us to not be able to treat patients covered by the applicable program or prohibit us from billing for the treatment services provided to such patients; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal and state laws that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented and billed using codes that accurately reflect the services rendered; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">federal and state laws pertaining to the provision and coverage of services by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-physician</div> practitioners, such as advanced nurse practitioners, physician assistants and other clinical professionals, physician supervision of such services and reimbursement requirements that may be dependent on the manner in which the services are provided and documented; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal laws that impose civil administrative sanctions for, among other violations, inappropriate billing of services to federal healthcare programs, inappropriately reducing hospital inpatient lengths of stay for such patients or employing individuals who are excluded from participation in federally funded healthcare programs. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we believe that our business will continue to be subject to increasing regulation, the scope and effect of which we cannot predict. See Item 1. Business&#8212;&#8220;Government Regulation.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may in the future become the subject of regulatory or other investigations, audits or proceedings, and our interpretations of applicable laws, rules and regulations may be challenged. For example, regulatory authorities or other parties may assert that our arrangements with our affiliated professional entities constitute fee splitting or the corporate practice of medicine and seek to invalidate these arrangements, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. See Item 1. Business&#8212;&#8220;Government Regulation&#8212;Fee Splitting; Corporate Practice of Medicine.&#8221; Regulatory authorities or other parties also could assert that our relationships, including fee arrangements, among our affiliated professional contractors, hospital clients or referring physicians violate the anti-kickback, fee splitting or self-referral laws and regulations or that we have submitted false claims or otherwise failed to comply with government program reimbursement requirements. See Item 1. Business&#8212;&#8220;Government Regulation&#8212;Fraud and Abuse Provisions&#8221; and &#8220;&#8212;Government Regulatory Requirements.&#8221; Such investigations, proceedings and challenges could result in substantial defense costs to us and a diversion of management&#8217;s time and attention. In addition, violations of these laws are punishable by monetary fines, civil and criminal penalties, exclusion from participation in GHC Programs, and forfeiture of amounts collected in violation of such laws and regulations, any of which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Additionally, federal and state fraud and abuse laws, rules and regulations are not static and amendments, clarifications, revisions, or other modifications to these laws may occur from time to time. For instance, on December&#160;2, 2020, both CMS and the Department of Health and Human Services Office of Inspector General (&#8220;OIG&#8221;) issued Final Rules revising the federal anti-kickback statute, the CMPL, and the Stark Law regulations to foster arrangements that would promote care coordination, advance the delivery of value-based care, and protect consumers from harms caused by fraud and abuse through additional new statutory definitions, safe harbors, and exceptions. Both current and future arrangements may be eligible for additional protections under new exceptions and safe harbors and certain arrangements may need to be reconsidered in light of changes made to existing exceptions, safe </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">harbors, and agency definitions. Compliance with federal fraud and abuse laws such as the anti-kickback statute, the CMPL, and the Stark Law involves constant monitoring for regulatory changes, agency and court interpretations, and revisiting of arrangements based on new interpretations or clarifications, all of which will require ongoing compliance costs. In addition, these laws and their exceptions and safe harbors are complex and clear interpretations are not always available. Despite our efforts to comply, we cannot guarantee that a government agency will necessarily agree with our interpretations or that one or more of our arrangements will not be subject to challenge, nor can we provide any assurance that they will not have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities or other parties may assert that our business practices violate antitrust laws. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is subject to close antitrust scrutiny. The FTC, the Antitrust Division of the DOJ and state Attorneys General all actively review and, in some cases, take enforcement action against business conduct and acquisitions in the healthcare industry. Private parties harmed by alleged anticompetitive conduct can also bring antitrust suits. Violations of antitrust laws may be punishable by substantial penalties, including significant monetary fines and treble damages, civil penalties, criminal sanctions, and consent decrees and injunctions prohibiting certain activities or requiring divestiture or discontinuance of business operations. Any of these penalties could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our affiliated physicians and other individual providers may not satisfy all conditions of payment or otherwise appropriately record or document services that they provide. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our affiliated physicians and other individual providers are responsible for maintaining all required professional licensures or certifications in good standing, which is generally a condition of reimbursement in GHC Programs, and for appropriately recording and documenting the services that they provide. We use this information to seek reimbursement for their services from third-party payors. In addition, we utilize third-party contractors to perform certain revenue cycle management functions for healthcare providers, including medical coding. If our affiliated physicians or other individual providers and third-party contractors do not appropriately document, or where applicable, code for their services or our customers&#8217; services, we could be subjected to administrative, regulatory, civil, or criminal investigations or sanctions and our business, financial condition, results of operations and cash flows could be materially adversely affected. We are further obligated under the federal FCA to timely report and return any identified overpayments and to maintain reasonable internal audit mechanisms to identify overpayments. Failure to timely report and return overpayments to Medicare or Medicaid could subject us to liability under the federal FCA, and also equivalent false claims acts on the state level. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business Strategy </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not find suitable acquisition candidates or successfully integrate our acquisitions. Our acquisitions may expose us to greater business risks and could affect our payor mix. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have expanded and continue to seek to expand our presence in new and existing metropolitan areas by acquiring established physician group practices. Also, both independently and in collaboration with our hospital partners, we may seek to expand into new specialties and subspecialties. In addition, we have acquired physician and other healthcare services companies that are complementary to our physician practices. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our acquisition strategy involves numerous risks and uncertainties, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to identify suitable acquisition candidates or strategic opportunities or implement successfully or realize the expected benefits of any suitable opportunities. In addition, we compete for acquisitions with other potential acquirers, some of which may have greater financial or operational resources than we do. This competition may intensify due to the ongoing consolidation in the healthcare industry, which may increase our acquisition costs. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to complete acquisitions of physician practices or services companies or we may complete acquisitions on less favorable terms as a result of changes in tax laws, healthcare fraud and abuse laws, financial market or other economic or market conditions. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to successfully integrate completed acquisitions, including our recent acquisitions. Integrating completed acquisitions into our existing operations involves numerous short-term and long-term risks, including diversion of our management&#8217;s attention, failure to retain key personnel, long-term value of acquired intangible assets and acquisition expenses. In addition, we may be required to comply with laws, rules and regulations that may differ not only from those of the states in which our operations are currently conducted but from an expansion in the service offerings we provide in certain states for which the laws, rules and regulations may be different. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We cannot be certain that any acquired business will continue to maintain its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> revenue and growth rates or be financially successful. In addition, we cannot be certain of the extent of any unknown or contingent liabilities of any acquired business, including liabilities for failure to comply with applicable laws, or liabilities relating to medical malpractice claims. Generally, we obtain indemnification agreements from the sellers of businesses acquired with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> acts, omissions and other similar risks. It is possible that we may seek to enforce indemnification provisions in the future against sellers who may no longer have the financial wherewithal to satisfy their obligations to us. Accordingly, we may incur material liabilities for past activities of acquired businesses. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We could incur or assume indebtedness and issue equity in connection with acquisitions. The issuance of shares of our common stock for an acquisition may result in dilution to our existing shareholders and, depending on the number of shares that we issue, the resale of such shares could affect the trading price of our common stock. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may acquire businesses that derive a greater portion of their revenue from GHC Programs than what we recognize on a consolidated basis or that have business models with lower operating margins than ours. These acquisitions could affect our overall payor mix or operating results in future periods. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions of practices and services companies could entail financial and operating risks not fully anticipated. Such acquisitions could divert management&#8217;s attention and our resources. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An acquisition could be subject to a challenge under the antitrust laws either before or after it is consummated. Such a challenge could involve substantial legal costs and divert management&#8217;s attention and resources and could result in us having to abandon the transaction or make a divestiture. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not successful in integrating an acquisition, we may decide to dispose of such acquisition and may do so at a loss or record impairments in connection with such a disposition, such as in our disposition of our anesthesiology and radiology medical groups in 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to successfully execute our same-unit and organic growth strategies. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to our acquisition growth strategy, we seek opportunities for increasing revenue from our existing operations through same-unit and organic growth strategies. We also seek opportunities to grow organically outside of our existing operations. We may not be able to successfully execute our same-unit and organic growth strategies for reasons including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to expand the services that our affiliated physicians provide to our hospital partners or the services provided by our services companies to their customers. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to attract referrals to our office-based practices or neonatology transports to our hospital-based units. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to execute new contractual arrangements with hospitals, including through joint ventures, where we either currently provide or do not currently provide physician services. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to work with our hospital partners to develop integrated services programs for which we become a multi-specialty provider of solutions within the maternal-fetal, newborn, pediatric continuum of care. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not accurately project same-unit and organic growth performance, or we may experience a shift in the mix of services that certain of our customers request from us, potentially resulting in lower margins. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, certain of our organic growth strategies may involve risks and uncertainties similar to those for our acquisition strategy. See &#8220;We may not find suitable acquisition candidates or successfully integrate our acquisitions. Our acquisitions may expose us to greater business risks and could affect our payor mix.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not effectively manage our growth. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have historically experienced significant growth in our business, including growth outside of our core physician specialties. Growth in the number of our employees and affiliated physicians has in the past placed significant demands on our financial, operational and management resources. Significant growth may impair our ability to provide our services efficiently and to manage our employees adequately. While we are taking steps to manage our growth, our future results of operations could be adversely affected if we are unable to do so effectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to manage third-party service providers may adversely affect our ability to maintain the quality of service that we provide. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We outsource a certain portion of our revenue cycle management functions to third-party service providers, but we may increase the amount of revenue cycle management functions we outsource in the future. These functions are performed both domestically and in offshore locations, with our oversight. If our outsourcing partners fail to perform their obligations in a timely manner at satisfactory quality levels, in compliance with regulatory requirements, or if they are unable to attract or retain sufficient personnel with the necessary skill sets to meet our outsourcing needs, the efficiency, effectiveness and quality of our services could suffer. In addition, our reliance on a workforce in other countries exposes us to disruptions in the business, political and economic environment in those regions. Further, any changes to existing laws or the enactment of new legislation restricting offshore outsourcing in the United States may adversely affect our ability to outsource functions to third-party offshore service providers. Our ability to manage any difficulties encountered could be largely outside of our control. In addition, federal government and third-party payors may have prohibitions or restrictions on the use of third-party service providers outside of the United States and/or require notice for the use of such third-party service providers. Diminished service quality from outsourcing, our inability to utilize offshore service providers or the failure to comply with restrictions on the use of third-party service providers could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospitals or other customers may terminate their agreements with us, our physicians may lose the ability to provide services in hospitals or administrative fees paid to us by hospitals may be reduced. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our net revenue is derived primarily from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> billings for patient care and other services provided by our affiliated physicians and from administrative fees paid to us by hospitals. See Item 1. Business&#8212;&#8220;Relationships with Our Partners&#8212;Hospitals.&#8221; Our hospital partners or other customers may cancel or not renew their contracts with us, may reduce or eliminate our administrative fees in the future, or refuse to pay us our administrative fees if we fail to honor the terms of our agreement or fail to meet certain performance metrics under those agreements. Further, consolidation of hospitals, healthcare systems or other customers could adversely affect our ability to negotiate with these entities. Adverse economic conditions, including decreased federal and state funding to hospitals, could influence future actions of our hospital partners or other customers. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that our arrangements with our hospital partners or other customers are canceled, or are not renewed or replaced with other arrangements having at least as favorable terms, our business, financial condition and results of operations could be adversely affected. In addition, to the extent our affiliated physicians lose their privileges in hospitals or hospitals enter into arrangements with or employ other physicians, including our existing affiliated physicians, our business, financial condition, results of operations and cash flows could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Operating our Business </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are dependent upon our key management personnel for our future success. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends to a significant extent on the continued contributions of our key management personnel for the management of our business and implementation of our business strategy. We experienced significant management turnover in 2020 and the further loss of or changes in key management personnel could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our quarterly results will likely fluctuate from period to period. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have historically experienced and expect to continue to experience quarterly fluctuations in net revenue and net income. For example, we typically experience negative cash flow from operations in the first quarter of each year, principally as a result of bonus payments to affiliated physicians as well as discretionary matching contributions for participants in our qualified contributory savings plans. In addition, a significant number of our employees and associated professional contractors (primarily affiliated physicians) exceed the level of taxable wages for social security contributions during the first and second quarters. As a result, we incur a significantly higher payroll tax burden and our net income is lower during those quarters. Moreover, a lower number of calendar days are present in the first and second quarters of the year as compared to the remainder of the year. Because we provide services in the NICU on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hours-a-day</div></div></div> basis, 365 days a year, any reduction in service days will have a corresponding reduction in net revenue. In addition, any reduction in office days in our office-based practices will also have a corresponding reduction in net revenue. We also have significant fixed operating costs, including costs for our affiliated physicians, and as a result, are highly dependent on patient volume and capacity utilization of our affiliated physicians to sustain profitability. Quarterly results may also be impacted by the timing of acquisitions and any fluctuation in patient volume. As a result, our results of operations for any quarter are not indicative of results of operations for any future period or full fiscal year. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">We may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> intangible assets, such as goodwill. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of our intangible assets, which consists primarily of goodwill related to our acquisitions, is subject to testing at least annually, and more frequently if impairment indicators exist. Under current accounting standards, goodwill is tested for impairment on an annual basis and we have been subject to impairment losses as circumstances have changed after acquisition. If we record additional impairment losses related to our goodwill in the future, it could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to medical malpractice and other lawsuits that may not covered by insurance. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business entails an inherent risk of claims of medical malpractice against our affiliated physicians and us. We may also be subject to other lawsuits which may involve large claims and significant defense costs. Although we currently maintain liability insurance coverage intended to cover professional liability and other claims, there can be no assurance that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us where the outcomes of such claims are unfavorable to us. Generally, we self-insure our liabilities to pay retention amounts for professional liability matters through a wholly owned captive insurance </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. See Item 1. Business&#8212;&#8220;Other Legal Proceedings&#8221; and&#8212; &#8220;Professional and General Liability Coverage.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reserves that we have established related to our professional liability losses are subject to inherent uncertainties and if actual costs exceed our estimates this may lead to a reduction in our net earnings. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have established reserves for losses and related expenses that represent estimates involving actuarial projections. These actuarial projections are developed at a given point in time and represent our expectations of the ultimate resolution and administration of costs of losses incurred with respect to professional liability risks for the amount of risk retained by us. Insurance reserves are inherently subject to uncertainty. Our reserve estimates are based on actuarial valuations using historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions. The estimates of projected ultimate losses are developed at least annually. Our reserves have been, and could further be, significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating reserves, the complexity of the claims and wide range of potential outcomes often hamper timely adjustments to the assumptions used in these estimates. Actual losses and related expenses may deviate, perhaps substantially, from the reserve estimates reflected in our financial statements. If our estimated reserves are determined to be inadequate, we have been and could further be required to increase reserves at the time the deficiency is determined. See Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;&#8220;Application of Critical Accounting Policies and Estimates&#8212;Professional Liability Coverage.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to litigation risks. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we are involved in various litigation matters and claims, including regulatory proceedings, administrative proceedings, governmental investigations, and contract disputes, as they relate to our services and business. We may face potential claims or liability for, among other things, breach of contract, defamation, libel, fraud, negligence or data breaches. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also face employment-related litigation, including claims of age discrimination,&#160;sexual harassment, gender discrimination, immigration violations, or other local, state, and federal labor law violations. Because of the uncertain nature of litigation and insurance coverage decisions, the outcome of such actions and proceedings cannot be predicted with certainty and an unfavorable resolution of one or more of them could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. In addition, legal fees and costs associated with prosecuting and defending litigation matters could have an adverse effect on our business, financial condition, results of operation and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to collect reimbursements for our services from third-party payors. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our net revenue is derived from reimbursements from various third-party payors, including GHC Programs, private insurance plans and managed care plans, for services provided by our affiliated professional contractors. We are responsible for submitting reimbursement requests to these payors and collecting the reimbursements, and we assume the financial risks relating to uncollectible and delayed reimbursements. In the current healthcare environment, payors continue efforts to control expenditures for healthcare, including revisions to coverage and reimbursement policies. Due to the nature of our business and our participation in government-funded and private reimbursement programs, we are involved from time to time in inquiries, reviews, audits and investigations by governmental agencies and private payors of our business practices, including assessments of our compliance with coding, billing and documentation requirements. We may be required to repay these agencies or private payors if a finding is made that we were incorrectly reimbursed within a certain time period (60 days for government payors), or we may become involved in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">disputes with payors and could be subjected to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-payment</div> and post-payment reviews, which can be time-consuming and result in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> or delayed payment for the services we provide. We may also experience difficulties in collecting reimbursements because third-party payors may seek to reduce or delay reimbursements to which we are entitled for services that our affiliated physicians have provided, they experience administrative issues that result in a delay in reimbursements, or pursuant to binding arbitration proceedings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> items or services. In addition, GHC Programs may deny or revoke our application to become a participating provider if we do not disclose certain events relating to our affiliates or for other reasons that could cause us to not be able to provide services to patients or prohibit us from billing for such services. If we are not reimbursed fully or in a timely manner for such services or there is a finding that we were incorrectly reimbursed, our revenue, cash flows and financial condition could be materially, adversely affected. In addition, we may choose to challenge certain GHC reimbursement decisions through administrative appeal mechanisms. Currently, many of those appeal pathways are backlogged and slow to provide resolution, further affecting our ability to collect reimbursement for services rendered. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, adverse economic conditions could affect the timeliness and amounts received from our third-party and government payors which would impact our short-term liquidity needs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Capital Structure </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current indebtedness and any future indebtedness could adversely affect us by reducing our flexibility to respond to changing business and economic conditions and expose us to interest rate risk to the extent of any variable rate debt. In addition, a certain portion of our interest expense may not be deductible. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, our total indebtedness was $1.75&#160;billion, all of which was at fixed interest rates, of which $0.75&#160;billion was repaid in January 2021. We also had $900.0&#160;million of additional borrowing capacity under our revolving line of credit which was subject to a variable interest rate. Other debt we incur also could be variable rate debt. In addition, the Tax Cuts and Jobs Act of 2017 places certain limitations on the deductibility of interest expense at a percentage of taxable income. If interest rates increase, any variable rate debt will create higher debt service requirements, and if interest expense increases beyond a specified percentage of taxable income, a portion of that interest expense may not be deductible for income tax purposes, which could adversely affect our results of operations and cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited restrictions on incurring substantial additional indebtedness in the future. Our current indebtedness and any future increases in leverage could have adverse consequences on us, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a substantial portion of our cash flow from operations will be required to service interest and principal payments on our debt and will not be available for operations, working capital, capital expenditures, expansion, acquisitions, dividends or general corporate or other purposes; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain additional financing in the future may be impaired; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be more highly leveraged than our competitors, which may place us at a competitive disadvantage; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our flexibility in planning for, or reacting to, changes in our business and industry may be limited; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be more vulnerable in the event of a downturn in our business, our industry or the economy in general. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to make payments on and to refinance our debt will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, business, financial, competitive, legislative, regulatory, and other factors that are beyond our control. We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available under our revolving line of credit in an amount sufficient to enable us to pay our debt or to fund our other liquidity needs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in other defaults, disrupt our operations and cause a reduction of our credit rating, which could further harm our ability to finance or refinance our obligations and business operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our cash flows and capital resources are insufficient to fund our debt service requirements, we may be forced to reduce or delay acquisitions or other investments, or to seek additional capital, or restructure or refinance our indebtedness. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. We cannot assure you that we will be able to refinance any of our debt, including our revolving line of credit and senior notes, on commercially reasonable terms or at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions of our articles and bylaws could deter takeover attempts, but our business could be negatively affected as a result of shareholder activism. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Amended and Restated Articles of Incorporation, as amended, authorize our Board of Directors to issue up to 1,000,000 shares of undesignated preferred stock and to determine the powers, preferences and rights of these shares without shareholder approval. This preferred stock could be issued with voting, liquidation, dividend and other rights superior to those of the holders of common stock. The issuance of preferred stock under some circumstances could have the effect of delaying, deferring or preventing a change in control. In addition, provisions in our Amended and Restated Articles of Incorporation, as amended, and Bylaws, including those relating to calling shareholder meetings, taking action by written consent and other matters, could render it more difficult or discourage an attempt to obtain control of Mednax through a proxy contest or consent solicitation, however, there is no assurance that these provisions would have such an effect. These provisions could limit the price that some investors might be willing to pay in the future for our shares of common stock. Notwithstanding these provisions, we could, and have, become the target of activist shareholders who acquire ownership positions in our common stock and seek to influence our company. Responding to actions by activist shareholders can be costly and time-consuming, disrupt our business and divert the attention of our Board of Directors, management and employees. Additionally, perceived uncertainties as to our future direction, including the composition of our Board of Directors, as a result of shareholder activism may lead to the perception of a change in the direction of our business or other instability, which may be exploited by our competitors, cause concern to our current or potential customers and acquisition candidates, and make it more difficult for us to attract and retain qualified personnel, which could have a material adverse effect on our business, financial condition, results of operations, and cash flows and the trading prices of our securities. In addition, the trading prices of our securities may experience periods of increased volatility as a result of shareholder activism. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Labor </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to successfully recruit, onboard and retain qualified physicians and other clinicians and other personnel, and our compensation expense for existing clinicians and other personnel may increase. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are dependent upon our ability to recruit and retain a sufficient number of qualified physicians and other clinicians and other personnel to service existing units at hospitals and our affiliated practices and expand our business. We compete with many types of healthcare providers, including teaching, research and government institutions, hospitals and health systems and other practice and services groups, for the services of qualified clinicians. We may not be able to continue to recruit new clinicians or other personnel or renew contracts with existing clinicians or other personnel on acceptable terms. We have and may seek to renew clinician contracts prior to their existing renewal date for various reasons, including to move clinicians to a different compensation structure. We may not be successful in these early renewal efforts, and further, clinical compensation may increase as a result of incremental compensation incentives that may be required by clinicians to agree to the change in compensation structure. In addition, the recruiting and onboarding process for certain of our physicians and other clinicians can take several months, or longer, to complete due to various requirements, including state </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">licensing and hospital credentialing. In addition, if the demand exceeds the supply for physicians and other clinicians and personnel either in general or in specific markets, we could experience an increase in compensation expense, including premium pay and agency labor costs. If we are unable to recruit new physicians, renew contracts on acceptable terms or onboard physicians, clinicians and other personnel in a reasonable period of time, our ability to service existing or new hospital units and staff existing or new office-based practices could be adversely affected. In addition, if we experience a higher rate of growth in compensation expense, our business, financial condition, results of operations, cash flows and the trading price of our securities could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">A significant number of our affiliated physicians or other clinicians could leave our affiliated practices or our affiliated professional contractors may be unable to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> covenants of departed physicians. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our affiliated professional contractors usually enter into employment agreements with our affiliated physicians. Certain of our employment agreements can be terminated without cause by any party upon prior written notice. In addition, substantially all of our affiliated physicians have agreed not to compete within a specified geographic area for a certain period after termination of employment. The law governing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreements and other forms of restrictive covenants varies from state to state. Although we believe that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and other restrictive covenants applicable to our affiliated physicians are reasonable in scope and duration and therefore enforceable under applicable state law, courts and arbitrators in some states may be reluctant to enforce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreements and restrictive covenants against physicians. In addition, we have and may incur significant legal fees to pursue enforcement of such agreements and restrictive covenants. Our affiliated physicians or other clinicians may leave our affiliated practices for a variety of reasons, including in order to provide services for other types of healthcare providers, such as teaching, research and government institutions, hospitals and health systems and other practice groups. If a substantial number of our affiliated physicians or other clinicians leave our affiliated practices, we could incur significant legal fees to pursue enforcement of certain covenants within employment agreements or if our affiliated professional contractors are unable to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> covenants in the employment agreements, our business, financial condition, results of operations and cash flows could be adversely affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Information Systems, Cybersecurity and Data Privacy Risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to maintain effective and efficient information systems or properly safeguard our information systems. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operations are dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including errors and delays in billings and collections, difficulty satisfying requirements under hospital contracts, disputes with patients and payors, violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, information security risks have generally increased in recent years, and in particular during <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business or financial information. Despite our layered security controls, experienced computer programmers and hackers have been and may be able to penetrate our information systems and may have and may be able to misappropriate or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions, including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing or other tactics. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A failure in or breach of our information systems as a result of cyber-attacks or other tactics could disrupt our business, has and may result in the release or misuse of PHI, confidential or proprietary business information, and has or may cause financial loss, damage our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or individuals. Although we believe that we have reasonable and appropriate information security procedures and other safeguards in place, which are monitored and routinely tested internally and by external parties, as cyber threats continue to evolve, we have been and may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential customers and disruption of our operations, including, without limitation, our billing processes. In addition, breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary or confidential information about us, our patients, clients or customers, or other third-parties, could expose such persons&#8217; personal information to the risk of financial or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, have resulted in litigation and potential liability for us, and could damage our brand and reputation or otherwise harm our business. Additionally, under certain circumstances, we could be excluded temporarily or permanently from certain commercial or GHC Programs. Any of these disruptions or breaches of security could have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience difficulties implementing new technology, software and processes. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are engaged in various implementation efforts for new technology, software and processes, including cloud-based solutions for an enterprise resource planning system (&#8220;ERP&#8221;) and telehealth support, among others. These solutions are designed to provide greater efficiency and flexibility across our enterprise. The ERP cloud-based solution implementation will require significant investments of human and financial resources. In implementing this and other solutions, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of these solutions could adversely affect our ability to operate our business. While we have invested significant resources in planning and project management, unforeseen implementation issues may arise. In addition, our efforts to centralize various business processes and functions within our organization in connection with our system implementations may disrupt our operations. Any implementation issues or business operation disruptions could have a material effect on our business, financial condition, results of operations, cash flows, internal controls over financial reporting and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospitals could limit our ability to use our management information systems in our units by requiring us to use their own management information systems. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our management information systems are used to support our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations and ongoing clinical research and business analysis. If a hospital prohibits us from using our own management information systems, it may interrupt the efficient operation of our information systems which, in turn, may limit our ability to operate important aspects of our business, including billing and reimbursement as well as research and education initiatives. This inability to use our management information systems at hospital locations may have an adverse effect on our business, financial condition, results of operations and cash flows. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal and state laws that protect the privacy and security of personal information may increase our costs and limit our ability to collect and use that information and subject us to liability if we are unable to fully comply with such laws. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerous federal and state laws, rules and regulations govern the collection, dissemination, use, security and confidentiality of personal information, including individually identifiable health information. These laws include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions of HIPAA that limit how covered entities and business associates may use and disclose PHI, provide certain rights to individuals with respect to that information and impose certain security requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HITECH, which required the OCR to strengthen and expand the HIPAA Privacy Rule and Security Rule and imposes data breach notification obligations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other federal and state laws restricting the use and protecting the privacy and security of personal information, including health information, many of which are not preempted by HIPAA, and certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities, such as the California Consumer Protection Act (CCPA), as amended by the California Privacy Rights Act; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal and state consumer protection laws, including the Federal Trade Commission&#8217;s authority under Section&#160;5; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal and state laws regulating the conduct of research with human subjects. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our business operations, including our medical record keeping, third-party billing, research and other services, we collect and maintain PHI in paper and electronic format. Standards related to health information, whether implemented pursuant to HIPAA, HITECH, state laws, federal or state action or otherwise, could have a significant effect on the manner in which we handle personal information, including PHI, and communicate with payors, providers, patients and others, and compliance with these standards could impose significant costs on us or limit our ability to offer services, thereby negatively impacting the business opportunities available to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to the laws above, we may see more stringent state and federal privacy legislation in 2021 and beyond, including potential changes to HIPAA or the enactment of a federal privacy law, as the increased cyber-attacks during <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> have once again put a spotlight on data privacy and security in the U.S. and other jurisdictions. We cannot predict where new legislation might arise, the scope of such legislation, or the potential impact to our business and operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are alleged to not comply with existing or new laws, rules and regulations related to PHI or other personal information we could be subject to litigation and to sanctions that include monetary fines, civil or administrative penalties, civil damage awards or criminal penalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Competition and Consolidation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our industry is highly competitive. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry is highly competitive and subject to continual changes in the methods by which services are provided and the manner in which healthcare providers are selected and compensated. Because our operations consist primarily of physician services provided within hospital-based units, we compete with other healthcare services companies and physician groups for contracts with hospitals to provide our services to patients. We also face competition from hospitals themselves to provide our services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, consolidation within the healthcare industry could strengthen certain competitors that provide services to hospitals and other customers. Companies in other healthcare industry segments, some of which have </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">greater financial and other resources than ours, may become competitors in providing neonatal, maternal-fetal or other pediatric subspecialty care. Additionally, we face competition from healthcare-focused and other private equity firms. We may not be able to continue to compete effectively in this industry, additional competitors may enter metropolitan areas where we operate, and this increased competition may have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_4" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNRESOLVED STAFF COMMENTS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_5" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PROPERTIES </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our two corporate office buildings, which we own, are located in Sunrise, Florida and contain 260,000 square feet of office space. We also lease space in hospitals and other facilities for our business and medical offices, and other needs. We believe that our facilities and the equipment used in our business are in good condition, in all material respects, and sufficient for our present needs. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_6" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL PROCEEDINGS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The information required by this Item is included in and incorporated herein by reference to Item 1. Business of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> under &#8220;Government Investigations&#8221; and &#8220;Other Legal Proceedings.&#8221; </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_7" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MINE SAFETY DISCLOSURES </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc51794_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_9" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is traded on the New York Stock Exchange (the &#8220;NYSE&#8221;) under the symbol &#8220;MD.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;12, 2021, we had 208 holders of record of our common stock, and the closing sales price on that date for our common stock was $28.25 per share. We believe that the number of beneficial owners of our common stock is greater than the number of record holders because a significant number of shares of our common stock is held through brokerage firms in &#8220;street name.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We did not declare or pay any cash dividends on our common stock in 2020, 2019, or 2018. The payment of any future dividends will be at the discretion of our Board of Directors and will depend upon, among other things, future earnings, results of operations, capital requirements, our general financial condition, general business conditions and contractual restrictions on payment of dividends, if any, as well as such other factors as our Board of Directors may deem relevant. Our credit agreement (the &#8220;Credit Agreement&#8221;) imposes certain limitations on our ability to declare and pay cash dividends. See Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;&#8220;Liquidity and Capital Resources.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Graph </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following graph compares the cumulative total shareholder return on $100 invested on December&#160;31, 2015 in our common stock against the cumulative total return of the S&amp;P 500 Index, S&amp;P 600 Health Care Index, and the NYSE Composite Index. The returns are calculated assuming reinvestment of dividends. The graph covers the period from December&#160;31, 2015 through December&#160;31, 2020. The stock price performance included in the graph is not necessarily indicative of future stock price performance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference this annual report into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g51794g85y35.jpg" style="width: 410px; height: 246px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Base&#160;Period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company/Index</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2016</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mednax, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;P 500 Index</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109.54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;P 600 Health Care</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NYSE Composite Index</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">143.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuer Purchases of Equity Securities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended December&#160;31, 2020, we did not repurchase any shares of our equity securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Sales of Unregistered Equity Securities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended December&#160;31, 2020, we did not sell any unregistered shares of our equity securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Compensation Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Information regarding equity compensation plans is set forth in Item 12 of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and is incorporated herein by reference. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_10" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SELECTED FINANCIAL DATA </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following table includes selected consolidated financial data set forth as of and for each of the three years in the period ended December&#160;31, 2020 on a comparable basis. The balance sheet data at December&#160;31, 2020 and 2019, and the income statement data for the years ended December&#160;31, 2020, 2019 and 2018, have been derived from the Consolidated Financial Statements included in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> This selected financial data should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our Consolidated Financial Statements and the related notes included in Items 7 and 8, respectively, of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The selected consolidated financial data for the years ended December&#160;31, 2017 and 2016 has not been restated to present our anesthesiology services medical group and radiology services medical group that were divested on May&#160;6, 2020 and on December&#160;15, 2020, respectively, as discontinued operations and is therefore not comparable. See Note 9 to the Consolidated Financial Statements for additional information on the divestiture of our anesthesiology services and radiology services medical groups. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except per share and other operating data)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2016</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Income Statement Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733,951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,779,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723,107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,253,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,183,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,193,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,180,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,125,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,227,335</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118,416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">248,947</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">244,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">232,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385,864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372,572</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,635,819</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,608,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,474,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,798,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,611,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">248,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">571,687</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,051</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(110,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(92,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">952</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,984</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(112,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(69,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385,673</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">513,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(44,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(80,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(189,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,442</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">324,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(786,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,539,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(796,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,497,702</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">268,629</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320,372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">324,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per Common and Common Equivalent Share Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except per share and other operating data)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2016</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Operating Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Number of physicians at end of year</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Number of births</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">773,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">792,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">793,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">808,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">807,285</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NICU admissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,572</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114,864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,965</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NICU patient days</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,942,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,014,166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,977,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,990,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,977,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheet Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,123,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,698</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Working capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,105,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,565</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,347,948</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,145,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,937,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,160,065</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,339,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,600,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,646,905</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,849,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,747,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,578,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings under credit facility</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">739,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,110,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">963,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">747,717</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,498,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,087,884</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,412,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,760,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_11" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;7.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described. This discussion should be read in conjunction with our Consolidated Financial Statements and the related notes included in Item 8 of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> This discussion contains forward-looking statements. Please see the explanatory note concerning &#8220;Forward-Looking Statements&#8221; preceding Part I of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and Item 1A. Risk Factors for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. The operating results for the periods presented were not significantly affected by inflation. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OVERVIEW </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mednax is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 39 states and Puerto Rico. At December&#160;31, 2020, our national network comprised over 2,300 affiliated physicians, including 1,320 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#8220;NICUs&#8221;), to babies born prematurely or with medical complications. We have 425 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including 245 physicians providing pediatric intensive care, 100 physicians providing pediatric cardiology care, 175 physicians providing hospital-based pediatric care, 35 physicians providing pediatric surgical care and urology services, 10 physicians providing pediatric ear, nose and throat services, and five physicians providing pediatric ophthalmology services. Mednax divested its anesthesiology services medical group on May&#160;6, 2020 and its radiology medical group on December&#160;15, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by our affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, we experienced a significant decline in the number of elective surgeries at the facilities where&#160;our affiliated clinicians provided anesthesia services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology service line, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. We divested our anesthesiology and radiology services medical groups in May 2020 and December 2020, respectively, where operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our affiliated women&#8217;s and children&#8217;s office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. We believe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> either directly or indirectly, has also had an impact on our NICU patient volumes, and there is no assurance that impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not further adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business. Overall, our operating results were significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through December 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We implemented a number of actions to preserve financial flexibility and partially mitigate the significant impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to our transformational and restructuring programs, limiting these expenditures to those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;we temporarily reduced executive and key management base salaries, including 50% reductions in salaries for our named executive officers through June&#160;30, 2020; (ii) our Board of Directors agreed </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) we enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;we enacted significant operational and practice-specific expense reduction plans across our clinical operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also implemented a variety of solutions across specialties to support clinicians and patients during <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> including </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinician Shortage Support: Pediatric clinicians are lending their expertise to help fulfill the need for added adult care. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strengthening of Supply Chain: We helped to address the shortage of personal protective equipment (PPE) by partnering with vendors across industries to source high filtration respirators, surgical masks and other forms of PPE for protective use. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Expanded Virtual Care Offerings: Utilizing VSee, an internationally recognized telehealth platform, we have deployed a national multi-specialty virtual clinic to expand our telehealth offerings and make virtual care available to our clinical workforce, enabling continued patient consults and clinician collaboration while minimizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> exposure. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Early Virus Detection Using Cutting-Edge Imaging Diagnostic Tools: Our former radiology services medical group led early detection efforts through chest imaging and diagnosed one of the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the United States via chest computed tomography (&#8220;CT&#8221;), which showed findings consistent with a severe acute respiratory viral infection. In the absence of laboratory testing kits, chest CT can serve as a diagnostic tool. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Virtual Forum to Provide Clinician Support: To support frontline clinicians while abiding by social distancing recommendations, we have created a virtual doctors&#8217; lounge for clinicians across specialties to connect and socialize in the absence of typical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> lounges, helping to boost morale and preserve a sense of normalcy. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently expect that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will continue to materially impact our financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act our affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program, and our affiliated physician practices within continuing operations have received an aggregate of approximately $22.0&#160;million in relief payments during the year ended December&#160;31, 2020. We have applications pending for certain affiliated physician practices for incremental relief beyond what has been received. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. We utilized this deferral option throughout 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to conform to the current period presentation, specifically to reflect the impact of our anesthesiology and radiology services medical groups being classified as discontinued operations. See &#8211; &#8220;Divestiture of the Anesthesiology Services Medical Group&#8221; and &#8220;Divestiture of the Radiology Services Medical Group&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Acquisition Activity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, we completed the acquisition of one pediatric subspecialty practice. Based on our experience, we expect that we can improve the results of acquired physician practices through improved managed care contracting, improved collections, identification of growth initiatives and operating and cost savings based upon the significant infrastructure that we have developed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Anesthesiology Services Medical Group </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, we entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest our anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, we received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The operating results of the anesthesiology services medical group were reported as discontinued operations in our consolidated statements of income for the year ended December&#160;31, 2020 and prior period financial statements have been presented on a consistent basis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Radiology Services Medical Group </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;9, 2020, we entered into a securities purchase agreement with Radiology Partners, Inc. to divest our radiology services medical group, and the transaction closed on December&#160;15, 2020. The purchase consideration was comprised of $885&#160;million paid in cash at closing, subject to certain cash, minimum net working capital, indebtedness and other adjustments. The Company received approximately $865&#160;million at closing and used a portion of the proceeds of the transaction to redeem its $750&#160;million in outstanding principal amount of 5.25% senior notes due in 2023 (the &#8220;2023 Notes&#8221;) with a redemption date of January&#160;7, 2021. The operating results of the radiology services medical group were reported as a component of discontinued operations, net of income taxes, in our consolidated statements of income for the year ended December&#160;31, 2020 and prior period financial statements have been presented on a consistent basis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transformation and Restructuring Initiatives </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Beginning in 2019, we developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. We had broadly classified these workstreams in four broad categories including practice operations, revenue cycle management, information technology and human resources. We have included the expenses, which in certain cases represent estimates, related to such activity on a separate line item in our consolidated statements. A significant amount of transformational and restructuring activities were related to our anesthesiology services medical group, which was divested in May 2020, and to a lesser extent our radiology services medical group, which was divested in December 2020. Beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives that provided essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or were critical to our continuing operations. Various expenses related to our executive management and board restructuring in 2020 were recorded as transformation and restructuring related expenses during the third and fourth quarters of 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock Repurchase Programs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2013, our Board of Directors authorized the repurchase of shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. The share repurchase program allows us to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div></div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of our common stock to offset the dilutive impact from the issuance of shares, if any, related to our acquisition program. We did not repurchase any shares under this program during the twelve months ended December&#160;31, 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, we announced that our Board of Directors had authorized the repurchase of up to $500.0&#160;million of shares of our common stock in addition to our existing share repurchase program, of which $107.2&#160;million remained available as of January&#160;1, 2020. Under this share repurchase program, during the twelve months ended December&#160;31, 2020, we repurchased 0.5&#160;million shares of our common stock for $8.5&#160;million to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock. As of December&#160;31, 2020, $98.7&#160;million remained available under this share repurchase program. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Economic Conditions and Other Factors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our operations and performance depend significantly on economic conditions. Economic conditions in the United States (&#8220;U.S.&#8221;) have deteriorated, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and patient volumes have declined. During the year ended December&#160;31, 2020, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) increased as compared to the year ended December&#160;31, 2019. This increase was more pronounced during the three months ended December&#160;31, 2020. We could experience additional shifts toward GHC Programs if continued changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services. See Item 1A. Risk Factors, in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for additional discussion on the general economic conditions in the United States and recent developments in the healthcare industry that could affect our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare Reform </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite the ACA going into effect over a decade ago, continuous legal and Congressional challenges to the law&#8217;s provisions and persisting uncertainty with respect to the scope and effect of certain provisions have made compliance costly. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court&#8217;s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. Democratic attorneys general and the House appealed the Fifth Circuit&#8217;s decision to the Supreme Court. On March&#160;2, 2020, the Supreme Court agreed to hear the case, styled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">California v. Texas</div></div>, during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-21</div> term. Oral arguments took place on November&#160;2, 2020 and while the Court has yet to issue its opinion, it is predicted that the Supreme Court will find that even if the individual mandate is struck down, that the rest of the ACA can continue. Nevertheless, we cannot say for certain what the Supreme Court&#8217;s decision will be or what impact, if any, it may have on our business. Changes resulting from these proceedings could have a material impact on our business. In the meantime, it also is possible that as a result of these actions, enrollment in healthcare exchanges could decline. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In late 2020 and early 2021, the results of the federal and state elections have changed which persons and parties occupy the Office of the President of the United States and control both chambers of Congress and many states&#8217; governors and legislatures. The new Administration may propose sweeping changes to the U.S. healthcare system, including expanding government-funded health insurance options and replacing current healthcare financing mechanisms with systems that would be entirely administered by the federal government. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. Congress and the Administration have sought to convert Medicaid into a block grant or to institute per capita spending caps, among other things. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. Many states have recently shifted a majority or all of their Medicaid program beneficiaries into Managed Medicaid Plans. Managed Medicaid Plans have some flexibility to set rates for providers, but many states require minimum provider rates in their contracts with such plans. In July of each year, CMS releases the annual Medicaid Managed Care Rate Development Guide which provides federal baseline rules for setting reimbursement rates in managed care plans. We could be affected by lower reimbursement rates in some of all of the Managed Medicaid Plans with which we participate. We could also be materially impacted if we are dropped from the provider network in one or more of the Managed Medicaid Plans with which we currently participate. In Florida, more than 75% of the Medicaid population participates in a Managed Medicaid Plan, with even higher participation rates for children. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Medicare Access and CHIP Reauthorization Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act (&#8220;MACRA&#8221;) requires Medicare providers to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (&#8220;MIPS&#8221;) or Alternative </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment Models (&#8220;APMs&#8221;). Beginning in 2020, MIPS allowed eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an advanced APM, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians who are eligible to participate in the MIPS program will continue to be eligible to receive MIPS bonus payments, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicaid Expansion </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. To date, 38 states and the District of Columbia have expanded Medicaid eligibility to cover this additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Surprise&#8221; Billing Legislation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In late 2020, Congress enacted legislation intended to protect patients from &#8220;surprise&#8221; medical bills when services are furnished by providers who are not subject to contractual arrangements and payment limitations with the patient&#8217;s insurer. Effective January&#160;1, 2022, patients will be protected from unexpected or &#8220;surprise&#8221; medical bills that could arise from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> emergency care provided at an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> facility or at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> facilities by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> providers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> nonemergency care provided at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> facilities without the patient&#8217;s informed consent. Many states have passed similar legislation, but the federal government has been working to enact a ban on surprise billing for quite some time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the &#8220;No Surprises Act,&#8221; patients are only required to pay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> cost-sharing amount, which will be determined through an established formula and will count toward the patient&#8217;s health plan deductible and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> cost-sharing limits. Providers will generally not be permitted to balance bill patients beyond this cost-sharing amount. An <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider will only be permitted to bill a patient more than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-network</div> cost-sharing amount for care if the provider gives the patient notice of the provider&#8217;s network status and delivers to the patient or their health plan an estimate of charges within certain specified timeframes, and obtains the patient&#8217;s written consent prior to the delivery of care. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#8217;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Moreover, these measures could affect our ability to contract with certain payors and under historically similar terms and may cause, and the prospect of these changes may have caused, payors to terminate their contracts with us and our affiliated practices, further affecting our business, financial condition, results of operations, cash flows and the trading price of our securities. Should any relationships with payors continue on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> basis, the No Surprises Act requires that rate disputes be resolved through binding arbitration, in which both the payor and provider submit a requested rate and the arbitrator selects one submission without hearing or modification of the selected request. These unpredictable results will bind both the provider and payor for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicare Sequestration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">across-the-board</div></div> cuts (&#8220;sequestrations&#8221;) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. In connection with the CARES Act, the Medicare sequestrations were suspended beginning on May&#160;1, 2020 through December&#160;31, 2020. Aside from the suspension, the reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities as the services we provide that are reimbursed under Medicare programs are not material. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Geographic Coverage </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, 2019, and 2018, approximately 62%, 52% and 59%, respectively, of our net revenue from continuing operations was generated by operations in our five largest states. During 2020, 2019 and 2018, our five largest states consisted of Texas, Florida, Georgia, California, and Washington. During 2020, 2019 and 2018, our operations in Texas accounted for approximately 29%, 28% and 28%, respectively, of our net revenue. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payor Mix </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We bill payors for professional services provided by our affiliated physicians to our patients based upon rates for specific services provided. Our billed charges are substantially the same for all parties in a particular geographic area regardless of the party responsible for paying the bill for our services. We determine our net revenue based upon the difference between our gross fees for services and our estimated ultimate collections from payors. Net revenue differs from gross fees due to (i)&#160;managed care payments at contracted rates, (ii)&#160;GHC Program reimbursements at government-established rates, (iii)&#160;various reimbursement plans and negotiated reimbursements from other third-parties, and (iv)&#160;discounted and uncollectible accounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">private-pay</div> patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our payor mix is composed of contracted managed care, government, principally Medicare and Medicaid, other third-parties and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">private-pay</div> patients. We benefit from the fact that most of the medical services provided in the NICU are classified as emergency services, a category typically classified as a covered service by managed care payors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of our payor mix, expressed as a percentage of net revenue from continuing operations, exclusive of administrative fees and miscellaneous revenue, for the periods indicated: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The payor mix shown in the table above is not necessarily representative of the amount of services provided to patients covered under these plans. For example, the gross amount billed to patients covered under GHC Programs for the years ended December&#160;31, 2020, 2019 and 2018 represented approximately 57% of our total gross patient service revenue. These percentages of gross revenue and the percentages of net revenue provided in the table above include the payor mix impact of acquisitions completed through December&#160;31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarterly Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have historically experienced and expect to continue to experience quarterly fluctuations in net revenue and net income. These fluctuations are primarily due to the following factors: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">There are fewer calendar days in the first and second quarters of the year, as compared to the third and fourth quarters of the year. Because we provide services in NICUs on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hours-a-day</div></div></div> basis, 365 days a year, any reduction in service days will have a corresponding reduction in net revenue. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of physician services provided by our office-based practices consist of office visits and scheduled procedures that occur during business hours. As a result, volumes at those practices fluctuate based on the number of business days in each calendar quarter. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant number of our employees and our associated professional contractors, primarily physicians, exceed the level of taxable wages for social security during the first and second quarters of the year. As a result, we incur a significantly higher payroll tax burden and our net income is lower during those quarters. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have significant fixed operating costs, including physician compensation, and, as a result, are highly dependent on patient volume and capacity utilization of our affiliated professional contractors to sustain profitability. Additionally, quarterly results may be affected by the timing of acquisitions and fluctuations in patient volume. As a result, the operating results for any quarter are not necessarily indicative of results for any future period or for the full year. Our unaudited quarterly results are presented in further detail in Note 20 to our Consolidated Financial Statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Application of Critical Accounting Policies and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires estimates and assumptions that affect the reporting of assets, liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities. Note 3 to our Consolidated Financial Statements provides a summary of our significant accounting policies, which are all in accordance with GAAP. Certain of our accounting policies are critical to understanding our Consolidated Financial Statements because their application requires management to make assumptions about future results and depends to a large extent on management&#8217;s judgment, because past results have fluctuated and are expected to continue to do so in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the application of the accounting policies described in the following paragraphs is highly dependent on critical estimates and assumptions that are inherently uncertain and highly susceptible to change. For all of these policies, we caution that future events rarely develop exactly as estimated, and the best estimates routinely require adjustment. On an ongoing basis, we evaluate our estimates and assumptions, including those discussed below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize patient service revenue at the time services are provided by our affiliated physicians. Our performance obligations relate to the delivery of services to patients and are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of our patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to our patients are generally less than billed charges. We monitor our revenue and receivables from these sources and record an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. Management estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Collection of patient service revenue we expect to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. The evaluation of these historical and other factors involves complex, subjective judgments. On a routine basis, we compare our cash collections to recorded net patient service revenue and evaluate our historical allowance for contractual adjustments and uncollectibles based upon the ultimate resolution of the accounts receivable balance. These procedures are completed regularly in order to monitor our process of establishing appropriate reserves for contractual adjustments. We have not recorded any material adjustments to prior period contractual adjustments and uncollectibles in the years ended December&#160;31, 2020, 2019, or 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our agreements require hospitals to pay us administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that we receive a specified minimum revenue level. We also receive fees from hospitals for administrative services performed by our affiliated physicians providing medical director or other services at the hospital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">DSO is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Any significant change in our DSO results in additional analyses of outstanding accounts receivable and the associated reserves. We calculate our DSO using a three-month rolling average of net revenue. Our net revenue, net income and operating cash flows may be materially and adversely affected if actual adjustments and uncollectibles exceed management&#8217;s estimated provisions as a result of changes in these factors. As of December&#160;31, 2020, our DSO was 52.3 days. We had approximately $1.03&#160;billion in gross accounts receivable for continuing operations outstanding at December&#160;31, 2020, and considering this outstanding balance, based on our historical experience, a reasonably likely change of 0.5% to 1.50% in our estimated collection rate would result in an impact to net revenue of $4.9&#160;million to $14.7&#160;million. The impact of this change does not include adjustments that may be required as a result of audits, inquiries and investigations from government authorities and agencies and other third-party payors that may occur in the ordinary course of business. See Note 19 to our Consolidated Financial Statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Professional Liability Coverage </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. Our self-insured retention under our professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. The average lag period from the date a claim is reported to the date it reaches final settlement is approximately four years, although the facts and circumstances of individual claims could result in lag periods that vary from this average. Our actuarial assumptions incorporate multiple complex methodologies to determine the best liability estimate for claims incurred but not reported and the future development of known claims, including methodologies that focus on industry trends, paid loss development, reported loss development and industry-based expected pure premiums. The most significant assumptions used in the estimation process include the use of loss development factors to determine the future emergence of claim liabilities, the use of frequency and trend factors to estimate the impact of economic, judicial and social changes affecting claim costs, and assumptions regarding legal and other costs associated with the ultimate settlement of claims. The key assumptions used in our actuarial valuations are subject to constant adjustments as a result of changes in our actual loss history and the movement of projected emergence patterns as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">claims develop. We evaluate the need for professional liability insurance reserves in excess of amounts estimated in our actuarial valuations on a routine basis, and as of December&#160;31, 2020, based on our historical experience for continuing operations, a reasonably likely change of 2% to 6% in our estimates would result in an increase or decrease to net income of $1.2&#160;million to $4.3&#160;million. However, because many factors can affect historical and future loss patterns, the determination of an appropriate professional liability reserve involves complex, subjective judgment, and actual results may vary significantly from estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We record acquired assets, including identifiable intangible assets and liabilities at their respective fair values, recording to goodwill the excess of purchase price over the fair value of the net assets acquired. We test goodwill for impairment at a reporting unit level on an annual basis, and more frequently if impairment indicators exist. We may elect to perform a qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it is more likely than not that the fair value of our single reporting unit exceeds its carrying value, including goodwill. We may also bypass the qualitative assessment and perform a quantitative test. The quantitative test focuses on income and market-based valuation approaches to determine the fair value of reporting units. These approaches focus on various significant assumptions, including the weighted average cost of capital discount factor, revenue growth rates and market multiples for revenue and earnings before interest, taxes and depreciation and amortization (&#8220;EBITDA&#8221;). We consider the economic outlook for the healthcare services industry and various other factors during both the qualitative and quantitative testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Other significant accounting policies, not involving the same level of measurement uncertainties as those discussed above, are nevertheless important to an understanding of our Consolidated Financial Statements. For example, our Consolidated Financial Statements are presented on a consolidated basis with our affiliated professional contractors because we or one of our subsidiaries have entered into management agreements with our affiliated professional contractors meeting the &#8220;controlling financial interest&#8221; criteria set forth in accounting guidance for consolidations. Our management agreements are further described in Note 3 to our Consolidated Financial Statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The policies described in Note 3 often require difficult judgments on complex matters that are often subject to multiple sources of authoritative guidance and are frequently reexamined by accounting standards setters and regulators. See &#8220;New Accounting Pronouncements&#8221; below for matters that may affect our accounting policies in the future. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Measures </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In our analysis of our results of operations, we use certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. We have incurred certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted earnings before interest, taxes and depreciation and amortization from continuing operations, defined as income (loss) from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per share (&#8220;Adjusted EPS&#8221;) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations has been further adjusted to reflect the impacts from discrete tax events. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the years ended December&#160;31, 2020, 2019 and 2018, refer to the tables below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">219,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">264,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; white-space: nowrap;;text-align:center;">83,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; white-space: nowrap;;text-align:center;">84,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; white-space: nowrap;;text-align:center;">91,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations and diluted (loss) income from continuing operations per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $2,294, $1,814 and $1,701)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,882</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,442</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $5,281, $8,353 and $9,099)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses (net of tax of $18,450 and $15,222)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,668</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,541</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(455</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The statutory tax rate of 25% was used to calculate the tax effects of the adjustments for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth, for the periods indicated, certain information related to our continuing operations expressed as a percentage of our net revenue: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> expense, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December&#160;31, 2020 as Compared to Year Ended December&#160;31, 2019 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our net revenue attributable to continuing operations was $1.73&#160;billion for the year ended December&#160;31, 2020, as compared to $1.78&#160;billion for 2019. The decrease in revenue of $45.8&#160;million, or 2.6%, was primarily attributable to the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on same-unit revenue, driven by declines in volume, partially offset by an increase in revenue from net acquisitions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $66.6&#160;million, or 3.8%. The decline in same-unit net revenue was comprised of a decrease of $89.0&#160;million, or 5.1%, related to patient service volumes, partially offset by a net increase of $22.4&#160;million, or 1.3%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was primarily related to a decline across all our services, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The net increase in revenue related to net reimbursement-related factors was primarily due to approximately $22.0&#160;million in CARES Act relief, an increase in administrative fees received from our hospital partners and modest improvements in managed care contracting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits attributable to continuing operations increased $13.2&#160;million, or 1.1%, to $1.19&#160;billion for the year ended December&#160;31, 2020, as compared to $1.18&#160;billion for 2019. The increase was comprised of $13.2&#160;million from salaries and a net nominal change in benefits and incentive compensation, primarily reflecting increases in malpractice expense almost entirely offset by decreases in incentive compensation expense. We anticipate that we will experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Practice supplies and other operating expenses attributable to continuing operations decreased $5.2&#160;million, or 5.4%, to $90.7&#160;million for the year ended December&#160;31, 2020, as compared to $95.9&#160;million for 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year, primarily related to decreased activity across many expense categories such as travel, office expenses and professional services resulting from impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> partially offset by increases in supplies and other operating expenses related to acquisitions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were $248.9&#160;million for the year ended December&#160;31, 2020, as compared to $244.5&#160;million for 2019. The increase of $4.4&#160;million is primarily related to legal and professional services fees, partially offset by decreases in compensation from net staffing reductions primarily resulting from cost mitigation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> General and administrative expenses as a percentage of net revenue was 14.4% for the year ended December&#160;31, 2020, as compared to 13.7% for 2019. Certain general and administrative expenses related to corporate overhead represent various support services provided across the company, including approximately $18&#160;million in costs related to support for the anesthesiology services medical group divested in May 2020 through a transition services agreement and to a much lesser extent the recently divested radiology services medical group. Because a portion of such expenses were previously allocated to but not specifically identifiable to the anesthesiology services medical group, they are required to be presented as continuing operations. Therefore, general and administrative expenses do not reflect potential general and administrative cost savings that may be achieved in future periods. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Transformational and restructuring related expenses attributable to continuing operations were $73.8&#160;million for the year ended December&#160;31, 2020, as compared to $60.9&#160;million for 2019. Approximately $33.6&#160;million of the expenses incurred during the year ended December&#160;31, 2020 were for external consulting costs for various process improvement and restructuring initiatives and approximately $31.9&#160;million were for compensation-related expenses resulting from the restructuring changes in executive management and the board of directors, with the remainder for position eliminations and contract termination and other fees. Beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives critical to our business operations or those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Various activities related to executive management and board of directors restructuring were recorded as transformational and restructuring related expenses during the year ended December&#160;31, 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $28.4&#160;million for the year ended December&#160;31, 2020, as compared to $25.9&#160;million for 2019. The increase is primarily related to the amortization of intangible assets related to acquisitions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income from operations attributable to continuing operations decreased $73.7&#160;million, or 42.9%, to $98.1&#160;million for the year ended December&#160;31, 2020, as compared to $171.8&#160;million for 2019. Our operating margin was 5.7% for the year ended December&#160;31, 2020, as compared to 9.7% for the same period in 2019. The decrease in our operating margin was primarily due to a decrease in revenue related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and increases in transformation and restructuring related expenses and practice salaries and benefits. Excluding transformation and restructuring expenses, our income from operations attributable to continuing operations for the years ended December&#160;31, 2020 and 2019 was $171.9&#160;million and $232.7&#160;million, respectively, and our operating margin was 9.9% and 13.1%, respectively. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations; however, this comparison is affected by the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $91.0&#160;million for the year ended December&#160;31, 2020, as compared to $113.0&#160;million for 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to an increase in other income related to the transition services being provided to the buyers of our divested medical groups and a decrease in interest expense, primarily due to lower average borrowings under our Credit Agreement, partially offset by a decrease in equity earnings resulting from the impacts to the underlying joint venture from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the settlement of a litigation matter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our effective income tax rate attributable to continuing operations of 234.0% is not meaningful as calculated for the year ended December&#160;31, 2020 due to the decline in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income, primarily due to the impacts from our transformational and restructuring related expenses and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Our effective income tax rate attributable to continuing operations was 28.2% for the year ended December&#160;31, 2019. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations was $9.6&#160;million for the year ended December&#160;31, 2020, as compared to income from continuing operations of $42.2&#160;million for 2019. Adjusted EBITDA from continuing operations was $219.9&#160;million for the year ended December&#160;31, 2020, as compared to $264.5&#160;million for 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss from continuing operations per common and common equivalent share was $0.11 on weighted average shares outstanding of 83.4&#160;million for the year ended December&#160;31, 2020, as compared to diluted income per common and common equivalent share of $0.50 on weighted average shares outstanding of 84.0&#160;million for 2019. Adjusted EPS from continuing operations was $0.95 for the year ended December&#160;31, 2020, as compared to $1.40 for 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $786.9&#160;million for the year ended December&#160;31, 2020, as compared to loss from discontinued operations of $1.54&#160;billion for 2019. Diluted loss from discontinued operations per common and common equivalent share was $9.44 for the year ended December&#160;31, 2020, as compared to a diluted loss from discontinued operations per common and common equivalent share of $18.33 for 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $796.5&#160;million for the year ended December&#160;31, 2020, as compared to a net loss of $1.50&#160;billion for 2019. Diluted net loss per common and common equivalent share was $9.55 for the year ended December&#160;31, 2020, as compared to $17.83 for 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December&#160;31, 2019 as Compared to Year Ended December&#160;31, 2018 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our net revenue attributable to continuing operations was $1.78&#160;billion for the year ended December&#160;31, 2019, as compared to $1.72&#160;billion for 2018. The increase in revenue of $56.7&#160;million, or 3.3%, was primarily attributable to an increase in same-unit net revenue as well as an increase in revenue from net acquisitions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue grew by $34.7&#160;million, or 2.1%, in the year ended December&#160;31, 2019, as compared to the same period in 2018. The increase in same-unit net revenue was comprised of a net increase of $26.5&#160;million, or 1.6%, related to patient service volumes and a net increase of $8.2&#160;million, or 0.5%, from net reimbursement-related factors. The increase in revenue from patient service volumes was primarily related to growth across almost all of our services, driven by growth in neonatology and other pediatric services, including newborn nursery. The net increase in revenue related to net reimbursement-related factors was primarily due to modest increases from managed care contracting and an increase in administrative fees received from our hospital partners. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits attributable to continuing operations increased $55.1&#160;million, or 4.9%, to $1.18&#160;billion for the year ended December&#160;31, 2019, as compared to $1.13&#160;billion for 2018. This increase was primarily attributable to increased costs associated with physicians and other staff to support organic growth initiatives and growth at our existing units, as well as increases in malpractice expense due to unfavorable trends in claims experience. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense and malpractice expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses attributable to continuing operations increased $3.4&#160;million, or 3.7%, to $95.9&#160;million for the year ended December&#160;31, 2019, as compared to $92.5&#160;million for 2018. The increase was primarily attributable to increases in other practice operating expenses as compared to the prior year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$244.5&#160;million for the year ended December&#160;31, 2019, as compared to $232.2&#160;million for 2018. General and administrative expenses as a percentage of net revenue was 13.7% for the year ended December&#160;31, 2019, as compared to 13.5% for the same period in 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses attributable to continuing operations were $60.9&#160;million for the year ended December&#160;31, 2019 of which $40.3&#160;million was related to external consulting costs for various process improvement and restructuring initiatives, $17.6&#160;million was related to severance benefits for eliminated positions and $3.0&#160;million was associated with contract terminations and other such activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $25.9&#160;million for the year ended December&#160;31, 2019, as compared to $24.4&#160;million for 2019. The increase is primarily related to the amortization of intangible assets related to acquisitions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations attributable to continuing operations was $171.8&#160;million for the year ended December&#160;31, 2019, as compared to income from operations attributable to continuing operations of $248.4&#160;million for 2018. Our operating margin was 9.7% for the year ended December&#160;31, 2019, as compared to 14.4% for 2018. The decrease in our operating margin was primarily due to higher operating expense growth, including transformation and restructuring expenses, combined with lower revenue growth. Excluding the transformation and restructuring expenses, our income from operations attributable to continuing operations was $232.7&#160;million, and our operating margin was 13.1%. We believe excluding the impacts from the transformational and restructuring activity provides a more comparable view of our operating income and operating margin from continuing operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $113.0&#160;million for the year ended December&#160;31, 2019, as compared to $82.2&#160;million for 2018. The net increase of $30.8&#160;million, or 37.5%, was primarily related to an increase in interest expense related to a higher average interest rate on our outstanding debt, driven by the incremental senior notes issuances in late 2018 and early 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our effective income tax rate attributable to continuing operations was 28.2% and 26.9% for the years ended December&#160;31, 2019 and 2018, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations was $42.2&#160;million for the year ended December&#160;31, 2019, as compared to income from continuing operations of $121.5&#160;million for 2018. Adjusted EBITDA from continuing operations was $264.5&#160;million for the year ended December&#160;31, 2019, as compared to $283.5&#160;million for the same period in 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted income from continuing operations per common and common equivalent share was $0.50 on weighted average shares outstanding of 84.0&#160;million for the year ended December&#160;31, 2019, as compared to diluted income from continuing operations of $1.33 on weighted average shares outstanding of 91.6&#160;million for 2018. Adjusted EPS from continuing operations was $1.40 for the year ended December&#160;31, 2019, as compared to $1.68 for 2018. The decrease of 7.6&#160;million in our weighted average shares outstanding is primarily due to the impact of shares repurchased under a 2018 accelerated share repurchase program and through open market repurchase activity in 2018 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Loss from discontinued operations, net of tax, was $1.54&#160;billion for the year ended December&#160;31, 2019, reflecting the preliminary loss on the divestiture of MedData and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> goodwill impairment charge recorded during the year ended December&#160;31, 2019 primarily related to the anesthesiology medical group, as compared to income from discontinued operations, net of tax, of $147.1&#160;million for 2018. Diluted loss from discontinued operations per common and common equivalent share was $18.33 for the year ended December&#160;31, 2019, as compared to diluted income from discontinued operations per common and common equivalent share of $1.60 for 2018. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $1.50&#160;billion for the year ended December&#160;31, 2019, as compared to net income of $268.6&#160;million for 2018. Diluted net loss per common and common equivalent share was $17.83 for the year ended December&#160;31, 2019, as compared to diluted net income per common and common equivalent share of $2.93 for 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIQUIDITY AND CAPITAL RESOURCES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, we had $1.12&#160;billion of cash and cash equivalents attributable to continuing operations as compared to $107.9&#160;million at December&#160;31, 2019. Additionally, we had working capital attributable to continuing operations of $1.11&#160;billion at December&#160;31, 2020, an increase of $894.4&#160;million from our working capital from continuing operations of $210.7&#160;million at December&#160;31, 2019. The increase in cash and working capital relates primarily to the net proceeds of $865.0&#160;million received in December 2020 from the divestiture of the radiology services medical group, of which approximately $764.0&#160;million was used to redeem our 2023 Notes in January 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash provided by (used in) operating, investing and financing activities from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(58,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(84,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generated cash flow from operating activities for continuing operations of $153.9&#160;million, $74.1&#160;million and $59.0&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The net increase in cash flow provided of $79.8&#160;million for the year ended December&#160;31, 2020, as compared to the year ended December&#160;31, 2019, was primarily due to an increase in cash flow from deferred income taxes and income taxes payable as well as accounts receivable, partially offset by a decrease in cash from lower earnings and changes in prepaid expenses and other assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, cash flow from accounts receivable for continuing operations was $37.9&#160;million, as compared to $6.5&#160;million for the same period in 2019. The increase in cash flow from accounts receivable for the year ended December&#160;31, 2020 was primarily due to decreases in ending accounts receivable balances at existing units due to timing of cash collections. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSO is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 52.3 days at December&#160;31, 2020 as compared to 51.0 days at December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash flow from operating activities is significantly affected by the payment of physician incentive compensation. A large majority of our affiliated physicians participate in our performance-based incentive compensation program and almost all of the payments due under the program are made annually in the first quarter. As a result, we typically experience negative cash flow from operations in the first quarter of each year and fund our operations during this period with cash on hand or funds borrowed under our Credit Agreement. In addition, during the first quarter of each year, we use cash to make any discretionary matching contributions for participants in our qualified contributory savings plans. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generated cash flow from operating activities for continuing operations of $74.1&#160;million and $59.0&#160;million for the years ended December&#160;31, 2019 and 2018, respectively. The net increase in cash flow was primarily related to increases in cash flow from accounts receivable and a combination of favorable impacts from lower tax payments in 2019 and a decrease in cash flow in 2018 for tax payments made in the first quarter of 2018 for 2017 taxes that were deferred by the Internal Revenue Service for companies impacted by the 2017 hurricanes. Cash flow from operating activities in 2019 was also impacted by cash payments made for transformation and restructuring related expenses. Cash flow for the year ended December&#160;31, 2018 was impacted by a decrease in cash flow from income taxes payable resulting from tax payments made in the first quarter of 2018 for 2017 taxes that were deferred by the Internal Revenue Service for companies impacted by the 2017 hurricanes, as well as a net decrease in cash flow related to accounts receivable, partially offset by an increase in cash flow related to changes in deferred taxes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, our net cash used in investing activities for continuing operations of $58.3&#160;million consisted primarily of capital expenditures of $28.8&#160;million and net purchases of investments of $28.4&#160;million. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, our net cash used in financing activities for continuing operations of $2.9&#160;million primarily consisted of the repurchase of $8.5&#160;million of our common stock and payments of $1.2&#160;million for capital leases, partially offset by proceeds from the issuance of common stock of $7.0&#160;million. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, we amended and restated our Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by us from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that we maintain minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict our ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Credit Agreement provides for a $1.2&#160;billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-facility</div> for the issuance of letters of credit. The Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, we had no outstanding principal balance on our Credit Agreement. We had outstanding letters of credit of $0.1&#160;million which reduced the amount available on our Credit Agreement to $899.9&#160;million at December&#160;31, 2020, after giving effect to the temporary reduction of the capacity of our Credit Agreement described above through September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, we had an outstanding principal balance of $750.0&#160;million on our 5.25% senior unsecured notes due 2023 (the &#8220;2023 Notes&#8221;) and an outstanding principal balance of $1.0&#160;billion on our 6.25% senior unsecured notes due 2027 (the &#8220;2027 Notes&#8221;). On January&#160;7, 2021, we redeemed the outstanding principal balance of $750.0&#160;million on our 2023 Notes. Our obligations under the 2023 Notes were, and the 2027 Notes are, guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrued at the rate of 5.25% per annum, or $39.4&#160;million, and was payable semi-annually in arrears on June&#160;1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5&#160;million, and is payable semi-annually in arrears on January&#160;15 and July 15. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indenture under which the 2027 Notes are issued, among other things, limits our ability to (1)&#160;incur liens and (2)&#160;enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2027 Notes, upon the occurrence of a change in control of Mednax, we may be required to repurchase the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2027 Notes repurchased plus accrued and unpaid interest. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The exercise of employee stock options and the purchase of common stock by participants in our 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), and our 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;) generated cash proceeds of $7.0&#160;million, $11.3&#160;million and $16.3&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Because stock option exercises and purchases under the ESPP and SPP are dependent on several factors, including the market price of our common stock, we cannot predict the timing and amount of any future proceeds. </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at December&#160;31, 2020 was $315.9&#160;million, of which $50.6&#160;million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $61.4&#160;million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations as described below for at least the next 12 months from the date of issuance of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONTRACTUAL OBLIGATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, we had the following obligations and commitments (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments Due</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Obligation</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/>and&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024<br/>and&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026<br/>and&#160;Later</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1) </div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,137,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">823,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,064,897</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,202,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">842,685</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,068,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts include interest payments at the applicable rate as of December&#160;31, 2020 and assumed the amount outstanding under our 2023 Notes were paid on the early redemption date of January&#160;7, 2021, including the early redemption premium, and the 2027 Notes will be paid on their maturity date of January&#160;15, 2027. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At December&#160;31, 2020, our total liability for uncertain tax positions was $7.2&#160;million, all of which is included within other liabilities on our Consolidated Balance Sheets. The timing and amount of future cash flows for each year beyond 2020 cannot be reasonably estimated. See Note 14 to our Consolidated Financial Statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for more information regarding our uncertain tax positions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">OFF-BALANCE</div> SHEET ARRANGEMENTS </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We did not have any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements as of December&#160;31, 2020 that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NEW ACCOUNTING PRONOUNCEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance became effective for us on January&#160;1, 2021. We do not believe the adoption of this guidance will have a material impact on our consolidated financial statements and related disclosures. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_12" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;7A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At December&#160;31, 2020, we had no outstanding borrowings on our Credit Agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_13" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following Consolidated Financial Statements and Financial Statement Schedule of Mednax, Inc. and its subsidiaries are included in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> on the pages set forth below: </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AND FINANCIAL STATEMENT SCHEDULE </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_102">Report of Independent Registered Certified Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_103">Consolidated Balance Sheets at December&#160;31, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_104">Consolidated Statements of Income for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_105">Consolidated Statements of Equity for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_106">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_107">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statement Schedule</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc51794_109">Schedule II &#8211; Valuation and Qualifying Accounts for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc51794_102" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Shareholders of Mednax, Inc. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinions on the Financial Statements and Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have audited the accompanying consolidated balance sheets of Mednax, Inc<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, and the related consolidated statements of income, equity, and cash flows for each of the three years in the period ended December&#160;31, 2020, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control&#8212;Integrated Framework</div></div> (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019,<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2020, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control&#8212;Integrated Framework</div></div> (2013)&#160;issued by the COSO. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinions </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Definition and Limitations of Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matters </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i)&#160;relates to accounts or disclosures that are material to the consolidated financial statements and (ii)&#160;involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation of Patient Services Accounts Receivable &#8211; Allowance for Contractual Adjustments and Uncollectibles </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Notes 3 and 5 to the consolidated financial statements, patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. Payments for services rendered are generally less than billed charges. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by third-party payors for such services. Patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. Management estimates the allowance for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Patient services accounts receivable makes up a significant portion of the Company&#8217;s consolidated net accounts receivable balance of $241.9&#160;million as of December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal considerations for our determination that performing procedures relating to valuation of patient services accounts receivable&#8212;allowance for contractual adjustments and uncollectibles is a critical audit matter is the significant judgment by management to determine the estimated allowance to adjust the patient services accounts receivable to the amount that will be collected in the future under the terms of third-party payor contracts, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating the audit evidence obtained related to the valuation of patient services accounts receivable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of patient accounts receivable, which included controls over management&#8217;s model, data, and assumptions used to estimate the allowance for contractual adjustments and uncollectibles from third parties. These procedures also included, among others, (i)&#160;evaluating management&#8217;s process for developing the allowance for contractual adjustments and uncollectibles; (ii)&#160;testing the completeness and accuracy of underlying data used in the model; (iii)&#160;evaluating the historical accuracy of management&#8217;s process for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing the estimate of the amount which will ultimately be collected by comparing actual cash collections to the previously recorded patient services accounts receivable; and (iv)&#160;developing an independent expectation of the amount expected to be collected by management. Developing an independent expectation involved calculating the percentage of cash collections as compared to the recorded patient services accounts receivable balance as of the end of the prior year and comparing that percentage to management&#8217;s collection expectation used to determine the current year allowance for contractual adjustments and uncollectibles. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">PricewaterhouseCoopers LLP</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Miami, Florida</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">February&#160;18, 2021</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 1999.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div> <div id="toc51794_103" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,123,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">434,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,898</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,549,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">731,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,641,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,477,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and finance lease right-of-use assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OperatingAndFinanceLeaseRightOfUseAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OperatingAndFinanceLeaseRightOfUseAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,347,948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES&#160;&amp; EQUITY</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">423,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">410,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities held for sale</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">444,335</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">541,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities held for sale</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt and finance lease liabilities, net</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,742,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,730,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">265,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">204,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,600,231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,646,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock; $<span style="-sec-ix-hidden:hidden18208864">.<span style="-sec-ix-hidden:hidden18208865">01</span></span> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock; $<span style="-sec-ix-hidden:hidden18208866">.<span style="-sec-ix-hidden:hidden18208867">01</span></span> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">85,593</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional paid-in capital</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,029,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retained (deficit) earnings</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">286,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Mednax, Inc. shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">747,485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">747,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and equity</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,347,948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div> <div id="toc51794_104" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for per share data) </div></div></div></div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,733,951</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,779,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,723,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,193,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,180,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,125,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">95,911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">248,947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">244,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232,218</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,635,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,608,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,474,719</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98,132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">171,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">248,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">110,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net</div> non-operating expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">112,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">82,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">121,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">786,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,539,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">796,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,497,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">268,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="9" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">(Loss) income from continuing operations:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">(Loss) income from discontinued operations:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">9.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">18.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">9.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">18.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net (loss) income:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">9.55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">9.55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Weighted average common shares:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91,104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 50pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div> <div id="toc51794_105" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF EQUITY </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnings</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2017</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">93,721</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">937</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,017,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,048,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,066,454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">268,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">268,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Common stock issued under employee stock option, employee stock<br/> purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">770</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock swaps</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodSharesStockSwaps" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">79,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">222,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">302,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">87,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">992,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,087,884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,497,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,497,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18209834">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18209835">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock swaps</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodSharesStockSwaps" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,706</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">796,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">796,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contribution from noncontrolling interests, net of loss<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18210163">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18210164">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18210161">3,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_18210162">3,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock and conversion of deferred stock to common stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 49%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,593</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,029,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">282,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">747,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: 0pt;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented within retained (deficit) earnings as the balance is immaterial. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 40pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div></div> </div> </div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div> <div id="toc51794_106" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:center;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:center;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:center;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:center;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Cash flows from operating activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Net (loss) income</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">796,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,497,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">268,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Loss (income) from discontinued operations</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">786,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,539,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Adjustments to reconcile net income to net cash provided from operating activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Depreciation and amortization</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Amortization of premiums, discounts and issuance costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Deferred income taxes</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">55,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Other</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,886</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Changes in assets and liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,937</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Other long-term assets</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Payment of contingent consideration liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,518</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Net cash provided by operating activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">153,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Net cash provided by operating activities &#8211; discontinued operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">283,620</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">254,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">204,620</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">357,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">313,708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition payments, net of cash acquired</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities or sales of investments</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sales of businesses, net of cash sold</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash <div style="letter-spacing: 0px; top: 0px; font-size: 8pt;;display:inline;">(used in) </div>provided by<div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 8pt;;display:inline;">&#160;</div>investing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash <div style="letter-spacing: 0px; top: 0px; font-size: 8pt;;display:inline;">provided by (</div>used in<div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 8pt;;display:inline;">)</div> investing activities &#8211; discontinued operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">873,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">815,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">142,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings on credit agreement</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,247,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,723,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Payments on credit agreement</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,986,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of senior notes</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Payments for credit facility amendment and financing costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Payments of contingent consideration liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,263</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance lease obligations</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Proceeds from issuance of common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Contribution from noncontrolling interests</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Repurchases of common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">302,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">Net cash used in financing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">384,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">169,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities &#8211; discontinued operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,248</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">393,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">170,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 0.75pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents at beginning of year</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at end of year</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,123,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; border-top: 0.75pt solid black; border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; padding-bottom: 2.5pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid (refunded) for:</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">110,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">95,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">82,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">185,416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.39in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment financed through finance leases</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%; line-height: 8pt; font-size: 8pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment included in accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 16pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div><div id="toc51794_107" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General: </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; line-height: 0pt;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The principal business activity of Mednax, Inc. (&#8220;Mednax&#8221; or the &#8220;Company&#8221;) and its subsidiaries is to provide neonatal, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;fee-for-service</div></div> contracts, whereby hospitals and other customers agree, in exchange for the Company&#8217;s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company&#8217;s affiliated healthcare professionals, and (ii)&#160;administrative fee contracts, whereby the Company is assured a minimum </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">revenue level. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210630">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. See Note 9 &#8211; Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology and radiology services medical groups. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s affiliated women&#8217;s and children&#8217;s office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. The Company believes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> either directly or indirectly, has also had an impact on its neonatology intensive care unit (&#8220;NICU&#8221;) patient volumes, and there is no assurance that impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not further adversely affect its NICU patient volumes or otherwise adversely affect its NICU and related neonatology business. Overall, the Company&#8217;s operating results were significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through December 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of COVID-19. These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to COVID-19. In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including <ix:nonFraction name="md:PercentageIncreaseDecreaseInSalaryAndWage" contextRef="P01_01_2020To12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii)&#160;the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for non-clinical employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by COVID-19. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In response to the anticipated impact of COVID-19 on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $<ix:nonFraction name="md:DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction> million for the second and third quarters of 2020, reflecting average </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted </div></div>&#160;</div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210630" continuedAt="TextSelectionAppend_18210630_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>EBITDA</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</ix:nonNumeric> to <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</ix:nonNumeric> for the second and third quarters of 2020 and <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</ix:nonNumeric> for the fourth quarter of <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</ix:nonNumeric>, before returning to <div style="letter-spacing: 0px; top: 0px;;display:inline;">4.50:1:00</div> for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $<ix:nonFraction name="md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForThirdQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $<ix:nonFraction name="md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At <div style="letter-spacing: 0px; top: 0px;;display:inline;">December</div>&#160;3<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To12_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction>% senior unsecured notes due 2023 and its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To12_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction>% senior unsecured </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">months. At December&#160;31, 2020,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $<ix:nonFraction name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million which reduced the amount available on its Credit Agreement to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">899.9</ix:nonFraction> million at December&#160;31, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210630_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">100</ix:nonFraction>&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The remaining $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">70</ix:nonFraction> billion in aid is intended to focus on providers in areas particularly impacted by COVID-19, rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices within continuing operations received an aggregate of approximately $<ix:nonFraction name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" contextRef="PAsOn12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">22.0</ix:nonFraction> million during the year ended December&#160;31, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the deferred amount due December&#160;31, 2021 and the remaining <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% due December&#160;31, 2022. The Company utilize<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> this deferral option throughout 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The COVID-19 pandemic has materially impacted the Company&#8217;s financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210631">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Significant Accounting Policies: </div></div></div></div></td></tr></table> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company&#8217;s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the </div></div></div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_18210631" continuedAt="TextSelectionAppend_18210631_1">case of gross negligence, fraud or bankruptcy of the Company. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the Company&#8217;s affiliated professional contractors, in an amount that fluctuates based on the performance of the affiliated professional contractors and the change in the fair value of the Company&#8217;s interest in the affiliated professional contractors. The Company has exclusive responsibility for the provision of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-medical</div> services required for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operation and management of the Company&#8217;s affiliated professional contractors and establishes the guidelines for the employment and compensation of the physicians. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the Company&#8217;s affiliated professional contractors for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the agreements. Based upon the provisions of these agreements, the Company has determined that the affiliated professional contractors are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation. All significant intercompany and interaffiliate accounts and transactions have been eliminated.</ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_18210631_1" continuedAt="TextSelectionAppend_18210631_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company entered into a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn08_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction>% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#8217;s Consolidated Balance Sheets. The results from operations attributable to the noncontrolling interests during the fourth quarter <div style="letter-spacing: 0px; top: 0px;;display:inline;">of 2020 </div>were nominal and therefore not presented separately on the Company&#8217;s Consolidated Statements of Income. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210631_2" continuedAt="TextSelectionAppend_18210631_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2019 and 2018. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, the Company divested its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the year ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 9 &#8211; Discontinued Operations for more information. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_3" continuedAt="TextSelectionAppend_18210631_4"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance became effective for the Company on January&#160;1, 2021. The Company does not believe adoption of this new guidance will have a material impact on its Consolidated Financial Statements or related disclosures. </div></div> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_4" continuedAt="TextSelectionAppend_18210631_5"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting Estimates and Assumptions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#8217;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#8217;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates. </div></div> </ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_5" continuedAt="TextSelectionAppend_18210631_6"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue from continuing operations by service line (in percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neonatology and other pediatric subspecialties</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maternal-fetal medicine</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric cardiology</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210550"><ix:continuation id="TextSelectionAppend_18210631_6" continuedAt="TextSelectionAppend_18210631_7"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</div></div></div> </ix:continuation></ix:nonNumeric></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div></div></div><div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210550" continuedAt="TextSelectionAppend_18210550_1"><ix:continuation id="TextSelectionAppend_18210631_7" continuedAt="TextSelectionAppend_18210631_8"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee </div></div></div></ix:continuation></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210550_1"><ix:continuation id="TextSelectionAppend_18210631_8" continuedAt="TextSelectionAppend_18210631_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and GHC Programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from GHC Programs made up approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>% of net accounts receivable related to continuing operations at December&#160;31, 2020 and 2019, respectively. </div></div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_9" continuedAt="TextSelectionAppend_18210631_10"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are defined as all highly liquid financial instruments with maturities of <ix:nonNumeric name="md:CashAndCashEquivalentsMaturityDescription" contextRef="P01_01_2020To12_31_2020">90</ix:nonNumeric> days or less from the date of purchase. The Company&#8217;s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits. Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See &#8220;Fair Value Measurements&#8221; below. </div></div></ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_10" continuedAt="TextSelectionAppend_18210631_11"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments consist<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">primarily </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;corporate securities,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">municipal debt securities, federal home loan securities and certificates of deposit. The Company classifies its investments as available for sale. Although there is no stated expectation that the investments will be sold within <ix:nonNumeric name="md:ShortTermInvestmentMaturityPeriod" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric>, the investments are available for use, if needed, and accordingly are classified as short-term. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive income or loss. </div></div></ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_11" continuedAt="TextSelectionAppend_18210631_12"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">30</ix:nonNumeric> years for buildings; <span style="-sec-ix-hidden:hidden18209306"><span style="-sec-ix-hidden:hidden18209307"><span style="-sec-ix-hidden:hidden18209308"><span style="-sec-ix-hidden:hidden18209309">th</span>r</span>e</span>e</span> t<div style="letter-spacing: 0px; top: 0px;;display:inline;">o </div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and finance leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">earnings. </div></div></div></ix:continuation></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210646"><ix:continuation id="TextSelectionAppend_18210631_12" continuedAt="TextSelectionAppend_18210631_13">Business Acquisitions</ix:continuation></ix:nonNumeric> </div></div></div></div> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210631_13" continuedAt="TextSelectionAppend_18210631_14"><ix:continuation id="TextSelection_18210646" continuedAt="TextSelectionAppend_18210646_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to <ix:nonNumeric name="md:BusinessCombinationContingentConsiderationArrangementsTimePeriod" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:durwordsen">five years</ix:nonNumeric> ending after the acquisition dates. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures this contingent consideration at fair value at the acquisition </div></div></div></ix:continuation></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210631_14" continuedAt="TextSelectionAppend_18210631_15"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210646_1">date and records such contingent consideration as a liability or equity on the Company&#8217;s Consolidated Balance Sheets on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company&#8217;s Consolidated Statements of Income.</ix:continuation>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records acquired assets and assumed liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of <span style="-sec-ix-hidden:hidden18209310">one</span> to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">20</ix:nonNumeric> years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For 2020, the Company elected to perform the qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it was more likely than not that the fair value of its single reporting unit exceeded its carrying value, including goodwill. For 2019 and 2018, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">bypassed </div>the qualitative assessment and performed a quantitative test with any goodwill impairment measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. The Company used income and market-based valuation approaches to determine the fair value of its single continuing operations reporting unit. These approaches focused on discounted cash flows and revenue and EBITDA multiples based on the Company&#8217;s market capitalization to derive the fair value of the reporting unit. Significant assumptions used in these valuations included the weighted average cost of capital discount factor, revenue growth rates and revenue and EBITDA multiples. For both the qualitative and quantitative approaches, the Company considered the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company completed annual impairment tests for its continuing operations in the third quarter of 2020, 2019 and 2018 and determined that goodwill was not impaired. See Note 8 &#8211; Goodwill and Intangible Assets for more information. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210619"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. </div></div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210631_15" continuedAt="TextSelectionAppend_18210631_16"><ix:continuation id="TextSelection_18210619">The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December&#160;31, 2020 pursuant to current accounting standards.</ix:continuation></ix:continuation> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="md:CommonStockShareRepurchasesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210642"><ix:continuation id="TextSelectionAppend_18210631_16" continuedAt="TextSelectionAppend_18210631_17">Common Stock Repurchases</ix:continuation></ix:nonNumeric> </div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210631_17" continuedAt="TextSelectionAppend_18210631_18"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_18210642">The Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as retired as any repurchased shares become authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders&#8217; equity.</ix:continuation>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><ix:nonNumeric name="md:ProfessionalLiabilityCoveragePolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional Liability Coverage </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles or self-insured retention, exclusions and other restrictions. The Company&#8217;s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. </div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_18210631_18" continuedAt="TextSelectionAppend_18210631_19"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. If it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is provided against such deferred tax assets. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company&#8217;s reporting date. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock-based awards consisting primarily of restricted stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. The Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards on an annual basis and adjusts the estimates as necessary based on the number of awards that ultimately vest. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income Per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">88</div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_19" continuedAt="TextSelectionAppend_18210631_20"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div> </ix:continuation></ix:nonNumeric><ix:continuation id="TextSelectionAppend_18210631_20" continuedAt="TextSelectionAppend_18210631_21"> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_18210631_21" continuedAt="TextSelectionAppend_18210631_22"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">756,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">766,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,070,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,025,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210631_22">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</ix:continuation> </div></div> <ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:AvailableForSaleSecuritiesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Treasury securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210634">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,106,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,315,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">434,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To12_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,481,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To12_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,567,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2018To12_31_2018_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,529,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To12_31_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">218,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To12_31_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">197,340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2018To12_31_2018_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">181,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,733,951</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,779,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,723,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> payor mix, expressed as a percentage of net revenue, exclusive of administrative fees and other miscellaneous revenue, for the periods indicated: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To12_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To12_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2018To12_31_2018_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To12_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To12_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2018To12_31_2018_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To12_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To12_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2018To12_31_2018_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay patients</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To12_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To12_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2018To12_31_2018_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable consist primarily of amounts due from GHC Programs and third-party insurance payors for services provided by the Company&#8217;s affiliated physicians. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue consists primarily of gross billed charges for services provided by the Company&#8217;s affiliated physicians less an estimated allowance for contractual adjustments and uncollectibles to properly account for the anticipated differences between gross billed charge amounts and expected reimbursement amounts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s contractual adjustments and uncollectibles as a percentage of gross patient service revenue vary slightly each year depending on several factors, including improved managed care contracting, changes in reimbursement from state Medicaid programs and other GHC Programs, shifts in the percentage of patient services being reimbursed under GHC Programs and annual price increases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s annual price increases typically increase contractual adjustments as a percentage of gross patient service revenue. This increase is primarily due to Medicaid, Medicare and other GHC Programs that generally provide for reimbursements on a fee-schedule basis rather than on a gross charge basis. When the Company bills these programs, like other payors, on a gross-charge basis, it also increases its provision for contractual adjustments and uncollectibles by the amount of any price increase, resulting in a higher contractual adjustment percentage. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_18210634">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</ix:continuation> </div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210641"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment: </div></div></div></div> </td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelection_18210641" continuedAt="TextSelectionAppend_18210641_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Building</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BuildingsAndImprovementsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BuildingsAndImprovementsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Land" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Land" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment and other</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FixturesAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">203,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FixturesAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">192,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">236,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">225,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">160,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152,944</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210641_1">The Company recorded depreciation expense of $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.3</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">17.8</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</ix:continuation> </div></div> <ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company completed the acquisition of <ix:nonFraction name="md:NumberOfPediatricSubspecialtyPracticesAcquired" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> pediatric subspecialty practice for total consideration of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million, of which $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million was paid in cash and $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" contextRef="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million was recorded as a contingent consideration liability. This acquisition expanded the Company&#8217;s national network of physician practices. In connection with this acquisition, the Company recorded <div style="letter-spacing: 0px; top: 0px;;display:inline;">tax </div>deductible goodwill of $<ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million and other intangible assets consisting primarily of physician and hospital agreements of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company completed <ix:nonFraction name="md:NumberOfPhysicianGroupPracticesAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction> acquisitions, consisting of <ix:nonFraction name="md:NumberOfNeonatologyPracticesAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_Number" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> neonatology physician practices, <ix:nonFraction name="md:NumberOfRadiologyPracticesAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> maternal-fetal physician practices and <ix:nonFraction name="md:NumberOfPediatricSubspecialtyPracticesAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> other pediatric subspecialty practices for total cash consideration of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction> million and accrued purchase consideration of $<ix:nonFraction name="md:AccruedPurchaseConsideration" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million. These acquisitions expanded the Company&#8217;s national network of physician practices. In connection with these acquisitions, the Company recorded goodwill of $<ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="P01_01_2019To12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">36.5</ix:nonFraction> million, other intangible assets consisting primarily of physician and hospital agreements of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million and fixed assets of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million. The Company expects that all the goodwill recorded during the year ended December&#160;31, 2019 will be deductible for tax purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company paid $<ix:nonFraction name="us-gaap:PaymentsForPreviousAcquisition" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million for contingent consideration in connection with prior period acquisitions. <ix:nonFraction name="us-gaap:PaymentsForPreviousAcquisition" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> contingent consideration was paid by the Company in 2020. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210561"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill was $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.48</ix:nonFraction></ix:nonFraction> billion at December&#160;31, 2020 and 2019. Goodwill is tested for impairment on at least an annual basis, in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. Consistent with prior years, the Company performed its annual impairment test in the third quarter of 2020 and determined that goodwill was </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not impaired. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210561" continuedAt="TextSelectionAppend_18210561_1"><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net, consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">83,089</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">112,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">99,828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ther technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,417</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">103,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation></div> </div> </div> <div style="margin-block: 0em;">&#160;</div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210561_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company recorded intangible assets related to acquisitions totaling $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million, consisting primarily of physician and hospital agreements. The weighted-average amortization period for these physician and hospital agreements is approximately seven years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for existing intangible assets for the next five years is expected to be as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,966</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210639">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discontinued Operations: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Radiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;9, 2020, the Company entered into a securities purchase agreement with Radiology Partners, Inc.&#160;to divest the Company&#8217;s radiology services medical group, and the transaction closed on December&#160;15, 2020. The purchase consideration was comprised of a cash payment of $<ix:nonFraction name="md:PurchaseConsiderationCashPayment" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction>&#160;million paid at closing, subject to certain cash, minimum net working capital, indebtedness and other adjustments. The Company received approximately $<ix:nonFraction name="md:NetProceedsForTheRadiologyServicesMedicalGroup" contextRef="P12_15_2020To12_15_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">865</ix:nonFraction>&#160;million at closing and used the proceeds of the transaction to redeem its $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" contextRef="P07_01_2020To07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>&#160;million in outstanding principal amount of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction>% senior notes due 2023 (the &#8220;2023 Notes&#8221;) on January&#160;7, 2021. The operating results of the radiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. </div></div></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_18210639" continuedAt="TextSelectionAppend_18210639_1">The initial classification of the radiology services medical group to assets held for sale during the third quarter of 2020 impacted the net book value of the assets and liabilities expected to be transferred upon sale. The initial determination of the estimated fair value of the radiology services medical group was determined using the purchase price in the purchase agreement along with estimated broker, accounting, legal and other selling</ix:continuation> </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210639_1" continuedAt="TextSelectionAppend_18210639_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses. The Company deemed the carrying amount of other assets within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">of&#160;$</div><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P07_01_2020To09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">43.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which generated an additional $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million deferred tax asset that increased the fair value of the medical group. An incremental non-cash charge was then required to reduce the radiology services medical group&#8217;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental non-cash charge of $</div><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million for a total non-cash charge of $</div><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, reducing the goodwill balance of the radiology services medical group.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the divestiture, the Company recorded an additional loss on disposal of $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">36.4</ix:nonFraction>&#160;million based on estimated closing date net assets sold and final net proceeds. A closing working capital true up is expected to occur during the first quarter of 2021, and the Company will adjust the loss on sale as necessary at that time. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of income taxes, for the radiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">63.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">72.8</ix:nonFraction> million, respectively. Income from discontinued operations, net of income taxes, for the radiology services medical group for the year ended December&#160;31, 2018 was $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.4</ix:nonFraction> million. Net revenue for the radiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">451.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">489.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">444.0</ix:nonFraction> million, respectively. Operating loss for the radiology services medical group for the year ended December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">73.6</ix:nonFraction> million, including a non-cash goodwill impairment charge of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction> million and a preliminary loss on sale of $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">36.4</ix:nonFraction> million. Operating loss for the radiology services medical group for the year ended December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.3</ix:nonFraction> million, including a non-cash goodwill impairment charge of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">117.9</ix:nonFraction> million. Operating income for the radiology services medical group for the year ended December&#160;31, 2018 was $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelectionAppend_18210639_2" continuedAt="TextSelectionAppend_18210639_3">Divestiture of the Anesthesiology Services Medical Group</ix:continuation> </div></div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210639_3" continuedAt="TextSelectionAppend_18210639_4">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest the Company&#8217;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> to $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $<ix:nonFraction name="md:Accountsreceivableretained" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction> million at March&#160;31, 2020. The operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. A single anesthesiology practice was not included in the divestiture of the anesthesiology services medical group and continues to operate as an affiliate of the Company. Its results of operations are not material.</ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_18210639_4" continuedAt="TextSelectionAppend_18210639_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total loss on sale of the anesthesiology services medical group recorded during the year ended December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">663.7</ix:nonFraction> million. Upon completion of a valuation for the contingent economic interest, which is expected to be completed in the first quarter of 2021, the Company will adjust the loss on sale as necessary. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $<ix:nonFraction name="md:Capitallosscarryforward" contextRef="PAsOn12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.71</ix:nonFraction> billion capital loss carryforward that will expire in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">430.0</ix:nonFraction> million valuation allowance against this deferred tax asset as of December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of income taxes, for the anesthesiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">717.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.12</ix:nonFraction> billion, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><ix:continuation id="TextSelectionAppend_18210639_5" continuedAt="TextSelectionAppend_18210639_6"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">from discontinued operations, net of income taxes, for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $</div><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">99.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million. Net revenue for the anesthesiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">379.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion and $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.29</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion, respectively. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2020 was $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">716.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, including the loss on sale of $</div><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">663.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2019 was $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.23</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion, including a non-cash goodwill impairment charge of $</div><ix:nonFraction name="md:DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" contextRef="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.33</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion. Operating income for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $</div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">135.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million.</div></ix:continuation></div> <ix:continuation id="TextSelectionAppend_18210639_6"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, referred to as MedData. Loss from discontinued operations, net of tax, for MedData was $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">347.6</ix:nonFraction> million for the year ended December&#160;31, 2019, reflecting the loss on sale recorded during the year ended December&#160;31, 2019, as compared to income from discontinued operations, net of tax, of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million for 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company recorded a net incremental loss on the sale of MedData of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction> million, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consideration. </div></div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210640">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses: </div></div></div></div> </td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelection_18210640"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">incentive compensation</div> </div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedSalariesAndIncentiveCompensationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">184,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedSalariesAndIncentiveCompensationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">193,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,721</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">423,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">410,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210636"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted the new accounting guidance for leases on January&#160;1, 2019 using the modified retrospective method of applying the new guidance at the adoption date. Beginning with January&#160;1, 2019, the Company&#8217;s financial position is presented under the new guidance, while the prior period financial statements were not adjusted and continue to be reported in accordance with the previous guidance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company primarily leases property under operating leases and has one material equipment operating lease for an aircraft. The Company&#8217;s property leases are primarily for its regional, medical and business offices, storage space and temporary housing for medical staff. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of the lease payment using a discount rate that reflects the Company&#8217;s estimated incremental borrowing rate. Certain of the Company&#8217;s leases include rental escalation clauses and renewal options that are factored into the determination of lease payments when appropriate. Operating leases for office equipment are not material, and therefore are excluded from the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheet. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelection_18210636" continuedAt="TextSelectionAppend_18210636_1"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;table below presents the operating lease-related right-of-use assets and related liabilities recorded on the Company&#8217;s balance sheet and the weighted average remaining lease term and discount rate as of December&#160;31, 2020 and 2019 (dollars in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right-of-use assets</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Information:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average remaining lease term</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">4.0</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2019" format="ixt-sec:duryear">4.2</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents certain information related to the lease costs for operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equipment rent</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OtherEquipmentRent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OtherEquipmentRent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OperatingLeasesOtherCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:OperatingLeasesOtherCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="md:OperatingLeasesCashFlowRelatedInformationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows for operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210568"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the balance sheet as of December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> </div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 0pt;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210568"> <ix:continuation id="TextSelectionAppend_18210636_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount of payments representing interest</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current obligations</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:MalpracticeLossContingencyDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Professional Liabilities: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020 and 2019, the Company&#8217;s total accrued professional liabilities of $<ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscounted" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">315.9</ix:nonFraction> milli<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>n and $<ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscounted" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">249.6</ix:nonFraction> million, respectively, included incurred but not reported loss reserves of $<ix:nonFraction name="us-gaap:SelfInsuranceReserveCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">222.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SelfInsuranceReserveCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">187.6</ix:nonFraction>&#160;million, respectively, and loss reserves for reported claims of $<ix:nonFraction name="md:AccruedProfessionalLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">93.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="md:AccruedProfessionalLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">84.2</ix:nonFraction>&#160;million, respectively. Of the total liability, $<ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction> million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $<ix:nonFraction name="us-gaap:InsuranceSettlementsReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">61.4</ix:nonFraction> million recorded as a component of other assets for certain professional liability claims that are covered by third-party insurance policies. These reserves include the accrued professional liabilities for the Company&#8217;s continuing operations as<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">reflected in the table below as </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">well as certain retained professional liabilities related to the Company&#8217;s former anesthesiology and radiology medical groups that were divested in 2020. </div></div> <ix:nonNumeric name="md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s accrued professional liability for continuing operations, excluding the retained professional liabilities related to the Company&#8217;s former anesthesiology and radiology medical groups, for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">138,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities recognized, offset by insurance </div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">R</div>eceivable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision (adjustment) for losses related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToCurrentYear" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToCurrentYear" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToCurrentYear" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToPriorYear" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,551</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToPriorYear" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="md:ProvisionAdjustmentForLossesRelatedToPriorYear" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision for losses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyProvisionForLosses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyProvisionForLosses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyProvisionForLosses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Claim payments related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total payments</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,723</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">174,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net increase<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> in the Company&#8217;s total accrued professional liability for the years ended December&#160;31, 2020 and 2019 were primarily related to overall unfavorable trends in the Company&#8217;s claims experience that impacted its provision for losses. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210570">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line of Credit, Long-Term Debt and Finance Lease Obligations: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amended and restated </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $<ix:nonFraction name="md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction> million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis">4.50:1:00</ix:nonNumeric> to <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">5.00:1:00</ix:nonNumeric> for the second and third quarters of <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</ix:nonNumeric> and <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</ix:nonNumeric> for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> maintain minimum availability under the Credit Agreement of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v)&#160;temporarily restrict </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement provides for a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_31_2020_UnsecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction> million sub-facility for the issuance of letters of credit. The</div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_18210570" continuedAt="TextSelectionAppend_18210570_1">Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of the Company&#8217;s subsidiaries and affiliated professional associations and corporations. At the Company&#8217;s option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the <ix:nonNumeric name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_FederalFundsEffectiveSwapRateMemberusgaapVariableRateAxis">Federal Funds Rate plus 1/2 of 1.00%</ix:nonNumeric> and (c)&#160;<ix:nonNumeric name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis">LIBOR for an interest period of one month plus <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</ix:nonNumeric>) plus an applicable margin rate ranging from <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% to <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.750</ix:nonFraction>% based on the Company&#8217;s consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company&#8217;s consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.150</ix:nonFraction>% to <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.200</ix:nonFraction>% of the unused lending commitments, based on the Company&#8217;s consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that requires the Company to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability of the Company to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute a</ix:continuation></div>n event of default under the Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement. </div> <ix:continuation id="TextSelectionAppend_18210570_1" continuedAt="TextSelectionAppend_18210570_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2015, the Company completed a private offering of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">750.0</ix:nonFraction> million aggregate principal amount of <ix:nonNumeric name="md:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">2023</ix:nonNumeric> Notes. In November 2018, the Company completed a private offering of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million aggregate principal amount of <ix:nonNumeric name="md:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">2027</ix:nonNumeric> Notes and in February 2019, the Company completed a private offering of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_28_2019_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:numdotdecimal">500.00</ix:nonFraction> million aggregate principal amount of Additional 2027 Notes. At December&#160;31, 2019, the outstanding balance on the 2027 Notes was $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion. The Company&#8217;s obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Credit Agreement. Interest on the 2023 Notes accrues at the rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction></ix:nonFraction>%&#160;per annum, or $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">39.4</ix:nonFraction> million, and is <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateDescription" contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">payable semi-annually in arrears on June 1 and December 1</ix:nonNumeric>. Interest on the 2027 Notes accrues at the rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction></ix:nonFraction>%&#160;per annum, or $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">62.5</ix:nonFraction> million, and is <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateDescription" contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">payable semi-annually in arrears on January 15 and July 15</ix:nonNumeric>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">was able to</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> redeem all or a portion of the 2023 Notes, at the redemption prices of <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">101.313</ix:nonFraction>% in 2020 and <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% in 2021 and thereafter, plus accrued and unpaid interest to the redemption date. The 2023 Notes were redeemed </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">in full </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on January&#160;7, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any time prior to January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes at a redemption price equal to 100% of the principal amount of the notes being redeemed plus an applicable redemption premium and accrued and unpaid interest to the redemption date. In addition, at any time prior to January&#160;15, 2022, the Company may redeem up to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>% of the aggregate principal amount of the 2027 Notes at a redemption price of <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">106.250</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, using proceeds from one or more equity offerings. On or after January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes, at the redemption prices of <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">104.688</ix:nonFraction>% in 2022, <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFourMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">103.125</ix:nonFraction>% in 2023, <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFiveMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">101.563</ix:nonFraction>% in 2024 and <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodSixAndThereafterMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% in 2025 and thereafter, plus accrued and unpaid interest to the redemption date. </div></div> </ix:continuation></div> </div> <div style="margin-block: 0em;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">&#160;</div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210570_2" continuedAt="TextSelectionAppend_18210570_3"></ix:continuation></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indenture under which the 2027 Notes are issued, among other things, limits our ability to (1)&#160;incur liens and (2)&#160;enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the&#160;2027 Notes, upon the occurrence of a change in control of Mednax, we may be required to repurchase the&#160;2027 Notes at a purchase price equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">101</ix:nonFraction></ix:nonFraction>% of the aggregate principal amount of the 2027 Notes repurchased plus accrued and unpaid interest.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210570_3"><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of the Company&#8217;s long-term debt was $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction></ix:nonFraction> billion at December&#160;31, 2020 and 2019 and consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,733,657</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,731,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,730,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:LongTermDebtNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,727,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company presents issuance costs related to long-term debt liabilities, other than revolving credit arrangements, as a direct deduction from the carrying value of that long-term debt. The Company has one outstanding letter of credit which reduced the amount available under the Credit Agreement by $<ix:nonFraction name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million at December&#160;31, 2020. At December&#160;31, 2020, the Company had an available balance on its Credit Agreement of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">899.9</ix:nonFraction> million, after giving effect to the temporary reduction of the capacity of its Credit Agreement through September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of the Company&#8217;s variable rate revolving line of credit approximates fair value due to the short-term nature of the interest rates.<div style="display:inline;">&#160;</div><ix:nonNumeric name="md:SummaryOfEstimatedFairValueOfNotesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210572">The estimated fair value of the Company&#8217;s 2023 Notes and 2027 Notes were estimated using trading prices as of December&#160;31, 2020 and 2019, respectively, as Level 2 inputs to estimate fair value and are summarized as follows (in thousands):</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_18210572">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">756,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">766,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,070,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,025,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <ix:nonNumeric name="md:ScheduleOfFinanceLeaseObligationsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s finance lease obligations</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">, related to equipment used in its newborn hearing screen program,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease obligations</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">98</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210644">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes:</div></div></div></div> </td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelection_18210644" continuedAt="TextSelectionAppend_18210644_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax provision (benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,719</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,954</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,573</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,227</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> </div> </div> </div> <div><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:continuation id="TextSelectionAppend_18210644_1" continuedAt="TextSelectionAppend_18210644_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files its tax return on a consolidated basis with its subsidiaries, and its affiliated professional contractors file tax returns on an individual basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective tax rate for continuing operations was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">234.0</ix:nonFraction>%, <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">28.2</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">26.9</ix:nonFraction>% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The increase in the effective tax rate for the year ended December&#160;31, 2020 as compared to the years ended December&#160;31, 2019 and 2018 was due to a significant reduction in pre-tax income as a result of the impacts from the transformational and restructuring related expenses and <br/> COVID-19. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210577">The differences between the effective rate and the United States federal income tax statutory rate are as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="display:inline;"><ix:continuation id="TextSelection_18210577">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">24.34</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.45</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.41</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">60.44</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.98</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.85</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">98.61</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.45</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.78</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in accrual estimates relating to uncertain tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.22</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">9.63</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">23.67</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.39</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.71</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.45</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.42</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax law</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.71</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">233.99</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">28.19</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">26.91</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation></div></ix:continuation></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="display:inline;"><ix:continuation id="TextSelectionAppend_18210644_2" continuedAt="TextSelectionAppend_18210644_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the Company&#8217;s deferred tax assets and liabilities are classified as long-term. The significant components of deferred income tax assets and liabilities are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for uncollectible accounts</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">79,755</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,123</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves and accruals</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,445</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,685</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,517</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,493</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss and other carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,767</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,691</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">447,854</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,082</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="md:DeferredTaxAssetsOperatingLeaseAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,042</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="md:DeferredTaxAssetsOperatingLeaseAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,389</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,044</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,986</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">571</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">634,995</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">279,449</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">458,708</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,286</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net of valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">176,287</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">260,163</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152,969</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,587</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting method changes</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="md:DeferredTaxLiabilitiesChangeInAccountingMethod" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,352</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="md:DeferredTaxLiabilitiesChangeInAccountingMethod" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,532</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,405</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">183</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">463</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">183,561</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">229,987</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="width: 69%;"><div style="margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Net deferred tax (liabilities) assets</div> </div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,274</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,176</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation></div></ix:nonNumeric></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:continuation id="TextSelectionAppend_18210644_3" continuedAt="TextSelectionAppend_18210644_4"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s net deferred tax liabilities were $<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million as of December&#160;31, 2020, as compared to net deferred tax assets of $<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">30.2</ix:nonFraction> million at December&#160;31, 2019. The increase in net deferred tax liabilities of $<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction> million during the year ended December&#160;31, 2020 was primarily related to a decrease in deferred tax assets related to allowance for uncollectible accounts partially offset by decrease in deferred tax liabilities for accounting method changes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020, 2019 and 2018, income tax expense of $<ix:nonFraction name="md:IncomeTaxExpenseForExcessTaxDeficiencies" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million, $<ix:nonFraction name="md:IncomeTaxExpenseForExcessTaxDeficiencies" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million and $<ix:nonFraction name="md:IncomeTaxExpenseForExcessTaxDeficiencies" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million, respectively, was recognized for excess tax deficiencies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For</div> the year ended December&#160;31, 2020, the Company estimates that it will generate a $<ix:nonFraction name="md:CapitalLossesIncurred" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion capital loss, from the sale of its anesthesiology services medical group, which will expire in 2025. Total capital loss carryforwards as of December 31, 2020 was</div>&#160;$<ix:nonFraction name="md:CapitalLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion. As of December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2020, management has determined that it is more likely than not that the tax benefits related to these carryforwards will not be realized and has recorded a full valuation allowance against the related deferred tax assets. Additionally, the Company has net operating loss carryforwards for federal and state<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>tax purposes totaling $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">35.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.8</ix:nonFraction> million at December&#160;31, 2020, 2019 and 2018, respectively. With respect to the December&#160;31, 2020 balance, $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction> million expires at various times from <ix:nonNumeric name="md:NetOperatingLossCarryForwardsExpirationDate" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">2022</ix:nonNumeric> through <ix:nonNumeric name="md:NetOperatingLossCarryForwardsExpirationDate" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">2040</ix:nonNumeric>, and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">13.1</ix:nonFraction> million does not expire. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, 2019 and 2018, the Company&#8217;s liability for uncertain tax positions, excluding accrued interest and penalties, was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction> million, respectively. As of December&#160;31, 2020, the Company had $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million of uncertain tax positions that, if recognized, would favorably impact its effective tax rate.</div></div> </ix:continuation></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="display:inline;"><ix:continuation id="TextSelectionAppend_18210644_4" continuedAt="TextSelectionAppend_18210644_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s liability for uncertain tax positions for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,409</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,185</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,972</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">369</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">385</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,041</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,700</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,900</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to divestitures</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="md:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">300</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to lapse of statutes of limitation</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,845</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,072</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,168</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,409</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,185</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation></div></ix:nonNumeric></div> <div style="display:inline;"><ix:continuation id="TextSelectionAppend_18210644_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company decreased its liability for uncertain tax positions by $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million, primarily related to a reduction in tax liability for prior year positions. During the year ended December&#160;31, 2019, the Company decreased its liability for uncertain tax positions by $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million, primarily related to expiration of statutes of limitation, partially offset by additional taxes on current and prior year positions. In addition, the Company anticipates that its liability for uncertain tax positions will decrease by $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million over the next 12 months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company includes interest and penalties related to income tax liabilities in income tax expense. During the year ended December&#160;31, 2020, the Company included $<ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million of interest and penalties in income tax expense. The impact to income tax expense related to penalties and interest was not material during the years <div style="letter-spacing: 0px; top: 0px;;display:inline;">ended </div>December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2019 and 2018. At December&#160;31, 2020 and 2019, the Company&#8217;s accrued liability for interest and penalties related to income tax liabilities totaled $<ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is currently subject to U.S. Federal and various state income tax examinations for the tax years <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2020To12_31_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis">2015</ix:nonNumeric> through <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2019To12_31_2019_LatestTaxYearMemberusgaapTaxPeriodAxis">2019</ix:nonNumeric>. </div></div> </ix:continuation></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div></div></td></tr></table> <div style="display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per share calculation for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;">&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,395</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,495</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91,104</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">516</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">502</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">equivalent shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,395</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,011</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91,606</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">net income per common share calculation</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,034</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">516</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">214</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div>&#160;</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the year ended December&#160;31, 2020, no incremental shares are included because the effect would be antidilutive. </div></div></td></tr></table> </ix:nonNumeric></div></ix:nonNumeric></div> <div style="display:inline;"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210580"><div style="font-size: 12pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</div></div></ix:nonNumeric></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210580" continuedAt="TextSelectionAppend_18210580_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the A&amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and generally become exercisable on a pro rata basis over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards and stock options ratably over the corresponding vesting periods. At December&#160;31, 2020, the Company had <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million shares available for future grants and awards under its Amended and Restated 2008 Incentive Plan. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Company&#8217;s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. Under the Company&#8217;s 2015 <br/> Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To12_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of the ESPP and the SPP provide for the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the year ended December&#160;31, 2020, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million shares in the aggregate were issued under the ESPP and SPP. At December&#160;31, 2020, the Company had approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">21.1</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">33.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">36.4</ix:nonFraction>&#160;million of stock-based compensation expense related to its stock incentive plans, the ESPP and the SPP during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210654"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s restricted stock and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December&#160;31, 2020 are as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:nonNumeric><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_18210654">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Fair<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at January 1, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,723,115</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">40.77</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,361,712</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">23.54</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">173,455</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">31.68</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,700,255</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">34.88</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at December 31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,211,117</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">30.97</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr></table></ix:continuation></ix:continuation><div>&#160;</div></div></div></div> <div> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210580_1" continuedAt="TextSelectionAppend_18210580_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of the restricted and deferred stock that vested during the years ended December&#160;31, 2020, 2019 and 2018 was <br/> $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">59.3</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.4</ix:nonFraction> million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant-date fair value of restricted and deferred stock awards that were granted during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">23.54</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">33.28</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">51.99</ix:nonFraction>, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, the total stock-based compensation cost related to non-vested restricted and deferred stock remaining to be recognized as compensation expense over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2020To12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.8</ix:nonNumeric> years was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction> million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted various performance-based stock options during the year ended December&#160;31, 2020 with vesting dependent on both continued employment and the achievement of various stock price hurdles over a </div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_18210580_2"> <div style="text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">period of three years. The Company used a Monte Carlo simulation analysis to estimate the fair value of each stock option on the date of grant during 2020. The Monte Carlo simulation uses a series of functions that define a range of possibilities, or probability density functions and repeatedly samples from the ranges of those possibilities. Finally, the model calculates and sums the weighted average results of all the iterations. The weighted average grant date fair value for the stock options granted in 2020 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.21</ix:nonFraction>. The key assumptions used in the Monte Carlo simulation analysis were expected volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%, expected term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:durwordsen">three years</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;and a</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> discount rate using the three year&#160;U.S. Treasury bond rate. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity and certain other information related to the Company&#8217;s outstanding stock option awards for the year ended December&#160;31, 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="white-space: nowrap;"></td>
<td style="white-space: nowrap;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">72,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">32.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">982,731</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">56,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">31.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">999,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">17.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">2.58</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">16,560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">36.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">0.34</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2019 and 2018 were $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, the total stock-based compensation related to non-vested stock options remaining to be recognized as compensation expense over a weighted average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.6</ix:nonNumeric> years was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash proceeds received from the exercise of stock options for the years ended December&#160;31, 2019 and 2018 were $<ix:nonFraction name="us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million, respectively. </div></div> </ix:continuation> <ix:nonNumeric name="md:CommonStockRepurchasesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210638"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the year ended December&#160;31, 2020. </div></div></ix:nonNumeric> </div> </div> <div style="margin-block: 0em;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210638" continuedAt="TextSelectionAppend_18210638_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn08_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $<ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.2</ix:nonFraction> million remained available for repurchase as of January&#160;1, 2020. Under this share repurchase program, during the twelve months ended December&#160;31, 2020, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> repurchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapCollateralAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million shares of </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">its</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> common stock for $<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction> million to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company repurchased approximately <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapCollateralAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction>&#160;million shares of its common stock for $<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">145.3</ix:nonFraction> million, inclusive of <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">96,918</ix:nonFraction> shares withheld to satisfy minimum statutory withholding obligations of $<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million in connection with the vesting of restricted stock during the year ended December&#160;31, 2019.</div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_18210638_1">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</ix:continuation> </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retirement Plans: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains three qualified contributory savings plans as allowed under Section&#160;401(k) of the Internal Revenue Code and Section&#160;1165(e) of the Puerto Rico Income Tax Act of 1954 (the &#8220;401(k) Plans&#8221;). The 401(k) Plans permit participant contributions and allow elective and, in certain situations, non-elective Company contributions based on each participant&#8217;s contribution or a specified percentage of eligible wages. Participants may defer a percentage of their annual compensation subject to the limits defined in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">401(k) Plans. The Company&#160;</div> recorded expense for its continuing operations of $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.9</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">24.9</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, primarily related to the 401(k) Plans. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of December&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">104&#160;</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:QuarterlyFinancialInformationTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210529">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Quarterly Financial Information (Unaudited): </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_18210172"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth a summary of the Company&#8217;s selected quarterly financial information for each of the four quarters ended December&#160;31, 2020 and 2019 (in thousands, except for per share data): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">441,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">415,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">460,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">416,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">316,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">282,985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">309,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">284,772</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,751</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">430,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">380,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">440,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">384,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other (expense) income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,534</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.78in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">(Loss) income from continuing operations before<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Loss) income from continuing operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,652</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">679,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">38,392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">68,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">105&#160;</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_18210172"> <ix:continuation id="TextSelection_18210529">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td>
<td style="vertical-align: bottom; width: 2%;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%; white-space: nowrap;"></td>
<td style="width: 0%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">427,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">439,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">454,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">458,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">284,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">301,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">300,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,705</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,023</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">387,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">396,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">406,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">418,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,144</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,657</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">255,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,772</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,268,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (loss) income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table> </ix:continuation> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_14" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_15" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;9A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONTROLS AND PROCEDURES </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Securities Exchange Act of 1934, as amended). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> promulgated under the Securities Exchange Act of 1934, as amended. The Company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of the end of the period covered by this report. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in &#8220;Internal Control&#8212;Integrated Framework (2013).&#8221; Based on our assessment we concluded that, as of the end of the period covered by this report, the Company&#8217;s internal control over financial reporting was effective based on those criteria. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s independent registered certified public accounting firm, PricewaterhouseCoopers LLP, has audited our internal control over financial reporting as of December&#160;31, 2020 as stated in their report which appears in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control Over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No change in our internal control over financial reporting occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_16" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;9B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OTHER INFORMATION </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have scheduled the Company&#8217;s 2021 annual meeting of shareholders (the &#8220;2021 Annual Meeting&#8221;) for May&#160;12, 2021. The time and location of the 2021 Annual Meeting will be specified in the Company&#8217;s notice and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">proxy statement for the 2021 Annual Meeting. In accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;14a-5(f)&#160;under</div> the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), we are informing shareholders of the Company that those shareholders who wish to have a proposal considered for inclusion in the Company&#8217;s proxy materials for the 2021 Annual Meeting pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;14a-8&#160;under</div> the Exchange Act must ensure that such proposal is received by the Company&#8217;s Secretary at Mednax, Inc., 1301 Concord Terrace, Sunrise, Florida 33323, on or prior to March&#160;10, 2021, which the Company has determined to be a reasonable time before it expects to begin to print and send notice of its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the SEC in order to be eligible for inclusion in the proxy materials for the 2021 Annual Meeting. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc51794_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_18" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference to the applicable information in the definitive proxy statement for our 2021 Annual Meeting of Shareholders, which is to be filed with the SEC within 120 days after our fiscal year end. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_19" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE COMPENSATION </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference to the applicable information in the definitive proxy statement for our 2021 Annual Meeting of Shareholders, which is to be filed with the SEC within 120 days after our fiscal year end. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_20" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;12.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information as of December&#160;31, 2020, with respect to shares of our common stock that may be issued under existing equity compensation plans, including our Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;), our ESPP and our SPP. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 19%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 19%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 19%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Plan Category</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;securities&#160;to&#160;be&#160;issued<br/> upon&#160;exercise&#160;of&#160;outstanding<br/> options,&#160;warrants&#160;and&#160;rights</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average&#160;exercise</div><br/> price&#160;of&#160;outstanding<br/> options,&#160;warrants&#160;and&#160;rights</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;securities&#160;remaining<br/> available&#160;for&#160;future&#160;issuance<br/> under&#160;equity&#160;compensation<br/> plans&#160;(excluding&#160;securities<br/> reflected&#160;in&#160;column&#160;(a))</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(b)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(c)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation plans approved by security holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">(1)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,563,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">(2)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation plans not approved by security holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,563,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All shares are issuable under the Amended and Restated 2008 Incentive Plan. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Amended and Restated 2008 Incentive Plan, 5,018,358 shares remain available for future issuance, and under the ESPP and the SPP, an aggregate of 544,914 shares remain available for future issuance. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining information required by this Item is incorporated by reference to the applicable information in the definitive proxy statement for our 2021 Annual Meeting of Shareholders, which is to be filed with the SEC within 120 days after our fiscal year end. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_21" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference to the applicable information in the definitive proxy statement for our 2021 Annual Meeting of Shareholders, which is to be filed with the SEC within 120 days after our fiscal year end. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_22" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRINCIPAL ACCOUNTANT FEES AND SERVICES </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference to the applicable information in the definitive proxy statement for our 2021 Annual Meeting of Shareholders, which is to be filed with the SEC within 120 days after our fiscal year end. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc51794_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART IV </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_24" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;15.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULE </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(1)&#160;&#160;&#160;&#160;Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The information required by this Item is included in Item 8 of Part II of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(2)&#160;&#160;&#160;&#160;Financial Statement Schedule </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following financial statement schedule for the years ended December&#160;31, 2020, 2019 and 2018, is included in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> as set forth below (in thousands). </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mednax, Inc. </div></div></div> <div id="toc51794_109" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule II: Valuation and Qualifying Accounts </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">746,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">641,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount charged against operating revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,776,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,760,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,459,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable contractual adjustments and write-offs (net of recoveries)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,730,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,763,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,351,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">791,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">746,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All other schedules have been omitted because they are not applicable, not required or the information is included elsewhere herein. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(3) Exhibits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">See Item 15(b) of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(b)</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312509000041/dex21.htm">Agreement and Plan of Merger, dated as of December&#160;29, 2008, between Mednax, Inc., Pediatrix Medical Group, Inc. and PMG Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K12B,</span> dated January&#160;2, 2009). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519265496/d811805dex21.htm">Securities Purchase Agreement, dated October&#160;10, 2019, by and between Mednax Services, Inc. and FH MD Buyer, Inc. (incorporated by reference to Exhibit 2.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed on October&#160;10, 2019).</a>**</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520140531/d915708dex21.htm">Securities Purchase Agreement, dated as of May&#160;6, 2020, by and between Mednax Services, Inc. and NMSC II, LLC (incorporated by reference to Exhibit 2.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on May&#160;12, 2020).</a>**</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520245502/d48531dex21.htm">Securities Purchase Agreement, dated as of September&#160;9, 2020, by and between Mednax Services, Inc. and Radiology Partners, Inc. (incorporated by reference to Exhibit 2.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on September&#160;15, 2020).</a>**</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312514045903/d661956dex31.htm">Composite Articles of Incorporation of Mednax, Inc. (incorporated by reference to Exhibit 3.1 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the period ended December&#160;31, 2013). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312518319651/d651142dex31.htm">Amended and Restated <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">By-laws</span> of Mednax, Inc. (incorporated by reference to Exhibit 3.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated November&#160;6, 2018). </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312515397783/d32768dex43.htm">Form of 5.25% Senior Notes due 2023 (incorporated by reference to Exhibit A of the First Supplemental Indenture filed as Exhibit 4.3 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated December&#160;8, 2015). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312518325590/d612902dex43.htm">Form of 6.25% Senior Notes due 2027 (incorporated by reference to Exhibit A of the Fifth Supplemental Indenture filed as Exhibit 4.3 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated November&#160;13, 2018). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312515397783/d32768dex42.htm">Indenture, dated as of December&#160;8, 2015, by and between Mednax, Inc. and U.S. Bank National Association, as Trustee. (incorporated by reference to Exhibit 4.2 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated December&#160;8, 2015). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312515397783/d32768dex43.htm">First Supplemental Indenture dated as of December&#160;8, 2015 to the Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee. (incorporated by reference to Exhibit 4.3 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated December&#160;8, 2015). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312518045748/d463027dex104.htm">Second Supplemental Indenture dated as of March&#160;30, 2017 to the Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee. (incorporated by reference to Exhibit 10.4 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the period ended December&#160;31, 2017). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312518045748/d463027dex105.htm">Third Supplemental Indenture dated as of November&#160;9, 2017 to the Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee. (incorporated by reference to Exhibit 10.5 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2017). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519040891/d671465dex107.htm">Fourth Supplemental Indenture dated as of November&#160;13, 2018 to the Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 10.7 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2018). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312518325590/d612902dex43.htm">Fifth Supplemental Indenture dated as of November&#160;13, 2018 to Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee. (incorporated by reference to Exhibit 4.3 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> dated November&#160;13, 2018). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519135054/d709210dex102.htm">Sixth Supplemental Indenture dated as of February&#160;21, 2019 to the Indenture, dated as of December&#160;8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 10.2 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the period ended March&#160;31, 2019). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520042622/d834090dex410.htm">Description of Securities of Mednax, Inc. (incorporated by reference to Exhibit 4.10 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the period ended December&#160;31, 2019). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312517329442/d240444dex101.htm">Credit Agreement, dated as of October&#160;30, 2017, among Mednax, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lender parties thereto, JPMorgan Chase Bank, N.A. as Administrative Agent and Bank of America, N.A., Fifth Third Bank, Mizuho Bank, Ltd., SunTrust Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., and Wells Fargo Bank, National Association as Syndication Agents, and BBVA Compass, Citizens Bank, N.A., PNC Bank, Regions Bank, and U.S. Bank National Association, as Senior Documentation Agents and BB&amp;T as Documentation Agent. JPMorgan Chase Bank, N.A, Fifth Third Bank, Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated, Mizuho Bank, Ltd., SunTrust Robinson Humphrey, Inc., The Bank of Tokyo-Mitsubishi UFJ, Ltd., and Wells Fargo Securities, LLC, acted as Joint Lead Arrangers and Joint Bookrunners. (incorporated by reference to Exhibit 10.1 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the period ended September&#160;30, 2017). </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519040891/d671465dex1010.htm">Amendment No.&#160;1, dated as of November&#160;21, 2018, to the Credit Agreement, dated as of October&#160;30, 2017, among Mednax, Inc. certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders parties thereto and JPMorgan Chase Bank, N.A. as Administrative Agent (incorporated by reference to Exhibit 10.10 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2018).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519135054/d709210dex101.htm">Amendment No.&#160;2, dated as of March&#160;28, 2019, to the Credit Agreement, dated as of October&#160;30, 2017, among Mednax, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders parties thereto, and JPMorgan Chase Bank, N.A. as Administrative Agent (incorporated by reference to Exhibit 10.1 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the period ended March&#160;31, 2019). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520136311/d888266dex101.htm">Amendment No.3, dated as of March&#160;25, 2020, to the Credit Agreement, dated as of October&#160;30, 2017, among Mednax, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. (incorporated by reference to Exhibit 10.1 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the period ended March&#160;31, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312515323425/d62915ddef14a.htm">Amended and Restated Mednax, Inc. 1996 <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</span> Employee Stock Purchase Plan (incorporated by reference to Exhibit A to Mednax&#8217;s Definitive Proxy Statement on Schedule 14A, filed with the SEC on September&#160;18, 2015).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312515323425/d62915ddef14a.htm">2015 <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</span> Stock Purchase Plan of Mednax, Inc., dated September&#160;14, 2015 (incorporated by reference to Exhibit B to Mednax&#8217;s Proxy Statement dated September&#160;18, 2015).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/0001042910-98-000741.txt">Executive <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</span> Deferred Compensation Plan of Pediatrix, dated October&#160;13, 1997 (incorporated by reference to Exhibit 10.35 to Pediatrix&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the period ended June&#160;30, 1998).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000095014402011954/g79340exv4w5.txt">Amended and Restated Thrift and Profit Sharing Plan of Pediatrix (incorporated by reference to Exhibit 4.5 to Pediatrix&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> (Registration No.<span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-101222)).*</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000095014404011924/g92297exv4w3.txt">Pediatrix Medical Group of Puerto Rico Thrift and Profit Sharing Plan (incorporated by reference to Exhibit 4.3 to Pediatrix&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> dated December&#160;9, 2004).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312519092753/d716213ddef14a.htm#rom716213_93">Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan (incorporated by reference to Exhibit A to Mednax&#8217;s Definitive Proxy Statement on Schedule 14A dated March&#160;29, 2019).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.11</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312509040133/dex1017.htm">Mednax, Inc. Form of <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</span> Stock Option Agreement for <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</span> Stock Options Awarded Under the 2008 Incentive Compensation Plan (incorporated by reference to Exhibit 10.17 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2008).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.12</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312509040133/dex1018.htm">Mednax, Inc. Form of Restricted Stock Agreement for Restricted Stock Awarded Under the 2008 Incentive Compensation Plan (incorporated by reference to Exhibit 10.18 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2008).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.13</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520191602/d82405dex102.htm">Separation Agreement, dated July&#160;12, 2020, by and between Mednax Services, Inc. and Roger J. Medel, M.D. (incorporated by reference to Exhibit 10.2 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on July&#160;13, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.14</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520203325/d919859dex101.htm">Employment Agreement, dated July&#160;12, 2020, by and between Mednax Services, Inc. and Mark S. Ordan (incorporated by Reference to Exhibit 10.1 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the quarter ended June&#160;30, 2020, filed on July&#160;30, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.15</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520287356/d44327dex104.htm">Employment Agreement, effective September&#160;8, 2020, by and between Mednax Services, Inc. and C. Marc Richards (incorporated by reference to Exhibit 10.4 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the quarter ended September&#160;30, 2020, filed on November&#160;6, 2020).* </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520287356/d44327dex105.htm">Employment Agreement, effective September&#160;27, 2020, by and between Mednax Services, Inc. and Dominic J. Andreano (incorporated by reference to Exhibit 10.5 to Mednax&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the quarter ended September&#160;30, 2020, filed on November&#160;6, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.17</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520042622/d834090dex1025.htm">Employment Agreement, dated August&#160;1, 2019, by and between Mednax Services, Inc. and John C. Pepia (incorporated by reference to Exhibit 10.25 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2019, filed on February&#160;20, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.18</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1028.htm">First Amendment to Employment Agreement, effective April&#160;1, 2020, by and between Mednax Services, Inc. and John C. Pepia (incorporated by reference to Exhibit 10.28 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019, filed on April&#160;28, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.19</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1023.htm">Amended and Restated Employment Agreement, dated February&#160;13, 2020, by and between Mednax Services, Inc. and Stephen D. Farber (incorporated by reference to Exhibit 10.23 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019, filed on April&#160;28, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1024.htm">First Amendment to Amended and Restated Employment Agreement, effective April&#160;1, 2020, by and between Mednax Services, Inc. and Stephen D. Farber. (incorporated by reference to Exhibit 10.24 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019, filed on April&#160;28, 2020).* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.21+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex1021.htm">Amended and Restated Employment Agreement, effective September&#160;27, 2020, by and between Mednax Services, Inc. and Roger Mack Hinson, M.D.* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.22</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312512089192/d255020dex1031.htm">Form of Exclusive Management and Administrative Services Agreement with affiliated professional contractors (incorporated by reference to Exhibit 10.31 to Mednax&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> for the year ended December&#160;31, 2011). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.23</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520191602/d82405dex101.htm">Agreement, dated as of July&#160;12, 2020, by and among Mednax, Inc., Starboard Value LP and certain of its affiliates (incorporated by reference to Exhibit 10.1 to Mednax&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on July&#160;13, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;21.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex211.htm">Subsidiaries of the Registrant. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;23.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex231.htm">Consent of PricewaterhouseCoopers LLP. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex311.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex312.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32++</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d51794dex32.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Interactive Data File</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Schema Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Calculation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Definition Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Label Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Presentation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management contracts or compensation plans, contracts or arrangements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Portions of this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> because they are both (i)&#160;not material and (ii)&#160;would likely cause competitive harm to the registrant if publicly disclosed. The schedules and similar </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">++</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furnished herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc51794_25" style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> SUMMARY </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 5%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 44%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MEDNAX, INC.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: February&#160;18, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mark S. Ordan</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;&#160;&#160;&#160;&#160;Mark S. Ordan</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;&#160;&#160;&#160;&#160;Chief Executive Officer</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mark S. Ordan</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mark S. Ordan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer, Director</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Executive Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ C. Marc Richards</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">C. Marc Richards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Financial Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Financial Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John C. Pepia</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John C. Pepia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Vice President and</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Accounting Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Accounting Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Guy P. Sansone</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guy P. Sansone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director and Chair of the Board</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Manuel Kadre</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manuel Kadre</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Lead Independent Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Karey D. Barker</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karey D. Barker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Waldemar A. Carlo, M.D.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Waldemar A. Carlo, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Paul G. Gabos</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul G. Gabos</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Thomas A. McEachin</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thomas A. McEachin</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Roger J. Medel, M.D.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roger J. Medel, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Michael A. Rucker</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael A. Rucker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John M. Starcher, Jr.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John M. Starcher, Jr.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Shirley A. Weis</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shirley A. Weis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">February&#160;18, 2021</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>d51794dex1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.21 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is made and entered into by and between <B>MEDNAX
SERVICES, INC.</B>, a Florida corporation (&#147;<U>Employer</U>&#148;), and Roger Mack Hinson, M.D. (&#147;<U>Employee</U>&#148;) effective as of September&nbsp;27, 2020 (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Employer is presently engaged in &#147;Employer&#146;s Business&#148; as defined on <U>Exhibit</U><U></U><U>&nbsp;A</U>
hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer desires to continue employing Employee and benefit from Employee&#146;s contributions to Employer; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer and Employee previously entered in an Employment Agreement dated August&nbsp;1, 2019, as amended, which will be
superseded in its entirety upon the execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants and
premises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Employee hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. Employment. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1
<I>Employment and Term</I>. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an &#147;<U>Initial Term</U>&#148; commencing as of the Effective Date and continuing
for a period of three (3)&nbsp;years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee hereunder shall automatically renew for successive one (1)&nbsp;year periods until terminated in accordance herewith. The
Initial Term and any automatic renewals shall be referred to as the &#147;<U>Employment Period</U>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <I>Duties of Employee</I>.
As of the Effective Date and thereafter during the remaining Employment Period, Employee shall serve as President, Pediatrix&nbsp;&amp; Obstetrix Medical Groups, of Employer and MEDNAX, Inc., a Florida corporation and the parent corporation of
Employer (&#147;<U>MEDNAX</U>&#148;), and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by the most senior executive officer of MEDNAX (&#147;<U>Employee&#146;s
Supervisor</U>&#148;) or the Board of Directors of MEDNAX (the &#147;<U>Board</U>&#148;) including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of MEDNAX; <I>provided, </I>that
such duties as assigned shall be customary to Employee&#146;s role as an executive officer of Employer and MEDNAX. Employee&#146;s employment shall be full-time and, as such, Employee agrees to devote substantially all of Employee&#146;s attention
and professional time to the business and affairs of Employer and MEDNAX. Employee shall perform Employee&#146;s duties honestly, diligently, competently, in good faith and in the best interest of Employer and MEDNAX. During the Employment Period,
Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar capacity for
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any institution other than Employer and MEDNAX, and their respective subsidiaries and affiliates in accordance with this <U>Section</U><U></U><U>&nbsp;1.2</U>. During the Employment Period, it
shall not be a violation of this Agreement to (i)&nbsp;serve on civic or charitable boards or committees, or (ii)&nbsp;deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities have been approved
by Employee&#146;s Supervisor and do not interfere with the performance of Employee&#146;s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of <U>Section</U><U></U><U>&nbsp;8</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <I>Place of Performance</I>. Employee shall be based at Employer&#146;s offices located in Seattle, Washington, except for required travel
relating to Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. Base Salary and Performance Bonus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <I>Base Salary</I>. Employer shall pay Employee during the Employment Period an annual salary of Five Hundred Fifty Thousand Dollars
($550,000) (the &#147;<U>Base Salary</U>&#148;), payable in accordance with Employer&#146;s normal business practices for senior executives (including tax withholding), but in no event less frequently than monthly. Employee&#146;s Base Salary shall
be reviewed at least annually by the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;) and may be increased in its discretion. After any such increase in Base Salary, the term &#147;<U>Base Salary</U>&#148; shall
refer to the increased amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <I>Performance Bonus</I>. Employee shall be eligible to receive a cash bonus (the &#147;<U>Performance
Bonus</U>&#148;) for each year (or prorated with respect to any partial years of employment) during the Employment Period, provided that, except as otherwise provided herein, Employee has remained employed by Employer as of the end of the applicable
year (or as of the end of the Employment Period for the final calendar year of the Employment Period). Employee&#146;s target bonus opportunity for any particular year (&#147;<U>Target Bonus</U>&#148;) shall be one hundred percent (100%) of Base
Salary. The amount of bonus payable to Employee for any particular year will be determined by the Compensation Committee, in its sole discretion, taking into account the performance of Employer and Employee for that particular year (or portion
thereof). All such bonuses shall be paid no later than March 15th of the calendar year immediately following the calendar year in which it is earned. Notwithstanding the foregoing, the Performance Bonus with respect to the 2020 calendar year shall
be paid at one hundred percent (100%) of Base Salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Benefits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <I>Expense Reimbursement</I>. Employer shall promptly reimburse Employee for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employer&#146;s Business pursuant to the reimbursement standards and guidelines of
Employer in effect from time to time, including reimbursement for appropriate professional organizations. Employee shall account for such expenses and submit reasonable supporting documentation in accordance with Employer&#146;s policies in effect
from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <I>Employee Benefits</I>. During the Employment Period, Employee shall be entitled to participate in such health,
welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and
programs are applicable to other similarly situated employees of Employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <I>Leave Time</I>. During the Employment Period, Employee shall be entitled to paid
vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by
Employer policy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <I>Equity Plans. </I>During the Employment Period, the Chief Executive Officer of MEDNAX shall recommend to the
Compensation Committee that Employee receive, on an annual basis following the Effective Date, and at the same time as other executive officers of Employer, grants of awards (each an &#147;<U>Equity Award</U>&#148;) pursuant to MEDNAX&#146;s Amended
and Restated 2008 Incentive Compensation Plan, as amended (the &#147;<U>2008 Plan</U>&#148;), or any other similar plan adopted by MEDNAX (together with the 2008 Plan, each an &#147;<U>Equity Plan</U>&#148;), with a grant value determined by the
Compensation Committee in the same manner as for other executive officers of Employer. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and the terms of the applicable Equity Plan, and shall be made
subject to an award agreement that is consistent with terms applicable to other executive officers of Employer. Notwithstanding any contrary provision in this Agreement or any Equity Plan then maintained by MEDNAX, if Employee remains continuously
employed with Employer through the date of a Change in Control (as defined in the Equity Plan pursuant to which the Equity Award is issued), then upon such Change in Control (i)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX shall
immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable and (ii)&nbsp;all performance-based Equity Awards for which the applicable performance condition has been met at the time of
such Change in Control shall immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable. For purposes of clarification, the vesting of any performance-based Equity Awards for which the
performance condition has not been met at the time of such Change in Control shall not be accelerated or otherwise modified pursuant to this <U>Section</U><U></U><U>&nbsp;3.4</U> but such Equity Awards may nonetheless be accelerated or otherwise
modified as determined by the Company under the terms of the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. Termination; Compensation and Benefits Upon Termination.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <I>Termination for Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement for Cause (as defined below).
The termination date for a termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.1</U> shall be the date specified by Employer in a written notice to Employee of finding of Cause. If
Employee&#146;s employment is terminated for Cause, Employer shall pay (i)&nbsp;Employee&#146;s Base Salary through the termination date at the rate in effect at the termination date, (ii)&nbsp;reimbursement for reasonable business expenses incurred
prior to the termination date, subject to Employer policy and the provisions of <U>Section</U><U></U><U>&nbsp;3.1</U> hereof, and (iii)&nbsp;any other benefits that are vested benefits under applicable Employer benefit plans or that are required by
applicable law (the foregoing clauses (i)-(iii), the &#147;<U>Accrued Obligations</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <I>Disability</I>. Employer may terminate Employee&#146;s employment under this
Agreement upon the Disability (as defined below) of Employee. The termination date for a termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U> shall be the date specified by Employer in a notice to Employee. In the
event of Employee&#146;s Disability, (i)&nbsp;Employee shall continue to receive Employee&#146;s Base Salary for ninety (90)&nbsp;days under the Company&#146;s short term disability policy, which may be amended or modified in the Company&#146;s
discretion upon written notice to Employee (the &#147;<U>Initial Disability Period</U>&#148;), and (ii)&nbsp;following such Initial Disability Period, if Employee&#146;s Disability continues, the Company may terminate Employee&#146;s employment
immediately upon written notice. If Employee&#146;s employment is terminated in connection with Employee&#146;s Disability, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of
<U>Section</U><U></U><U>&nbsp;5</U> hereof, Employee shall be eligible to receive (A)&nbsp;a bonus with respect to Employer&#146;s fiscal year in which the termination date occurs, equal to Employee&#146;s minimum Target Bonus for the year of
termination, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365) (a &#147;<U><FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus</U>&#148;) payable
within thirty (30)&nbsp;days of the termination date; and (B)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX prior to termination of Employee&#146;s employment shall immediately become fully vested,
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable, and all performance-based shares awards shall remain outstanding and shall vest based upon actual performance determined at the end of the applicable
performance period (the &#147;<U>Equity Acceleration</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <I>Death</I>. Employee&#146;s employment under this Agreement shall
terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employee&#146;s estate. The date of Employee&#146;s death shall be the termination date for a termination of Employee&#146;s employment under this
Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.3</U>. Upon Employee&#146;s death during the Employment Period, Employer shall pay or provide to the person or entity designated by Employee in a notice filed with Employer or, if no person
is designated, to Employee&#146;s estate (i)&nbsp;the Accrued Obligations; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; and (iii)&nbsp;the Equity Acceleration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <I>Termination by Employer Without Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement without Cause by
giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90)&nbsp;days from the date of such notice. Upon any termination of Employee&#146;s
employment without Cause pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U>, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of <U>Section</U><U></U><U>&nbsp;5</U> hereof,
Employee shall be eligible to receive: (i)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; (ii)&nbsp;severance payments equivalent to Employee&#146;s monthly Base Salary for a period of twenty-four (24)&nbsp;months after the
termination date (the &#147;<U>Severance Period</U>&#148;), payable in installments in Employer&#146;s normal payroll; (iii)&nbsp;continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as
regular, full-time employees of Employer and their eligible dependents during the Severance Period (or, at Employer&#146;s option, Employer may provide health insurance to Employee and Employee&#146;s eligible dependents through an insurance
carrier(s) selected by Employer in lieu of providing the foregoing coverage, provided the coverage afforded by such insurance is substantially comparable to the foregoing coverage, and Employee shall pay the cost of such insurance up to the amount
that would have been paid by Employee under the foregoing coverage and Employer shall pay the excess cost, if any); and (iv)&nbsp;an amount equal to the greater of (A) 1.5 times Employee&#146;s Average Annual Performance Bonus (as defined below) or
(B) 1.5 times Employee&#146;s Target Bonus amount, payable within thirty (90)&nbsp;days of the termination date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <I>Termination by Employee without Good Reason</I>. Employee may terminate
Employee&#146;s employment under this Agreement without Good Reason (as defined below) upon not less than ninety (90)&nbsp;days prior written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, accelerate the
effective date of Employee&#146;s termination of employment at any time in advance of the expiration of such ninety (90)&nbsp;day period (which acceleration shall not constitute Good Reason or a termination by Employer without Cause). The
termination date under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall be the date specified by Employer, but in no event more than ninety (90)&nbsp;days after Employer&#146;s receipt of notice from Employee as contemplated by this
<U>Section</U><U></U><U>&nbsp;4.5</U>. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U>, Employee shall be entitled to the Accrued Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <I>Termination by Employee for Good Reason.</I> Employee may terminate Employee&#146;s employment hereunder for Good Reason. If Employee
desires to terminate Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, Employee must, within ninety (90)&nbsp;days after the occurrence of events giving rise to the Good Reason, provide Employer
with a written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty (30)&nbsp;days after the date of Employee&#146;s notice, then this Agreement shall terminate as of the end of such thirty
(30)&nbsp;day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30)&nbsp;day cure period. If Employee&#146;s employment under this
Agreement is terminated pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, then Employee shall be eligible to receive the same payments and benefits, subject to the same conditions, for a termination without Cause as set forth in
<U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <I>Continuation of Benefit Plans</I>. Following any termination that results in the
expiration of Employee&#146;s continued benefit plan coverage, Employee and each of Employee&#146;s eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to COBRA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <I>Continuing Obligations</I>. The obligations imposed on Employee with respect to <FONT STYLE="white-space:nowrap">non-competition,</FONT>
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and assignment of rights to inventions or developments in this Agreement or any other agreement executed by the parties
shall continue, notwithstanding the termination of the employment relationship between the parties and regardless of the reason for such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. Conditions to Severance; Certain Definitions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <I>Release. </I>Employer shall provide Employee with a general release in the form attached as <U>Exhibit</U><U></U><U>&nbsp;B</U> (subject
to such modifications as Employer may reasonably request) (the &#147;<U>Release</U>&#148;) within seven (7)&nbsp;days after Employee&#146;s termination date. Payments or benefits to which Employee may be entitled pursuant to
<U>Section</U><U></U><U>&nbsp;4</U> hereof (other than the Accrued Obligations) (the &#147;<U>Severance Amounts</U>&#148;) shall be conditioned upon (i)&nbsp;Employee executing the Release within twenty one (21)&nbsp;days after receiving it from
Employer (or such longer period as may be set forth in the Release) and the Release becoming irrevocable upon the expiration of seven (7)&nbsp;days following Employee&#146;s execution of it, (ii)&nbsp;Employee agreeing to submit to a reasonable exit
interview if requested by Employer, and (iii)&nbsp;Employee&#146;s compliance with all post-termination obligations to Employer and its subsidiaries and affiliates and surrendering to Employer all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary or confidential information and articles belonging to Employer or its subsidiaries or affiliates. Payment of the Severance Amounts shall be suspended during the period (the
&#147;<U>Suspension Period</U>&#148;) that begins on Employee&#146;s termination date and ends on the date (&#147;<U>Suspension Termination Date</U>&#148;) that is at least forty-five (45)&nbsp;days after Employee&#146;s termination date; provided,
however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage (or COBRA reimbursement) that would be required under <U>Section</U><U></U><U>&nbsp;4</U> hereof during the Suspension
Period. If Employee executes the Release and the Release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll
period that follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <I>Certain Definitions</I>. As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Average Annual Performance Bonus</U>&#148; shall mean an amount equal to the average of the percentage of the Performance Bonus
target achieved by Employee for the three (3)&nbsp;full calendar years prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on Employee&#146;s Base Salary and Target Bonus in
Employee&#146;s current position. For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#146;s Target Bonus in each of the three full calendar years prior to termination, and Employee&#146;s current Target Bonus was 100% of
Base Salary, and Base Salary was $450,000.00, then Employee&#146;s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $450,000.00 = $315,000.00). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Cause</U>&#148; shall mean the occurrence of any of: (i)&nbsp;Employee&#146;s engagement in (A)&nbsp;willful misconduct resulting
in material harm to MEDNAX or Employer, or (B)&nbsp;gross negligence; (ii)&nbsp;Employee&#146;s conviction of, or pleading nolo contendere to, a felony or any other crime involving fraud, financial misconduct, or misappropriation of Employer&#146;s
assets; (iii)&nbsp;Employee&#146;s willful and continual failure, after written notice from Employee&#146;s Supervisor or the Board to (A)&nbsp;perform substantially Employee&#146;s employment duties consistent with Employee&#146;s position and
authority, or (B)&nbsp;follow, consistent with Employee&#146;s position, duties, and authorities, the reasonable lawful mandates of Employee&#146;s Supervisor or the Board; (iv)&nbsp;Employee&#146;s failure or refusal to comply with a reasonable
policy, standard or regulation of Employer in any material respect, including but not limited to Employer&#146;s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies; or (v)&nbsp;Employee&#146;s breach
of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof resulting in material harm to MEDNAX or Employer. No act or omission shall be deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Employee in a good
faith belief that such act or omission to act was in the best interests of Employer or MEDNAX or if done at the express direction of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Subject to the requirements of applicable law, &#147;<U>Disability</U>&#148; shall mean (i)&nbsp;Employee&#146;s inability to perform
Employee&#146;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii)&nbsp;a determination by an independent qualified physician selected by Employer and acceptable to Employee
(which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional ninety (90)&nbsp;or more days in any
one hundred twenty (120)&nbsp;day period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Good Reason</U>&#148; shall mean: (i)&nbsp;a decrease in Employee&#146;s Base
Salary; (ii)&nbsp;a decrease in Employee&#146;s Target Bonus opportunity; (iii)&nbsp;Employee is assigned any position, duties, responsibilities or compensation that is inconsistent with the position, duties, or responsibilities of Employee
contemplated herein as of the Effective Date or compensation of Employee as of the Effective Date, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after
receipt of written notice; (iv)&nbsp;Employee experiences a material diminution in Employee&#146;s authorities, duties or responsibilities, excluding for this purpose any isolated and inadvertent action not taken in bad faith and which is remedied
by Employer promptly after receipt of written notice; (v)&nbsp;Employee is required to report to any person other than the senior most executive officer of MEDNAX, the Board, or a duly constituted committee thereof, or there is a material diminution
in the authority, duties or responsibilities of the senior most executive officer of MEDNAX; (vi)&nbsp;the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employee resides as of the
Effective Date, except for travel reasonably required in the performance of Employee&#146;s duties; or (vii)&nbsp;any other action or inaction that constitutes a material breach of this Agreement by Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. Successors; Binding Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <I>Successors</I>. Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise)
acquiring a majority of Employer&#146;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, &#147;<U>Employer</U>&#148; shall mean Employer as previously defined and any successor to
its business and/or assets which executes and delivers the agreement provided for in this <U>Section</U><U></U><U>&nbsp;6</U> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <I>Benefit</I>. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by
Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee under this
Agreement if Employee had continued to live, including under <U>Section</U><U></U><U>&nbsp;5</U> hereof, then such amounts shall be paid to Employee&#146;s devisee, legatee, or other designee or, if there is no such designee, Employee&#146;s estate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. Conflicts</B>. Except as otherwise provided in this Agreement, this Agreement constitutes the entire agreement among the parties
pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely determinative of the subject matter hereof. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <I>No Material Competition</I>. Employer and Employee acknowledge and agree that a strong relationship and connection exists
between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and agree that the
restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following:
(1)&nbsp;the use and disclosure of the Confidential Information as described in <U>Section</U><U></U><U>&nbsp;8.4</U> hereof; (2)&nbsp;the professional development activities described in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof; and
(3)&nbsp;the goodwill of Employer, as promoted by Employee as provided in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof. The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such
interests. Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the
goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, <B>Employee shall
not</B>, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an
interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee,
consultant, independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, &#147;<U>Employer&#146;s Business</U>,&#148; as
defined on <U>Exhibit</U><U></U><U>&nbsp;A</U> hereto. Employee acknowledges that, as of the date hereof, Employee&#146;s responsibilities will include matters affecting the businesses of Employer listed on <U>Exhibit</U><U></U><U>&nbsp;A</U>. For
purposes of this <U>Section</U><U></U><U>&nbsp;8</U>, the &#147;<U>Restricted Period</U>&#148; shall mean the Employment Period plus (i)&nbsp;eighteen (18)&nbsp;months in the event this Agreement is terminated pursuant to
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof, and (ii)&nbsp;twenty-four (24)&nbsp;months in the event the Agreement is terminated for any other reason. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <I>No Hire</I>. Employee further agrees that <B>Employee shall not</B>, at any time during the Employment Period and for a period of
eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly employ, or
intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a)&nbsp;employ or otherwise engage (i)&nbsp;any person who is a then current employee or exclusive independent contractor of
Employer or one of its affiliates, or (ii)&nbsp;any person who was an employee or exclusive independent contractor of Employer or one of its affiliates in the prior six (6)&nbsp;month period, or (b)&nbsp;take any action that would reasonably be
expected to induce an employee or independent contractor of Employer or one of its affiliates to leave his or her employment or engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer
of Employee). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <I><FONT STYLE="white-space:nowrap">Non-Solicitation.</FONT> </I>Employee further agrees
that <B>Employee shall not</B>, at any time during the Employment Period and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm,
partnership, corporation or employer, intentionally, knowingly, or willingly solicit or accept business from or take any action that would reasonably be expected to materially interfere with, diminish or impair the valuable relationships that
Employer or its affiliates have with (i)&nbsp;hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships, (ii)&nbsp;patients,
(iii)&nbsp;referral sources, (iv)&nbsp;vendors, (v)&nbsp;any other clients of Employer or its affiliates, or (vi)&nbsp;prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that Employer or any
affiliate of Employer was in the process of soliciting at the time of Employee&#146;s termination (including potential acquisition targets). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <I>Confidential Information</I>. At all times during the term of this Agreement, Employer shall provide Employee with access to
&#147;<U>Confidential Information</U>.&#148; As used in this Agreement, the term &#147;<U>Confidential Information</U>&#148; means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly,
verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to: (i)&nbsp;patients with whom Employer has a physician/patient relationship;
(ii)&nbsp;the present or future business of Employer; or (iii)&nbsp;the research and development of Employer. Without limiting the generality of the foregoing, Confidential Information includes: (a)&nbsp;the development and operation of
Employer&#146;s medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically
including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b)&nbsp;contractual arrangements between Employer and insurers or managed care associations or other payors;
(c)&nbsp;the databases of Employer; (d)&nbsp;the clinical and research protocols of Employer, including coding guidelines; (e)&nbsp;the referral sources of Employer; (f)&nbsp;other confidential information of Employer that is not generally known to
the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and
related data, lists or other written records used in Employer&#146;s business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and
projections, and computer programs. The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer&#146;s business and its
goodwill. Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might
otherwise obtain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Confidential Information shall not include any information that (i)&nbsp;was known by
Employee from a third party source before disclosure by or on behalf of Employer, (ii)&nbsp;becomes available to Employee from a source other than Employer that is not, to Employee&#146;s knowledge, bound by a duty of confidentiality to Employer,
(iii)&nbsp;becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv)&nbsp;has been independently developed by Employee and may be disclosed by Employee without
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach of this Agreement, provided, in each case, that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions. Pursuant to the
Defend Trade Secrets Act of 2016, Employee acknowledges that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A)&nbsp;is made (i)&nbsp;in confidence to a
federal, state, or local government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Employee files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee&#146;s
attorney and may use the trade secret information in the court proceeding, if Employee (X)&nbsp;files any document containing the trade secret under seal and (Y)&nbsp;does not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless disclosure is otherwise required by applicable law or stock exchange rules,
Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section. Employee shall keep the terms of this Agreement strictly confidential and will not, without the prior written consent of
Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employee&#146;s representatives (such as tax advisors and attorneys) who need to know such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employee&#146;s employment with Employer, in
any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information
of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this <U>Section</U><U></U><U>&nbsp;8.4</U> resulting in material harm to MEDNAX or Employer is a material breach of this
Agreement and shall constitute &#147;<U>Cause</U>&#148; for the termination of Employee&#146;s employment hereunder pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> hereof. In the event that Employee is ordered to disclose any Confidential
Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of
a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement. In the case of any disclosure required by law, Employee shall disclose only that
portion of the Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, other
written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or control shall be and remain
Employer&#146;s sole property (collectively &#147;<U>Employer Property</U>&#148;). Upon termination or expiration of this Agreement, or earlier upon Employer&#146;s request, Employee shall promptly deliver to Employer all Employer Property,
retaining none. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <I>Ownership of Work Product.</I> Employee agrees and acknowledges that (i)&nbsp;all
copyrights, patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee
during the course of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#146;s Business (collectively, the
&#147;<U>Work Product</U>&#148;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be
considered a work made for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration.
Upon request of Employer, Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all
right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or
modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#146;s successors and assigns, as fully and as entirely as
the same might be held by Employee had this assignment not been made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <I>Clearance Procedure for Proprietary Rights Not Claimed by
Employer.</I> In the event that Employee wishes to create or develop, <I>other than</I> on Employer&#146;s time or using Employer&#146;s resources, anything that may be considered Work Product but to which Employee believes Employee should be
entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently
detailed written description of the work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with
respect to such request or description. Employer will determine in its sole discretion, within thirty (30)&nbsp;days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer. If Employer
determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If Employer fails to so
notify Employee within such thirty (30)&nbsp;day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any significant
improvement, modification, or adaptation that could reasonably be related to Employer&#146;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer. Clearance under
this procedure does not relieve Employee of the restrictive covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <I><FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT> </I>During the Employment
Period and for a period of ten (10)&nbsp;years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or
willingly make any comment that would reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employee&#146;s
work conditions or circumstances surrounding Employee&#146;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <I>Review by Employee.</I> Employee has carefully read and considered the terms and provisions of this
<U>Section</U><U></U><U>&nbsp;8</U>, and having done so, agrees that the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;8</U> are fair and reasonably required for the protection of the interests of Employer. In the event that any term
or provision set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed
from this Agreement without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants
set forth in this <U>Section</U><U></U><U>&nbsp;8</U>, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall
be held to be invalid, overbroad, or unenforceable by an arbitrator or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in
any manner, affecting the remaining portions of this <U>Section</U><U></U><U>&nbsp;8</U> (all of which shall remain in full force and effect). In the event that any provision of this <U>Section</U><U></U><U>&nbsp;8</U> related to time period or
areas of restriction shall be declared by an arbitrator or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitrator or court deems reasonable and enforceable, said time period or areas of restriction
shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <I>Survival; Notice of Breach and Right to Cure. </I>If Employer reasonably believes that Employee has breached a provision of this
<U>Section</U><U></U><U>&nbsp;8</U>, Employer shall provide prompt written notice thereof to Employee that explains such reasonably believed breach (the &#147;<U>Alleged Breach</U>&#148;). Employer agrees to work in good faith with Employee to
provide Employee a reasonable opportunity to promptly cure such Alleged Breach. In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a
comment made by Employee that Employer reasonably believes is in breach of <U>Section</U><U></U><U>&nbsp;8.7</U> hereof, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this
<U>Section</U><U></U><U>&nbsp;8</U> with respect to the Alleged Breach. Employer and Employee further agree that Employee shall not be deemed to be in breach of any term of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof unless such breach results in
material harm to MEDNAX or Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> shall survive the termination of this
Agreement and Employee&#146;s employment with Employer. In the event of a breach of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof, Employer retains the right to
terminate any continuing payments to Employee provided for in <U>Section</U><U></U><U>&nbsp;4</U> hereof. In the event of a breach of any provisions of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to
<U>Section</U><U></U><U>&nbsp;11</U> hereof, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities
constituting such breach shall have been finally terminated, in each case as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof. The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> are expressly intended to benefit and
be enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof. Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. Tax Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1
<I>Section</I><I></I><I>&nbsp;409A</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>In General. </I>The parties intend that this Agreement will be administered in accordance
with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section&nbsp;409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> For purposes of
Section&nbsp;409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. The parties agree that this Agreement may be amended, as reasonably requested by either
party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. Employer makes no
representation or warranty and shall have no liability to Employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption
from, or the conditions of, Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I><FONT STYLE="white-space:nowrap">Six-Month</FONT> Delay. </I>Anything in this
Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Code, Employer determines that Employee is a &#147;specified employee&#148; within the meaning of
Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s &#147;separation from service&#148; (within the meaning of Section&nbsp;409A)
that would be considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;, such payment shall not be payable and such benefit shall not be provided until the date that is within fifteen (15)&nbsp;days after the
end of the <FONT STYLE="white-space:nowrap">six-month</FONT> period beginning on the date of such &#147;separation from service&#148; or, if earlier, within fifteen (15)&nbsp;days after the appointment of the personal representative or executor of
Employee&#146;s estate following Employee&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that
would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Reimbursements. </I>All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement under
this Agreement shall be provided by Employer or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after
the last day of the taxable year following the taxable year in which the expense was incurred. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not affect the
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to
reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <I>Separation from Service. </I>To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or
benefits shall be payable only upon Employee&#146;s &#147;separation from service&#148; as defined under Section&nbsp;409A. The determination of whether and when a separation from service has occurred shall be made in accordance with the
presumptions set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <I>Later Calendar
Year</I>. To the extent that any payment or benefit described in this Agreement constitutes <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and not otherwise exempt from
the application of Section&nbsp;409A, then, if the period during which Employee may consider and sign the Release or the period in which the Employer can make a severance payment spans two calendar years, any payment or benefit described in this
Agreement will not be made or begin until the later calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2 <B><I>Section</I></B><B><I></I></B><B><I>&nbsp;280G</I></B>.
Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#146;s benefit
pursuant to the terms of this Agreement or otherwise (the &#147;<U>Covered Payments</U>&#148;) constitute parachute payments (the &#147;<U>Parachute Payments</U>&#148;) within the meaning of Section&nbsp;280G of the Code and, but for this
<U>Section</U><U></U><U>&nbsp;9</U>, would be subject to the excise tax imposed under Section&nbsp;4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to
such taxes (collectively, the &#147;<U>Excise Tax</U>&#148;), then prior to making the Covered Payments, a calculation shall be made comparing (i)&nbsp;the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the
Excise Tax to (ii)&nbsp;the Net Benefit to Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i)&nbsp;above is less than the amount under
(ii)&nbsp;above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#147;<U>Reduced Amount</U>&#148;). &#147;<U>Net Benefit</U>&#148;
shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Any such reduction shall be made in accordance with Section&nbsp;409A and the following: (i)&nbsp;the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section&nbsp;409A shall
be reduced first, in reverse chronological order; (ii)&nbsp;all other Covered Payments consisting of cash payments, and Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. &#167; <FONT
STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> does not apply, and that in either case do not constitute nonqualified deferred compensation subject to Section&nbsp;409A, shall be reduced second, in
reverse chronological order; (iii)&nbsp;all Covered Payments consisting of cash payments that constitute nonqualified deferred compensation subject to Section&nbsp;409A shall be reduced third, in reverse chronological order; and (iv)&nbsp;all
Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg. &#167; <FONT STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> applies shall be the last Covered Payments to be
reduced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any determination required under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made
in writing in good faith by an independent accounting firm selected by Employer (the &#147;<U>Accountants</U>&#148;). Employer and Employee shall provide the Accountants with such information and documents as the Accountants may reasonably request
in order to make a determination under this <U>Section</U><U></U><U>&nbsp;9</U>. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Accountants may rely on reasonable, good-faith
assumptions and approximations concerning the application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The Accountants&#146; determinations shall be final and binding on Employer and Employee. Employer shall be responsible for all fees
and expenses incurred by the Accountants in connection with the calculations required by this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) It
is possible that after the determinations and selections made pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after
application of this <U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Overpayment</U>&#148;) or less than the amount intended or required to be provided after application of this <U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Underpayment</U>&#148;).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event that: (A)&nbsp;the Accountants determine, based upon the assertion of a deficiency by the Internal
Revenue Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B)&nbsp;it is established pursuant to a final determination of a court or an Internal Revenue
Service proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in
Section&nbsp;7872(f)(2)(A) of the Code) from the date of Employee&#146;s receipt of the Overpayment until the date of repayment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event that: (A)&nbsp;the Accountants, based upon controlling precedent or substantial authority, determine that an
Underpayment has occurred or (B)&nbsp;a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by Employer to or for the benefit of Employee together with interest at the applicable
federal rate (as defined in Section&nbsp;7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee until the payment date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3 <I>Tax Withholding. </I>All amounts payable under this Agreement shall be subject to applicable income and employment tax withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Dispute Resolution; Injunctive Relief</B>. If any controversy or claim arises out of or relating to this Agreement, or any alleged
breach hereof, Employee and Employer shall first try to resolve such controversy or claim through mediation using the services of the American Arbitration Association. If any such controversy or claim cannot be resolved by mediation pursuant to the
foregoing, Employee and Employer agree that such controversy or claim shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that if Employee and Employer are unable to agree upon a single arbitrator
after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employer shall bear all costs associated with such mediation and, if necessary, arbitration,
including but not limited to all costs of the mediator and arbitrator, and shall reimburse Employee on a monthly basis for Employee&#146;s reasonable legal and other expenses, including all fees, incurred in connection with any such mediation and,
if necessary, arbitration, provided, however, that if Employer ultimately prevails in any arbitration (as determined by the arbitrator), the arbitrator shall have the power to require Employee to reimburse Employer for all or a portion of the
advanced legal fees and other expenses as determined by the arbitrator (and, if the arbitrator finds that Employer prevailed on certain claims and Employee prevailed on others, the arbitrator shall have the power to require Employee to reimburse
Employer for a portion of the advanced legal fees and other expenses determined by the arbitrator based on those claims on which Employer prevailed). The mediation and, if necessary, arbitration proceedings shall be held in Sunrise, Florida, unless
otherwise mutually agreed by the parties, and shall be conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect. Judgment on any award rendered by the arbitrator may be
entered and enforced by any court having jurisdiction thereof. Any such mediation and, if necessary, arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any
judgment or order issued by the arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if Employer or Employee shall require
immediate injunctive relief, then the party shall be entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the
State of Florida and to the applicable service of process. Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i)&nbsp;they are not subject to the jurisdiction of such
courts, (ii)&nbsp;they are immune from any legal process issued by such courts and (iii)&nbsp;any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. In the event that Employer brings suit against Employee
seeking injunctive relief, Employer agrees to advance all of Employee&#146;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided, however, that if Employer ultimately prevails in
seeking injunctive relief, Employee shall reimburse Employer all such advanced legal fees and other expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. Governing Law</B>.
This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of
the State of Florida. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. Notices</B>. Any notice required or permitted to be given under this Agreement shall be in writing and shall
be deemed to have been given when (i)&nbsp;delivered by hand, (ii)&nbsp;delivered by electronic mail that is confirmed by <FONT STYLE="white-space:nowrap">non-automated</FONT> means, or (iii)&nbsp;when delivered or delivery is refused if sent by
registered or certified U.S. mail, return receipt requested, postage prepaid, or via reputable overnight courier, addressed as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Employer:</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX Services, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: dominic_andreano@mednax.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Employee:</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roger Mack Hinson, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o MEDNAX Services, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: Roger_Hinson@mednax.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. Benefits; Binding Effect</B>. This Agreement shall be for the benefit of and binding upon the parties hereto and their respective
heirs, personal representatives, legal representatives, successors and, where applicable, assigns. Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer. This Agreement
may be assigned by Employer upon notice to Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. Severability</B>. The invalidity of any one or more of the words, phrases,
sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event
that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or
clauses, or section or sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15. Waivers</B>. The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not
operate nor be construed as a waiver of any subsequent breach or violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16. Damages</B>. Nothing contained herein shall be
construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17. No Third Party Beneficiary</B>. Except as provided in <U>Section</U><U></U><U>&nbsp;8.9</U> hereof, nothing expressed or implied in this
Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#146;s heirs, personal representative(s) and/or legal representative) any rights or remedies under
or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or representations are not set forth
expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder
of this page has been left blank intentionally. </I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Agreement effective as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYER:</B></P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>MEDNAX SERVICES, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Mark S. Ordan</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Roger Mack Hinson, M.D.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark S. Ordan</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Roger Mack Hinson, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Shirley A. Weis</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shirley A. Weis</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chair, Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amended and Restated Employment Agreement] </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS OF EMPLOYER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively
referred to herein as &#147;<U>Employer&#146;s Business</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) Neonatology, including hospital well baby care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Maternal-Fetal Medicine, including Obstetrical Hospitalist Care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Pediatric Cardiology; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4)
Pediatric Intensive Care, including Pediatric Hospitalist Care; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) Newborn hearing screening services; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6) Pediatric Surgery; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(7)
Pediatric Emergency Medicine; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(8) Radiology and Teleradiology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to Employer&#146;s Business in this Agreement shall include such other medical service lines, practice management services and
other businesses in which Employer is engaged during the Employment Period; <I>provided,</I> that to be considered a part of Employer&#146;s Business, Employer must have engaged in such other service line, practice management service or other
business at least six (6)&nbsp;months prior to the termination date of this Agreement. For purposes of this <U>Exhibit</U><U></U><U>&nbsp;A</U>, businesses of Employer shall include the businesses conducted by Employer&#146;s subsidiaries, entities
under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for
financial reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and
clarifications regarding the scope of Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <I>Hospital Services. </I>Employer and Employee acknowledge that, as
of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer&#146;s Business where such hospitals,
hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#146;s Business. Therefore, the parties desire to clarify their intent with respect to the limitations on
Employee&#146;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period. <U>Section</U><U></U><U>&nbsp;8.1</U> shall not be deemed to
restrict Employee&#146;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer&#146;s Business. Furthermore, even if a hospital,
hospital system or university provides medical services that are included in Employer&#146;s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the
hospital&#146;s, hospital system&#146;s or university&#146;s provision of medical services that are Employer&#146;s Business. For the avoidance of doubt, Employer and Employee agree that if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee becomes the President, Chief Medical Officer, Chief Clinical Officer, or Chief Executive Officer of a hospital system or health system, or other executive officer of similar level to the
foregoing, that Employee shall not be in breach of the provisions of this Agreement. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or
university that are included in Employer&#146;s Business so long as such hospital, hospital system or university is located at least ten (10)&nbsp;miles from a medical practice owned or operated by Employer or its affiliate. Subject to paragraph B
below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <I>De Minimus Exception. </I>Employer agrees that a medical service line (other than those listed in items (1)&nbsp;through (8) above),
practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#146;s Business if such medical service line, practice management service or other business constitutes less than three
percent (3%) of Employer&#146;s annual revenues. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <I>Divested Lines of Service. </I>Employer agrees that any medical service line
(including those listed in items (1)&nbsp;through (8) above), practice management, or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity, or otherwise after the Effective Date shall not
be considered to be a part of Employer&#146;s Business effective as of the effective date of such divestiture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. <I>Certain Ownership
Interests. </I>It shall not be deemed to be a violation of <U>Section</U><U></U><U>&nbsp;8.1</U> for Employee to: (i)&nbsp;own, directly or indirectly, one percent (1%) or less of a publicly-traded entity that has a market capitalization of
$1&nbsp;billion or more; (ii)&nbsp;own, directly or indirectly, five percent (5%) or less of a publicly-traded entity that has a market capitalization of less than $1&nbsp;billion; or (iii)&nbsp;own, directly or indirectly, less than ten percent
(10%) of a privately-held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>GENERAL RELEASE OF CLAIMS </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Roger Mack Hinson, M.D. (&#147;<U>Employee</U>&#148;), for himself or herself and his or her family, heirs, executors, administrators,
legal representatives and their respective successors and assigns, in exchange for the consideration received pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#149;] of that certain Employment Agreement, dated as of September&nbsp;27, 2020, by and
between Employee and Employer, to which this release is attached as <U>Exhibit</U><U></U><U>&nbsp;B</U> (the &#147;<U>Employment Agreement</U>&#148;), does hereby release and forever discharge MEDNAX Services, Inc. (&#147;<U>Employer</U>&#148;), its
subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#147;<U>Released Parties</U>&#148;) from any and all
actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or
in connection with Employee&#146;s employment or termination thereof, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or
defamation or injuries incurred on the job or incurred as a result of loss of employment. Employee acknowledges that Employer encouraged Employee to consult with an attorney of Employee&#146;s choosing, and through this General Release of Claims
encourages Employee to consult with Employee&#146;s attorney with respect to possible claims under the Age Discrimination in Employment Act (&#147;<U>ADEA</U>&#148;) and that Employee understands that the ADEA is a Federal statute that, among other
things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that Employee may have
as of the date hereof. Employee further understands that by signing this General Release of Claims Employee is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1
that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i)&nbsp;any actions to enforce rights to receive any payments or benefits which
may be due Employee pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#149;] of the Employment Agreement, or under any of Employer&#146;s employee benefit plans, (ii)&nbsp;any rights or claims that may arise as a result of events occurring after the
date this General Release of Claims is executed, (iii)&nbsp;any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv)&nbsp;any claims for benefits under any
directors&#146; and officers&#146; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v)&nbsp;any rights as a holder of equity securities of Employer, (vi)&nbsp;any
claims that cannot be waived as a matter of law, (vii)&nbsp;any claims Employee may have to government-sponsored and administered benefits such as unemployment insurance, workers&#146; compensation insurance (excluding claims for retaliation under
workers&#146; compensation laws), state disability insurance, and paid family leave benefits, and (viii)&nbsp;any benefits that vested on or prior to the termination date pursuant to a written benefit plan sponsored by Employer and governed by the
federal law known as &#147;ERISA&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Employee represents that Employee has not filed against the Released Parties any
complaints, charges, or lawsuits arising out of Employee&#146;s employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that Employee will never individually or with any person
file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a
&#147;<U>Proceeding</U>&#148;), provided, however, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived Employee&#146;s rights under ADEA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency; however, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other
individual remedies, provided that, for purposes of clarity, this limitation on monetary recovery does not apply to whistleblower proceedings before the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Employee hereby acknowledges that Employer has informed Employee that Employee has up to <FONT STYLE="white-space:nowrap">twenty-one</FONT>
(21)&nbsp;days to sign this General Release of Claims and Employee may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this General Release of Claims earlier. Employee also
understands that Employee shall have seven (7)&nbsp;days following the date on which Employee signs this General Release of Claims within which to revoke it by providing a written notice of Employee&#146;s revocation to Employer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal
laws of the State of Florida applicable to contracts made and to be performed entirely within such State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Employee acknowledges that
Employee has read this General Release of Claims, that Employee has been advised that Employee should consult with an attorney before Employee executes this general release of claims, and that Employee understands all of its terms and executes it
voluntarily and with full knowledge of its significance and the consequences thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This General Release of Claims shall take effect
on the eighth day following Employee&#146;s execution of this General Release of Claims unless Employee&#146;s written revocation is delivered to Employer within seven (7)&nbsp;days after such execution. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">_______________, 20__</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d51794dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Number&nbsp;of&nbsp;Omitted<BR>Subsidiaries&nbsp;Operating</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Subsidiary</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>State of<BR>Incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Line of<BR>Business</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>in the<BR>United<BR>States</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Foreign<BR>Countries</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mednax Services, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Florida</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Physician<BR>Services</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pediatrix Medical Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Florida</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Physician<BR>Services</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d51794dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (Nos. <FONT
STYLE="white-space:nowrap">333-181667,</FONT> <FONT STYLE="white-space:nowrap">333-153397,</FONT> <FONT STYLE="white-space:nowrap">333-151272,</FONT> <FONT STYLE="white-space:nowrap">333-101225,</FONT>
<FONT STYLE="white-space:nowrap">333-208698,</FONT> and <FONT STYLE="white-space:nowrap">333-231826)</FONT> of Mednax, Inc. of our report dated February&nbsp;18, 2021 relating to the financial statements and financial statement schedule and the
effectiveness of internal control over financial reporting, which appears in this Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Miami, Florida </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;18,
2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d51794dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Mark S. Ordan,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Mednax, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;18, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d51794dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, C. Marc
Richards, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Mednax, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;18, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ C. Marc Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">C. Marc Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial
Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>d51794dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C Section&nbsp;1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Adopted by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Mednax, Inc. on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2020 (the &#147;Report&#148;), each of the undersigned hereby certifies, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities
Exchange Act of 1934 and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Mednax, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to Mednax, Inc. and will be retained by Mednax,
Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">February&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark S. Ordan </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ C. Marc Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">C. Marc Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial
Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>md-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-February-2021 [01:05:24] {AM}-->
<schema targetNamespace="http://www.mednax.com/20201231" elementFormDefault="qualified" xmlns:md="http://www.mednax.com/20201231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.mednax.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" id="ConsolidatedStatementsOfIncome">
<link:definition>1004 - Statement - Consolidated Statements of Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" id="ConsolidatedStatementsOfEquity">
<link:definition>1005 - Statement - Consolidated Statements of Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/General" id="General">
<link:definition>1007 - Disclosure - General</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" id="CoronavirusPandemicCovid19">
<link:definition>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/Investments" id="Investments">
<link:definition>1010 - Disclosure - Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
<link:definition>1011 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1012 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinations" id="BusinessCombinations">
<link:definition>1013 - Disclosure - Business Combinations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
<link:definition>1014 - Disclosure - Goodwill and Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
<link:definition>1015 - Disclosure - Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
<link:definition>1016 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeases" id="OperatingLeases">
<link:definition>1017 - Disclosure - Operating Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilities" id="AccruedProfessionalLiabilities">
<link:definition>1018 - Disclosure - Accrued Professional Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations" id="LineOfCreditLongTermDebtAndFinanceLeaseObligations">
<link:definition>1019 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1020 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
<link:definition>1021 - Disclosure - Common and Common Equivalent Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
<link:definition>1022 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
<link:definition>1023 - Disclosure - Common Stock Repurchase Programs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/RetirementPlans" id="RetirementPlans">
<link:definition>1024 - Disclosure - Retirement Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1025 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformation" id="SelectedQuarterlyFinancialInformation">
<link:definition>1026 - Disclosure - Selected Quarterly Financial Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/InvestmentsTables" id="InvestmentsTables">
<link:definition>1029 - Disclosure - Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
<link:definition>1030 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1031 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
<link:definition>1032 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
<link:definition>1033 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
<link:definition>1034 - Disclosure - Operating Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables" id="AccruedProfessionalLiabilitiesTables">
<link:definition>1035 - Disclosure - Accrued Professional Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables" id="LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables">
<link:definition>1036 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1037 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
<link:definition>1038 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables" id="StockIncentivePlansAndStockPurchasePlansTables">
<link:definition>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables" id="SelectedQuarterlyFinancialInformationTables">
<link:definition>1040 - Disclosure - Selected Quarterly Financial Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" id="CoronavirusPandemicCovid19AdditionalInformationDetail">
<link:definition>1041 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail">
<link:definition>1043 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail">
<link:definition>1044 - Disclosure - Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail">
<link:definition>1045 - Disclosure - Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail" id="InvestmentsScheduleOfInvestmentsDetail">
<link:definition>1046 - Disclosure - Investments - Schedule of Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<link:definition>1047 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<link:definition>1048 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<link:definition>1049 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" id="PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail">
<link:definition>1050 - Disclosure - Property Plant and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail" id="PropertyAndEquipmentAdditionalInformationDetail">
<link:definition>1051 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail" id="BusinessCombinationsAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Business Combinations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" id="GoodwillAndIntangibleAssetsAdditionalInformationDetail">
<link:definition>1053 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" id="GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail">
<link:definition>1054 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail" id="GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail">
<link:definition>1055 - Disclosure - Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" id="DiscontinuedOperationsAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Discontinued Operations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<link:definition>1057 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails" id="OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<link:definition>1058 - Disclosure - Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" id="OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails">
<link:definition>1059 - Disclosure - Operating Leases - Schedule of lease costs for operating leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" id="OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
<link:definition>1060 - Disclosure - Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" id="OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
<link:definition>1061 - Disclosure - Operating Leases - Schedule of operating lease liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail" id="AccruedProfessionalLiabilitiesAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Accrued Professional Liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" id="AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail">
<link:definition>1063 - Disclosure - Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail" id="LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail">
<link:definition>1064 - Disclosure - Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail" id="LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail">
<link:definition>1065 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail" id="LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail">
<link:definition>1066 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail" id="LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail">
<link:definition>1067 - Disclosure - Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" id="IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail">
<link:definition>1068 - Disclosure - Income Taxes - Summary of Components of Income Tax Provision (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1069 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" id="IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail">
<link:definition>1070 - Disclosure - Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail">
<link:definition>1071 - Disclosure - Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" id="IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail">
<link:definition>1072 - Disclosure - Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<link:definition>1073 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<link:definition>1074 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail" id="StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail">
<link:definition>1075 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail" id="StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail">
<link:definition>1076 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
<link:definition>1077 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail" id="RetirementPlansAdditionalInformationDetail">
<link:definition>1078 - Disclosure - Retirement Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail" id="SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail">
<link:definition>1079 - Disclosure - Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_OperatingAndFinanceLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" substitutionGroup="xbrli:item" />
<element name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesStockSwaps" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodSharesStockSwaps" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueStockSwaps" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodValueStockSwaps" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockRepurchasesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CommonStockRepurchasesTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockShareRepurchasesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CommonStockShareRepurchasesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ProfessionalLiabilityCoveragePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ProfessionalLiabilityCoveragePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesCashFlowRelatedInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccruedProfessionalLiabilityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfEstimatedFairValueOfNotesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFinanceLeaseObligationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfFinanceLeaseObligationsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAbstract" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseDecreaseInSalaryAndWage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageIncreaseDecreaseInSalaryAndWage" substitutionGroup="xbrli:item" />
<element name="SupplementaryLeverageRatioRequired" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_SupplementaryLeverageRatioRequired" substitutionGroup="xbrli:item" />
<element name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ContributionsInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfDeferredPaymentOfSocialSecurityTaxes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" substitutionGroup="xbrli:item" />
<element name="DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExtraordinaryItemsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsDomain" substitutionGroup="xbrli:item" />
<element name="CovidNinenteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CovidNinenteenMember" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondAndThirdQuartersOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondAndThirdQuartersOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFourthQuarterOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFourthQuarterOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFirstQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFirstQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="ForecastForThirdQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForThirdQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="CreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="RuralAreaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RuralAreaMember" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2023Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2023Member" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2027Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2027Member" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UnnamedCorporateJointVentureOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureOneMember" substitutionGroup="xbrli:item" />
<element name="UnnamedCorporateJointVentureTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureTwoMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationContingentConsiderationArrangementsTimePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentsMaturityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CashAndCashEquivalentsMaturityDescription" substitutionGroup="xbrli:item" />
<element name="ShortTermInvestmentMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ShortTermInvestmentMaturityPeriod" substitutionGroup="xbrli:item" />
<element name="RegulatoryAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RegulatoryAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="SalesAndRevenueServicesNetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_SalesAndRevenueServicesNetMember" substitutionGroup="xbrli:item" />
<element name="MaternalFetalMedicineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_MaternalFetalMedicineMember" substitutionGroup="xbrli:item" />
<element name="NeonatologyAndOtherPediatricSubspecialtiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NeonatologyAndOtherPediatricSubspecialtiesMember" substitutionGroup="xbrli:item" />
<element name="PediatricCardiologyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PediatricCardiologyMember" substitutionGroup="xbrli:item" />
<element name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MoneyMarketFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MutualFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TwoThousandTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfFinancingReceivablesLineItems" substitutionGroup="xbrli:item" />
<element name="HospitalsContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_HospitalsContractsMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" substitutionGroup="xbrli:item" />
<element name="ContractedManagedCareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ContractedManagedCareMember" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" substitutionGroup="xbrli:item" />
<element name="NumberOfPhysicianGroupPracticesAcquired" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NumberOfPhysicianGroupPracticesAcquired" substitutionGroup="xbrli:item" />
<element name="NumberOfNeonatologyPracticesAcquired" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NumberOfNeonatologyPracticesAcquired" substitutionGroup="xbrli:item" />
<element name="NumberOfPediatricSubspecialtyPracticesAcquired" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NumberOfPediatricSubspecialtyPracticesAcquired" substitutionGroup="xbrli:item" />
<element name="NumberOfRadiologyPracticesAcquired" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NumberOfRadiologyPracticesAcquired" substitutionGroup="xbrli:item" />
<element name="AccruedPurchaseConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedPurchaseConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PhysicianGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PhysicianGroupMember" substitutionGroup="xbrli:item" />
<element name="PediatricSubspecialtyPracticeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PediatricSubspecialtyPracticeMember" substitutionGroup="xbrli:item" />
<element name="DeferredtaxassetsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredtaxassetsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredtaxassetsgoodwillDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredtaxassetsgoodwillDomain" substitutionGroup="xbrli:item" />
<element name="GoodwillAndOtherIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_GoodwillAndOtherIntangibleAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="PhysicianAndHospitalAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PhysicianAndHospitalAgreementsMember" substitutionGroup="xbrli:item" />
<element name="OtherTechnologyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_OtherTechnologyMember" substitutionGroup="xbrli:item" />
<element name="MaximumConsiderationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MaximumConsiderationReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Accountsreceivableretained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_Accountsreceivableretained" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Capitallosscarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_Capitallosscarryforward" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PurchaseConsiderationCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_PurchaseConsiderationCashPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetProceedsForTheRadiologyServicesMedicalGroup" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NetProceedsForTheRadiologyServicesMedicalGroup" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredTaxAssetsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsDomain" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsIntangibleAssetsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsIntangibleAssetsMember" substitutionGroup="xbrli:item" />
<element name="NorthAmericanPartnersInAnesthesiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NorthAmericanPartnersInAnesthesiaMember" substitutionGroup="xbrli:item" />
<element name="DivestitureOfMeddataMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DivestitureOfMeddataMember" substitutionGroup="xbrli:item" />
<element name="RadiologyServicesMedicalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RadiologyServicesMedicalGroupMember" substitutionGroup="xbrli:item" />
<element name="AnesthesiologyServicesMedicalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AnesthesiologyServicesMedicalGroupMember" substitutionGroup="xbrli:item" />
<element name="TaxYearTwoThousandAndTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TaxYearTwoThousandAndTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedPayrollTaxesAndBenefitsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedSalariesAndIncentiveCompensationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedSalariesAndIncentiveCompensationCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeasesAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_OperatingLeasesAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_OperatingLeasesLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="OtherInformationRelatedToOperatingLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_OtherInformationRelatedToOperatingLeaseAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesOtherCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_OperatingLeasesOtherCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherEquipmentRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_OtherEquipmentRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedProfessionalLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedProfessionalLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedProfessionalLiabilitiesAssumedThroughAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MalpracticeLossContingencyProvisionForLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_MalpracticeLossContingencyProvisionForLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProvisionAdjustmentForLossesRelatedToCurrentYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ProvisionAdjustmentForLossesRelatedToCurrentYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProvisionAdjustmentForLossesRelatedToPriorYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_ProvisionAdjustmentForLossesRelatedToPriorYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="UnsecuredRevolvingCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnsecuredRevolvingCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="AlternateBaseRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AlternateBaseRateMember" substitutionGroup="xbrli:item" />
<element name="ApplicableMarginRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ApplicableMarginRateMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentRedemptionPeriodSixAndThereafterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DebtInstrumentMaturityYear" substitutionGroup="xbrli:item" />
<element name="EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" substitutionGroup="xbrli:item" />
<element name="ChangeInControlMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ChangeInControlMember" substitutionGroup="xbrli:item" />
<element name="RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LongTermDebtNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentFairValueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DebtInstrumentFairValueTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DebtInstrumentFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DebtInstrumentFairValueLineItems" substitutionGroup="xbrli:item" />
<element name="IncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="NetOperatingLossCarryForwardsExpirationDate" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NetOperatingLossCarryForwardsExpirationDate" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpenseForExcessTaxDeficiencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_IncomeTaxExpenseForExcessTaxDeficiencies" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalLossesIncurred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CapitalLossesIncurred" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CapitalLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_CapitalLossCarryforwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsOperatingLeaseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DeferredTaxAssetsOperatingLeaseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesChangeInAccountingMethod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DeferredTaxLiabilitiesChangeInAccountingMethod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestrictedAndDeferredStockUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RestrictedAndDeferredStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedTwoThousandEightPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AmendedAndRestatedTwoThousandEightPlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommonStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockLineItems" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>md-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-February-2021 [01:05:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" roleURI="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="loc_MD_OperatingAndFinanceLeaseRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_MD_OperatingAndFinanceLeaseRightOfUseAssets" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="35" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="25" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="38" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesOtherCosts" xlink:label="loc_MD_OperatingLeasesOtherCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_MD_OperatingLeasesOtherCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherEquipmentRent" xlink:label="loc_MD_OtherEquipmentRent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_MD_OtherEquipmentRent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyProvisionForLosses" xlink:label="loc_MD_MalpracticeLossContingencyProvisionForLosses" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xlink:label="loc_MD_ProvisionAdjustmentForLossesRelatedToCurrentYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MD_MalpracticeLossContingencyProvisionForLosses" xlink:to="loc_MD_ProvisionAdjustmentForLossesRelatedToCurrentYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToPriorYear" xlink:label="loc_MD_ProvisionAdjustmentForLossesRelatedToPriorYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MD_MalpracticeLossContingencyProvisionForLosses" xlink:to="loc_MD_ProvisionAdjustmentForLossesRelatedToPriorYear" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_MD_PracticeSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSalariesAndBenefits" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="16" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsOperatingLeaseAssets" xlink:label="loc_MD_DeferredTaxAssetsOperatingLeaseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_MD_DeferredTaxAssetsOperatingLeaseAssets" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="loc_MD_DeferredTaxLiabilitiesChangeInAccountingMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_MD_DeferredTaxLiabilitiesChangeInAccountingMethod" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_Land" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_FixturesAndEquipmentGross" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedSalariesAndIncentiveCompensationCurrent" xlink:label="loc_MD_AccruedSalariesAndIncentiveCompensationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_MD_AccruedSalariesAndIncentiveCompensationCurrent" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>md-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-February-2021 [01:05:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#InvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#BusinessCombinationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" roleURI="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#RetirementPlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#General" roleURI="http://www.mednax.com/role/General" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#Investments" roleURI="http://www.mednax.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#InvestmentsTables" roleURI="http://www.mednax.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilities" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilities" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesTables" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligations" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#RetirementPlans" roleURI="http://www.mednax.com/role/RetirementPlans" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformation" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformation" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformationTables" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipment" roleURI="http://www.mednax.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipmentTables" roleURI="http://www.mednax.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxes" roleURI="http://www.mednax.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesTables" roleURI="http://www.mednax.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansTables" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeases" roleURI="http://www.mednax.com/role/OperatingLeases" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesTables" roleURI="http://www.mednax.com/role/OperatingLeasesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#BusinessCombinations" roleURI="http://www.mednax.com/role/BusinessCombinations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StatementTable_99" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_812923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_812923" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_812920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_812920" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_812916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_812916" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_812905" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_812902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_StatementTable_812902" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_812907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_md_ExtraordinaryItemsAxis_812907" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_812908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_ExtraordinaryItemsAxis_812907" xlink:to="loc_md_ExtraordinaryItemsDomain_812908" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_812908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_ExtraordinaryItemsAxis_812907" xlink:to="loc_md_ExtraordinaryItemsDomain_812908_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_812909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ExtraordinaryItemsDomain_812908" xlink:to="loc_md_CovidNinenteenMember_812909" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_812910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_TitleOfIndividualAxis_812910" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_812910" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_812910" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_812912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" xlink:to="loc_srt_ExecutiveOfficerMember_812912" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_812913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_StatementScenarioAxis_812913" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_812914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_812913" xlink:to="loc_srt_ScenarioUnspecifiedDomain_812914" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_812914_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_812913" xlink:to="loc_srt_ScenarioUnspecifiedDomain_812914_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_812915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_812915" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_812917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_812917" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_812918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_812918" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_812919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_812919" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForThirdQuarterOf2021Member" xlink:label="loc_md_ForecastForThirdQuarterOf2021Member_825804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForThirdQuarterOf2021Member_825804" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_812921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_CreditFacilityAxis_812921" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_812922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_812921" xlink:to="loc_us-gaap_CreditFacilityDomain_812922" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_812922_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_812921" xlink:to="loc_us-gaap_CreditFacilityDomain_812922_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_812924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_812922" xlink:to="loc_md_CreditAgreementMember_812924" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_812925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_812922" xlink:to="loc_us-gaap_LetterOfCreditMember_812925" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_812927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_RangeAxis_812927" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_812927" xlink:to="loc_srt_RangeMember_813359" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_812927" xlink:to="loc_srt_RangeMember_813359_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813359" xlink:to="loc_srt_MaximumMember_813360" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_813361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813359" xlink:to="loc_srt_MinimumMember_813361" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_812931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_GeographicDistributionAxis_812931" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_812932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_812931" xlink:to="loc_us-gaap_GeographicDistributionDomain_812932" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_812932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_812931" xlink:to="loc_us-gaap_GeographicDistributionDomain_812932_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_812934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_812932" xlink:to="loc_md_RuralAreaMember_812934" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_812935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_DebtInstrumentAxis_812935" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_812936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_812935" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_812936" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_812936_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_812935" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_812936_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_812937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_812936" xlink:to="loc_md_Seniorunsecurdnotes2023Member_812937" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_812938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_812936" xlink:to="loc_md_Seniorunsecurdnotes2027Member_812938" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_812939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_812939" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_812941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_SupplementaryLeverageRatioRequired_812941" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_812943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_812943" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_812944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_812944" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_812945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_812945" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_812946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_812946" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_812947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_812947" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_812948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_812948" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization_825800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization_825800" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xlink:label="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement_825803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement_825803" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xlink:label="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod_207" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CashAndCashEquivalentsMaturityDescription" xlink:label="loc_md_CashAndCashEquivalentsMaturityDescription_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_CashAndCashEquivalentsMaturityDescription_203" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_202" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_201" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_208" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_206" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ShortTermInvestmentMaturityPeriod" xlink:label="loc_md_ShortTermInvestmentMaturityPeriod_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_ShortTermInvestmentMaturityPeriod_205" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" xlink:to="loc_us-gaap_AccountsReceivableMember_189" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_177" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_177" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_178" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_177" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_178_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_178" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_190" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_CreditFacilityAxis_179" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_179" xlink:to="loc_us-gaap_CreditFacilityDomain_180" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_179" xlink:to="loc_us-gaap_CreditFacilityDomain_180_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_BuildingMember_194" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_ComputerEquipmentMember_196" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_EquipmentMember_195" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_198" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_197" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_srt_RangeAxis_184" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_184" xlink:to="loc_srt_RangeMember_185" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_185_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_184" xlink:to="loc_srt_RangeMember_185_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_185" xlink:to="loc_srt_MaximumMember_199" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_185" xlink:to="loc_srt_MinimumMember_200" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_181" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_181_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_181" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_193" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_554497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_181" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_554497" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_554481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_554481" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_554482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_554481" xlink:to="loc_us-gaap_SegmentDomain_554482" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_554482_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_554481" xlink:to="loc_us-gaap_SegmentDomain_554482_default" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_222" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_222" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_231" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_222" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SalesAndRevenueServicesNetMember" xlink:label="loc_md_SalesAndRevenueServicesNetMember_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" xlink:to="loc_md_SalesAndRevenueServicesNetMember_223" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_217" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_217" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_218" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_218_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_217" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_218_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_218" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_224" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_srt_ProductOrServiceAxis_219" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_219" xlink:to="loc_srt_ProductsAndServicesDomain_220" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_219" xlink:to="loc_srt_ProductsAndServicesDomain_220_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaternalFetalMedicineMember" xlink:label="loc_md_MaternalFetalMedicineMember_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_MaternalFetalMedicineMember_228" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NeonatologyAndOtherPediatricSubspecialtiesMember" xlink:label="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember_225" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricCardiologyMember" xlink:label="loc_md_PediatricCardiologyMember_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_PediatricCardiologyMember_230" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393319" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393319" xlink:to="loc_us-gaap_StatementTable_393316" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393317" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393317" xlink:to="loc_us-gaap_ClassOfStockDomain_393318" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393318_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393317" xlink:to="loc_us-gaap_ClassOfStockDomain_393318_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_395284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_395284" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_395285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_395285" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_395287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_395287" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393319" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_393323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_393323" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_393325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_393325" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_499981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_md_MutualFundsFairValueDisclosure_499981" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393336" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393336" xlink:to="loc_us-gaap_StatementTable_393333" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393333" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393334" xlink:to="loc_us-gaap_ClassOfStockDomain_393335" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393334" xlink:to="loc_us-gaap_ClassOfStockDomain_393335_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_395206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393333" xlink:to="loc_us-gaap_DebtInstrumentAxis_395206" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_395207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_395206" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_395207" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_395207_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_395206" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_395207_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_395214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_395207" xlink:to="loc_md_TwoThousandTwentyThreeMember_395214" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_395215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_395207" xlink:to="loc_md_TwoThousandTwentySevenMember_395215" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_393340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393336" xlink:to="loc_us-gaap_LiabilitiesAbstract_393340" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_393341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_393340" xlink:to="loc_us-gaap_NotesPayable_393341" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393336" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_393391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_393391" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" xlink:to="loc_us-gaap_InvestmentTypeAxis_234" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_234" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_235" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_234" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_235_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_CertificatesOfDepositMember_240" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_812988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_812988" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_238" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_554131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_554131" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_813378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" xlink:to="loc_us-gaap_AvailableForSaleSecurities_813378" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_Depreciation_295" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_393273" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_StatementTable_393269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393270" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393270" xlink:to="loc_us-gaap_ClassOfStockDomain_393271" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393270" xlink:to="loc_us-gaap_ClassOfStockDomain_393271_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_393276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_393276" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_393276" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_393276" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianGroupMember" xlink:label="loc_md_PhysicianGroupMember_393278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" xlink:to="loc_md_PhysicianGroupMember_393278" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember_812995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" xlink:to="loc_md_PediatricSubspecialtyPracticeMember_812995" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsAxis" xlink:label="loc_md_DeferredtaxassetsAxis_812997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_md_DeferredtaxassetsAxis_812997" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsgoodwillDomain" xlink:label="loc_md_DeferredtaxassetsgoodwillDomain_812998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_DeferredtaxassetsAxis_812997" xlink:to="loc_md_DeferredtaxassetsgoodwillDomain_812998" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsgoodwillDomain" xlink:label="loc_md_DeferredtaxassetsgoodwillDomain_812998_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_DeferredtaxassetsAxis_812997" xlink:to="loc_md_DeferredtaxassetsgoodwillDomain_812998_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_393274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_393274" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_393275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_393275" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_393279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_393279" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_393280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_393280" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPhysicianGroupPracticesAcquired" xlink:label="loc_md_NumberOfPhysicianGroupPracticesAcquired_395265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfPhysicianGroupPracticesAcquired_395265" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfNeonatologyPracticesAcquired" xlink:label="loc_md_NumberOfNeonatologyPracticesAcquired_395266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfNeonatologyPracticesAcquired_395266" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_395267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_395267" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfRadiologyPracticesAcquired" xlink:label="loc_md_NumberOfRadiologyPracticesAcquired_395268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfRadiologyPracticesAcquired_395268" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_499982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_499982" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPurchaseConsideration" xlink:label="loc_md_AccruedPurchaseConsideration_499983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_AccruedPurchaseConsideration_499983" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_554191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_554191" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_574648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_574648" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_GoodwillAndOtherIntangibleAssetsLineItems" xlink:label="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_341" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_334" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_334" xlink:to="loc_us-gaap_SegmentDomain_333" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_333_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_334" xlink:to="loc_us-gaap_SegmentDomain_333_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_339" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_Goodwill_336" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_350" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_349" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianAndHospitalAgreementsMember" xlink:label="loc_md_PhysicianAndHospitalAgreementsMember_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" xlink:to="loc_md_PhysicianAndHospitalAgreementsMember_352" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherTechnologyMember" xlink:label="loc_md_OtherTechnologyMember_813430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" xlink:to="loc_md_OtherTechnologyMember_813430" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_413717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_413717" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_413567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_AssetImpairmentCharges_413567" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_StatementTable_468356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsIntangibleAssetsMember" xlink:label="loc_md_DeferredTaxAssetsIntangibleAssetsMember_468392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DeferredTaxAssetsDomain_468388" xlink:to="loc_md_DeferredTaxAssetsIntangibleAssetsMember_468392" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_813007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_813007" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_813008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_813007" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_813008" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_813008_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_813007" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_813008_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_813010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_813010" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_813021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_DivestitureOfMeddataMember_813021" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_813022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_813022" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="loc_md_AnesthesiologyServicesMedicalGroupMember_813661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_AnesthesiologyServicesMedicalGroupMember_813661" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_813013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_813013" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_813013" xlink:to="loc_srt_RangeMember_813014" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813014_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_813013" xlink:to="loc_srt_RangeMember_813014_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813014" xlink:to="loc_srt_MaximumMember_813015" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_813016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813014" xlink:to="loc_srt_MinimumMember_813016" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_813656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_813656" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_813657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_813656" xlink:to="loc_us-gaap_TaxPeriodDomain_813657" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_813657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_813656" xlink:to="loc_us-gaap_TaxPeriodDomain_813657_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_813658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_813657" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_813658" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_574665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_574665" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_574666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_574666" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_813004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_813004" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_813005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_813005" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Accountsreceivableretained" xlink:label="loc_md_Accountsreceivableretained_813006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_Accountsreceivableretained_813006" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Capitallosscarryforward" xlink:label="loc_md_Capitallosscarryforward_813017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_Capitallosscarryforward_813017" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_813018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_813018" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_813019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_813019" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xlink:label="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss_813020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss_813020" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_813023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_813023" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_813024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_813024" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_813660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_813660" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PurchaseConsiderationCashPayment" xlink:label="loc_md_PurchaseConsiderationCashPayment_824842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_PurchaseConsiderationCashPayment_824842" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetProceedsForTheRadiologyServicesMedicalGroup" xlink:label="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup_824843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup_824843" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393125" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_us-gaap_StatementTable_393122" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393123" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393123" xlink:to="loc_us-gaap_ClassOfStockDomain_393124" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393124_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393123" xlink:to="loc_us-gaap_ClassOfStockDomain_393124_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesAssetsAbstract" xlink:label="loc_md_OperatingLeasesAssetsAbstract_393127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OperatingLeasesAssetsAbstract_393127" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_OperatingLeasesAssetsAbstract_393127" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393128" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesLiabilitiesAbstract" xlink:label="loc_md_OperatingLeasesLiabilitiesAbstract_393129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OperatingLeasesLiabilitiesAbstract_393129" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_OperatingLeasesLiabilitiesAbstract_393129" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393130" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_OperatingLeasesLiabilitiesAbstract_393129" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393131" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_393133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_393133" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherInformationRelatedToOperatingLeaseAbstract" xlink:label="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_393132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_393132" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393157" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_StatementTable_393154" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393154" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393155" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393155" xlink:to="loc_us-gaap_ClassOfStockDomain_393156" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393156_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393155" xlink:to="loc_us-gaap_ClassOfStockDomain_393156_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_393158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_OperatingLeaseCost_393158" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_393159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_VariableLeaseCost_393159" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesOtherCosts" xlink:label="loc_md_OperatingLeasesOtherCosts_393161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_md_OperatingLeasesOtherCosts_393161" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_393162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_LeaseCost_393162" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherEquipmentRent" xlink:label="loc_md_OtherEquipmentRent_499989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_md_OtherEquipmentRent_499989" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393169" xlink:to="loc_us-gaap_StatementTable_393166" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393166" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393167" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393167" xlink:to="loc_us-gaap_ClassOfStockDomain_393168" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393167" xlink:to="loc_us-gaap_ClassOfStockDomain_393168_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_393170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393169" xlink:to="loc_us-gaap_OperatingLeasePayments_393170" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393177" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_StatementTable_393174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393175" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393175" xlink:to="loc_us-gaap_ClassOfStockDomain_393176" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393175" xlink:to="loc_us-gaap_ClassOfStockDomain_393176_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_393179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_393179" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_393180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_393180" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_393181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_393181" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_393182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_393182" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_393183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_393183" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_393184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_393184" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393187" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393188" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413589" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_413590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiability_413590" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555217" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_396" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_416" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_415" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_418" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentMaturityYear" xlink:label="loc_md_DebtInstrumentMaturityYear_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_DebtInstrumentMaturityYear_423" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_419" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_420" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_425" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_422" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_413" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_426" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_400" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_CreditFacilityAxis_393" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_393" xlink:to="loc_us-gaap_CreditFacilityDomain_394" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_394_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_393" xlink:to="loc_us-gaap_CreditFacilityDomain_394_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_411" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_us-gaap_LetterOfCreditMember_410" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_412" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_812962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_CreditAgreementMember_812962" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnsecuredRevolvingCreditFacilityMember" xlink:label="loc_md_UnsecuredRevolvingCreditFacilityMember_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_UnsecuredRevolvingCreditFacilityMember_409" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_DebtInstrumentAxis_395" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_395" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_397" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_395" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_397_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AlternateBaseRateMember" xlink:label="loc_md_AlternateBaseRateMember_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_397" xlink:to="loc_md_AlternateBaseRateMember_427" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ApplicableMarginRateMember" xlink:label="loc_md_ApplicableMarginRateMember_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_397" xlink:to="loc_md_ApplicableMarginRateMember_428" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember_432" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_435" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_434" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember_436" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_433" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_430" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsByNameAxis" xlink:label="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsNameDomain" xlink:label="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" xlink:to="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsNameDomain" xlink:label="loc_us-gaap_OtherOwnershipInterestsNameDomain_402_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" xlink:to="loc_us-gaap_OtherOwnershipInterestsNameDomain_402_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ChangeInControlMember" xlink:label="loc_md_ChangeInControlMember_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" xlink:to="loc_md_ChangeInControlMember_437" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_srt_RangeAxis_403" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_403" xlink:to="loc_srt_RangeMember_404" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_403" xlink:to="loc_srt_RangeMember_404_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_404" xlink:to="loc_srt_MaximumMember_439" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_404" xlink:to="loc_srt_MinimumMember_438" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_VariableRateAxis_407" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_407" xlink:to="loc_us-gaap_VariableRateDomain_408" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_407" xlink:to="loc_us-gaap_VariableRateDomain_408_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_408" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_441" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_408" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_442" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_srt_StatementScenarioAxis_406" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_406" xlink:to="loc_srt_ScenarioUnspecifiedDomain_405" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_406" xlink:to="loc_srt_ScenarioUnspecifiedDomain_405_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xlink:label="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember_440" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_812965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_812965" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_813365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_813365" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LongTermDebt_424" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_812958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_812958" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_812964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_SupplementaryLeverageRatioRequired_812964" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_554301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_554301" use="optional" order="58" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_447" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_451" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_us-gaap_DebtInstrumentTable_448" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_448" xlink:to="loc_us-gaap_CreditFacilityAxis_445" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_445" xlink:to="loc_us-gaap_CreditFacilityDomain_446" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_445" xlink:to="loc_us-gaap_CreditFacilityDomain_446_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_446" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_449" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_446" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_450" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtNet" xlink:label="loc_md_LongTermDebtNet_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_md_LongTermDebtNet_453" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_452" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueLineItems" xlink:label="loc_md_DebtInstrumentFairValueLineItems_458" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DebtInstrumentFairValueLineItems_458" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_466" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueTable" xlink:label="loc_md_DebtInstrumentFairValueTable_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_DebtInstrumentFairValueLineItems_458" xlink:to="loc_md_DebtInstrumentFairValueTable_459" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_461" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_461" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_461" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_555319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_555319" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_CreditFacilityAxis_456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_456" xlink:to="loc_us-gaap_CreditFacilityDomain_457" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_457_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_456" xlink:to="loc_us-gaap_CreditFacilityDomain_457_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_457" xlink:to="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_465" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_457" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_464" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_469" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxLineItems" xlink:label="loc_md_IncomeTaxLineItems_493" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_522" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_517" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_516" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_505" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetOperatingLossCarryForwardsExpirationDate" xlink:label="loc_md_NetOperatingLossCarryForwardsExpirationDate_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_NetOperatingLossCarryForwardsExpirationDate_515" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_OpenTaxYear_523" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_OperatingLossCarryforwards_514" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxExpenseForExcessTaxDeficiencies" xlink:label="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies_513" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxTable" xlink:label="loc_md_IncomeTaxTable_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_IncomeTaxTable_494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_srt_RangeAxis_495" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_495" xlink:to="loc_srt_RangeMember_496" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_495" xlink:to="loc_srt_RangeMember_496_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_496" xlink:to="loc_srt_MaximumMember_525" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_496" xlink:to="loc_srt_MinimumMember_524" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_srt_StatementScenarioAxis_500" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_500" xlink:to="loc_srt_ScenarioUnspecifiedDomain_498" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_498_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_500" xlink:to="loc_srt_ScenarioUnspecifiedDomain_498_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_498" xlink:to="loc_srt_ScenarioForecastMember_526" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xlink:label="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_TaxPeriodAxis_501" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_501" xlink:to="loc_us-gaap_TaxPeriodDomain_502" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_502_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_501" xlink:to="loc_us-gaap_TaxPeriodDomain_502_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_502" xlink:to="loc_us-gaap_EarliestTaxYearMember_528" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_502" xlink:to="loc_us-gaap_LatestTaxYearMember_529" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_508" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_505887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_505887" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_518" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_520" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_519" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossesIncurred" xlink:label="loc_md_CapitalLossesIncurred_583582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_CapitalLossesIncurred_583582" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_597884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxLiabilities_597884" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossCarryforwards" xlink:label="loc_md_CapitalLossCarryforwards_812993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_CapitalLossCarryforwards_812993" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_812994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_812994" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_598" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_599" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_602" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RestrictedAndDeferredStockUnitsMember" xlink:label="loc_md_RestrictedAndDeferredStockUnitsMember_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_md_RestrictedAndDeferredStockUnitsMember_605" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_597" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_596" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_600" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_812976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_812976" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_812977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_812977" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812978" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_812980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_812980" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_646" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_md_CommonStockTable_637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_CollateralAxis_642" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_642" xlink:to="loc_us-gaap_CollateralDomain_638" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_642" xlink:to="loc_us-gaap_CollateralDomain_638_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_824954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_638" xlink:to="loc_us-gaap_CommonStockMember_824954" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="21" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>md-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-February-2021 [01:05:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, cash equivalents at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="loc_md_OperatingAndFinanceLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingAndFinanceLeaseRightOfUseAssets" xml:lang="en-US">Operating And Finance Lease Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_OperatingAndFinanceLeaseRightOfUseAssets" xml:lang="en-US">Operating and finance lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="lab_md_OperatingAndFinanceLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OperatingAndFinanceLeaseRightOfUseAssets" xml:lang="en-US">Operating and finance lease right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES &amp; EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities excluding accrued income taxes current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Less: Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: Current obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long-term debt and finance lease liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long term debt and capital lease obligations excluding long term line of credit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock; $.01 par value; 200,000 shares authorized; 85,593 and 84,248 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained (deficit) earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total MEDNAX, Inc. shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term portion of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term portion of operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, aggregate shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income from continuing operations before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net (loss) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings (loss) per share, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings (loss) per share, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Weighted average common shares:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common and common equivalent shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">(Loss) income from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss (income) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (provision)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment and other income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment and other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net non-operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total non-operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSalariesAndBenefits" xlink:to="lab_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice Supplies And Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Transformational and restructuring related expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">(Loss) income from continuing operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">It represents Income (Loss) from continuing operations, per basic and diluted share</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Income from continuing operations, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Income from continuing operations, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">(Loss) income from discontinued operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Loss from discontinued operations, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Loss from discontinued operations, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Retained Earnings And Accumulated Other Comprehensive Income [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Forfeitures of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock swaps, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock issued during period shares stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Forfeitures of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock Issued During Period Value Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock swaps</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodValueStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock issued during period value stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchased common stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchased common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Stock Repurchased During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Repurchased common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Common stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized holding gain on investments, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Contribution from noncontrolling Interests, net of loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Property and equipment included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xml:lang="en-US">Capital Lease Obligations Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xml:lang="en-US">Equipment financed through finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments for credit facility amendment and financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from issuance of senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in financing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payments of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Repurchases of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Payments on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Payments on finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Borrowings on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xml:lang="en-US">Proceeds from Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xml:lang="en-US">Contribution from noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in financing activities &#8211; discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition payments, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash (used in) provided by investing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from maturities or sales of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from sales of businesses, net of cash sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by (used in) investing activities &#8211; discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash provided from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of premiums, discounts and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by operating activities &#8211; discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by operating activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">General</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic ("COVID-19")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable And Net Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable and Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts receivable and net revenue disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationsAbstract" xml:lang="en-US">Health Care Organizations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationsAbstract" xlink:to="lab_us-gaap_HealthCareOrganizationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyDisclosureTextBlock" xlink:label="loc_us-gaap_MalpracticeLossContingencyDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyDisclosureTextBlock" xml:lang="en-US">Malpractice Loss Contingency Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyDisclosureTextBlock" xml:lang="en-US">Accrued Professional Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyDisclosureTextBlock" xlink:to="lab_us-gaap_MalpracticeLossContingencyDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xlink:label="loc_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xml:lang="en-US">Debt and Capital Leases Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xml:lang="en-US">Line of Credit, Long-Term Debt and Capital Lease Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xlink:to="lab_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Common and Common Equivalent Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Incentive Plans and Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchase Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockRepurchasesTextBlock" xlink:to="lab_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Entire disclosure of common stock repurchases.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Retirement Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Selected Quarterly Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockShareRepurchasesPolicyTextBlock" xlink:label="loc_md_CommonStockShareRepurchasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockShareRepurchasesPolicyTextBlock" xml:lang="en-US">Common Stock Share Repurchases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockShareRepurchasesPolicyTextBlock" xml:lang="en-US">Common Stock Repurchases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockShareRepurchasesPolicyTextBlock" xlink:to="lab_md_CommonStockShareRepurchasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockShareRepurchasesPolicyTextBlock" xml:lang="en-US">Common stock share repurchases policy.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Income Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Other Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProfessionalLiabilityCoveragePolicyTextBlock" xlink:label="loc_md_ProfessionalLiabilityCoveragePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProfessionalLiabilityCoveragePolicyTextBlock" xml:lang="en-US">Professional Liability Coverage Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProfessionalLiabilityCoveragePolicyTextBlock" xml:lang="en-US">Professional Liability Coverage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProfessionalLiabilityCoveragePolicyTextBlock" xlink:to="lab_md_ProfessionalLiabilityCoveragePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProfessionalLiabilityCoveragePolicyTextBlock" xml:lang="en-US">Professional liability coverage policy.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Accounting Estimates and Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Tabular disclosure of financial instruments measured at carrying amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Net Revenue by Service Line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xml:lang="en-US">Schedule of Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedule of Percentage of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Intangible Assets, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xml:lang="en-US">Amortization Expenses for Existing Intangible Assets for the Next Five Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:label="loc_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:to="lab_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Tabular disclosure of operating lease related assets and liabilities and other related information.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xlink:label="loc_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xml:lang="en-US">Operating Leases Cash Flow Related Information Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xml:lang="en-US">Operating Leases Cash Flow Related Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xlink:to="lab_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xml:lang="en-US">Tabular disclosure of operating lease related cash flow information.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xlink:label="loc_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xml:lang="en-US">Schedule Of Accrued Professional Liability [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xml:lang="en-US">Schedule of Accrued Professional Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xlink:to="lab_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xml:lang="en-US">Schedule of accrued professional liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Long-Term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xlink:label="loc_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xml:lang="en-US">Summary of Estimated Fair Value of Notes Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xml:lang="en-US">Summary of Estimated Fair Value of Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xlink:to="lab_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xml:lang="en-US">Summary of Estimated Fair Value of Notes Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xlink:label="loc_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xml:lang="en-US">Schedule Of Finance Lease Obligations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xml:lang="en-US">Schedule of Financial Lease Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xlink:to="lab_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xml:lang="en-US">Schedule Of Finance Lease Obligations.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Summary of Components of Income Tax Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Significant Components of Deferred Income Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xml:lang="en-US">Schedule of Activity Related to Gross Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Schedule of Restricted Stock and Deferred Stock Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Activity and Certain Other Information Related to Stock Option Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US">Summary of Company's Selected Quarterly Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAbstract" xlink:to="lab_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Decrease In Salary | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Leverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SupplementaryLeverageRatioRequired" xlink:to="lab_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Deferred Payment Of Social Security Taxes | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:to="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xml:lang="en-US">Letters of Credit Outstanding, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xml:lang="en-US">Letters of credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xml:lang="en-US">Letters of credit outstanding amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of credit remaining borrowing capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit facility, available balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Deemed Consolidated Earnings Before Interest Taxes Depreciation And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Deemed Consolidated EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Deemed consolidated earnings before interest taxes depreciation and amortization.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xlink:label="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xml:lang="en-US">Line Of Credit Facility Minimum Availability Under Credit Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xlink:to="lab_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xml:lang="en-US">Line of credit facility minimum availability under credit agreement.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAxis" xlink:to="lab_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsDomain" xlink:to="lab_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">COVID-19 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CovidNinenteenMember" xlink:to="lab_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:to="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFourthQuarterOf2020Member" xlink:to="lab_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFirstQuarterOf2021Member" xlink:to="lab_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondQuarterOf2021Member" xlink:to="lab_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForThirdQuarterOf2021Member" xlink:label="loc_md_ForecastForThirdQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForThirdQuarterOf2021Member" xml:lang="en-US">Forecast For Third Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForThirdQuarterOf2021Member" xlink:to="lab_md_ForecastForThirdQuarterOf2021Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CreditAgreementMember" xlink:to="lab_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letters of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionAxis" xml:lang="en-US">Geographic Distribution [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionDomain" xml:lang="en-US">Geographic Distribution [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RuralAreaMember" xlink:to="lab_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">SeniorUnsecurdNotes2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">Senior Unsecurd Notes 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2023Member" xlink:to="lab_md_Seniorunsecurdnotes2023Member" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">SeniorUnsecurdNotes2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">Senior Unsecurd Notes 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2027Member" xlink:to="lab_md_Seniorunsecurdnotes2027Member" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_md_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xml:lang="en-US">Government Contracts Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xml:lang="en-US">Government Contracts Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingMember" xml:lang="en-US">Building [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BuildingMember" xml:lang="en-US">Buildings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Medical Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureOneMember" xlink:to="lab_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureTwoMember" xml:lang="en-US">Unnamed Corporate Joint Venture Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_UnnamedCorporateJointVentureTwoMember" xml:lang="en-US">Unnamed Corporate Joint Venture Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureTwoMember" xlink:to="lab_md_UnnamedCorporateJointVentureTwoMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_md_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xlink:label="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xml:lang="en-US">Business Combination Contingent Consideration Arrangements Time Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xml:lang="en-US">Additional amounts to be paid in cash or common stock based on achievement of performance measures within period, maximum years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xlink:to="lab_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xml:lang="en-US">Business combination, contingent consideration arrangements, time period.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CashAndCashEquivalentsMaturityDescription" xlink:label="loc_md_CashAndCashEquivalentsMaturityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashAndCashEquivalentsMaturityDescription" xml:lang="en-US">Cash And Cash Equivalents Maturity Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CashAndCashEquivalentsMaturityDescription" xml:lang="en-US">Cash and cash equivalents maturity description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashAndCashEquivalentsMaturityDescription" xlink:to="lab_md_CashAndCashEquivalentsMaturityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CashAndCashEquivalentsMaturityDescription" xml:lang="en-US">Cash and cash equivalents maturity description.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Percentage of net accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Net revenue in percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method ownership percentage in joint venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Intangible assets finite lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property and equipment estimated useful lives, years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ShortTermInvestmentMaturityPeriod" xlink:label="loc_md_ShortTermInvestmentMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ShortTermInvestmentMaturityPeriod" xml:lang="en-US">Short Term Investment Maturity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ShortTermInvestmentMaturityPeriod" xml:lang="en-US">Short-Term investments maturity period, in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ShortTermInvestmentMaturityPeriod" xlink:to="lab_md_ShortTermInvestmentMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ShortTermInvestmentMaturityPeriod" xml:lang="en-US">Short term investment maturity period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RegulatoryAssetsAbstract" xlink:label="loc_md_RegulatoryAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RegulatoryAssetsAbstract" xml:lang="en-US">Regulatory Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RegulatoryAssetsAbstract" xlink:to="lab_md_RegulatoryAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RegulatoryAssetsAbstract" xml:lang="en-US">Regulatory Assets [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SalesAndRevenueServicesNetMember" xlink:label="loc_md_SalesAndRevenueServicesNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SalesAndRevenueServicesNetMember" xml:lang="en-US">Sales And Revenue Services Net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SalesAndRevenueServicesNetMember" xml:lang="en-US">Sales Revenue, Services, Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SalesAndRevenueServicesNetMember" xlink:to="lab_md_SalesAndRevenueServicesNetMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xml:lang="en-US">Product Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xml:lang="en-US">Product Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaternalFetalMedicineMember" xlink:label="loc_md_MaternalFetalMedicineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MaternalFetalMedicineMember" xml:lang="en-US">Maternal Fetal Medicine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MaternalFetalMedicineMember" xml:lang="en-US">Maternal-Fetal Medicine [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MaternalFetalMedicineMember" xlink:to="lab_md_MaternalFetalMedicineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MaternalFetalMedicineMember" xml:lang="en-US">Maternal fetal medicine.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NeonatologyAndOtherPediatricSubspecialtiesMember" xlink:label="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NeonatologyAndOtherPediatricSubspecialtiesMember" xml:lang="en-US">Neonatology And Other Pediatric Subspecialties [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NeonatologyAndOtherPediatricSubspecialtiesMember" xml:lang="en-US">Neonatology and Other Pediatric Subspecialties [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember" xlink:to="lab_md_NeonatologyAndOtherPediatricSubspecialtiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NeonatologyAndOtherPediatricSubspecialtiesMember" xml:lang="en-US">Neonatology and other pediatric subspecialties.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricCardiologyMember" xlink:label="loc_md_PediatricCardiologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PediatricCardiologyMember" xml:lang="en-US">Pediatric Cardiology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PediatricCardiologyMember" xml:lang="en-US">Pediatric Cardiology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PediatricCardiologyMember" xlink:to="lab_md_PediatricCardiologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PediatricCardiologyMember" xml:lang="en-US">Pediatric cardiology.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money Market Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MoneyMarketFundsFairValueDisclosure" xlink:to="lab_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Fair value of money market funds.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MutualFundsFairValueDisclosure" xlink:to="lab_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual funds fair value disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">2023 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentyThreeMember" xlink:to="lab_md_TwoThousandTwentyThreeMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">2027 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentySevenMember" xlink:to="lab_md_TwoThousandTwentySevenMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAbstract" xml:lang="en-US">Investments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Corporate Securities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">Federal Home Loan Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">US Treasury Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">US Treasury Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">Municipal Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Other Corporate Bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Corporate Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherCorporateBondsMember" xlink:to="lab_us-gaap_AllOtherCorporateBondsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Schedule of Avaliable-For-Sale Securities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesAbstract" xml:lang="en-US">Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Gross accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for contractual adjustments and uncollectibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems" xlink:to="lab_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule of financing receivables.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Health Care, Patient Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Net patient service revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospital contract administrative fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_HospitalsContractsMember" xlink:to="lab_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xml:lang="en-US">Health Care Organization Revenue and Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage Of Net Patient Service Revenue By Type Of Payor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue by type payor.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Self-Pay [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Private-Pay Patients [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContractedManagedCareMember" xlink:to="lab_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember" xlink:to="lab_us-gaap_GovernmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Third-Party Payor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Other Third-Parties [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FixturesAndEquipmentGross" xml:lang="en-US">Fixtures and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FixturesAndEquipmentGross" xml:lang="en-US">Equipment and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixturesAndEquipmentGross" xlink:to="lab_us-gaap_FixturesAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Land" xml:lang="en-US">Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Land" xml:lang="en-US">Land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Buildings and Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Building</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:label="loc_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xml:lang="en-US">Property Plant And Equipment Capitalized Interest Costs [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:to="lab_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xml:lang="en-US">Property Plant And Equipment Capitalized Interest Costs [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Recorded depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Total business acquisition consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xml:lang="en-US">Goodwill, Acquired During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Other intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition" xml:lang="en-US">Payments for Previous Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition" xml:lang="en-US">Contingent consideration payments related to prior-period acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForPreviousAcquisition" xlink:to="lab_us-gaap_PaymentsForPreviousAcquisition" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPhysicianGroupPracticesAcquired" xlink:label="loc_md_NumberOfPhysicianGroupPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NumberOfPhysicianGroupPracticesAcquired" xml:lang="en-US">Number Of Physician Group Practices Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NumberOfPhysicianGroupPracticesAcquired" xlink:to="lab_md_NumberOfPhysicianGroupPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NumberOfPhysicianGroupPracticesAcquired" xml:lang="en-US">Number of physician group practices acquired.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfNeonatologyPracticesAcquired" xlink:label="loc_md_NumberOfNeonatologyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NumberOfNeonatologyPracticesAcquired" xml:lang="en-US">Number Of Neonatology Practices Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NumberOfNeonatologyPracticesAcquired" xlink:to="lab_md_NumberOfNeonatologyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NumberOfNeonatologyPracticesAcquired" xml:lang="en-US">Number of neonatology practices acquired.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" xml:lang="en-US">Number Of Pediatric Subspecialty Practices Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:to="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" xml:lang="en-US">Number of other pediatric subspecialty practices acquired.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfRadiologyPracticesAcquired" xlink:label="loc_md_NumberOfRadiologyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NumberOfRadiologyPracticesAcquired" xml:lang="en-US">Number Of Radiology Practices Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NumberOfRadiologyPracticesAcquired" xlink:to="lab_md_NumberOfRadiologyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NumberOfRadiologyPracticesAcquired" xml:lang="en-US">Number of radiology practices acquired.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Business acquisition consiideration paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPurchaseConsideration" xlink:label="loc_md_AccruedPurchaseConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedPurchaseConsideration" xml:lang="en-US">Accrued Purchase Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedPurchaseConsideration" xlink:to="lab_md_AccruedPurchaseConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedPurchaseConsideration" xml:lang="en-US">Accrued purchase consideration.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Business acquisitions contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianGroupMember" xlink:label="loc_md_PhysicianGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PhysicianGroupMember" xml:lang="en-US">Physician Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PhysicianGroupMember" xml:lang="en-US">Physician Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PhysicianGroupMember" xlink:to="lab_md_PhysicianGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PhysicianGroupMember" xml:lang="en-US">Physician group.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PediatricSubspecialtyPracticeMember" xlink:to="lab_md_PediatricSubspecialtyPracticeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsAxis" xlink:label="loc_md_DeferredtaxassetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredtaxassetsAxis" xml:lang="en-US">DeferredTaxAssets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredtaxassetsAxis" xlink:to="lab_md_DeferredtaxassetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DeferredtaxassetsAxis" xml:lang="en-US">DeferredTaxAssetsAxis .</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsgoodwillDomain" xlink:label="loc_md_DeferredtaxassetsgoodwillDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredtaxassetsgoodwillDomain" xml:lang="en-US">DeferredTaxAssetsGoodwill [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredtaxassetsgoodwillDomain" xlink:to="lab_md_DeferredtaxassetsgoodwillDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DeferredtaxassetsgoodwillDomain" xml:lang="en-US">DeferredTaxAssetsGoodwillMember .</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_GoodwillAndOtherIntangibleAssetsLineItems" xlink:label="loc_md_GoodwillAndOtherIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_GoodwillAndOtherIntangibleAssetsLineItems" xml:lang="en-US">Goodwill And Other Intangible Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_GoodwillAndOtherIntangibleAssetsLineItems" xml:lang="en-US">Goodwill And Other Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems" xlink:to="lab_md_GoodwillAndOtherIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_GoodwillAndOtherIntangibleAssetsLineItems" xml:lang="en-US">Goodwill And Other Intangible Assets [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense for intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Intangible assets related to acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianAndHospitalAgreementsMember" xlink:label="loc_md_PhysicianAndHospitalAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PhysicianAndHospitalAgreementsMember" xml:lang="en-US">Physician And Hospital Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PhysicianAndHospitalAgreementsMember" xml:lang="en-US">Physician And Hospital Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PhysicianAndHospitalAgreementsMember" xlink:to="lab_md_PhysicianAndHospitalAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PhysicianAndHospitalAgreementsMember" xml:lang="en-US">Physician And Hospital Agreements [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherTechnologyMember" xlink:label="loc_md_OtherTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OtherTechnologyMember" xml:lang="en-US">Other Technology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_OtherTechnologyMember" xml:lang="en-US">Other Technology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OtherTechnologyMember" xlink:to="lab_md_OtherTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OtherTechnologyMember" xml:lang="en-US">Other technology.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Amortization expense for existing other intangible assets, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Amortization expense for existing other intangible assets, 2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Amortization expense for existing other intangible assets, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Amortization expense for existing other intangible assets, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Amortization expense for existing other intangible assets, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Non-cash charge against goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Operating Income From Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Preliminary gain loss on sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum Consideration Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum Consideration Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MaximumConsiderationReceivable" xlink:to="lab_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">MaximumConsiderationReceivable</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Accountsreceivableretained" xlink:label="loc_md_Accountsreceivableretained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Accountsreceivableretained" xml:lang="en-US">AccountsReceivableRetained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Accountsreceivableretained" xml:lang="en-US">Accounts Receivable Retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Accountsreceivableretained" xlink:to="lab_md_Accountsreceivableretained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_Accountsreceivableretained" xml:lang="en-US">AccountsReceivableRetained</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Capitallosscarryforward" xlink:label="loc_md_Capitallosscarryforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Capitallosscarryforward" xml:lang="en-US">CapitalLossCarryForward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Capitallosscarryforward" xml:lang="en-US">Capital loss carry forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Capitallosscarryforward" xlink:to="lab_md_Capitallosscarryforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_Capitallosscarryforward" xml:lang="en-US">CapitalLossCarryForward</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xlink:label="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xml:lang="en-US">Disposal Group Not Discontinued Operation Goodwill Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xml:lang="en-US">Disposal Group Not Discontinued Operation Goodwill Impairment Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xlink:to="lab_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xml:lang="en-US">Disposal Group Not Discontinued Operation Goodwill Impairment Loss</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xml:lang="en-US">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xml:lang="en-US">Repayment of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt, interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt instrument interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Loss from Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PurchaseConsiderationCashPayment" xlink:label="loc_md_PurchaseConsiderationCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PurchaseConsiderationCashPayment" xml:lang="en-US">Purchase Consideration Cash Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PurchaseConsiderationCashPayment" xml:lang="en-US">Purchase consideration cash payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PurchaseConsiderationCashPayment" xlink:to="lab_md_PurchaseConsiderationCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PurchaseConsiderationCashPayment" xml:lang="en-US">Purchase consideration cash payment.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetProceedsForTheRadiologyServicesMedicalGroup" xlink:label="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NetProceedsForTheRadiologyServicesMedicalGroup" xml:lang="en-US">Net Proceeds For The Radiology Services Medical Group</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NetProceedsForTheRadiologyServicesMedicalGroup" xml:lang="en-US">Net proceeds for the radiology services medical group</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup" xlink:to="lab_md_NetProceedsForTheRadiologyServicesMedicalGroup" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NetProceedsForTheRadiologyServicesMedicalGroup" xml:lang="en-US">Net proceeds for the radiology services medical group.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsAxis" xml:lang="en-US">Deferred Tax Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsAxis" xlink:to="lab_md_DeferredTaxAssetsAxis" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsDomain" xml:lang="en-US">Deferred Tax Assets [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsDomain" xlink:to="lab_md_DeferredTaxAssetsDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsIntangibleAssetsMember" xlink:label="loc_md_DeferredTaxAssetsIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsIntangibleAssetsMember" xml:lang="en-US">Deferred Tax Assets Intangible Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsIntangibleAssetsMember" xlink:to="lab_md_DeferredTaxAssetsIntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="lab_md_NorthAmericanPartnersInAnesthesiaMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture Of Meddata [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture Of Meddata [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DivestitureOfMeddataMember" xlink:to="lab_md_DivestitureOfMeddataMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RadiologyServicesMedicalGroupMember" xml:lang="en-US">Radiology Services Medical Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RadiologyServicesMedicalGroupMember" xml:lang="en-US">Radiology Services Medical Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RadiologyServicesMedicalGroupMember" xlink:to="lab_md_RadiologyServicesMedicalGroupMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="loc_md_AnesthesiologyServicesMedicalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AnesthesiologyServicesMedicalGroupMember" xml:lang="en-US">Anesthesiology Services Medical Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AnesthesiologyServicesMedicalGroupMember" xml:lang="en-US">Anesthesiology Services Medical Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AnesthesiologyServicesMedicalGroupMember" xlink:to="lab_md_AnesthesiologyServicesMedicalGroupMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax Year Two Thousand And Twenty Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TaxYearTwoThousandAndTwentyFiveMember" xlink:to="lab_md_TaxYearTwoThousandAndTwentyFiveMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Accrued professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued Payroll Taxes And Benefits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses, total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedSalariesAndIncentiveCompensationCurrent" xlink:label="loc_md_AccruedSalariesAndIncentiveCompensationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedSalariesAndIncentiveCompensationCurrent" xml:lang="en-US">Accrued Salaries and Incentive Compensation Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedSalariesAndIncentiveCompensationCurrent" xml:lang="en-US">Accrued salaries and incentive compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedSalariesAndIncentiveCompensationCurrent" xlink:to="lab_md_AccruedSalariesAndIncentiveCompensationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedSalariesAndIncentiveCompensationCurrent" xml:lang="en-US">Accrued salaries and incentive compensation.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesAssetsAbstract" xlink:label="loc_md_OperatingLeasesAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingLeasesAssetsAbstract" xml:lang="en-US">Operating Leases Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OperatingLeasesAssetsAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingLeasesAssetsAbstract" xlink:to="lab_md_OperatingLeasesAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OperatingLeasesAssetsAbstract" xml:lang="en-US">Represents operating lease assets abstract.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesLiabilitiesAbstract" xlink:label="loc_md_OperatingLeasesLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingLeasesLiabilitiesAbstract" xml:lang="en-US">Operating Leases Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OperatingLeasesLiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingLeasesLiabilitiesAbstract" xlink:to="lab_md_OperatingLeasesLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherInformationRelatedToOperatingLeaseAbstract" xlink:label="loc_md_OtherInformationRelatedToOperatingLeaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OtherInformationRelatedToOperatingLeaseAbstract" xml:lang="en-US">Other Information Related to Operating Lease [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OtherInformationRelatedToOperatingLeaseAbstract" xml:lang="en-US">Other Information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OtherInformationRelatedToOperatingLeaseAbstract" xlink:to="lab_md_OtherInformationRelatedToOperatingLeaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OtherInformationRelatedToOperatingLeaseAbstract" xml:lang="en-US">Representing other information related to operating lease.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted-average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesOtherCosts" xlink:label="loc_md_OperatingLeasesOtherCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OperatingLeasesOtherCosts" xml:lang="en-US">Operating Leases Other Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_OperatingLeasesOtherCosts" xml:lang="en-US">Other operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OperatingLeasesOtherCosts" xlink:to="lab_md_OperatingLeasesOtherCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OperatingLeasesOtherCosts" xml:lang="en-US">Represents other costs of operating leases.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherEquipmentRent" xlink:label="loc_md_OtherEquipmentRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_OtherEquipmentRent" xml:lang="en-US">Other Equipment Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_OtherEquipmentRent" xml:lang="en-US">Other equipment rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_OtherEquipmentRent" xlink:to="lab_md_OtherEquipmentRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_OtherEquipmentRent" xml:lang="en-US">Other equipment rent.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: Amount of payments representing interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:label="loc_us-gaap_InsuranceSettlementsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InsuranceSettlementsReceivable" xml:lang="en-US">Insurance Settlements Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InsuranceSettlementsReceivable" xml:lang="en-US">Insurance receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivable" xlink:to="lab_us-gaap_InsuranceSettlementsReceivable" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedProfessionalLiability" xlink:label="loc_md_AccruedProfessionalLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedProfessionalLiability" xml:lang="en-US">Accrued Professional Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedProfessionalLiability" xml:lang="en-US">Accrued professional liability incurred and loss reserves reported for claims</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedProfessionalLiability" xlink:to="lab_md_AccruedProfessionalLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedProfessionalLiability" xml:lang="en-US">Accrued professional liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReserveCurrent" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xml:lang="en-US">Self Insurance Reserve, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xml:lang="en-US">Accrued professional liability incurred but loss reserves not reported for claims</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xml:lang="en-US">Total accrued professional liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xlink:label="loc_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xml:lang="en-US">Accrued Professional Liabilities Assumed Through Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xml:lang="en-US">Liabilities recognized, offset by insurance Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xlink:to="lab_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xml:lang="en-US">Accrued professional liabilities assumed through acquisition.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xlink:label="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xml:lang="en-US">Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology and Radiology Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xml:lang="en-US">Balance at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xml:lang="en-US">Balance at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xlink:to="lab_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xml:lang="en-US">Malpractice loss contingency accrual undiscounted excluding retained professional liabilities related to anesthesiology and radiology operations.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xml:lang="en-US">Claim payments related to Current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred in Prior Periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xml:lang="en-US">Claim payments related to Prior years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xml:lang="en-US">Total payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyProvisionForLosses" xlink:label="loc_md_MalpracticeLossContingencyProvisionForLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MalpracticeLossContingencyProvisionForLosses" xml:lang="en-US">Malpractice Loss Contingency Provision For Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_md_MalpracticeLossContingencyProvisionForLosses" xml:lang="en-US">Total provision for losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MalpracticeLossContingencyProvisionForLosses" xlink:to="lab_md_MalpracticeLossContingencyProvisionForLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MalpracticeLossContingencyProvisionForLosses" xml:lang="en-US">Malpractice loss contingency provision for losses.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xlink:label="loc_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xml:lang="en-US">Provision Adjustment For Losses Related To Current Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xml:lang="en-US">Provision (adjustment) for losses related to Current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xlink:to="lab_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xml:lang="en-US">Provision (adjustment) for losses related to current year.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToPriorYear" xlink:label="loc_md_ProvisionAdjustmentForLossesRelatedToPriorYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToPriorYear" xml:lang="en-US">Provision Adjustment For Losses Related To Prior Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToPriorYear" xml:lang="en-US">Provision (adjustment) for losses related to Prior years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProvisionAdjustmentForLossesRelatedToPriorYear" xlink:to="lab_md_ProvisionAdjustmentForLossesRelatedToPriorYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProvisionAdjustmentForLossesRelatedToPriorYear" xml:lang="en-US">Provision (adjustment) for losses related to prior year.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xml:lang="en-US">Line of Credit Facility [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xml:lang="en-US">Line of Credit Facility [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xml:lang="en-US">Five Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xml:lang="en-US">5.25% Senior Unsecured Notes Due 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:to="lab_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xml:lang="en-US">Five point two five percent senior unsecured notes due two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xml:lang="en-US">Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xml:lang="en-US">6.25% Senior Unsecured Notes Due 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:to="lab_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xml:lang="en-US">Six point two five percent senior unsecured notes due two thousand twenty seven.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnsecuredRevolvingCreditFacilityMember" xlink:label="loc_md_UnsecuredRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnsecuredRevolvingCreditFacilityMember" xml:lang="en-US">Unsecured Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_UnsecuredRevolvingCreditFacilityMember" xml:lang="en-US">Unsecured Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnsecuredRevolvingCreditFacilityMember" xlink:to="lab_md_UnsecuredRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnsecuredRevolvingCreditFacilityMember" xml:lang="en-US">Unsecured Revolving Credit Facility [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AlternateBaseRateMember" xlink:label="loc_md_AlternateBaseRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AlternateBaseRateMember" xml:lang="en-US">Alternate Base Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AlternateBaseRateMember" xml:lang="en-US">Alternate Base Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AlternateBaseRateMember" xlink:to="lab_md_AlternateBaseRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AlternateBaseRateMember" xml:lang="en-US">Alternate base rate.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ApplicableMarginRateMember" xlink:label="loc_md_ApplicableMarginRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ApplicableMarginRateMember" xml:lang="en-US">Applicable Margin Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ApplicableMarginRateMember" xml:lang="en-US">Applicable Margin Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ApplicableMarginRateMember" xlink:to="lab_md_ApplicableMarginRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ApplicableMarginRateMember" xml:lang="en-US">Applicable margin rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xml:lang="en-US">Debt Instrument Redemption Period Before Two Thousand Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xml:lang="en-US">Redemption Before 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xlink:to="lab_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xml:lang="en-US">Debt instrument redemption period before two thousand twenty two.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xml:lang="en-US">Redemption in 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xml:lang="en-US">Redemption in 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xml:lang="en-US">Debt Instrument Redemption Period Six And Thereafter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xml:lang="en-US">Redemption in 2025 and Thereafter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xlink:to="lab_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xml:lang="en-US">Debt instrument redemption period six and thereafter.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Redemption in 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Redemption in 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt instrument, variable interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Debt instrument, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Aggregate principal amount of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentMaturityYear" xlink:label="loc_md_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DebtInstrumentMaturityYear" xml:lang="en-US">Debt instrument, maturity year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DebtInstrumentMaturityYear" xlink:to="lab_md_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DebtInstrumentMaturityYear" xml:lang="en-US">Debt instrument maturity year.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt instrument maturity date description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Redemption percentage of principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Redemption price percentage of aggregate principal amount redeemed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit facility, borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xml:lang="en-US">Interest accrued periodically</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsByNameAxis" xlink:label="loc_us-gaap_OtherOwnershipInterestsByNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOwnershipInterestsByNameAxis" xml:lang="en-US">Other Ownership Interests Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOwnershipInterestsByNameAxis" xml:lang="en-US">Other Ownership Interests Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsByNameAxis" xlink:to="lab_us-gaap_OtherOwnershipInterestsByNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsNameDomain" xlink:label="loc_us-gaap_OtherOwnershipInterestsNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOwnershipInterestsNameDomain" xml:lang="en-US">Other Ownership Interests, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOwnershipInterestsNameDomain" xml:lang="en-US">Other Ownership Interests, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsNameDomain" xlink:to="lab_us-gaap_OtherOwnershipInterestsNameDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ChangeInControlMember" xlink:label="loc_md_ChangeInControlMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ChangeInControlMember" xml:lang="en-US">Change In Control [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ChangeInControlMember" xml:lang="en-US">Change In Control [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ChangeInControlMember" xlink:to="lab_md_ChangeInControlMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ChangeInControlMember" xml:lang="en-US">Change in control.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xml:lang="en-US">Federal Funds Effective Swap Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xml:lang="en-US">Federal Funds Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xml:lang="en-US">LIBOR [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xlink:label="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xml:lang="en-US">Redeem Up to Thirty Five Percentage of Aggregate Principal Amount [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xml:lang="en-US">Redeem up to 35% of Aggregate Principal Amount [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xlink:to="lab_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xml:lang="en-US">Redeem up to thirty five percentage of aggregate principal amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Debt instrument principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtNet" xlink:label="loc_md_LongTermDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LongTermDebtNet" xml:lang="en-US">Long Term Debt Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_LongTermDebtNet" xml:lang="en-US">Long term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LongTermDebtNet" xlink:to="lab_md_LongTermDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LongTermDebtNet" xml:lang="en-US">Long term debt net.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized debt issuance cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xml:lang="en-US">Debt Instrument, Fair Value Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:to="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueTable" xlink:label="loc_md_DebtInstrumentFairValueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DebtInstrumentFairValueTable" xml:lang="en-US">Debt Instrument Fair Value [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DebtInstrumentFairValueTable" xml:lang="en-US">Debt Instrument Fair Value [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DebtInstrumentFairValueTable" xlink:to="lab_md_DebtInstrumentFairValueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DebtInstrumentFairValueTable" xml:lang="en-US">Debt Instrument Fair Value [Table]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xml:lang="en-US">Measurement Basis [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xml:lang="en-US">Measurement Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xml:lang="en-US">Portion at Fair Value Measurement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueLineItems" xlink:label="loc_md_DebtInstrumentFairValueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DebtInstrumentFairValueLineItems" xml:lang="en-US">Debt Instrument Fair Value [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DebtInstrumentFairValueLineItems" xml:lang="en-US">Debt Instrument Fair Value [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DebtInstrumentFairValueLineItems" xlink:to="lab_md_DebtInstrumentFairValueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DebtInstrumentFairValueLineItems" xml:lang="en-US">Debt Instrument Fair Value [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State, Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal income tax provision, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal, Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">State income tax provision, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxTable" xlink:label="loc_md_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomeTaxTable" xlink:to="lab_md_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxLineItems" xlink:label="loc_md_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomeTaxLineItems" xlink:to="lab_md_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Company's accrued liability for interest and penalties related to income tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xml:lang="en-US">Operating loss carryforwards not subject to expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xml:lang="en-US">Operating loss carryforwards subject to expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetOperatingLossCarryForwardsExpirationDate" xlink:label="loc_md_NetOperatingLossCarryForwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NetOperatingLossCarryForwardsExpirationDate" xml:lang="en-US">Net Operating Loss Carry Forwards Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NetOperatingLossCarryForwardsExpirationDate" xml:lang="en-US">Expiration period of operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NetOperatingLossCarryForwardsExpirationDate" xlink:to="lab_md_NetOperatingLossCarryForwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NetOperatingLossCarryForwardsExpirationDate" xml:lang="en-US">Net operating loss carry forwards expiration date.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Federal and state income tax examinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards for federal and state tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxExpenseForExcessTaxDeficiencies" xlink:label="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomeTaxExpenseForExcessTaxDeficiencies" xml:lang="en-US">Income Tax Expense For Excess Tax Deficiencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomeTaxExpenseForExcessTaxDeficiencies" xml:lang="en-US">Income tax expense for excess tax deficiencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies" xlink:to="lab_md_IncomeTaxExpenseForExcessTaxDeficiencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomeTaxExpenseForExcessTaxDeficiencies" xml:lang="en-US">Income tax expense for excess tax deficiencies.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (decrease) in net deferred tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Uncertain tax position liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xml:lang="en-US">Increase (decrease) in uncertain tax position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossesIncurred" xlink:label="loc_md_CapitalLossesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CapitalLossesIncurred" xml:lang="en-US">Capital Losses Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CapitalLossesIncurred" xml:lang="en-US">Capital losses incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CapitalLossesIncurred" xlink:to="lab_md_CapitalLossesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CapitalLossesIncurred" xml:lang="en-US">Capital losses incurred.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Net deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Net deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossCarryforwards" xlink:label="loc_md_CapitalLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CapitalLossCarryforwards" xml:lang="en-US">Capital loss carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CapitalLossCarryforwards" xml:lang="en-US">Capital loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CapitalLossCarryforwards" xlink:to="lab_md_CapitalLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CapitalLossCarryforwards" xml:lang="en-US">Capital loss carryforwards</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax , Penalties and Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Scenario, Forecast [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xlink:label="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xml:lang="en-US">Nature of Uncertainty [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xml:lang="en-US">Nature of Uncertainty [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xlink:to="lab_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LatestTaxYearMember" xml:lang="en-US">Latest Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LatestTaxYearMember" xml:lang="en-US">Latest Tax Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income tax, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax at statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in tax law</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Change in accrual estimates relating to uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Equity compensation adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred tax assets before valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Operating loss and other carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xml:lang="en-US">Capital loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsOperatingLeaseAssets" xlink:label="loc_md_DeferredTaxAssetsOperatingLeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsOperatingLeaseAssets" xml:lang="en-US">Deferred Tax Assets Operating lease assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DeferredTaxAssetsOperatingLeaseAssets" xml:lang="en-US">Operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="lab_md_DeferredTaxAssetsOperatingLeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DeferredTaxAssetsOperatingLeaseAssets" xml:lang="en-US">Deferred Tax Assets Operating lease assets</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Allowance for uncollectible accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xml:lang="en-US">Reserves and accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Gross deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="loc_md_DeferredTaxLiabilitiesChangeInAccountingMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxLiabilitiesChangeInAccountingMethod" xml:lang="en-US">Deferred Tax Liabilities Change in Accounting Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_md_DeferredTaxLiabilitiesChangeInAccountingMethod" xml:lang="en-US">Accounting method changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:to="lab_md_DeferredTaxLiabilitiesChangeInAccountingMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DeferredTaxLiabilitiesChangeInAccountingMethod" xml:lang="en-US">Deferred tax liabilities change in accounting method.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increases related to current year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increases related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xml:lang="en-US">Decreases related to lapse of statutes of limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Decreases related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:label="loc_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xml:lang="en-US">Unrecognized Tax Benefits Decrease Resulting from Divestitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xml:lang="en-US">Decreases related to divestitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:to="lab_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Divestitures</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities not included in the diluted net income per common share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Weighted average number of dilutive common share equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RestrictedAndDeferredStockUnitsMember" xlink:label="loc_md_RestrictedAndDeferredStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RestrictedAndDeferredStockUnitsMember" xml:lang="en-US">Restricted And Deferred Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RestrictedAndDeferredStockUnitsMember" xml:lang="en-US">Restricted and Deferred Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RestrictedAndDeferredStockUnitsMember" xlink:to="lab_md_RestrictedAndDeferredStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RestrictedAndDeferredStockUnitsMember" xml:lang="en-US">Restricted and deferred stock units.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated Two Thousand Eight Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated 2008 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and restated two thousand eight plan.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 non-qualified employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation expense related to non-vested restricted stock, weighted-average period in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unrecognized compensation expense related to non-vested restricted shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xml:lang="en-US">Proceeds and Excess Tax Benefit from Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xml:lang="en-US">Cash proceeds received from the exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:to="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of restricted and deferred stock awards granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Fair Value, Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Aggregate fair value of restricted and deferred stocks vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Vesting period of options, maximum years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for future grants and awards under Stock Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock at which employees are permitted to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Aggregate number Shares issued under Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Options Grants In Period Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Stock Option, Share Based Compensation Cost Not Yet Recognized Period For Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Shares, Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares, Non-vested shares at January 1, 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares, Non-vested shares at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Fair Value, Non-vested shares at January 1, 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Fair Value, Non-vested shares at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of Shares, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Fair Value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Shares, Exercisable at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding at January 1, 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at January 1, 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding at December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Stock Options Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Stock Options Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockTable" xlink:to="lab_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockLineItems" xlink:to="lab_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Adjustments Related to Tax Withholding for Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Amount withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Common stock authorized for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Number of shares withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Company's Common stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralAxis" xml:lang="en-US">Collateral Held [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollateralAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralDomain" xml:lang="en-US">Collateral Held [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollateralDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Expense of retirement plans related to the 401(k) Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>md-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-February-2021 [01:05:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#General" roleURI="http://www.mednax.com/role/General" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#Investments" roleURI="http://www.mednax.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipment" roleURI="http://www.mednax.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#BusinessCombinations" roleURI="http://www.mednax.com/role/BusinessCombinations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeases" roleURI="http://www.mednax.com/role/OperatingLeases" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilities" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilities" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligations" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxes" roleURI="http://www.mednax.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#RetirementPlans" roleURI="http://www.mednax.com/role/RetirementPlans" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformation" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformation" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#InvestmentsTables" roleURI="http://www.mednax.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipmentTables" roleURI="http://www.mednax.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesTables" roleURI="http://www.mednax.com/role/OperatingLeasesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesTables" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesTables" roleURI="http://www.mednax.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansTables" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformationTables" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail" roleURI="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#InvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" roleURI="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#BusinessCombinationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail" roleURI="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" roleURI="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail" roleURI="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" roleURI="http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#RetirementPlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20201231.xsd#SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail" roleURI="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_494056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_494056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_494062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentAnnualReport_494062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_494063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_494063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_500141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_500141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_494057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_494057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_500152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_500152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_500153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_500153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_494058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_494058" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_500154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_500154" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_500155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_500155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_554127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_554127" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_494068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_494068" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_494069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_494069" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_494079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_494079" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_554128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityVoluntaryFilers_554128" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_494064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_494064" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_494065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_494065" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_494066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_494066" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_494070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFileNumber_494070" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_494071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityIncorporationStateCountryCode_494071" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_494072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityTaxIdentificationNumber_494072" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_494073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressAddressLine1_494073" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_494076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressCityOrTown_494076" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_494075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_494075" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_494078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressPostalZipCode_494078" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_494077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CityAreaCode_494077" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_494074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_LocalPhoneNumber_494074" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_494059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_494059" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_494061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_494061" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_494060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_494060" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_494067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_494067" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_554667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityPublicFloat_554667" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_813196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_IcfrAuditorAttestationFlag_813196" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_AssetsAbstract_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_OtherAssetsCurrent_41" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsCurrent_42" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Goodwill_32" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="loc_md_OperatingAndFinanceLeaseRightOfUseAssets_812881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_md_OperatingAndFinanceLeaseRightOfUseAssets_812881" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_34" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Assets_35" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_53" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrent_54" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_PreferredStockValue_55" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_393147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_393147" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_812882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_MinorityInterest_812882" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_812883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_812883" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_63" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesIssued_64" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_66" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesIssued_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSalariesAndBenefits_89" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_91" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_393211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_RestructuringCharges_393211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_500469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_500469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeNet_79" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InterestExpense_80" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_395230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_395230" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareAbstract_71" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareBasic_74" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" xlink:to="loc_us-gaap_StatementTable_99" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementLineItems_98" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_812916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_812916" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_812920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_812920" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_812923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_812923" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_122" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_ProfitLoss_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_ShareBasedCompensation_134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_148" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_149" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_151" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_156" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_169" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_131" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_131" xlink:to="loc_us-gaap_InterestPaidNet_171" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_131" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_172" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_126" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_126" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_138" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_126" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_139" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/General">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_690" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_690" xlink:to="loc_us-gaap_NatureOfOperations_691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_813346" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_813347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_813346" xlink:to="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_813347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_693" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_693" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_694" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/Investments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_720" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_720" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_721" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_727" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_727" xlink:to="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_735" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_735" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_736" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_409864" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_409865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_409864" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_409865" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_494134" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_494136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_494134" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_494136" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_751" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_751" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_393112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393111" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_393112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationsAbstract_757" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyDisclosureTextBlock" xlink:label="loc_us-gaap_MalpracticeLossContingencyDisclosureTextBlock_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationsAbstract_757" xlink:to="loc_us-gaap_MalpracticeLossContingencyDisclosureTextBlock_758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_763" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xlink:label="loc_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_763" xlink:to="loc_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_772" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_772" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_781" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_781" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchasePrograms">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_794" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_794" xlink:to="loc_md_CommonStockRepurchasesTextBlock_795" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/RetirementPlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_797" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_797" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SelectedQuarterlyFinancialInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_806" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_806" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_807" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_696" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_699" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_UseOfEstimates_700" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_701" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_702" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_703" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_705" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_707" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_708" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_709" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockShareRepurchasesPolicyTextBlock" xlink:label="loc_md_CommonStockShareRepurchasesPolicyTextBlock_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_md_CommonStockShareRepurchasesPolicyTextBlock_710" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProfessionalLiabilityCoveragePolicyTextBlock" xlink:label="loc_md_ProfessionalLiabilityCoveragePolicyTextBlock_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_md_ProfessionalLiabilityCoveragePolicyTextBlock_711" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_712" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_713" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_714" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_696" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_715" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_717" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_554922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_717" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_554922" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_718" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_554920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_717" xlink:to="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_554920" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/InvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_723" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_723" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_730" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_738" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_738" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_739" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_747" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_747" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_748" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_747" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_749" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_754" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_754" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393114" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:label="loc_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock_393115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393114" xlink:to="loc_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock_393115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_393116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393114" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_393116" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesCashFlowRelatedInformationTableTextBlock" xlink:label="loc_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock_393117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393114" xlink:to="loc_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock_393117" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_393118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393114" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_393118" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationsAbstract_760" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock" xlink:label="loc_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationsAbstract_760" xlink:to="loc_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock_761" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_766" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_766" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_767" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfEstimatedFairValueOfNotesTableTextBlock" xlink:label="loc_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_766" xlink:to="loc_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock_768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfFinanceLeaseObligationsTableTextBlock" xlink:label="loc_md_ScheduleOfFinanceLeaseObligationsTableTextBlock_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_766" xlink:to="loc_md_ScheduleOfFinanceLeaseObligationsTableTextBlock_769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_775" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_775" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_776" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_775" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_777" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_775" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_775" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_779" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_784" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_790" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_790" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_790" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_792" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_809" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_809" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_810" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_812893" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_812902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_812893" xlink:to="loc_us-gaap_StatementTable_812902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_812907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_md_ExtraordinaryItemsAxis_812907" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_812908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAxis_812907" xlink:to="loc_md_ExtraordinaryItemsDomain_812908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_812909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsDomain_812908" xlink:to="loc_md_CovidNinenteenMember_812909" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_812910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_TitleOfIndividualAxis_812910" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_812910" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_812912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812911" xlink:to="loc_srt_ExecutiveOfficerMember_812912" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_812913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_StatementScenarioAxis_812913" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_812914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_812913" xlink:to="loc_srt_ScenarioUnspecifiedDomain_812914" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_812915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_812915" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_812917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_812917" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_812918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_812918" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_812919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_812919" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForThirdQuarterOf2021Member" xlink:label="loc_md_ForecastForThirdQuarterOf2021Member_825804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_812914" xlink:to="loc_md_ForecastForThirdQuarterOf2021Member_825804" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_812921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_CreditFacilityAxis_812921" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_812922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_812921" xlink:to="loc_us-gaap_CreditFacilityDomain_812922" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_812924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_812922" xlink:to="loc_md_CreditAgreementMember_812924" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_812925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_812922" xlink:to="loc_us-gaap_LetterOfCreditMember_812925" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_812927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_srt_RangeAxis_812927" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_812927" xlink:to="loc_srt_RangeMember_813359" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813359" xlink:to="loc_srt_MaximumMember_813360" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_813361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813359" xlink:to="loc_srt_MinimumMember_813361" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_812931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_GeographicDistributionAxis_812931" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_812932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_812931" xlink:to="loc_us-gaap_GeographicDistributionDomain_812932" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_812934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_812932" xlink:to="loc_md_RuralAreaMember_812934" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_812935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_DebtInstrumentAxis_812935" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_812936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_812935" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_812936" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_812937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_812936" xlink:to="loc_md_Seniorunsecurdnotes2023Member_812937" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_812938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_812936" xlink:to="loc_md_Seniorunsecurdnotes2027Member_812938" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_812905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_812902" xlink:to="loc_us-gaap_StatementLineItems_812905" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_812939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_812939" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization_825800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization_825800" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_812941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_SupplementaryLeverageRatioRequired_812941" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement" xlink:label="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement_825803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement_825803" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_812943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_812943" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_812944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_812944" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_812945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_812945" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_812946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_812946" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_812947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_812947" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_812948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812905" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_812948" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_174" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174" xlink:to="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_srt_RangeAxis_184" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_184" xlink:to="loc_srt_RangeMember_185" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_185" xlink:to="loc_srt_MaximumMember_199" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_185" xlink:to="loc_srt_MinimumMember_200" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_182" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_BuildingMember_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_EquipmentMember_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_ComputerEquipmentMember_196" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_197" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_183" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_198" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_177" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_177" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_178" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_178" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_190" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_176" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_175" xlink:to="loc_us-gaap_AccountsReceivableMember_189" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_186" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_181" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_181" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_193" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_554497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_181" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_554497" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_CreditFacilityAxis_179" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_179" xlink:to="loc_us-gaap_CreditFacilityDomain_180" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_554481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_554481" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_554482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_554481" xlink:to="loc_us-gaap_SegmentDomain_554482" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesTable_188" xlink:to="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_201" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_202" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CashAndCashEquivalentsMaturityDescription" xlink:label="loc_md_CashAndCashEquivalentsMaturityDescription_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_CashAndCashEquivalentsMaturityDescription_203" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ShortTermInvestmentMaturityPeriod" xlink:label="loc_md_ShortTermInvestmentMaturityPeriod_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_ShortTermInvestmentMaturityPeriod_205" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_206" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_BusinessCombinationContingentConsiderationArrangementsTimePeriod" xlink:label="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod_207" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_SummaryOfSignificantAccountingPoliciesLineItems_187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_208" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RegulatoryAssetsAbstract" xlink:label="loc_md_RegulatoryAssetsAbstract_214" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_RegulatoryAssetsAbstract_214" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_217" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_217" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_218" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_216" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SalesAndRevenueServicesNetMember" xlink:label="loc_md_SalesAndRevenueServicesNetMember_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_215" xlink:to="loc_md_SalesAndRevenueServicesNetMember_223" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_srt_ProductOrServiceAxis_219" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_219" xlink:to="loc_srt_ProductsAndServicesDomain_220" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NeonatologyAndOtherPediatricSubspecialtiesMember" xlink:label="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_NeonatologyAndOtherPediatricSubspecialtiesMember_225" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaternalFetalMedicineMember" xlink:label="loc_md_MaternalFetalMedicineMember_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_MaternalFetalMedicineMember_228" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricCardiologyMember" xlink:label="loc_md_PediatricCardiologyMember_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_220" xlink:to="loc_md_PediatricCardiologyMember_230" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_221" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_222" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_222" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_231" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393314" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393314" xlink:to="loc_us-gaap_StatementTable_393316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393317" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393317" xlink:to="loc_us-gaap_ClassOfStockDomain_393318" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_395190" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_395284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_395284" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_395285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_395283" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_395285" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_395202" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_395287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_395203" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_395287" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393316" xlink:to="loc_us-gaap_StatementLineItems_393319" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393319" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_393323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_393323" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_393325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_393325" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_499981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_393322" xlink:to="loc_md_MutualFundsFairValueDisclosure_499981" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393331" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393331" xlink:to="loc_us-gaap_StatementTable_393333" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393333" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393334" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393334" xlink:to="loc_us-gaap_ClassOfStockDomain_393335" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_395206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393333" xlink:to="loc_us-gaap_DebtInstrumentAxis_395206" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_395207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_395206" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_395207" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_395214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_395207" xlink:to="loc_md_TwoThousandTwentyThreeMember_395214" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_395215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_395207" xlink:to="loc_md_TwoThousandTwentySevenMember_395215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393333" xlink:to="loc_us-gaap_StatementLineItems_393336" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_393340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393336" xlink:to="loc_us-gaap_LiabilitiesAbstract_393340" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_393341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_393340" xlink:to="loc_us-gaap_NotesPayable_393341" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393336" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_393391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_393390" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_393391" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_233" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_233" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" xlink:to="loc_us-gaap_InvestmentTypeAxis_234" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_234" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_235" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_554131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_554131" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_238" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_CertificatesOfDepositMember_240" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_812988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_235" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_812988" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_237" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_813378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_236" xlink:to="loc_us-gaap_AvailableForSaleSecurities_813378" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_249" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_md_ScheduleOfFinancingReceivablesLineItems_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_281" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_Land_282" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_FixturesAndEquipmentGross_283" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_284" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_285" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_280" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_286" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:label="loc_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract_288" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract_288" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_Depreciation_295" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_393267" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_393267" xlink:to="loc_us-gaap_StatementTable_393269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393270" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393270" xlink:to="loc_us-gaap_ClassOfStockDomain_393271" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_393276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_393276" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_393276" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianGroupMember" xlink:label="loc_md_PhysicianGroupMember_393278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" xlink:to="loc_md_PhysicianGroupMember_393278" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember_812995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_393277" xlink:to="loc_md_PediatricSubspecialtyPracticeMember_812995" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsAxis" xlink:label="loc_md_DeferredtaxassetsAxis_812997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_md_DeferredtaxassetsAxis_812997" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredtaxassetsgoodwillDomain" xlink:label="loc_md_DeferredtaxassetsgoodwillDomain_812998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredtaxassetsAxis_812997" xlink:to="loc_md_DeferredtaxassetsgoodwillDomain_812998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_393273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393269" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_393273" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_393274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_393274" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_393275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_393275" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_393279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_393279" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_393280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_393280" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_574648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_574648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPhysicianGroupPracticesAcquired" xlink:label="loc_md_NumberOfPhysicianGroupPracticesAcquired_395265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfPhysicianGroupPracticesAcquired_395265" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfNeonatologyPracticesAcquired" xlink:label="loc_md_NumberOfNeonatologyPracticesAcquired_395266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfNeonatologyPracticesAcquired_395266" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_395267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_395267" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NumberOfRadiologyPracticesAcquired" xlink:label="loc_md_NumberOfRadiologyPracticesAcquired_395268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_NumberOfRadiologyPracticesAcquired_395268" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_499982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_499982" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPurchaseConsideration" xlink:label="loc_md_AccruedPurchaseConsideration_499983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_md_AccruedPurchaseConsideration_499983" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_554191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393273" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_554191" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_328" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_334" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_334" xlink:to="loc_us-gaap_SegmentDomain_333" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_GoodwillAndOtherIntangibleAssetsLineItems" xlink:label="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_Goodwill_336" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_339" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_GoodwillAndOtherIntangibleAssetsLineItems_331" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_341" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_344" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_344" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_345" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PhysicianAndHospitalAgreementsMember" xlink:label="loc_md_PhysicianAndHospitalAgreementsMember_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" xlink:to="loc_md_PhysicianAndHospitalAgreementsMember_352" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherTechnologyMember" xlink:label="loc_md_OtherTechnologyMember_813430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347" xlink:to="loc_md_OtherTechnologyMember_813430" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_349" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_350" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_346" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_359" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_360" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_362" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" xlink:to="loc_us-gaap_StatementTable_468356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsIntangibleAssetsMember" xlink:label="loc_md_DeferredTaxAssetsIntangibleAssetsMember_468392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsDomain_468388" xlink:to="loc_md_DeferredTaxAssetsIntangibleAssetsMember_468392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_813013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_813013" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_813013" xlink:to="loc_srt_RangeMember_813014" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813014" xlink:to="loc_srt_MaximumMember_813015" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_813016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813014" xlink:to="loc_srt_MinimumMember_813016" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_813007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_813007" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_813008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_813007" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_813008" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_813010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_813010" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_813021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_DivestitureOfMeddataMember_813021" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_813022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_813022" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="loc_md_AnesthesiologyServicesMedicalGroupMember_813661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_813008" xlink:to="loc_md_AnesthesiologyServicesMedicalGroupMember_813661" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_813656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_813656" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_813657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_813656" xlink:to="loc_us-gaap_TaxPeriodDomain_813657" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_813658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_813657" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_813658" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_StatementLineItems_468359" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_413567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_AssetImpairmentCharges_413567" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_413717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_413717" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetProceedsForTheRadiologyServicesMedicalGroup" xlink:label="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup_824843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_NetProceedsForTheRadiologyServicesMedicalGroup_824843" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_574665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_574665" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_574666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_574666" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_813004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_813004" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_813005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_813005" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Accountsreceivableretained" xlink:label="loc_md_Accountsreceivableretained_813006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_Accountsreceivableretained_813006" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_Capitallosscarryforward" xlink:label="loc_md_Capitallosscarryforward_813017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_Capitallosscarryforward_813017" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_813018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_813018" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_813019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_813019" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss" xlink:label="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss_813020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss_813020" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_813023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_813023" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_813024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_813024" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_813660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_813660" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PurchaseConsiderationCashPayment" xlink:label="loc_md_PurchaseConsiderationCashPayment_824842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_PurchaseConsiderationCashPayment_824842" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_364" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableCurrent_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedSalariesAndIncentiveCompensationCurrent" xlink:label="loc_md_AccruedSalariesAndIncentiveCompensationCurrent_824169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedSalariesAndIncentiveCompensationCurrent_824169" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_InterestPayableCurrent_370" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393120" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393120" xlink:to="loc_us-gaap_StatementTable_393122" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393123" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393123" xlink:to="loc_us-gaap_ClassOfStockDomain_393124" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393122" xlink:to="loc_us-gaap_StatementLineItems_393125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesAssetsAbstract" xlink:label="loc_md_OperatingLeasesAssetsAbstract_393127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OperatingLeasesAssetsAbstract_393127" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_OperatingLeasesAssetsAbstract_393127" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393128" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesLiabilitiesAbstract" xlink:label="loc_md_OperatingLeasesLiabilitiesAbstract_393129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OperatingLeasesLiabilitiesAbstract_393129" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_OperatingLeasesLiabilitiesAbstract_393129" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393130" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_OperatingLeasesLiabilitiesAbstract_393129" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393131" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherInformationRelatedToOperatingLeaseAbstract" xlink:label="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_393132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_OtherInformationRelatedToOperatingLeaseAbstract_395101" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_393132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_393133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_393133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393152" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393152" xlink:to="loc_us-gaap_StatementTable_393154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393154" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393155" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393155" xlink:to="loc_us-gaap_ClassOfStockDomain_393156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393154" xlink:to="loc_us-gaap_StatementLineItems_393157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_393158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_OperatingLeaseCost_393158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_393159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_VariableLeaseCost_393159" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OtherEquipmentRent" xlink:label="loc_md_OtherEquipmentRent_499989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_md_OtherEquipmentRent_499989" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_OperatingLeasesOtherCosts" xlink:label="loc_md_OperatingLeasesOtherCosts_393161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_md_OperatingLeasesOtherCosts_393161" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_393162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393157" xlink:to="loc_us-gaap_LeaseCost_393162" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393164" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393164" xlink:to="loc_us-gaap_StatementTable_393166" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393166" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393167" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393167" xlink:to="loc_us-gaap_ClassOfStockDomain_393168" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393166" xlink:to="loc_us-gaap_StatementLineItems_393169" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_393170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393169" xlink:to="loc_us-gaap_OperatingLeasePayments_393170" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_393172" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393172" xlink:to="loc_us-gaap_StatementTable_393174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393175" xlink:to="loc_us-gaap_ClassOfStockDomain_393176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393174" xlink:to="loc_us-gaap_StatementLineItems_393177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555217" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_393179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_393179" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_393180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_393180" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_393181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_393181" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_393182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_393182" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_393183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_393183" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_393184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_393184" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413589" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_413590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiability_413590" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393187" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393177" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393188" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_374" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReserveCurrent" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_376" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedProfessionalLiability" xlink:label="loc_md_AccruedProfessionalLiability_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_md_AccruedProfessionalLiability_377" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_378" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:label="loc_us-gaap_InsuranceSettlementsReceivable_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_us-gaap_InsuranceSettlementsReceivable_379" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_381" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xlink:label="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations_382" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition" xlink:label="loc_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition_383" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToCurrentYear" xlink:label="loc_md_ProvisionAdjustmentForLossesRelatedToCurrentYear_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_ProvisionAdjustmentForLossesRelatedToCurrentYear_384" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ProvisionAdjustmentForLossesRelatedToPriorYear" xlink:label="loc_md_ProvisionAdjustmentForLossesRelatedToPriorYear_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_ProvisionAdjustmentForLossesRelatedToPriorYear_385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyProvisionForLosses" xlink:label="loc_md_MalpracticeLossContingencyProvisionForLosses_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_MalpracticeLossContingencyProvisionForLosses_386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_387" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_388" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations" xlink:label="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_381" xlink:to="loc_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations_390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_392" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_392" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_CreditFacilityAxis_393" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_393" xlink:to="loc_us-gaap_CreditFacilityDomain_394" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnsecuredRevolvingCreditFacilityMember" xlink:label="loc_md_UnsecuredRevolvingCreditFacilityMember_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_UnsecuredRevolvingCreditFacilityMember_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_us-gaap_LetterOfCreditMember_410" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_411" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_412" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_812962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_394" xlink:to="loc_md_CreditAgreementMember_812962" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_DebtInstrumentAxis_395" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_395" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_397" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AlternateBaseRateMember" xlink:label="loc_md_AlternateBaseRateMember_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_397" xlink:to="loc_md_AlternateBaseRateMember_427" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ApplicableMarginRateMember" xlink:label="loc_md_ApplicableMarginRateMember_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_397" xlink:to="loc_md_ApplicableMarginRateMember_428" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_VariableRateAxis_407" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_407" xlink:to="loc_us-gaap_VariableRateDomain_408" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_408" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_441" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_408" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_442" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_398" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_430" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember_432" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_433" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_434" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_435" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentRedemptionPeriodSixAndThereafterMember" xlink:label="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_399" xlink:to="loc_md_DebtInstrumentRedemptionPeriodSixAndThereafterMember_436" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsByNameAxis" xlink:label="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOwnershipInterestsNameDomain" xlink:label="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsByNameAxis_401" xlink:to="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ChangeInControlMember" xlink:label="loc_md_ChangeInControlMember_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsNameDomain_402" xlink:to="loc_md_ChangeInControlMember_437" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_srt_RangeAxis_403" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_403" xlink:to="loc_srt_RangeMember_404" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_404" xlink:to="loc_srt_MinimumMember_438" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_404" xlink:to="loc_srt_MaximumMember_439" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_srt_StatementScenarioAxis_406" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_406" xlink:to="loc_srt_ScenarioUnspecifiedDomain_405" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember" xlink:label="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember_440" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_812965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_812965" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_813365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_405" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_813365" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_400" xlink:to="loc_us-gaap_DebtInstrumentLineItems_396" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_413" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_415" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_416" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_418" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_419" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_420" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_421" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_422" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentMaturityYear" xlink:label="loc_md_DebtInstrumentMaturityYear_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_DebtInstrumentMaturityYear_423" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LongTermDebt_424" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_425" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_426" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_554301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_554301" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_812958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_812958" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_812964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_396" xlink:to="loc_md_SupplementaryLeverageRatioRequired_812964" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_444" xlink:to="loc_us-gaap_DebtInstrumentTable_448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_448" xlink:to="loc_us-gaap_CreditFacilityAxis_445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_445" xlink:to="loc_us-gaap_CreditFacilityDomain_446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_446" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_449" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_446" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_450" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_448" xlink:to="loc_us-gaap_DebtInstrumentLineItems_447" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_452" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_LongTermDebtNet" xlink:label="loc_md_LongTermDebtNet_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_447" xlink:to="loc_md_LongTermDebtNet_453" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_455" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueTable" xlink:label="loc_md_DebtInstrumentFairValueTable_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_455" xlink:to="loc_md_DebtInstrumentFairValueTable_459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_CreditFacilityAxis_456" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_456" xlink:to="loc_us-gaap_CreditFacilityDomain_457" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember" xlink:label="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_457" xlink:to="loc_md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember_464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_457" xlink:to="loc_md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_460" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_461" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_461" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_555319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_555316" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_555319" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DebtInstrumentFairValueLineItems" xlink:label="loc_md_DebtInstrumentFairValueLineItems_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DebtInstrumentFairValueTable_459" xlink:to="loc_md_DebtInstrumentFairValueLineItems_458" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DebtInstrumentFairValueLineItems_458" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_466" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_471" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_471" xlink:to="loc_us-gaap_FinanceLeaseLiability_472" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_471" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_473" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_471" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_474" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_481" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_482" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_483" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_484" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_485" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_486" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_481" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_490" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxTable" xlink:label="loc_md_IncomeTaxTable_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_490" xlink:to="loc_md_IncomeTaxTable_494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_srt_RangeAxis_495" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_495" xlink:to="loc_srt_RangeMember_496" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_496" xlink:to="loc_srt_MinimumMember_524" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_496" xlink:to="loc_srt_MaximumMember_525" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_srt_StatementScenarioAxis_500" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_500" xlink:to="loc_srt_ScenarioUnspecifiedDomain_498" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_498" xlink:to="loc_srt_ScenarioForecastMember_526" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_491" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_492" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_TaxPeriodAxis_501" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_501" xlink:to="loc_us-gaap_TaxPeriodDomain_502" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_502" xlink:to="loc_us-gaap_EarliestTaxYearMember_528" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_502" xlink:to="loc_us-gaap_LatestTaxYearMember_529" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis" xlink:label="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis_497" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain_499" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxLineItems" xlink:label="loc_md_IncomeTaxLineItems_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxTable_494" xlink:to="loc_md_IncomeTaxLineItems_493" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_505" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_508" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_IncomeTaxExpenseForExcessTaxDeficiencies" xlink:label="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_IncomeTaxExpenseForExcessTaxDeficiencies_513" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_OperatingLossCarryforwards_514" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NetOperatingLossCarryForwardsExpirationDate" xlink:label="loc_md_NetOperatingLossCarryForwardsExpirationDate_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_NetOperatingLossCarryForwardsExpirationDate_515" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_516" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_517" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_518" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_519" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_520" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_522" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_OpenTaxYear_523" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_505887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_505887" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_597884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_DeferredTaxLiabilities_597884" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossesIncurred" xlink:label="loc_md_CapitalLossesIncurred_583582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_CapitalLossesIncurred_583582" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CapitalLossCarryforwards" xlink:label="loc_md_CapitalLossCarryforwards_812993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_md_CapitalLossCarryforwards_812993" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_812994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomeTaxLineItems_493" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_812994" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_531" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_532" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_533" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_534" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_812981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_812981" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_535" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_536" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_537" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_538" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_541" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_548" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_549" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_550" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_812983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_812983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_812984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_812984" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxAssetsOperatingLeaseAssets" xlink:label="loc_md_DeferredTaxAssetsOperatingLeaseAssets_812985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_md_DeferredTaxAssetsOperatingLeaseAssets_812985" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_552" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_553" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_554" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_555" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_556" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_543" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="loc_md_DeferredTaxLiabilitiesChangeInAccountingMethod_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" xlink:to="loc_md_DeferredTaxLiabilitiesChangeInAccountingMethod_544" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_812986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_812986" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_546" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_542" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_547" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_597861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_597861" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_500458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541" xlink:to="loc_us-gaap_DeferredTaxLiabilities_500458" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_559" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_560" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_561" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_562" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_563" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:label="loc_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_812987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_812987" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_565" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_559" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_RestrictedAndDeferredStockUnitsMember" xlink:label="loc_md_RestrictedAndDeferredStockUnitsMember_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_md_RestrictedAndDeferredStockUnitsMember_605" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_596" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_597" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_598" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_599" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_600" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_602" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_812976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_812976" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_812977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_812977" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812978" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_812980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_812980" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_609" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_610" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_611" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_612" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_613" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_614" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_615" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_617" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_812968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_812968" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_812969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_812969" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_623" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_625" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_812970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_812970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_812973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_812973" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_628" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_630" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_812974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_812974" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_631" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_619" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_632" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_634" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_634" xlink:to="loc_md_CommonStockTable_637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_CollateralAxis_642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_642" xlink:to="loc_us-gaap_CollateralDomain_638" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_824954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_638" xlink:to="loc_us-gaap_CommonStockMember_824954" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_md_CommonStockLineItems_636" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_645" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_646" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_653" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_653" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_654" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_669" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_md_PracticeSalariesAndBenefits_670" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20201231.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses_671" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_672" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_673" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_554193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_RestructuringCharges_554193" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_OperatingExpenses_674" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_OperatingIncomeLoss_675" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_InvestmentIncomeNet_676" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_InterestExpense_677" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_678" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_679" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_680" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_681" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_554200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_554200" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_554202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_554202" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_554217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_NetIncomeLoss_554217" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_554208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_554208" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_554209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_554209" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_554210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_554210" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_554211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_554211" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_EarningsPerShareBasic_685" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_EarningsPerShareDiluted_686" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554212" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_554213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_668" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_554213" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g51794g85y35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51794g85y35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X=GY:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F1S<# T-3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @56YT:71L960M,2YA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,3@M1F5B+3(P,C @,C$Z,# Z-3@F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,3@M1F5B+3(P,C @,3$Z,S Z-3@F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F
M(WA!.R8C>$$[XH"B(#$@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S;VQU=&EO
M;B!B96QO=R R-C4N)B-X03LF(WA!.^* HB R,B!B;&%C:R!R=6QE<R!C:&%N
M9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT
M<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @
M5&EM97,M4F]M86XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N(&9L86=G
M960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L;W<@<F5S
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!5;G1I=&QE
M9"TQ+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X03M,
M;V-A;"!4:6UE.B @(" @(" @(" @(" Q."U&96(M,C R," R,3HP,3HU,R8C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q."U&96(M,C R," Q,3HS,3HU
M,R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R
M871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @
M(" @(" @3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @5&EM97,M4F]M86XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&1S<# T-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,38M1F5B+3(P
M,C$@,3 Z,#8Z,3DF(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,38M1F5B
M+3(P,C$@,# Z,S8Z,3DF(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I;65S+5)O;6%N)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U
M;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z
M9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 R
M+3$V5#$P.C V.C(T*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C R,2TP,BTQ-E0Q,#HP-CHR-"LP-3HS,#PO
M>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q
M+3 R+3$V5#$P.C V.C(T*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N
M86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ-38\+WAM<$=);6<Z:&5I
M9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO
M>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM
M86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA
M1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!
M04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G
M549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!
M-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P
M645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!
M;D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!
M04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F
M(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!
M9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A-
M>%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO
M34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD
M6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH
M26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I
M63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F
M(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q
M=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I7
M5VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T51
M35)!1#A!.4EA3F\R:G9O.6DW,DYU>G1B>$8F(WA!.VU-4T5K;$)5:S!X5D=F
M;U!24#A!<3,R,R]);5 K;4MQ1CE995=B0WIN=F)Y,7,W93!T;S)L=4HU26\Q
M4DDP2$IM66MB04%9<6=D178F(WA!.V9);74V4619,&1,3R]W0D]8;4100D-R
M54UF,FPT:&5F265&2S1Q;$5F;FHX<7!9;&QH34TX8G=.9$(T9%!N;$%I:G1O
M-W1I945,8U,F(WA!.TE*,&9I9FDS<%-T4FER8BMD=GEP:F522EAT;VYI:F5A
M5DIB2U=.;&IJ5V1N6F<X27!X*W!Y9S$O85AJ.6]Q0U943S Q2'E.9#,Y.7 F
M(WA!.SET8E%Y,U=M<#9L-FDR5&M)<%):1E!0,'5$96]S9TUF16YN4G5.94Q5
M0W1A6'$O-6-A<3%S;&A0<&,X.3)0.$%2-UEE9THR4'!#67 F(WA!.S9,56Q$
M<D=E5$E6-4M/;T=+;S-6-'9+5VHV9%!Q5W R.6YA5T9S03 Y>$I%9U9!4T9"
M3D8X5&EQ2#!U-CAJ87)O<#%V5%5S<G939W,F(WA!.VIF5S1O5EI+4E9$,&]T
M5'@T;G1I<5=.-74O3$9B3S1V2U%M0S%H:'5*>71H37IR1F-Y0TM*=4%H3&YK
M>D190V]"<61T.$MT,U!M>C@F(WA!.W-,835N='!48D-A,FIJ;6Y68DXS-'AZ
M4D=A3FE6:4EO>6108VAF=$U!5E9:=DUF-5IX+S,X=&AA+W=#:E(S<69766QT
M*V-%<V)Z2S@F(WA!.V9Q;VY/:V-437=7<%=N>$%91E)/;6%N*UA7<51R8C9D
M8V%69%A42W)#,6I.=5IW2%%Y3'EI+W9&2E%&<49A,$=+<'8K9SE%+S9T.70F
M(WA!.R]W06E9+S99<6AT3G1F2W5P,E56.7 Y=EHS5FY/0UE:-&\T,E)G0U9.
M0T(R27!I<5-*-7 O3%(Q:UI206939W5,;'=,2U-V;S)D9E@F(WA!.UE$,'%T
M>#1M9T<W55!'=497>C5N+TQ-4C(W,71F.4MH4S5I5#9O,U P<$I':58S5# K
M4T1K:C$U9U5#<U1S<D5+=$1Z4BM7<&=S-VHF(WA!.VI!='9F9W1B5$Y:4TMN
M1EHQ=&E867A!4F=3>4M$>G Q<CEN9D97<C-Z6BM61FUS8C-&-W!1:&LT8THQ
M155K5EI05$MG>6]'45976D<F(WA!.S-0,E=$9EHS=TMI,C%B.'9L=35,5GA:
M;S!*4EI*,V=#,GEV27-B<$=B:V])4%5D6C1Y<6,K4D1#9WA61S934$IE<U<W
M6$]K1%1D4G0F(WA!.VMF,#-N=%!1;E%0>$0X4S!F258T=7!P-$59<6E,;E10
M3'1R03 Y>%HR<U5+535Y3D9'1E5%,'%X<'-013ES5E%T,F9*.7!P1C-Q.#$F
M(WA!.W1A+V\V>5-75S5U23=C4T)59W(V<$%J4FUB:GA.94E05$95:6XX.&9L
M5$,V2S=115-Q-W=Y<%E44$9):V%",V1*16A:2%966F%L5%0F(WA!.S1L+VU7
M<%9&5R]M4#AV3&E/5C1R6E0V37DR-5$V8F-+-WES.&E"26MA04Y+83(X;&94
M1%5#:VYB1E98.5 O;&5/26MV=$=H:V)B,%HF(WA!.VYT;W!686]"5F\U3TQQ
M=TI!2W-!461J=F=6=CE/+VQH-FM-83,R:E!,8V5N-D534U=Z=31L;U5+<7!*
M25E-1W(P<'8P>%8P=70O;'8F(WA!.T99,E=O>5,V8W5M-F=:1G1T4312;3)*
M:%9M:T1Z:&93:C0K;7=03FAU3U!88D96:V9M4#AR6&YE1#8Y;S942DQ,05DU
M2'0T,DUK07(F(WA!.TM%1#AE9D0Y;W)51#9-5E0O=T1196EF.5<K,B\U17@O
M,'A60C9Z;S)J<&\Y.#973G5R<F)Y;%=%4T%G:$119S!X5D=A2"]X>$Y0.$$F
M(WA!.RM984@O:S)-5E)U2W!.-6<X;F56+TU.=E!$<2MM5SDR8FE&<F0U,VI8
M,6A'=TEO:W1/854U1VA",GA62W9+=C5595)03$=M:7@P,U,F(WA!.S0R;S=3
M9EA*=TI,<FTT<'E%.4$V,$%O3TI&4&YI<7E$.&]F>3ET-'A&8C97,$M+='EI
M:4\V=3!O3#%&:G5+1EI187E+9T)06$954E F(WA!.RM6,VM3-3E0-C%P675V
M5&-/=C%I865F9FTP:D)V56MB:W-J3U1)<#)F.7%U2W%U;B]L-358,#(W5S9S
M27)I,FTY1DQA5FQV3'!V5F<F(WA!.VIH34UC8W9/4G59:E4O0EAD5'5$=6%Q
M<F1)+TQF>69O.35"96%B8517.7IB<#955')E6&@O9&QG-5%Q,'!6;$Q,56AG
M450X>FEQ=#4F(WA!.W$X:&564$Y&;&,R=7(V9D1+,3!I>'E886]I,TE64T-!
M<S%#-CE02$953#5A+TLO>5(U8S!T3D\P-U19=W-9:T-88V=$6%%%,6563&<F
M(WA!.T):4G-X04EA;S=9<7!29FQ(*UAS9#%.9$QP4#<K-6E3,VYD<FDU8FQ&
M1S932VA$4T55-7A+96TO9G%A<7!L<79K9GEZ<3$U3F5A:&$F(WA!.W908U1O
M235'33EW;S1+<DM%0W))1E92>DQC5D9/9G@O84%/2V]+.2]+-WE.93-.<&18
M3VYV2F-734M7.6Y*.5IU;$U58U5B4DIW-'DF(WA!.VEJ2W)N-'9T5BM+=DMH
M>%8R9V9L9#5&.'9A;4Y4,&)45%HS;TQT-G%4,T1636=+=GE6<$=5:#8Q6455
M2E94,5)A2W!R<FYL6'DW<FLF(WA!.U5Q87)P,79D4$Q#,78V-WAO6FMJ6455
M:FQ)-7!4:U-#<#)/*TMP6#58+TQ$>4XU6G1O-V93.4IH2&]Y*W9$3D]O;FU2
M.6I62EIE5'(F(WA!.U%I;V]D:FEQ;$HK53-K0U,O6%5*3DU:-S%9-6]23S%Z
M9$9U1G=R<$M.-65R<DMW2C8O8TU64CDS-4,X<#-C.$4X.6=$3&$R.&1N058F
M(WA!.VQM44Q"13-*62M+3W%K9&I59D5V=VUQ;6U+;T<O=T1Y;SAG,SEJ83).
M-7!:;71B2T]71S)J831U9F=395%3>6EO:S5(;7DW:VUT4&@F(WA!.RMZ=&EQ
M:VXU469L-T=K85(V8DI'<TQI4T5*95AI.$A66555<GAM2$=I5W-A:6Y953=M
M<7%+=69Y>3AL,TYK.6A,6GDO57!"0TI,9&(F(WA!.W4W4DA.=D9(1$4W2VMQ
M:&Y73T9&-6XT=FA&5&EQ66574$M(;#-Y=F%4,F5H5UES<F4U;6$U;E%02DIY
M;5E"5V-M4FY.4T9'2W1A,34F(WA!.T\X<C8P2D1Q5VU7,7A,34975S1A2E!7
M2W%2.%!Q,#5G549.:C!X5D12+VPS-4II<UIB2U!2-V%/1UI*66DX56%X5$Q(
M34-R;VLP45,F(WA!.U9">&-Q3TQB1%EB67%V:SAH*U9(:F5-5U!P4E-.8TTX
M8T5S,$-K,VIP2F-(:D4V1#DT,%-K+U0T;7%Q2'10>3$X;3)A5')A5U5S2#$F
M(WA!.VTT:G4U1VIU<G1813A28V\X8FE8;$@O97-P-$5!<65**TAB1E5T,6(X
M;5!)96]26'@K<51W6%8X6&ME-%,X=DYP,C4P;4U9;4-->70F(WA!.TE4=4U6
M4D(O2U1Y3$ID5VPW4%EY>5@Y;C92:'5F<F0T<D(T='=W<$XQ3&9%,69T2&1Q
M;D965V(X<2])8W9L=3 X=%!P:"]19&M:1W0F(WA!.W)*8FDU5E9-,TQM4WEY
M:#)R>F(W4E!81E503"M49C5C4U@S,3ET2E Q=T-I>G)D6&%U;T)Q9U%R2T])
M:DY$2'@K=U%P5VA684MS,'@F(WA!.U9"834O=T%C5%50*UEA8B]!2DYN1EAN
M;75(.'I6=F)%*UA"979P3&%$1W%#,B]2>7)(9F-X4G@Y8TI-:#1&95-T>$A%
M2&EX63=&57DF(WA!.S!69GI56'I95'%%:E-E6&YV<&U8,45S67EL;S!-:%9#
M<TQY>69$3C91:5E-5TDU;5-N=V="5UIT8S-P=7!)231);4-+<F@R;%I3434F
M(WA!.UE$65)T+THT-'%U.515=CDX42\X:FTO-G!9<3<Q3E,O,WA$+T%-:FTO
M=T-Q5TMU.515=CDX42\X:FTO-G!9<3<Q3E,O,WA$+T%-:FTF(WA!.R]W0W%7
M2W4Y5%5V.3A1+SAJ;2\V<%EQ-S%.4R\S>$0O04UJ;2]W0W%72W4Y5%5V.3A1
M+SAJ;2\V<%EQ-S%.4R\S>$0O04UJ;2]W0W$F(WA!.U=+=3E4578Y.%$O.&IM
M+S9P67$W,4Y3+S-X1"]!36IM+W=#<5=+=3E4578Y.%$O.&IM+S9P67$W,4Y3
M+S-X1"]!36IM+W=#<5=+=3DF(WA!.U15=CDX42\X:FTO-G!9<3<Q3E,O,WA$
M+T%-:FTO=T-Q5TMU.515=CDX42\X:FTO-G!9<3<Q3E,O,WA$+T%-:FTO=T-Q
M5TMU.515=CDF(WA!.SA1+SAJ;2\V<%EQ-S%.4R\S>$0O04UJ;2]W0W%72W4Y
M5%5V.3A1+SAJ;2\V<%EQ-S%.4R\S>$0O04UJ;2]W0W%72W4Y5%5V.3A1+S@F
M(WA!.VIM+S9P67$W,4Y3+S-X1"]!36IM+W=#<5=+=3E4578Y.%$O.&IM+S9P
M67$W,4Y3+S-X1"]!36IM+W=#<5=+=3E4578Y.%$O.&IM+S8F(WA!.W!9<3<Q
M3E,O,WA$+T%-:FTO=T-Q5TMU.515=CDX42\X:FTO-G!9<79T-3)K3'!*-EEM
M:DE$>'AV>C1G:6\U5E932R],1E9$6% K3THF(WA!.W%(+TU.3B]Y8D]+=3!0
M.$$T-&UN+W=$34Y$+WEB1TMO,T953D@O>#!P+SA!:D1$+T%-4VQX5D4T<3=&
M6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ;U@Q+UDR1G$Y,V98161R87AI<VLX>D)%6#5S
M>$%X5DIV,'@F(WA!.W)U<79W,%<P*W R4C8V='%#379,+VI"85935B\Y85%O
M3S0U1$95=CAO95%,>GDY-6HQ;E<U.69U.5=F5RM"=5EB<$EW;V5,-%DR6# F
M(WA!.W=O6&EN=S!644]N9TU66DAR;B](13%$+T%*:'!V*U1:>%9+<EAZ6#59
M,'5W<TQ05717<S=+-D9H1&-T1&-4>'A-25-&:D5H-6M5578F(WA!.SA)2C9N
M1E5Z="]-3V=83GET<F)A;&%Z,TQS-DI"2%!'-W,P47));U972DI4.7)W>%97
M:B]!3T]L4"]X:&@O-&Q,:7%*>%8R2W5X5C(F(WA!.TMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%94=6)M,G192DQI
M-6Q30S-I0F%785)G:4MO-FPF(WA!.VUA9T%X5DEJ<BMQ86]7:CAV5VXW9VIB
M5TPQ5U,R,S=W>$1J3&-F.$%#265Z;D9697@X<E=K9'A(9F%L32MR-FY'955D
M,V1C4W-49C@F(WA!.W4X2V=242M&5EAK4CEP:FEQ9%EQ-T951G)N+TA%,40O
M04IH<'8K5%IX5FE.,2M81FIR-U='<U-A;F5733=A4$AP<G!A9E9G<E%T4C(F
M(WA!.S5M5T=5=E5->3A8<6]"4$5!:VY#<4DP5#AQ9DQM:F%X1'%T<E!D=%!$
M26MI>'E01UEZ-D9Q.6Q!<$%J5G%1=U--<3!.5%=R8VIG5FLF(WA!.V8Q1S%K
M,5,T6C!Q5$9%5'5E<&%4,SES5E8O,%I:9C<W+W=#1V(K=4MU+U)L;"]V=B]H
M;2]R:7)V,%I:9C<W+S1:=C8T<3<Y1U=8*RLF(WA!.R]W1&AM+W)I<G8P6EIF
M-S<O=T-'8BMU2W4O4FQL+W9V+VAM+W)I<G8P6EIF-S<O-%IV-C1Q-SE'5U@K
M*R]W1&AM+W)I<G8P6EIF-S<F(WA!.R]W0T=B*W5+=2]2;&PO=G8O:&TO<FER
M=C!:6F8W-R\T6G8V-'$W.4=76"LK+W=$:&TO<FER=C!:6F8W-R]W0T=B*W5+
M=2]2;&PO=G8F(WA!.R]H;2]R:7)V,%I:9C<W+S1:=C8T<3<Y1U=8*RLO=T1H
M;2]R:7)V,%I:9C<W+W=#1V(K=4MU+U)L;"]V=B]H;2]R:7)V,%I:9C<W+S0F
M(WA!.UIV-C1Q-SE'5U@K*R]W1&AM+W)I<G8P6EIF-S<O=T-'8BMU2V]A*UA1
M=%!H5V4K:VIT;U=D26QK;&M+2UAK64MI,4HV:VY&56TO4VLF(WA!.U=P;&]V
M3%9J.6155D(Q5V1P27)!2'A2>%8W:C(Y26-4,$QR:%98=&9),FYV2DAD83%)
M9%AV;WIZ:F%51DQE2G9'0S-"6E9P,EIY-VHF(WA!.RMB07%D+V]Y>2\S,R]W
M04TS.6-69"MJ3$PO9F8O1$XO6$989F]Y>2\S,R]W>F8Q>%9I9FLO=T1.3'E4
M-6@X>#,O;&Y22DIM,4A4;&TF(WA!.VQU5F5.;&IP0DMS1&Q82DYF:6-5>%9L
M1W5F.$%(13%$+VU';2]W0U1:>%8R:"\X04A%,"\O;4=H+W=#5%EX5D<T<6AO
M+W=$:G!4+S@F(WA!.UE99BM*4S1Q:6-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<4(Q4%AD1C!O2613=F],4#%.;VQM:U8F
M(WA!.T=C*T-+5%9J-T1&54(O:65E-5!(4W1(=F)Y=7=N;6HK<%%J,TIU:D9+
M4C=P1S)+=&969D]6-% Y279B6%-9>C%J<V]Z9%1$+T%&8FDF(WA!.S1%8V8S
M,BM+<$0U=2]*-U)F3F1T87<V<G)'<FPW4UE80WEP9$PX56EI:7-9<$DU248T
M,5 Y,T=V=C)X5FY%:W-.=&)M4V56631O,2LF(WA!.T]747%Q9T1A<$]Y:D95
M;F)Z<C5E66QB2V0Y5&-F<S9D1DQE0W9G6&=6-#$O,E1$1EAF<&)Z3F,O-WAA
M2#E86"]!2#5Q5GI(1#$W<6PF(WA!.W-,<VXU3590>7A6<CE&96%R;B]E>E<Q
M=%8O,S-P='-K8E4X1VMU:F0Q*V%Q=4MU2&MR44I.-RM+6%94,R]333!T,FQF
M15%Y<S!++S<F(WA!.T9":7%J;T@U9&53=DPR<C-/<V%,<%56;'%6,FIX,T9X
M1UAQ>5-/<VIR>$Q&44,V03=$1E4R,7HO04DT;6]F.$%-3DXO>6)/2W-!,4@F
M(WA!.WIF-7@P<E<Y1C W5'1083@P96)43$M74C1R1S9U1U=34S9I:&Y,>E)L
M54%3,V)K;UAK=TY3-$,P3T959&\S;7IZ.6-E8E<P-CDP;$(F(WA!.V]Z6# X
M54XY2&$S:U$K<4Q$2DEJ=$I0=T%D2%-.1TI4:DE8+T%(97EK:TMY-S9X375P
M,T%7,6QC0TM)5E5X55!X4V(O04)/3596+W(F(WA!.V,O.$%Y>%1F9D0O,55X
M5C,Q=68O04I9<'9V:"\V<5EQ-S8S4"]W07-5,S-W+W=$5E1&6&97-2\K5TMB
M-S1F.$%Q<&ER=G)C+R],1DXF(WA!.SDX4"]!1E5X5C,Q=68O;&EM*RM(+W%P
M:7)V<F,O=T1Y>%1F9D0O,55X5C,Q=68X0359<'9V:"\V<5EQ-S8S4"]!37-5
M,S-W+SE6358F(WA!.V0Y8FXO=T-72V(W-&8K<6U+=2MT>B\X04Q&3CDX4#A!
M,55X5C,Q=68O;&EM*RM(+T%+<5EQ-S8S4"]Y>%1F9D0O=T)63593-CDX,S8F
M(WA!.TI9='AV8FE',6%T3TTQ>F%2;79H.%5W>%9#9C0O=T)%8B]E94LW=D(O
M3EI7-S-9.&5T=C9O>'!65"]&.#=O>C(S;#=6<#%51G8W;4<F(WA!.T%K1&9:
M8FUA0FHX<59X5FIN;$AZ9"M:;74R,3$Y83AT:E)8:G5:4D9.9F@K6F=:>3!.
M3&%S26-Q:$-S4DU.>#<T<6YV-D4Q3S8S,6$F(WA!.S@Q2S95.6)A,F5#>&="
M+WEF<3AI,T906G!M>%9(-EIP5VPV5U=B5#E%*W)34V8S<W-A,C1K9C-E5#%/
M8FXS631Q,W%F;694=$Q#9G F(WA!.T0O4E=K+W5O-4I)03AH2&%.4%4U3V9:
M4FEQ0U!M:E<W>4QL;S-L-C9L<CEM8E5'4W=I+S1&*V1X+W=!:V%E*TMV4%!Z
M5R]+2'IB*UDF(WA!.V\P=#<O55ER3CE.*W-C25E,5E-G1G@V93-*<F]S>$AP
M8FYB+T%&4FEO3#!'>#AP-D9B2D-:9$9E.'595E5,8S-J4C-C9TE&2W$Y>$XF
M(WA!.TMY+U%C2W V3'%904%757=!,D%":"\V<5E&9#EB;B\U67!V=F@O-G%9
M<3<V,U X03AS53,S=R\Y5DU69#EB;B]!3U=+8C<T9BMQ;4LF(WA!.W%&:')U
M;C,Q>DIA>$]29'A":DQB;6AD07)C2W5&3&-+=%5,>6]7;V%B1$96*W5F.&-4
M55 K66%B+VLR8U9D;V8O2$4P+W=$-6AO9BLF(WA!.U19>%9'-'%H;R\X06IP
M5"]!4$='2"]I575+;VY&6%EQ-T9867$W1EA9<3=&6%EQ9V16,3-2=$EH13)Q
M6#!&;$<R>4=E4E4U2'=513$F(WA!.UDK=WA6:54S-75A4%!584AA5#9O:6MH
M-W-*27-#16)58U)X>C-+-SDO47 W-&%6-"]W0V-F>FLX-G(K84=G5W1V9F96
M9$MR2$1C3%HF(WA!.TQ#9V%/-FU66G546%1Z4F-K5D)X855*>#9K2T181EAR
M9&YE-F1F1&Y,*VXW,V]42D1E;W=!,F\Q3DMU078S1$9#2BMR+VPK4B]P96@F
M(WA!.S-D>30S4#$S4SE1=E-#2V(X-5E::#(V:'-5<&Q:95EF265N:FAB>5=U
M;4Q3;$=H*W!I:&]0,C!J1DYV;&EQ3V@X-"M52C(T=S8U<#@F(WA!.W)B-TID
M47-D:E$Y1W=+;4-8.6DX3'IP8U).1$=V3U-53W!65D%R5FUR44-M2W!01C4O
M.$%).#A8<5=U=E=&-$]804IA6$56>3=0,30F(WA!.V]K3$\W3C=+2S1Q,C)U
M-C-E0VUK84Y*=TYE3C-Q5&95;W%E26DT>3-.9EHT:RME2W):9$DQ5V%*<'1D
M,7AO<F111$Q"640V:D-",S4F(WA!.U1&<$QJ+UI,2VYY>%9"-F)Q9FM(5%I*
M1&]S85AD,4EA5'IA8D)*9E1/96XW-F5&6E=R-WE0:7%0+U10;5,U3DQ(45=H
M6"]F=7!8154F(WA!.T-K94MR8B]82"MH;%4T<6QU<RM8=E!'<7)(+W5C:# S
M:7-N25=%3&\Y1U=N<&U35C51=V(K8U)G<BMY2S=G<6UA*UAT5#1"6#AX86DF
M(WA!.U8R<6=7=T@P8VQT16(X8T-T+S171%8Y6%9T4VM044@V>5DV1#520TU9
M<3,O04E2,'%T9E@Q3"]U2V%J+T%.;$=+=&8T3#AU;BLX=#4F(WA!.THK-3EE
M-'5*<6YX8C%*1W%F8S0R<F@U2#AM-SAT1'-:1TIQ6&QT-'!'4#A!<VY6:FEQ
M+U)02U!L+U$U<%ID2G1&<S)U0WAU1FE*5DHF(WA!.T-Z8W%S9U!%;&9S<'0X
M2R]#3G1S5E)E=68X8U154#A!;4=M+S5.;D96=6AY4FI33D]J3$0Q1&%X345R
M=5%%544P.$YX:7%0>%9#>',F(WA!.W8V575&<4]19V=*2&5H95=N-G-64E=+
M=4I!1E1S0FEQ53-N;3=Y;EI%<F5A,5E7>D19:6$V:&I0+T1-3593-F(X>B]Y
M.6I.1CAW5U8F(WA!.W=X-DQA>6DU4#-196]C5E-B>F(K8R]L,U%V3%8S<F1R
M85@R;VDQ.4DK;CE3=F)A26E75EDV;35L='A#;7HQ2$DO1C!(6$95<#!0.$$F
M(WA!.U!:.5HX=E<K<C)N;'5:4'),>5)X3%!E5VM58FU.:78W;W,S<GEN8F-*
M0U-09D956D8U:B]!1&PQ<55J5$Y#<V1)<S)',7IQ1%0X;$HF(WA!.S9G2WEX
M4U9(=D)1-%9243AG964Y4B\T-S-N;3=-5%5*='1*9VHP+VI8<6]N46U2<61J
M=#AS0W%U;F9K=#5*=$I6;FU3-79R=%18-C<F(WA!.V-41F)K;GAA94%1>70O
M<VUX=%=142M39DM56E9J<$YT3DEN,EIR:4U816=P+W=!5U1C,R]!0GA62&Y2
M9$E-;VQ.;$-:5CE09R]P<E8F(WA!.V92679(43 R-$UX27 T-'%O,VYL:GDQ
M979Z=DY*<S=L*W9+83-I:U S<W!X5D,O-$PX=G!55SAD>%IG+W,R9#-D,G$O
M.$1"3$=V8G<F(WA!.WA6=SAT,VM9<&$V+W%50R]Y<S%T8T0V5&-15% O=T%.
M:7%Y8E-03D1,=R]3;&YD4F<X9W0W64=2<6ET4&EI;FA59&5V1$95;#%8>6PF
M(WA!.V,S5FQC43-(;')1<F]V139#-5-S57$X;$ER2$<Q<E X439J.34Q=W%X
M:CAN+TE7=6558DQ53&93=%!7>$8T.%1Y5#9T2S X=V]N5D4F(WA!.V=G=&Q+
M3E=V07E":S9.=C!696@O;TA83&YF54YE;F]F=%%71556<$52.#)&>&-$+T%'
M37=W2W9J.&UE5U9L13 Q:70U3W4V5#-Z4&4F(WA!.WER+W%Y6$Q3=5!O3TMP
M>7%Q<6A604-G54%'=T%'2W0T<3=&6%EQ-T9867$W1EA9<3=&549R;B](13%$
M+T%*:'!V*U1:>%9G5V]F;&XF(WA!.V,V-W)':F59-$Y19W,O43 R>'0S4C=5
M>GE0.$%68G%/.%@T>DMG5F9H2R]!1F)F8W-0:$)616584'EL3VDK67)F5U P
M=3%X-D4S<F4F(WA!.V=93T).3%)R5V=F,4=O6F5F<7IN:BLX8TMF:'!G5FA9
M+W=#8V4Y5FXO3F95=DTW*UDU<D<P=5IP<G=.<'I.0F5O3'8Q5E=.2E-(5F4F
M(WA!.U!2:E1C94=+,GDV-2]*2S!U22M%,VTS>DQC9T=O4S<Q1G!O+T1D3TLT
M<6Q5=B]/3S)H=%AJ95)Z13DW=3%%>D5E-TQ*13,P9VI$86\F(WA!.W5Z+TI0
M.4AN;%DS.$5*2%))579R9EDY9FI7.65N+T$T,G%:9C1(.'IX;78Q-F$U<"]W
M0G)N53=F:T0O,&MC8694:7)'4'I0.'%E8V\F(WA!.R])5W-T6E<Y,V182&]G
M3$1$<F5O6'-H5FY53U)B>5<X87EC5DIA;DQT-#1Q,2M39&YQ=6QE43E08E5V
M3#)P,DXV4393,V-%5G%S:VLF(WA!.V%Y15)M4TUL8G):4C-J3W=&359,4'8X
M0458;#E0.38Y6'9D4#A4<455;&MV5VXR<FU'2F5V975+<&Y9+U5B*U Q3$A7
M6'4T+S4T2F\F(WA!.W!&,SDQ531&4E V36LO-6)R;B]G:R\U;WA6,S9-:R\U
M8G)N+T%)2E K84U69"MJ2E K5S8U+S1*4"MA359D*VI*4#A!;'5U9BM#5"\F
M(WA!.T%*;WA6,S9-:R\U8G)N+V=K+S5O>%8S-DUK+S5B<FXO04E*4"MA359D
M*VI*4"M7-C4O-$I0*V%-5F0K:DI0.$%L=75F*T-4+T%*;W@F(WA!.U8S-DUK
M+S5B<FXO9VLO-6]X5C,V36LO-6)R;B]!24I0*V%-5F0K:DI0*U<V-2\T2E K
M84U69"MJ2E X06QU=68K0U0O04IO>%8S-DTF(WA!.VLO-6)R;B]G:R\U;WA6
M,S9-:R\U8G)N+T%)2E K84U69"MJ2E K5S8U+S1*4"MA359D*VI*4#A!;'5U
M9BM#5"]!2F]X5C,V36LO-6(F(WA!.W)N+V=K+S5O>%8S-DUK+S5B<FXO04E*
M4"MA359D*VI*4"M7-C4O-$I0*V%-5E).=$%954M'5U-A<')Y:TE**U=W1S)+
M;V984"M/2G$F(WA!.T@O34Y.+WEB3TMU,% O:FEA9CA!.'<P4"]*<UEQ:F-6
M43!F+T%",' O=T1J1$0O>$M81E54:7)S5F1I<G-69&ER<U9D:7%76#-L:GDF
M(WA!.S-F>2MT939885A%.6%I85-'3G!!5#-$:V-G9F-(1E5-9DM';GAJ+U%R
M=2]S5T@R9E)V3&AK559R.$U->GEW:B]!241&5R\P5#5M:$XF(WA!.V)86&I.
M,3(Q0S!H;4@P9E94631Q=TAZ2G(S-38R4#5G-E!:5T=L,CDO=T-7;CE-,S@Q
M<D5!:G%84')C;FUK<D,V<#EG8W%6.&5M2W,F(WA!.S@O>&A944=M<5=T-7!*
M2%9R=4%M168V,7A!6G)C9E1*:7%A,D]O-F9Q1G5T>EE8358S8G0Y;6%",6M1
M+TIK2D=+;VI&6%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1E5&<FXO04)X3E$O-6AP=CA!:S)C5EDU-6PX,DXU4R],9%!-0W=X5"]5
M-$Q0;$902UDF(WA!.U5+>79&17A,<7-R9D-R;'%+:$IP44%N8D951&]V-7!V
M<5!M=S9!*VQR141F5%=C5C-(9'!C0C0T;UI*:VU#>'!X-E$P;%AN5TES9TXF
M(WA!.U-307%Y-S8U0VUP,T%:6E-21D50:&EL66).2C-65&EQ=BMK25 U2G8K
M4D4S+TY'2W4O4T5(.&LS+TEI8B]M:D989G!#1"M38B]K4DXF(WA!.R]W03!9
M<3<Y25%F>51F.$%):6(O04IO>%8S-E%G+VMM+W=#4D4S+TY'2W4O4T5(.&LS
M+TEI8B]M:D989G!#1"M38B]K4DXO>E)I<G8F(WA!.S!H0B]*3B]Y26TO-6]X
M5C,V46<O:VTO-4549C@P67$W.4E19GE49CAI2G8K84U69"MK25 U2G8K4D4S
M+T%$4FER=C!H0B]*3B]W06DF(WA!.TIV.$%M:D95<'9T13AR6'1Y8G5B5&U7
M.5 O2#E"0E!"8R]24$-S8V\O=T-#>%91*V]A:F$P+U)M=%AY<78R8F4O=%AV
M66=0.6)J1&,F(WA!.VXV6G-682]X1#5M=% Y-CE(+U-%9&%E<G S<7))4C1M
M0S931D8K:5IS5E9(."\X06QQ,U-U<%-4-E5E-#%#,FYT;'(T0U-20D4O.$$F
M(WA!.W-'3TMT*U=F>D,X;V5A24HU.4%V+W="27A7>BMN3S!-32]W3G93;TM!
M-S R4%$Y<U94;CE)469Y5&8X04EI8B]!2F]X5C,V46<O:VTF(WA!.R]W0U)%
M,R].1TMU+U-%2#AK,R]):6(O;6I&6&9P0T0K4V(O:U).+WI2:7)V,&A"+TI.
M+WE);2\U;WA6,S919R]K;2\U151F.#!9<3<F(WA!.SE)469Y5&8X:4IV*V%-
M5F0K:TE0-4IV*U)%,R]!1%)I<G8P:$(O2DXO=T%I2G8X06UJ1EAF<$-$*U-B
M+T%*151F.#!9<7)1>DI+<%HF(WA!.U%W04Y0:E)K4#-/1D]+;UA84#A!:FEA
M:"]W07<P,R]*<S1Q=#!:1691.5!6,41,.5AG3D-+:6]24T]V9V-64BM+;V%0
M+VIP5"]W1$<F(WA!.T=(+VE5=4MO;D9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1E9+-W1B93=T6G)3-6I%='1C23!5,%1D1U)W5EI4-T4F
M(WA!.TA&5TAE5E!Y6B],;GEZ8E1W5U=K43-0,6E4,4AK=FQ7-F-D9W%T241X
M564S,#%X5D\O.$%"6&QG9C-D:TE.<69U2DI99'9F,#)8-DTF(WA!.V)6<RM5
M3DLS<&-A:T0T+W!45514-D1/4FER6"M&,E@K-3%J56]Q+SA8<DIV-"]V:VPO
M<&ER6C!(5GAU=FU454-E=V5,5'EV,&AB5E0F(WA!.RM/2W-%+TY4>60K8U=P
M,C)M<#52.'EM37=Z<SDR0U):3U)294)-:TDK3D9)87%%9"LK2W,S=#=,>GES
M15-Y-G9P>GEQ9T5J+T%+3VTF(WA!.RM*9T)5-UAQ:G(W1$96-6DX-G)50S8P
M,E=N4B]Q.#AD9CEJ-CAL4"M#>%8S<F5D5C,K<6%B2T\V9E=:-"]W1&AV46LO
M-&II<F8Q=GHF(WA!.W!8+VIL86)4+W1O>B]W1%I$:7)8-E,X,7(Y=E))5W Y
M<C!R,$Y8+U8U>%(Q.7$P>%9H9C5F+VU,*UE/=F9M0G)U:&$U-6(O4F5J864F
M(WA!.TI$83-F<'EQ=UI*46E+.')K>%,K;VA,07AG9$\T>%8V1G)N+T%">$Y1
M+S5H<'8X06LR8U9D;V8O04)X3E O-6AO9CA!:S)-5E)U2V\F(WA!.V%0.$$T
M-E4O+T='2"]I575+;VY&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<6=T
M8R\T-&UO9CAW,#,O2G,T<3=1+W=$:FEA9B]!37<P4"]*<UEQ=V9Y,35/."\R
M4&UY-3%#.3%52%)8,5<X=30F(WA!.W),-C-C>DXY56U764I',&)Q279I:VMJ
M64M+0TU2:6Y*;6,T<7IG,BMO9EA:6FMM:5=.,%)61%)S>"M%=60V3W8X,DMQ
M;G V;"]V.$$F(WA!.V@O-45T+S%6>%8S<#9L+W8K2"]K4S,O5EA&6&5N<5@K
M+W=#2"]K4S,O5EA&6&5N<5@K+S1F*U),9CE68U9A6DY5-&YJ4$%7<'-$0SDF
M(WA!.TLO.$%),T982VUQ8U)Y;F=$53-!:&5L9BM2=4MT*VYQ6"LO-&8K4DQF
M.59C5F0V97!F-R]!268K4DQF.59C5F0V97!F-R]H+S5%="\F(WA!.S%6>%8S
M<#9L+W8X06@O-45T+S%6>%9A53%8,4%"3D)W;V52.4HV,7%+8F5R.#A66&5N
M<5@K+S1F*U),9CE68U9D-F5P9C<O:"]W0U(F(WA!.TQF.$%66$9896YQ6"LO
M-&8K4DQF.59C5F0V97!F-R]H+W=#4DQF.$%66$9896YQ6"LO-&8K4DQF.59C
M5E=O;7%L5'IM9T)Q84%23V0F(WA!.W%N:B]!3'0X359896YQ6"LO=T-(+VM3
M,R]66$9896YQ6"LO-&8K4DQF.59C5F0V97!F-R]!268K4DQF.59C5F0V97!F
M-R]H+S5%="\F(WA!.S%6>%9A>6%R>51J3D%15#A:350W0V@V9G9F1VU+<G94
M,4PO9CA0.$%Y2F(O04MQ-'$W,#E3+S,O04$O.&E7+S9Q-'$W,#E3+S,O1"\F
M(WA!.T%-:5<O=T-Q=4MU.5!5=CDO=T%0+TEL=BMQ=4MU.5!5=CDO=R]W1$EL
M=CA!<7)I<7!B:39!8UA$27@U9G4R:E5R5F5)-F=S,B]+=F8F(WA!.T954')N
M+TA%,40O;4=M+S5.;D9884@O>'A.4"]!3UEA2"]K,DU666QR4#5B,SDY8UA%
M.71Q9'1A>7DV:DQQ544U<VUK;70R:W1O<F0F(WA!.U)#-C-%9D9W,%!Q33E0
M:4IO4G@U0FQ53F(O;$9$8F%H2DYA,W-.=%DS16MW=6109W13:5!B5$=Z5C1E
M9G)&:'IH<U!4:UDQ-6-Y47$F(WA!.SDQ57@P3#AU,3!Z6$Q$5G!,=4MA87=I
M=F]9+U1G94II;#ED>5A*5#1P<%DQ4E!55E)23UAW+V$T;FII<DUS5F1I<58K
M871%9EA03&TF(WA!.V\V3VMY,GHS,$11<F-02#9O:DQ$6BM!84]P6'%0:4<K
M2W-/;"]+43-!,6]81CEA9C=L6GA.82MJ66Q0<6YX2WIU9V$T9%=N9C!)954F
M(WA!.W!'-5-P53%/1S%6-W8X<G)M-%,T03%G474Q-F)U=VUJ='E(=%9K,4(W
M*UI9:C8Q4%5K<DA(>G K=T1X,W!G5FMV:R]Y."]L,WDW86$F(WA!.T\Q>CEB
M*W$K<%-F9UDV<3AR4TMT0S!J9D-'-#%:,EIQ5DI*3TMP>FER<U999C5T.&A4
M83E.<6IP9#)S4V%N63(Q:3!6,5IM-E948GHF(WA!.U131U=G;F<U17)C8U8V
M1E-!=TYE:7%586PK560Q8VE+5S$Q;4]Y,49)24DU3E%3>DQ44U1X6$LS56PP
M-T=C2#%(;$1L84@T435"-6(F(WA!.UEB5DYO9GDP,&U05C0W=W)B=&)7="]"
M9E=&<V)C1C1&=#=&3%)9:VU,<W<O95%2>3AG0CEN:5%E=4)7631Q-T9814)G
M45)52%EG.4LF(WA!.UEQ.#-S+WEJ=6]F<7E486I9,T5.=EI15U5S6C K4F9R
M2#%A27)%8FMI-R]E24IE16Y#;3-!045667-B5G%(.&Y8:3!E-C!P9%A2<F$F
M(WA!.U,R.4=Z5G)484-C5U9V67!04EIL-71(2$)*=S9(.35U4U)5:%=5*U=V
M2V8V13%86#<O-C$V-#%Y.$8U-EAP.%!325%*>#5C;C4O6C@F(WA!.T(X=75+
M<V=X5C)+<V0X,RM66G1F3F<P5GA"03%I,7<O1S5T=G)58VYR,C!L=49D4%5H
M0E%.24A:5%5.>'!I<D=6+THP9F]E,G-7,4<F(WA!.T0V,4):6'1M.3AL;5$X
M;C%U,F$Q:D)$>G521D)%26=S9DMV-W-F1TMN0W%V<D@U5UA&+T9C33)O>'9D
M,U5-,&,X:&=#.#5:3'DS=4DF(WA!.UAK-71/<G@R.%9O:UAO<VA$<BLP=&-6
M6GAP;&PY4C R,'-V5F5F-G)$2$0V,&AQ-RMM;UAK>#=S,4MN07%*>%8R2W-!
M=F9Y=&UU-VDF(WA!.WI,,SET.59T.5%V8C):5%I-6C-T-RM:-4I,4DIH8T0P
M,6%+6C1N4$5H=U%E26]-5E<R;C551T1863E33V]1+U905W5R:30P,DLP354F
M(WA!.U5J,T)I:VI51EII46M5.$-Z04=T5W)U0G1H=%9(4F9Y>F)Y,4AQ3W!.
M9GA433%J9GAV8C(Q<CE5:3585$I+94,K<DYW:5%W,5--8D(F(WA!.VYC9R]&
M44MS-C!0+T%)-&UN+SA!34Y$+T%-;7AG5D<T<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&549R;B](13%$+VU';2\U3FY&6&%(+WAX3E O04]9
M84@O:S)-5E)U2W5X5C)+=7@F(WA!.U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5D)A
M-2]X>$Y1+S4F(WA!.VAP=BM46GA63&]0,$8V169O9G!$,$]).4PP+S!J=S15
M*TAJ5&%L3VQ-2W(O05!C5"]W0G),+W5:67$W+T%(12\Y<DPO04QM5TMU+S,F
M(WA!.T4O.$%A>2\W;5=+=2]W0GA0+V%Y+W=#-6QI<G8Y>% O04=S=BLU;&ER
M=CA!8U0O,G-V.$%U6EEQ-R]C5"]W0G),+W5:67$W+T%(12\F(WA!.SER3"]!
M3&U72W4O,T4O.$%A>2\W;5=+=2]W0GA0+V%Y+W=#-6QI<G8Y>% O04=S=BLU
M;&ER=CA!8U0O,G-V.$%U6EEQ-R]C5"]W0G(F(WA!.TPO=5I9<3<O04A%+SER
M3"]!3&U72W4O,T4O.$%A>2\W;5=+=2]W0GA0+V%Y+W=#-6QI<G8Y>% O04=S
M=BLU;&ER=CA!8U0O,G-V.$$F(WA!.W5:67$W+V-4+W="<DPO=5I9<3<O04A%
M+SER3"]!3&U72W4O,T4O.$%A>2\W;5=+=2]W0GA0+V%Y+W=#-6QI<G8Y>% O
M04=S=BLU;&DF(WA!.W)V.$%C5"\R<W8X075:67$W+V-4+W="<DPO=5I9<3<O
M04A%+SER3"]!3&U72W4O,T4O.$%A>2\W;5=+=2]W0GA0+V%Y+W=#-6QI<G8F
M(WA!.SEX4"]!1W-V*S5L:7)V.$%C5"\R<W8X075:67%S;B]16&]3978K:U!1
M-&XQ9E4O4U!$:%0T=59D<54V,7A6+R\R43T]/"]X;7!'26UG.FEM86=E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#I",S4X138W-#8U-D9%0C$Q.48U045%0S<Y,C@W
M-T8Y03PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#I",S4X138W-#8U-D9%0C$Q.48U045%0S<Y,C@W-T8Y
M03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S
M<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP
M+FEI9#I",C4X138W-#8U-D9%0C$Q.48U045%0S<Y,C@W-T8Y03PO<W12968Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#I",C4X138W-#8U-D9%0C$Q.48U045%0S<Y,C@W-T8Y03PO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)$
M1#4V0D-#,#0U,D5!,3$Y-D,X0D5".#4T-C4X04(Q/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 R+3$X
M5#(P.C0Y.C4P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I",S4X138W-#8U-D9%0C$Q
M.48U045%0S<Y,C@W-T8Y03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,BTQ-E0Q,#HP-CHR-"LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL
M=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP
M+R(^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN
M=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*
M(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3$N,# P,# P/"]S=$1I
M;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX-"XP,# P,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!I8V%S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97,M4F]M86X\+W-T1FYT.F9O
M;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4
M:6UE<SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/E)O;6%N/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y
M<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/C P
M,2XP,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y425)?7U]?,"Y0
M1D([(%1)4E]?7U\P+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @
M(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y"
M;&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!2960\+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0TU92R!996QL;W<\+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D--64L@1W)E96X\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!#
M>6%N/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($)L=64\+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0TU92R!-86=E;G1A/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3$U($T],3 P(%D].3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,30N.3DY.3DX/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T].3 @63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],"!-/3@P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C@P+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @
M33TU,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TS
M-2!9/3@U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XS-2XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU($T],"!9/3DP
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-2XP,# P
M,#$\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(P($T],"!9/3$P,"!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$Y+CDY.3DY.#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],"!9/3$P,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3$P,"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STQ,#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P
M,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STY,"!-/3,P(%D].34@2STS,#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.3 N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,S N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS,"XP,# P
M,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3<U($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STX,"!-/3$P(%D]-#4@2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXX,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P
M,#(\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C0U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STW,"!-/3$U(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C<P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$T+CDY.3DY.#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,].#4@33TU,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3$P,"!-/3DU(%D]-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C4N,# P,# Q/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P
M,"!-/3$P,"!9/3(U($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXR-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3<U($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P
M($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T]
M,3 P(%D],S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,S4N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,S4N
M,# P,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,"!-
M/3$P,"!9/34P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,3 N,# P,# R/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-3 N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY
M-2!9/3(P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$Y+CDY.3DY
M.#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR-2!-/3(U(%D]
M-# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXR-2XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XR-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C,Y+CDY.3DY-CPO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/30U(%D]-3 @
M2STU/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY
M.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XT-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C4N,# P,# Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/34P(%D]-C @2STR
M-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV,"XP,# P,#0\+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34U($T]-C @63TV-2!+/30P
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU-2XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8U+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C,Y+CDY.3DY-CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C4@33TT,"!9/38U($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,SDN.3DY.3DV/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],S @33TU,"!9/3<U($L],3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,P+C P,# P,CPO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N
M,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STS-2!-/38P(%D].# @2STR-3PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# T/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-C4@63TY,"!+/3,U/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XV-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,U+C P
M,# P-#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-# @33TW,"!9/3$P,"!+/34P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XW,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]-S @63TX,"!+/3<P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XW,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C@P+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<P+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA
M;64^1W)A>7,\+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3DP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C@Y+CDY.30P-3PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3 @63TP($L].# \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-SDN.3DX-SDU/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXV.2XY.3DW,#(\+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @
M33TP(%D],"!+/38P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C4Y+CDY.3$P-#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP
M($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STT,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS.2XY
M.3DT,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3,P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(Y+CDY.#@P,CPO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],C \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3DN.3DY-S Q/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXY+CDY.3$P,SPO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXT+CDY.#@P,SPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F]U<$YA;64^0G)I9VAT<SPO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @
M(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,3 P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TW
M-2!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-S4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,"!9
M/3DU($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DP(%D],"!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/38P($T].3 @63TP($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-C N,# P,# T/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,S Y.3PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# S,#DY/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P
M+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #V 9H# 1$  A$! Q$!
M_\0 'P !  $$ P$! 0            <%!@@* 00) @,+_\0 4A    8" 0$#
M!0H,!0(#!@<  @,$!08'  $($0D25Q,6(9?7%!47&!DQ=Y66U2(C-T%155:4
MM+;2U@HR,SAV)$(U4F$H-D-49'$E-%-S@;'P_\0 & $! 0$! 0
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M:? #D=>,N1RR3P]7;7'%IH>/UI-R& 2#93F0SVU?=</**0)3%IS3(P1]G71
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M@GZ/UHS!9NZ;E29.N]:WK>MZUO6];UO6]==;UOT;UO6_1O6]?/K!#\/<:3N
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MDY"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M+;8[#X8PM<9C+$@*WO8$;2QLR5$VMZ8(A"'Y)*F*!L8ACWK8Q"%L9+LP!@#
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M[_QAU_AQ98;UW7DD5S[/P23D*, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MQ,>2<L;!$[]R#-%<L6)5D]\1C.1Y8TH0<25T*[NUW2P4NLFGH914#PMXI<7
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M3L\N%3A4K'>[WA8U*4K<7[F8[!P&OMS8F4$J[3OGPT%A:6T.HS$FGA%7 &$
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MP/D)W!5Z74DA.H0X1T,1FJQWG<=TVS-[>'U<+-Y?/F1,FM=-=/T>CT[WO?\
M_.]^G?\ ]]^G!!@&GI<'Y6K1^D6;?S*YYWPW+LO!SFSYQ _VP49]'4?_ (;.
M/ZGWQ=SV@^U>_EF1^8-# (VN+\EL]_XPZ_PXLL-Z[KR2*Y]GX))R%& , 8 P
M!@# & , 8 P"W)3,(E!F=1(9M*8Y#F!)KJJ?)2]MD?9TVNFQ=5#F[*DB(G7=
M"(74P\/H#O?S:W@'FQ<G;8=E91>E1<UYLTP[+4?? :VU:ZN5UN&E(.H=HQD4
M^US?295HS7DC"UAB8*<SKI6,@(1B"-KZ<;NA?O9YD>;\C_Q1W#%^=U,4XXU/
M;US2<&C/<*R8.5?4?"5XM!'LOW,MDLG?[+<-[V'O&)&"I'QVT6+7N9L5G_\
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M';#KH,OBBJY=W+8M7Y4RJ9OU)XQ\?^8O+DPW\4D?*?XZRZ)UH<K'_HE[N/D
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M=61S;WAK6EZ-1N36M3."!65OYC4RQ(8<G/+W^891@P[_ #;P9*A@# & , 8
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MI3DY5Z9W&9V"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M:>EP?E:M'Z19M_,KGG?#<NR\'.;/G$#_ &P49]'4?_ALX_J??%W/:#[5[^69
M'Y@T, C:XOR6SW_C#K_#BRPWKNO)(KGV?@DG(48 P!@# & , 8 P!@# & ,
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M")-LWIHL+!S>A3P(>]_,$(&^$*!;%Z?\O3O:WZ-ZUO'\:O);F6HU?#+O-?\
M$G2/7*ZR[N;BBKCW)]&:ULO<>Y"J7KOZWZ=;![VU0I[VMZ].N[UZ_FQ95Y+<
MEM%F]B^O?6X?V%K7UKRCV,8LJ\EN+:+-[#WTN']A:U]:\H]C&+*O);BVBS>P
M]]+A_86M?6O*/8QBRKR6XMHLWL/?2X?V%K7UKRCV,8LJ\EN+:+-[#WTN']A:
MU]:\H]C&+*O);BVBS>P]]+A_86M?6O*/8QBRKR6XMHLWL/?2X?V%K7UKRCV,
M8LJ\EN+:+-[#WTN']A:U]:\H]C&+*O);BVBS>P]]+A_86M?6O*/8QBRKR6XM
MHLWL/?2X?V%K7UKRCV,8LJ\EN+:+-[#WTN']A:U]:\H]C&+*O);BVBS>P]]+
MA_86M?6O*/8QBRKR6XMHLWL/?2X?V%K7UKRCV,8LJ\EN+:+-[#WTN']A:U]:
M\H]C&+*O);BVBS>Q76!;.U*LT$IC<29D.DXA$*6":O,E5F*]&E: 0:B<8!%"
M24XB=GF"5 7GFA-+**TC& X9Q"SHWE+\L6]4LY_A%VY"C -/2X/RM6C](LV_
MF5SSOAN79>#G-GSB!_M@HSZ.H_\ PV<?U/OB[GM!]J]_+,CNFNN]]-==ZUK>
M^GIWK77>M;W\_36][Z:_-UW^G>8-'. 1M<7Y+9[_ ,8=?X<66&]=UY)%<^S\
M$DY"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /-'F[V1?!7
MM"IM";(Y,56X2"=05L)CR&41:822$.SS$2'!4ZE1"3*(ZO1^_#&0X+G!2A$,
M)3PTC<7$+0[-X%RL!PW#'%!/A<IX)^YG9&:FK*'0*)5=&X'%6NO()&V:'Q"'
MELJ(]BC\9C[<G:69F;T2LH\LM&WMR4A*2$7?'LLO6S!C'L0MC$W.<[;Y]9U(
M_D/$OBM+N_YU\9^/LG\KU\IYPTS7+UY3K\_?]\HVI[_7\_>Z]?SX+-U9!<A[
M+#LU)1W]N_ CB'LPSKLQ0V<?*O858][^<0EC#&FU5L?Y]#\MWM;].MZWZ<%X
MXE_5%6]EB_([]FZ1_P"#<96>'_\ E^#VP;>K?R7_ .QYA6#'/<_3_MV1Y/N^
MCN].FL!11+KG)W=_CZCY)WBZV^F#S;F?6(]>DL5?]H!S4:@D[]'39*=QO1W2
M%ZUTUK0-)_)=-=-@W@<;_P#7WAA?X'R:@$7_ +M\^NTPC7=_T_\ VK3IOY/I
M\WY5X18/ENG_ -5Y?O?]_>WO?4.*?],-;I>'I</B+\G&/72#=J_S70:#_D!/
MX+PLLX'3KUT$P;KQ::E1H?S;WM2$W>OG-Z^G XEZ(<XO^P^+#VC[=_X+VHR!
MT[O^3X0^#E,OW>Z?_K[@,TJKO]?F%Y#2;\^PZ#^8)PS^WK<F[J6SS-23MJ>-
MO;G.W-NO5*!]OWD8Q)6&(%4;9?$FMK(K.MH\^@%L;R-?#H?.;!1U9/$D@$I/
M>91*9H$QY8T[6\D.J)A;RVIA=]/EGRT]OIOZ?"YR3MGQ--NSI8JNQ6WWFU-6
MK=VU[-7, 12]Z[.>4RU'"8JEE)TB;^1#%(%,C3L2 I[-?'6,.DDC2YX-<P*A
MN;A'F= QJUHCU+2V(D!B=*6/%\,W*<NESV^6X%[;D_;#MV^\=2W9O2@L/IV%
MOY(\EXDI-Z;].@%K^,$I3EB%KYM#5C"'T]1;Z:ZA_"L2_P *?_)'&[O[5=K_
M  7'L_\ BY)>[_F.B?: 2)O[_P"G92:4\.T'S_/H)JLOY^FQ:^? E#TB?9PR
M_P"36IS\9_M&TG_B/9;IUW3IWO-/G!23IWOT^2\Z8K!N]_Z>4\CU_/W<"2Z1
M9IKQ/\C?,SFDW[ZOW9+<E?)!_P YT3Y"\(91U_3LI.IY#QY89^?IH28L6_SA
M#O>L"2]:]U%^$SCY0FU4.^Y(>RY[1MM,#OH,;3%N+$O2A_3L)L:Y6+U!H=?F
MV4C'L7IZ!W^<)+U0OVB_,(^4L(3_ /C' KM,&?I_G_\ 9,<9)W/T_P#N-+Y7
MY3IT_P#@>5Z_]O7KKJ'#=;#;C*7><CGY4ZED?IDG'KM#(@#7^<V0=GCR[$07
M^G8E#'5#T0+6OGWLHPS73TZZ]==0X7T<+_Q0KRT>#W,G_%7(:%Y8&5-3W&1=
M/:7A"B/)+#DEH$6%3EKORET;FYV>R(K )I%F)Y@XV%.X>X489_'3U$A6I3%A
M*5L953>XJAZ0_1;AFVDW.24FL)M364_P;>,3DK;,XM&I@R^Z=L\K8&:2M.UB
M<217[VOK<F=$/NI*/>QIE/N545Y=./>Q$F]XL6][#O!XE?P#3TN#\K5H_2+-
MOYE<\[X;EV7@YS9\X@?[8*,^CJ/_ ,-G']3[XNY[0?:O?RS(_,&A@$;7%^2V
M>_\ &'7^'%EAO7=>217/L_!).0HP!@# & , 8 P!@# & , 8 P!@# & , 8
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MKGV?@DG(48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI^)*JUV$W1Z;E*<;3>VM8PH5E/6.!1)'4YE:0A<JG,"<X$,;S(C"S!@L[82
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MF)63FG:EUZSJE03ME)K+"C=21,A1@&GI<'Y6K1^D6;?S*YYWPW+LO!SFSYQ
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ME+HQ*CDSG WJSVUC6Z"=[XIQKX%'7F0)GL;=YJC$A&Q;?PR<93(8)*[&XF+
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MJ\UQ8&P;.0A,4FM:]0^AT_=G7IAW.Y-^,9D]D%L3)SDL69IE8M*690B1]BL
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MYS9\X@?[8*,^CJ/_ ,-G']3[XNY[0?:O?RS(_,&A@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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<Q"+V<46H"69LL0@;&$7=%L/3>^A6)*B1YG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>d51794d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20201231.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn02_12_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_UnsecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:UnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">md:PhysicianAndHospitalAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">md:OtherTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">md:RestrictedAndDeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">md:PhysicianAndHospitalAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">md:OtherTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PhysicianGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:AlternateBaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_FederalFundsEffectiveSwapRateMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:AlternateBaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:ApplicableMarginRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:ApplicableMarginRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapCollateralAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:PediatricCardiologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:MaternalFetalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">md:DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodSixAndThereafterMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">md:DebtInstrumentRedemptionPeriodSixAndThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFiveMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFourMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">md:DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherOwnershipInterestsByNameAxis">md:ChangeInControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherOwnershipInterestsByNameAxis">md:ChangeInControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">md:RestrictedAndDeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis">md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapCollateralAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:PediatricCardiologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:MaternalFetalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PhysicianGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LatestTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:PediatricCardiologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:MaternalFetalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:NeonatologyAndOtherPediatricSubspecialtiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">md:SalesAndRevenueServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:AnesthesiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis">md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForThirdQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForThirdQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">md:RuralAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="P12_15_2020To12_15_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="PAsOn07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="P07_01_2020To07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis">md:DeferredTaxAssetsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2019_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Number">
        <measure>md:Number</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To12_31_2020">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      id="hidden18208864"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      id="hidden18208865"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      id="hidden18208866"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      id="hidden18208867"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"
      id="hidden18209306">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"
      id="hidden18209307">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="hidden18209308">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"
      id="hidden18209309">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      id="hidden18209310">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To12_31_2020">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To12_31_2020" id="hidden18210623">FL</dei:EntityIncorporationStateCountryCode>
    <dei:DocumentType contextRef="P01_01_2020To12_31_2020">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2020To12_31_2020">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To12_31_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To12_31_2020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To12_31_2020">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To12_31_2020">MEDNAX, INC.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2020To12_31_2020">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To12_31_2020">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To12_31_2020">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2020To12_31_2020">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To12_31_2020">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2020To12_31_2020">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To12_31_2020">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2020To12_31_2020">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To12_31_2020">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To12_31_2020">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2020To12_31_2020">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To12_31_2020">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2020To12_31_2020">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To12_31_2020">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2020To12_31_2020">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P01_01_2020To12_31_2020">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2020"
      decimals="0"
      unitRef="Unit_USD">1251965108</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn02_12_2021"
      decimals="INF"
      unitRef="Unit_shares">85631836</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1123843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">104870000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">241931000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">434266000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16898000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17108000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">61806000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11837000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">85916000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1549348000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">731507000</us-gaap:AssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1641580000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">76191000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">72677000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1477968000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1479850000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26642000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">28587000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">55972000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56413000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">54472000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">86644000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">107355000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">48643000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3347948000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">423157000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">410637000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2219000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18933000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18254000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6039000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">106888000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">444335000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">541818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46005000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1742586000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1730238000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">40970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">265274000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">204914000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">61746000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56468000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">45320000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22819000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2600231000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2646905000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">85593000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">85593000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">856000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1029453000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3530000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-286354000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">510134000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">747485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">232000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">747717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3347948000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1733951000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1779759000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1723107000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1193940000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1180759000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1125671000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">90690000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">95911000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">92475000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">248947000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">244512000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">232218000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28441000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">25931000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">24355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">73801000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">60890000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1635819000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1608003000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1474719000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">98132000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">171756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">248388000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17913000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3686000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3051000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">110482000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">118928000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">92945000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1585000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2270000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">7714000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-90984000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-112972000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-82180000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">58784000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">166208000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16728000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">44694000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-9580000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">42208000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">121514000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-786908000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1539910000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">147115000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-796488000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1497702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">268629000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.50</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.50</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.33</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.44</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-18.44</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.44</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-18.33</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.60</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">83395000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">83495000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">91104000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">83395000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">84011000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">91606000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">93721000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">937000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1017328000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2048189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">3066454000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">268629000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">268629000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">495000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">18914000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">18919000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">770000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">38703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">38703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <md:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-56000</md:StockIssuedDuringPeriodSharesStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2660000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-2661000</md:StockIssuedDuringPeriodValueStockSwaps>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-69000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">7041000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">70000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">79631000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">222459000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">302160000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">87820000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">992647000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2094359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3087884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1497702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1497702000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_18209834"
      unitRef="Unit_USD">78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      id="Fact_18209835"
      unitRef="Unit_USD">78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">533000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11942000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11947000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1113000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">42758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">42758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <md:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-20000</md:StockIssuedDuringPeriodSharesStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-689000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-689000</md:StockIssuedDuringPeriodValueStockSwaps>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-132000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">5066000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">51000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">58706000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">86523000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">145280000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84248000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-796488000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-796488000</us-gaap:NetIncomeLoss>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_18210163"
      unitRef="Unit_USD">232000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      id="Fact_18210164"
      unitRef="Unit_USD">232000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_18210161"
      unitRef="Unit_USD">3452000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      id="Fact_18210162"
      unitRef="Unit_USD">3452000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">538000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7004000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7009000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1450000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">43009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-173000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">470000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8489000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8493000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85593000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1029453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-282592000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">747717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-796488000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1497702000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">268629000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-786908000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1539910000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">147115000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28441000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">25931000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">24355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7163000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5672000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4572000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">39042000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">33410000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">36589000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">36292000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-55715000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-35894000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">198000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-6553000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1886000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-37937000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-6512000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">35262000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47956000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">24621000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-15087000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-13916000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-32121000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1736000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47908000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46196000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-3039000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6931000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-24120000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-61408000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1093000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4336000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5413000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-6393000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3518000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-25469000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3615000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">153888000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74091000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">59021000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50732000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">283620000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">254687000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">204620000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">357711000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">313708000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2225000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46975000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">65370000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">61845000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">35101000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15884000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33432000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">51105000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">13710000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28788000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">19269000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">17120000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1080000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-58346000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-50240000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-84664000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">873857000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">152695000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-58105000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">815511000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">102455000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-142769000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1247300000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1723500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1986800000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2094500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">7090000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1394000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">5263000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1161000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7009000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11258000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">16258000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">245000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8493000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">145280000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">302160000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2910000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-384110000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-169255000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1248000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-8960000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-1355000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-4158000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-393070000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-170610000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1015973000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">67096000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">329000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">40774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">40445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1123843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">40774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">110488000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">95444000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">82540000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-27775000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">86268000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">185416000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12507000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2305000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2415000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; line-height: 0pt;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The principal business activity of Mednax, Inc. (&#x201c;Mednax&#x201d; or the &#x201c;Company&#x201d;) and its subsidiaries is to provide neonatal, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (&#x201c;affiliated professional contractors&#x201d;), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i)&#160;fee-for-service&lt;/div&gt;&lt;/div&gt; contracts, whereby hospitals and other customers agree, in exchange for the Company&#x2019;s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company&#x2019;s affiliated healthcare professionals, and (ii)&#160;administrative fee contracts, whereby the Company is assured a minimum &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;revenue level. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Coronavirus Pandemic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;):&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and related &#x201c;stay at home&#x201d; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#x2019;s affiliated clinicians. Beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#x2019;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; procedures and the prohibition of such procedures by several states. Within the Company&#x2019;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; studies. See Note 9 &#x2013; Discontinued Operations for information regarding the divestment of the Company&#x2019;s anesthesiology and radiology services medical groups. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s affiliated women&#x2019;s and children&#x2019;s office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. The Company believes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; either directly or indirectly, has also had an impact on its neonatology intensive care unit (&#x201c;NICU&#x201d;) patient volumes, and there is no assurance that impacts from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; will not further adversely affect its NICU patient volumes or otherwise adversely affect its NICU and related neonatology business. Overall, the Company&#x2019;s operating results were significantly impacted by the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through December 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of COVID-19. These steps included a suspension of most activities related to the Company&#x2019;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#x2019;s response to COVID-19. In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii)&#160;the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for non-clinical employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by COVID-19. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In response to the anticipated impact of COVID-19 on the Company&#x2019;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2 million for the second and third quarters of 2020, reflecting average &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjusted &lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;EBITDA&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.50:1:00&lt;/div&gt; for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#x2019;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&lt;/div&gt;&#160;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;months. At December&#160;31, 2020,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.1 million which reduced the amount available on its Credit Agreement to $899.9 million at December&#160;31, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CARES Act &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The remaining $70 billion in aid is intended to focus on providers in areas particularly impacted by COVID-19, rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#x201c;HHS&#x201d;) is administering this program and began disbursing funds in April 2020, of which the Company&#x2019;s affiliated physician practices within continuing operations received an aggregate of approximately $22.0 million during the year ended December&#160;31, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company utilize&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; this deferral option throughout 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The COVID-19 pandemic has materially impacted the Company&#x2019;s financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. &lt;/div&gt;&lt;/div&gt; </md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock>
    <md:PercentageIncreaseDecreaseInSalaryAndWage
      contextRef="P01_01_2020To12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageIncreaseDecreaseInSalaryAndWage>
    <md:DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">139200000</md:DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</md:SupplementaryLeverageRatioRequired>
    <md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForThirdQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement>
    <md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</md:LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To12_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To12_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">899900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-9"
      unitRef="Unit_USD">100000000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis"
      decimals="-9"
      unitRef="Unit_USD">70000000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn12_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-5"
      unitRef="Unit_USD">22000000.0</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summary of Significant Accounting Policies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company&#x2019;s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;case of gross negligence, fraud or bankruptcy of the Company. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the Company&#x2019;s affiliated professional contractors, in an amount that fluctuates based on the performance of the affiliated professional contractors and the change in the fair value of the Company&#x2019;s interest in the affiliated professional contractors. The Company has exclusive responsibility for the provision of all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-medical&lt;/div&gt; services required for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;day-to-day&lt;/div&gt;&lt;/div&gt; operation and management of the Company&#x2019;s affiliated professional contractors and establishes the guidelines for the employment and compensation of the physicians. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the Company&#x2019;s affiliated professional contractors for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the agreements. Based upon the provisions of these agreements, the Company has determined that the affiliated professional contractors are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation. All significant intercompany and interaffiliate accounts and transactions have been eliminated. &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is a party to a joint venture in which it owns a 37.5% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the Company entered into a joint venture in which it owns a 51% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#x2019;s Consolidated Balance Sheets. The results from operations attributable to the noncontrolling interests during the fourth quarter &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of 2020 &lt;/div&gt;were nominal and therefore not presented separately on the Company&#x2019;s Consolidated Statements of Income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the years ended December&#160;31, 2019 and 2018. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2020, the Company divested its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the year ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 9 &#x2013; Discontinued Operations for more information. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance became effective for the Company on January&#160;1, 2021. The Company does not believe adoption of this new guidance will have a material impact on its Consolidated Financial Statements or related disclosures. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting Estimates and Assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#x2019;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#x2019;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has one reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue from continuing operations by service line (in percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Neonatology and other pediatric subspecialties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maternal-fetal medicine&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pediatric cardiology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and GHC Programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from GHC Programs made up approximately 22% and 21% of net accounts receivable related to continuing operations at December&#160;31, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents are defined as all highly liquid financial instruments with maturities of 90 days or less from the date of purchase. The Company&#x2019;s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits. Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See &#x201c;Fair Value Measurements&#x201d; below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments consist&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;primarily &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;corporate securities,&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;municipal debt securities, federal home loan securities and certificates of deposit. The Company classifies its investments as available for sale. Although there is no stated expectation that the investments will be sold within one year, the investments are available for use, if needed, and accordingly are classified as short-term. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive income or loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally 30 years for buildings; &lt;span style="-sec-ix-hidden:hidden18209306"&gt;&lt;span style="-sec-ix-hidden:hidden18209307"&gt;&lt;span style="-sec-ix-hidden:hidden18209308"&gt;&lt;span style="-sec-ix-hidden:hidden18209309"&gt;th&lt;/span&gt;r&lt;/span&gt;e&lt;/span&gt;e&lt;/span&gt; t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o &lt;/div&gt;seven years for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and finance leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;Business Acquisitions&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to five years ending after the acquisition dates. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures this contingent consideration at fair value at the acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;date and records such contingent consideration as a liability or equity on the Company&#x2019;s Consolidated Balance Sheets on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company&#x2019;s Consolidated Statements of Income.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Other Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records acquired assets and assumed liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of &lt;span style="-sec-ix-hidden:hidden18209310"&gt;one&lt;/span&gt; to 20 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For 2020, the Company elected to perform the qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it was more likely than not that the fair value of its single reporting unit exceeded its carrying value, including goodwill. For 2019 and 2018, the Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;bypassed &lt;/div&gt;the qualitative assessment and performed a quantitative test with any goodwill impairment measured as the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value. The Company used income and market-based valuation approaches to determine the fair value of its single continuing operations reporting unit. These approaches focused on discounted cash flows and revenue and EBITDA multiples based on the Company&#x2019;s market capitalization to derive the fair value of the reporting unit. Significant assumptions used in these valuations included the weighted average cost of capital discount factor, revenue growth rates and revenue and EBITDA multiples. For both the qualitative and quantitative approaches, the Company considered the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company completed annual impairment tests for its continuing operations in the third quarter of 2020, 2019 and 2018 and determined that goodwill was not impaired. See Note 8 &#x2013; Goodwill and Intangible Assets for more information. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December&#160;31, 2020 pursuant to current accounting standards.Common Stock Repurchases&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as retired as any repurchased shares become authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders&#x2019; equity.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional Liability Coverage &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles or self-insured retention, exclusions and other restrictions. The Company&#x2019;s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. If it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is provided against such deferred tax assets. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company&#x2019;s reporting date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company grants stock-based awards consisting primarily of restricted stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. The Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards on an annual basis and adjusts the estimates as necessary based on the number of awards that ultimately vest. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Income Per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level 2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level 1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;756,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,070,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value. If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company&#x2019;s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn08_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance became effective for the Company on January&#160;1, 2021. The Company does not believe adoption of this new guidance will have a material impact on its Consolidated Financial Statements or related disclosures. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting Estimates and Assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#x2019;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#x2019;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has one reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue from continuing operations by service line (in percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Neonatology and other pediatric subspecialties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maternal-fetal medicine&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pediatric cardiology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue from continuing operations by service line (in percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Neonatology and other pediatric subspecialties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maternal-fetal medicine&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pediatric cardiology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_NeonatologyAndOtherPediatricSubspecialtiesMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_MaternalFetalMedicineMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_PediatricCardiologyMembersrtProductOrServiceAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and GHC Programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from GHC Programs made up approximately 22% and 21% of net accounts receivable related to continuing operations at December&#160;31, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_GovernmentContractsConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents are defined as all highly liquid financial instruments with maturities of 90 days or less from the date of purchase. The Company&#x2019;s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits. Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See &#x201c;Fair Value Measurements&#x201d; below. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <md:CashAndCashEquivalentsMaturityDescription contextRef="P01_01_2020To12_31_2020">90</md:CashAndCashEquivalentsMaturityDescription>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments consist&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;primarily &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;corporate securities,&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;municipal debt securities, federal home loan securities and certificates of deposit. The Company classifies its investments as available for sale. Although there is no stated expectation that the investments will be sold within one year, the investments are available for use, if needed, and accordingly are classified as short-term. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive income or loss. &lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <md:ShortTermInvestmentMaturityPeriod contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">P1Y</md:ShortTermInvestmentMaturityPeriod>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally 30 years for buildings; &lt;span style="-sec-ix-hidden:hidden18209306"&gt;&lt;span style="-sec-ix-hidden:hidden18209307"&gt;&lt;span style="-sec-ix-hidden:hidden18209308"&gt;&lt;span style="-sec-ix-hidden:hidden18209309"&gt;th&lt;/span&gt;r&lt;/span&gt;e&lt;/span&gt;e&lt;/span&gt; t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o &lt;/div&gt;seven years for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and finance leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2020To12_31_2020">Business Acquisitions&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to five years ending after the acquisition dates. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures this contingent consideration at fair value at the acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;date and records such contingent consideration as a liability or equity on the Company&#x2019;s Consolidated Balance Sheets on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company&#x2019;s Consolidated Statements of Income.</us-gaap:BusinessCombinationsPolicy>
    <md:BusinessCombinationContingentConsiderationArrangementsTimePeriod contextRef="P01_01_2020To12_31_2020">P5Y</md:BusinessCombinationContingentConsiderationArrangementsTimePeriod>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Other Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records acquired assets and assumed liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of &lt;span style="-sec-ix-hidden:hidden18209310"&gt;one&lt;/span&gt; to 20 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For 2020, the Company elected to perform the qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it was more likely than not that the fair value of its single reporting unit exceeded its carrying value, including goodwill. For 2019 and 2018, the Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;bypassed &lt;/div&gt;the qualitative assessment and performed a quantitative test with any goodwill impairment measured as the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value. The Company used income and market-based valuation approaches to determine the fair value of its single continuing operations reporting unit. These approaches focused on discounted cash flows and revenue and EBITDA multiples based on the Company&#x2019;s market capitalization to derive the fair value of the reporting unit. Significant assumptions used in these valuations included the weighted average cost of capital discount factor, revenue growth rates and revenue and EBITDA multiples. For both the qualitative and quantitative approaches, the Company considered the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company completed annual impairment tests for its continuing operations in the third quarter of 2020, 2019 and 2018 and determined that goodwill was not impaired. See Note 8 &#x2013; Goodwill and Intangible Assets for more information. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December&#160;31, 2020 pursuant to current accounting standards.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <md:CommonStockShareRepurchasesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">Common Stock RepurchasesThe Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as retired as any repurchased shares become authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders&#x2019; equity.</md:CommonStockShareRepurchasesPolicyTextBlock>
    <md:ProfessionalLiabilityCoveragePolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional Liability Coverage &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles or self-insured retention, exclusions and other restrictions. The Company&#x2019;s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. &lt;/div&gt;&lt;/div&gt;</md:ProfessionalLiabilityCoveragePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. If it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is provided against such deferred tax assets. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company&#x2019;s reporting date. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company grants stock-based awards consisting primarily of restricted stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. The Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards on an annual basis and adjusts the estimates as necessary based on the number of awards that ultimately vest. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Income Per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level 2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Level 1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1010000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16775000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">104870000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">15841000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14264000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;756,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,070,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">756225000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">766875000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1070000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1025600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. Treasury securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. Treasury securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">71095000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">32962000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">18707000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">29066000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8017000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8013000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5991000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4469000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1060000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USTreasurySecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">104870000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecurities>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable and Net Revenue: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,106,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(864,463&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,315,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;434,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,481,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,567,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,529,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;181,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733,951&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,779,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,723,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&#x2019;s&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; payor mix, expressed as a percentage of net revenue, exclusive of administrative fees and other miscellaneous revenue, for the periods indicated: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay patients&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable consist primarily of amounts due from GHC Programs and third-party insurance payors for services provided by the Company&#x2019;s affiliated physicians. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue consists primarily of gross billed charges for services provided by the Company&#x2019;s affiliated physicians less an estimated allowance for contractual adjustments and uncollectibles to properly account for the anticipated differences between gross billed charge amounts and expected reimbursement amounts. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s contractual adjustments and uncollectibles as a percentage of gross patient service revenue vary slightly each year depending on several factors, including improved managed care contracting, changes in reimbursement from state Medicaid programs and other GHC Programs, shifts in the percentage of patient services being reimbursed under GHC Programs and annual price increases. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s annual price increases typically increase contractual adjustments as a percentage of gross patient service revenue. This increase is primarily due to Medicaid, Medicare and other GHC Programs that generally provide for reimbursements on a fee-schedule basis rather than on a gross charge basis. When the Company bills these programs, like other payors, on a gross-charge basis, it also increases its provision for contractual adjustments and uncollectibles by the amount of any price increase, resulting in a higher contractual adjustment percentage. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,106,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(864,463&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,315,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;434,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1106394000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1750264000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">864463000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1315998000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">241931000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">434266000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,481,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,567,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,529,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;181,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 55%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733,951&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,779,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,723,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1481331000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1567624000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1529561000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">218495000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">197340000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">181050000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">34125000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14795000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1733951000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1779759000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1723107000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&#x2019;s&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; payor mix, expressed as a percentage of net revenue, exclusive of administrative fees and other miscellaneous revenue, for the periods indicated: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay patients&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To12_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To12_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2018To12_31_2018_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To12_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.27</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To12_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2018To12_31_2018_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To12_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To12_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2018To12_31_2018_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To12_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To12_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2018To12_31_2018_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Building&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;203,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;236,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(160,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152,944&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; The Company recorded depreciation expense of $19.3 million, $18.7 million and $17.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Building&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;203,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;236,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(160,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152,944&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26934000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">26934000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:Land
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6683000</us-gaap:Land>
    <us-gaap:Land
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6683000</us-gaap:Land>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">203017000</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">192004000</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">236634000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">225621000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">160443000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">152944000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">76191000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">72677000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">19300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">18700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">17800000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business Combinations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, the Company completed the acquisition of one pediatric subspecialty practice for total consideration of $2.1 million, of which $1.9 million was paid in cash and $0.2 million was recorded as a contingent consideration liability. This acquisition expanded the Company&#x2019;s national network of physician practices. In connection with this acquisition, the Company recorded &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax &lt;/div&gt;deductible goodwill of $0.8 million and other intangible assets consisting primarily of physician and hospital agreements of $1.3 million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, the Company completed eight acquisitions, consisting of two neonatology physician practices, two maternal-fetal physician practices and four other pediatric subspecialty practices for total cash consideration of $47.0 million and accrued purchase consideration of $0.3 million. These acquisitions expanded the Company&#x2019;s national network of physician practices. In connection with these acquisitions, the Company recorded goodwill of $36.5 million, other intangible assets consisting primarily of physician and hospital agreements of $10.5 million and fixed assets of $0.2 million. The Company expects that all the goodwill recorded during the year ended December&#160;31, 2019 will be deductible for tax purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, the Company paid $1.8 million for contingent consideration in connection with prior period acquisitions. No contingent consideration was paid by the Company in 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <md:NumberOfPediatricSubspecialtyPracticesAcquired
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_Number">1</md:NumberOfPediatricSubspecialtyPracticesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="P01_01_2020To12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn12_31_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <md:NumberOfPhysicianGroupPracticesAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_Number">8</md:NumberOfPhysicianGroupPracticesAcquired>
    <md:NumberOfNeonatologyPracticesAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_Number">2</md:NumberOfNeonatologyPracticesAcquired>
    <md:NumberOfRadiologyPracticesAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_Number">2</md:NumberOfRadiologyPracticesAcquired>
    <md:NumberOfPediatricSubspecialtyPracticesAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_Number">4</md:NumberOfPediatricSubspecialtyPracticesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">47000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <md:AccruedPurchaseConsideration
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">300000</md:AccruedPurchaseConsideration>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="P01_01_2019To12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">36500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">10500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019_PhysicianGroupMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:PaymentsForPreviousAcquisition
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1800000</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:PaymentsForPreviousAcquisition
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Intangible Assets: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill was $1.48 billion at December&#160;31, 2020 and 2019. Goodwill is tested for impairment on at least an annual basis, in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. Consistent with prior years, the Company performed its annual impairment test in the third quarter of 2020 and determined that goodwill was &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;not impaired. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net, consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Physician and hospital agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(83,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;112,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Physician and hospital agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99,828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(73,506&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,322&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;O&lt;/div&gt;ther technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,417&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, the Company recorded intangible assets related to acquisitions totaling $1.3 million, consisting primarily of physician and hospital agreements. The weighted-average amortization period for these physician and hospital agreements is approximately seven years. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expense for intangible assets was $7.6 million, $7.3 million and $6.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expense for existing intangible assets for the next five years is expected to be as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,966&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-7"
      unitRef="Unit_USD">1480000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-7"
      unitRef="Unit_USD">1480000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net, consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Physician and hospital agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(83,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;112,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt; Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Physician and hospital agreements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99,828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(73,506&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,322&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;O&lt;/div&gt;ther technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,417&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">107246000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">83089000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">24157000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5197000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2712000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2485000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">112443000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">85801000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26642000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">99828000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">73506000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_PhysicianAndHospitalAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">26322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3682000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1417000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_OtherTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2265000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">103510000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74923000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">28587000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">7600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">7300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expense for existing intangible assets for the next five years is expected to be as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,966&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5245000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4264000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2883000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1966000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discontinued Operations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of the Radiology Services Medical Group &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;9, 2020, the Company entered into a securities purchase agreement with Radiology Partners, Inc.&#160;to divest the Company&#x2019;s radiology services medical group, and the transaction closed on December&#160;15, 2020. The purchase consideration was comprised of a cash payment of $885&#160;million paid at closing, subject to certain cash, minimum net working capital, indebtedness and other adjustments. The Company received approximately $865&#160;million at closing and used the proceeds of the transaction to redeem its $750&#160;million in outstanding principal amount of 5.25% senior notes due 2023 (the &#x201c;2023 Notes&#x201d;) on January&#160;7, 2021. The operating results of the radiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt;The initial classification of the radiology services medical group to assets held for sale during the third quarter of 2020 impacted the net book value of the assets and liabilities expected to be transferred upon sale. The initial determination of the estimated fair value of the radiology services medical group was determined using the purchase price in the purchase agreement along with estimated broker, accounting, legal and other selling &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses. The Company deemed the carrying amount of other assets within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;of&#160;$&lt;/div&gt;43.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which generated an additional $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million deferred tax asset that increased the fair value of the medical group. An incremental non-cash charge was then required to reduce the radiology services medical group&#x2019;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental non-cash charge of $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million for a total non-cash charge of $&lt;/div&gt;47.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million, reducing the goodwill balance of the radiology services medical group.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon completion of the divestiture, the Company recorded an additional loss on disposal of $36.4&#160;million based on estimated closing date net assets sold and final net proceeds. A closing working capital true up is expected to occur during the first quarter of 2021, and the Company will adjust the loss on sale as necessary at that time. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of income taxes, for the radiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $63.8 million and $72.8 million, respectively. Income from discontinued operations, net of income taxes, for the radiology services medical group for the year ended December&#160;31, 2018 was $37.4 million. Net revenue for the radiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $451.4 million, $489.4 million and $444.0 million, respectively. Operating loss for the radiology services medical group for the year ended December&#160;31, 2020 was $73.6 million, including a non-cash goodwill impairment charge of $47.0 million and a preliminary loss on sale of $36.4 million. Operating loss for the radiology services medical group for the year ended December&#160;31, 2019 was $75.3 million, including a non-cash goodwill impairment charge of $117.9 million. Operating income for the radiology services medical group for the year ended December&#160;31, 2018 was $48.4 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Divestiture of the Anesthesiology Services Medical GroupOn May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#x201c;NAPA&#x201d;) to divest the Company&#x2019;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0 million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250 million based upon the multiple of invested capital returned to NAPA&#x2019;s owners upon exit of the investment. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $110.0 million at March&#160;31, 2020. The operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. A single anesthesiology practice was not included in the divestiture of the anesthesiology services medical group and continues to operate as an affiliate of the Company. Its results of operations are not material. &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total loss on sale of the anesthesiology services medical group recorded during the year ended December&#160;31, 2020 was $663.7 million. Upon completion of a valuation for the contingent economic interest, which is expected to be completed in the first quarter of 2021, the Company will adjust the loss on sale as necessary. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $1.71 billion capital loss carryforward that will expire in 2025. Based on management&#x2019;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $430.0 million valuation allowance against this deferred tax asset as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of income taxes, for the anesthesiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $717.2 million and $1.12 billion, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;from discontinued operations, net of income taxes, for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $&lt;/div&gt;99.7&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million. Net revenue for the anesthesiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $&lt;/div&gt;379.4&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million, $&lt;/div&gt;1.25&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; billion and $&lt;/div&gt;1.29&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; billion, respectively. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2020 was $&lt;/div&gt;716.3&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million, including the loss on sale of $&lt;/div&gt;663.7&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2019 was $&lt;/div&gt;1.23&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; billion, including a non-cash goodwill impairment charge of $&lt;/div&gt;1.33&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; billion. Operating income for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $&lt;/div&gt;135.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; million.&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of MedData &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the Company divested its management services organization, referred to as MedData. Loss from discontinued operations, net of tax, for MedData was $347.6 million for the year ended December&#160;31, 2019, reflecting the loss on sale recorded during the year ended December&#160;31, 2019, as compared to income from discontinued operations, net of tax, of $10.0 million for 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8 million, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consideration. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <md:PurchaseConsiderationCashPayment
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">885000000</md:PurchaseConsiderationCashPayment>
    <md:NetProceedsForTheRadiologyServicesMedicalGroup
      contextRef="P12_15_2020To12_15_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">865000000</md:NetProceedsForTheRadiologyServicesMedicalGroup>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="P07_01_2020To07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">750000000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn07_01_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetImpairmentCharges
      contextRef="P07_01_2020To09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">43000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn09_30_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020_DeferredTaxAssetsIntangibleAssetsMemberMDDeferredTaxAssetsAxis_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">47000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">36400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">63800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">72800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">37400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">451400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">489400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2018To12_31_2018_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">444000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">73600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">47000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">36400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">75300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2019To12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">117900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">48400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000.0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:Accountsreceivableretained
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">110000000.0</md:Accountsreceivableretained>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">663700000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <md:Capitallosscarryforward
      contextRef="PAsOn12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis"
      decimals="-7"
      unitRef="Unit_USD">1710000000</md:Capitallosscarryforward>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">430000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">717200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-7"
      unitRef="Unit_USD">1120000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">99700000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">379400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-7"
      unitRef="Unit_USD">1250000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-7"
      unitRef="Unit_USD">1290000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">716300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">663700000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-7"
      unitRef="Unit_USD">1230000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <md:DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss
      contextRef="P01_01_2019To12_31_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-7"
      unitRef="Unit_USD">1330000000</md:DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_AnesthesiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">135000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">347600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Payable and Accrued Expenses: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;incentive compensation&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;184,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,721&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;423,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;incentive compensation&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;184,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,721&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;423,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59771000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">35410000</us-gaap:AccountsPayableCurrent>
    <md:AccruedSalariesAndIncentiveCompensationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">184849000</md:AccruedSalariesAndIncentiveCompensationCurrent>
    <md:AccruedSalariesAndIncentiveCompensationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">193631000</md:AccruedSalariesAndIncentiveCompensationCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43945000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54768000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50607000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44699000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32721000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">32910000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">51264000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">49219000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">423157000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">410637000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating Leases: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company adopted the new accounting guidance for leases on January&#160;1, 2019 using the modified retrospective method of applying the new guidance at the adoption date. Beginning with January&#160;1, 2019, the Company&#x2019;s financial position is presented under the new guidance, while the prior period financial statements were not adjusted and continue to be reported in accordance with the previous guidance. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company primarily leases property under operating leases and has one material equipment operating lease for an aircraft. The Company&#x2019;s property leases are primarily for its regional, medical and business offices, storage space and temporary housing for medical staff. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of the lease payment using a discount rate that reflects the Company&#x2019;s estimated incremental borrowing rate. Certain of the Company&#x2019;s leases include rental escalation clauses and renewal options that are factored into the determination of lease payments when appropriate. Operating leases for office equipment are not material, and therefore are excluded from the Company&#x2019;s &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated Balance Sheet. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;table below presents the operating lease-related right-of-use assets and related liabilities recorded on the Company&#x2019;s balance sheet and the weighted average remaining lease term and discount rate as of December&#160;31, 2020 and 2019 (dollars in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease right-of-use assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Information:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average remaining lease term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.2&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below presents certain information related to the lease costs for operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,972&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other equipment rent&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,051&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below presents supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows for operating leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the balance sheet as of December&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Amount of payments representing interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of future minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Current obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion of operating leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;table below presents the operating lease-related right-of-use assets and related liabilities recorded on the Company&#x2019;s balance sheet and the weighted average remaining lease term and discount rate as of December&#160;31, 2020 and 2019 (dollars in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease right-of-use assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Information:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average remaining lease term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.2&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">44926000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56413000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18933000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18254000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">40970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2019">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below presents certain information related to the lease costs for operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,972&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other equipment rent&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,051&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20972000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23085000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4519000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3102000</us-gaap:VariableLeaseCost>
    <md:OtherEquipmentRent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4128000</md:OtherEquipmentRent>
    <md:OtherEquipmentRent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3931000</md:OtherEquipmentRent>
    <md:OperatingLeasesOtherCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">684000</md:OperatingLeasesOtherCosts>
    <md:OperatingLeasesOtherCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">933000</md:OperatingLeasesOtherCosts>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">30303000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">31051000</us-gaap:LeaseCost>
    <md:OperatingLeasesCashFlowRelatedInformationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below presents supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows for operating leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:OperatingLeasesCashFlowRelatedInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27933000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">28722000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the balance sheet as of December&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Amount of payments representing interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of future minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Current obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion of operating leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 17%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19681000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12397000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8125000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3877000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64727000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4824000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59903000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18933000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">40970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Professional Liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2020 and 2019, the Company&#x2019;s total accrued professional liabilities of $315.9 milli&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;n and $249.6 million, respectively, included incurred but not reported loss reserves of $222.9&#160;million and $187.6&#160;million, respectively, and loss reserves for reported claims of $93.0&#160;million and $84.2&#160;million, respectively. Of the total liability, $50.6 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $61.4 million recorded as a component of other assets for certain professional liability claims that are covered by third-party insurance policies. These reserves include the accrued professional liabilities for the Company&#x2019;s continuing operations as&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;reflected in the table below as &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;well as certain retained professional liabilities related to the Company&#x2019;s former anesthesiology and radiology medical groups that were divested in 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to the Company&#x2019;s accrued professional liability for continuing operations, excluding the retained professional liabilities related to the Company&#x2019;s former anesthesiology and radiology medical groups, for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities recognized, offset by insurance &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;eceivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision (adjustment) for losses related to:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total provision for losses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Claim payments related to:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;174,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net increase&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; in the Company&#x2019;s total accrued professional liability for the years ended December&#160;31, 2020 and 2019 were primarily related to overall unfavorable trends in the Company&#x2019;s claims experience that impacted its provision for losses. &lt;/div&gt;&lt;/div&gt;</us-gaap:MalpracticeLossContingencyDisclosureTextBlock>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">315900000</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">249600000</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">222900000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">187600000</us-gaap:SelfInsuranceReserveCurrent>
    <md:AccruedProfessionalLiability
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">93000000.0</md:AccruedProfessionalLiability>
    <md:AccruedProfessionalLiability
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">84200000</md:AccruedProfessionalLiability>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">50600000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InsuranceSettlementsReceivable
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">61400000</us-gaap:InsuranceSettlementsReceivable>
    <md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to the Company&#x2019;s accrued professional liability for continuing operations, excluding the retained professional liabilities related to the Company&#x2019;s former anesthesiology and radiology medical groups, for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities recognized, offset by insurance &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;eceivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision (adjustment) for losses related to:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total provision for losses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Claim payments related to:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;174,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">151397000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">128799000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">138643000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3922000</md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition>
    <md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10354000</md:AccruedProfessionalLiabilitiesAssumedThroughAcquisition>
    <md:ProvisionAdjustmentForLossesRelatedToCurrentYear
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">45674000</md:ProvisionAdjustmentForLossesRelatedToCurrentYear>
    <md:ProvisionAdjustmentForLossesRelatedToCurrentYear
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">42733000</md:ProvisionAdjustmentForLossesRelatedToCurrentYear>
    <md:ProvisionAdjustmentForLossesRelatedToCurrentYear
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">37203000</md:ProvisionAdjustmentForLossesRelatedToCurrentYear>
    <md:ProvisionAdjustmentForLossesRelatedToPriorYear
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1551000</md:ProvisionAdjustmentForLossesRelatedToPriorYear>
    <md:ProvisionAdjustmentForLossesRelatedToPriorYear
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-7766000</md:ProvisionAdjustmentForLossesRelatedToPriorYear>
    <md:ProvisionAdjustmentForLossesRelatedToPriorYear
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-7087000</md:ProvisionAdjustmentForLossesRelatedToPriorYear>
    <md:MalpracticeLossContingencyProvisionForLosses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">44123000</md:MalpracticeLossContingencyProvisionForLosses>
    <md:MalpracticeLossContingencyProvisionForLosses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">34967000</md:MalpracticeLossContingencyProvisionForLosses>
    <md:MalpracticeLossContingencyProvisionForLosses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">30116000</md:MalpracticeLossContingencyProvisionForLosses>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">33000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24580000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22690000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">39910000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24639000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22723000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">39960000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">174803000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">151397000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">128799000</md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations>
    <us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line of Credit, Long-Term Debt and Finance Lease Obligations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;25, 2020, &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amended and restated &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2 million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; maintain minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v)&#160;temporarily restrict &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&#x2019;s&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Credit Agreement provides for a $1.2 billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5 million sub-facility for the issuance of letters of credit. The&lt;/div&gt;&lt;/div&gt;Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of the Company&#x2019;s subsidiaries and affiliated professional associations and corporations. At the Company&#x2019;s option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company&#x2019;s consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company&#x2019;s consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on the Company&#x2019;s consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that requires the Company to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability of the Company to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute a &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2015, the Company completed a private offering of $750.0 million aggregate principal amount of 2023 Notes. In November 2018, the Company completed a private offering of $500.0 million aggregate principal amount of 2027 Notes and in February 2019, the Company completed a private offering of $500.00 million aggregate principal amount of Additional 2027 Notes. At December&#160;31, 2019, the outstanding balance on the 2027 Notes was $1.0 billion. The Company&#x2019;s obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25%&#160;per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25%&#160;per annum, or $62.5 million, and is payable semi-annually in arrears on January 15 and July 15. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Company &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was able to&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; redeem all or a portion of the 2023 Notes, at the redemption prices of 101.313% in 2020 and 100% in 2021 and thereafter, plus accrued and unpaid interest to the redemption date. The 2023 Notes were redeemed &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in full &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on January&#160;7, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At any time prior to January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes at a redemption price equal to 100% of the principal amount of the notes being redeemed plus an applicable redemption premium and accrued and unpaid interest to the redemption date. In addition, at any time prior to January&#160;15, 2022, the Company may redeem up to 35% of the aggregate principal amount of the 2027 Notes at a redemption price of 106.250% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, using proceeds from one or more equity offerings. On or after January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes, at the redemption prices of 104.688% in 2022, 103.125% in 2023, 101.563% in 2024 and 100% in 2025 and thereafter, plus accrued and unpaid interest to the redemption date. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value of the Company&#x2019;s long-term debt was $1.7 billion at December&#160;31, 2020 and 2019 and consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unamortized&lt;br/&gt; Debt&lt;br/&gt; Issuance&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733,657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revolving line of credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,731,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unamortized&lt;br/&gt; Debt&lt;br/&gt; Issuance&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,730,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revolving line of credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,727,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents issuance costs related to long-term debt liabilities, other than revolving credit arrangements, as a direct deduction from the carrying value of that long-term debt. The Company has one outstanding letter of credit which reduced the amount available under the Credit Agreement by $0.1 million at December&#160;31, 2020. At December&#160;31, 2020, the Company had an available balance on its Credit Agreement of $899.9 million, after giving effect to the temporary reduction of the capacity of its Credit Agreement through September&#160;30, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying values of the Company&#x2019;s variable rate revolving line of credit approximates fair value due to the short-term nature of the interest rates.&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;The estimated fair value of the Company&#x2019;s 2023 Notes and 2027 Notes were estimated using trading prices as of December&#160;31, 2020 and 2019, respectively, as Level 2 inputs to estimate fair value and are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;756,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,070,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s finance lease obligations&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, related to equipment used in its newborn hearing screen program,&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock>
    <md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">139200000</md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis">4.50:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">5.00:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</md:SupplementaryLeverageRatioRequired>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_31_2020_UnsecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-8"
      unitRef="Unit_USD">1200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">37500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_FederalFundsEffectiveSwapRateMemberusgaapVariableRateAxis">Federal Funds Rate plus 1/2 of 1.00%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis">LIBOR for an interest period of one month plus 1.00%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_AlternateBaseRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MinimumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_ApplicableMarginRateMemberusgaapDebtInstrumentAxis_LondonInterbankOfferedRateLIBORMemberusgaapVariableRateAxis_MaximumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00750</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">750000000.0</us-gaap:DebtInstrumentFaceAmount>
    <md:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">2023</md:DebtInstrumentMaturityYear>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:DebtInstrumentFaceAmount>
    <md:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">2027</md:DebtInstrumentMaturityYear>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_28_2019_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-4"
      unitRef="Unit_USD">500000000.00</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-8"
      unitRef="Unit_USD">1000000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2015_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">39400000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="P01_01_2020To12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis">payable semi-annually in arrears on June 1 and December 1</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn11_30_2018_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">62500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="P01_01_2020To12_31_2020_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis">payable semi-annually in arrears on January 15 and July 15</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="5"
      unitRef="Unit_pure">1.01313</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">0.35</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMembersrtStatementScenarioAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="5"
      unitRef="Unit_pure">1.06250</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="5"
      unitRef="Unit_pure">1.04688</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFourMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="5"
      unitRef="Unit_pure">1.03125</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodFiveMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="5"
      unitRef="Unit_pure">1.01563</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_DebtInstrumentRedemptionPeriodSixAndThereafterMemberusgaapDebtInstrumentRedemptionPeriodAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2020To12_31_2020_ChangeInControlMemberusgaapOtherOwnershipInterestsByNameAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value of the Company&#x2019;s long-term debt was $1.7 billion at December&#160;31, 2020 and 2019 and consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unamortized&lt;br/&gt; Debt&lt;br/&gt; Issuance&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,733,657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revolving line of credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,731,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unamortized&lt;br/&gt; Debt&lt;br/&gt; Issuance&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,730,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revolving line of credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,727,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2019"
      decimals="-8"
      unitRef="Unit_USD">1700000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020"
      decimals="-8"
      unitRef="Unit_USD">1700000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">16343000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2020_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1733657000</md:LongTermDebtNet>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">2260000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">-2260000</md:LongTermDebtNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18603000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1731397000</md:LongTermDebtNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">19762000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2019_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1730238000</md:LongTermDebtNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">2664000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">2664000</md:LongTermDebtNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22426000</us-gaap:UnamortizedDebtIssuanceExpense>
    <md:LongTermDebtNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1727574000</md:LongTermDebtNet>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="PAsOn12_31_2020_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">899900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <md:SummaryOfEstimatedFairValueOfNotesTableTextBlock contextRef="P01_01_2020To12_31_2020">The estimated fair value of the Company&#x2019;s 2023 Notes and 2027 Notes were estimated using trading prices as of December&#160;31, 2020 and 2019, respectively, as Level 2 inputs to estimate fair value and are summarized as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;756,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,070,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:SummaryOfEstimatedFairValueOfNotesTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">756225000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">766875000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1070000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1025600000</us-gaap:NotesPayableFairValueDisclosure>
    <md:ScheduleOfFinanceLeaseObligationsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s finance lease obligations&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, related to equipment used in its newborn hearing screen program,&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:ScheduleOfFinanceLeaseObligationsTableTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11118000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2219000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8899000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the income tax provision (benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,719&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(45,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,573&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,728&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company files its tax return on a consolidated basis with its subsidiaries, and its affiliated professional contractors file tax returns on an individual basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effective tax rate for continuing operations was 234.0%, 28.2% and 26.9% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The increase in the effective tax rate for the year ended December&#160;31, 2020 as compared to the years ended December&#160;31, 2019 and 2018 was due to a significant reduction in pre-tax income as a result of the impacts from the transformational and restructuring related expenses and &lt;br/&gt; COVID-19. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The differences between the effective rate and the United States federal income tax statutory rate are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="display:inline;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income tax, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;24.34&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;4.41&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;60.44&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3.98&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.85&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;98.61&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.78&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in accrual estimates relating to uncertain tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;4.22&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(9.63&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.84&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;23.67&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.39&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1.42&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax law&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;233.99&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;28.19&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;26.91&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the Company&#x2019;s deferred tax assets and liabilities are classified as long-term. The significant components of deferred income tax assets and liabilities are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for uncollectible accounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;79,755&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;170,123&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserves and accruals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;64,445&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;54,685&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,517&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,493&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating loss and other carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;16,767&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6,691&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;447,854&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;17,082&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;15,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;15,389&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3,986&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;571&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets before valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;634,995&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;279,449&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(458,708&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(19,286&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;176,287&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;260,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(152,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(144,587&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting method changes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(16,352&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(71,532&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(14,057&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(13,405&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(183&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(463&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(183,561&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(229,987&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Net deferred tax (liabilities) assets&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(7,274&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;30,176&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s net deferred tax liabilities were $7.3 million as of December&#160;31, 2020, as compared to net deferred tax assets of $30.2 million at December&#160;31, 2019. The increase in net deferred tax liabilities of $37.5 million during the year ended December&#160;31, 2020 was primarily related to a decrease in deferred tax assets related to allowance for uncollectible accounts partially offset by decrease in deferred tax liabilities for accounting method changes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, income tax expense of $7.1 million, $3.8 million and $1.3 million, respectively, was recognized for excess tax deficiencies. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For&lt;/div&gt; the year ended December&#160;31, 2020, the Company estimates that it will generate a $1.7 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion capital loss, from the sale of its anesthesiology services medical group, which will expire in 2025. Total capital loss carryforwards as of December 31, 2020 was&lt;/div&gt;&#160;$1.8 billion. As of December&#160;31,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2020, management has determined that it is more likely than not that the tax benefits related to these carryforwards will not be realized and has recorded a full valuation allowance against the related deferred tax assets. Additionally, the Company has net operating loss carryforwards for federal and state&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;tax purposes totaling $35.4 million, $31.5 million and $27.8 million at December&#160;31, 2020, 2019 and 2018, respectively. With respect to the December&#160;31, 2020 balance, $22.3 million expires at various times from 2022 through 2040, and $13.1 million does not expire. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, 2019 and 2018, the Company&#x2019;s liability for uncertain tax positions, excluding accrued interest and penalties, was&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt; $6.2 million, $7.4 million and $11.2 million, respectively. As of December&#160;31, 2020, the Company had $6.2 million of uncertain tax positions that, if recognized, would favorably impact its effective tax rate.&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity related to the Company&#x2019;s liability for uncertain tax positions for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,409&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;10,972&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;369&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;385&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(1,041&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;2,900&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to divestitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(300&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to lapse of statutes of limitation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(5,845&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6,168&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,409&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, the Company decreased its liability for uncertain tax positions by $1.2 million, primarily related to a reduction in tax liability for prior year positions. During the year ended December&#160;31, 2019, the Company decreased its liability for uncertain tax positions by $3.8 million, primarily related to expiration of statutes of limitation, partially offset by additional taxes on current and prior year positions. In addition, the Company anticipates that its liability for uncertain tax positions will decrease by $1.1 million over the next 12 months. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company includes interest and penalties related to income tax liabilities in income tax expense. During the year ended December&#160;31, 2020, the Company included $0.5 million of interest and penalties in income tax expense. The impact to income tax expense related to penalties and interest was not material during the years &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended &lt;/div&gt;December&#160;31,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2019 and 2018. At December&#160;31, 2020 and 2019, the Company&#x2019;s accrued liability for interest and penalties related to income tax liabilities totaled $1.0 million and $0.6 million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is currently subject to U.S. Federal and various state income tax examinations for the tax years 2015 through 2019. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the income tax provision (benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,719&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(45,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,573&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,728&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16610000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">63697000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">65403000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28719000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-45660000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-29667000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12109000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18037000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">35736000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2954000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">8561000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15185000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7573000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-10022000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-6227000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4619000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1461000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">8958000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16728000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">44694000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">2.340</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.282</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.269</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2020To12_31_2020">The differences between the effective rate and the United States federal income tax statutory rate are as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;21.00&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income tax, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;24.34&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;4.41&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;60.44&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3.98&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.85&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;98.61&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.78&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in accrual estimates relating to uncertain tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;4.22&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(9.63&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.84&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;23.67&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;0.39&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.45&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1.42&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax law&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(0.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;233.99&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;28.19&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;26.91&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.2434</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0645</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.0441</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.6044</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0398</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.0085</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.9861</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0645</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.0078</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0422</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0963</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">-0.0084</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.2367</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0039</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0171</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0045</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.0142</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">-0.0071</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">2.3399</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.2819</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.2691</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="display:inline;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the Company&#x2019;s deferred tax assets and liabilities are classified as long-term. The significant components of deferred income tax assets and liabilities are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for uncollectible accounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;79,755&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;170,123&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserves and accruals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;64,445&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;54,685&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,517&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,493&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating loss and other carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;16,767&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6,691&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;447,854&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;17,082&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;15,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;15,389&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;3,986&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;571&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets before valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;634,995&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;279,449&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(458,708&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(19,286&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;176,287&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;260,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(152,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(144,587&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting method changes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(16,352&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(71,532&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(14,057&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(13,405&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(183&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(463&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(183,561&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(229,987&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Net deferred tax (liabilities) assets&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(7,274&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;30,176&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">79755000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">170123000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64445000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54685000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7517000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11493000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16767000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6691000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">447854000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17082000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <md:DeferredTaxAssetsOperatingLeaseAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15042000</md:DeferredTaxAssetsOperatingLeaseAssets>
    <md:DeferredTaxAssetsOperatingLeaseAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15389000</md:DeferredTaxAssetsOperatingLeaseAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3044000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3986000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">571000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">634995000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">279449000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">458708000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">19286000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">176287000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">260163000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">152969000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">144587000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <md:DeferredTaxLiabilitiesChangeInAccountingMethod
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16352000</md:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <md:DeferredTaxLiabilitiesChangeInAccountingMethod
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">71532000</md:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14057000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13405000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">183000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">463000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">183561000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">229987000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7274000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">30176000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">7300000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">30200000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">37500000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <md:IncomeTaxExpenseForExcessTaxDeficiencies
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">7100000</md:IncomeTaxExpenseForExcessTaxDeficiencies>
    <md:IncomeTaxExpenseForExcessTaxDeficiencies
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3800000</md:IncomeTaxExpenseForExcessTaxDeficiencies>
    <md:IncomeTaxExpenseForExcessTaxDeficiencies
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">1300000</md:IncomeTaxExpenseForExcessTaxDeficiencies>
    <md:CapitalLossesIncurred
      contextRef="P01_01_2020To12_31_2020"
      decimals="-8"
      unitRef="Unit_USD">1700000000</md:CapitalLossesIncurred>
    <md:CapitalLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-8"
      unitRef="Unit_USD">1800000000</md:CapitalLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">35400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">31500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">27800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">22300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <md:NetOperatingLossCarryForwardsExpirationDate contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">2022</md:NetOperatingLossCarryForwardsExpirationDate>
    <md:NetOperatingLossCarryForwardsExpirationDate contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">2040</md:NetOperatingLossCarryForwardsExpirationDate>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">13100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">6200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">7400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">11200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">6200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="display:inline;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity related to the Company&#x2019;s liability for uncertain tax positions for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,409&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;10,972&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;369&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;385&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(1,041&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;2,900&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to divestitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(300&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decreases related to lapse of statutes of limitation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(5,845&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;(3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;6,168&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;7,409&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;11,185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7409000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">11185000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">10972000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">385000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1041000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <md:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-300000</md:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5845000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3072000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6168000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7409000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">11185000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1200000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3800000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear contextRef="P01_01_2020To12_31_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P01_01_2019To12_31_2019_LatestTaxYearMemberusgaapTaxPeriodAxis">2019</us-gaap:OpenTaxYear>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common and Common Equivalent Shares: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="display:inline;"&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per share calculation for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,495&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;91,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;516&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;502&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equivalent shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;84,011&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;91,606&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net income per common share calculation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;516&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;214&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the year ended December&#160;31, 2020, no incremental shares are included because the effect would be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per share calculation for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,495&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;91,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;516&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;502&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equivalent shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;83,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;84,011&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;91,606&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net income per common share calculation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;1,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;516&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;214&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the year ended December&#160;31, 2020, no incremental shares are included because the effect would be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">83395000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">83495000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">91104000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">516000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">502000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">83395000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">84011000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">91606000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">1034000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">516000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">214000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 12pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive Plans and Stock Purchase Plans: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;A&amp;amp;R 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the A&amp;amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards and stock options ratably over the corresponding vesting periods. At December&#160;31, 2020, the Company had 5.0&#160;million shares available for future grants and awards under its Amended and Restated 2008 Incentive Plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Company&#x2019;s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company&#x2019;s common stock at 85% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. Under the Company&#x2019;s 2015 &lt;br/&gt; Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at 90% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#x2019;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the year ended December&#160;31, 2020, 0.5&#160;million shares in the aggregate were issued under the ESPP and SPP. At December&#160;31, 2020, the Company had approximately 0.5&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized $21.1 million, $33.4 million and $36.4&#160;million of stock-based compensation expense related to its stock incentive plans, the ESPP and the SPP during the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to the Company&#x2019;s restricted stock and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December&#160;31, 2020 are as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested shares at January 1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,723,115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;40.77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awarded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,361,712&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;23.54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;(173,455&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;31.68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;(1,700,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;34.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested shares at December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,211,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;30.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate fair value of the restricted and deferred stock that vested during the years ended December&#160;31, 2020, 2019 and 2018 was &lt;br/&gt; $59.3 million, $31.5 million and $27.4 million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant-date fair value of restricted and deferred stock awards that were granted during the years ended December&#160;31, 2020, 2019 and 2018 was $23.54, $33.28 and $51.99, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2020, the total stock-based compensation cost related to non-vested restricted and deferred stock remaining to be recognized as compensation expense over a weighted-average period of 1.8 years was $11.6 million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company granted various performance-based stock options during the year ended December&#160;31, 2020 with vesting dependent on both continued employment and the achievement of various stock price hurdles over a &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;period of three years. The Company used a Monte Carlo simulation analysis to estimate the fair value of each stock option on the date of grant during 2020. The Monte Carlo simulation uses a series of functions that define a range of possibilities, or probability density functions and repeatedly samples from the ranges of those possibilities. Finally, the model calculates and sums the weighted average results of all the iterations. The weighted average grant date fair value for the stock options granted in 2020 was $5.21. The key assumptions used in the Monte Carlo simulation analysis were expected volatility of 50%, expected term of three years&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;and a&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; discount rate using the three year&#160;U.S. Treasury bond rate. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity and certain other information related to the Company&#x2019;s outstanding stock option awards for the year ended December&#160;31, 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January&#160;1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,808&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awarded&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;982,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;999,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2019 and 2018 were $0.6 million and $2.8 million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2020, the total stock-based compensation related to non-vested stock options remaining to be recognized as compensation expense over a weighted average period of approximately 2.6 years was $4.3 million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cash proceeds received from the exercise of stock options for the years ended December&#160;31, 2019 and 2018 were $0.1 million and $3.7 million, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">5000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To12_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">2600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2020To12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">21100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">33400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">36400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to the Company&#x2019;s restricted stock and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December&#160;31, 2020 are as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested shares at January 1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,723,115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;40.77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awarded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,361,712&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;23.54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;(173,455&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;31.68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;(1,700,255&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;34.88&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested shares at December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;1,211,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;30.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">1723115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">40.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1361712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">23.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">173455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">31.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1700255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">34.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1211117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">59300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">31500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">27400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">23.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">33.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">51.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2020To12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2020_RestrictedAndDeferredStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity and certain other information related to the Company&#x2019;s outstanding stock option awards for the year ended December&#160;31, 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td style="white-space: nowrap;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January&#160;1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,808&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awarded&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;982,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;999,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">72808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">32.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">982731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">56248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">31.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">999291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">7400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">16560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">36.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2020To12_31_2020">P0Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
    <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
    <md:CommonStockRepurchasesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock Repurchase Programs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. No shares were purchased under this program during the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0 million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $107.2 million remained available for repurchase as of January&#160;1, 2020. Under this share repurchase program, during the twelve months ended December&#160;31, 2020, &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; repurchased 0.5&#160;million shares of &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;its&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; common stock for $8.5 million to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, the Company repurchased approximately 5.1&#160;million shares of its common stock for $145.3 million, inclusive of 96,918 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock during the year ended December&#160;31, 2019.&lt;/div&gt;&lt;/div&gt; The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn08_31_2018"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="PAsOn12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">107200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapCollateralAxis"
      decimals="-5"
      unitRef="Unit_shares">500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">8500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapCollateralAxis"
      decimals="-5"
      unitRef="Unit_shares">5100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">145300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">96918</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Retirement Plans: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains three qualified contributory savings plans as allowed under Section&#160;401(k) of the Internal Revenue Code and Section&#160;1165(e) of the Puerto Rico Income Tax Act of 1954 (the &#x201c;401(k) Plans&#x201d;). The 401(k) Plans permit participant contributions and allow elective and, in certain situations, non-elective Company contributions based on each participant&#x2019;s contribution or a specified percentage of eligible wages. Participants may defer a percentage of their annual compensation subject to the limits defined in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;401(k) Plans. The Company&#160;&lt;/div&gt; recorded expense for its continuing operations of $19.9 million, $20.4 million and $24.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, primarily related to the 401(k) Plans. &lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">19900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">20400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">24900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of December&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#x2019;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#x2019;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Selected Quarterly Financial Information (Unaudited): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables set forth a summary of the Company&#x2019;s selected quarterly financial information for each of the four quarters ended December&#160;31, 2020 and 2019 (in thousands, except for per share data): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020 Quarters&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;First&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Second&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Third&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fourth&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;441,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;415,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;460,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;416,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice salaries and benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;316,279&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;282,985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;309,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;284,772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice supplies and other operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;23,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;22,440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;24,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;67,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;60,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;66,346&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;54,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,692&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transformational and restructuring related expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;16,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;34,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;430,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;380,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;440,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;384,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income from operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;34,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;32,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment and other (expense) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;3,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in earnings of unconsolidated affiliates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.78in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total non-operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(24,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(16,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(21,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;(Loss) income from continuing operations before&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(17,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(3,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(6,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(5,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(Loss) income from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(18,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2,652&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(679,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(38,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(68,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(18,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(672,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(41,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(64,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Per common and common equivalent share data (1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income from continuing operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common shares:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;84,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;85,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019 Quarters&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;First&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Second&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Third&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fourth&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;427,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;439,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;454,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;458,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice salaries and benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;294,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;284,627&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;301,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;300,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice supplies and other operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;24,705&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;25,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;22,581&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;23,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;59,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;63,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;63,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;59,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transformational and restructuring related expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;2,439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;16,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;28,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;387,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;396,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;406,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;418,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income from operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;39,989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;43,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;48,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;40,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment and other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;1,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;726&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(30,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(31,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(29,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in earnings of unconsolidated affiliates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;503&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total non-operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(29,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(26,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;11,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;13,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;13,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (provision)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;1,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(6,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(7,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(3,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(255,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(14,772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,268,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(242,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,255,916&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;9,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Per common and common equivalent share data (1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common shares:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;86,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;86,545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables set forth a summary of the Company&#x2019;s selected quarterly financial information for each of the four quarters ended December&#160;31, 2020 and 2019 (in thousands, except for per share data): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020 Quarters&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;First&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Second&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Third&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fourth&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;441,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;415,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;460,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;416,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice salaries and benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;316,279&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;282,985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;309,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;284,772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice supplies and other operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;23,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;22,440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;24,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;67,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;60,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;66,346&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;54,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,692&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transformational and restructuring related expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;16,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;34,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;430,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;380,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;440,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;384,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income from operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;34,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;32,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment and other (expense) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;3,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in earnings of unconsolidated affiliates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.78in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total non-operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(24,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(16,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(21,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;(Loss) income from continuing operations before&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(17,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;10,356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(3,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(6,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(5,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(Loss) income from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(18,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2,652&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;4,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(679,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(38,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(68,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(18,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(672,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(41,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(64,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Per common and common equivalent share data (1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income from continuing operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common shares:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;84,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;85,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="vertical-align: bottom; width: 2%;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%; white-space: nowrap;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019 Quarters&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;First&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Second&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Third&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fourth&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;427,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;439,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;454,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;458,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice salaries and benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;294,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;284,627&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;301,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;300,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Practice supplies and other operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;24,705&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;25,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;22,581&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;23,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;59,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;63,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;63,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;59,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;7,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transformational and restructuring related expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;2,439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;16,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;28,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;387,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;396,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;406,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;418,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income from operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;39,989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;43,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;48,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;40,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment and other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;1,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;726&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(30,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(31,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(29,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(27,657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in earnings of unconsolidated affiliates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;503&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total non-operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(29,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(28,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(26,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;11,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;13,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;20,247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;13,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (provision)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;1,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(6,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(7,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(3,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;6,527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;12,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(255,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(14,772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,268,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(242,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(8,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(1,255,916&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;9,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Per common and common equivalent share data (1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(2.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(15.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common shares:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;86,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;86,545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;82,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;83,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top; width: 96%;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">441245000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">415441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">460635000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">416630000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">316279000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">282985000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">309904000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">284772000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23842000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20173000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">22440000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24235000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">67442000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">60488000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">66346000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">54671000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6803000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">6751000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7692000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16076000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10479000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">34291000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12955000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">430442000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">380876000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">440176000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">384325000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10803000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">34565000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32305000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1046000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3576000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10534000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4849000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27665000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">28265000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">27250000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27302000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">494000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">305000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">504000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-28217000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-24384000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-16434000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-21949000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-17414000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10181000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">4025000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10356000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1085000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">6677000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5869000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18499000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7084000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2652000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4487000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-213000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-679520000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-38392000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-68783000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-41044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-64296000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.81</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.11</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.81</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83490000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">84316000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83744000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P10_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">85082000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">427092000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">439154000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">454913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">458600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">294753000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">284627000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">301306000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">300073000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">24705000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">25402000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">22581000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23223000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">59023000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">63011000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">63284000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">59194000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6183000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6239000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6408000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7101000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2439000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">16820000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">12766000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">28865000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">387103000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">396099000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">406345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">418456000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">39989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">43055000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">48568000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">40144000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1249000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">726000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">802000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">909000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">30349000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">31013000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">29909000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">27657000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">464000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">503000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">786000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">517000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-28636000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-29784000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-28321000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-26231000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11353000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">13271000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">20247000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13913000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1514000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6744000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">7360000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3986000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">12867000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6527000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">12887000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">9927000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-255739000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-14772000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1268803000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-596000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1255916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">9331000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.16</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.97</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.96</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.31</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">86073000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83234000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">82441000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">82592000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">86545000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83689000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">82883000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P10_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">83288000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_18209834"
          xlink:label="Fact_18209834"
          xlink:type="locator"/>
        <link:footnote id="FN_65625" xlink:label="FN_65625" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Presented within retained (deficit) earnings as the balance is immaterial.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18209834"
          xlink:to="FN_65625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_18209835"
          xlink:label="Fact_18209835"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18209835"
          xlink:to="FN_65625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_18210161"
          xlink:label="Fact_18210161"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18210161"
          xlink:to="FN_65625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_18210162"
          xlink:label="Fact_18210162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18210162"
          xlink:to="FN_65625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_18210163"
          xlink:label="Fact_18210163"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18210163"
          xlink:to="FN_65625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_18210164"
          xlink:label="Fact_18210164"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_18210164"
          xlink:to="FN_65625"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344435960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDNAX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,631,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,251,965,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344229896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,123,843<span></span>
</td>
<td class="nump">$ 107,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">104,870<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">241,931<span></span>
</td>
<td class="nump">434,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">16,898<span></span>
</td>
<td class="nump">17,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">61,806<span></span>
</td>
<td class="nump">11,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,549,348<span></span>
</td>
<td class="nump">731,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,641,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">76,191<span></span>
</td>
<td class="nump">72,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,477,968<span></span>
</td>
<td class="nump">1,479,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">26,642<span></span>
</td>
<td class="nump">28,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease right-of-use assets</a></td>
<td class="nump">55,972<span></span>
</td>
<td class="nump">56,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">54,472<span></span>
</td>
<td class="nump">86,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">107,355<span></span>
</td>
<td class="nump">48,643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,347,948<span></span>
</td>
<td class="nump">4,145,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">423,157<span></span>
</td>
<td class="nump">410,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">18,933<span></span>
</td>
<td class="nump">18,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">444,335<span></span>
</td>
<td class="nump">541,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">1,742,586<span></span>
</td>
<td class="nump">1,730,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">40,970<span></span>
</td>
<td class="nump">44,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">265,274<span></span>
</td>
<td class="nump">204,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">61,746<span></span>
</td>
<td class="nump">56,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">45,320<span></span>
</td>
<td class="nump">22,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,600,231<span></span>
</td>
<td class="nump">2,646,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 85,593 and 84,248 shares issued and outstanding, respectively</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,029,453<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained (deficit) earnings</a></td>
<td class="num">(286,354)<span></span>
</td>
<td class="nump">510,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total MEDNAX, Inc. shareholders' equity</a></td>
<td class="nump">747,485<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">747,717<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 3,347,948<span></span>
</td>
<td class="nump">$ 4,145,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586435477192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,593,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,593,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344706872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 416,630<span></span>
</td>
<td class="nump">$ 460,635<span></span>
</td>
<td class="nump">$ 415,441<span></span>
</td>
<td class="nump">$ 441,245<span></span>
</td>
<td class="nump">$ 458,600<span></span>
</td>
<td class="nump">$ 454,913<span></span>
</td>
<td class="nump">$ 439,154<span></span>
</td>
<td class="nump">$ 427,092<span></span>
</td>
<td class="nump">$ 1,733,951<span></span>
</td>
<td class="nump">$ 1,779,759<span></span>
</td>
<td class="nump">$ 1,723,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">284,772<span></span>
</td>
<td class="nump">309,904<span></span>
</td>
<td class="nump">282,985<span></span>
</td>
<td class="nump">316,279<span></span>
</td>
<td class="nump">300,073<span></span>
</td>
<td class="nump">301,306<span></span>
</td>
<td class="nump">284,627<span></span>
</td>
<td class="nump">294,753<span></span>
</td>
<td class="nump">1,193,940<span></span>
</td>
<td class="nump">1,180,759<span></span>
</td>
<td class="nump">1,125,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">24,235<span></span>
</td>
<td class="nump">22,440<span></span>
</td>
<td class="nump">20,173<span></span>
</td>
<td class="nump">23,842<span></span>
</td>
<td class="nump">23,223<span></span>
</td>
<td class="nump">22,581<span></span>
</td>
<td class="nump">25,402<span></span>
</td>
<td class="nump">24,705<span></span>
</td>
<td class="nump">90,690<span></span>
</td>
<td class="nump">95,911<span></span>
</td>
<td class="nump">92,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">54,671<span></span>
</td>
<td class="nump">66,346<span></span>
</td>
<td class="nump">60,488<span></span>
</td>
<td class="nump">67,442<span></span>
</td>
<td class="nump">59,194<span></span>
</td>
<td class="nump">63,284<span></span>
</td>
<td class="nump">63,011<span></span>
</td>
<td class="nump">59,023<span></span>
</td>
<td class="nump">248,947<span></span>
</td>
<td class="nump">244,512<span></span>
</td>
<td class="nump">232,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,692<span></span>
</td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">6,751<span></span>
</td>
<td class="nump">6,803<span></span>
</td>
<td class="nump">7,101<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">6,183<span></span>
</td>
<td class="nump">28,441<span></span>
</td>
<td class="nump">25,931<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">12,955<span></span>
</td>
<td class="nump">34,291<span></span>
</td>
<td class="nump">10,479<span></span>
</td>
<td class="nump">16,076<span></span>
</td>
<td class="nump">28,865<span></span>
</td>
<td class="nump">12,766<span></span>
</td>
<td class="nump">16,820<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">73,801<span></span>
</td>
<td class="nump">60,890<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">384,325<span></span>
</td>
<td class="nump">440,176<span></span>
</td>
<td class="nump">380,876<span></span>
</td>
<td class="nump">430,442<span></span>
</td>
<td class="nump">418,456<span></span>
</td>
<td class="nump">406,345<span></span>
</td>
<td class="nump">396,099<span></span>
</td>
<td class="nump">387,103<span></span>
</td>
<td class="nump">1,635,819<span></span>
</td>
<td class="nump">1,608,003<span></span>
</td>
<td class="nump">1,474,719<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">32,305<span></span>
</td>
<td class="nump">20,459<span></span>
</td>
<td class="nump">34,565<span></span>
</td>
<td class="nump">10,803<span></span>
</td>
<td class="nump">40,144<span></span>
</td>
<td class="nump">48,568<span></span>
</td>
<td class="nump">43,055<span></span>
</td>
<td class="nump">39,989<span></span>
</td>
<td class="nump">98,132<span></span>
</td>
<td class="nump">171,756<span></span>
</td>
<td class="nump">248,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income</a></td>
<td class="nump">4,849<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">17,913<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(27,302)<span></span>
</td>
<td class="num">(27,250)<span></span>
</td>
<td class="num">(28,265)<span></span>
</td>
<td class="num">(27,665)<span></span>
</td>
<td class="num">(27,657)<span></span>
</td>
<td class="num">(29,909)<span></span>
</td>
<td class="num">(31,013)<span></span>
</td>
<td class="num">(30,349)<span></span>
</td>
<td class="num">(110,482)<span></span>
</td>
<td class="num">(118,928)<span></span>
</td>
<td class="num">(92,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">7,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net non-operating expenses</a></td>
<td class="num">(21,949)<span></span>
</td>
<td class="num">(16,434)<span></span>
</td>
<td class="num">(24,384)<span></span>
</td>
<td class="num">(28,217)<span></span>
</td>
<td class="num">(26,231)<span></span>
</td>
<td class="num">(28,321)<span></span>
</td>
<td class="num">(29,784)<span></span>
</td>
<td class="num">(28,636)<span></span>
</td>
<td class="num">(90,984)<span></span>
</td>
<td class="num">(112,972)<span></span>
</td>
<td class="num">(82,180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">10,356<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">10,181<span></span>
</td>
<td class="num">(17,414)<span></span>
</td>
<td class="nump">13,913<span></span>
</td>
<td class="nump">20,247<span></span>
</td>
<td class="nump">13,271<span></span>
</td>
<td class="nump">11,353<span></span>
</td>
<td class="nump">7,148<span></span>
</td>
<td class="nump">58,784<span></span>
</td>
<td class="nump">166,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(5,869)<span></span>
</td>
<td class="num">(6,677)<span></span>
</td>
<td class="num">(3,097)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
<td class="num">(7,360)<span></span>
</td>
<td class="num">(6,744)<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="num">(16,728)<span></span>
</td>
<td class="num">(16,576)<span></span>
</td>
<td class="num">(44,694)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">(Loss) income from continuing operations</a></td>
<td class="nump">4,487<span></span>
</td>
<td class="num">(2,652)<span></span>
</td>
<td class="nump">7,084<span></span>
</td>
<td class="num">(18,499)<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">12,887<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">12,867<span></span>
</td>
<td class="num">(9,580)<span></span>
</td>
<td class="nump">42,208<span></span>
</td>
<td class="nump">121,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">(Loss) income from discontinued operations, net of tax</a></td>
<td class="num">(68,783)<span></span>
</td>
<td class="num">(38,392)<span></span>
</td>
<td class="num">(679,520)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="num">(1,268,803)<span></span>
</td>
<td class="num">(14,772)<span></span>
</td>
<td class="num">(255,739)<span></span>
</td>
<td class="num">(786,908)<span></span>
</td>
<td class="num">(1,539,910)<span></span>
</td>
<td class="nump">147,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (64,296)<span></span>
</td>
<td class="num">$ (41,044)<span></span>
</td>
<td class="num">$ (672,436)<span></span>
</td>
<td class="num">$ (18,712)<span></span>
</td>
<td class="nump">$ 9,331<span></span>
</td>
<td class="num">$ (1,255,916)<span></span>
</td>
<td class="num">$ (8,245)<span></span>
</td>
<td class="num">$ (242,872)<span></span>
</td>
<td class="num">$ (796,488)<span></span>
</td>
<td class="num">$ (1,497,702)<span></span>
</td>
<td class="nump">$ 268,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract', window );"><strong>(Loss) income from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">1.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>(Loss) income from discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic</a></td>
<td class="num">(0.81)<span></span>
</td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(8.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(15.39)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="num">(2.97)<span></span>
</td>
<td class="num">(9.44)<span></span>
</td>
<td class="num">(18.44)<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted</a></td>
<td class="num">(0.81)<span></span>
</td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(8.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(15.31)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="num">(2.96)<span></span>
</td>
<td class="num">(9.44)<span></span>
</td>
<td class="num">(18.33)<span></span>
</td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">(0.76)<span></span>
</td>
<td class="num">(0.49)<span></span>
</td>
<td class="num">(8.06)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="num">(15.23)<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(2.82)<span></span>
</td>
<td class="num">(9.55)<span></span>
</td>
<td class="num">(17.94)<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (8.03)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (15.15)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (9.55)<span></span>
</td>
<td class="num">$ (17.83)<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">84,316<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,490<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">82,592<span></span>
</td>
<td class="nump">82,441<span></span>
</td>
<td class="nump">83,234<span></span>
</td>
<td class="nump">86,073<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">83,495<span></span>
</td>
<td class="nump">91,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">85,082<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,744<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">83,288<span></span>
</td>
<td class="nump">82,883<span></span>
</td>
<td class="nump">83,689<span></span>
</td>
<td class="nump">86,545<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">84,011<span></span>
</td>
<td class="nump">91,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents Income (Loss) from continuing operations, per basic and diluted share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586334761800">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,066,454<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 1,017,328<span></span>
</td>
<td class="nump">$ 2,048,189<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">268,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">18,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodValueStockSwaps', window );">Stock swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,661)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(302,160)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">(79,631)<span></span>
</td>
<td class="num">(222,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">992,647<span></span>
</td>
<td class="nump">2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,497,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,497,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,947<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodValueStockSwaps', window );">Stock swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(145,280)<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
<td class="num">(58,706)<span></span>
</td>
<td class="num">(86,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(796,488)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(796,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contribution from noncontrolling Interests, net of loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,009<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,493)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(8,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 747,717<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 1,029,453<span></span>
</td>
<td class="num">$ (282,592)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Presented within retained (deficit) earnings as the balance is immaterial.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodValueStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodValueStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339497496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (796,488)<span></span>
</td>
<td class="num">$ (1,497,702)<span></span>
</td>
<td class="nump">$ 268,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss (income) from discontinued operations</a></td>
<td class="nump">786,908<span></span>
</td>
<td class="nump">1,539,910<span></span>
</td>
<td class="num">(147,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28,441<span></span>
</td>
<td class="nump">25,931<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">7,163<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">39,042<span></span>
</td>
<td class="nump">33,410<span></span>
</td>
<td class="nump">36,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">36,292<span></span>
</td>
<td class="num">(55,715)<span></span>
</td>
<td class="num">(35,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">6,553<span></span>
</td>
<td class="num">(1,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">37,937<span></span>
</td>
<td class="nump">6,512<span></span>
</td>
<td class="num">(35,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(47,956)<span></span>
</td>
<td class="num">(24,621)<span></span>
</td>
<td class="nump">15,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">13,916<span></span>
</td>
<td class="nump">32,121<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">47,908<span></span>
</td>
<td class="nump">46,196<span></span>
</td>
<td class="num">(3,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(6,931)<span></span>
</td>
<td class="num">(24,120)<span></span>
</td>
<td class="num">(61,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">4,336<span></span>
</td>
<td class="nump">5,413<span></span>
</td>
<td class="num">(6,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">3,518<span></span>
</td>
<td class="num">(25,469)<span></span>
</td>
<td class="nump">3,615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities &#8211; continuing operations</a></td>
<td class="nump">153,888<span></span>
</td>
<td class="nump">74,091<span></span>
</td>
<td class="nump">59,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities &#8211; discontinued operations</a></td>
<td class="nump">50,732<span></span>
</td>
<td class="nump">283,620<span></span>
</td>
<td class="nump">254,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">204,620<span></span>
</td>
<td class="nump">357,711<span></span>
</td>
<td class="nump">313,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(2,225)<span></span>
</td>
<td class="num">(46,975)<span></span>
</td>
<td class="num">(65,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(61,845)<span></span>
</td>
<td class="num">(35,101)<span></span>
</td>
<td class="num">(15,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">33,432<span></span>
</td>
<td class="nump">51,105<span></span>
</td>
<td class="nump">13,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(28,788)<span></span>
</td>
<td class="num">(19,269)<span></span>
</td>
<td class="num">(17,120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sales of businesses, net of cash sold</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities &#8211; continuing operations</a></td>
<td class="num">(58,346)<span></span>
</td>
<td class="num">(50,240)<span></span>
</td>
<td class="num">(84,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) investing activities &#8211; discontinued operations</a></td>
<td class="nump">873,857<span></span>
</td>
<td class="nump">152,695<span></span>
</td>
<td class="num">(58,105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">815,511<span></span>
</td>
<td class="nump">102,455<span></span>
</td>
<td class="num">(142,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on credit agreement</a></td>
<td class="nump">527,500<span></span>
</td>
<td class="nump">1,247,300<span></span>
</td>
<td class="nump">1,723,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on credit agreement</a></td>
<td class="num">(527,500)<span></span>
</td>
<td class="num">(1,986,800)<span></span>
</td>
<td class="num">(2,094,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for credit facility amendment and financing costs</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
<td class="num">(7,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,394)<span></span>
</td>
<td class="num">(5,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on finance lease obligations</a></td>
<td class="num">(1,161)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">7,009<span></span>
</td>
<td class="nump">11,258<span></span>
</td>
<td class="nump">16,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contribution from noncontrolling interests</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(8,493)<span></span>
</td>
<td class="num">(145,280)<span></span>
</td>
<td class="num">(302,160)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash used in financing activities &#8211; continuing operations</a></td>
<td class="num">(2,910)<span></span>
</td>
<td class="num">(384,110)<span></span>
</td>
<td class="num">(169,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities &#8211; discontinued operations</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(8,960)<span></span>
</td>
<td class="num">(1,355)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,158)<span></span>
</td>
<td class="num">(393,070)<span></span>
</td>
<td class="num">(170,610)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,015,973<span></span>
</td>
<td class="nump">67,096<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents at beginning of year</a></td>
<td class="nump">107,870<span></span>
</td>
<td class="nump">40,774<span></span>
</td>
<td class="nump">40,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">1,123,843<span></span>
</td>
<td class="nump">107,870<span></span>
</td>
<td class="nump">40,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">110,488<span></span>
</td>
<td class="nump">95,444<span></span>
</td>
<td class="nump">82,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="num">(27,775)<span></span>
</td>
<td class="nump">86,268<span></span>
</td>
<td class="nump">185,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Equipment financed through finance leases</a></td>
<td class="nump">12,507<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">$ 2,305<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344640440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General: </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; line-height: 0pt;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The principal business activity of Mednax, Inc. (&#8220;Mednax&#8221; or the &#8220;Company&#8221;) and its subsidiaries is to provide neonatal, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;fee-for-service</div></div> contracts, whereby hospitals and other customers agree, in exchange for the Company&#8217;s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company&#8217;s affiliated healthcare professionals, and (ii)&#160;administrative fee contracts, whereby the Company is assured a minimum </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">revenue level. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339277400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock', window );">Coronavirus Pandemic ("COVID-19")</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. See Note 9 &#8211; Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology and radiology services medical groups. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s affiliated women&#8217;s and children&#8217;s office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. The Company believes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> either directly or indirectly, has also had an impact on its neonatology intensive care unit (&#8220;NICU&#8221;) patient volumes, and there is no assurance that impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not further adversely affect its NICU patient volumes or otherwise adversely affect its NICU and related neonatology business. Overall, the Company&#8217;s operating results were significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through December 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of COVID-19. These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to COVID-19. In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii)&#160;the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for non-clinical employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by COVID-19. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In response to the anticipated impact of COVID-19 on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2 million for the second and third quarters of 2020, reflecting average </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted </div></div>&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>EBITDA</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to <div style="letter-spacing: 0px; top: 0px;;display:inline;">4.50:1:00</div> for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At <div style="letter-spacing: 0px; top: 0px;;display:inline;">December</div>&#160;3<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">months. At December&#160;31, 2020,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.1 million which reduced the amount available on its Credit Agreement to $899.9 million at December&#160;31, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The remaining $70 billion in aid is intended to focus on providers in areas particularly impacted by COVID-19, rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices within continuing operations received an aggregate of approximately $22.0 million during the year ended December&#160;31, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company utilize<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> this deferral option throughout 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The COVID-19 pandemic has materially impacted the Company&#8217;s financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344529640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Significant Accounting Policies: </div></div></div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company&#8217;s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the </div></div></div>case of gross negligence, fraud or bankruptcy of the Company. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the Company&#8217;s affiliated professional contractors, in an amount that fluctuates based on the performance of the affiliated professional contractors and the change in the fair value of the Company&#8217;s interest in the affiliated professional contractors. The Company has exclusive responsibility for the provision of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-medical</div> services required for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operation and management of the Company&#8217;s affiliated professional contractors and establishes the guidelines for the employment and compensation of the physicians. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the Company&#8217;s affiliated professional contractors for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the agreements. Based upon the provisions of these agreements, the Company has determined that the affiliated professional contractors are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation. All significant intercompany and interaffiliate accounts and transactions have been eliminated. <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a 37.5% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company entered into a joint venture in which it owns a 51% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#8217;s Consolidated Balance Sheets. The results from operations attributable to the noncontrolling interests during the fourth quarter <div style="letter-spacing: 0px; top: 0px;;display:inline;">of 2020 </div>were nominal and therefore not presented separately on the Company&#8217;s Consolidated Statements of Income. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2019 and 2018. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, the Company divested its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the year ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 9 &#8211; Discontinued Operations for more information. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance became effective for the Company on January&#160;1, 2021. The Company does not believe adoption of this new guidance will have a material impact on its Consolidated Financial Statements or related disclosures. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting Estimates and Assumptions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#8217;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#8217;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue from continuing operations by service line (in percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neonatology and other pediatric subspecialties</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maternal-fetal medicine</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric cardiology</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and GHC Programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from GHC Programs made up approximately 22% and 21% of net accounts receivable related to continuing operations at December&#160;31, 2020 and 2019, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are defined as all highly liquid financial instruments with maturities of 90 days or less from the date of purchase. The Company&#8217;s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits. Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See &#8220;Fair Value Measurements&#8221; below. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments consist<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">primarily </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;corporate securities,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">municipal debt securities, federal home loan securities and certificates of deposit. The Company classifies its investments as available for sale. Although there is no stated expectation that the investments will be sold within one year, the investments are available for use, if needed, and accordingly are classified as short-term. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive income or loss. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally 30 years for buildings; <span style="-sec-ix-hidden:hidden18209306"><span style="-sec-ix-hidden:hidden18209307"><span style="-sec-ix-hidden:hidden18209308"><span style="-sec-ix-hidden:hidden18209309">th</span>r</span>e</span>e</span> t<div style="letter-spacing: 0px; top: 0px;;display:inline;">o </div>seven years for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and finance leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">earnings. </div></div></div>Business Acquisitions<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to five years ending after the acquisition dates. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures this contingent consideration at fair value at the acquisition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">date and records such contingent consideration as a liability or equity on the Company&#8217;s Consolidated Balance Sheets on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company&#8217;s Consolidated Statements of Income.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records acquired assets and assumed liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of <span style="-sec-ix-hidden:hidden18209310">one</span> to 20 years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For 2020, the Company elected to perform the qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it was more likely than not that the fair value of its single reporting unit exceeded its carrying value, including goodwill. For 2019 and 2018, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">bypassed </div>the qualitative assessment and performed a quantitative test with any goodwill impairment measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. The Company used income and market-based valuation approaches to determine the fair value of its single continuing operations reporting unit. These approaches focused on discounted cash flows and revenue and EBITDA multiples based on the Company&#8217;s market capitalization to derive the fair value of the reporting unit. Significant assumptions used in these valuations included the weighted average cost of capital discount factor, revenue growth rates and revenue and EBITDA multiples. For both the qualitative and quantitative approaches, the Company considered the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company completed annual impairment tests for its continuing operations in the third quarter of 2020, 2019 and 2018 and determined that goodwill was not impaired. See Note 8 &#8211; Goodwill and Intangible Assets for more information. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. </div></div></div>The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December&#160;31, 2020 pursuant to current accounting standards.Common Stock Repurchases<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as retired as any repurchased shares become authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders&#8217; equity.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional Liability Coverage </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles or self-insured retention, exclusions and other restrictions. The Company&#8217;s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. If it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is provided against such deferred tax assets. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company&#8217;s reporting date. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock-based awards consisting primarily of restricted stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. The Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards on an annual basis and adjusts the estimates as necessary based on the number of awards that ultimately vest. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income Per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">756,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,070,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338883128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Treasury securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338928936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,106,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(864,463</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,315,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">434,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,481,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,567,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,529,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733,951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,779,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723,107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> payor mix, expressed as a percentage of net revenue, exclusive of administrative fees and other miscellaneous revenue, for the periods indicated: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay patients</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable consist primarily of amounts due from GHC Programs and third-party insurance payors for services provided by the Company&#8217;s affiliated physicians. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue consists primarily of gross billed charges for services provided by the Company&#8217;s affiliated physicians less an estimated allowance for contractual adjustments and uncollectibles to properly account for the anticipated differences between gross billed charge amounts and expected reimbursement amounts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s contractual adjustments and uncollectibles as a percentage of gross patient service revenue vary slightly each year depending on several factors, including improved managed care contracting, changes in reimbursement from state Medicaid programs and other GHC Programs, shifts in the percentage of patient services being reimbursed under GHC Programs and annual price increases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s annual price increases typically increase contractual adjustments as a percentage of gross patient service revenue. This increase is primarily due to Medicaid, Medicare and other GHC Programs that generally provide for reimbursements on a fee-schedule basis rather than on a gross charge basis. When the Company bills these programs, like other payors, on a gross-charge basis, it also increases its provision for contractual adjustments and uncollectibles by the amount of any price increase, resulting in a higher contractual adjustment percentage. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337402520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment: </div></div></div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Building</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment and other</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(160,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152,944</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> The Company recorded depreciation expense of $19.3 million, $18.7 million and $17.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338843000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company completed the acquisition of one pediatric subspecialty practice for total consideration of $2.1 million, of which $1.9 million was paid in cash and $0.2 million was recorded as a contingent consideration liability. This acquisition expanded the Company&#8217;s national network of physician practices. In connection with this acquisition, the Company recorded <div style="letter-spacing: 0px; top: 0px;;display:inline;">tax </div>deductible goodwill of $0.8 million and other intangible assets consisting primarily of physician and hospital agreements of $1.3 million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company completed eight acquisitions, consisting of two neonatology physician practices, two maternal-fetal physician practices and four other pediatric subspecialty practices for total cash consideration of $47.0 million and accrued purchase consideration of $0.3 million. These acquisitions expanded the Company&#8217;s national network of physician practices. In connection with these acquisitions, the Company recorded goodwill of $36.5 million, other intangible assets consisting primarily of physician and hospital agreements of $10.5 million and fixed assets of $0.2 million. The Company expects that all the goodwill recorded during the year ended December&#160;31, 2019 will be deductible for tax purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company paid $1.8 million for contingent consideration in connection with prior period acquisitions. No contingent consideration was paid by the Company in 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338907816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill was $1.48 billion at December&#160;31, 2020 and 2019. Goodwill is tested for impairment on at least an annual basis, in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. Consistent with prior years, the Company performed its annual impairment test in the third quarter of 2020 and determined that goodwill was </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not impaired. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net, consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107,246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(83,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,712</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,828</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(73,506</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ther technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,417</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74,923</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company recorded intangible assets related to acquisitions totaling $1.3 million, consisting primarily of physician and hospital agreements. The weighted-average amortization period for these physician and hospital agreements is approximately seven years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for intangible assets was $7.6 million, $7.3 million and $6.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for existing intangible assets for the next five years is expected to be as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,966</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338834536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discontinued Operations: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Radiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;9, 2020, the Company entered into a securities purchase agreement with Radiology Partners, Inc.&#160;to divest the Company&#8217;s radiology services medical group, and the transaction closed on December&#160;15, 2020. The purchase consideration was comprised of a cash payment of $885&#160;million paid at closing, subject to certain cash, minimum net working capital, indebtedness and other adjustments. The Company received approximately $865&#160;million at closing and used the proceeds of the transaction to redeem its $750&#160;million in outstanding principal amount of 5.25% senior notes due 2023 (the &#8220;2023 Notes&#8221;) on January&#160;7, 2021. The operating results of the radiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. </div></div>The initial classification of the radiology services medical group to assets held for sale during the third quarter of 2020 impacted the net book value of the assets and liabilities expected to be transferred upon sale. The initial determination of the estimated fair value of the radiology services medical group was determined using the purchase price in the purchase agreement along with estimated broker, accounting, legal and other selling <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses. The Company deemed the carrying amount of other assets within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">of&#160;$</div>43.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which generated an additional $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million deferred tax asset that increased the fair value of the medical group. An incremental non-cash charge was then required to reduce the radiology services medical group&#8217;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental non-cash charge of $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million for a total non-cash charge of $</div>47.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, reducing the goodwill balance of the radiology services medical group.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the divestiture, the Company recorded an additional loss on disposal of $36.4&#160;million based on estimated closing date net assets sold and final net proceeds. A closing working capital true up is expected to occur during the first quarter of 2021, and the Company will adjust the loss on sale as necessary at that time. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of income taxes, for the radiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $63.8 million and $72.8 million, respectively. Income from discontinued operations, net of income taxes, for the radiology services medical group for the year ended December&#160;31, 2018 was $37.4 million. Net revenue for the radiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $451.4 million, $489.4 million and $444.0 million, respectively. Operating loss for the radiology services medical group for the year ended December&#160;31, 2020 was $73.6 million, including a non-cash goodwill impairment charge of $47.0 million and a preliminary loss on sale of $36.4 million. Operating loss for the radiology services medical group for the year ended December&#160;31, 2019 was $75.3 million, including a non-cash goodwill impairment charge of $117.9 million. Operating income for the radiology services medical group for the year ended December&#160;31, 2018 was $48.4 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> Divestiture of the Anesthesiology Services Medical GroupOn May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest the Company&#8217;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0 million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250 million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $110.0 million at March&#160;31, 2020. The operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the years ended December&#160;31, 2020, 2019 and 2018. A single anesthesiology practice was not included in the divestiture of the anesthesiology services medical group and continues to operate as an affiliate of the Company. Its results of operations are not material. <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total loss on sale of the anesthesiology services medical group recorded during the year ended December&#160;31, 2020 was $663.7 million. Upon completion of a valuation for the contingent economic interest, which is expected to be completed in the first quarter of 2021, the Company will adjust the loss on sale as necessary. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $1.71 billion capital loss carryforward that will expire in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $430.0 million valuation allowance against this deferred tax asset as of December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of income taxes, for the anesthesiology services medical group for the years ended December&#160;31, 2020 and December&#160;31, 2019 was $717.2 million and $1.12 billion, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">from discontinued operations, net of income taxes, for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $</div>99.7<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million. Net revenue for the anesthesiology services medical group for the years ended December&#160;31, 2020, 2019 and 2018 was $</div>379.4<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, $</div>1.25<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion and $</div>1.29<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion, respectively. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2020 was $</div>716.3<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million, including the loss on sale of $</div>663.7<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million. Operating loss for the anesthesiology services medical group for the year ended December&#160;31, 2019 was $</div>1.23<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion, including a non-cash goodwill impairment charge of $</div>1.33<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> billion. Operating income for the anesthesiology services medical group for the year ended December&#160;31, 2018 was $</div>135.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> million.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, referred to as MedData. Loss from discontinued operations, net of tax, for MedData was $347.6 million for the year ended December&#160;31, 2019, reflecting the loss on sale recorded during the year ended December&#160;31, 2019, as compared to income from discontinued operations, net of tax, of $10.0 million for 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8 million, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consideration. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338921128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses: </div></div></div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,771</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">incentive compensation</div> </div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,699</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,721</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586425241432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Operating Leases</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted the new accounting guidance for leases on January&#160;1, 2019 using the modified retrospective method of applying the new guidance at the adoption date. Beginning with January&#160;1, 2019, the Company&#8217;s financial position is presented under the new guidance, while the prior period financial statements were not adjusted and continue to be reported in accordance with the previous guidance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company primarily leases property under operating leases and has one material equipment operating lease for an aircraft. The Company&#8217;s property leases are primarily for its regional, medical and business offices, storage space and temporary housing for medical staff. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of the lease payment using a discount rate that reflects the Company&#8217;s estimated incremental borrowing rate. Certain of the Company&#8217;s leases include rental escalation clauses and renewal options that are factored into the determination of lease payments when appropriate. Operating leases for office equipment are not material, and therefore are excluded from the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheet. </div></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;table below presents the operating lease-related right-of-use assets and related liabilities recorded on the Company&#8217;s balance sheet and the weighted average remaining lease term and discount rate as of December&#160;31, 2020 and 2019 (dollars in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right-of-use assets</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Information:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average remaining lease term</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents certain information related to the lease costs for operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equipment rent</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">684</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,051</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows for operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the balance sheet as of December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 17%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount of payments representing interest</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current obligations</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338883128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Professional Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationsAbstract', window );"><strong>Health Care Organizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyDisclosureTextBlock', window );">Accrued Professional Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Professional Liabilities: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020 and 2019, the Company&#8217;s total accrued professional liabilities of $315.9 milli<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>n and $249.6 million, respectively, included incurred but not reported loss reserves of $222.9&#160;million and $187.6&#160;million, respectively, and loss reserves for reported claims of $93.0&#160;million and $84.2&#160;million, respectively. Of the total liability, $50.6 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $61.4 million recorded as a component of other assets for certain professional liability claims that are covered by third-party insurance policies. These reserves include the accrued professional liabilities for the Company&#8217;s continuing operations as<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">reflected in the table below as </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">well as certain retained professional liabilities related to the Company&#8217;s former anesthesiology and radiology medical groups that were divested in 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s accrued professional liability for continuing operations, excluding the retained professional liabilities related to the Company&#8217;s former anesthesiology and radiology medical groups, for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities recognized, offset by insurance </div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">R</div>eceivable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision (adjustment) for losses related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision for losses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,116</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Claim payments related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(59</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total payments</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net increase<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> in the Company&#8217;s total accrued professional liability for the years ended December&#160;31, 2020 and 2019 were primarily related to overall unfavorable trends in the Company&#8217;s claims experience that impacted its provision for losses. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the accrual for malpractice loss contingencies (general and professional liability) which may include the policy used for accruing the loss contingency, the nature and amount of any accrual, and any significant estimate used to determine the accrual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337451832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Finance Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock', window );">Line of Credit, Long-Term Debt and Capital Lease Obligations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line of Credit, Long-Term Debt and Finance Lease Obligations: </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amended and restated </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2 million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> maintain minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021, (iv)&#160;provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v)&#160;temporarily restrict </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement provides for a $1.2 billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5 million sub-facility for the issuance of letters of credit. The</div></div>Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of the Company&#8217;s subsidiaries and affiliated professional associations and corporations. At the Company&#8217;s option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company&#8217;s consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company&#8217;s consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on the Company&#8217;s consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that requires the Company to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability of the Company to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute a <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2015, the Company completed a private offering of $750.0 million aggregate principal amount of 2023 Notes. In November 2018, the Company completed a private offering of $500.0 million aggregate principal amount of 2027 Notes and in February 2019, the Company completed a private offering of $500.00 million aggregate principal amount of Additional 2027 Notes. At December&#160;31, 2019, the outstanding balance on the 2027 Notes was $1.0 billion. The Company&#8217;s obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25%&#160;per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25%&#160;per annum, or $62.5 million, and is payable semi-annually in arrears on January 15 and July 15. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">was able to</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> redeem all or a portion of the 2023 Notes, at the redemption prices of 101.313% in 2020 and 100% in 2021 and thereafter, plus accrued and unpaid interest to the redemption date. The 2023 Notes were redeemed </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">in full </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on January&#160;7, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any time prior to January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes at a redemption price equal to 100% of the principal amount of the notes being redeemed plus an applicable redemption premium and accrued and unpaid interest to the redemption date. In addition, at any time prior to January&#160;15, 2022, the Company may redeem up to 35% of the aggregate principal amount of the 2027 Notes at a redemption price of 106.250% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, using proceeds from one or more equity offerings. On or after January&#160;15, 2022, the Company may redeem all or a portion of the 2027 Notes, at the redemption prices of 104.688% in 2022, 103.125% in 2023, 101.563% in 2024 and 100% in 2025 and thereafter, plus accrued and unpaid interest to the redemption date. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of the Company&#8217;s long-term debt was $1.7 billion at December&#160;31, 2020 and 2019 and consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,343</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,731,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,730,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,727,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company presents issuance costs related to long-term debt liabilities, other than revolving credit arrangements, as a direct deduction from the carrying value of that long-term debt. The Company has one outstanding letter of credit which reduced the amount available under the Credit Agreement by $0.1 million at December&#160;31, 2020. At December&#160;31, 2020, the Company had an available balance on its Credit Agreement of $899.9 million, after giving effect to the temporary reduction of the capacity of its Credit Agreement through September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of the Company&#8217;s variable rate revolving line of credit approximates fair value due to the short-term nature of the interest rates.<div style="display:inline;">&#160;</div>The estimated fair value of the Company&#8217;s 2023 Notes and 2027 Notes were estimated using trading prices as of December&#160;31, 2020 and 2019, respectively, as Level 2 inputs to estimate fair value and are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">756,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,070,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s finance lease obligations</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">, related to equipment used in its newborn hearing screen program,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease obligations</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338760328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes:</div></div></div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax provision (benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,697</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(45,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files its tax return on a consolidated basis with its subsidiaries, and its affiliated professional contractors file tax returns on an individual basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective tax rate for continuing operations was 234.0%, 28.2% and 26.9% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The increase in the effective tax rate for the year ended December&#160;31, 2020 as compared to the years ended December&#160;31, 2019 and 2018 was due to a significant reduction in pre-tax income as a result of the impacts from the transformational and restructuring related expenses and <br/> COVID-19. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The differences between the effective rate and the United States federal income tax statutory rate are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="display:inline;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">24.34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">4.41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">60.44</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3.98</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.85</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">98.61</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.78</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in accrual estimates relating to uncertain tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">4.22</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(9.63</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">23.67</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.39</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1.71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1.42</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax law</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">233.99</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">28.19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">26.91</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the Company&#8217;s deferred tax assets and liabilities are classified as long-term. The significant components of deferred income tax assets and liabilities are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for uncollectible accounts</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">79,755</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">170,123</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves and accruals</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">64,445</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">54,685</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,517</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,493</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss and other carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">16,767</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6,691</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">447,854</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">17,082</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">15,042</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">15,389</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3,044</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3,986</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">571</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">634,995</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">279,449</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(458,708</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(19,286</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net of valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">176,287</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">260,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(152,969</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(144,587</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting method changes</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(16,352</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(71,532</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(14,057</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(13,405</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(183</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(463</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(183,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(229,987</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="width: 69%;"><div style="margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Net deferred tax (liabilities) assets</div> </div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(7,274</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">30,176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s net deferred tax liabilities were $7.3 million as of December&#160;31, 2020, as compared to net deferred tax assets of $30.2 million at December&#160;31, 2019. The increase in net deferred tax liabilities of $37.5 million during the year ended December&#160;31, 2020 was primarily related to a decrease in deferred tax assets related to allowance for uncollectible accounts partially offset by decrease in deferred tax liabilities for accounting method changes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020, 2019 and 2018, income tax expense of $7.1 million, $3.8 million and $1.3 million, respectively, was recognized for excess tax deficiencies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For</div> the year ended December&#160;31, 2020, the Company estimates that it will generate a $1.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion capital loss, from the sale of its anesthesiology services medical group, which will expire in 2025. Total capital loss carryforwards as of December 31, 2020 was</div>&#160;$1.8 billion. As of December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2020, management has determined that it is more likely than not that the tax benefits related to these carryforwards will not be realized and has recorded a full valuation allowance against the related deferred tax assets. Additionally, the Company has net operating loss carryforwards for federal and state<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>tax purposes totaling $35.4 million, $31.5 million and $27.8 million at December&#160;31, 2020, 2019 and 2018, respectively. With respect to the December&#160;31, 2020 balance, $22.3 million expires at various times from 2022 through 2040, and $13.1 million does not expire. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, 2019 and 2018, the Company&#8217;s liability for uncertain tax positions, excluding accrued interest and penalties, was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> $6.2 million, $7.4 million and $11.2 million, respectively. As of December&#160;31, 2020, the Company had $6.2 million of uncertain tax positions that, if recognized, would favorably impact its effective tax rate.</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s liability for uncertain tax positions for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,409</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">10,972</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">369</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">385</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(1,041</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">100</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1,700</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">2,900</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to divestitures</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(300</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to lapse of statutes of limitation</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(5,845</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6,168</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,409</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company decreased its liability for uncertain tax positions by $1.2 million, primarily related to a reduction in tax liability for prior year positions. During the year ended December&#160;31, 2019, the Company decreased its liability for uncertain tax positions by $3.8 million, primarily related to expiration of statutes of limitation, partially offset by additional taxes on current and prior year positions. In addition, the Company anticipates that its liability for uncertain tax positions will decrease by $1.1 million over the next 12 months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company includes interest and penalties related to income tax liabilities in income tax expense. During the year ended December&#160;31, 2020, the Company included $0.5 million of interest and penalties in income tax expense. The impact to income tax expense related to penalties and interest was not material during the years <div style="letter-spacing: 0px; top: 0px;;display:inline;">ended </div>December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2019 and 2018. At December&#160;31, 2020 and 2019, the Company&#8217;s accrued liability for interest and penalties related to income tax liabilities totaled $1.0 million and $0.6 million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is currently subject to U.S. Federal and various state income tax examinations for the tax years 2015 through 2019. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338913160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div></div></td></tr></table> <div style="display:inline;"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per share calculation for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;">&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,495</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">91,104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">516</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">502</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">equivalent shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">84,011</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">91,606</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">net income per common share calculation</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">516</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">214</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div>&#160;</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the year ended December&#160;31, 2020, no incremental shares are included because the effect would be antidilutive. </div></div></td></tr></table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338956424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the A&amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards and stock options ratably over the corresponding vesting periods. At December&#160;31, 2020, the Company had 5.0&#160;million shares available for future grants and awards under its Amended and Restated 2008 Incentive Plan. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Company&#8217;s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at 85% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. Under the Company&#8217;s 2015 <br/> Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at 90% of market value on January&#160;1st,&#160;April&#160;1st,&#160;July&#160;1st and October&#160;1st of each year. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the year ended December&#160;31, 2020, 0.5&#160;million shares in the aggregate were issued under the ESPP and SPP. At December&#160;31, 2020, the Company had approximately 0.5&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized $21.1 million, $33.4 million and $36.4&#160;million of stock-based compensation expense related to its stock incentive plans, the ESPP and the SPP during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s restricted stock and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December&#160;31, 2020 are as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Fair<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at January 1, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,723,115</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">40.77</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,361,712</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">23.54</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(173,455</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">31.68</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(1,700,255</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">34.88</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at December 31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,211,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">30.97</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of the restricted and deferred stock that vested during the years ended December&#160;31, 2020, 2019 and 2018 was <br/> $59.3 million, $31.5 million and $27.4 million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant-date fair value of restricted and deferred stock awards that were granted during the years ended December&#160;31, 2020, 2019 and 2018 was $23.54, $33.28 and $51.99, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, the total stock-based compensation cost related to non-vested restricted and deferred stock remaining to be recognized as compensation expense over a weighted-average period of 1.8 years was $11.6 million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted various performance-based stock options during the year ended December&#160;31, 2020 with vesting dependent on both continued employment and the achievement of various stock price hurdles over a </div></div>  <div style="text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">period of three years. The Company used a Monte Carlo simulation analysis to estimate the fair value of each stock option on the date of grant during 2020. The Monte Carlo simulation uses a series of functions that define a range of possibilities, or probability density functions and repeatedly samples from the ranges of those possibilities. Finally, the model calculates and sums the weighted average results of all the iterations. The weighted average grant date fair value for the stock options granted in 2020 was $5.21. The key assumptions used in the Monte Carlo simulation analysis were expected volatility of 50%, expected term of three years<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;and a</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> discount rate using the three year&#160;U.S. Treasury bond rate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity and certain other information related to the Company&#8217;s outstanding stock option awards for the year ended December&#160;31, 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">982,731</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">999,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2019 and 2018 were $0.6 million and $2.8 million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, the total stock-based compensation related to non-vested stock options remaining to be recognized as compensation expense over a weighted average period of approximately 2.6 years was $4.3 million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash proceeds received from the exercise of stock options for the years ended December&#160;31, 2019 and 2018 were $0.1 million and $3.7 million, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586431259160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the year ended December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0 million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $107.2 million remained available for repurchase as of January&#160;1, 2020. Under this share repurchase program, during the twelve months ended December&#160;31, 2020, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> repurchased 0.5&#160;million shares of </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">its</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> common stock for $8.5 million to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, the Company repurchased approximately 5.1&#160;million shares of its common stock for $145.3 million, inclusive of 96,918 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock during the year ended December&#160;31, 2019.</div></div> The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344686120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retirement Plans: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains three qualified contributory savings plans as allowed under Section&#160;401(k) of the Internal Revenue Code and Section&#160;1165(e) of the Puerto Rico Income Tax Act of 1954 (the &#8220;401(k) Plans&#8221;). The 401(k) Plans permit participant contributions and allow elective and, in certain situations, non-elective Company contributions based on each participant&#8217;s contribution or a specified percentage of eligible wages. Participants may defer a percentage of their annual compensation subject to the limits defined in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">401(k) Plans. The Company&#160;</div> recorded expense for its continuing operations of $19.9 million, $20.4 million and $24.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, primarily related to the 401(k) Plans. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586431259160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of December&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339355368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Information</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Quarterly Financial Information (Unaudited): </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth a summary of the Company&#8217;s selected quarterly financial information for each of the four quarters ended December&#160;31, 2020 and 2019 (in thousands, except for per share data): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">441,245</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">415,441</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">460,635</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">416,630</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">316,279</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">282,985</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">309,904</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">284,772</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">23,842</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,173</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">22,440</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">24,235</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">67,442</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">60,488</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">66,346</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">54,671</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,751</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,195</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,692</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">16,076</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,479</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">34,291</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,955</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">430,442</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">380,876</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">440,176</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">384,325</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">34,565</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,459</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">32,305</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other (expense) income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,046</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">3,576</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,534</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,849</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,665</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,265</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,250</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,302</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">494</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">305</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">504</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.78in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,217</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(24,384</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(16,434</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(21,949</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">(Loss) income from continuing operations before<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(17,414</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,181</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,025</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,356</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,085</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(3,097</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(6,677</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(5,869</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Loss) income from continuing operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(18,499</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,084</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2,652</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,487</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(213</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(679,520</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(38,392</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(68,783</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(18,712</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(672,436</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(41,044</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(64,296</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.14</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.46</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.46</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.06</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.49</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.49</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,799</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,490</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">84,316</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,799</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,744</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">85,082</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">427,092</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">439,154</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">454,913</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">458,600</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">294,753</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">284,627</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">301,306</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">300,073</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">24,705</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">25,402</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">22,581</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">23,223</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">59,023</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">63,011</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">63,284</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">59,194</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,183</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,239</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,408</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,101</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">2,439</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">16,820</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">28,865</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">387,103</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">396,099</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">406,345</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">418,456</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">39,989</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">43,055</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">48,568</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">40,144</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">1,249</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">726</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">802</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">909</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(30,349</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(31,013</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(29,909</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,657</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">503</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">786</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">517</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,636</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(29,784</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,321</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(26,231</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">11,353</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">13,271</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,247</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">13,913</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">1,514</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(6,744</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(7,360</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(3,986</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,867</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,527</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,887</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">9,927</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(255,739</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(14,772</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,268,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (loss) income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(242,872</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8,245</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,255,916</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">9,331</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.96</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.31</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.82</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.23</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">86,073</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,234</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,441</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,592</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">86,545</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,689</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,883</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,288</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338631672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company&#8217;s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance became effective for the Company on January&#160;1, 2021. The Company does not believe adoption of this new guidance will have a material impact on its Consolidated Financial Statements or related disclosures. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting Estimates and Assumptions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#8217;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#8217;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue from continuing operations by service line (in percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neonatology and other pediatric subspecialties</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maternal-fetal medicine</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric cardiology</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by GHC Programs and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and GHC Programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from GHC Programs made up approximately 22% and 21% of net accounts receivable related to continuing operations at December&#160;31, 2020 and 2019, respectively. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are defined as all highly liquid financial instruments with maturities of 90 days or less from the date of purchase. The Company&#8217;s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits. Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See &#8220;Fair Value Measurements&#8221; below. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments consist<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">primarily </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;corporate securities,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">municipal debt securities, federal home loan securities and certificates of deposit. The Company classifies its investments as available for sale. Although there is no stated expectation that the investments will be sold within one year, the investments are available for use, if needed, and accordingly are classified as short-term. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive income or loss. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally 30 years for buildings; <span style="-sec-ix-hidden:hidden18209306"><span style="-sec-ix-hidden:hidden18209307"><span style="-sec-ix-hidden:hidden18209308"><span style="-sec-ix-hidden:hidden18209309">th</span>r</span>e</span>e</span> t<div style="letter-spacing: 0px; top: 0px;;display:inline;">o </div>seven years for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and finance leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">earnings. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Acquisitions</a></td>
<td class="text">Business Acquisitions<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to five years ending after the acquisition dates. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures this contingent consideration at fair value at the acquisition </div></div></div>date and records such contingent consideration as a liability or equity on the Company&#8217;s Consolidated Balance Sheets on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company&#8217;s Consolidated Statements of Income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records acquired assets and assumed liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of <span style="-sec-ix-hidden:hidden18209310">one</span> to 20 years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For 2020, the Company elected to perform the qualitative assessment, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it was more likely than not that the fair value of its single reporting unit exceeded its carrying value, including goodwill. For 2019 and 2018, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">bypassed </div>the qualitative assessment and performed a quantitative test with any goodwill impairment measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. The Company used income and market-based valuation approaches to determine the fair value of its single continuing operations reporting unit. These approaches focused on discounted cash flows and revenue and EBITDA multiples based on the Company&#8217;s market capitalization to derive the fair value of the reporting unit. Significant assumptions used in these valuations included the weighted average cost of capital discount factor, revenue growth rates and revenue and EBITDA multiples. For both the qualitative and quantitative approaches, the Company considered the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company completed annual impairment tests for its continuing operations in the third quarter of 2020, 2019 and 2018 and determined that goodwill was not impaired. See Note 8 &#8211; Goodwill and Intangible Assets for more information. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. </div></div></div>The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December&#160;31, 2020 pursuant to current accounting standards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockShareRepurchasesPolicyTextBlock', window );">Common Stock Repurchases</a></td>
<td class="text">Common Stock RepurchasesThe Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as retired as any repurchased shares become authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProfessionalLiabilityCoveragePolicyTextBlock', window );">Professional Liability Coverage</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional Liability Coverage </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles or self-insured retention, exclusions and other restrictions. The Company&#8217;s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. If it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is provided against such deferred tax assets. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company&#8217;s reporting date. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Incentive Plans</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock-based awards consisting primarily of restricted stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. The Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards on an annual basis and adjusts the estimates as necessary based on the number of awards that ultimately vest. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Common Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income Per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockShareRepurchasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock share repurchases policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockShareRepurchasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProfessionalLiabilityCoveragePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional liability coverage policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProfessionalLiabilityCoveragePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338714824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Net Revenue by Service Line</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue from continuing operations by service line (in percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neonatology and other pediatric subspecialties</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maternal-fetal medicine</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric cardiology</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual funds</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Level 1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">756,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,070,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586341199960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Treasury securities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586425442024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,106,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(864,463</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,315,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">434,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,481,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,567,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,529,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733,951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,779,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723,107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> payor mix, expressed as a percentage of net revenue, exclusive of administrative fees and other miscellaneous revenue, for the periods indicated: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay patients</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338830616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Building</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment and other</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(160,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152,944</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338707560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets, Net</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net, consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107,246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(83,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,712</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physician and hospital agreements</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,828</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(73,506</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ther technology</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,417</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74,923</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Amortization Expenses for Existing Intangible Assets for the Next Five Years</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for existing intangible assets for the next five years is expected to be as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,966</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344809336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,771</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">incentive compensation</div> </div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,699</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,721</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338926136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock', window );">Operating Lease Related Assets And Liabilities And Other Related Information</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;table below presents the operating lease-related right-of-use assets and related liabilities recorded on the Company&#8217;s balance sheet and the weighted average remaining lease term and discount rate as of December&#160;31, 2020 and 2019 (dollars in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right-of-use assets</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Information:</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average remaining lease term</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents certain information related to the lease costs for operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equipment rent</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">684</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,051</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock', window );">Operating Leases Cash Flow Related Information</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows for operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the balance sheet as of December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 17%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount of payments representing interest</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future minimum lease payments</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current obligations</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of operating leases</div></div> </td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 17%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating lease related assets and liabilities and other related information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingLeasesCashFlowRelatedInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating lease related cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingLeasesCashFlowRelatedInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586345516952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Professional Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationsAbstract', window );"><strong>Health Care Organizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock', window );">Schedule of Accrued Professional Liability</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s accrued professional liability for continuing operations, excluding the retained professional liabilities related to the Company&#8217;s former anesthesiology and radiology medical groups, for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities recognized, offset by insurance </div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">R</div>eceivable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision (adjustment) for losses related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision for losses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,116</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Claim payments related to:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(59</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior years</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total payments</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued professional liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338934936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of the Company&#8217;s long-term debt was $1.7 billion at December&#160;31, 2020 and 2019 and consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,343</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,733,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,731,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unamortized<br/> Debt<br/> Issuance<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,730,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revolving line of credit</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,727,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock', window );">Summary of Estimated Fair Value of Notes</a></td>
<td class="text">The estimated fair value of the Company&#8217;s 2023 Notes and 2027 Notes were estimated using trading prices as of December&#160;31, 2020 and 2019, respectively, as Level 2 inputs to estimate fair value and are summarized as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">756,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,070,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ScheduleOfFinanceLeaseObligationsTableTextBlock', window );">Schedule of Financial Lease Obligations</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s finance lease obligations</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">, related to equipment used in its newborn hearing screen program,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease obligations</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ScheduleOfFinanceLeaseObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Finance Lease Obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ScheduleOfFinanceLeaseObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SummaryOfEstimatedFairValueOfNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Estimated Fair Value of Notes Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SummaryOfEstimatedFairValueOfNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586341109224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Components of Income Tax Provision</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax provision (benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,697</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(45,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate</a></td>
<td class="text">The differences between the effective rate and the United States federal income tax statutory rate are as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">21.00</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">24.34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">4.41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">60.44</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3.98</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.85</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">98.61</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.78</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in accrual estimates relating to uncertain tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">4.22</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(9.63</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">23.67</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">0.39</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1.71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1.42</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax law</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(0.71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">233.99</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">28.19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">26.91</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Income Tax Assets and Liabilities</a></td>
<td class="text"><div style="display:inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the Company&#8217;s deferred tax assets and liabilities are classified as long-term. The significant components of deferred income tax assets and liabilities are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for uncollectible accounts</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">79,755</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">170,123</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves and accruals</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">64,445</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">54,685</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,517</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,493</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss and other carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">16,767</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6,691</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">447,854</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">17,082</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">15,042</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">15,389</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3,044</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">3,986</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">571</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">634,995</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">279,449</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(458,708</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(19,286</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net of valuation allowance</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">176,287</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">260,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(152,969</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(144,587</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting method changes</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(16,352</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(71,532</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(14,057</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(13,405</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(183</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(463</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(183,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(229,987</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="width: 69%;"><div style="margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Net deferred tax (liabilities) assets</div> </div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(7,274</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">30,176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 69%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Activity Related to Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="display:inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s liability for uncertain tax positions for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,409</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">10,972</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">369</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">385</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(1,041</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">100</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1,700</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">2,900</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to divestitures</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(300</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreases related to lapse of statutes of limitation</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(5,845</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">6,168</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">7,409</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">11,185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337403080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per share calculation for the years ended December&#160;31, 2020, 2019, and 2018 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;">&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap;">&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,495</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">91,104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">516</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">502</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">equivalent shares outstanding</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">83,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">84,011</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">91,606</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">net income per common share calculation</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">1,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">516</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">214</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div>&#160;</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the year ended December&#160;31, 2020, no incremental shares are included because the effect would be antidilutive. </div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338866536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock and Deferred Stock Awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to the Company&#8217;s restricted stock and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December&#160;31, 2020 are as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Fair<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at January 1, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,723,115</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">40.77</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,361,712</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">23.54</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(173,455</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">31.68</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">(1,700,255</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">34.88</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested shares at December 31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">1,211,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><div style="display:inline;">30.97</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="display:inline;">&#160;</div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity and Certain Other Information Related to Stock Option Awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity and certain other information related to the Company&#8217;s outstanding stock option awards for the year ended December&#160;31, 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td style="white-space: nowrap;"/>
<td style="white-space: nowrap;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">982,731</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">999,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339412872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Company's Selected Quarterly Financial Information</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth a summary of the Company&#8217;s selected quarterly financial information for each of the four quarters ended December&#160;31, 2020 and 2019 (in thousands, except for per share data): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">441,245</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">415,441</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">460,635</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">416,630</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">316,279</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">282,985</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">309,904</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">284,772</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">23,842</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,173</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">22,440</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">24,235</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">67,442</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">60,488</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">66,346</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">54,671</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,751</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,195</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,692</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">16,076</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,479</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">34,291</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,955</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">430,442</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">380,876</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">440,176</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">384,325</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">34,565</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,459</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">32,305</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other (expense) income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,046</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">3,576</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,534</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,849</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,665</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,265</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,250</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,302</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">494</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">305</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">504</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.78in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,217</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(24,384</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(16,434</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(21,949</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">(Loss) income from continuing operations before<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(17,414</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,181</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,025</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">10,356</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,085</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(3,097</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(6,677</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(5,869</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Loss) income from continuing operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(18,499</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,084</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2,652</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">4,487</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(213</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(679,520</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(38,392</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(68,783</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(18,712</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(672,436</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(41,044</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(64,296</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.14</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.46</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 0%;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.46</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.06</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.49</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8.03</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.49</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,799</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,490</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">84,316</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,799</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,744</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">85,082</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/>
<td style="vertical-align: bottom; width: 2%;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%; white-space: nowrap;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019 Quarters</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Second</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Third</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fourth</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">427,092</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">439,154</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">454,913</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">458,600</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice salaries and benefits</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">294,753</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">284,627</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">301,306</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">300,073</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Practice supplies and other operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">24,705</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">25,402</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">22,581</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">23,223</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">59,023</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">63,011</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">63,284</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">59,194</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,183</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,239</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,408</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">7,101</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transformational and restructuring related expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">2,439</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">16,820</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">28,865</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">387,103</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">396,099</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">406,345</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">418,456</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">39,989</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">43,055</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">48,568</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">40,144</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">1,249</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">726</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">802</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">909</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(30,349</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(31,013</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(29,909</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(27,657</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">503</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">786</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">517</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total non-operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,636</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(29,784</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(28,321</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(26,231</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">11,353</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">13,271</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">20,247</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">13,913</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">1,514</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(6,744</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(7,360</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(3,986</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,867</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">6,527</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">12,887</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">9,927</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(255,739</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(14,772</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,268,803</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (loss) income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(242,872</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(8,245</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(1,255,916</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">9,331</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data (1):</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.96</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.31</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.82</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.23</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(2.81</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(15.15</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">0.11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">86,073</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,234</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,441</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,592</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">86,545</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,689</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">82,883</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">83,288</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top; width: 96%;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. </div></div> </td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344211736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 899.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member', window );">Senior Unsecurd Notes 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member', window );">Senior Unsecurd Notes 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Deemed Consolidated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member', window );">Forecast For Fourth Quarter Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.75:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member', window );">Forecast For First Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member', window );">Forecast For Second Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement', window );">Line Of Credit Facility Minimum Availability Under Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForThirdQuarterOf2021Member', window );">Forecast For Third Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement', window );">Line Of Credit Facility Minimum Availability Under Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue', window );">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes', window );">Deferred Payment Of Social Security Taxes | %</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Rural Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 70,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageIncreaseDecreaseInSalaryAndWage', window );">Decrease In Salary | %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ContributionsInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ContributionsInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed consolidated earnings before interest taxes depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility minimum availability under credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageIncreaseDecreaseInSalaryAndWage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase Decrease In Salary And Wage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageIncreaseDecreaseInSalaryAndWage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Deferred Payment Of Social Security Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfDeferredPaymentOfSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SupplementaryLeverageRatioRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Leverage Ratio Required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SupplementaryLeverageRatioRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForThirdQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForThirdQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAxis=md_CovidNinenteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=md_RuralAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=md_RuralAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586435015176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CashAndCashEquivalentsMaturityDescription', window );">Cash and cash equivalents maturity description</a></td>
<td class="text">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod', window );">Additional amounts to be paid in cash or common stock based on achievement of performance measures within period, maximum years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember', window );">Unnamed Corporate Joint Venture Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government Contracts Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of net accounts receivable</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ShortTermInvestmentMaturityPeriod', window );">Short-Term investments maturity period, in years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets finite lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets finite lives</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives, years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BusinessCombinationContingentConsiderationArrangementsTimePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration arrangements, time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BusinessCombinationContingentConsiderationArrangementsTimePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashAndCashEquivalentsMaturityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents maturity description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashAndCashEquivalentsMaturityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ShortTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ShortTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586434532936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail) - Product Concentration Risk [Member] - Sales Revenue, Services, Net [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net revenue in percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Neonatology and Other Pediatric Subspecialties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net revenue in percentage</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Maternal-Fetal Medicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net revenue in percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Pediatric Cardiology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net revenue in percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=md_SalesAndRevenueServicesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=md_SalesAndRevenueServicesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_NeonatologyAndOtherPediatricSubspecialtiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_NeonatologyAndOtherPediatricSubspecialtiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_MaternalFetalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_MaternalFetalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_PediatricCardiologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_PediatricCardiologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337103416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual funds</a></td>
<td class="nump">15,841<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 104,870<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339067000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">756,225<span></span>
</td>
<td class="nump">766,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember', window );">2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="nump">$ 1,025,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586425106312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 104,870<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">71,095<span></span>
</td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">18,707<span></span>
</td>
<td class="nump">29,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">8,017<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">5,991<span></span>
</td>
<td class="nump">4,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Avaliable-For-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337235272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,106,394<span></span>
</td>
<td class="nump">$ 1,750,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(864,463)<span></span>
</td>
<td class="num">(1,315,998)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 241,931<span></span>
</td>
<td class="nump">$ 434,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344353784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 416,630<span></span>
</td>
<td class="nump">$ 460,635<span></span>
</td>
<td class="nump">$ 415,441<span></span>
</td>
<td class="nump">$ 441,245<span></span>
</td>
<td class="nump">$ 458,600<span></span>
</td>
<td class="nump">$ 454,913<span></span>
</td>
<td class="nump">$ 439,154<span></span>
</td>
<td class="nump">$ 427,092<span></span>
</td>
<td class="nump">$ 1,733,951<span></span>
</td>
<td class="nump">$ 1,779,759<span></span>
</td>
<td class="nump">$ 1,723,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481,331<span></span>
</td>
<td class="nump">1,567,624<span></span>
</td>
<td class="nump">1,529,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,495<span></span>
</td>
<td class="nump">197,340<span></span>
</td>
<td class="nump">181,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,125<span></span>
</td>
<td class="nump">$ 14,795<span></span>
</td>
<td class="nump">$ 12,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586340663912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337311624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property Plant and Equipment - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">$ 26,934<span></span>
</td>
<td class="nump">$ 26,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">6,683<span></span>
</td>
<td class="nump">6,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Equipment and other</a></td>
<td class="nump">203,017<span></span>
</td>
<td class="nump">192,004<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">236,634<span></span>
</td>
<td class="nump">225,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(160,443)<span></span>
</td>
<td class="num">(152,944)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 76,191<span></span>
</td>
<td class="nump">$ 72,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338681928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Recorded depreciation expense</a></td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344460104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total business acquisition consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Contingent consideration payments related to prior-period acquisitions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NumberOfPhysicianGroupPracticesAcquired', window );">Number Of Physician Group Practices Acquired | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NumberOfNeonatologyPracticesAcquired', window );">Number Of Neonatology Practices Acquired | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NumberOfPediatricSubspecialtyPracticesAcquired', window );">Number Of Pediatric Subspecialty Practices Acquired | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NumberOfRadiologyPracticesAcquired', window );">Number Of Radiology Practices Acquired | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedPurchaseConsideration', window );">Accrued Purchase Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=md_PhysicianGroupMember', window );">Physician Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember', window );">Pediatric Subspecialty Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total business acquisition consideration</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition consiideration paid in cash</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Business acquisitions contingent consideration liability</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfNeonatologyPracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of neonatology practices acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfNeonatologyPracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfPediatricSubspecialtyPracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of other pediatric subspecialty practices acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfPediatricSubspecialtyPracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfPhysicianGroupPracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of physician group practices acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfPhysicianGroupPracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfRadiologyPracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of radiology practices acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfRadiologyPracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=md_PhysicianGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=md_PhysicianGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586334323448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_GoodwillAndOtherIntangibleAssetsLineItems', window );"><strong>Goodwill And Other Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,477,968<span></span>
</td>
<td class="nump">$ 1,479,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets related to acquisitions</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_GoodwillAndOtherIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill And Other Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_GoodwillAndOtherIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586424930600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 112,443<span></span>
</td>
<td class="nump">$ 103,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(85,801)<span></span>
</td>
<td class="num">(74,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">26,642<span></span>
</td>
<td class="nump">28,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_PhysicianAndHospitalAgreementsMember', window );">Physician And Hospital Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">107,246<span></span>
</td>
<td class="nump">99,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(83,089)<span></span>
</td>
<td class="num">(73,506)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">24,157<span></span>
</td>
<td class="nump">26,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_OtherTechnologyMember', window );">Other Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,197<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,712)<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 2,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_PhysicianAndHospitalAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_PhysicianAndHospitalAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_OtherTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=md_OtherTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337328120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expense for existing other intangible assets, 2021</a></td>
<td class="nump">$ 7,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense for existing other intangible assets, 2022</a></td>
<td class="nump">5,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense for existing other intangible assets, 2023</a></td>
<td class="nump">4,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense for existing other intangible assets, 2024</a></td>
<td class="nump">2,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense for existing other intangible assets, 2025</a></td>
<td class="nump">$ 1,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339461432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash charge against goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (68,783)<span></span>
</td>
<td class="num">(38,392)<span></span>
</td>
<td class="num">$ (679,520)<span></span>
</td>
<td class="num">$ (213)<span></span>
</td>
<td class="num">$ (596)<span></span>
</td>
<td class="num">$ (1,268,803)<span></span>
</td>
<td class="num">$ (14,772)<span></span>
</td>
<td class="num">$ (255,739)<span></span>
</td>
<td class="num">$ (786,908)<span></span>
</td>
<td class="num">$ (1,539,910)<span></span>
</td>
<td class="nump">$ 147,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_Accountsreceivableretained', window );">Accounts Receivable Retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717,200<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="nump">99,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss', window );">Disposal Group Not Discontinued Operation Goodwill Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Tax Year Two Thousand And Twenty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_Capitallosscarryforward', window );">Capital loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember', window );">Divestiture Of Meddata [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">347,600<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember', window );">Radiology Services Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash charge against goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">117,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NetProceedsForTheRadiologyServicesMedicalGroup', window );">Net proceeds for the radiology services medical group</a></td>
<td class="nump">$ 865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,400<span></span>
</td>
<td class="nump">489,400<span></span>
</td>
<td class="nump">444,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating Income From Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,600<span></span>
</td>
<td class="nump">75,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,800<span></span>
</td>
<td class="nump">72,800<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PurchaseConsiderationCashPayment', window );">Purchase consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_AnesthesiologyServicesMedicalGroupMember', window );">Anesthesiology Services Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,400<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating Income From Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,300<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum Consideration Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum Consideration Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsIntangibleAssetsMember', window );">Deferred Tax Assets Intangible Assets [Member] | Radiology Services Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash charge against goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Deferred Tax Assets, Goodwill and Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_Accountsreceivableretained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AccountsReceivableRetained</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_Accountsreceivableretained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_Capitallosscarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CapitalLossCarryForward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_Capitallosscarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Not Discontinued Operation Goodwill Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>MaximumConsiderationReceivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NetProceedsForTheRadiologyServicesMedicalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds for the radiology services medical group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NetProceedsForTheRadiologyServicesMedicalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PurchaseConsiderationCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase consideration cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PurchaseConsiderationCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_AnesthesiologyServicesMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_AnesthesiologyServicesMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586334291976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 59,771<span></span>
</td>
<td class="nump">$ 35,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedSalariesAndIncentiveCompensationCurrent', window );">Accrued salaries and incentive compensation</a></td>
<td class="nump">184,849<span></span>
</td>
<td class="nump">193,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">43,945<span></span>
</td>
<td class="nump">54,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">50,607<span></span>
</td>
<td class="nump">44,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">32,721<span></span>
</td>
<td class="nump">32,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">51,264<span></span>
</td>
<td class="nump">49,219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 423,157<span></span>
</td>
<td class="nump">$ 410,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedSalariesAndIncentiveCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued salaries and incentive compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedSalariesAndIncentiveCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586334279464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingLeasesAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 44,926<span></span>
</td>
<td class="nump">$ 56,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingLeasesLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">18,933<span></span>
</td>
<td class="nump">18,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">$ 40,970<span></span>
</td>
<td class="nump">$ 44,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OtherInformationRelatedToOperatingLeaseAbstract', window );"><strong>Other Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingLeasesAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents operating lease assets abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingLeasesAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingLeasesLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingLeasesLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OtherInformationRelatedToOperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Representing other information related to operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OtherInformationRelatedToOperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337193080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of lease costs for operating leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 20,972<span></span>
</td>
<td class="nump">$ 23,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">4,519<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OtherEquipmentRent', window );">Other equipment rent</a></td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_OperatingLeasesOtherCosts', window );">Other operating lease costs</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 30,303<span></span>
</td>
<td class="nump">$ 31,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingLeasesOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents other costs of operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingLeasesOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OtherEquipmentRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other equipment rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OtherEquipmentRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339184312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 27,933<span></span>
</td>
<td class="nump">$ 28,722<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344422840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of operating lease liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 19,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">16,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">12,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">8,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">64,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount of payments representing interest</a></td>
<td class="num">(4,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">59,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current obligations</a></td>
<td class="num">(18,933)<span></span>
</td>
<td class="num">$ (18,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating leases</a></td>
<td class="nump">$ 40,970<span></span>
</td>
<td class="nump">$ 44,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586338618328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Professional Liabilities - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscounted', window );">Total accrued professional liability</a></td>
<td class="nump">$ 315,900<span></span>
</td>
<td class="nump">$ 249,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveCurrent', window );">Accrued professional liability incurred but loss reserves not reported for claims</a></td>
<td class="nump">222,900<span></span>
</td>
<td class="nump">187,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedProfessionalLiability', window );">Accrued professional liability incurred and loss reserves reported for claims</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">84,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">50,607<span></span>
</td>
<td class="nump">$ 44,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivable', window );">Insurance receivables</a></td>
<td class="nump">$ 61,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedProfessionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued professional liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedProfessionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586425362040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations', window );">Balance at beginning of year</a></td>
<td class="nump">$ 151,397<span></span>
</td>
<td class="nump">$ 128,799<span></span>
</td>
<td class="nump">$ 138,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition', window );">Liabilities recognized, offset by insurance Receivable</a></td>
<td class="nump">3,922<span></span>
</td>
<td class="nump">10,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProvisionAdjustmentForLossesRelatedToCurrentYear', window );">Provision (adjustment) for losses related to Current year</a></td>
<td class="nump">45,674<span></span>
</td>
<td class="nump">42,733<span></span>
</td>
<td class="nump">37,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProvisionAdjustmentForLossesRelatedToPriorYear', window );">Provision (adjustment) for losses related to Prior years</a></td>
<td class="num">(1,551)<span></span>
</td>
<td class="num">(7,766)<span></span>
</td>
<td class="num">(7,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MalpracticeLossContingencyProvisionForLosses', window );">Total provision for losses</a></td>
<td class="nump">44,123<span></span>
</td>
<td class="nump">34,967<span></span>
</td>
<td class="nump">30,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod', window );">Claim payments related to Current year</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods', window );">Claim payments related to Prior years</a></td>
<td class="num">(24,580)<span></span>
</td>
<td class="num">(22,690)<span></span>
</td>
<td class="num">(39,910)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredNet', window );">Total payments</a></td>
<td class="num">(24,639)<span></span>
</td>
<td class="num">(22,723)<span></span>
</td>
<td class="num">(39,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations', window );">Balance at end of year</a></td>
<td class="nump">$ 174,803<span></span>
</td>
<td class="nump">$ 151,397<span></span>
</td>
<td class="nump">$ 128,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued professional liabilities assumed through acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Malpractice loss contingency accrual undiscounted excluding retained professional liabilities related to anesthesiology and radiology operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MalpracticeLossContingencyProvisionForLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Malpractice loss contingency provision for losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MalpracticeLossContingencyProvisionForLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProvisionAdjustmentForLossesRelatedToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision (adjustment) for losses related to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProvisionAdjustmentForLossesRelatedToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProvisionAdjustmentForLossesRelatedToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision (adjustment) for losses related to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProvisionAdjustmentForLossesRelatedToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized for asserted and unasserted malpractice claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asserted and unasserted malpractice claims that were originally recognized in a prior period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs associated with malpractice claims and insurance premiums incurred during an accounting period, less insurance recoveries and returns of previously paid premiums.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060100&amp;loc=d3e8578-115644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339710120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit facility, borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit facility, available balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 899,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_AlternateBaseRateMember', window );">Alternate Base Rate [Member] | Federal Funds Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Federal Funds Rate plus 1/2 of 1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_AlternateBaseRateMember', window );">Alternate Base Rate [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">LIBOR for an interest period of one month plus 1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_ApplicableMarginRateMember', window );">Applicable Margin Rate [Member] | LIBOR [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_ApplicableMarginRateMember', window );">Applicable Margin Rate [Member] | LIBOR [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_UnsecuredRevolvingCreditFacilityMember', window );">Unsecured Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit facility, borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember', window );">5.25% Senior Unsecured Notes Due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">payable semi-annually in arrears on June 1 and December 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DebtInstrumentMaturityYear', window );">Debt instrument, maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember', window );">5.25% Senior Unsecured Notes Due 2023 [Member] | Change In Control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember', window );">5.25% Senior Unsecured Notes Due 2023 [Member] | Redemption in 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.313%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">payable semi-annually in arrears on January 15 and July 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DebtInstrumentMaturityYear', window );">Debt instrument, maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Change In Control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption Before 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption Before 2022 [Member] | Redeem up to 35% of Aggregate Principal Amount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage of aggregate principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption in 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption in 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption in 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.563%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member] | Redemption in 2025 and Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit facility, borrowing capacity</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Estimated EBITDA</a></td>
<td class="nump">$ 139,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Forecast For First Quarter Of 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Forecast For Fourth Quarter Of 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">4.75:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember', window );">Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SupplementaryLeverageRatioRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Leverage Ratio Required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SupplementaryLeverageRatioRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_AlternateBaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_AlternateBaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_ApplicableMarginRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_ApplicableMarginRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_UnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_UnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsByNameAxis=md_ChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsByNameAxis=md_ChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=md_DebtInstrumentRedemptionPeriodSixAndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=md_DebtInstrumentRedemptionPeriodSixAndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344665032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument principal amount</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="num">(18,603)<span></span>
</td>
<td class="num">(22,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtNet', window );">Long term debt</a></td>
<td class="nump">1,731,397<span></span>
</td>
<td class="nump">1,727,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember', window );">5.25% Senior Unsecured Notes Due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument principal amount</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="num">(16,343)<span></span>
</td>
<td class="num">(19,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtNet', window );">Long term debt</a></td>
<td class="nump">1,733,657<span></span>
</td>
<td class="nump">1,730,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(2,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtNet', window );">Long term debt</a></td>
<td class="num">$ (2,260)<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586334377512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail) - Level 2 [Member] - Estimate of Fair Value Measurement [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember', window );">5.25% Senior Unsecured Notes Due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DebtInstrumentFairValueLineItems', window );"><strong>Debt Instrument Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">$ 756,225<span></span>
</td>
<td class="nump">$ 766,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">6.25% Senior Unsecured Notes Due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DebtInstrumentFairValueLineItems', window );"><strong>Debt Instrument Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="nump">$ 1,025,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DebtInstrumentFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fair Value [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DebtInstrumentFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586339225176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 11,118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 8,899<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586341117000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Income Tax Provision (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,610)<span></span>
</td>
<td class="nump">$ 63,697<span></span>
</td>
<td class="nump">$ 65,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal, Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,719<span></span>
</td>
<td class="num">(45,660)<span></span>
</td>
<td class="num">(29,667)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax provision, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,109<span></span>
</td>
<td class="nump">18,037<span></span>
</td>
<td class="nump">35,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,954)<span></span>
</td>
<td class="nump">8,561<span></span>
</td>
<td class="nump">15,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State, Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,573<span></span>
</td>
<td class="num">(10,022)<span></span>
</td>
<td class="num">(6,227)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State income tax provision, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
<td class="nump">8,958<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision, Total</a></td>
<td class="nump">$ 5,869<span></span>
</td>
<td class="nump">$ 6,677<span></span>
</td>
<td class="nump">$ 3,097<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 3,986<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="nump">$ 6,744<span></span>
</td>
<td class="num">$ (1,514)<span></span>
</td>
<td class="nump">$ 16,728<span></span>
</td>
<td class="nump">$ 16,576<span></span>
</td>
<td class="nump">$ 44,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586345603224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233.99%<span></span>
</td>
<td class="nump">28.19%<span></span>
</td>
<td class="nump">26.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Increase (decrease) in net deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxExpenseForExcessTaxDeficiencies', window );">Income tax expense for excess tax deficiencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards for federal and state tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,400<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax position liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,168<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
<td class="nump">$ 11,185<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase (decrease) in uncertain tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Company's accrued liability for interest and penalties related to income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CapitalLossesIncurred', window );">Capital losses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income Tax , Penalties and Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Federal and state income tax examinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Federal and state income tax examinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase (decrease) in uncertain tax position</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NetOperatingLossCarryForwardsExpirationDate', window );">Expiration period of operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NetOperatingLossCarryForwardsExpirationDate', window );">Expiration period of operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital loss carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CapitalLossesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital losses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CapitalLossesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomeTaxExpenseForExcessTaxDeficiencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax expense for excess tax deficiencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomeTaxExpenseForExcessTaxDeficiencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NetOperatingLossCarryForwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carry forwards expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NetOperatingLossCarryForwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344764776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">24.34%<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">60.44%<span></span>
</td>
<td class="nump">3.98%<span></span>
</td>
<td class="nump">0.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity compensation adjustments</a></td>
<td class="nump">98.61%<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="nump">0.78%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Change in accrual estimates relating to uncertain tax positions</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="num">(9.63%)<span></span>
</td>
<td class="num">(0.84%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">23.67%<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, net</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="num">(0.45%)<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax law</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.71%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">233.99%<span></span>
</td>
<td class="nump">28.19%<span></span>
</td>
<td class="nump">26.91%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344631400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for uncollectible accounts</a></td>
<td class="nump">$ 79,755<span></span>
</td>
<td class="nump">$ 170,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Reserves and accruals</a></td>
<td class="nump">64,445<span></span>
</td>
<td class="nump">54,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">11,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss and other carryforwards</a></td>
<td class="nump">16,767<span></span>
</td>
<td class="nump">6,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">447,854<span></span>
</td>
<td class="nump">17,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DeferredTaxAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">15,042<span></span>
</td>
<td class="nump">15,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">634,995<span></span>
</td>
<td class="nump">279,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(458,708)<span></span>
</td>
<td class="num">(19,286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">176,287<span></span>
</td>
<td class="nump">260,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Gross deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Amortization</a></td>
<td class="num">(152,969)<span></span>
</td>
<td class="num">(144,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DeferredTaxLiabilitiesChangeInAccountingMethod', window );">Accounting method changes</a></td>
<td class="num">(16,352)<span></span>
</td>
<td class="num">(71,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease liabilities</a></td>
<td class="num">(14,057)<span></span>
</td>
<td class="num">(13,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(183,561)<span></span>
</td>
<td class="num">(229,987)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="num">$ (7,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DeferredTaxAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating lease assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DeferredTaxAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DeferredTaxLiabilitiesChangeInAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities change in accounting method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DeferredTaxLiabilitiesChangeInAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586425160472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 7,409<span></span>
</td>
<td class="nump">$ 11,185<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures', window );">Decreases related to divestitures</a></td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Decreases related to lapse of statutes of limitation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,845)<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 6,168<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
<td class="nump">$ 11,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Decrease Resulting from Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586344583288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">84,316<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,490<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">82,592<span></span>
</td>
<td class="nump">82,441<span></span>
</td>
<td class="nump">83,234<span></span>
</td>
<td class="nump">86,073<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">83,495<span></span>
</td>
<td class="nump">91,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="nump">85,082<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,744<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">83,288<span></span>
</td>
<td class="nump">82,883<span></span>
</td>
<td class="nump">83,689<span></span>
</td>
<td class="nump">86,545<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">84,011<span></span>
</td>
<td class="nump">91,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the diluted net income per common share calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586424845480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 21.1<span></span>
</td>
<td class="nump">$ 33.4<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of restricted and deferred stocks vested</a></td>
<td class="nump">$ 59.3<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="nump">$ 27.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of restricted and deferred stock awards granted</a></td>
<td class="nump">$ 23.54<span></span>
</td>
<td class="nump">$ 33.28<span></span>
</td>
<td class="nump">$ 51.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation', window );">Cash proceeds received from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options Grants In Period Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense related to non-vested restricted stock, weighted-average period in years</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock Option, Share Based Compensation Cost Not Yet Recognized Period For Recognition</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=md_RestrictedAndDeferredStockUnitsMember', window );">Restricted and Deferred Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense related to non-vested restricted stock, weighted-average period in years</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to non-vested restricted shares</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=md_RestrictedAndDeferredStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=md_RestrictedAndDeferredStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586341110568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Non-vested shares at January 1, 2020</a></td>
<td class="nump">1,723,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Awarded</a></td>
<td class="nump">1,361,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(173,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(1,700,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Non-vested shares at December 31, 2020</a></td>
<td class="nump">1,211,117<span></span>
</td>
<td class="nump">1,723,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Non-vested shares at January 1, 2020</a></td>
<td class="nump">$ 40.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Awarded</a></td>
<td class="nump">23.54<span></span>
</td>
<td class="nump">$ 33.28<span></span>
</td>
<td class="nump">$ 51.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Forfeited</a></td>
<td class="nump">31.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Vested</a></td>
<td class="nump">34.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Non-vested shares at December 31, 2020</a></td>
<td class="nump">$ 30.97<span></span>
</td>
<td class="nump">$ 40.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586341625704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at January 1, 2020 | shares</a></td>
<td class="nump">72,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Options Awarded | shares</a></td>
<td class="nump">982,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Stock Options Expired | shares</a></td>
<td class="num">(56,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at December 31, 2020 | shares</a></td>
<td class="nump">999,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable at December 31, 2020 | shares</a></td>
<td class="nump">16,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at January 1, 2020</a></td>
<td class="nump">$ 32.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Awarded</a></td>
<td class="nump">16.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">31.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at December 31, 2020</a></td>
<td class="nump">17.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2020</a></td>
<td class="nump">$ 36.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding at December 31, 2020</a></td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable at December 31, 2020</a></td>
<td class="text">4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue', window );">Aggregate Intrinsic Value Expired</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at December 31, 2020 | $</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2020 | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586345481576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock repurchased</a></td>
<td class="nump">$ 8,493<span></span>
</td>
<td class="nump">$ 145,280<span></span>
</td>
<td class="nump">$ 302,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Amount withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586337375576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense of retirement plans related to the 401(k) Plans</a></td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140586424865880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 416,630<span></span>
</td>
<td class="nump">$ 460,635<span></span>
</td>
<td class="nump">$ 415,441<span></span>
</td>
<td class="nump">$ 441,245<span></span>
</td>
<td class="nump">$ 458,600<span></span>
</td>
<td class="nump">$ 454,913<span></span>
</td>
<td class="nump">$ 439,154<span></span>
</td>
<td class="nump">$ 427,092<span></span>
</td>
<td class="nump">$ 1,733,951<span></span>
</td>
<td class="nump">$ 1,779,759<span></span>
</td>
<td class="nump">$ 1,723,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">284,772<span></span>
</td>
<td class="nump">309,904<span></span>
</td>
<td class="nump">282,985<span></span>
</td>
<td class="nump">316,279<span></span>
</td>
<td class="nump">300,073<span></span>
</td>
<td class="nump">301,306<span></span>
</td>
<td class="nump">284,627<span></span>
</td>
<td class="nump">294,753<span></span>
</td>
<td class="nump">1,193,940<span></span>
</td>
<td class="nump">1,180,759<span></span>
</td>
<td class="nump">1,125,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">24,235<span></span>
</td>
<td class="nump">22,440<span></span>
</td>
<td class="nump">20,173<span></span>
</td>
<td class="nump">23,842<span></span>
</td>
<td class="nump">23,223<span></span>
</td>
<td class="nump">22,581<span></span>
</td>
<td class="nump">25,402<span></span>
</td>
<td class="nump">24,705<span></span>
</td>
<td class="nump">90,690<span></span>
</td>
<td class="nump">95,911<span></span>
</td>
<td class="nump">92,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">54,671<span></span>
</td>
<td class="nump">66,346<span></span>
</td>
<td class="nump">60,488<span></span>
</td>
<td class="nump">67,442<span></span>
</td>
<td class="nump">59,194<span></span>
</td>
<td class="nump">63,284<span></span>
</td>
<td class="nump">63,011<span></span>
</td>
<td class="nump">59,023<span></span>
</td>
<td class="nump">248,947<span></span>
</td>
<td class="nump">244,512<span></span>
</td>
<td class="nump">232,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,692<span></span>
</td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">6,751<span></span>
</td>
<td class="nump">6,803<span></span>
</td>
<td class="nump">7,101<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">6,183<span></span>
</td>
<td class="nump">28,441<span></span>
</td>
<td class="nump">25,931<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">12,955<span></span>
</td>
<td class="nump">34,291<span></span>
</td>
<td class="nump">10,479<span></span>
</td>
<td class="nump">16,076<span></span>
</td>
<td class="nump">28,865<span></span>
</td>
<td class="nump">12,766<span></span>
</td>
<td class="nump">16,820<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">73,801<span></span>
</td>
<td class="nump">60,890<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">384,325<span></span>
</td>
<td class="nump">440,176<span></span>
</td>
<td class="nump">380,876<span></span>
</td>
<td class="nump">430,442<span></span>
</td>
<td class="nump">418,456<span></span>
</td>
<td class="nump">406,345<span></span>
</td>
<td class="nump">396,099<span></span>
</td>
<td class="nump">387,103<span></span>
</td>
<td class="nump">1,635,819<span></span>
</td>
<td class="nump">1,608,003<span></span>
</td>
<td class="nump">1,474,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">32,305<span></span>
</td>
<td class="nump">20,459<span></span>
</td>
<td class="nump">34,565<span></span>
</td>
<td class="nump">10,803<span></span>
</td>
<td class="nump">40,144<span></span>
</td>
<td class="nump">48,568<span></span>
</td>
<td class="nump">43,055<span></span>
</td>
<td class="nump">39,989<span></span>
</td>
<td class="nump">98,132<span></span>
</td>
<td class="nump">171,756<span></span>
</td>
<td class="nump">248,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other (expense) income</a></td>
<td class="nump">4,849<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">17,913<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(27,302)<span></span>
</td>
<td class="num">(27,250)<span></span>
</td>
<td class="num">(28,265)<span></span>
</td>
<td class="num">(27,665)<span></span>
</td>
<td class="num">(27,657)<span></span>
</td>
<td class="num">(29,909)<span></span>
</td>
<td class="num">(31,013)<span></span>
</td>
<td class="num">(30,349)<span></span>
</td>
<td class="num">(110,482)<span></span>
</td>
<td class="num">(118,928)<span></span>
</td>
<td class="num">(92,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">7,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(21,949)<span></span>
</td>
<td class="num">(16,434)<span></span>
</td>
<td class="num">(24,384)<span></span>
</td>
<td class="num">(28,217)<span></span>
</td>
<td class="num">(26,231)<span></span>
</td>
<td class="num">(28,321)<span></span>
</td>
<td class="num">(29,784)<span></span>
</td>
<td class="num">(28,636)<span></span>
</td>
<td class="num">(90,984)<span></span>
</td>
<td class="num">(112,972)<span></span>
</td>
<td class="num">(82,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income from continuing operations before income taxes</a></td>
<td class="nump">10,356<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">10,181<span></span>
</td>
<td class="num">(17,414)<span></span>
</td>
<td class="nump">13,913<span></span>
</td>
<td class="nump">20,247<span></span>
</td>
<td class="nump">13,271<span></span>
</td>
<td class="nump">11,353<span></span>
</td>
<td class="nump">7,148<span></span>
</td>
<td class="nump">58,784<span></span>
</td>
<td class="nump">166,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="num">(5,869)<span></span>
</td>
<td class="num">(6,677)<span></span>
</td>
<td class="num">(3,097)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
<td class="num">(7,360)<span></span>
</td>
<td class="num">(6,744)<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="num">(16,728)<span></span>
</td>
<td class="num">(16,576)<span></span>
</td>
<td class="num">(44,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">(Loss) income from continuing operations</a></td>
<td class="nump">4,487<span></span>
</td>
<td class="num">(2,652)<span></span>
</td>
<td class="nump">7,084<span></span>
</td>
<td class="num">(18,499)<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">12,887<span></span>
</td>
<td class="nump">6,527<span></span>
</td>
<td class="nump">12,867<span></span>
</td>
<td class="num">(9,580)<span></span>
</td>
<td class="nump">42,208<span></span>
</td>
<td class="nump">121,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">(Loss) income from discontinued operations, net of tax</a></td>
<td class="num">(68,783)<span></span>
</td>
<td class="num">(38,392)<span></span>
</td>
<td class="num">(679,520)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="num">(1,268,803)<span></span>
</td>
<td class="num">(14,772)<span></span>
</td>
<td class="num">(255,739)<span></span>
</td>
<td class="num">(786,908)<span></span>
</td>
<td class="num">(1,539,910)<span></span>
</td>
<td class="nump">147,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (64,296)<span></span>
</td>
<td class="num">$ (41,044)<span></span>
</td>
<td class="num">$ (672,436)<span></span>
</td>
<td class="num">$ (18,712)<span></span>
</td>
<td class="nump">$ 9,331<span></span>
</td>
<td class="num">$ (1,255,916)<span></span>
</td>
<td class="num">$ (8,245)<span></span>
</td>
<td class="num">$ (242,872)<span></span>
</td>
<td class="num">$ (796,488)<span></span>
</td>
<td class="num">$ (1,497,702)<span></span>
</td>
<td class="nump">$ 268,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations, Basic</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations, Diluted</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">1.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss from discontinued operations, Basic</a></td>
<td class="num">(0.81)<span></span>
</td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(8.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(15.39)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="num">(2.97)<span></span>
</td>
<td class="num">(9.44)<span></span>
</td>
<td class="num">(18.44)<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss from discontinued operations, Diluted</a></td>
<td class="num">(0.81)<span></span>
</td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(8.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(15.31)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="num">(2.96)<span></span>
</td>
<td class="num">(9.44)<span></span>
</td>
<td class="num">(18.33)<span></span>
</td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share, Basic</a></td>
<td class="num">(0.76)<span></span>
</td>
<td class="num">(0.49)<span></span>
</td>
<td class="num">(8.06)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="num">(15.23)<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(2.82)<span></span>
</td>
<td class="num">(9.55)<span></span>
</td>
<td class="num">(17.94)<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share, Diluted</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (8.03)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (15.15)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (9.55)<span></span>
</td>
<td class="num">$ (17.83)<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, Basic</a></td>
<td class="nump">84,316<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,490<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">82,592<span></span>
</td>
<td class="nump">82,441<span></span>
</td>
<td class="nump">83,234<span></span>
</td>
<td class="nump">86,073<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">83,495<span></span>
</td>
<td class="nump">91,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares, Diluted</a></td>
<td class="nump">85,082<span></span>
</td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">83,744<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">83,288<span></span>
</td>
<td class="nump">82,883<span></span>
</td>
<td class="nump">83,689<span></span>
</td>
<td class="nump">86,545<span></span>
</td>
<td class="nump">83,395<span></span>
</td>
<td class="nump">84,011<span></span>
</td>
<td class="nump">91,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWTK9<"D'_GI]WF_W,;+"?2E'Y<:)UN]G%S;]*^2:3<J:G&)HA8M3W(>SI/V
MQJ?Y'*E]1)92Q"J2'IG%<2)U*1^N^21CC*WP=HJ;\G% L^P=C-2/-F1IA#FS
M!G#%"K+"YBGNS1G9+#)2'SI'.Y;BB%I*ABM6D!5F3W&W/N9,A2'4GJ51[O,%
M66Z%EC'YFIC8B,B#%)9U-)ER)U6V_?K+L-?I<MKCW4'KI8RJL'Z*.W9&]5T%
M262@O8>5$$A=/H*XTEQA:2K\GN(F_>B;0!*UAA[MX^H3S'DWT4!8"H0KG68:
MZSL+VV>X3T/KX*63_"U<J:",J$+@?H)Q%$;/<'\^YH3<OKI;$4&#?L[H*X3F
M3\M;C*@P>%;+X.W<(?,D7)6;4X6(XU"P3THQ^V2%LS/<BG,C<)4&=Q*VX[M(
M_0EFEX9E"/-=V^7HE6<.5Y_>89"%Q[-:'O\H7LG, WORU[Z;DF)9Q"59M\F[
MW:L.[V&$A=.S6DX_\CSPJ?CB>$#NX#GR-2K/'2Y)N4,A[W9@//(H-?@TUL6R
MPOM9+>_/6<?V#,;Z$8IG*2<NMTPB[:,--BO,G]4R_QPMGX<+K5[\Z'T",CY<
M$Y^#105@M2I CK904(H"\I>_.[\X<$7..>,86U$,6(6%IV1:BO,HN$"_T\9^
MI!?6SW'GOE-IG[^%]@M9FA4BO-=N.O2J@Q$518#7ZO;3<DW&,)LV2I=6R0J=
M.Z&A@(Q<5X(0R'@'28RQ* N\5EE8AB((R$T2P^VXM+6HT*GZH<M/=EMJ587;
M4.J-+>6_@8+9VJ9L)Z+R].&"E6A%+>"U:L%R"PT_"H3+5 (5UL]K6?\B606^
M2Z:!$F7M\R13Z9XTIY1U:+_;H4ZOO#WEA:5SW(-GX^D#&26>;\ K1\9(\*:T
M/I[;,:G0.[>;U#K9)[5S(]UOCHEKNX3#EFE^-=_3'J4[N:WB\<.&^+VP4RLF
M@5Q#J'-Y!?G1ASWFPXE1NW37=:6,46%ZN)7"D]H^ /?72IGCB?V"?*=_^!]0
M2P,$%     @ '#A24BATC;4S!P  UAX  !@   !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6RMF6MOVS84AO\*8118!R2Q>-$M30*DR2X%NC5HVFU?&8F.A4JB
M1]))LU\_4G)$6[PD _8ED:Q#ZCU'Y'D.R;-'+K[)-6,*?._:7IXOUDIM3I=+
M6:U91^4)W[!>/UEQT5&E;\7]4FX$H_70J&N7*$FR94>;?G%Q-OQV(R[.^%:U
M3<]N!)#;KJ/BZ3UK^>/Y BZ>?_C<W*^5^6%Y<;:A]^R6J:^;&Z'OEE,O==.Q
M7C:\!X*MSA>7\/2*(--@L/BC88]R[QH85^XX_V9N/M3GB\0H8BVKE.F"ZG\/
M[(JUK>E)Z_A[U^EB>J=IN'_]W/O/@_/:F3LJV15O_VQJM3Y?% M0LQ7=MNHS
M?_R5[1Q*37\5;^7P%SSN;),%J+92\6[76"OHFG[\3[_O K'7 ))  [1K@%[;
M .\:X,'14=G@UC55].),\$<@C+7NS5P,L1E::V^:WGS&6R7TTT:W4Q=7O)>\
M;6JJ6 W>TY;V%0.WICL)CL'7VVOP]LV/X UH>O!ES;>2]K4\6RK]9M-^6>W>
M\GY\"PJ\Y9I5)P##(X 2E'B:7[VZ.2P/FR^UOY/3:'(:#?WAD--;(5BO )52
M^WD:Z1%//>*A1Q+JD<HUT+$!E;E@?V^;!]KJ5WAC-7:5#5V9:?9P 2'"!<%G
MRX?]H'CLDKS(D\GL0"J9I)*HU-LU%^I8,='IC_K I.I".L=^TH/WD_WWCS)=
MLYRD,* RG52F49675<6W6I=.%173P;QKV1'HF?+I3!T!B, 2PYE.UXQ@@K+,
M+S2;A&91H3>";6A3 _9=9U;)O(',W$!F15G,]'FL<I@4?GGY)"^/RONDUDSH
M1+(_X'T2<^?E&2R2;";1M8*PP+E?8C%)+.*?>A %UJRM@>82D'KF^"06SLOG
M(]&U*-(2!CYP.<DKH_*^<$7;5T2P=&.3DA*3^6=V[7(,TR001)C81)[\+V'<
M=1.+H\<$9@2F16!2PSW:P!=FBRY A'H:<J5)DQN3?8(S>]?;0; R6,YGML\,
M97DHI!83$$75_L)Y_=BTK5<:<F-$\KS,YM_;;U@6:2B8ECDP#IT/O:+]?:-3
MXVY8AN.(W129903-I7K,BK0(Q=$2!\:1\TE_<ZJ:_G[X[*NF'ZJ,ENGR"PA3
M9QWSU?%6LLCL@BYETK3,'0\\9GKDXH 'ED8PCJ-KMF(Z =0:F17O&%#T>TRL
MBYJ4$%>L:U;HKT("8BV18!Q)8\Z/R/.0)LEQFL[UN7:DR$@HF!9),,ZD,:-&
M]+F8P5A/&2>5>@P))&F9P(!$BR18O*I";!MZU[2-:EBT3(06)C!.DZFNV= G
M.LQ</2-H58DMB]<0T.4&01H<^3PF'CN89"%((\L7%.?+<T@VNGPT"S"^FLWD
MO5CY'$ N5! RY?R!?(]5($\B"QT4AXY'.9\RTNNTNX"!18GG!;O7#*6!"8WV
MEBMQ#GV8D@Z;!HY7IHL:-"_A/#99@LN 1,LB%&?11QO ETL0Y')F7H)X3/0H
M+HI .8PLBU"<18?EW$O?W<4)(03C>:;TV*4$%C"DUG('Q;GSW\+J\L0)JV<1
ME"5)&M!ID8/BR/G(^_MQ35FS.^7!_%Z@@U4*\JV "$H+9PS[#'&BU] !/RR:
M4!Q-UH__FB$\*$I*9ZWL,R-!I"++*Q1?0UG=&\%73)I=-CW,7Q+M+IA0EJ*<
MS%5[[!)2PE!BLS1$<1KZRJJ7-+M\R_0H<8:(:Z8+P2PP0+"E((Y3<*RM7M"(
M78B1%*/Y8/"8(53 0"[&EG<XSKLQQ;VDT645TID .=LF7D.2E:&D@2W6<!QK
M5[SKFG'[:=P[X[V9<*RO0IJC_9D=[U.YH14[7VP$DTP\L,4%\&TW_@\='?J\
MMT^(HX7E[9H*MN9MS83\85@!JZ?H!J0%&XZ#[48\3R:I>/7M'7ASDD!=+0CP
M0-LM>P?@49(D0!H!.MY;M>:B^8?5[T#/>P8:*74)ZHVZ"S=G),=,#OVQZ,-Q
M])G1H8NU@#,H24+N%.E16N)A1!7D")'BV6AT<7C MTKJQ7.MA]L1T,\V;#A.
M:)^\ ?"LT])YPO$9[2VP#X-@N8KC7+VLZT:-N=SL,AXW/:CHIM'SVRO4M[!#
MI<X]<[&N85GH!59(K^4GCO-3+V^VW;8=3A/XN/7(.SV'UN;@YX'M\KQ7NV?1
MEV)GH+E6>2BG6WCB.#P_,T7U3S5X6[-54S7J1\"HZ/78\&<AEX;'J,AP.L>F
MQS"%"<0!;&*+3?R:+<G??KK^_?*O(Z!7!R?C$)_E%:]XS_8CR4DQKV@]=I"4
M15D&=E.))2B)$_1WWIM$+WC;FNJJZ779PJ2W("0>0.+Y+HK'*'1"8@E*7D/0
M<!2)9\.1Y#F<+\8]=O$H6G:2.#L=QD\[J@'%R#E,\N^I> S]>RK+O4-'<^+[
M&Q7W32]UN;S2+9.37'LMQD/4\4;QS7 .><>5XMUPN694#UACH)^O.%?/-^9H
M<SK*OO@74$L#!!0    ( !PX4E)K<A^9I@(  (L(   8    >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&ULE99=;]HP%(;_BA7M8I,Z\@'AHPJ16JIJNYB$BK9=
M3+LPR8%8=6QF.]#MU^_8@0A*: ,78#OG?<]S?(R<9"?5LRX #'DIN=!3KS!F
M<^O[.BN@I+HG-R#PR4JJDAJ<JK6O-PIH[D0E]Z,@&/HE9<)+$[<V5VDB*\.9
M@+DBNBI+JO[> Y>[J1=ZAX4GMBZ,7?#39$/7L #S?3-7./,;EYR5(#23@BA8
M3;V[\'8VL?$NX >#G3X:$UO)4LIG._F:3[W  @&'S%@'BC];F 'GU@@Q_NP]
MO2:E%1Z/#^Z/KG:L94DUS"3_R7)33+VQ1W)8T8J;)[G[ OMZ8NN72:[=-]G5
ML?'((UFEC2SW8B0HF:A_Z<M^'XX$X>""(-H+HJZ"_E[0=X769*ZL!VIHFBBY
M(\I&HYL=N+UQ:JR&"=O%A5'XE*'.I#,IM.0LIP9R<D\Y%1F0A;73Y..<*A"F
M ,,RRC^1S^0#\8DN<%4GOL'LUL//]IGNZTS1A4P/D/5(/[PA41 %+?)99WDX
M.97[6'-3>-04'CF__@6_A<&2\3@:(E?DD0DLG%%.YE(S=[Y^W2VU47C*?K^1
MK-\DZ[MD@PO)YG@V02G<8FQH]GQ#-E21+>45M.UC[35R7O9?N$V#7A F_O9X
MM]X).L$<-)B#ZS#K7A-:F4(J]@_R-MS:,SXB"0/W>47\?MP)=-Q Q]=!,ZVK
M=M+XC. UXUL1)W3#AF[X)MU,EB6>IBYM'W9I^SM!)XRCAG%T!6.GGH_.]BD*
M@M:N=XD\H1XWU./KJ2_W?GS&,8[C2?\<N"5P$ W&%WDG#>_D>EZ\5[6A(F=B
MW08]Z0K=$M@.[1]=%?::_D;5F@E-.*Q0&O1&Z*'JJZ^>&+EQM\=2&KR+W+#
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M%V,$*,9I/,> DE811=XA2@BJ#32NV))<, 54K!BYX@RMA&%D)>8AY9AV5!:
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MA"F C-!4!F"*@B[$'%$F:)XLT$)H&V@ 4"SN.%ORMH/%^UM8L[Q.FY+A=7.
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MFZ@A=L?JWF7U?5XUJ. K&"YXU1XKJW<GU7874FRZDU5W0DI1=C_7/ -FT@K
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M;NO/!PG$W1+H2W=?HVK3!S#L2E(@"=H/>OO_"-OEF>H&MZ4+\8F(0\N7;6
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M1?=#[;WD)"?EPU+O.1!'+.H%NT/))_4S9GB>V)H'<<=UQ^1%0E(/@2&/S-W
M]M]RHZKUF3![QQ#0\V,V,U3B_$Q)RMM\OJ>JBF_*V WAG@M 3<,MN*[\Y&LY
M\2AL#>F@\9XV]EJSNJB7BQ@0P4U6Z4W6^.:CL.Z]+YNJ9UKR"ZN%89/0R>)
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M<VAE971S+W-H965T,3 N>&ULG51+;]LP#+[G5Q!>,6R $3_B/)<$:-(6ZZ%
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MX/*QXN8%-AA7BAN.&GZ>;[51]$1^G0@:M4&C.FCT?ST]#8[ZT,'/N@IDF"?
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ME76@^U1*<U1L@';K+O\ 4$L#!!0    ( !PX4E*Q"GDEC04  .0-   9
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M$E#OD%;]JBRY7$_ELLN8+ )F07&1I7H"VO>H=<0E?$26JDR9^'V[UFH_[.(
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MLXDSF_QO@;Z(9YOU1C<LPY5'W:A1/:&W3L=PV<[-\_Z>:7@3CI,4MC1U'6*
M@HWU%M40< <3!>'B#)EK,*@-YD"' O"Z85Q1GQKH,"IDVI >_43+*MLT7/O
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M6FBEM676:[CU&N(3&J*8_: :6QKV=9.+_*F")=P9?8H'GV[C%S6^$=F")5'
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M76@2P'JAE!T^R,#X[K_^&U!+ P04    "  <.%)2>V@B]_ #   :"0  &0
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MZ%RK-_"S?/)FQ=NE+2]>EHK: 1F0C0V4#3_E ;G?(-;*<"I# L%.2]<$B0^
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MT7A@.9>]@6%8=R,<L+3B#L<8I-7>V#GRWUD'4P$;Z0+D("2.(S8BM3&!RO8
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MEM@GW7@^G[!?5'GQCYKGSD'W196K+43: >H&<@,P_MPV]=X_/CP$CNTSX47
M6M !3%-(ZYW1T,\A-)U, N:9C;_#X.DR3,E^XF4-'2"+C>VS.R"GW%W^5.?T
MD"SR*;4*?8#W($/P=$VY<\H:R2 >LWM<Z7D,U2)I>(/7OGR0B_ 9D@*Q.&P
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MW,Q99C=I5[0_N]N_V"$>3?K6KFC\+[OM>74X9^NN:5TY",.#,J_Z9WHWY.%
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M+ L:E*B= YWG2MF=X0CVHW?V#U!+ P04    "  <.%)2Z"M%P.4#   >"0
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MY>*95-WP)Q_PB=J=UI1 9@W;5V&)%U78DV7=:<LV[1SBWU:#=%PW7)?4BIA
MTLH+@BTE&PXYX;+2P$7%2V:P>K^2K@<!T+&&"0JS@I(IA'P&'X?'%#YZG^4C
M*F&+%&*:0YP/CT$,9L-5]4/+%&E20TJ;F36E_1M%;P:#M/>\DZR&B#:'GQ>%
MH1V]/ \)(]CK60VJM>O,&MS[IV]?X^K8_"_[GO=RO/]R^,K4F@L--:[(-#R;
M4B&KOAOW$R-;UP&7TE _=<,-?<"@L@=H?R6EV4VL@_&3:/$?4$L#!!0    (
M !PX4E) .6+BG (  'D%   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;(5436^C,!"]\RLLU$,CH0"&D"9*(B5M5[O25HK:_3BL]N# )%@UF-JF:?_]
MCDU"4ZG-7O",/?-FWICGV5ZJ1UT"&/)2B5K/_=*89AJ&.B^A8GHH&ZCQ9"M5
MQ0RZ:A?J1@$K7%(E0AI%65@Q7ON+F=M;J\5,MD;P&M:*Z+:JF'I=@9#[N1_[
MQXU[OBN-W0@7LX;MX ',SV:MT M[E()74&LN:Z)@._>7\725VG@7\(O#7I_8
MQ#+92/EHG6_%W(]L0R @-Q:!X?(,UR"$!<(VG@Z8?E_2)I[:1_0OCCMRV3 -
MUU+\YH4IY_Z53PK8LE:8>[G_"@<^(XN72Z'=E^R[V!0KYJTVLCHDHU_QNEO9
MRV$.)PE7T2<)])! 7=]=(=?E#3-L,5-R3Y2-1C1K.*HN&YOCM;V4!Z/PE&.>
M6:P5WJ\RKX35!;E]:GF#$S?D\@?;"-"#66BPB T-\P/@J@.DGP#&E-S)VI2:
MW-8%%.\!0NRN;Y$>6US1LX@WD ])$@>$1C0Z@Y?TE!.'E_R'<D#6@B'7]\S_
M+#?:*/Q9_IXIE?:E4E<J_:34 VJH: 40N24?3_JC 9_%M"J=ZH;E,/=1AAK4
M,_B+]^C0L\DERD<;;1LP)9"M%"A#7N_():]Q1[8:$_1@ZN&4H=J LI/V[*1Q
MW/'$6[5<%#;^@M LF"1I;WC?;:DLR*Z2[NN]#=&>2*RG$"0)HGA,X@D-HBCU
M:(*QB$+I*,AH["WSO*U:P0P4*"8DE'/FY'H99U&0I@D9H#FBP21-R<"[(.,L
MB"<Q=C&F038>?W1)X8D<*E [)WJ-LVAKTRFCW^W?E64GI[?P[E&Z8VK':TT$
M;#$U&HY'/E&=T#O'R,:):R,-2M69);Z-H&P GF^E-$?'%NA?V\4_4$L#!!0
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MBCO%?AA$7=KA6RN:BJAG^9?X892CP#0..X%#'CE#DSQAR$#ODS2\/")SPN+
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MN<6GEAOO@.MKK=UQX E.C_?\7U!+ P04    "  <.%)2L3!D-"@$  !)"@
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MWDF7S?/@]7CSR/K(])IC# )6J!J=9]BPNGFX- NK*O]86"J+3P\O8H8+T.X
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MU5VCNP<CM_;JNI &%V&[W B.>8\VX/M*2G-\( /]_S)N_@%02P,$%     @
M'#A24DC<: Q) P  B@<  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MC95M;],P$,??]U.<@H285#4/3<<VVDKK-L1>@*9U@!#BA9M<&PO'+GYHQ[?G
M[*3I*FC%F\0/=S__SV>?QUNE?YH*T<)S+:291)6UZZLX-D6%-3,#M49),TNE
M:V:IJU>Q66MD97"J19PER7E<,RZCZ3B,/>CI6#DKN,0'#<;5-=._9RC4=A*E
MT6[@D:\JZP?BZ7C-5CA'^WG]H*D7=Y22UR@-5Q(T+B?1=7HUR[U],/C"<6M>
MM,%'LE#JI^_<EY,H\8)08&$]@=%O@S<HA >1C%\M,^J6](XOVSOZ^Q [Q;)@
M!F^4^,I+6TVBBPA*7#(G[*/:?L VGI'G%4J8\(5M:YM$4#AC5=TZDX*:R^;/
MGMM]^!^'K'7(@NYFH:#REEDV'6NU!>VMB>8;(=3@3>*X]$F96TVSG/SL]$;5
MM=\<64+;O/OE^(8)E!;F%=-HX,T36P@T9^/8THK>+RY:^JRA9T?H:08?E;25
M@3M98GD(B$EJIS?;Z9UE)XFW6 Q@F/8A2[+D!&_8Q3\,O.$1WAW3DLN5@0?4
M3;SP_7IAK*;C\N,$/^_X>>#G1_ASND6E$PAJ"3=,%$ZP<!JIV^[N9X,E< DS
M9G@1$G'+A;,T^(GNY+TL5(U[=?_*P4D%_E9?F34K<!+1M36H-QA-GRJ$XE".
M:>2X5HXEBT4GJ6PE29+$&TEKDA1\#D!4)H+K;V3: /JL ^4,ZP69[_+FO^EE
M/Y"I=0'< #/D*ZA&T'D+RRMG:-Z<7?6^!=;=7ZR>9P54H/2^ABM(1FR#FBH*
M2!=,*;BB.=MMC%2<C"4X)1XNAOWAY<C_<OI=IOTTR4^1PDY0(3E  G:7AN2S
M,WC]ZB)+LW<P2L]AE&3_(<WO1=O<PTX)SOM)FGK!Y\EY[UI:WBDS6#C-+2='
MJ4*^A"OW63V2RX-X7J8T[2?#/$22I7G/1W?K$*P"!D(92IM6-7F3 NF\0'HP
M=/ T!Z?A^&&0RNO02+7>,K&+V<OHI"^P8'0R PR72RKI5.V=\!.T<_O8!_"O
M.QN_J(\UZE5X!0QI=M(VI;(;[1Z:ZZ:^[LV;5^HCTRM.D0E<DFLR>#N*0#>5
MO^E8M0[5=J$LU>[0K.BQ1.T-:'ZIE-UU_ +=\SO] U!+ P04    "  <.%)2
MIG=KU?8#   ^"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R=5MMN
MVS@0??=7#-QBX0"*+I1DV8EMP+DLM@NT,9)N^K#8!UH:VT(DT26I./G['5*R
MXK:)-]@76^)PYISAG.%HLA/R06T0-3R51:6F_8W6VS//4^D&2ZY<L<6*+"LA
M2Z[I5:X]M97(,^M4%A[S_:%7\KSJSR9V;2%G$U'K(J]P(4'59<GE\P468C?M
M!_W]PFV^WFBSX,TF6[[&.]1_;1>2WKPN2I:76*E<5"!Q->W/@[.+V.RW&^YS
MW*F#9S"9+(5X,"^?LFG?-X2PP%2;")S^'O$2B\($(AK?VYC]#M(X'C[OH_]N
M<Z=<EESAI2B^Y9G>3/NC/F2XXG6A;\7N#VSSL01342C["[MVK]^'M%9:E*TS
M,2CSJOGG3^TYO,>!M0[,\FZ +,LKKOEL(L4.I-E-T<R#3=5Z$[F\,D6YTY*L
M.?GIV9T6Z0-\JE*LS/' HN"5 EYET%@6M4PWE'5K&'SERP+5R<33!&Y">&D+
M=-$ L3>  @:?1:4W"JZK#+,? WC$NJ/.]M0OV-&(5YBZ$ 8.,)_Y1^*%W5&$
M-E[X5KQ<I850M400*[@4)0E?<:N=6RRXQHP6E58.W&VXQ%,CA@P6_)DTJA7\
M/5\J+4EE_QSA$G5<(LLE>JLLU'Q975@FMTAQ\]3@-S4QU;G"%4K9+<UW7&;J
MM:H<Q_FZP:8Q<OU,/=9DJ05H6C<GP*OGWSZ,6)"<*S)W/%3'(]OS:)<L#VLQ
M(5)!-K455997:]C9%J&]_!$E=3RL):_T:4:@L.*YA$=>U*B KAKK_8Q< AJU
M4+HIEDN47;V!*@#<["WH7E%GAJ4?GK__K_>EM@'I@&TY%7QKZ?6^B.KTD9(U
M634FKN%/7M5T:\$>/W 2%CI!$,-'B'PW27JV!N03..&0K"3XC\!"-XYZ='^L
M,#?Q!D$2.E$<PPD9P\ =CGKW#=* 7'S?87M;Y(Y&KS/Y]2P"AP4!<4F,H^^.
MDR,*C#L%QN]6X'RO$%/72Y2:+GNXH1))NCF:P7#8):2?1I4W6[O^MCB/4_A!
MG 8Z;:&%A<X/H/]#NC2-E.:-"ANABH9:J]?_H[A# 1UD^Z(CF+<ROWY"F>;F
M#J7VP1?[@%(QB.H$YNNUQ+5IA'O3 ]94YD5A I[T;@[HOR+%A#DC?V1JS]QH
MW.EP/&).$@:T'@S=\;AW_;3-3:<.XJ'#HM%>@N$8[#FQ\Y]Q?CV"\7CLL+$-
MF;BA#\R-#6[B1KTV23,>WA#IT(F'OL$<NBP&WPVC/?!K<O4.9EJ)<FTGMZ(;
MI:YT,]ZZU>[C8-[,Q)?MS9?%9R[7.16FP!6Y4J^2[&0SK9L7+;9V0BZ%IGEK
M'S?T@8/2;"#[2@B]?S$ W2?3[%]02P,$%     @ '#A24NM!.4:B!P  Y!,
M !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULU5A9<^.X$7[7KT I4XE<
MQ4@X"!+TVJZ:&>]LIBJ;.#M.]B&5!UJ$+-92I :@?.37YVOPD+SC<][R(C;
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M]QA />-\$M#V[>B)L<9Q<$"I+!(Z)@JHDN&$$66BA'\7>LH,**E50,M$IIB
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M:W3U[2^*6K/H*)[9ZFO)E:[E;#/1]3D(,T%_7W&N-AT3H*KXAW\!4$L#!!0
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MH&P OL^E-&\;.Q[;OV'R!U!+ P04    "  <.%)2T\6PGKX"  !6"   &0
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M^[XN*JBIOI!;$'BREJJF!K=JX^NM EHZ4,W]* A2OZ9,>'GFWMVJ/).-X4S
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M*WV4VV&A+ULLC$"_7W&NMA-SGG?7=_H74$L#!!0    ( !PX4E+EER!;9 (
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MB]H%T/Y"*;N9N 2#A>=_ 5!+ P04    "  <.%)2=5B:90$$  #)#@  &0
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M9,HN@/]W4IK3P#HHN]?EOU!+ P04    "  <.%)2^57KCZL"   7!P  &0
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M3)FJ:[F=@7+MVMQ"HFF:;EB;6PJ4W6#6EU+BSK"=<[CWBC]02P,$%     @
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MB__/)6L/2NTT\4,NT;>@+F^T)(-WK#7:0PIEMB#%)%6K0_W.FJ]^QN"-6Z+
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MJ#\-X-I S>>,R9>.OLRZ?Y?Y7U!+ P04    "  <.%)2^RY#+@H#  #P"
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R=5F%/VS 0_2NGB&E#6DF:
MI(6BMA(KFC:):6B,\=DDU\;"L3/;H>/?[^R$K$":L7UI;=^]EWOO'#OSK=)W
MID"T\*L4TBR"PMKJ- Q-5F#)S)&J4%)DK73)+$WU)C251I9[4"G".(JF8<FX
M#)9SOW:IEW-56\$E7FHP=5DR_? !A=HN@G'PN/"-;PKK%L+EO&(;O$)[75UJ
MFH4=2\Y+E(8K"1K7B^!L?+J:N7R?\(/CUNR,P2FY5>K.33[GBR!R!:' S#H&
M1G_WN$(A'!&5\;/E#+I'.N#N^)']H]=.6FZ9P942-SRWQ2(X"2#'-:N%_::V
MG[#5,W%\F1+&_\*VS8T"R&IC5=F"J8*2R^:?_6I]V &,TSV N 7$SP#Q9 \@
M:0&)%]I4YF6=,\N6<ZVVH%TVL;F!]\:C20V7KHM75E.4$\XNOU:HF>5R Q=(
M;A@8P17ME+P6"&H-J@L+%QYI%,QB#MJY,U+K46T0F#%H#3!)ZVU<<';+!;><
M&#5F2N>T2%VS!<)*E163#V\-^2^8S!":_>KP+K[UUE,^NZ>';Y (W';LB@"+
MNO39.3>9JJ4%JA'AW3E:QH4Y) W75^?P[N 0#H!+^%ZHVE"^F8>6+'/"PZRU
MYT-C3[S'GG/,CB 9OX<XBJ,>^.K5\/'L*3RD1G7=BKMNQ9XOV<-WYIT^'6!*
M.J;$,Z5_[7OC:4]#^]QJ2*>>U!T0]\LTG<73>7B_:\K+K,DT'2==UI.*TZ[B
M=%#[Q9\M-63 I*.;#!JPJK5&VCJ5TOX\>;G9=S=QGQ<-_V1'Y?ADEB3/O.C+
MBB=IOQ?3KOCI8/$72FY&_C7X__*G+UL9S8ZC9^7W9*73=$\KC[ORCP=;^95>
M<PV?97,)4?E##3WI2$\&/;EICXW1T+'19\0P;0H/R'2?@ZM7 2&&4DE;&!C'
MD+,',R!UUDF=O4IJ=T(^.0C[- [S38ZBZ$V?PG^&-7+"G?O(?0M\87K#I:$^
MK(DH.CJFUT$W]VLSL:KR5]2MLG3A^6%!GR2H70+%UTK9QXF[];J/G.5O4$L#
M!!0    ( !PX4E)'Z__3I0(  &H'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;(V5;6_:,!#'OXH5]44K;<T3X:$"I *;-FG5JM)VKPTYB%7'3FVG
M=-]^9R=D% )%2,0^W_W]NXMS'FZD>M$9@"'O.1=ZY&7&%#>^KY<9Y%1?RP($
MKJRDRJG!J5K[NE! 4Q>4<S\*@JZ?4R:\\=#9[M5X*$O#F8![1729YU3]G0"7
MFY$7>EO# UMGQAK\\;"@:YB#>2KN%<[\1B5E.0C-I" *5B/O-KR9]JR_<WAF
ML-$[8V(S64CY8B<_TY$76"#@L#16@>+C#:; N15"C-=:TVNVM(&[XZWZ=Y<[
MYK*@&J:2_V&IR49>WR,IK&C)S8/<_( ZG\3J+277[I]L:M_ (\M2&YG7P4B0
M,U$]Z7M=AYV L'LD(*H#HOV SI& N Z(7:(5F4MK1@T=#Y7<$&6]4<T.7&U<
M-&;#A'V+<Z-PE6&<&?\N0%'#Q)K\ JR&)E_)'$]*6G(@<D6X-9*EU$83/#)$
M-NZ\<K^<@:&,ZRL,?)K/R.7%%;D@3)#'3)::BE0/?8.<=C=_63--*J;H"%,8
MD3LI3*;)-Y%"^E' QP2;+*-MEI/HI.(,EM<D#K^0*(B"%J#IV>'AX 1.W!0]
M=GJ=3XN^4]^V.E4R72=CO\>W<10,>M'0?]N%;_&*@W[2>'U@[#2,G9.,SU0Q
MNL!3\ EBI9+L;-Y);)$^$!XZQ6$0M0,F#6!RNH@F T7@M60%=A6#+468-L#D
M$#",^GN AT[Q( [; ;L-8/<,0'GNN^X>('3[G3W,0Y]!'+=3]AK*WDG*1VDH
M/Y^R=W#6X@!_>YPM7F&0[-?3WVE;.:BUZ^8:]RZ%J;[MQMI<&+>N3^[9)WB1
M5'W_OTQU"]U1M69"8U8KE RN>U@[577V:F)DX9KC0AILM6Z8X64(RCK@^DI*
MLYW8#9KK=?P/4$L#!!0    ( !PX4E+-&FA00 (   H%   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8P+GAM;(U4RV[;,!#\E8600P*TD2SE#5E ;+=H@08-
MXJ8],]+*(D*1*DG%R=]W2<JJF]II+Q(?.\/962[SM=*/ID&T\-P*::918VUW
M%<>F;+!EYEAU*&FG5KIEEJ9Z%9M.(ZL\J!5QFB1G<<NXC(K<K]WJ(E>]%5SB
MK0;3MRW3+S,4:CV-)M%FX8ZO&NL6XB+OV J7:.^[6TVS>&2I>(O2<"5!8SV-
MKB=7\\S%^X#O'-=F:PPNDP>E'MWD<S6-$B<(!9;6,3#Z/>$<A7!$)./GP!F-
M1SK@]GC#_M'G3KD\,(-S)7[PRC;3Z"*""FO6"WNGUI]PR.?4\95*&/^%]1";
M1%#VQJIV )."ELOP9\^##UN R=D>0#H TM> DSV ; !XY^*@S*>U8)85N59K
MT"Z:V-S >^/1E V7KHI+JVF7$\X67SO4S'*Y@B](;AAX#TNZ*54O$%1-Q>TZ
M@50URP24S#104]V!RW!_0BD%LUB!5:!&,A'(#A=H&1?FB&COEPLX/#B" T+#
MMT;UALG*Y+&E+)R6N!P4SX+B=(_B20HW2MK&P =98?4G04SICQZD&P]FZ9N,
M"RR/(9N\@S1)DQV"YO\-GUR^(2<;2Y)YOI-_EF0TW #Y_9>]N[P+U&>>VG7P
M4Y&>7V99'C]M)[0CZN(\3<>HH#O>NE8MZI7O-@.EZJ4-[HZK8T-?^WO\:GU&
MC1[Z\C=->"5NF%YQ:2BAFBB3X_/3"'3HO#"QJO.7]T%9:@4_;.BQ0NT":+]6
MRFXF[H#Q^2M^ 5!+ P04    "  <.%)2O%\/Q@0#   X"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,2YX;6R5EEUOVC 4AO^*%?6BE=;F^ZL"I!8T;5*G
MH=)NUP8<L.K$F>U ^^]WG(24-0YT-\2._9[G]2$Y)Z,]%R]R2XA"KSDKY-C:
M*E7>VK9<;4F.Y0TO20$K&1<Y5C 5&UN6@N!U+<J9[3E.9.>8%M9D5-^;B\F(
M5XK1@LP%DE6>8_%V3QC?CRW7.MQXI)NMTC?LR:C$&[(@ZKF<"YC9790US4DA
M*2^0(-G8NG-OIZZG!?6.7Y3LY=$8Z:,L.7_1D^_KL>5H1X21E=(A,%QV9$H8
MTY' QY\VJ-4QM?!X?(C^M3X\'&:))9ER]INNU79L)19:DPQ73#WR_3?2'BC4
M\5:<R?H7[=N]CH56E50\;\7@(*=%<\6O;2*.!&XP(/!:@?=9@=\*_/J@C;/Z
M6#.L\&0D^!X)O1NBZ4&=FUH-IZ&%_AL72L J!9V:_"R)P(H6&_1 (!L27:,%
M/"KKBA'$,\2[9::7$:-X21E5%'9>SHC"E,DKT#PO9NCRX@I=(%J@IRVO)"[6
M<F0KL*A!]JJU<]_8\0;LS,CJ!OGN%^0YGF.03S\M=]-_Y38DILN.UV7'J^,%
M _' A6LZ1*.*:I5^4783-XT2V+HSP/P.YI^#>298HPJ/85&8!&98T,&"<S#?
M! OZ,,]/8S,L[&#A.5A@@H4]6.)ZH9D5=:SH'"LTL:(>*W BW\R*.U9\DO6T
M)5 Z,T6$B1CWB'X2#V0RZ8C):2)7F.DZ0/,J;]_)$K]!757&MRWI>8B"V!LP
MD78FTI,F'HB4M^@NYU6A=)$X&("R#JU$PE 7#%I 7HA4)EMIS]9UD'@#C[3K
MO-<RYZ2Q>4-'.\RJNGQEE:H$^8]\M8!C9V&:.@//B7M49=U/I&Q:":']\26C
M&ZS;F-F$VT^/FZ3^NXNV%KJ],@3[O' HC^]5SSU=]AYXL;F&?R]')1=UM^VW
M K/S?F$,G#1V/AHW; NBX&.6[:.VIK\I?F"QH84$?@8ZYR:&#(FF33<3Q<NZ
MTRVY@KY9#[?P:4.$W@#K&>?J,-'-L_M8FOP%4$L#!!0    ( !PX4E(Z$-)D
MN (  (L'   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;*U576O;,!3]
M*\+TH86M_HS3E"20)HP55@C]V![&'A3[)A&5)4^2D_;?[TIVC3LGH8R]V))U
MS[WG'%W)X[U4SWH+8,A+P86>>%MCRFO?U]D6"JHO90D"5]92%=3@5&U\72J@
MN0,5W(^"(/4+RH0W';MO2S4=R\IP)F"IB*Z*@JK7&^!R/_%"[^W#/=MLC?W@
M3\<EW< #F*=RJ7#FMUER5H#03 JB8#WQ9N'U?&CC7<!W!GO=&1.K9"7ELYW<
MYA,OL(2 0V9L!HJO'<R!<YL(:?QN<GIM20OLCM^R?W':4<N*:IA+_H/E9COQ
MKCR2PYI6W-S+_5=H] QLODQR[9YDW\0&'LDJ;631@)%!P43]IB^-#QU F!P!
M1 T@^B@@;@"Q$UHS<[(6U-#I6,D]438:L]F!\\:A40T3=A<?C,)5AC@SG669
MJB G2R77H.W>4$Z^,;IBG!D&FGPFLSQGIEZX%77?V TX7X"AC%]@Q-/#@IR?
M79 SP@1YW,I*4Y'KL6^0H"WC9PV9FYI,=(3, K)+$H>?2!1$P0'X_,/P</0>
M[J,MK3=1ZTWD\L5'\BWI*UUQ] #5$&<4Y9K\G*VT4=A^OTZ4B-L2L2N1'"GQ
M* W:2IM-*+N;P)M->#WD8YTU=5GM0=U-XW P"M"T7=>O?EB4C-).V#O224LZ
M.4EZ=I(N]D!6*87KJ\H0+K7&TZY![=!((0U.2JD,+F,KD8Q35ASLE)K"H$L]
MBOH*^V'AU?"HPD&K</!?%-K&>*_P@^H&/=JC..B)ZT==)=$Q;6FK+?UW;7CB
M#]%->T0&01H,_Z*;]KHM2=+1Z##=84MW>)+NK="5HB(#M#8#MG,G\A#'8:]Z
M&B8]L_S.56E_4W=4;9C0A,,:<<'E$$6J^NJO)T:6[O9<28-WL1MN\6\)R@;@
M^EI*\S:Q%W+[_YW^ 5!+ P04    "  <.%)2-><$E,T#  "L#   &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,RYX;6RMEUV/XC84AO^*%>W%C+0[B9WO%2#-
MD%:MM"NAF=WVHNJ%20RXZ\34=F#IKZ_M9#(0#*55;R!VWG-\'A]_G$SV7'R3
M&T(4^%ZS1DZ]C5+;C[XORPVIL7S@6]+H-RLN:JQT4ZQ]N14$5]:H9CX*@L2O
M,6V\V<3V+<1LPEO%:$,6 LBVKK$X/!'&]U,/>J\=SW2]4:;#GTVV>$U>B/JZ
M70C=\@<O%:U)(REO@""KJ?<(/Q80&0.K^(62O3QZ!@9ER?DWT_BYFGJ!B8@P
M4BKC NN_'9D3QHPG'<>?O5-O&-,8'C^_>O_1PFN8)99DSMFOM%*;J9=YH"(K
MW#+US/<_D1XH-OY*SJ3]!?M>&WB@;*7B=6^L(ZAIT_WC[_U$'!G Y((!Z@W0
MV""Z8!#V!N&M!E%O$-F9Z5#L/!18X=E$\#T01JV]F0<[F=9:X]/&Y/U%"?V6
M:CLU>RQ+T9(*+ 1?$6FRB1GX1/&2,JHHD> #>-%KK6H9 7P%KLH/X*X@"E-V
MKZV^OA3@[MT]> =H [YL>"MQ4\F)KW309FB_[ -\Z@)$%P*$"'SFC=I(\$-3
MD>K4@:]I!V3TBOR$KGHL2/D 0O@>H  %CH#F-YO#W&%>W&Z>7:$)AP2&UE]X
MP=\"'_"2Z43IZ>W2@YD$OSTNI1)Z4_U^98AH&"*R0T07AGC"##<E 5B!)5G3
MIJ'-VBR& \'"E=#.6V*]F7-G-X,Q#/-TXN^.I]DA0UF:YZ>RPB$+LR0*!]D)
M4SPPQ5>9CI>X("5?-_0O4KW76"NI3]OE02];V0K+_4Q*0G=FEEVTW3CQ47QA
MCM"(]5P$@S".W S)P)!<9=";<$?M 7R'JS_T6:'/8W4/]&4 &)?2DC&L]'95
M',Q;(?3KBTE+SB*,XB2-1AP.%4K#<)2R<U68HN!"QM*!-OW_:!>"ZG[#ZCQR
MTK, /\ XAB-8ARI-DV0$ZU(%6>J&S0;8["KL%Z[TP;H=D-\H73C9>58BB$99
MF9^KPBA/1KNR<*@""!,W3C[@Y%=QY@S3&FSQP>3L7RW+_'QVX]$),7=HSI:D
MRT_@AH+!V]T9_$>L?UA_O=^3<% 49\&(S*E#23[2%2Y=F.?P$N%1=0!O68<]
MH1,%NE"2<)PDIPZEXU5:N'0:);F$@MY0T*VW&-%7Y97[JW=T<N6D41:,-Y1+
MY[CH"I?N]*;KD/RC,JXF8FW+80E*WC:J*V^&WJ'D?K2%YJC_R93BMCQ\<]/5
M\9^QT!>X!(RLM,O@(=7S++K2N&LHOK7%XI(K77K:QXW^G"#""/3[%>?JM6$&
M&#Y09G\#4$L#!!0    ( !PX4E*.\PB64 @  /<S   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;+6;;6_;.!+'OPIA[ &[0&OK67*1!,A#W<LBW?;2
M]N[%XEXP,FT+JP<O13D-<!_^AI+J41)Y*"=57S22K?EK.$/^.*3DD_M"_E5N
MA%#L>Y;FY>EDH]3VW6Q6QAN1\7):;$4.WZP*F7$%IW(]*[=2\&5ME*4SQ[*"
M6<:3?')V4G_V69Z=%)5*DUQ\EJRLLHS+APN1%O>G$WORXX/;9+U1^H/9V<F6
MK\47H;YM/TLXF^U5EDDF\C(I<B;%ZG1R;K_[$,VU07W%OQ-Q7W:.F6[*75'\
MI4^NEZ<32WLD4A$K+<'ASTY<BC352N#'WZWH9']/;=@]_J&^J!L/C;GCI;@L
MTO\D2[4YG403MA0K7J7JMKC_IV@;Y&N]N$C+^G]VWUYK35A<E:K(6F/P($OR
MYB__W@:B8V![!PR<UL!Y8N#/#QBXK8$[] Y>:^ --?!; W^H0= :!$,-PM8@
MK)/51+=.S157_.Q$%O=,ZJM!31_4^:VM(2-)KKOB%R7AVP3LU-D-G+-BQ2ZE
M6";J#;LI\O7;KT)F[$K<*<;S)5LD.<]CP6X$I)Q]NDN3-=?=J&1OV?D2K."8
MI^PZ;P:&[F"_7@G%D_0WN.+;EROVZR^_L5]8DK.OFZ(J0;,\F2EP7KLPBUM'
M+QI'G0..?N1RRAS_#7,LQ^HQOZ3-KT0\9:Y]T/QJL+D][S%_3YLOQ!TX'QTT
M7]#F?Q0[N+M5FT<]YA^&.^\_-I]!=]GW&6??9YQ:SSVH!SWC.B^5K !*BOU9
M=Z)K);+ROX2\NY=W:WEO4)=D*QXG::(>WK"[0H)4DJ]9S+?PJ7KHZP>->%"+
M:Q#OSMS0MR#GNQZ?O+U/'NT3# NF]+!80N/[;MO8^YW;VJ&E_^UOW/0S[YE[
M3Z][Y*"_=]!_6=#X#@8BOTL%$#O5X[C/>?^94]%\/C_D4[#W*2!]^ICD259E
M[,^/(KL3DNH;X5XR'*/K17OYB/2XED_V\F_8CLND#EZ20_9%J9CDJC>$M+ U
MM?U_$ [.]P[.Z9#R[T-#:ELX!5AC!-7NS#'V6&$U*%M3QZ+B:B/3;(=4.D_!
MDQR\8!=ZFKO51S^BS/['%F(I),QRBPIFK\??4K='YMGN*#E @-DTP9[EP!QZ
M6K G(MNT*ID]<S2([*E%9P;)9M-H,V3FYOKBT^V@9""W[&"49"#%[/!G)X,6
M;(( !1A4;"BV%3(IECH;!?B?%;G:M#DR)0>!:8]&3(.RT4=DIDU#\WR[39.X
M=@JJR#74H70?@@^.F+H<Y*PS"F<=Y*PS&F<-RC!_.>0$YG2*1P-H7Y"-X;.>
M@\1U1B&N@\1UCB3N$=F@E:UI2"<#V>K0;/V6ER*NH&9DMV)7I#M=7+<EY*(M
M(0=%'='JC()6!]'J&$CXNM5#J_ZH/G>(^MQ!4CHTSVZ$@JR7'=^&!!8AY\Q'
M690AO5QKJ/]QXW]1J5+!:E['E&=%E?<NC%K91Q$]%$T74>?20/*GP"/V1>0)
MS'G8B_\HE"C9527T.M\=$F$7P>6.L^SMK'OIA>_Y>BW%NBZD9)+'R1:JJR:N
M.N@'%IX?W.<+7KW>/1ABY)=[%+_,U#+HU2GK;<'1=H];A+1S:=H];5'&524U
MXI8ZZ$M1QC+9Z@VLWM;1VEO^4+.]%%GREN=YQ=/T0>]Y<2D%U^,F9[]7T&'L
M>E/M2L1UUV0VU3+$JDLOM9_--?NF/<#->YM#"^KA0WF&/'9I'E__Z#4\CF4%
M0[0I2J$"@/CT.O:<P.[<.]B=D;\NS=_CB %5Q^6&YVL8X#F[A,I9%ND@G""P
MW5& [2&P/1K8M[! R^KNK&,>PSWXNIX:G]*E=SN+UK8M4WGN(<J]GXER2$RG
M83"^](;ND,QX"'IO%-!["'J/!OWK,D-KZ\RXMDNFIK/K2:,W&)":<%#PD=&>
M/TKP$94>3;87S;+O6]$NE?R>[=V%^;K';B-'O:.V#,RSL4$O.# ;+XZW>]PB
M!+)WU-;!<;.Q07O0;,SA8_G ;+^>D7^O4GU,-0W9[M$[#L=/QP9!/<X(SWR<
M%'Q#%6]\D.'WUNO$$PH$O4^#_NA2H-7KNA(X!Y_E^ AXG]Z". YK+RT%?)P/
M_%&V(GSDN$]S_%43CD';7 KXG8=8=!%]=&(Z#;L0JT+65SB#LH,3AC_*EH6/
M:/=II+XN.[0V#%U3=A#8/@W5GYV=]@J1L6K+5,%<4(=6XP3]>=_^\V:"'I)7
MA+0_2@$>(&N#$0MP@[;K&](:()8#&LM=-V42BR?.\L/UDJRS)Y:]_M,WM2U3
M(1$@SH.?C/-G"XA!Q B0Y\$H/ ^0Y\&(/#=HVY8W#:*(3 T"/1@/Z$UJ!FWB
M!9U7$D:!>8 P#T:$N4';MES3<Y@ :1Z,1_,F-=Z@U""/@U%X'"*/PQ%Y;-#6
M59 ?D,ON$(D<TG!\?6J:)<W7#=3;? 55]Z!W<!"XX2@;)"$"-!QQ@\2@;:Z(
M0N1P2+.R?9!S#C.D:"(Q(,P(SW"4K9 081C26R&O>U9V$3[?ZW")A6+8><F+
MYMS[4B6P8H8N__[B^NO5>>_->Q[4N7/GX,V1BR'-Q8,YU6\!00T;<UC!P@%;
M)!*._E5QJ0?8IY4>=_:@'H!(#$=!8H1(C$P/]79"ZK$E]8N[?7$V"#Q_G?:Q
M)\B\B&;>\+ 7E52;)W$?M ,<(>"B40 7(> BPSNNYKC3 MXT]-_9[RPR^,BQ
MZ(4<.^Y5F C1%HV"M@C1%AG09@XP+>!-?<L88"1:1!.-#/#PMUNBSHNLT2@!
M1C1%]([D@ #3 GH!>S# L\XO&O1/8IHWA4J6BA6(Z?=?)DPVOS)I3E2QK7_D
M<%<H563UX4;PI9#Z OA^54#QU)[HWTWL?^MS]G]02P,$%     @ '#A24HU.
M+>-( P  @PL  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULM99AC]HX
M$(;_RBCJ2:W4W<0)2: "I!:TNI6VO=72O?M0]8-)!K#JV)SM0-M?7]ND@:6!
M7:E;/I XF7GS>/)ZXN%6JB]ZA6C@:\6%'@4K8]9OPE 7*ZRHOI1K%/;.0JJ*
M&CM4RU"O%=+2)U4\C*,H"RO*1# >^FNW:CR4M>%,X*T"75<55=_>(9?;44""
MGQ?NV')EW(5P/%S3)<[0W*]OE1V%K4K)*A2:20$*%Z/@+7DS(:E+\!'_,MSJ
M@W-P4YE+^<4-KLM1$#DBY%@8)T'M88,3Y-PI68[_&]&@?:9+/#S_J7[E)V\G
M,Z<:)Y+_QTJS&@7] $I<T)J;.[G]&YL)><!"<NW_8=O$1@$4M3:R:I(M0<7$
M[DB_-H4X2""]$PEQDQ _-2%I$A(_T1V9G]:4&CH>*KD%Y:*MFCOQM?'9=C9,
MN-<X,\K>93;/C&_L&.0")@I+9E[#C13+BX^H*ICBW  5)5PQ046!<(.V7/#/
MG+,E=:] PP7,K*W*FGN)H]274S24\5<VZGXVA9<O7L$+8 (^KF2MK:X>AL9.
MP&&$10/[;@<;GX"=8G$)"7D-<11''>F3)Z>3P</TT):MK5W<UB[V>LE)/3O-
M:Z&-JJVQ#7SRQ;PV6.G/9^235C[Q\KUS\FPOOU9,%&Q-.=!*UL)TU6^GF'E%
MMX(W8Y*GD?T-P\UAH1Z/>X#<:Y%[9Y'OA453AGW'TJXEAZ]U[<U32-T)O--+
M#T N2#^+DB/>CK X[L59-V[:XJ9G<9UCP3C'.M@NO/27YY(\(<D@/^+KBHOS
M-.]U V8M8'86,+V,T[]@AH))!?="8U';=0H?I$$-TQK=0DC@TWNLYJC.>2YO
M'YC_"4OW6_G^LUNZWU':+DL_'O< >= B#Y[9TH,.2V=)[]C276&#/(N[<4FT
M;^C1;YJZ$3AR=9*EQZ[N#K26ZY^ //CJD+.0=[B1?,,LZ>[# U>T8)R9;T\Q
M,]DW:/)'.C39MVCR[#UZTD@>5O6$1\F^[Y+G;KRDLZ5FQZNJ,RS+3O0ULN^\
MY'=;;R.0/0;X:U@'7WBP0W+;T_=4+>UK XX+FQ9=YE9%[79\NX&1:[]IFDMC
MMV#^=&5WR:A<@+V_D+8'-P.W#VOWW>,?4$L#!!0    ( !PX4E($BX1%J0(
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M1*&;)Z8)K*I\ERZ5I9[WPX)>9=0N@=972MG7P#5^]\ZG_P!02P,$%     @
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M0A[UU>->7J4)*P'R_992<1J4#IK+^?A_4$L#!!0    ( !PX4E+=)N\,=@4
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MV8_+A2^*A4G'PIB@&RG,6J.Y2%BR;Z /7E2ND"=7+HC7XHS%)RC$[Q )"'8
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M'^/Q<%_LRB463$:DP_W&1( /N*]8+%>"_UN2T8()V/H&6&!-#4R*VS1!/-O
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M"$<5Y[+%C9&;_!QQ(8V167ZY9A2XT0K ^Z64YNG&+E"=CD__ U!+ P04
M"  <.%)2X0H5O=4#  #!#0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6R=5TUOVS@0_2N$@ )=H-5W%+NP#<1QBLVAW2!INX?%'FAI9&LKD2Y)Q<Z_
MWR&E*+9!T]Z]V"*E]SCS9L@93K9<_)1K $5V3<WDU%LKM?D4!#)?0T.ESS?
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M\<#2*;K[0C=0?&,ZZ"57V(^;QS7>L4#H#_!]R;EZ'>@%AEO;[%]02P,$%
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M#K,7[OF-EW<GS!G<LDX PA3YPLH*;QPR'()EO<_([*,OLM.<AIY/Z6CJG'H
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M<6V@]E>,R>U$'U#WMN._4$L#!!0    ( !PX4E*U:OH99@(  -8%   9
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M:;Y)43#8&>NM<9.&/-\JKK7T\_U\>HD!3#,MXW-L@+S%2O%S; @PQ84BWD8
MBZUFI&]CA"G'Y3DV 9ATOG?GV!1@PC GSK%9B'$CI8O)4.>(,\[$[IQ;($Y(
MSLR!.UO]^+#Z<>?J?VYDE-VE496LDC+SNX7?%:*O:9[>^RT$"6+G+S[IB+#*
M&#+^?HA)YAPCLSE WH2S9*6'P!O7PI!)&J%&&3-DI<<(XY)I(@@X4M\J$03
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MQ /DS:\@/4T C+-PGP"8%Z*BF0+";*SI7H$P/]"8R@$,P3E+ P/ G.524"V
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M6:9E _B_WQ=%_?*A:>#PPO3M_P!02P,$%     @ '#A24J^A;+Q# @  6@L
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M<+_;MONSQ,&S BECG< %=H$H*(C6H,2=<9K.3?!%"K7V9E\8A9DB>W^QPOV
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ '#A24FOGF3S=!0  :30
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MR/G]2#V>H9BP+F$O3,80[F@OU*9WU3KTYZ'_K)QL*2922\*LE@O5:3<FT;M
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M2P$"% ,4    "  <.%)24WDW/^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  <.%)2F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( !PX4E(S%;IAGP4  /47   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  <.%)2*'2-M3,'  #6'@
M&               @('B#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ '#A24FMR'YFF @  BP@  !@              ("!2Q4  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !PX4E(3-MV,N L
M *@]   8              " @2<8  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  <.%)2ERU,ZK0'   [*   &               @($5
M)   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ '#A24@)@
MD. X"@  12\  !@              ("!_RL  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( !PX4E);R\4'40,  $4'   8
M  " @6TV  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  <
M.%)2F%K2K\D)  "R%P  &               @('T.0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ '#A24D+(CY=C&0  K4T  !@
M         ("!\T,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( !PX4E+BNVSOH (  ($%   9              " @8Q=  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ '#A24K$*>26-!0  Y T
M !D              ("!8V   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  <.%)2 3=G_(("  !I!0  &0              @($G9@
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !PX4E*Q]$0C
MR@,  . )   9              " @>!H  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ '#A24@XI/>QT!   *@H  !D
M ("!X6P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  <
M.%)27>D<:W4(  !S&P  &0              @(&,<0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !PX4E(?GGK_OP(  !,&   9
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M970R,"YX;6Q02P$"% ,4    "  <.%)2 ?$;GR\#  !]!P  &0
M    @(&WF@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M !PX4E)2%*7=+ D  'D:   9              " @1V>  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ '#A24L.RKOX?!   X@H  !D
M             ("!@*<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  <.%)2H5"ZX!$#  "I!@  &0              @('6JP  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !PX4E(\Y97)OP4
M '8/   9              " @1ZO  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ '#A24K?)Z9Z@!P   !0  !D              ("!
M%+4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  <.%)2
MO_&M:,07  #72P  &0              @('KO   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( !PX4E(:;BJ-)00   T*   9
M      " @>;4  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ '#A24CASW=ZN @  A@4  !D              ("!0MD  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  <.%)2Z"M%P.4#   >"0
M&0              @($GW   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( !PX4E) .6+BG (  'D%   9              " @4/@  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ '#A24H:;?3A?
M P  D@<  !D              ("!%N,  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  <.%)26(\8^=@"   3!@  &0
M@(&LY@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !PX
M4E(HJ4I6V@0  %0-   9              " @;OI  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ '#A24FSEL=^D P  R <  !D
M         ("!S.X  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  <.%)2L3!D-"@$  !)"@  &0              @(&G\@  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !PX4E('ZO&=YP8  -<0
M   9              " @0;W  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ '#A24DC<: Q) P  B@<  !D              ("!)/X
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  <.%)2IG=K
MU?8#   ^"0  &0              @(&D 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( !PX4E+K03E&H@<  .03   9
M  " @=$% 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M'#A24OKQ,PCE!   PQ4  !D              ("!J@T! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  <.%)2S=G)87 %  #_'0  &0
M            @('&$@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( !PX4E)B!3):.0,  /T+   9              " @6T8 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ '#A24D64 LFO @
M&0<  !D              ("!W1L! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  <.%)2T\6PGKX"  !6"   &0              @('#
M'@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( !PX4E*,
MK:'&'@,  %4,   9              " @;@A 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ '#A24CR6PF5_ @  $P8  !D
M     ("!#24! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !PX4E)U6)IE 00  ,D.   9              "
M@>DT 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ '#A2
M4OE5ZX^K @  %P<  !D              ("!(3D! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    "  <.%)2/_&/5T8#  !]"P  &0
M        @($#/ $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( !PX4E)< N$H= (   ,'   9              " @8 _ 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ '#A24JHLJI$5!P  \R
M !D              ("!*T(! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    "  <.%)2AS$I^_D"  #'"   &0              @(%W20$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( !PX4E+[+D,N
M"@,  / (   9              " @:=, 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ '#A24D?K_].E @  :@<  !D
M ("!Z$\! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  <
M.%)2S1IH4$ "   *!0  &0              @('$4@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( !PX4E*\7P_&! ,  #@)   9
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M970V-2YX;6Q02P$"% ,4    "  <.%)2!(N$1:D"  #Y!@  &0
M    @(%O:P$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M !PX4E)U(AH49P(  /,%   9              " @4]N 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ '#A24EVS8#[V P  J \  !D
M             ("![7 ! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    "  <.%)2W2;O#'8%   I%P  &0              @($:=0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( !PX4E+A"A6]U0,
M ,$-   9              " @<=Z 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ '#A24B-,XO)^!   "A   !D              ("!
MTWX! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  <.%)2
MW*.MV5L#  "4"@  &0              @(&(@P$ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( !PX4E+2\Y9Z"00  #8/   9
M      " @1J' 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ '#A24H4#TD^.!@  V!T  !D              ("!6HL! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    "  <.%)2*LF"(H<#  #%"P
M&0              @($?D@$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( !PX4E+4B@8 #@0  '(.   9              " @=V5 0!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ '#A24KZJ%P)3
M P  YPH  !D              ("!(IH! 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    "  <.%)2M6KZ&68"  #6!0  &0
M@(&LG0$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( !PX
M4E*4$PB2R L  #P]   9              " @4F@ 0!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ '#A24J^A;+Q# @  6@L   T
M         ( !2*P! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  <.%)2EXJ[
M',     3 @  "P              @ &VK@$ 7W)E;',O+G)E;'-02P$"% ,4
M    "  <.%)2:^>9/-T%  !I-   #P              @ &?KP$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ '#A24KM)TM]B @  M"X  !H
M     ( !J;4! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ '#A24MTG:PL8 @  A2T  !,              ( !0[@! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %< 5P#8%P  C+H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>200</ContextCount>
  <ElementCount>503</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Accrued Professional Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccruedProfessionalLiabilities</Role>
      <ShortName>Accrued Professional Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations</Role>
      <ShortName>Line of Credit, Long-Term Debt and Finance Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/RetirementPlans</Role>
      <ShortName>Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Selected Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SelectedQuarterlyFinancialInformation</Role>
      <ShortName>Selected Quarterly Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/Investments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/PropertyAndEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/OperatingLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Accrued Professional Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables</Role>
      <ShortName>Accrued Professional Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccruedProfessionalLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables</Role>
      <ShortName>Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Selected Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables</Role>
      <ShortName>Selected Quarterly Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/SelectedQuarterlyFinancialInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CoronavirusPandemicCovid19</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Property Plant and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property Plant and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Business Combinations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail</Role>
      <ShortName>Business Combinations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Discontinued Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Operating Leases - Schedule of lease costs for operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Schedule of lease costs for operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Operating Leases - Schedule of operating lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Schedule of operating lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Accrued Professional Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Accrued Professional Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail</Role>
      <ShortName>Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail</Role>
      <ShortName>Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail</Role>
      <ShortName>Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail</Role>
      <ShortName>Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail</Role>
      <ShortName>Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Income Taxes - Summary of Components of Income Tax Provision (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail</Role>
      <ShortName>Income Taxes - Summary of Components of Income Tax Provision (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Retirement Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail</Role>
      <ShortName>Retirement Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d51794d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail</Role>
      <ShortName>Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="d51794d10k.htm">d51794d10k.htm</File>
    <File>d51794dex1021.htm</File>
    <File>d51794dex211.htm</File>
    <File>d51794dex231.htm</File>
    <File>d51794dex311.htm</File>
    <File>d51794dex312.htm</File>
    <File>d51794dex32.htm</File>
    <File>md-20201231.xsd</File>
    <File>md-20201231_cal.xml</File>
    <File>md-20201231_def.xml</File>
    <File>md-20201231_lab.xml</File>
    <File>md-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g51794g85y35.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d51794d10k.htm": {
   "axisCustom": 2,
   "axisStandard": 27,
   "contextCount": 200,
   "dts": {
    "calculationLink": {
     "local": [
      "md-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "md-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d51794d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "md-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "md-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 684,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 14
   },
   "keyCustom": 62,
   "keyStandard": 441,
   "memberCustom": 45,
   "memberStandard": 40,
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.mednax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Investments",
     "role": "http://www.mednax.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Accounts Receivable and Net Revenue",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Property and Equipment",
     "role": "http://www.mednax.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Business Combinations",
     "role": "http://www.mednax.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.mednax.com/role/GoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Discontinued Operations",
     "role": "http://www.mednax.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Operating Leases",
     "role": "http://www.mednax.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Accrued Professional Liabilities",
     "role": "http://www.mednax.com/role/AccruedProfessionalLiabilities",
     "shortName": "Accrued Professional Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations",
     "shortName": "Line of Credit, Long-Term Debt and Finance Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Income Taxes",
     "role": "http://www.mednax.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Common and Common Equivalent Shares",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentShares",
     "shortName": "Common and Common Equivalent Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Common Stock Repurchase Programs",
     "role": "http://www.mednax.com/role/CommonStockRepurchasePrograms",
     "shortName": "Common Stock Repurchase Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Retirement Plans",
     "role": "http://www.mednax.com/role/RetirementPlans",
     "shortName": "Retirement Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Commitments and Contingencies",
     "role": "http://www.mednax.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Selected Quarterly Financial Information",
     "role": "http://www.mednax.com/role/SelectedQuarterlyFinancialInformation",
     "shortName": "Selected Quarterly Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Investments (Tables)",
     "role": "http://www.mednax.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.mednax.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.mednax.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Accrued Professional Liabilities (Tables)",
     "role": "http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables",
     "shortName": "Accrued Professional Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables",
     "shortName": "Line of Credit, Long-Term Debt and Finance Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.mednax.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans (Tables)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Selected Quarterly Financial Information (Tables)",
     "role": "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables",
     "shortName": "Selected Quarterly Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
     "shortName": "Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CashAndCashEquivalentsMaturityDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CashAndCashEquivalentsMaturityDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Net Revenue by Service Line (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesAndRevenueServicesNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of fair value on a recurring basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail)",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of financial instruments that are not carried at fair value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Investments - Schedule of Investments (Detail)",
     "role": "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail",
     "shortName": "Investments - Schedule of Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Equity",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BuildingsAndImprovementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Property Plant and Equipment - Schedule of Property and Equipment (Detail)",
     "role": "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Property Plant and Equipment - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BuildingsAndImprovementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Business Combinations - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail",
     "shortName": "Business Combinations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail)",
     "role": "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)",
     "role": "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail",
     "shortName": "Goodwill and Intangible Assets - Amortization Expenses for Existing Intangible Assets for the Next Five Years (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Discontinued Operations - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
     "shortName": "Discontinued Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details)",
     "role": "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "Operating Leases - Schedule of operating lease-related right-of-use assets and related liabilities recorded on the Company's balance sheet and the weighted average remaining lease term and discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Operating Leases - Schedule of lease costs for operating leases (Details)",
     "role": "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails",
     "shortName": "Operating Leases - Schedule of lease costs for operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:OperatingLeasesCashFlowRelatedInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details)",
     "role": "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
     "shortName": "Operating Leases - Schedule of supplemental cash flow information related to operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:OperatingLeasesCashFlowRelatedInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Operating Leases - Schedule of operating lease liabilities (Details)",
     "role": "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Schedule of operating lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Accrued Professional Liabilities - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail",
     "shortName": "Accrued Professional Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock",
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail)",
     "role": "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail",
     "shortName": "Accrued Professional Liabilities - Schedule of Accrued Professional Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:ScheduleOfAccruedProfessionalLiabilityTableTextBlock",
       "us-gaap:MalpracticeLossContingencyDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "lang": null,
      "name": "md:MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
     "shortName": "Line of Credit, Long-Term Debt and Finance Lease Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail)",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail",
     "shortName": "Line of Credit, Long-Term Debt and Finance Lease Obligations - Schedule of Long-Term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure -  Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail)",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
     "shortName": "Line of Credit, Long-Term Debt and Finance Lease Obligations - Summary of Estimated Fair Value of Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMemberusgaapCreditFacilityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:ScheduleOfFinanceLeaseObligationsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail)",
     "role": "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail",
     "shortName": "Line of Credit, Long-Term Debt and Financial Lease Obligations - Schedule of Financial Lease Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:ScheduleOfFinanceLeaseObligationsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Income Taxes - Summary of Components of Income Tax Provision (Detail)",
     "role": "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail",
     "shortName": "Income Taxes - Summary of Components of Income Tax Provision (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInDeferredLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - General",
     "role": "http://www.mednax.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)",
     "role": "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail",
     "shortName": "Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail)",
     "role": "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail)",
     "role": "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Schedule of Restricted Stock and Deferred Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Retirement Plans - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail",
     "shortName": "Retirement Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail)",
     "role": "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail",
     "shortName": "Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Coronavirus Pandemic (\"COVID-19\")",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19",
     "shortName": "Coronavirus Pandemic (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d51794d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 86,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable and net revenue disclosure.",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable and Net Revenue"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_Accountsreceivableretained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AccountsReceivableRetained",
        "label": "AccountsReceivableRetained",
        "terseLabel": "Accounts Receivable Retained"
       }
      }
     },
     "localname": "Accountsreceivableretained",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll taxes and benefits current.",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "terseLabel": "Accrued payroll taxes and benefits"
       }
      }
     },
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedProfessionalLiabilitiesAssumedThroughAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional liabilities assumed through acquisition.",
        "label": "Accrued Professional Liabilities Assumed Through Acquisition",
        "terseLabel": "Liabilities recognized, offset by insurance Receivable"
       }
      }
     },
     "localname": "AccruedProfessionalLiabilitiesAssumedThroughAcquisition",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedProfessionalLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional liability.",
        "label": "Accrued Professional Liability",
        "terseLabel": "Accrued professional liability incurred and loss reserves reported for claims"
       }
      }
     },
     "localname": "AccruedProfessionalLiability",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedPurchaseConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued purchase consideration.",
        "label": "Accrued Purchase Consideration"
       }
      }
     },
     "localname": "AccruedPurchaseConsideration",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedSalariesAndIncentiveCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued salaries and incentive compensation.",
        "label": "Accrued Salaries and Incentive Compensation Current",
        "terseLabel": "Accrued salaries and incentive compensation"
       }
      }
     },
     "localname": "AccruedSalariesAndIncentiveCompensationCurrent",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AlternateBaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternate base rate.",
        "label": "Alternate Base Rate [Member]",
        "terseLabel": "Alternate Base Rate [Member]"
       }
      }
     },
     "localname": "AlternateBaseRateMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated two thousand eight plan.",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "terseLabel": "Amended and Restated 2008 Plan [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_AnesthesiologyServicesMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anesthesiology Services Medical Group [Member]",
        "terseLabel": "Anesthesiology Services Medical Group [Member]"
       }
      }
     },
     "localname": "AnesthesiologyServicesMedicalGroupMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ApplicableMarginRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable margin rate.",
        "label": "Applicable Margin Rate [Member]",
        "terseLabel": "Applicable Margin Rate [Member]"
       }
      }
     },
     "localname": "ApplicableMarginRateMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_BusinessCombinationContingentConsiderationArrangementsTimePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, contingent consideration arrangements, time period.",
        "label": "Business Combination Contingent Consideration Arrangements Time Period",
        "terseLabel": "Additional amounts to be paid in cash or common stock based on achievement of performance measures within period, maximum years"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsTimePeriod",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "md_CapitalLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital loss carryforwards",
        "label": "Capital loss carryforwards",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "CapitalLossCarryforwards",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CapitalLossesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital losses incurred.",
        "label": "Capital Losses Incurred",
        "terseLabel": "Capital losses incurred"
       }
      }
     },
     "localname": "CapitalLossesIncurred",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_Capitallosscarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CapitalLossCarryForward",
        "label": "CapitalLossCarryForward",
        "terseLabel": "Capital loss carry forward"
       }
      }
     },
     "localname": "Capitallosscarryforward",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CashAndCashEquivalentsMaturityDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents maturity description.",
        "label": "Cash And Cash Equivalents Maturity Description",
        "terseLabel": "Cash and cash equivalents maturity description"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMaturityDescription",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ChangeInControlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control.",
        "label": "Change In Control [Member]",
        "terseLabel": "Change In Control [Member]"
       }
      }
     },
     "localname": "ChangeInControlMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_CommonStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "terseLabel": "Common Stock [Line Items]"
       }
      }
     },
     "localname": "CommonStockLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockRepurchasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of common stock repurchases.",
        "label": "Common Stock Repurchases [Text Block]",
        "terseLabel": "Common Stock Repurchase Programs"
       }
      }
     },
     "localname": "CommonStockRepurchasesTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchasePrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CommonStockShareRepurchasesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock share repurchases policy.",
        "label": "Common Stock Share Repurchases [Policy Text Block]",
        "terseLabel": "Common Stock Repurchases"
       }
      }
     },
     "localname": "CommonStockShareRepurchasesPolicyTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CommonStockTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "terseLabel": "Common Stock [Table]"
       }
      }
     },
     "localname": "CommonStockTable",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ContractedManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "terseLabel": "Contracted Managed Care [Member]"
       }
      }
     },
     "localname": "ContractedManagedCareMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (\"COVID-19\")"
       }
      }
     },
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CovidNinenteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covid Ninenteen [Member]",
        "label": "Covid Ninenteen [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "localname": "CovidNinenteenMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DebtInstrumentFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fair Value [Line Items]",
        "label": "Debt Instrument Fair Value [Line Items]",
        "terseLabel": "Debt Instrument Fair Value [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DebtInstrumentFairValueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fair Value [Table]",
        "label": "Debt Instrument Fair Value [Table]",
        "terseLabel": "Debt Instrument Fair Value [Table]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueTable",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DebtInstrumentMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maturity year.",
        "label": "Debt Instrument Maturity Year",
        "terseLabel": "Debt instrument, maturity year"
       }
      }
     },
     "localname": "DebtInstrumentMaturityYear",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "md_DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument redemption period before two thousand twenty two.",
        "label": "Debt Instrument Redemption Period Before Two Thousand Twenty Two [Member]",
        "terseLabel": "Redemption Before 2022 [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodBeforeTwoThousandTwentyTwoMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DebtInstrumentRedemptionPeriodSixAndThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument redemption period six and thereafter.",
        "label": "Debt Instrument Redemption Period Six And Thereafter [Member]",
        "terseLabel": "Redemption in 2025 and Thereafter [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodSixAndThereafterMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed consolidated earnings before interest taxes depreciation and amortization.",
        "label": "Deemed Consolidated Earnings Before Interest Taxes Depreciation And Amortization",
        "verboseLabel": "Deemed Consolidated EBITDA"
       }
      }
     },
     "localname": "DeemedConsolidatedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DeferredTaxAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAxis",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DeferredTaxAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetsDomain",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Intangible Assets [Member]"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssetsMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Operating lease assets",
        "label": "Deferred Tax Assets Operating lease assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseAssets",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DeferredTaxLiabilitiesChangeInAccountingMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities change in accounting method.",
        "label": "Deferred Tax Liabilities Change in Accounting Method",
        "negatedLabel": "Accounting method changes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesChangeInAccountingMethod",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DeferredtaxassetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredTaxAssetsAxis .",
        "label": "DeferredTaxAssets [Axis]"
       }
      }
     },
     "localname": "DeferredtaxassetsAxis",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DeferredtaxassetsgoodwillDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredTaxAssetsGoodwillMember .",
        "label": "DeferredTaxAssetsGoodwill [Domain]"
       }
      }
     },
     "localname": "DeferredtaxassetsgoodwillDomain",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Not Discontinued Operation Goodwill Impairment Loss",
        "label": "Disposal Group Not Discontinued Operation Goodwill Impairment Loss",
        "terseLabel": "Disposal Group Not Discontinued Operation Goodwill Impairment Loss"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGoodwillImpairmentLoss",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DivestitureOfMeddataMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestiture Of Meddata [Member]",
        "terseLabel": "Divestiture Of Meddata [Member]"
       }
      }
     },
     "localname": "DivestitureOfMeddataMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Estimated EBITDA"
       }
      }
     },
     "localname": "EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ExtraordinaryItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Abstract]",
        "label": "Extraordinary Items [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Axis]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAxis",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Domain]"
       }
      }
     },
     "localname": "ExtraordinaryItemsDomain",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount.",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "terseLabel": "Financial Instruments Measured At Carrying Amount"
       }
      }
     },
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point two five percent senior unsecured notes due two thousand twenty three.",
        "label": "Five Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Three [Member]",
        "terseLabel": "5.25% Senior Unsecured Notes Due 2023 [Member]"
       }
      }
     },
     "localname": "FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForFirstQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecast For First Quarter Of 2021 [Member]",
        "label": "Forecast For First Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For First Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForFirstQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForFourthQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecast For Fourth Quarter Of 2020 [Member]",
        "label": "Forecast For Fourth Quarter Of 2020 [Member]",
        "terseLabel": "Forecast For Fourth Quarter Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForFourthQuarterOf2020Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondAndThirdQuartersOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "label": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "terseLabel": "Forecast For Second And Third Quarters Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondAndThirdQuartersOf2020Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecast For Second Quarter Of 2021 [Member]",
        "label": "Forecast For Second Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For Second Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForThirdQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast For Third Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForThirdQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_GoodwillAndOtherIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill And Other Intangible Assets [Line Items]",
        "label": "Goodwill And Other Intangible Assets [Line Items]",
        "terseLabel": "Goodwill And Other Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndOtherIntangibleAssetsLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_HospitalsContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospitals Contracts [Member]",
        "label": "Hospitals Contracts [Member]",
        "terseLabel": "Hospital contract administrative fees [Member]"
       }
      }
     },
     "localname": "HospitalsContractsMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_IncomeTaxExpenseForExcessTaxDeficiencies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense for excess tax deficiencies.",
        "label": "Income Tax Expense For Excess Tax Deficiencies",
        "terseLabel": "Income tax expense for excess tax deficiencies"
       }
      }
     },
     "localname": "IncomeTaxExpenseForExcessTaxDeficiencies",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share",
        "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]",
        "terseLabel": "(Loss) income from continuing operations:"
       }
      }
     },
     "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "md_LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility minimum availability under credit agreement.",
        "label": "Line Of Credit Facility Minimum Availability Under Credit Agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMinimumAvailabilityUnderCreditAgreement",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit.",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "verboseLabel": "Long-term debt and finance lease liabilities, net"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_LongTermDebtNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt net.",
        "label": "Long Term Debt Net",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "LongTermDebtNet",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Malpractice loss contingency accrual undiscounted excluding retained professional liabilities related to anesthesiology and radiology operations.",
        "label": "Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology and Radiology Operations",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MalpracticeLossContingencyProvisionForLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Malpractice loss contingency provision for losses.",
        "label": "Malpractice Loss Contingency Provision For Losses",
        "totalLabel": "Total provision for losses"
       }
      }
     },
     "localname": "MalpracticeLossContingencyProvisionForLosses",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MaternalFetalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maternal fetal medicine.",
        "label": "Maternal Fetal Medicine [Member]",
        "terseLabel": "Maternal-Fetal Medicine [Member]"
       }
      }
     },
     "localname": "MaternalFetalMedicineMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_MaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MaximumConsiderationReceivable",
        "label": "Maximum Consideration Receivable",
        "terseLabel": "Maximum Consideration Receivable"
       }
      }
     },
     "localname": "MaximumConsiderationReceivable",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MutualFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_NeonatologyAndOtherPediatricSubspecialtiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neonatology and other pediatric subspecialties.",
        "label": "Neonatology And Other Pediatric Subspecialties [Member]",
        "terseLabel": "Neonatology and Other Pediatric Subspecialties [Member]"
       }
      }
     },
     "localname": "NeonatologyAndOtherPediatricSubspecialtiesMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NetOperatingLossCarryForwardsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carry forwards expiration date.",
        "label": "Net Operating Loss Carry Forwards Expiration Date",
        "terseLabel": "Expiration period of operating loss carryforwards"
       }
      }
     },
     "localname": "NetOperatingLossCarryForwardsExpirationDate",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "md_NetProceedsForTheRadiologyServicesMedicalGroup": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds for the radiology services medical group.",
        "label": "Net Proceeds For The Radiology Services Medical Group",
        "terseLabel": "Net proceeds for the radiology services medical group"
       }
      }
     },
     "localname": "NetProceedsForTheRadiologyServicesMedicalGroup",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1996 non-qualified employee stock purchase plan.",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North American Partners In Anesthesia [Member]",
        "terseLabel": "North American Partners In Anesthesia [Member]"
       }
      }
     },
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NumberOfNeonatologyPracticesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of neonatology practices acquired.",
        "label": "Number Of Neonatology Practices Acquired"
       }
      }
     },
     "localname": "NumberOfNeonatologyPracticesAcquired",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "md_NumberOfPediatricSubspecialtyPracticesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of other pediatric subspecialty practices acquired.",
        "label": "Number Of Pediatric Subspecialty Practices Acquired"
       }
      }
     },
     "localname": "NumberOfPediatricSubspecialtyPracticesAcquired",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "md_NumberOfPhysicianGroupPracticesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of physician group practices acquired.",
        "label": "Number Of Physician Group Practices Acquired"
       }
      }
     },
     "localname": "NumberOfPhysicianGroupPracticesAcquired",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "md_NumberOfRadiologyPracticesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of radiology practices acquired.",
        "label": "Number Of Radiology Practices Acquired"
       }
      }
     },
     "localname": "NumberOfRadiologyPracticesAcquired",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "md_OperatingAndFinanceLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease right-of-use assets.",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "terseLabel": "Operating and finance lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating lease related assets and liabilities and other related information.",
        "label": "Operating Lease Related Assets And Liabilities And Other Related Information Table Text Block",
        "verboseLabel": "Operating Lease Related Assets And Liabilities And Other Related Information"
       }
      }
     },
     "localname": "OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_OperatingLeasesAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating lease assets abstract.",
        "label": "Operating Leases Assets [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeasesAssetsAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "md_OperatingLeasesCashFlowRelatedInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating lease related cash flow information.",
        "label": "Operating Leases Cash Flow Related Information Table Text Block",
        "verboseLabel": "Operating Leases Cash Flow Related Information"
       }
      }
     },
     "localname": "OperatingLeasesCashFlowRelatedInformationTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_OperatingLeasesLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases Liabilities [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeasesLiabilitiesAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "md_OperatingLeasesOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other costs of operating leases.",
        "label": "Operating Leases Other Costs",
        "verboseLabel": "Other operating lease costs"
       }
      }
     },
     "localname": "OperatingLeasesOtherCosts",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_OtherEquipmentRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other equipment rent.",
        "label": "Other Equipment Rent",
        "terseLabel": "Other equipment rent"
       }
      }
     },
     "localname": "OtherEquipmentRent",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_OtherInformationRelatedToOperatingLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Representing other information related to operating lease.",
        "label": "Other Information Related to Operating Lease [Abstract]",
        "verboseLabel": "Other Information:"
       }
      }
     },
     "localname": "OtherInformationRelatedToOperatingLeaseAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "md_OtherTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other technology.",
        "label": "Other Technology [Member]",
        "terseLabel": "Other Technology [Member]"
       }
      }
     },
     "localname": "OtherTechnologyMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PediatricCardiologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric cardiology.",
        "label": "Pediatric Cardiology [Member]",
        "terseLabel": "Pediatric Cardiology [Member]"
       }
      }
     },
     "localname": "PediatricCardiologyMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Subspecialty Practice",
        "label": "Pediatric Subspecialty Practice [Member]",
        "terseLabel": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "localname": "PediatricSubspecialtyPracticeMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase Decrease In Salary And Wage.",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "terseLabel": "Decrease In Salary | %"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfDeferredPaymentOfSocialSecurityTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Deferred Payment Of Social Security Taxes.",
        "label": "Percentage Of Deferred Payment Of Social Security Taxes",
        "terseLabel": "Deferred Payment Of Social Security Taxes | %"
       }
      }
     },
     "localname": "PercentageOfDeferredPaymentOfSocialSecurityTaxes",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net patient service revenue by type payor.",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "terseLabel": "Percentage of net patient service revenue"
       }
      }
     },
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PhysicianAndHospitalAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician And Hospital Agreements [Member]",
        "label": "Physician And Hospital Agreements [Member]",
        "terseLabel": "Physician And Hospital Agreements [Member]"
       }
      }
     },
     "localname": "PhysicianAndHospitalAgreementsMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PhysicianGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician group.",
        "label": "Physician Group [Member]",
        "terseLabel": "Physician Group [Member]"
       }
      }
     },
     "localname": "PhysicianGroupMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PracticeSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Practice salaries and benefits.",
        "label": "Practice Salaries and Benefits",
        "terseLabel": "Practice salaries and benefits"
       }
      }
     },
     "localname": "PracticeSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.",
        "label": "Practice Supplies And Other Operating Expenses",
        "terseLabel": "Practice supplies and other operating expenses"
       }
      }
     },
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProfessionalLiabilityCoveragePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional liability coverage policy.",
        "label": "Professional Liability Coverage Policy [Text Block]",
        "terseLabel": "Professional Liability Coverage"
       }
      }
     },
     "localname": "ProfessionalLiabilityCoveragePolicyTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant And Equipment Capitalized Interest Costs [Abstract]",
        "label": "Property Plant And Equipment Capitalized Interest Costs [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "xbrltype": "stringItemType"
    },
    "md_ProvisionAdjustmentForLossesRelatedToCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": 1.0,
       "parentTag": "md_MalpracticeLossContingencyProvisionForLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision (adjustment) for losses related to current year.",
        "label": "Provision Adjustment For Losses Related To Current Year",
        "terseLabel": "Provision (adjustment) for losses related to Current year"
       }
      }
     },
     "localname": "ProvisionAdjustmentForLossesRelatedToCurrentYear",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProvisionAdjustmentForLossesRelatedToPriorYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": 2.0,
       "parentTag": "md_MalpracticeLossContingencyProvisionForLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision (adjustment) for losses related to prior year.",
        "label": "Provision Adjustment For Losses Related To Prior Year",
        "terseLabel": "Provision (adjustment) for losses related to Prior years"
       }
      }
     },
     "localname": "ProvisionAdjustmentForLossesRelatedToPriorYear",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_PurchaseConsiderationCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase consideration cash payment.",
        "label": "Purchase Consideration Cash Payment",
        "terseLabel": "Purchase consideration cash payment"
       }
      }
     },
     "localname": "PurchaseConsiderationCashPayment",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Radiology Services Medical Group [Member]",
        "terseLabel": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "localname": "RadiologyServicesMedicalGroupMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeem up to thirty five percentage of aggregate principal amount.",
        "label": "Redeem Up to Thirty Five Percentage of Aggregate Principal Amount [Member]",
        "terseLabel": "Redeem up to 35% of Aggregate Principal Amount [Member]"
       }
      }
     },
     "localname": "RedeemUpToThirtyFivePercentageOfAggregatePrincipalAmountMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RegulatoryAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Assets [Abstract]",
        "label": "Regulatory Assets [Abstract]"
       }
      }
     },
     "localname": "RegulatoryAssetsAbstract",
     "nsuri": "http://www.mednax.com/20201231",
     "xbrltype": "stringItemType"
    },
    "md_RestrictedAndDeferredStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted and deferred stock units.",
        "label": "Restricted And Deferred Stock Units [Member]",
        "terseLabel": "Restricted and Deferred Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedAndDeferredStockUnitsMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RuralAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "terseLabel": "Rural Area [Member]"
       }
      }
     },
     "localname": "RuralAreaMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_SalesAndRevenueServicesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales And Revenue Services Net [Member]",
        "terseLabel": "Sales Revenue, Services, Net [Member]"
       }
      }
     },
     "localname": "SalesAndRevenueServicesNetMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ScheduleOfAccruedProfessionalLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued professional liability.",
        "label": "Schedule Of Accrued Professional Liability [Table Text Block]",
        "terseLabel": "Schedule of Accrued Professional Liability"
       }
      }
     },
     "localname": "ScheduleOfAccruedProfessionalLiabilityTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_ScheduleOfFinanceLeaseObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Finance Lease Obligations.",
        "label": "Schedule Of Finance Lease Obligations [Table Text Block]",
        "terseLabel": "Schedule of Financial Lease Obligations"
       }
      }
     },
     "localname": "ScheduleOfFinanceLeaseObligationsTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of financing receivables.",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "terseLabel": "Schedule Of Financing Receivables [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_Seniorunsecurdnotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeniorUnsecurdNotes2023 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2023 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2023Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_Seniorunsecurdnotes2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeniorUnsecurdNotes2027 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2027 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2027Member",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ShortTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment maturity period.",
        "label": "Short Term Investment Maturity Period",
        "terseLabel": "Short-Term investments maturity period, in years"
       }
      }
     },
     "localname": "ShortTermInvestmentMaturityPeriod",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point two five percent senior unsecured notes due two thousand twenty seven.",
        "label": "Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "6.25% Senior Unsecured Notes Due 2027 [Member]"
       }
      }
     },
     "localname": "SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock swaps.",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "md_StockIssuedDuringPeriodValueStockSwaps": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock swaps.",
        "label": "Stock Issued During Period Value Stock Swaps",
        "terseLabel": "Stock swaps"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockSwaps",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_SummaryOfEstimatedFairValueOfNotesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Estimated Fair Value of Notes Table [Text Block]",
        "label": "Summary of Estimated Fair Value of Notes Table [Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Notes"
       }
      }
     },
     "localname": "SummaryOfEstimatedFairValueOfNotesTableTextBlock",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_SupplementaryLeverageRatioRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary Leverage Ratio Required.",
        "label": "Supplementary Leverage Ratio Required",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "SupplementaryLeverageRatioRequired",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_TaxYearTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year Two Thousand And Twenty Five [Member]"
       }
      }
     },
     "localname": "TaxYearTwoThousandAndTwentyFiveMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Seven [Member]",
        "verboseLabel": "2027 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentySevenMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three [Member]",
        "verboseLabel": "2023 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture [Member]",
        "label": "Unnamed Corporate Joint Venture One [Member]",
        "terseLabel": "Unnamed Corporate Joint Venture One [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureOneMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]",
        "verboseLabel": "Unnamed Corporate Joint Venture Two [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Decrease Resulting from Divestitures",
        "label": "Unrecognized Tax Benefits Decrease Resulting from Divestitures",
        "terseLabel": "Decreases related to divestitures"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_UnsecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured Revolving Credit Facility [Member]",
        "label": "Unsecured Revolving Credit Facility [Member]",
        "terseLabel": "Unsecured Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "UnsecuredRevolvingCreditFacilityMember",
     "nsuri": "http://www.mednax.com/20201231",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r311",
      "r314",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r311",
      "r314",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r289",
      "r290",
      "r481",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r289",
      "r290",
      "r481",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r291",
      "r311",
      "r314",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r291",
      "r311",
      "r314",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r275",
      "r312",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r215",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued expenses, total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Gross, Current",
        "terseLabel": "Gross accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r17",
      "r38",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r31",
      "r489",
      "r512"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r259"
     ],
     "calculation": {
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r71",
      "r72",
      "r73",
      "r514",
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Adjustments Related to Tax Withholding for Share-based Compensation",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r316",
      "r318",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in corporate fixed maturity debt securities classified as other.",
        "label": "Other Corporate Bonds [Member]",
        "verboseLabel": "Corporate Securities [Member]"
       }
      }
     },
     "localname": "AllOtherCorporateBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r318",
      "r343",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r45",
      "r218",
      "r231"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r108",
      "r454"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r108",
      "r241",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r108",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Non-cash charge against goodwill"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r120",
      "r191",
      "r203",
      "r210",
      "r229",
      "r415",
      "r421",
      "r442",
      "r487",
      "r511"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r19",
      "r21",
      "r69",
      "r120",
      "r229",
      "r415",
      "r421",
      "r442"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r12",
      "r14",
      "r256",
      "r262"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "verboseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r220",
      "r234"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r320",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r23",
      "r258"
     ],
     "calculation": {
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r310",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r310",
      "r313",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r406",
      "r407",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "verboseLabel": "Total business acquisition consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "verboseLabel": "Business acquisitions contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r116",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Capital Lease Obligations Incurred",
        "terseLabel": "Equipment financed through finance leases"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r16",
      "r46",
      "r110"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash, cash equivalents at beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r111",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r104",
      "r443"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities \u2013 discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r10",
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by (used in) investing activities \u2013 discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r10",
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "verboseLabel": "Net cash provided by operating activities \u2013 discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r135",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r135",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r146",
      "r147",
      "r149",
      "r151",
      "r163",
      "r164",
      "r165",
      "r229",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r63",
      "r274",
      "r494",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r37",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,593 and 84,248 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r214",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r214",
      "r439",
      "r440",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r214",
      "r439",
      "r440",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r174",
      "r175",
      "r214",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Net revenue in percentage",
        "verboseLabel": "Percentage of net accounts receivable"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r214",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r384",
      "r391"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal, Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r384",
      "r391"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State, Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock": {
     "auth_ref": [
      "r279",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.",
        "label": "Debt and Capital Leases Disclosures [Text Block]",
        "terseLabel": "Line of Credit, Long-Term Debt and Capital Lease Obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeasesDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r488",
      "r491",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r32",
      "r277",
      "r491",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Debt instrument principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Debt instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r453",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r59",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate",
        "verboseLabel": "Debt, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Debt instrument maturity date description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to interest.",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Interest accrued periodically"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "terseLabel": "Redemption in 2024 [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "terseLabel": "Redemption in 2023 [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Redemption in 2022 [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption in 2020 [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage of aggregate principal amount redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Redemption percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r61",
      "r124",
      "r281",
      "r282",
      "r283",
      "r284",
      "r452",
      "r453",
      "r455",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r385",
      "r391"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal, Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r123",
      "r385",
      "r391",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r33",
      "r34",
      "r375",
      "r490",
      "r509"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r385",
      "r391"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State, Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "verboseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedLabel": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Operating loss and other carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for uncollectible accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Reserves and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r359",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Net deferred tax liabilities",
        "verboseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Gross deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 14.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": {
       "order": 13.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSignificantComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense of retirement plans related to the 401(k) Plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/RetirementPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r108",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Recorded depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r108",
      "r186"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r12",
      "r14",
      "r253",
      "r262"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "verboseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Operating Income From Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r9",
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Net Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r108",
      "r255",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Preliminary gain loss on sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year [Member]"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net (loss) income:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r83",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r140",
      "r142",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r500",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Earnings (loss) per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r83",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r142",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r500",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Earnings (loss) per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Common and Common Equivalent Shares"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in tax law"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Equity compensation adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Change in accrual estimates relating to uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r361",
      "r394"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfDifferencesBetweenEffectiveRateAndUnitedStatesFederalIncomeTaxStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense related to non-vested restricted stock, weighted-average period in years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation expense related to non-vested restricted shares"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock Option, Share Based Compensation Cost Not Yet Recognized Period For Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Medical Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r139",
      "r162",
      "r230",
      "r280",
      "r285",
      "r346",
      "r347",
      "r348",
      "r387",
      "r388",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r306",
      "r429",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r428",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r292",
      "r294",
      "r299",
      "r306",
      "r429",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r292",
      "r294",
      "r299",
      "r306",
      "r429",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r306",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r116",
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Federal Funds Effective Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate [Member]"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r122",
      "r360"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Federal income tax provision, Total"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r458",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: Current portion",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinancialLeaseObligationsScheduleOfFinancialLeaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets finite lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Amortization expense for existing other intangible assets, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Amortization Expenses for Existing Intangible Assets for the Next Five Years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Amortization expense for existing other intangible assets, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Amortization expense for existing other intangible assets, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Amortization expense for existing other intangible assets, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Amortization expense for existing other intangible assets, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAmortizationExpensesForExistingIntangibleAssetsForTheNextFiveYearsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r242",
      "r244",
      "r247",
      "r250",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail",
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r247",
      "r483"
     ],
     "calculation": {
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail",
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r247",
      "r482"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Intangible assets related to acquisitions"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixturesAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.",
        "label": "Fixtures and Equipment, Gross",
        "terseLabel": "Equipment and other"
       }
      }
     },
     "localname": "FixturesAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r233",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r237",
      "r238",
      "r486"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r240",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Government Contracts Concentration Risk [Member]"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "terseLabel": "Government [Member]"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]"
       }
      }
     },
     "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization Revenue and Expense [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueAndExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organizations [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenue [Member]"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r252",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r191",
      "r202",
      "r206",
      "r209",
      "r211",
      "r484",
      "r497",
      "r503",
      "r527"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income taxes",
        "verboseLabel": "(Loss) income from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r120",
      "r130",
      "r191",
      "r202",
      "r206",
      "r209",
      "r211",
      "r229",
      "r413",
      "r442"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "(Loss) income from continuing operations",
        "verboseLabel": "(Loss) income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r77",
      "r83",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r149",
      "r150",
      "r495",
      "r498",
      "r500",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r77",
      "r83",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r149",
      "r150",
      "r151",
      "r500",
      "r521",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]",
        "terseLabel": "(Loss) income from discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r14",
      "r397",
      "r522"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss (income) from discontinued operations",
        "terseLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "(Loss) income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r8",
      "r13",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from Discontinued Operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r81",
      "r83",
      "r146",
      "r149",
      "r150",
      "r500",
      "r522",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss from discontinued operations, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss from discontinued operations, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r80",
      "r108",
      "r188",
      "r226",
      "r496",
      "r520"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 15.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r373",
      "r380",
      "r389",
      "r395",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Company's accrued liability for interest and penalties related to income tax liabilities"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income Tax , Penalties and Interest Expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r138",
      "r139",
      "r189",
      "r360",
      "r390",
      "r396",
      "r528"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 16.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (provision)",
        "negatedTerseLabel": "Income tax provision",
        "totalLabel": "Income tax provision, Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r116",
      "r356",
      "r357",
      "r373",
      "r374",
      "r379",
      "r386",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Increase (decrease) in net deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r151"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted average number of dilutive common share equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InsuranceSettlementsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.",
        "label": "Insurance Settlements Receivable",
        "terseLabel": "Insurance receivables"
       }
      }
     },
     "localname": "InsuranceSettlementsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r78",
      "r185",
      "r451",
      "r454",
      "r501"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 14.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r101",
      "r105",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 13.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment and other income",
        "verboseLabel": "Investment and other (expense) income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "verboseLabel": "Corporate Securities [member]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r485",
      "r505",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r22",
      "r48"
     ],
     "calculation": {
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year [Member]"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r465",
      "r467"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amount of payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding amount",
        "verboseLabel": "Letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r120",
      "r204",
      "r229",
      "r416",
      "r421",
      "r422",
      "r442"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r44",
      "r120",
      "r229",
      "r442",
      "r493",
      "r517"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES &amp; EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r120",
      "r229",
      "r416",
      "r421",
      "r422",
      "r442"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r12",
      "r14",
      "r256",
      "r262"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r12",
      "r14",
      "r253",
      "r262"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit facility, borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of Credit facility, available balance",
        "verboseLabel": "Line of credit remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r53",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r32",
      "r278",
      "r491",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted",
        "terseLabel": "Total accrued professional liability"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscounted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "terseLabel": "Accrued professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod": {
     "auth_ref": [
      "r274",
      "r557"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_MalpracticeLossContingencyClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized for asserted and unasserted malpractice claims.",
        "label": "Malpractice Loss Contingency, Claims Incurred in Period",
        "negatedLabel": "Claim payments related to Current year"
       }
      }
     },
     "localname": "MalpracticeLossContingencyClaimsIncurredInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods": {
     "auth_ref": [
      "r274",
      "r557"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_MalpracticeLossContingencyClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asserted and unasserted malpractice claims that were originally recognized in a prior period.",
        "label": "Malpractice Loss Contingency, Claims Incurred in Prior Periods",
        "negatedLabel": "Claim payments related to Prior years"
       }
      }
     },
     "localname": "MalpracticeLossContingencyClaimsIncurredInPriorPeriods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyClaimsIncurredNet": {
     "auth_ref": [
      "r274",
      "r557",
      "r559"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs associated with malpractice claims and insurance premiums incurred during an accounting period, less insurance recoveries and returns of previously paid premiums.",
        "label": "Malpractice Loss Contingency, Claims Incurred, Net",
        "negatedTotalLabel": "Total payments"
       }
      }
     },
     "localname": "MalpracticeLossContingencyClaimsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesScheduleOfAccruedProfessionalLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the accrual for malpractice loss contingencies (general and professional liability) which may include the policy used for accruing the loss contingency, the nature and amount of any accrual, and any significant estimate used to determine the accrual.",
        "label": "Malpractice Loss Contingency Disclosure [Text Block]",
        "terseLabel": "Accrued Professional Liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r67",
      "r120",
      "r229",
      "r442",
      "r492",
      "r516"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 35.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r166",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash used in financing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by investing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r104",
      "r106",
      "r109"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r104",
      "r106",
      "r109"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r82",
      "r109",
      "r120",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r148",
      "r191",
      "r202",
      "r206",
      "r209",
      "r211",
      "r229",
      "r442",
      "r499",
      "r523"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r286",
      "r414",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contribution from noncontrolling Interests, net of loss"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total non-operating expenses",
        "totalLabel": "Net non-operating expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r32",
      "r491",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Estimated fair value",
        "verboseLabel": "Notes Payable Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Federal and state income tax examinations"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r191",
      "r202",
      "r206",
      "r209",
      "r211"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income from operations",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r460",
      "r467"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: Current obligations",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Long-term portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Long-term portion of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r459",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r464",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r463",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards for federal and state tax"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding gain on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOwnershipInterestsByNameAxis": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by ownership interests about other units or shares or classes of ownership in a partnership. Excludes limited or general partners' ownership interests.",
        "label": "Other Ownership Interests Name [Axis]",
        "terseLabel": "Other Ownership Interests Name [Axis]"
       }
      }
     },
     "localname": "OtherOwnershipInterestsByNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOwnershipInterestsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the ownership interest, which details special or unusual rights. Does not include limited or general partners' ownership interests.",
        "label": "Other Ownership Interests, Name [Domain]",
        "terseLabel": "Other Ownership Interests, Name [Domain]"
       }
      }
     },
     "localname": "OtherOwnershipInterestsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedLabel": "Payment of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForPreviousAcquisition": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.",
        "label": "Payments for Previous Acquisition",
        "verboseLabel": "Contingent consideration payments related to prior-period acquisitions"
       }
      }
     },
     "localname": "PaymentsForPreviousAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments for credit facility amendment and financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r90",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Business acquisition consiideration paid in cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition payments, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r291",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/RetirementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r320",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsSummaryOfEstimatedFairValueOfNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r18",
      "r20",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.",
        "label": "Proceeds and Excess Tax Benefit from Share-based Compensation",
        "terseLabel": "Cash proceeds received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsAndExcessTaxBenefitFromSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from issuance of senior notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r94",
      "r125"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on credit agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contribution from noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Proceeds from maturities or sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "verboseLabel": "Proceeds from sales of businesses, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Other revenue [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r103",
      "r120",
      "r130",
      "r138",
      "r139",
      "r191",
      "r202",
      "r206",
      "r209",
      "r211",
      "r229",
      "r413",
      "r418",
      "r419",
      "r424",
      "r425",
      "r442",
      "r503"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r258"
     ],
     "calculation": {
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r260",
      "r518"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/PropertyPlantAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r116",
      "r260",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r28",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r28",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment estimated useful lives, years"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Information"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of uncertainty related to unrecognized tax benefits.",
        "label": "Nature of Uncertainty [Axis]",
        "terseLabel": "Nature of Uncertainty [Axis]"
       }
      }
     },
     "localname": "ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r98",
      "r125"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on credit agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "terseLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r108",
      "r266",
      "r268",
      "r269"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Transformational and restructuring related expenses",
        "verboseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r40",
      "r285",
      "r349",
      "r515",
      "r536",
      "r538"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained (deficit) earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r201",
      "r207",
      "r208",
      "r212",
      "r213",
      "r214",
      "r288",
      "r289",
      "r481"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Avaliable-For-Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Components of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Income Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r242",
      "r246",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table]",
        "terseLabel": "Debt Securities, Held-to-maturity [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r49",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/PropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Company's Selected Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r191",
      "r194",
      "r205",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r191",
      "r194",
      "r205",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of Net Revenue by Service Line"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r320",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock and Deferred Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r325",
      "r335",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of Activity and Certain Other Information Related to Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r171",
      "r174",
      "r175",
      "r176",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Net Revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetRevenueByServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfInsuranceReserveCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Current",
        "terseLabel": "Accrued professional liability incurred but loss reserves not reported for claims"
       }
      }
     },
     "localname": "SelfInsuranceReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccruedProfessionalLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Private-Pay Patients [Member]"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Fair Value, Awarded",
        "verboseLabel": "Weighted average grant-date fair value of restricted and deferred stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Non-vested shares at December 31, 2020",
        "periodStartLabel": "Number of Shares, Non-vested shares at January 1, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Fair Value, Non-vested shares at December 31, 2020",
        "periodStartLabel": "Weighted Average Fair Value, Non-vested shares at January 1, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of restricted and deferred stocks vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfRestrictedStockAndDeferredStockAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Stock Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Stock Options Awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options Grants In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r327",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Outstanding at December 31, 2020",
        "periodStartLabel": "Number of Shares, Outstanding at January 1, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at December 31, 2020",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at January 1, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r317",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r116",
      "r320",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Vesting period of options, maximum years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r340",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansScheduleOfActivityAndCertainOtherInformationRelatedToStockOptionAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid for Tax Withholding for Share Based Compensation",
        "terseLabel": "Number of shares withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The nature of the uncertainty for which it is reasonably possible that the total amount of the unrecognized tax benefit will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]",
        "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r121",
      "r360",
      "r390"
     ],
     "calculation": {
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "State income tax provision, Total"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r240",
      "r263",
      "r267",
      "r270",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r119",
      "r120",
      "r142",
      "r146",
      "r147",
      "r149",
      "r151",
      "r163",
      "r164",
      "r165",
      "r229",
      "r280",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r65",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r139",
      "r162",
      "r230",
      "r280",
      "r285",
      "r346",
      "r347",
      "r348",
      "r387",
      "r388",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r162",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfOperatingLeaseRelatedRightOfUseAssetsAndRelatedLiabilitiesRecordedOnTheCompanySBalanceSheetAndTheWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
      "http://www.mednax.com/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueOnARecurringBasisDetail",
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Forfeitures of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeitures of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r36",
      "r37",
      "r285",
      "r319",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Gross",
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized for repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Company's Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchased common stock, shares",
        "terseLabel": "Repurchased common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r36",
      "r37",
      "r280",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchased common stock",
        "terseLabel": "Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r37",
      "r42",
      "r43",
      "r120",
      "r219",
      "r229",
      "r442"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total MEDNAX, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r120",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r229",
      "r230",
      "r285",
      "r346",
      "r347",
      "r348",
      "r387",
      "r388",
      "r411",
      "r412",
      "r423",
      "r442",
      "r444",
      "r445",
      "r449",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheets",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r450",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r450",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r364",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Other Third-Parties [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r292",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Federal Home Loan Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r292",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal Debt Securities [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r292",
      "r306",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/InvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsScheduleOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r355",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Uncertain tax position liability"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decreases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in uncertain tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Decreases related to lapse of statutes of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesScheduleOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r461",
      "r467"
     ],
     "calculation": {
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "verboseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/OperatingLeasesScheduleOfLeaseCostsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/LineOfCreditLongTermDebtAndFinanceLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r151"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding",
        "verboseLabel": "Weighted average shares, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r151"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Weighted average shares, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/SelectedQuarterlyFinancialInformationSummaryOfCompanysSelectedQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=68049836&loc=d3e5870-115623"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/subtopic&trid=2289286"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=68060100&loc=d3e8578-115644"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r565": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r566": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r567": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r568": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r569": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r571": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001193125-21-047064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-047064-xbrl.zip
M4$L#!!0    ( !PX4E*2I!?A%A4# $F$)P .    9#4Q-SDT9#$P:RYH=&WL
MO7M3&TF6-_S_$['?H<*[LT]WA, (C&WL[GX"8^AFUP8&X>F9]Q]'J2HEU;A4
MI:D+H/GT[[ED9F66JI   0+EQJQ;2'7)R\ES_9US?OE_U^/8NQ19'J7)KZ^Z
MFUNO/)$$:1@EPU]?E<5@X_TK[__]]A__YY=1 1?"Q4G^81S^^FI4%),/KU]?
M75UMCD68^->;03I^O;VUO=7=WNF^DE?&4?+#NO:ZG\6;:3:$*[=V7N//?3\7
MZG+\-8ST#>;%;U_SC_K2F4=?[="UW;V]O=?TJ[XTCYHNA(=V7__]ZY=>,!)C
M?R-*\L)/ FLLT0UCKU\?BMK <Q%L#M/+U_ #K<O&5G>C6IDH3]]L=]_=] *^
MHGK^)!.!7XBP]9Z]UWX69&DL7E<7J]N#M$R*;-H\1/ECPS"#,LN 'MKND[\V
MW"BN@U'S3?A+PPV)'P5Y\QWT$]S2?6??DD=!\PWP0\,;\F*2M5P/O^#SW]LW
ME/G&T/<G^IZ!G_=IK>4/#>^XCF_8T;]_,:BR++(;-A)^U</.BMD1P)=-1'7=
M]L@N$BP<"O'W3^=?JLN+YNNK2U\7F9_D@S0;^P5P"'S2[L;6]L;V6_.<W#3I
M^AF'EV[ NEMWJ'V8]][WU5S;CSXRJE?$L80?XG^+J(C%;]VMC?_]Y35_AB_'
MHO"]($T*D< B%.*Z>(TW?O2"D9_EHOCUV\41\CY\RX;X5QE=_OKJ@"_?N)A.
MQ*O7^)37ZAW]-)QZ>3&-Q:^O7OWV2QA=RK_^;QCED]B??O"2-!'_][=?HNL/
M>)/(^&,4AB*AC_#[23D6611XB3^&YP#C^+ _%DD(_U\<Q?[P%0_XNC@7@U]?
MG6UUO\/_D HNTN[V]QW^_.JW@1_GXI?7UB/5&XXR/\ %E:^0A/SA+!,# 6<Y
M[!5I\./,STZS7H'LXV]^7(HSD?5@56 +(V0^-.3N^^VM]^_?OJF-:3\_38RQ
M>&42\2_?X,/W;[W/WR<B^RZ?%HH@&L-@?WUU?'+TZK>MS:VN&K8:YT.->_>&
M<7?W'GS<!^EXG":W'?3;IUWLNPWZW2.MM'UV*@))X7'%]"SVDV(_"0_A)$_P
M/'W+Q:",OT2#F3'O[6S5%[KYI'W7#_LJQGV1E3F^LO6-GZ;(-_:OH_S[URB)
MQN68;P-6?NXG0_KEU6]G._]H.;K+G&!]4UHF"#L^*0N1/=^)OE]LHJWC_-Y+
M!\45T"*\47W\+"Y%G-*[#]*\R&^Y*(\U];W%IGY49G#P2IKA$0AG^'3;&2US
MFX_@487X$EV*\#@!!7L8]6.QGX-$OFFRW:U[[C,,M+O80%$J?TZ#DH1RE =^
M#,PO2L,C^"Y?4$(?+?ZJPP14END!O"SSX^,D%-?_*Z8+OF8+_N_]WL[>F[V%
M7W= &KV<V#^$GQTFX6=@\PN^<6.CNPTZVBUG=PP&9S9),U+U2*H<L$%RD(;U
MS>YNO=W>6729OS0-9)"F19(6@IY[=/+][>[;[5W2*C\ B8/5*Y*-;ST@"#@(
ML!0B]*ZB8A0E7@8J(ZBGH?=3* 91$!4_>[! "5C*N>?G7C$27M^/T2;THMR+
MQJ"ZPDO]>)-&H5_[&_UI*'ZDPX 9)?+??D%M^4-.%BG,S2,[]D,!Y^S75WDT
MGL2H1M-WHPRG/@XWE,F]>9V#L?=:/D)IW;=\R'<P&S=A)=0%:$S>H-N3K3GA
M=:+-^U*]5CU"FJ0WF^KP$.(RD<AGG0*+6_H+NQONNTQ  +==)J098&UKM$BQ
MW[_M(L$M(EZ7]0$.>]OU@5N",GYN1^UUC<G1GWE:9O07.=H^2(9.3+F-H7N_
M>?)J07)#_QF%^,4@$IE'O%,T>A<.CO_7EHGUF^%YKQN?/R$)K__,"S\K4"K^
MIEPP:);4?ZO&&E;72O%H_Z)?J]_SVEJ4QC6J&W\KLC;L%BT:9JM^N?=LT6I<
MN=EV]Y8X6T7_W;V*_E=HUB;]P[P7IO_Z&MV+_O4:O3?6Z/UJKM'[6ZS1^P=8
M(^2C6SLKQRONP4>W=I:V1F^,-7K[?6=KM=?HS2W6Z.W&SM9RUNB=L49[*[]&
M[VZQ1GO+6J/NUG/26;I;3Z&SF')-\:.7(=>6SX]HC20_6N$U6I0?X;5+YT>T
M1GLKOT:+\B.\=NG\Z'GHD OSHZ7JD&A5;+U?.=W1L"K><]![^3;4BLYVN1;C
MUO9WF# (L>X*SG:[BT"*[O;R9KMZVJOE#;#X__(H^=T*SK;[[H%\']M;W[\E
M&#\)#V3(1/Q/&B7%WV!D929.$Z%C6XAK"\M8G XP9%=,OXIBE(;'R:7("PQ>
MS7XKQ D\F<)AC["DDM>+(0Y&_AW"^ZXG,097>!Y>&,'/#$Z$.7VXYZ3&X8>%
MEN^7UXVCJ?:K&O:J>,6(,F#]81KAN;A,X\LH&1[ 'U%QY =13,M2A77M7U9V
MSS7VI&FXM)N+3/EY;N=1="G.D#HOKE+Z++( QM43291F>N(G:2'RSZ6 BRY&
M:9G[27AQ!9=-+T:9$"]PRY>W+,^3+ @2*,+]!&@^)PB6,<?#:#@J$*IA03C@
M;\4$OQ^.)W$Z%8)P7*<3#"69U^Y?^5FHH2JK3!_FK)@R;K,R[7N_\ #J2Z6^
M;UWAYTEO:R),U(\O4)"<C:8Y#-9/X&3\D>:3J/#C_2&P01RJ!?9J1U_EGZ9?
M_7^FV4'LY_G*[_#MY@&L8Y$E>IZ;?UJ,1'8A@E&2QNEPZG8;=KMQ39[G]IY$
MB0 ;)Z'_3GO1]4F:_+7T8US4T))$9V46C/Q<H S<3TS1>!0-Z!'&G3-WM.D3
M*TT8LRK"XR[7\R2IP[R($+MX.CCRHXSP_?K#YR@/XC0'#=MB).IG.&["QU\)
M(.SG$1VZ[_KWXV12%OD7!%!OMSQ ?_P#-M^'%9W2Y?R<];:(YBRSJ8+>8@N7
MH D_I:EVE]6[@<:,1;R!:MW!7N[!!D9\#SKIP7,2=ZX?[UPO;;O<L5["L5[O
MP_.$-+K*1($>L"P*"G*'?3:S9#'/TC+ZGX_+KSY2V.:%YOD\M_"+* J1G0Z8
MPE_:$54_-LWR>>[7&4S 1V+LE?U\(H+(CXOI&:4I!Y96]:G,P?S,\_W@7V64
M4T[0RN]A^YC1>S9_YL]S2YMTA>Y=#%?UFZ'?Y><H@[(H&<[7N(\R\:\2*ZVL
M/)TL11WK/H1V>,-RSEQ]PS:]'$*^DP?&$?)2[0I'R+<DY/E.O<^B7QS#&S-*
MT5]Y.FL<+LC4EP=<F&]ZOM2M>_;6Y$%Z&848,TDP\L%#_OKY\+K(_#0+H\3/
MIL>%&*]NJ!!VI76T\%O3_)[G3KT8>,^:H&M.TJP8[5-U$C\Y\[,B$5E^G.R#
MK56,1![Y%G^,\DF:^_'O65I.**8-RQSXRAC[?N%?8\T6@__L*Q:$/C#S47 I
MUZU9>4*8,VD9UUUL&9>@B-47#OG](LO^/,GS6^\B(Q429!AHCQ&6C3#)J$)>
M/PNFTCA<]6/[7)_GWAU@E0\Z*B(_'7P6<(IL-^)+VKP;)OL\=^];[_?T4F0)
MCJPW29,\S41X"-=GDRS*18[*YSJ<R=NOPG/=;ZI\EH/H.$MCF$[@Q[VR'T:7
M$:[7"][A1>;]//=T/XX):JB3C3ZE2?AB=_*FV3[#_>ONK3O>[#EGX"RU'E.-
M+%Q&Q&-D1#SD#KJ,B!7/B'C(S7<9$4^>$?&0V[NZ*-<U5R>>'<S5P=?=P7;P
M]9=WKAU\?96.M58T*<#SLG&2#5-]GIOF@)$.&/EH>++')F0'C'QZB>4(^9:$
M[("1+V?K'##RN6R=P\<\W[US^)CGO'L.'[-Z^)B'W6^'CWD*?,Q#[JG#QSP\
M/N9!&E/5VJJ>96E8!M@=MB>RRR@0-$^>0IX5\N?33/ZZLMN(%:9;!FOTXFV=
MZK(W<27ZS+5LN8($Y <IMJ8-%"3@A6PW&"MM,URK719^7(P._$R<^:! 8)"$
M5NE%[;4ZVC=/=IVVO2JJ0EE6ID!^_@EDC9-;I]UU*8+KL,OGLEOYH6Q1#AK+
M?A"48VP?+$*IB(XGF1CALEX*;,(^MOS%9'?@<G!3#;PZQ0S9U8>_S1LYU8VZ
M^_*L$QGMQX7($C16L-<T_/=FM_3W+V#3I,DQ>B#Z?O+C=(!MGT.\\<OQI]-S
M\^Z_^5GD]V-ZZLJ35)M+NV5]EA#8:E@>73-KD45V5-I.I4<B%)D?'Y5@@!_"
MZ@4%'/'>E3^IW_NL:/0&BEE@PDL@V:4=DI='H;=1NKY_]:^C<3G65M:YGPQ7
MG_R6J(XM9,Z9JX)_6ZNV3K2UGJ7\5Z(B_RJ3Q=UZ';P0ZKC/Y->)2/8G.$74
M&K[ZV3!*'E;%?V:2[1Y2YOXZ4^O&.-OB19^0*'GN)\2<@3LA+_^$K U3?X%;
MMR[<YN5MW7X0I"6CUT5T26S0D"L':8));1G5R3N/\A^?II]$$HS&?O:#Y$R%
M&]/Q[9E[YCSP602);AZWNFKQU5B";)FW-R9FJ&63UXG0U8Z(\*N?^$,18HC>
M),TJ<'^:#?TD^C<O+&++2]%+P;X3JQ^SNL4DJ&!MZYJL$VE4QW:=Z6&6B:T?
M)5R,HBS$PJ_3,W^:9HX<)A\:EV2=:*(GX@%,W='"Y(.U%.M$ P?I>)PF,S"V
M@S1&H$?FQRN_VS-#K7ZH36V=]M7UO7Z$<,BJ]+U>94)L83 O%SSGV \Z7\*0
M:KOX\9D?A<?)@4^Y NM% 3<NPCI1@TPLN*O_['O/CRG!3ZEPG'>0GXABSA/J
M;J/5I:D%!H^5N>8LQ,,XWQK\@3?OZ%K1MNKM"?9&&!G505NR?]QAN&O"6>M*
M/X[+V1V_53Q^7WV"SL9'@B1K"---;DZ_<P?PK@?PAK5V1W!]C^") !6W('X,
M&T.I04T-KW5]#7<NEWPN;[L![K"N[V%=\QKKSZ]ERRH3TWK7]7["\MDOCY1:
M,9+?>^F@N/(S@25EY,?/6"(UG3 <*;<;T@"KA^$44_2V8QD:]-'1E<\$C[78
M^+4K<M'%N8>H=8!0.YPQ*<$,TMMR2]I[9F#@NU%ERR(Y&EP.#3K:NX'V',VM
M&,VM"X+^J>GYY='<_66MH[W'E>,OCP9;2<C9)2MIEZQKMM-1F2514=**'T77
M^.FVY.?8Y3V)OGT/'"6^9$/E,<H@.$J\/25^*B.8J=U=:KW$L+T"Z[3W=E&$
M<Q&*,576.J-'?Q*#-&L(XURE)JW<_ Q6 M<Z C)_@3@B<K_-6$:4V(5J'NMH
MP9)B6L1(9,(?%")S!^IYT.DC'_IF,G''2*T/;K,[.NMX=!:[N*(/=V;TFJ2E
M$S?NS"Q '^[,J#69TP77'9IU/S1K"FU\)/\!?BG&WR87*58C*:8&Y?A#<3K8
M'PXS,83)G651$D03/]X?8\$K[1G5N:@]N,>'Y[H3^G).Z%.Z3M")W4A<JC_,
M?0AWG3C)P0A# \<)E21+K11X2M4XO4K@)(^B"55,%7F1?YJJXA3N(*_\09Z[
MA[(@71,5N&.PX#%P62M/EK7B#L+CVF.W5B'=V5C]L[%,>VR^;O?RSDS5DW0?
MGBX&(LMD<:UO263C[)YO>T[2JA>8YSIM?%,>\_0,*_OJQL.\[9_*/$I$GN\'
M_RJCG,HNK3P!M(_9K';2/O-U(H1S7Y9\44GD5'_"CW_/TG)B2<PHGZ2Y_.$@
M]O,<]BGPGP5!S!\[\HCY*[%.A*&XY(5_O9_GHLA!\P0-,^K'@O_FN7_]/',A
M.^ <72V#KN8.A5Q9#1N@O%P+;>(ZT?6A#U>".@!+\@_A6W%-^,I2'%>7\.HC
MU4E-39-;I]T]2;-BM#^&!P5^@C7(T6P^3O9!'0 S.H_\M6(]"Z[&.A&(GKL3
M3M3+;,'E6"<2.4@OHQ +5B=8=EJI.8?71>:G61@E?C8]+L28]9S#:Q&4V-3Z
M= "KJ_!V>59<1$4,7QXG802/*U>XX#M&I-I&B[\U3_%^.DOS:JH>,[/KOT[T
MQZZTDEUI88*>-/C^7;O[<F4I:UXGQ1MGZK9\9VVV?&?]MOPS,-2\H&2RTP$(
MW- OUDLY;5^ %TT&W;V*#+I[JC@GYG.S\D7A/JU%M!2G7+VMOZ&29JU89.-4
M'W++NWN+;SE<^^!;_D>:4[^"7+=\?%';#4>[;89KM<NZ6=89,#Z*D-(JO:B]
MGNT,UC39==KV<U'X8+J$AWZ61,D0J_3N!T$Y+K&7%M<0QNHOF1CA\EZ*XR1(
MQU;$[>7V;Z% [-V79YW(R#597F*5:M=D>74)7>V(:[)L.L">I,GRJI&&:[+\
M5$V65XT27)/EIV^RO&HTX9HL/WZ3Y56C ==D^67N:P77G=G;YPM#5M\W3FZ=
M=M=U+E['77>=BY^R<_&J48/K2;<,1Y)K!;>2M.TZ%[O.Q>[X/=7Q<YV+7>=B
M=P2?] BZSL6N<[$[K,_DL)Z-ICE,T4]FLE]>7NYWPU37::M=4NZ*)'NO&F%\
M@0>^T)38AJFMT\ZZ?,>5RW=<-1)Q.=,KEC.]:@3B4I6>)%7IZ<G@O4$&[UVJ
MTB-L^?M;;/G[A]]REZJT%KOL4I4>)55IQ;;=I2JUCWR54Y56C(Q<!L?J9'"L
M&&FX#(XGR^!8,4IP&1PKD,&Q8C3A,CB>((-CQ6C H8*?%!6\8M3@,@,>)3-@
MQ7;=H7P<N.;%TK;#@CLLN#M^3W7\'!;<8<'=$7S2(^BPX X+[@[K,SFL#BVX
M>FC!%2,1AR%?%0SYBA&&@Y&N&HQTQ0C$P4B?!D;Z5&2PGY\F>OMW73_EI^NG
M?#<BBA(@%;@<=\\F"_7+W<FB^WUG2T:!H^M[3+^'ML,+I(JEK<H#$@7PBN[&
MSM92B&+K7=4D96N/B<,U(5T1777N4)Y%$])WBW=]V=HSZ/K>,G!KY_OVKFPM
M1\=]?P@\NXZ*>R&,JW&&#\>$<+-V-K9WER:9[KI9WX_23 1^7L!_>P(>BYWF
M">+UUQ)H#93_TP$^53LY-32@!YS=AT&N[):C>[%MM*C W&;BR_#I.<IKI3QS
MW6G9NR^:WMJFZZCL$?C;<R>S)>_TTMGHK>AZI>BLHC%0YI= ;T=IF14C<SU>
MMAAMG>]SYVMUE=RDN'DJN7GM_;R3RZ;.*,N+Y\X,;T&<+=-UM+F"M'EW2^3[
MURB)QN587W4.)OMJ)_Z^/!MEH6F;&X-_6QOG3LD#GQ+_VIV29WE*S(USIZ3M
ME#PO*; 2A.78[T*$]>P8YQTYB--^;^V?>B<)*KV,PI,(\^6$"F=^_7QX761^
MFH41"*_I,8BRU<T"A,UK'2T5B9B=WX-[>-XMU9-XAYWZ?EYBM[-,6-B?WT4Z
MS/S)* H^1]@>JU^N=.QUJ3N[,(>X<9$PR&NO[#.AI8J.6)RXT_^07/W=+;CZ
MN^6H"[O?M]ZJ_=6?'5QTU>"BN.F[&UMO%R40\]K[B_V*,%HUPY=/,H^A9JXR
M.=H2QB2P^VLK!H&UV;1K2F"+&:R.P!8FL!=/1FN\U=WM[UWE_*@^.Z3IJF1%
MP69WMS>ZBSHOK&OOK\5H%+,CB*<D"/OLF\#?Y8'4W5:OQ%;?!^5M7GO_L^^R
M%E:+GA9QT*Q>UH+-NO:6E5]3HU!'8BLCG9:[Q>\YW1*V^%N2^&,1'J39),V
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M:65@H&OV=LTDQVF.7 3Q*?&4I:1 Z9H+V/90E2;_5TD%Z#H4??@O23U'%"R
M<=3)YXRXV5&<^O7H 79#W7K[?6=+4@WV':1?JLZ8H0@BL))R=C_"RP5],NDK
M*<=A6L@+X01UMG>[G;VWNYWNEBXTI ;W&RA?*-U1<GC_U7VWV=WR@CC-D<=.
M@ X%*@F\ZQY%5I"?\O6X8BWH-5HH>$@AR]ORNW(OAN7%6RD:@S76&UW"+UC"
MX^&2561O<YC2LB!-"W<%+CL2_0PH;JH@9D3<72*^>;1G]'^F=J#Y:?7H)F+<
M_@Y<#)]>)T;5_K2BQ^.3HP4I\OUNY^U.M_-^Y^T,.6ZZ5,=;DM3GTX-O7P]/
M+GI8@/3T_.ST?!][V7WZAW=^>'1X?GAR<#@WG?'1!$L#AU5QLTN,_Z;74R]7
M?9 M/ :9)374!>JZFN48Q9JM@'<5Y.Z^V>_P<X!R)Q(0@8^DT\.=8KRO0I""
M"8>0#L@(MEID.>H_51$I5G@R,0#M- $>&27>&4@ [_CX6 >X'Z;Q%3>KH@V4
M@R?#KN!5"T'L9B)*-G%9Q*28F6V4\+'$Y9!E5!E8<./<\#4/-QU9'<43F'81
MRA8'-PR(IX@;$@J@$VWI:E(!-CC!W< +TT&K@OALHI$64-7U9GTYO5E;@</F
M/+MFNV&UIV)L^6/[ HXU^F/C*W^:&^ZSD?;U6F'G:E%AT,8*=7=W.I[ZY^>/
MKU[?KL%RO3FR2@N3G9'7MJ'R8[\66Y[CNBQ==5J\!8M]6)98U?4>X[[MD?TJ
MPL2_[GC'2;#9H$$]I([Z1 MMMU4[/?&.3L^_/J@2\\(7](DH5_66P?9CWB&Y
M_57W,ND0Z;)#9#W(^HEVX?CD\^'?%UMA\UTS/3>6M4;F\^^OOCP+J-Q26KTM
MAI5[&$S;^R4A\.9\O@\X@-?XWB5;FFHMS,T%OI'H'SA1V%1!=[OO]MY\[[[Z
M[6P?!.=QI7[>+66ZI?#$C3.W3^A+>E/;^QH0,"M1@6-%"/3,'XJG)\(GY"Q8
M3>!.R)H'(/[ZK)HL1.6 W=@1MZG?=3<%RS8?Z8WS*[>LBF;5P'NW0=\JQ%B&
M1#8]A2)L9L6W*I=[#Q;U!*1FLB3R%\Q[S<ZMB;G)"'2,P3&&E60,.Q9CV-_T
MSJ/\AW?D!T6:.>XPESMLOW/LP;&'E\L>WECLX=.F]RW)!"CWER+T>H4_8&R&
M'5-PO*+Y-6_V'*]PO.+E\HI=DU=L;WIG63K!O1".-SC>X'C#6O.&MR9OV-GT
MOHBA'R.'" 25-'$LPK$(QR+6FD6\,UG$FTWO*USI]?R!**;>YRA'V'V9.5W"
M,8I61G'#@>P^^H'L+NM KB)VH^'XOE?1W=;P[D.<T]N?T >1)H\WF/O=\>1'
MU,GRM9#E>Z8LWP59SGF2F$K?T =/IG<=_JN,BFD'KH@IK8'2L#C!!!Z 8^*<
M%JY+[)V563#R<\X0XWN-[!>G)LQ[S>[6FJH)C@>M!0_J;IE,Z"V6HI2U/XYT
M=0:L5.HXQ5Q.L>TXA>,4+YA3=$U.\0[5E9ER,.B!*#E_%G60_<2/IWE$ND?%
M3@[2).3:07C-N<C+N*!+3B=8, ^3_!VWF<MMWCANX[C-"^8V%A;SW?ZF]U?,
MQH^PH-*E(,X!7\3J;\/UZ>WWT[)0QA0"M1PWF?>:=PZ_Z;C)2^8F%H#S_::A
MC?14I1!VF_3*R22FO_ULZBR?Q;B'TT4<]WC)W,/"=^YM>@=4+0B+^1#/ .7#
M'V9"<A$JE[//529]_ (,G?VJZ"3>8+A6M-[BV,R\UW2W'(S<\9F7S&<L;.@>
MV#Q8BB9+8U9-" <6HHFSZ9B%8Q:.6:PWL[# HGN?-KU3*KE\7%7G<US"<0F'
M EO%L_N.86!,%\<.#.; 8$Z>K[L\?V\ED6YM>I^C3%""><<[O!9!28&.T\$@
M"A3&ZT!5M_5^QX8:Z%1P?H0%A/ZZ0K\=*UD/5F(!2[O=38-_8,<1D>3./G"L
MPK$*QRJV+?AG=WM3@<.GWNE5 GK&*)I036S8(#]*O$\B$:" 8.B"?R<]I$*"
M24A7*S3=L1S'<AS+66^68^%(NSN;FKD0WT#X)S"=W.(D%T8#J(Z,N;)QY!W#
M7DRP*Z6S?1QW<=QE[;F+7</S#1;8B9(@FH#&4H$RO",A6S_U1'89!2X3;@'6
MT5W75#@7*WG* [VC4N;_YJ(D+DKBQ/MZBW>[U.8NNC9'43\JP"QHP'1[O6 D
MPC)VEL$"XKV[IN)])5C'2^$4#4?60C5VWV[*-J#8=D,]9XD=P?"QOWF]<@SS
MF=:/O3OPYH'??<H##_]BRR>;[(-8^!F];H0$>:VIC_:^[P<_AAF8<"&^G.E-
M;FO]Z,AQ+[G1V/:;EL/S$G3OH]/S/_?//V]\.3W]W^.3W[W>Q?[%(3>%;E>Z
MVUC6K?H_SR[T8MVT9Z:@'(EFAV(P_N,2F]>EV;P&Q8_1<'GL3[')L.PZS!V'
M,7U^>^LCC/G*S\*-.$U_8*:([F&=TP5=.G[!B!XA9]7Q^F7A^9F@_L5Q-(X*
M>FK'N!EFB6Y5>""\+2TS+^W_4P08# :="<:9L",$JPT58A@)Z6#UX]A\R$\I
MH4N+$3%M_74Z\&#9BC1#;N$-_*#(?\:+8%!AF(D<GHVOHF)#'4]<\DT9S/]2
MQ.F$'T+77^$F%"()X;)K;#7=P5;>_Z0/?1%'< />B#G Z,TIA'<5P1#A*UR/
M- C*3+69'I1%F8E-[V(D<F&.%A<J'<!+O&#D8[=XD0$!$BG QW&4I'$ZG'IY
M":OLYVI?Y-L[:A?DUZ-T,O,=#*7^537@^B_Y*"WCL/ZM7(3:M[A/]>]P_O7O
MY-+5O\V+:-PP K7 ]:_3G.HSB)EA2"*9JJ^)<(#J8C_#7<,-KUSTN-I]/\>C
ME\!RYN5X0@Y\_C'/X6+>EK$?"MP#),YQ%4J$W8R137(W=!'1*V#'Z,#B,_A+
M^ K;E.-9MZFQ@*,=PEAD/T O4'4G<D5B,#2F%9L>\=E,[@/N\(%OFFHJY$/K
M3V#U)ED$Z['I[2=3K_WX/AYWP26GU?1SN6I>B$>%NYCSML!! PF*G/('L@TO
M+(LISJF<T*5PH#)Q&>6XQ/(H5#/I  L2M#+P A^;PI<Q[4\"C-W@NAVUKM6)
MIP6]@N>2_M>V4HJ5#4L?BY\)KELF'P8[36]0^X\7YR5Q,YQ %N4_>/-*N((D
M ;*=3>]X##R?W+[5?OI(#W#\O, O<:Y!40+)\(1@FC/TT)>MH."7("(BQU>&
MT0 DB(=G"R@ACH$*LG1\$RGX1&QYD$5]H+Z')XR.I P6&"0%@"AXJ7(N-E>,
MF"#4(3=[VZB##@-%'=[#WC>M&H ATM\O:G;<5G,R'K^T]J.WTAYOI\@L:]J/
MHP)N-[92OND_QCA=O_DE]INOEG<MF\^O[VN79$"U\YW]W"OS1Q4]91*CX$2Y
M$R"I7Q>5,@ 2]U]EE*%Q@+^C%J[U[J\B3/QKK8+B[_(7!+&"=C*C$,\HN&5N
M:JKR2U SU;=D *(@QX=/?*DF\L,]^7[O. DV077RCH#E1*'O*1N2]!RIA^+,
MJ)LKF9:@E.11&/F@J^*\L[0<CJ3Q%H$.H'0)P>H ZQZ@.Z""6I)6^A,VEV8C
M+8:1J 7Y_'<Y\)]AN=(A:V)4;T#^1$78_,$@BB.V<9768HR9M#'070>LK(/6
M [IX&D2^5(VMG\S[.MK A*?WX17%5"Y6)(/IL(*%! V"Q:@,H&HXM4<G169I
M&3]74"!K!8%'POR\D7\I]%VRS@*:# N\H"-7GS1& <-$33>F[AH"BTKQ/H%.
M" ^XC$!_GHRF.<(<8202(( ')E"C0WU.)F67\%WJG4=!NMDD%1^;ET0AO+/J
M);TZ3K&5]7MQ<+E1\VE1([;OIN7-/.+^"BQY;4F/"$0<RU[+O[[:>D5_RP?3
MWW(,W(::7J#L8E*E/GJ6KG6/Y9>-KI&!^9,<OE:?]$_6?%_50C_S8SD6A5==
MN_7X&YK98YS'](_3P;(WYV';:!]?''Z5\8]-F]#FNMY;QM[*9)AI/'2P:'YH
M:&7/^Z=OO>.3PUZ35]M[E #%DO9F,1_YRF[#Z=\.S_]V?/CGK4W.5@/T\0,0
MC[A<K(QZ$;K=@ ;)DR.5E0P5I$:%1;E\$G$%O!>T57)4@6ZT,1"%'X.N)T#'
M*K(H\ (_"R-V?U?NS^IGU,<F L$5J/3YZ%T_!=4K(<T0M*A$%%=I]@/'ARIA
M%I';=V#I9FJ$H+J-4JUI!3!!<M?B4U')VMEKU:_V"^^S",2X+S+FICO=CK>]
MM;W5(45P9C3&4("M>MN=G:VMYB%UC-7J=G:VM]J&FPAX0X'#-<>-6G,$Y *$
M0'HI3&.4YI,(+MQ@%[B^C_S[.:;BT83+!"T"I2N?'!]\RTT='UA*'Y53W#YX
MAX -+#.P"5"')P5X#%M$HX"IQO")-/5-[T_!ZC+-^\WV[@(;8=,&4T$_+T3!
MWG3](APU#(P]Z.A4'1.QY)5W'A=1CX>T<C$D: Y,I%HG+)X&<AX'(3 N8VOR
M>KV,T4Y0FP?2EK0G-]F/\U3%P_(;"#?*"VN;F23>[-IOP+6@LZ6?8&]8!S6D
M>;<8ATG>\Z[E-34JL1X!]^W,'5U> H_2^T+.[TQ&L20?P!'/>PH(M0Y(K%S%
M5;(4;*'J ?CE %=@SF/2R0BLJ'A, ]B4!K078J@1]S0B7SI\'HD\L@>IR0O%
MYP0#1E_]J>Q)P$><!H%/R/QP[LTVE^CN\B-N<%TO4W98]H$M/$R7@G?EYW9$
M&DZ$\C' Q^VMK7<\:?:=Y&4 <\U3\E><R36_QD6FN?^.<U?."K9VY[R@N_=N
MCX_21$/DA4X43JG0 'LHXI0/,A!%=V>KBQY+>&KH78@,CB30::],D,]V].-W
M=G:V=YB'P/,+$8O)"!0B+REQ6W!*/^WMOOEY^8ZGG?=O-K;@N&VVZPE+TK^Z
M[Y^Y O;MW#O[XQ^]XX/C_1.O=W8(__UR<7S8\_9//GL]U,X.#INUY'51NBX0
M3 #F:WJ%?"ZLFANH"%Y.Y&WH7E)'4@XQ\@R2P)00!REL/\P)HCGJ/%'R_P"7
M;R6(\$_1HK0NH*99ZIE2$8E:@,M*)1 H1*D#N:E0DE+8T7[DU-!]; U[5F>J
MJ3]:S^0K48KBUY7"J9^0E%DNI,)%4) L;[0+>"&T+@F*^V! %S*.HUJH"@:$
M\R3=:^?]%L^-M/ZWK5K_B358AI6D&%Y'=RRLGP@[N,Y+%R5K^$ 11\.H'PLX
M"AO^9!)/-P9IIM:9J;?3"@:LV15D?\#!E,JS"$M^ #/&S ?" *:*S>XTEP1R
MOMU!(K8J0TC\D[C6VF !UD6!J M%0FUTG6$8"HD+[)"0+S&FX(>7B#@QQHP3
MJ*83)1+,I'ZB]RJDQ4B .!C1[!(APER"97!^3.I1,J JT6@(B1B#,7QVU /T
M78QV(J9&J)85"#8\KO+\IU !IBKVHQ@F,AH%M0*V)P:(:R$S-1D17@B7\E_4
M,&2*BQDP#B<&RLP8AZF)38+:@A^2%C>]7CH6"D[%/@8=:XMAH&#0,,M+<PP@
M(=AN&*5E;G+SRNQ$U^$SX%5)6M#9QXA:5%CG'.>Z]/?5WP4K!NM8E#+RF D*
MO)6$NIJ1,GPT2):P03,C%+7T& J@'XJV*EF^^GNQ] =NO]D8P>G)-_R-T)\V
M</1GL"@Y0@MQ^#B+*R%^6.,/4,- T@"BD?I37DXFQ!1&;-#&'/W/R(6A%280
M(F-4QZ8:8>A?^E%,,3:451CG+^-"LWY6B#0;"C&X3$)'4J+^1<7&O3Z5T"D8
M*8@\S$"UP@,U\U?BK,EAJ#Q@LSXRO!JEFY*6<2S\88EJ59"E&H51)D4V;;6-
M[P7A6SY*[^GQ>8]H]^S4+,,[14(<%&^)4+P5T:_6YK4OZ30KF]U/F#$S+(DD
MC#)A\FF.P&H$DV?^E5=.TD3J,Q4&C$5$@7@Y2T*,0)$1"7V>P.-@CS8XBH:]
MOV\0$A0RD1&R&&0;(;P0:B9C2G8DB.PIF$_=F0!##M(T ZT6T52F$7>KB%"5
MR0&O*_/*M''.L=9@L-J@([&R+K(HD23)?B.*)L@HUXSW;#:66!%%F9 O0/H%
M3">8H>0O2+&&C:U#FY%*@&--KG)H=70>6.WI#3Z$CJ=]4?+GI>N[XRC<N**D
M/06KC8O,S],D'<+S]**A?5.@8PYTO%R 9,ZQ4>]BJ^,<:ZOI6+-I]?:^->T(
MXP2YX6@#\W]N/'6:%9_>Z:"I2+T=[A_#)-))BDU;[=C_E40KM)OMA0$8T3(G
M9 :"T[Q*87XU#V%-SL"ZY4+QD2H3U _'4<%9LYY/MB++8.D<FFX^'DK0XN'
M2E7"(0*9HZ24KJMJ-\F"Y+VCK9-):[3UN']>6&;*C:A68JK0[M():4\6M@%,
MR#$NM9#1*\6KT[* E64T-@6]F+L;CD@7<)T#--91DX,*'_+<9'<KR$4Y2(GR
M.M*M#7)Q%,4A^U+"-!8Y&A**=M1Y34!HD8]D),"F V(<B$"F7?H!^?9#]1.H
MP#[B# Q)[H?4/_[F9[7H#0VS 78S(QBU=I#)>J3Z5)@)![E6&*K'-NH*(ABE
M_#XENCOR^7#;,$ES%. %7*4U$8HX7(LL0!. %'G%&3>]L\8Y/&=Q/B,LK9-!
M7CA+<%;K;0M(A,-+1&"+A,2<CIO(K]K(64(D,/L-<9B'#X@\$1\S&(4Z)?]F
M60R+%6BEWF &V@:UUU2)D)FSVWSR><%O??:KR'DNBX$IEN9=1CE5#M-.6L)N
MR[C<>$P#%3,N7S$6&;P)1"G<72K$Y>DBG"6_P>JN:3P<WEC4$%<;XMOJ$2L.
MY5B%O)QI/1<517RXXJD]$_B\.L+ZJ5;'P)XL"+EM$(HJHL&(W.I[=0SKWR/&
M57!N8B/45)^7.8#6R@.VZ1TG6CQT9K2"RE.6"_'#/%\JB&1F!4H%G.P9-+ ,
M#(^/N3QE[&=L )$B7HU1\Y$L3<<=CUB"5.2E.HX/9>E/BD0VK4W3"#=UI"U5
M\2V?\**1S-3$N*G-K84J1A1D$:4</3T^]O%LK=FX!'[6N4SW4H*,YQ$Y!S?9
M L<ZO(?<I<T'8*IYYO$A+:\-1,[:$,J6Q30A/U-> T412+9<9"E*_EFB-"9]
M/A-)3:5O$(#-60:4<VX[ &?"^6W8^UJRQ)F9+*%19>^VJA.X*LK9FI#R'P;_
M7H2037X_GY U]Y+D6AFI.O7!*!Z%R,B@+(2D8$6V,V1:?V4]P4%2;/4RPR1
MMBR]*"IYZ8RQ!@QKK(DDB]T3#))J2%U3:2X8Y^ZNH]PGHMP>:AC9=!&B5<I(
MFPW$_DAMVF0^Q^?(5Z>!?^AKK'AGAV[!@GOP3+![QU2BH2I79L,<=<8/112Q
MOI8N1,$>3;)]*]7##AZB"J)5%667(=I8R$\@$<JQ5#H,=2L)9%)/.YM7%46L
M7$&I)1J/XORDNHX'.T-N#WQM (L6I0.?:CGK]5;1C4P:B,4(#*@ ;YW9FTUO
M7TVQ91UX4#:_L*Q4RQJ%\Q13 4.U3"J\ CNK5LQX6*=AX3K>$":8I;AI,-%$
MS2R;6@8M!H=!-#?E=VER -[0SUZW($0<EF=UK*4W-V)Y'%['X75>S&L?O&S5
M&BHEWS(I<MO4DK,&F<HEC@R59%8ZDCTF(PVBP_%$*V='ZLH:Y(Y11%_Z'I10
M5)K*30I!%;$E!VI>J3F6#LW.37IPJEZEW;T?O7X,UJO(.MZ/*$R$-8H(2Y#B
MTXNL9* 4B^XLD[@I*6*!Z4WS(LV#=(*?HRPHQUS%\Z."491)^%&F3Z-PACGD
ME9,'D4[:@'"*^2.>@4/TXYTH/]X%^_&4 ^#PY**J'#;_D,#E)G4RW=>U;*!D
M+"?K\X;K(Z#]B1WE3&3K+_AQ:XU8N^I)XYM0K E$6:/'4J8R@8I8FM4YM%)8
MI>A7"2;P(*\H^U12#Z85$8@P'2NH71XE9:X.AJ/F1Z7F4[L^PGR2G?%R#](
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MRBN61?@-,]9L?>I[@S*6[]/F7$-N<I/PD064R !E@?,\*Y"L_@/O55#,AIH
MN2LB5)24<Z,YTT3/TS*3;$,)_,H4[]A?2E,:>0\=$SAO$SB&?&99XPM)O<F1
M1("Q@\H?@>8&%%1E3BIU@D 8J(:83@A#RY%=G[0KNZK;MW!SX)::XKFNMFSY
M 7B(E;>J)K3@G(<R6@LOH8B(:KYD:I<8_P2& 0?T,HU+65B+A2%"8S"5GV(6
M5HKH6XX[VV>J7CFD.9SME+$'5\9J93E7524[G*G[QWXK72'.%NPLT-CZR2P,
M%!Y>]M;:(@B(?['*-43H>4/UP/DE1"7BS*K[IY'\B@$HA:93+Q]F:CX=;XQX
M8Q!V'H)'9&@I$\KR!!X';\LB@BU*Q-8(QIEFA&I6!3<5OAK9#Z'ZA<IL8?7
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M]4XK-_@-*5/<-L$;B)"<J-,-S&4%O@;WLQ=4FJK(VRK+-VUL,F!8G0KLC4*
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MW$*(CY+RM7HGW3Q_!ARXB9*X8:=L1"$76.9MX6DREWJV%9CNOJQ$"K>]-H2
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M#AOE*((KD6\W@M3/HWH<;.SB(^JK0<''IA%V6(DA<=6VABSC8Y12$Q*7>H5
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MB!>]^UD#/O1K/ZS[XF".47?) ;*!*1W02Y;][ !J#@/B5:4Y2,MG5 O!MI?
MA\24YXJ8 8?\O*XF<OT1S_  Q:3N^Y(E^KIACN8*'T[;3SEB0]J-,=]&PL#'
M(B^T@Q288V@/=U4-#Y_QUP.L@%X6 !RGY)Z^"8N!#E*?EG[V^NQ-3$RGJ]FA
M9SK\+<IL]FR:\_,V!.:W2-^5?T$BKGUE_7R."69RD.%9;_WP@B58AQY!/N;Q
MB46I^U3"C89M>L?Z-N7'/!?1L=%GWK\\(^0D,4H.:J#78!!N?)%PG%=@"G#B
MKJ!D8=>(P(<9,6N5"61J[)=- S_=P"?0)Z,J4326OL8E_3Y<)TLJ_&#'*<-
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MF6"'8)M^!IL4-L-1LTQ/*#VGQ.:1Z;:H!:$T_)Y5IIU")$*:X4LR_BWU^$9
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MHK_2O.$]:=Y^IBGQ-$QWN5'5$_3A=LR%1D+R*/#,QL>K=;H#[Z-X +%&$-T
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M&Q9K2CR9V,+96X?@ JS6OP+#/+HAZ*&(":,=UJ]1\(C$H<82J*>S: \%G^8
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M>X&,<19EU$K-'#\WGMH)/L)DY%P@GS,;L@N,LD^&#U("[0=GBCVI-&F@"XD
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M[[B^7<.M[9@<T -H!1'>[)\0*E/Z6WS#="8^WXCTT_:DOO4V_9>0(U_+JMQ
M>!3-^VZ0>F>AZF^<*-$CN] MBA%660\A/9>,N:/95$'<#V.<6#;8C(^/SFN_
MXH=G)R"9%C\7="B;&)6,( 8JJ.T5=?IXH_.-.B*C\62!M/13AB\W>-QVT6?0
MG%QR!!NM"&\:.<@%9C%]4M/PY9SLI#,BCB 2(2:R8YARJBJKTN)X/J<@0)H,
MWOEN?'#C<M@1#9,2H4WYAJ)P;@]A#%_%V@'XW!:M2M*P<R@<*WC2F0$OH(J[
MB XU\Q249@9?%E7U+T@NG0VVY V<B\:$,^FJR#!OB)X_A;$*)N4QYR-B./F9
MO!39!$B)*7T6R;*7/"2>>MH*"SYUM\HW.%GR7AE'S#O$EICF!L'S1F!6J%?H
MFFJF0QAD.)^JCFUTU=I 7%%\FL2-XPJ9(H9]^ZCKE_\X^_'H\7?'^XMI7[;G
M]K*V34JO-W2&HVA:Q=11X"]5#_& <6'#8F,WVXHZN&!E(;/F.(P'EA^'3'1>
M%^$<Z7#PNN94T[8F,S,/_26FKAD<(I[ :"?Y08R]$H.BN/C\4-"^K[7 )U\?
M"MJ'@O9GOH@%.LNA8A?0AFT1WTX],>3[*(C'Q9_'LQ\'<CH1QYY=$QCEQ06?
MI7PE/$@I><V^R-A[X].;FA]%VUG+U7340?"48SWB5*WK'F]?Z0:7S6+00O-"
M6HM&F4@YQ345&<-8=2IR;04[!&0W)PF:9,>T@.0>!6-WM.^>(U>FR*!'6N-
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M5*-;<["V-[6V/\?Y_0UB[Z,?PL'&2EJ?LCA,$$J17IJE $?;43H[%R;&7S?
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MP\.O*N'F'^]>*I022MI2)O[7X&[0_\J(7)*$0U9Y0>LXH:7X]>ST[V#AX1W
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MTPI>'QT3<$"3V]2AUU F49!)T[HM@^496$,]S.+JI?1.PNGTVZJ$C0GOD0(
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M;JZW ]9:HJ@[BNR#4CKH*3K2Q3/=&>SE)J;<S"/L8C\XO/.*>N.M,<V(S>P
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M=-U5.GR\QUZI9I4'\^"Q;>A=*STCC@P(YK._4Z?4*)X75'@1RS29JC5S/W3
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M=I'HE#M3%L'$G><%=]ABX6;1NM<!HQBC*J.A-7.@"M9YO>*PP:0 Z[M..<(
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MV<KGR)76FG?-(KVEJ<@[!%Z ^W#$#LMOW>]GQ@FZ:")SEJ52J=GH?L2Y["J
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M2!E[XF+34V 2.S7WN%,36)JF K;3Q7H KWNMDT6AKDE5X J,+):9<4&\ (?
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MFQ*2>5VA::-/9,<2Z)$/P%$"+X9=SJ63F*34%=AI^8UOD_(VL+>!-\(&[I8
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M8\K;<#$-MDGBTO2;T1!9(Q,<(Z>)L@_O<@I4W-DP"W"P9YV4E8#<'19+IJY
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M@#"S.99'<[->-/XG[*?)>Q*'VOW!MIJQ!*I*9Z-P("Z)V]N$ ,]:N$:W&]&
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MK'^HIV/ST]OY?RSN=7&?=):*I3*CIS=+#'0!Z#0J9FV%:?1KT5*V[FQT%P'
M6="SK4"X:"4&]=9P*@YK;W'(M\8]:NI&H_MN*6*QMBV-4Q]W]18TD.)-WH[;
M]VPM/R4DU1<WH&]2AWI*M]1!+G& R\M+P\=OO;/+4),925**K;%_A&2PN5]4
M91LB.P?253+9.YFIV\RD&P?Z5<K>[>JDKEHOLCT1;J6QP\,RLH2'T%*!&=:3
MSV:JB!.!F,!"?#MCCZ;W55BQMJ6EN(]XGCYBU7KICLNBSHE4@X\L$+]8A!F!
M$@45B&C"\D7D@MD<N7U4MTQD4QZGI^^X(%FM^3DER$8U!9HPSE<"RYD][[I-
M/.]G,V6:CS\IP@$9!V=Z:X!L%YFN'>!: R JWX(]Q=4T+V !/,4OCXHQ%8(F
MV,A!7E#.W4E!/<=_#\)^OX__SWM!CT<O!+OSI9]=312AUI5@,'W1+J(!J2*!
M,L=9.-14CQ=ST16UIR'3:^0\4*#R#FR\0^3GQO;/L8D"G7[T%Y=>:[B*%B\H
M&]<Y:UWV9(0:NM;"\0!E&65-?<(%UR/G%C*%EU R-,YL!C*&7LH@<_C"2"!G
MVJMB?ZW$4L/F$ "G(HUB&U)C.&$M0HL>TZ-(!&('$,5-J.=+8J_<&B?N::.L
M=&[/K416OHMCX)Z?Z*B[8IGIX[9#X70MJNYS-@TG:C.X$$@& 6=$I3%:!#B5
M U'CJ!!/\/!X-P3V1,/&<H\+3C&@B)+I#B2=FY1PD;3\:Z'C),PUF !\X6^@
M,:.O#AXW4.DK#Y9"$S(OS$I*@@JHA!138%V:Z&3:H9:AS@5]P9+]QFXOP^-D
MLL4:A]*Y-A;C<Y9P>PJCL-!S2VE!5R4=S1FR*?+XC;1_B1O?K  P^"+FO#9Y
M]GU>X>$PMG%[\63GT*)X[_$K0MT]1_TS"$W/(3P6R8V#BDTQ.9M!:(/<X$S=
M:3+'_M6D<GG2794H<F[7M./%==X2S(,>\JV>8X2QHM@@(72O0GIB$7XGY?:=
M9GMLTYQOY"] 0JB"-P-9*G/M^66)&0;.Z$7J=M!3TW 0N[;OL'V,ZIFIQ:@%
M-%OJ-AC9PC$]NP4RI6$:A8ZW+>@>6K2!5TMLAXN;ZR>[0H:JS/6*EN D'!NW
MU(.6W 3SB 9?IGE263B41BZ:72?8%R!)I@FA:WU1]%DT,SN0&<6WM;1QL\<H
MX)64FI.KN"PQ\&AP] OVE=#6N$>:9(6=G6?F9S;]M8?$KVZ-)NY$9C)6V$KH
MJ?O<0IOB="8S-(;XTUP\/<895E$E:-[?:I%MC27]H$UMOQ(4FV]B^]/H63+G
ME[N60?@4=8)SU+(1R;ON<WL[PI_S2^>$1R;2/\.F$6X7UPTDD]P91W[[DP*>
MWL(GZ'G[**NG73<B%;2E[DY&;K["#L[\K@UV:[_-3M89X2I5#BBE9H,&4I<>
MJR@]C/J:!NHFZS+!2*(&\6HQ9\'KH%]IE(&F#8UPF62*(/)O5)"AV&@S1IV:
M5+4HB>9J^>E!N2@)*\'Y=G="E&D5Q]3F7'#*&H@<#0IWX&$NH=K9*;UZ#S-@
M(6<;;+FZV06*1=%E>0,5M.MP==V.$.-HGMA #JU/,!''+;B/QGJ<5\ZM=X>X
MHN;E= ?HZ3%-5(9+-&"<P#@T-BT'JP(GN-D%4^J2@;LIU>=*$A..:]/3RC<'
M!COBT92\&@%%$XA/#A:'\EXR*IS7N,*GK;+I]P(4UK@)_H"6E9FKT(;K FNM
M]957A3+@::X7VOW!2[:)\(L&IQ%A+B@<-(0$B:^3P&*ZW'7HT=#'N!,#QF/4
M$O9[RG'6-(<E%B'S+2*<8_<B\Z[=8C?$:_>9G&2?\MS8Y-#!H4]Y/LN4YRXQ
M<0H:."NU/-3ZG;(;[//"GUIR-)E(V_>,K1+$?"I9H]?S>;K@R4SW,)2L=E6)
M./"FPH91@J03.]9Y(!L9:D!;95;SM)6!V-&N7)V#K$WJ&06NR(V_HKD&#%TM
M PTMAE&=V621M37<T=)MLZ+#5""+0AP']]8[+$>R2)W\D1ZO/!$L^99!NV1E
M8E(*EF9V5:Q.-,HJ,#.7+EPQT]M$MN^$1&($*W=K=&<^=Q%.T B\J::KM^DQ
M8;-O_["MB2@T@8JMU[(:*L[8MZX1PT%@A?;L2C>D8\;Z"C!A;<K9XZ,RREG3
MQCP(%*"INLLSV35$XP4&8EX!9S JFH1X\B';'^Y)S+JD.4 !Z3BL.LF=T0!L
M%'--"KDT*S>^%YPW+=ONAV@P1TJ?&<1X3(=QI!0CWMDB8%@J\JS9K=$)%? O
MDKAM?3>FXVB\ECO0#&E-8_)7Q'[6?B[[Z@:GXTJ9<4X@LR/20 XX#XM-GG2M
MOTHBR98"G$O#T07L_J+@>$ ^51I9T]+=*0C-"Y[F8" LKI7#S>@Y:-AV]A)0
M^E<$"N..XAVI-%'7-D7T6.?.R6MVKE]P$44PW#(E@\#(C?I#@R &D<\IDKHY
M0Z @FUE+&:=6U7D9TPJVF#)[A9!<0U@2ZG/&*2^ZLK3^: H>9:1K6%F./3YO
MK""F3")VCWD;I[ 1I6"@(%=G. ,C,*&',)^&DC,IEN<LXCT6)!5!]U8\D@:Z
M3>WP<2:N9X2ACJ@("C7L$>E$L[2PF'>$QO@KRP</C'$LC.S,)L3$GU7?MU/0
ML9O_W.YK46K93J1PMP;)"<STOJ9"T\Q^4CM!MXAT?=6?-T[;R;5[V)T;;7$^
M5 [K K>>AST%EWQXPN!\,4(:D='.#ML;'/7T$>'ZP6WCO)=/<_WI--<,BP"H
MY85A8$53*),'29Q=T2*-(8&!P7%J9S115S75 %!QZ-+5SSL7]:%5J]W(2R'N
M5T95Y%@(PIE_HI\S0:R3HN_<JG390#!3-$[@TAVFV,0M@#'^_XHM1E&88-#:
M3MB -6&D0%_D DMWO*"C-MS5V?#5&MF>JL[H/D&6;@Z1$8PB*:- GJN2<K+@
MU(D-GXO)9\-8.B@3FJEV&E-?L*TI#B6#>.S(,JJDXTMX+DB\T#/R)HD.C%6+
MYKM=J]?,YUL*[DM]0POUV4P6=:;*=N#$W>6P;G?[QRWU_,THD\NM6C'PS" R
M=.UX/TMO.AY(EV !YIS&@\P$BAUVJT"/XD%\OO,/?[]XLS<XE4T;V6%X>)(J
M%4^S/,VO]/ <.G263ZC"A:)5R).J --%?!4TRU W[D55%<5?W'F$8L; _T\J
MF3Q<<7DSFZ9AHWK*&C(.97O!&X6GB(U*G*E 1:6:W%+7R)!B$NT;DXM>5V3H
M$C*^*96:P@+QW\VAM.)>&1!ZV+>* X7=8L_<U/!G7%V6E%2E"V=64,MP1> F
M)UC:BX%N'HPI1SMO!EOM^T2]H;\1<?^O>_+=2T.-0,I+; A!O(VVNIS6%;8:
M\U!HF3?16KJ,?Q9AB.8GR*.B9EA0"@>X]:E8'XJYPS*?5#?BP_ H O+U$3F%
M4BAHZEMY3G??("VD(([B.&9/=:LT!I03'J)981\]'Q)QAVGM3ITK#>.L4Q[@
MC1W39FRE.!24&8WB)>'/Z=B4HO8\\=,2F!#F]6ZU-D;W8=D7FY:LT!37@@XA
MKT:A]BAR\)(".*\S+KN<3Y-R*F%O\0K)3RI[[1R>S[IN7,+JX,AG79]EUG4'
M#)R-.TQGIKN5PF?. .:5&KA9V=,T0-KR5'=F=92YAZ##K3ZW':\-K5"@0A=;
MZ>,O%^&2DG"5M+%H&MJ9C0]:&@UK(7UL#1Z<Y R^030CB&]J] ,#QHY7YJ0R
M!;*Z#?9P>;R TU))LP5HNK';62NSDE')44#:1A4Y<I91@U -FO:6<+Z.ZCKQ
M<0IF.^9/IYU,=4YCFFEI#0KCPI>"NQ0K77F.QL4,%"B8G-*^ QH6C$P,6F'?
MBH;8SSBO0UUYA)Z!O]&6 S4$$*^@A@9[R9F\B2$_&G%H(]5M ]&%T64\VP:1
M35MMJSA095.G9[6#%C.@'5&"S0H[XE+/[YRI<<(_+;J?T&$R%>8^2FS+7-'N
MNCL[T\V> !,-$*>7'6.J2BM+XX3K7#\^ 9F8<EE..G]5SX*U3_4I[W3-0Y/R
MLX#_$O^4SA^IEUOJ - CV%OI=H?8VLFI,],*2.LJE9N8TS:Z$Z=W^+7+. SO
M:[.#S8U?5DM$5\<"J!Q#'T)#-6?LN9W&0RQMZE#PZ%/B@)V)$H&@!L>OY<?6
MNZ5V44L&*XI00N& <KR>%ETMM -7. )&S\F2=W'IIY$S.7MT5FQ6V*K8())(
M#60W]HM;H]<MYUBIQ6TKH<.OCL@<%5&FZ^&U\&QZ&P9?P-8M-_N2.&QCD@QN
MHZ*3NJ!&'F10E 3@8^1%5"0\40RH 7J1G1!*B]J$A6[%QLO<H6VP!CU+2[6B
M5T83,AL[3N\FS7R_IQF\R<F#QP]^KYSRJ,.<2/)&7 ;8TWC9#/-A!-]S#FO_
MH4=57A'**QPU7<_<BAAK#3B1(K.[">M&">(TK\=2D:8GUTE"..-R&#@?I3)&
M@ 6-E(#,2X+EZ[]^^^DC_6OP^A4?,3 R=9ZVGB.R?XB85:@]46Z5ND_6OI0C
M]Y@Y94M$9YFO* !4F(R)Q(I=,,LH+D@R8\S=K)D+3F!=G1_9)B-!5X@AU$C?
M.L@>E->N9Q$+<F>>NK:02%<W6)WT@Z-8]=<:K!'GP+AO9;/$C6A3Y:3S*/=X
ML:QMW._8(81PHTFGVSV)T!RE7<I 5*V=N65@C@MA/E<FN.@TT$R35!G+DXF)
MV^"LU1J8+BBIL"Q!P]G^6]1E&$8HT81MK5QFKE(4C1F@83D1=SACZ!7F+E($
M2M GRYF@+D=%.C.R6,^=H*0\F77%590E_VLFQ\<8Y8R%E:1(3(Y(<YDRS;03
M:8CWL?NS\JYT3T.M=C>QKE=]AL8;,2'J@/! W-- <SQD"_^$JO7*M?W:7TSY
MBXLET#I_M7C23K-Z5X1!^)=KE4<Z@T9-<Z5^#'=/Y3?9'0_;$!7]X>ZOIAJ8
M4B;%L#XB,FS^#.5QM(#OWX/_-*C<JGX!Q9K;+CO62;:NR@$_B-)%F>C**)/(
MU?.'2S. N"XU-M/=;!!2)SZ5OHEOK3%/I,3!RJM;0E\4#PE)0=5%%G+A6A>C
M:T63H(M"98,1EJI6QB>V0LX:.MJO9C_*G;<;X<QR4/XTG- A&N)^:?$.<HKB
M4J6 TX"P^^:#YW2C@B,9.\I@_1Y/JR)J==633[4\8:KEV*=:GF6JY8'QPK?$
MJ'DG<7KIE^+*<4FP2T&%ADLR!4(F5,3%&LOAOT:;-*,^:+>I4Y?H$>QX 5L^
M45-ZTUL%H9H-)!NV2SJZV!C.@GJ1%^P)4#@1/VU#K*4GVN[W]4P5Z&5-.O<=
M%%FM<0>EOHL4&2=O!!M)%ZN%S7AVB%L7!HTBUG8IV0J&:9:XZ\00EEK0O1,N
M^)- 1J-\A\,7Q++\".6'BOH)%7Y"Q=-/J&BBFOYR\?'LC.4Z:X!I?D,="9CP
MI#R0K@RT7E)9YG%B.I0(^)ES>W&*:2+*E>OPI,Z$",0DY3E-@IDU )CH<YEP
MT*E?T)$I[9-LS:53W.H'='FIY:76#DNM7RX^OSW_19>%V)(,,'P^G'_B#E1@
MWBOX1>;B5>$%+.-,RTXMQ2J76I"8W["D*1$'*=+52-A.C)%XCL]8]'DO<;S$
M\1)GAR7.!^Z%[W;#3>^QE))K(T@\<_WK;W'.75]KV:,*&5L/[K6%<5C1-<?^
MT+E@RY*@DSH9;2UQ*SG%4+% *<<H/Y;T9!%U9)CY4#0+(9+Y"-)5@ ESDH7=
MW^&,XG!QR[35Z/0S RG.$6(O+[(DPK!3B>XN%L-4DA4\ P/PY?GYQ[-7+OHV
M?E3K9MMY208EW.<EL9?$7A+OL"1>#H7&6H+,K0191NA7@;[S<Q&!+WJ>SV8)
M00!(C62IQT$@D@P5 5[RPWCW#OW$5B]=O'1Y=M)%+#R.LIO) ]A<6 DJ$J?!
M*7K%%6^2 UFNB_4C6;^W2:BD-H[EN0N=/?U4:"!U[ 7"@HR#+TK-J:? %M O
M=+U#"V!'E_<S;H_4?ML,F($Z^/C+!7=OS[%3'H,-MM&3+?9><(GS1:BGI;"H
M^%UV_<U4,?RDKFM#' :$P1'$)S'J=0#$S0DM]?+(>!FW_#UL%KZYE86VD (Y
M'#8M8Q1,]C"H*#$;,_#CK=X*!7PYJS2;U5A@H_' -;:!@W'4P#[@8E=S\SQ-
MJ&6&[I4R2T-& 1#B8+#[&9S#1"P+*@/L+HI!<&IG9PFR:[1P9W#!DR/KN3E\
MAF4T6 ]&@7 SBI8J6YY^U*!3PZF;.TA\1:-<>IH$&IQG@:#7FEW1E)]*-QII
M+M).GNL2 C<,^\,!)P!H+' #R]2V^1 8=FGXU0RM1C=3PSA%RZ]",#1Q$)U:
MWD9;WR,!(]#YR DU](I@^^J*0/[R*J6Q0UA-NM(5EK+AWWN7/4>0_!/^6(Z3
M6(I7[6S .4[O@Y-W0R.5T,MV:<YCCJA&EV'#&79.HZ YEX::S'8CF(LUL%UC
MK,_RA,QGI$8LI&Z$S?DLCG$OW%J$-B+M;9EW1ZJC.FB!]K?J+MPF(F>@=ZOW
M"8/8D2ZFEE08I<ZQ!9+[RB:XG2#2D^N$Q'ZK+W0.YRV5_C"Z1!JEHAL2H1BD
M*1*L"TCMI5M:7_R@TVO.+4@;[0Q&K/)41NAYN*_[ D\A( ?PY@*GQB$2LY3^
MR'#ZYUWP@]TW3G?I[:1JU%G9/F-'\8H&FH$MB=.L<, @67$&A-*!FAR;UH.V
MS=<%2TEWEF3ARIT&.QL! W_2@$)-H#&,T.!,.E"7,^F3G%@42;LLLR1I'M$U
MP-*/1'7X8H@[<V98U#JK-<_C<7FZ9L&^D"$O.4Z=-T:P6/!,IZN*6S#DF31F
MD*U6TN($0C,!XR-PP!RY+MQYV%3-@&K7:N5SG]YX?"J/V\QR:8A5X8!JQ<%@
M!>ID>9TF6SU-SY1'-@%8T?-J3CIB %/=9=TC@<]L8^:>=ZVA5%<"]4,XO28;
M0\:CGY6RL:7D)[Z4W)>2;SD3ZT9?V^;2 #K7("1@#Z"6*4.!+Z&QM:Z(1-^6
M!"3WFH.O F(QY(Y(< GV)JKBD)+V9Q!,I$ (LWI$F/<10F"B7&SC*("67J$5
MC2C=F^0Q-9JYJ-3@4(-BQY(>!'M(]'"S.X:O:8/  ,>FXH=3 Q(+[-!%:G&)
M0+W%-,X +"9,BX,KABU&&($0MQR^1EJI0K&7Z,&VX=A^Y,-T*:T#EV&%#/E^
M-318EQYZAFFE9 P",8\/!\>G!__OX,62HKA_"LG=G.]IQ;S;B[SX_/8WWKW!
M3[VFW[;;2:A-]*U_?__I[>6'7__^]DUP^?GLW;O@_,-OO[U]__FRTZ/>MAS4
MQKGJ[^&SO6#=-L%ZN&V"=>CEZA/+U8^?/GQ\^^GSQ5LO2!\L)ES=H.E>('P:
MS>3#F7]@'B<IRJ<RM,GG_ 8!-,$0)S0 !GFZK#-.B[T#P92,(]W+2'&@X5$_
M[/?[0?FO&F^;*,55 _P*RA;:\!UC?-(O R?LV!B#!5_%P(H\P:>=3]-U!OP"
MR6+SK1D.I:27-5 S\1'.4[5-CY[/G)*DM8#%-]_% *E7>3YV?08<0I:F%LE&
MVJAD'<XD<;WX.=8ZX(P^7IS79]NESXZV39_M>WWVQ/KLU[<_G_T:@%8[?_OV
MS<7[GW==K7V>-F&'W4GN%+ZY(, QTY).LI9'<1B5A$,J"H638+##E$;:QQ1O
MHGL'O> G4QDD^*;OX'WK+T\9]/?^6PC)I<F")/BS'0)W81"#$\%]'0ZX9%FN
MY1:67VD6P4<$;5.D9'OZ4B_\MT7X'V^;\#_PPO^)A?]O%^_?!I=G[]Y^_D?P
MYN+R_-</E[]_\I[-0X6(*F?4Z_V,:Y\+?I)<\*G/!3^O7'!#D9Z\N#>C/UOH
ML8]GGSX'%Q?WJG.4]PR_WU0<>E-Q+:;BZ;:9BH?>5'QJ4_'LTW^__1R\^_ I
M^/3VYXO+SY_.WG^6'ME+2BY^>!^\_9_?+S[_(X0K?CW[3)G'#^?__<N'7]^\
M_13\=O;Y\]M/E\'9^S?!Q>7E[_"KC[]_.O_E[!(,S@_OY-[@\NWY[Y\NGC2^
M[HNSJ?<EG\UPRC4(C2_/N@K[ V%@$C%*(D924HD-@F1P*2J^\Q]Y\46(]?8K
M5UP'+_&/$F=Y_X_+MV:\ T=KJ&]G,8-=UQ?]]J85=WEV=;]G%#-[IT9%'14+
MJ289AM1A)N.WQO##23"%LZ)XQJPT<4JAD[M5H<F?(.P<S=R(4JHHI\HH@3,9
M8Y9)9T :.WT3E<$/PY/>\!![=H)R2A5M[90-/C^K9S@[#-8P4AG-BL"LSTTF
M2UQZ,O"0+M:C<KSF,^2+]#?J@;S-UDQ[.:UKY7NF*AV;L:.C(O^B"NSWH2(Z
M#&X*[V'5M(*G1C-U-Q-N<M?/(W+K&T0IQ&%O'W-PZQ?/6DS^@?.*QE2-.59Q
MBAE)''N%HT2R!9<ICH5<I2YY;+(J]9'V\:P/3JEM$?YQPC-H9'XN=8C"TR9U
MA2,A[?,(D0B+0/DT(LYDH5RX_)_RB$7$FP0.5Z6'NM-]/.P^J.<TCM%.V,'0
M/>6;Y75@663\BY6UF(Q-WQRICJ^7@=_=E9WZCR:;:_Y6FN0U-J/4G,%E4"G"
MYLQ<PAAJA BK#&0*76!^Z@LU26LF0+F*-#1?1:D9#;J\!F'#8P-C[$FM@N@*
M :7PK:Z".^<_GND_&F6G$?-T+X:=UV?XP.G"UKPC8^];C-,++I7B-,MQ+_C-
MC LP8"UO8.=KPF^A)YS)M 92*H;VYYJ^=,TGNYD?S&;2 X>OY=M^36!#QQH8
M^5RV^9,96G0_>>E#>D\GG0[[/J3WO$)ZZ[54MCU<IPI*>6.>^N<BFD^?M:F"
M%L4D3]/\!EV"*Z('-846BG$FXGI&3?QHX><HZLG"9G,<=").UT'5]0.<:#N0
M#7[Q1L4*C7(I;AF0+7.HJ[4:U@XA2)15]^OT*VB07'#Y[]%L_OIC< AONX M
M^1J:7QW!KWYAP)ASU)KR9^WUH--)?8O@_%3R5S:H^ U<.!9':5QS7WM4EO4,
MB8+E#7IJ7\.XX-LUS;"/A=$E5)'D8V[E64$%[8)T_7G8Y^<R;=@]FSL\ZQ9C
M5.;]H-?1W,P4#1ZF#F)$#H^9E#B[E@VW%4]]K.;:;W!RZ-\F-/A=H[.<YZ&U
MDL3=Y\"E,E,5>!U,1NFJ0BM0M8I?&E4O([;OM0U+D#$RP$G?0L.C&I4R/-(Q
MJ\VL.YQ[E;-IG]"0*1LAN32-2P0 "KLZ.-W?UZ@FSE]-V,5>=A#B/%XUKS3N
M#8[]1L@DF4].O6KH3M.\"ON-2T.)&^N7ZDE#)CM&V!(,/H-:T_$K&.)T"?EK
M>](E*Y[_/4K2><(C6++W6^3__3__D<RNP)"K_O;B15 6\=]>7%&^Y.KD<+%_
MV/OG_*J=-SD8T&JU33<\.,+DS%__\S]&Q5^W:(._-1_&B^1\&-MA&Y\A:W"=
M^?,2?N/P+V3!KX);'':DR7BKFK?=Y]_^T=O^:,Y#+;/9?>P$,@KN#2^Z8K&!
MG%7K[LVKU]\ _7F?QRP_# X>'+7L;R^&+^YZL)Q,_G'/\7;[88#_]ZI]B986
MSHF7OXAI1& @C=2N<28?+S']4U0JILM'LGN_,3F]&;LW.'FNV_</%8';\I;0
MXY>\D0?;RZ>7%@^UG4%7-7OG'G];S/&^!L*]0JJ#C2G ^%/Q6T8?6OR5?/B5
ME1%>VC^ N,#HQ59*^.>\8T=^Q[9LQX[]CFW9CIWX'=NR'3OU.[9=.S;L;Z0_
MPB&YE0Z)4VCK;L:P?Q &P_T3^)_#PU=WNBT\QV1U7F:/TO,/7;/=R##3&S=J
M-,EO:IQ%7\/@(HM[?](A6'T"[^"Q+K?OQ7_^\)U/<,\<Y?I?8Z=SO]?O?_?2
MOO4+MX RI_N]_M 39IDPQP>]PV-/F&7"'!SU^H>>,,N$V3_I'9]XPG00YJ W
M7"_'/*#MX:V*-5@52R5'WK1X?L=^T#_M'1YXRG109K_?.QEXRG109CCL'7GK
MHHLRAR>]OC=(NRASLM\[7B]E?&QCEZR05I6SMT6>H8SH#WJGWA;IM$6.>_U3
M3YDNC=OO'7C*=&K<?N_84Z:#,D,X38?K#0+Y6,=F6QE=35+>Q'A^1Q_#'7WO
MU'<Z]4>]H8^,=U%F,.P-O%FZPBS%(CQ/F27*'.SW!NLUOOYC*P#1MAWMYZ(L
M:U4$'^LBGD8E RZ]Y8F$3AOJ<VZL?P-$R*YX".&T4#24OIJ6@>INM1"\GQN+
M'%2HN5"7FH&;P%8R_?'^DPP]RWY26+467!+J&9#Q]ZQ05TD)SX#]\+R[5MXM
M"6D)N+9VB>Q9^#OW1;CT7 ^4QV[\CVF4;0BW7C1FB5Q%!8U>E7V.W47/:=%)
M";M/ Y>J*:)9\,B0X>--"J%9)N6=XTQZ7=A('L;JJ6&L!A[&ZMG 6*%S\)Q1
MR@?];8,I/_(PY4]L+5R^_?7M.4*/O[MX?_;^_.+LU^#-V>>S'9]HTP0T8Z$A
MD%EH;J0JKF@<?49=+:3R+1(I_!PY-DE4,LKJF""1582PH1/'+%Y0\[S@< GL
MUVTV,N*B10*O1@L;164B,&*C*"7@J7**T,.TD*A:]1Q<$D/#:G@SM&%F".^E
M,:?H"1.!AN*%WFZ^X_/T@T_"8!I=(XB3R@*09<FU$D S?-JY2SP+)7JIWUVV
M,,H>U)03,0,T3)S];6_I-*_3,6)2@<2E50$#_+/."#P65 +LM88=?S@<U= =
M.8<>T-UTU+M;*,:D ]]*-:F+-G,9'-.5)Z&>:@K[E2["1S"D+?75_0[7?3ER
M<*QY\0A8L10,-I41ZB\]N,K-B%;"S<W@#U,%VY3F5^A6%M<X9M:,G47Y-*=G
M%M'X]HL$$HU1E0V@X6^18+ ?.8=P">AP<*C/4W,KX!,0B1ED6I+5^$##%MH+
M0>0T,CSI6ZV08)S?][#SP:G&;KN;<Y#.:";A*^ O+GZ;(/7SMR6$"B@N^2H:
MWH=JY5U>D@?YVD"0KX/3VT&^!@\'/.4?_3"/_IX:BX=$XGI)MD!>EQ'AL@L8
MI9DEX8P#%]D(YANJC%??D!ZZ;V^V;Z=^T'9JOU?/"*S []7V0('XO=H>H!V_
M5X\&8^5;9!ZV>'43HZ,-%_J"HV?&?P[>@.'YXW=!"_X):7#OK^_TV';@J9YF
MGF:>9IOY5$^SYE-]*\N&M[(H+*&\5EG]O4VRFUDY'1[O[X>GAT_7I+&I9#D^
M#8\/GZZA;U/),MP/!T^(N;"19-D/AX?[X?ZI/T0ML@Q.X/_7?(A6*4P1\ATY
MJ@VW;UZLKC)<J30EP,+U??.O'%MIA6?N5J/KJ!1]=I_Y"&=T5TCU3#[3<X3G
M",\1GB,\1WB.^),<X3-'NQ K^F *CM17;%)3Y8\^Z[/!GM<V?9VGV:8\U=/,
MT\QG?=:IR?<W3I-_+*(8J*:",DJC(I'>A9'*U"3!/M:G302MY3'=\?W!Z7YX
M>O!T8&8;39N3_G:GA!Z2-L/#\.AXBQ,@#T:;83@<'H?[^T^'X+[)M.GO#X ^
MZY4WWIG>+15<S^>I5L'MSA[M:.^L2C[MAT>G7A]W$.8P/!UXA=-!F&%X<.RU
M31<:[5%X</!TT*(;3)G!27BP9FA1[^)NMG[]&9S9(DI)JT;C69(E985*]5KM
MOE(='IR E[O%56P/2)F#\'#P=--/-Y@R^^#)#9X.LGMS*;-_<AB>''F]VD&9
MXV%X>+S>T^2]VUW0OF_4O%!Q$AFHIVB6 QG_EWZQNWH7S,P#[[-U$ :<V7U/
MF"Y[)-P_],YLQRSVD_#D\.F&06PN84Y.P^&:C1'ORFZV,OU<1%EI@.G$IT6
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M3WB>V-2XT19&A+X%\^B&KQCEZ7AY!YXH?O11%<%Y/IOE61!E8_U/G'MZ':5
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M,QUQ%^<)ZZ!%._HD&QVK#![=,M3O#H;]R6]ZG%C2X3!H\4'C/RL8FJ)P[<_
MWSF!OY&:Y 4&_M*;:%$ZVS\UCM)-,JZFN/+^7UX'FGOV<<5.+=G@<#\,]/^\
M>OWBKRLY:+#?&Y[@W8VE]HZ..U8KO[:_3_/XRUY9146U? _]32$GZ]O<D1(!
MS92 [XN"::$F?WOQ;U4>O_C/SWAB@GP2G,.UP#GE?_PUNB>'M42)D.FD=Y@
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MHOO@K!=\2LHOP3OA2^21R*4.K4D%-7X>D@GKY,*@@'MX<Z.RK&=SS8]E#@R
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M;DV5;<,"_P(>\QI,+=[N$,0-.AC88A>.M>S@T(IT6%*H=X%_2E4X&Q9I5OJ
M[BKERH4(%4<*ACE*+R22% 7@7<G3$&24OL</4=7G80=D2.'RUT?U.PZS$H&I
MOA_EB-V6Z3ZDHL51$9%O]B!5[UH(ID7*(7M>DN^L#HL4M!])?A$(,/ RLVF
MQ83PU]_(N4R5/3W2 -@0.F5I"CP<<QTOZWCD /X6T&>>S NN!O?%$M!O3M5?
MA;A.Y4?K%O<<[29^V00;5V,,6(T-HV;@EQ''%_%W(!0&T8(<N!:U#' OVG).
MD[X]R3KFG(B^2MB.LA>JTJ-CVYY-/3YKW+_ K LG"TZL4N7F2(67BN_G>X5'
MKW?R"\<=\5._%#,T0C7]]=7_Y9=S<^GQ1H\Q,)CE2HI]PTR7@C))-UHCM<6(
MRJ:=6J@,,E)EP53T'EQ<I(J*:KFX/TVN24W"";_N]SMR$6;V(AB)PW5.;EWR
M DPVCZ]'?2^U;1Z&-YF68F\N*6TRBMFZ6+?)"=7R@[6-BR#+AE8U5 O0W<0=
M5-X_5"HVVWW,ZJ%'2@.6:G#+W$[%3')#F9YC-5%I2N'LA69@ OG@ZJ_4O6;B
M$F5:F^7!M;(A)_I63(6STF2'T@:K=>61YE729X6V:"W+]!SD%'VI\3F-7^@3
MCQ64?T QS7US^#:J)*/URS(3,((WZ>)M2WH?L:1WT);TMB6]VP\C/3%GZ*L:
M16C/3XS.W"&GZ)%$PS)-R+(@E3\+QN0X:&L"G'(L%R$<)<?1S\H 79,DR0G%
M"G&?N*E:Q^$P(6/ZK3G8HQ\GJ$QB]^H*9PK"D!\TB92$(&R;TJT;<X>*,L^R
M<52@C.%EXC-NL?2Y4@0%T.N]TY  [ZDUF-J'C#-87H>Q4'^3-_\#W^S"!S0_
MZJM9_^JG#!5X'BUXQJ:WGQK\3D=_%6'&_?&GW%JV:*7 W]^S^V&P' @A2%'F
M$(/D#M'PVL6J"7C*H@#]%'!FE"ZI[8HV2!$ZNHLOXZYA,**5V*@F6DAO3AN\
M%VTGRW?'TNPVYBH4O,STT?C"MQ_!_!3G*+$%#@_32#Y\'\B'*["QP4+.87MX
M-=E?-"VY',;-<B\++BE)RKWFQ5S\X%(_93Q) ]V.J,QVI1[G$F[OW+I3[?U=
M=W]O*W3;Z\T!US)<$U]$-$1U<#1PX^SS(AU-L6&4&C5GM@; B2G@*7P"9W9J
M(Z%?N(J50GBG%HG%H*>=?CDU<1IXY9B.M$Z/UVMNW\T3Q!EW0!-R"\N:ZB8[
MWI<BS0J\C&)UP'YGF4[&L$MOXKEFJ[Y&H<$G2^5OY:5$/AL!XE2&X_&_'G0K
M41^LR!W^27+/6E2C(@/NP.ZT8/PG_*R;WBP4:R A* 0ID4"S@)^E5) 2>TA4
M7:!Q&40%)J)BJE*A?-'K+L6?^X-*$*HBN*@8<,Z^3!@+\HE%?85;%W.\5I\A
M VY<T6G34]1U:((=_ 3<31,JIZ;Y1G!C!("0*HR<K#36/ &R&;E(LHYY2GL#
MW:9,Q'1ML$U"L.L,7VLT6WA11-MUBVB XF'6ROL[R/MUEG$KZE'4GZMY[G#R
MR9T$OB6YENV^]S$>=2KB>YW/M4YR-R$#HO P2Z.[-%:Z CBH0)F^/CX>E&7<
MG/)-,4OG(-?RO%X4PV=\+B@N9@A@2=7*Y">R%,3TWE@-X69CIMMIJ'!$MV07
M$<,G7CCZH9P1.#ZLK-,NC:$B,](IE7P,P7BI<5:CC=A%'L.Y$0+CZZ.JL">Y
M:*8U.@CB$CF&1PXZ_<$/6&MB!SQB>!B^"2>Q[[W!5XH:IU]\PH_83"OK'UP$
MXS=[8[$0_CN("U!P L_/X>@U2F%MP>:2/J">;U!"HGT;U(-/QVJ5 (7;_59I
M/".E\:T$"D/G\+4$"?/1<>UV2%N4,!O[W=X)B6OC)9: ?S+L]X+/C\I^JNWY
M3]*+( [_+;$T>"#6?W$ES92PQ<RUF@@(?V;2HB[H0-F!]?4EOT@P"03.LHKU
M!1;_>J:+DO%)_&>&+M )V33@_C=3HK#VK9+L''O#- FPNLJ)VC&6#XKI##/?
M,WKUA.J1\,,>(AQ?,"RC6YG!\8.27-#U$Z/%"+M*#&@.4L]R4ZY&T]C&&:>4
MBS83$6Q:UB :";@_[5576:.JL2J'8(WD]GMH[J".H 49K"/"< QTK(KD0X;I
M<92O#*N)V/NKA5C'.RV%)JS8WP!%R8%@$L%;PF':T'/CW1/HIL$;MJ!=8A\D
M!)Z>P3. ;B3_-C,NZA]>0?$JW;%3$,^1-8PT@A+%<$; &CJ^G"\+E#)U-#7<
MNUC$D;2"+IAD[A]=E*GQ8\-,B<##VA1<YPBM0:2K[MRJ*W_H>/\,0*D5F;W'
M%9:P0%$._A22;DA(4&4"LH71U;PUPKIQ4NH;D]XLPZFBR*=A.I9\! +[8;T)
M6 M<O].(ZM9FJA\[4WW89JK;3/6+SU2#!SD#D7<.)_<=#%CC 7\10,-=,ET_
MQMY_%Q&J\=Z^WXCW5^13L,3^K709DMD2&K2F=))U#NT]H[US]2Q&G=EBR0I$
M'J0V8=0UDTFF.%0[#B/6.)(>IM@GA2(S# "/W!<5,<UD045% Y7)>00-PGI&
M@T:RDTI?<=<K?P8Y0H7K1<8M ]_)H,2<>?H=EJ0_?E]%^UM_(!;4PTGOX?^7
M&&JH$WG:GC=!:.[^INTZP72RXZ2*G]1U.!*KX=NT@9!9HJFI/>R-^>/63&#+
M7JOFK)/LE"4*'#C-&W.7AC&>$DNYE:8E8^1*19<&<79U;>=+K*X\+2Z*#,L(
M>\=DC0=QG!0QV^-!WB13"'!ZE5R1TOM!MYJ+6<-4H:WWM!9MR(773?+ QR>Q
M&_*ZUSWJ],LOY+I+M&L-.$*0+87'#!/\;MFI^86W8C#Q=O33QEZW4PE&KB ,
M7L_7Q]4OH(\*HC.;+$SX%#W/@GI],68P!15++L0P0N1AG:F1QCPS Q W<BGU
M[?!V+3S(D86W@P]+JVK:U^N3X\[16JH7ZRF[(MKVO&_B'^BO+739+Z$RHI<W
M4W#'QJ3G%$.;H^";%)29J1+111;V46OC8=(,*K]!05)\:#12$?J7>-@-Q])&
M03<V'_\AJMKT2YV5]?-GREOH*8T[9$M^=F.!@NRI4HH!H/8>*VQRJ$#A)[$U
M2:P=TK&;=XR36KP$79WP>^>\8Q(:4J6#+20)\:4[02[@IC%,6MPK7+KN1G(0
M3@T0OBR0)Z]TO/<W:"#Q]3Q,].\$I@QEO7Z%GOZBHZ)<+FE:CL8B1"\04Y^Z
M6_<H4I5@:+G<I\;.BB;P/WXY,QZ,;=?!_A/21$%Y^L4&6^F=R+!9_1 * <X2
M?KFV(4I1H51M:(?]0?.:HK%3O&:L HS63<,)PH,D.(W4<W>&AJ7-/H$(PV9O
M+QF-"FRVL;PZ5'"$(5Y 3!.9IB^< ,58'>'(M"%=*/TK#YQ_JT(E[FEZ IWA
M<#;B3;!10A_X3A%S*XH)RM%INK^SU2=1DF5L"U"G?DH9+(&!HNXRO)8=[XMN
M8S(93[*\2U1!CBA/9: 8*9H4Z(5=!I'#>A0EC6U[5/FYSEK,(O"S0,M.&3#?
M[<X.,X:;RCBG5RH6Q,&-83$K80GK *R9HD >**,4H)IT^(([ #&YJ*\,"P=3
MA&.9?!C@C*^A:1S74"X:V2", WD?_7%1:N>R$ZVP*+EVYJ[/,NXAYOX*)*J^
M$>Z87Q:S2Q[C.DFL^P!I9ABEODQ&J;%)%AT$OJC.W!4[6J4U%M89"[]8JGY5
M5*&_0P;!(UG"&*KX(F+@B\!C2@KB%(&AQN1+$%X?=: [Q1&G9[;$T0P#=].W
M)*HS'MVR/+>]H%O@,S ))NI 2^GV8;")%=:AH/1Q 2N$\;&-^E*E@EE\G9M1
M;ZA%.?Z2*??UDJ?D-&6&?>)A-M45C%4I#_).ZS+LVN9Q>'J,C.MU<V-O:&P!
MQJ3W!4P0?FTZG16X@R)=J20G"\?DR3M"W97+CJS!3N@P=9I.8"N81KN4)DQ]
M_Y6,QV'EZ,B/(8BF28B)4;:%':K0>9C%VH0@"Z= #ZE3WL\R_>\LO PCD+]1
MAD Y00C+/16\&2X0<MX[28."TU(!K%$A(@'.)P2+!8].:N]1F U5:0[Y/,DE
M3>@<@G;0JK@$9Z>N^G>^(#1F[!E'EFIRLV\&YS4286R/"NF1.7/07YQS_![A
MSH3=@<)@_7+RTGK%=/D"M,FQ;RJX2'Q]2_&0(G4AV75PQBX0*IA9&8XG M/G
M0@\B(IXP!;8.7XHSE$D@RD+(<)!%CQ/43[%,JY<W<1JYRMQ.C5X\%9KX (VD
M:$&V%!C91[Y9,KPU*\!7S[))@29<A@T8.9>?$=NX)A[!-[A<R>L<AX@?BE)F
MII WPVS&E];(%":L9DH:W<6P'#)%U5A_)19EYH7;9!:+<C*XH#[X',<ET4)I
MTD9IF1AS!D;#,+:]*GK)\E*.=G2\4R.#</;=&>7'>/4:]8']B/\3S,"X,FM;
M BPX^^W<<36S2H$, ;M>AEFE\*?"#+B]3*GOC#Y]&50]%*?>PVQ,6F92=6$P
M)BZ*<,S?15Z)"9^5E$!EZVU[]\XFS8_:I/F+3)IO4^,V<_5I7H:B*"D$MDG%
M4$*![\I[LF_%5AOS/#\$%P5C#&Q$-LUL+@T%6DCV\K+MR=H!P?#RX!J13K#;
MT/<8Q2;(I.=$/QE]>ZR (P46(45E45A#SI+0K]2'8>(I,/.<$:,04P]HBZ4D
M"+^IZX ''7-X"C>&\_6D1KNLY;CBJPJ?2NYNYYST$_4U&)>"GL8DSL-4] Z:
MYY? (F,WVHB.OSN^&2O+-?EYM#7I!U]LXM(.3]P=\L88K$;A613SJ8K&DD5U
M=V],$=@/F)090W]@"5OEL E7:.3L#5Z#"'DI3327$2IZR*K"3B6-Y*WH5V'I
MK 1P9+1$F!EF"H=*4P=#LQW8YRP9H>X<H:I/TE@MLE(!*C[DEP0M;H=B8,*'
M$SB9LS =%:'=J2:CM@/."_1#L*X?5@\>0QF^S(VIECZIAQS23)F _3(L^?3Y
M^HYK1.##%IF@GP:T"@/OLL,<[JJ14H)QZW$DI-E>OR>R%-OR@+!T6NE%P7Y=
MGB3?/;8JX2P^87VQB=/VG4)[1AIE\#@D.]I3"T7&'N;]%?5$)'.PKZ@<FA"P
M!--0.9>O?':$4850R/P!#.MA8+=>T. 3J3#QNS<&B>3;AU*3GG-)1H'!E +Q
M] DO,_PI(NA$;H7&&H.L$O>[JEWC,K_2HH>*H<;,(&5;ZA#F9#22S5]!;NS@
M4!.R$2NARUQ'#;#Y1'"AT4'EL(4!RVP A#1(T#@5'FM+:!$\ @Y.(0$OB-#I
M<+65K J_.-#-VBI.DRC2AJGCOMJX!"],<B(OLY("2UGLS6!0<^RX\:N=]639
MBS(@9%R*Y2C='"\XO$38L:09&,16Q\A3*@C'M,:<1U!_IIFP^ME?X%W47Z]_
ML1SII0[]).+N!'@5WNY,C"TV+M@HP"H;^I:.D7/BB<K*X /@6(<9[!MQ1KC(
M* ;*GCH.51(3VP,/SW',;W:EU+P2&3'*V6&L; ':>^:&4C@JA#\YN2]$PK/!
M+L=FF=LD)GO']$Z!/7%C0MP;!']T'&(R&7@%$B>\TG$A5H:8AC0P=\H, M=G
M:A<(3FN\,%2BZ;UIM2&#*5&%9JE=(Z^I00C($'03<H@KT+GW@0G[8B-2'\ME
M2F2 FS"AQ@RVH0P2 :D37W38G^.4;K[.E[X3ZJTK<8=%M#!8E^&X4[ZT],KR
M#216L?$BX 34?39$(BVIY*=YL 0.>:,.%XN2,M;2C(D 07P1X=]9J<X$;4?0
M4CK<;>W]B3MTU-?)71P,'NLP]D41X(N5,DH_72#:">)V@KKB>+4 =!/VH@XW
M2S19[JAD*_&1,Y%T^&MS.'!U+_#O8L.CN)(ZMES0CL0 +P7(1T5N7V0F[X0Y
MY[LQJH90J=P_,E?)G$%?66U6 U=9Q8M(;7.M;D*=(W+"LI0,4P>I=(E7V-<3
M;/=P'HH=!ZNXD B>DV?&S.^X$/ 5I\E(HQZ,#>*,0P?:'D^&'S,*-]P+WF3E
MM1Q2#"/"7N%<:J 3"C[+0.S;9<E"O]4I7EOSRHV?';#WC1*RX)\,X(IU !2G
MFP5_\@GBHZ-(]%X-O>0402!*:QJL[C?)1IO/?HD(K[7^]_HR84]JI*Y#FS'&
M2MB4EBF3W31^+7IBCBK57KFIV-,?E6]S["],#8R.UDAXT'->FR[\Q@/"M BF
MF7SO[+=S+*E55-O%$ \T\=GL0&^)LF=?\>J]M[E>[Q\%9FK$X#"XFJ+4\%RH
MY2TM(MDB;+@&$-=LHISEYW7_T9!CX2Q^PX.(V.@OFY-M.ANBDRW,( CC<$[A
M"/-F,H"':AEJ'K-?$PW!/@:#9:Z+'J0%G \I5CFV/5+77TP*G83 319FP?9+
M2X1#_3D"/AX'/C^3"C&.!@9TM :GV'T"HS?7+T$Z2,F7PMF%F'<SWZ1Z3<.Y
M(_#IQK"^%ZO<_S#.H(;?%_P=K#[3)B:>AT'DMVD>]IPPM:B;YL2A<T2Y*:WA
M6JZRZH_Q!.#8G<*BZHO9(5VPRXG+W,P4?*A! 1WO9XXT^5RL&F;4U8CQ)1[F
MR=<-?RI5*1'KE;R"DKF#SRI]_DF8P6W!RU)QA\%H/Z5L)N=E?_GXQ?NJ=$M!
MH$$"VWJ8FY-,YSE_.SW[:NMAQ.C([+,LN#WZ!-,DR<18,PK%Z#B0:U=&;M%L
M-U _<%5^@SN7[S'>X$==!J)+$KUS=E?->CY^L8E7N.RGD<S3A*^T"<Z=37 >
MMPG.%YG@?$Y,K"72;\E81;82Y/3+;Z88OH)1P7DE%%G<'ZG&-@1A %$SCAAP
MQ,&4P5G[SOBRY(N!7:TNE:[QT_D%*MG+%Q;==*8P %$)K,S IRNH=9*@'"QH
M!G=MHNC&0 D/CP*9+IT;%%# *IPLET]EP4SI5W D0YY,+5[8[&NELN_NE+(G
M34H"O\=5,&,/B"K#4^R7]=HP$P%KFA21?8(4&>-9L$6K"3I,XB*SQ"1/S"JO
M"K@DC1<BC<<.'K>?92[:&);U8+@G=L)!X&>-+0HM.*(ZE%8"@J1  WNZ5+N#
MS76E,DA3P<G>+/CA[' :/P\3,$(NTU99-R#$DLIPVS*UR15$SM1!C:4Q:L/R
M]S5%Z4MELOIXX%,S\T)'8;!)$\,-E3/ A:'#P2C"G%]U7&G:]-)B'( A;&TS
MSG2FD_=R;!C8P[+13'K<.%M=<0G@G+UR[;NMI\JXP$R-Z[FC]6;KALF)GZ2]
M2ANVY8/4^<IB8]<40Z3.^>ZLD]JZ;)NY;":,]$'7(>^24_9-DOLNDH&$63'V
M34G#IMBY*<G4,4XCYXB1,;G(X6X)OXWD9^DHTO49=37U&K804QR"A1#PNDSE
MP#3,0)&$H]+7(@S'TM)[^_L_5)/%<TPLZD]U< PL5D#XWOZQR28(][_7=41D
M7D;%;!@&E>KZVF53=NA2=VD[4G;K12AP4GM,).$=W?I5G<'&!E!#ML2IC3^U
MT6'YL-NDQ](":(6#MJG</XC@$,<+V:\.>IK*6QHF3CV0.$ [G)C1L!<X/LZ[
M@H7KJA3@K2G6-V&OO3[XD.9E4GX*=KK):;:2:)TD$JO]O$@)>%;/XO@IY/S3
MKSK-OEL2RJT,<8HWM:D2.:MV9S/.N?7)SILG(2(DR"HDT)!\..X134AE^Q7I
MRH Q%1OKU,9]M*U)=4\.+*_DG0HJ"4-$<Z?;1P>!2+*)V65J+&6Q1L;Q%,2T
MXWT@)8\V: WH1M^WN]1E5+)]G8$I8F-RPIW:B IN=R)^ZJF@ 25%OI=,]B3-
M5&)>.(;T0L6CA><&\,8H:< L>]);DP84SN#>P^!IN):EU^H78A;X/H::/B3M
M[(7&"_JDMX*CT)N9_$&Y H4:#EBLEVL87:&9-G%&=5Y+50IS]&41+P.T"1@1
MCICG@H#Z@C$[\U,CH)NVJ< ;!M3>K<4>R3D]=13!U*0LH7$^]P/YN1I R;3E
M?DH\K;.I/=/7 MM(?3SH)(Y,5&6LJT;NI?YYZ=31L-]#[!N*EU$(Q.#:BCXB
M.)(9 1IIKP&G3SMQ'\F*<%DTQT *BD 02D4=%SD]NO#\<0$*4E<X/9E+/$]&
MWU5>NL,E:I*9 -[V%VMT(&VD/P!.'&V/(=67P0=U2"F(*)Z #&Z91$;CDF=2
M<V)8:_ETZ+9*CC.)Z#XL40;_$AA?R5:)/-I%X9(1ZF6>V-@>8=0(Y+)A?#QK
MITQ9?]#<!UU90PAFK,S&X)Q>2HK2?1)C%89IZ0[QA>2P%D;8I]A9:L=):R /
MGF^(] 2)-TF#F0ZK)T-&#*B[JU<IGD&L!;Y,&)!5R2JI' M)X;([F:&781))
MH2/&X*L"'"@Q!0^<C6DLEQXJUQZ7^G"G/51&3V"5G6XJHD;X&:C/'$<:<9N6
M$^=Z#$7 5: ZP2"V.$=$;*Q93Z'CT](P).23<XV9'O=NO!CT;X#=]#@W%"#:
M8\%Z^36^B)F&DE+Z\495) \7G+2H!'D=$1VXE<"-W# 5F :FX9S >2S:D D\
MD?C5]HD=SD4(%T&!O5)ZN<"?W-]>;>6S+2WT#03JXK?AQ2!]*5R_7,U8V D$
M;B)$3QCT30* ]TK A ]Z!.=3)C4-DY$$PS2<R_)EGR;/0>V$3UO]T+@3;E:I
M6FRV>H3;2@,>,3LOT-RE;&261)>.;30,N40\2$&LI78:!AM5U'7"=W2!_AX%
MUD1K@-Q# 1'0*WF< +U.GYM^(LF&B+$W8L5?RS(-:(F&.S;^$=NDY2R?#A+2
MM_'Q_")=M5[$DB>A]+QF*+8#0\+1UXO72Y:P2,(2*]@^%YQT]\;!0EL)--6F
MA=#?Q3J#P4E;+-,6R[QX"'U3I7'.HC7=N: \I@U_*L8(/',FK9"G;-_TN[T>
M%7\0_)=M[C-S5K\%UR#L0>Q_!:M?39SO]7T;O]A]2X"'5NW!WO9H-$S9AR]R
M6R:5N:=HT4.Q=48?=$WGAM:GTH.2<H!#2C[Z/_AD,C&\D$\=70M&\\>N;BRP
M(?<OS$:IHA0D_,8TGFDKH]_M#Q"PF] L;1/<R,(6"E(R/AA-@(7VP$H[\AOV
M8;,1NMH*>&%IY;0]06RJ@]4^._WZX9S"7DZV.*VN@9$KLH+VB&\RQ6CN;%T]
MXTX3H E ]103I+9WA1_+Z!3<BRQG06.@5IPAIC&K]3X/Y"K)-((U9KH&(''=
M1%V;PHWM[L:T!^260%N$5-RHK61ZBNG8AS%R_F$!<<\T/MA."/7'0J=CJ [.
M[PK8"\@N ;8IC1\]1.DQZ/] 'QB<_.!KY#@"'O,U?[MHMH*Z6S,+C "791 @
MRZ;E:<P33+E&% ?+)3UA\*KM@IWU-GS)C,4D'"+"*_%MLQIP!!P'_&!A39@&
M?\!]AE?E6)^Q[JWEQ3/H3S"B(+K4N99IV4?R]8^9EO#_ZVGYE&N^'JQ.&N'T
MPNO=N-!_F!0 !5NDK79B\!N-U#=)0KP$C:6U,D_$)A3L&';;_2CAX='RPSL>
M0N3C@AA;G(++R]#:I(X"&5D;1)'!ZZ#F3"[E+3#DY@"+PU,PX'$!9AC9,CI"
M'F!]D,'"COB90 U=>D;4T4,++4+U'TZ^:DF@5(;/:TA(3+>H_ I3CS1!E"::
M3I1I]=75)!*STX'VL:TD!2_30)B0U-*PX)^<M_/KY /.2P22^TWX5L:(E)J'
M3?UQ*=2;\KS.-Z'^DM,>6+7DX)L.;HB;M[-/T8_1V*YE@X@ZF&G_L;I(<N:N
MREMH5P8*(1WOR=FS-'P37LH;:$@R"S:.RVK:4?Z/A5YV+^,-P(ZZA)7#PDP\
M2:[#8V8*/M.U1-DS ]D3\C""1&:+.R?N<H7O'*AOQVK##33FG8M1ZM>=R_WD
M6E?1^ ^#?VS-\TF@"[#=:E-=S;0LY,2W^?3Q['<NB+1C>4%GVOH).Y @T/-X
M03PMYA+Z+W\MX$)(9284HRRMWD*ZSB^N@AZ#!9,$:XNI.0AIE16S6< )O\3E
M78+:1B]4$[4\Z6,SPPX?0G!_E]SX7,8+(G%)B1H0(BH"J:186-%C?3/'C>/$
M&4&FX>F/?]RHR[)$_MM%COD16P@=_[__SW]Q%![W.<=JY/CB;Z^ZK^C?\F#Z
M=RFH2B^0P-T0)]JF_!OIQJ%@Z#M/AP&7N/5FO,0OV$/Y'<PS^+7^R?RI1(!7
MO*FTAFK.G\>56.71X >*^.;C^K\?PAZPEA@OM@YF\DF5O[;)SY5'#W;^T?#?
MM(ZJFT@?,M>=*'M(E>4_>L%E$HZ73J-AL9YPIHV&T^70_+RT_=L\9OEAP&?
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M1NK K+N3KU>!VK/!#A8]VA:DV9)A%%Z(HT&#"TVVUQU3:M[D5FUI08_>6<;
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MRCX@N$@512C8F<&XT0R-T @86J&KA3J(EH#!CSC'*(M^"WH]J];3\7Y2HZ!
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MS@;:. )_:.Q\QSG=6#ZV?M)[!7P9FL*%7RVX+B>.=C\D_UB0$-[HUC8X<&S
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M5&U4<$IL^[U+92 ]1\>4UE/'#>ZKVPF=M7Z2/]19-X[+2=]9;J5,)Y39VAT
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M!LPEDWLT%-TV%'V-4Y3^PS\@(ZC&#I/*76B'/6A)PH+?87<XFLLVSA/TE7]
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MZ@)>.3)NP:$P=4!&4_TB8? NPX"=Q@;/V63443-)=FLHURK:CX#664MPNVO
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M\1_F.H;NK1#;T[[6_[#+B23WB?.;C(_6<7X^T17B_&;;5 T.Y-3=\OKF.AN
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M8\#L>C%J\\*6=P^Z@N5@VO:4ED('A.,_F T<;?VR7_0A.KD179@-_8)$?<I
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M9\HMV!77#AC6,RY--! =J"J&6IX2.ZTY6!+S@&'I][J+JAV'-CP6R)5G2XO
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M?YU,4]N4,X]B1[8=8#J'RL=.NAZVD<>WQNL-UYIHI!_-P\+DCG!NP;9G7$4
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M:72+>7 P33I#'2ATMT*7+]-FJV&%>3&/,/TH4+%V!A%>\T8&/X+^!M>F]IV
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MI0?&3'OS=X?#4_)WF]8#5A2U7%S;7X%R@7*!\II+U\HI2FN:;*J^?*DL4ZW
MYAW]OCP=MCS(?;YHCQM=!:)]/)7'PY+'0 JT%V,^%8CV7E]6NB5/ Q?6T!D4
M@K5M/P+I ND"Z1>'])-*6/T>]<[M N0UIK/;?C&K[OSY88,_/X.$M.QF]J9/
M+6*M+5[W$*M,U1U)E1QO!2O<8-TJ#^"EU)/2%^9=JXSYW/KB\!5B[>R-M5JK
MYH8.OQV_<])*9:L!&1CE&\N65OJ++)&7M4TU0TE%T*V)C40)1CM"SPRK@?%*
MT"4=S,2";Q)RLVAW/8M&3U>Z@Y6TJDDLSPF?@*WY$!CP$MW2' EH4L=Q])JH
M(#[7"N+QG@KBVEOQ-[)8MY&+NO1RS_97$+/-TS)B]JNH)185DFVO);Y =#2Y
MBO@2T2'JAR.ZHD@_S20NWXL/!AD\%I #QT2UFS=2HN)TL97V]BXP36\7WXD;
MKUKC<9 /FX?-&KZ_0P,W7P9J"/!O#-Y8$L?2Q#P'?39AH=RM_:B:^G^IPX:_
M\-[R8%5.4O;8VK-)-&;2"T(F5[W,F,FHA![8OQ;@MKQ@FME*1!4T(VAF/\W$
M\U$;2#,E!&5_K4@[$7I'T<.L+ "AB6-2A*I1EJH1PKC6<]\K^]P+67&B?M$4
M0BFAAD$02I%*Q:40BO!SM$W?8&6V[E*WM:NU"L"\I%EL52L>#PCF.X#RAMY4
M*Z\HH<^4D"E%*A]-(I82*FX%L12I@#2)6,Y8"1'J1<'JQ9VM/ZF T+6Z\=NQ
M"OVB-/WBGAAX>:VGOX1Z,B$JBM0K!)$((MFK3UP"D=18K#8^J5BM:5/81%%_
ME55+[85.R[8CD'VIR#X/-_G92ZWSU;:R6WH<KS%U2VBS*A3K JTO@>HVHSJS
M=4>#42TLH3,H?F_;?EJ@'@MT"W0+=!?0JN-BNF1<S^=@NKG8C&%.]"?6NH#-
M=Y?6-LA[&Q9!&SNLV'6:1Z2%;:VDW_]Y(]W9UJ.MKEB+AS!G9R.!C>C9JCDG
MK*6$0UL\\+&'#CS8>M)Q9O%L(R4TP9#4Q4(W=&P (:V7&T>?ZZKI=-)[0;0;
M1=_#9AL^:IPX;L#\=AQIIAL&5H4M8>VD"(C#2AU$K40<%]Z&7ZK83X7B%1_O
M3V3R5$-2M?]XCHL9AXP:/!/;2A#0#H&D'-@?KF%-;%BQRF@N:/NAFL!A]#5]
M@:8O%L0F)BYZ1MQG0LRD[07DB*\B+VM""^-LHJ]FGNT07(9_R<72S4,"G@_
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M7(@62F568M[ZFD&_D]!4I514A95(CZH.UJ/T:%G:,WPF8_1OO@S/ C^5FKX
M4!(3]*09<9\),4]7S'QG7,*)]Q7-)'VU(_V 4_AHZE$-D9V6G>UPDXYZ(.',
M@G$%RS?)0G?Y/A_A+YMN "L0-8T^%%:8BX9WR.MW_MIK<R<JG.W+:QM%UT?0
M&@<0Q34E'Z /U47S&A0AWX>U2ZTQTNQ(UR:[ WD3?.KS9I_.T*: NTR@+U;
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MO<IV_K@ 16CR ,@\O218' +W\QFVDYP?]YVXMPN4]ZYKZS./YKH\6#]H\ 3
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MMDZM\R8SWIH<CSYLZF&^ WE8]@ T@=7*^6]?5KHE2U2A'K>-2;.TL[!_*GI
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M#[Z\4.D-IIU1"E0L4Y9LXJRQZNR)&!M9TLVYX6'W,YT9KYHT\US@1SAW%MT
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MLS>D.L-/MJ5@1]^H5NHYJ)VPKSX#<%"-O7[1G7W.OF'@[!OMF=8Y[>R.E),
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MN=A&L_;Y&?CX7'6P<?5GW7;<_X^M]'8!SU*"W=^C#,:GW8.I"B?;8I# ]^T
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MMP7KB^R-_?40!.A<-=XF6-=51?</B T7DY'0W!?6DU[17'@(!%PV AI2W=%
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MJTKCS/H"M [3A65K'D,<K')MDRM<&Y_&"?>HN"_/<(,YG;"$.;##A6VMZ ?
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M-UE9=\#4&*_[[JU 7YJ_]S629+5LDM=5EZK838YQK,4W&U.9Z,]MKR1'X9R
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MVZ(*[Z*P?795>,(6;/(XL59M1B!;(%L@NXV;*67J80%]%R^KE>+' ^:2Q;L
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M$]&N@7#@A,'E((5N%VPU= I/<2-LLK6C$^9.I6E*>^=.5:P\P;F<>T;H*J)
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ML%4]/4Q7&SKI8<>M!AR2]]-!_==];12SF0+-5*9 ^79\JL=+WQFLY_DD4%O
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MG[?BRA9UY/.W?!NZO(S+C\CSL,#F6)F#V'PMF]<A8[>E:WI3:X$*K_74UF#
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M^:HRCCPP6G+FO7;>U_J9\#G-]*D=CC8ZSZV(3/%'9KLOL0D^!#O0?<'>Q%B
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MDD[ADTD$5( [SW<<MQS^DO_P61WC7\/!#"BO*8_H(/JYSZWL0^0V8)+6&6Q
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MCI_3ITS&J=]@&";8IR6<'?QVE@#72)9PKD#]8_AC!;1?P%'A'.OE> Q3P'7
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M>EDV2FK4^AV3=>XA%I0UG/%8->\/*8BH/(VC/Y)Z!OO3H$6;?AJG"S(28*M
M_I,Z70$!Y,-!E2)YXT:6G?>K^^E.7 (/#J(7L/#H0Y*C\H#49_8*-*IB61]L
M<_)]E2-\<'"(1VAFU[):18XGQDZ=;. [>!&2HD"G1LV+!;KX%1GA[V"EX6']
MFDU!+IV#.*UQ'UZ5.3P&.N?>OS]^?#^^?__^?EN)M',SJC;,B1A2SQ5K'WZ!
M.YU[3691(?= <B/3L*4KU\#*_)U,/K&8!K4<_MYGQ17&+," O\2%DV4[16)D
M3R@)B#EL^BQ?=14\2P>TM\"J\-9?9ND5WXP<](-&-A%>)UK]2U2*BIK9]TOE
MO&J'L4X>[EO_+ZPVCOLO)@8L&/42[V>;9#5\@K\]B([)FD-Q2)Q7G\5'S7)B
MYY#8<G:Z;C*'5<OT$TCFY7*SZ^XKW00R>COW<ATG QEWD2']P0+(Q8;J&RA>
M]0Q$)/RN=1KFO<.!O-B?!)(AB4!R1^S!7R#'*F*$1-"B4)#C (X!3%3R/)!W
M!6G FPW[&Z]G'*G=0ZJN8Z?H[D'MYBJK4_^(.AV];9K48LG#MR+O)I$7M97Q
M&Z7%1/\)4CD'\QPV:SAP"^Q]LLM/IF)U3C-4"<9H[4W@#?2:=3_:[UZ[!J@E
M;>1DR@5HU,VR$ 79;^EXF>N[O75\SC_MG)FC!/0GS82[@>J \9MH#W7<?9PA
M7@&PJ.D.D.-("!R_X^DH(PNL^S73$L\X&'KLI>+M7\\@8KW/-5JG_E+#965%
MC )YR#]Q2NN5GY8/F$\%F%5GVY!T87/)K&Q8,8'C.$;=#WD'K3@U/K%%DDV0
MEX+D5N7Z35+!DX>/@>[EA,-CS^9S\@:E^4J<STKOK><*<7!G#<:JX"/8KH/H
M;=G@G4(#V6E=:,I<E.27P#\[3*!S"_$I"A^&0WJ.3NN"#=I.')'2QATH)@]!
M,>'(U!WI'P]9_SCYA+2;1F=I-A\MJUIBT'V:2 5TWI!K5QYM71IXYI=?W[T]
M=^;C+&O2>S78P^FSHKRJD@6LG!Z 6[G^$;#V[Y73>XMR_#&%F> /GLM_@&G2
M;)$7.E,>Y->2?+NC734EN*:C%-8T14)@0WY<%@4K^_UZS NGP,#"ETGA2+&R
M^Q81:9.5AI?V8IFA05:0"\SX,6$\CI%W78G6* E?35N,1M:BPAL8>HW*ZB(I
MLO\F%E1W9*8R&?'&S_PV<F1J!!S+[RA:SL2F<0Z3<KS$X9FY[:#P+<H<PURU
M7^1PT%GEK:L8#UG%</NB5X\)?;,YWZ. %& =Y^P59C:<+?!(8,FTO;,TR9M9
M/!Q<I?DTJ5)TLM4)&:V@JZ$8J(1<$O2W\C&PCV.*,TE=T'J1)P5_#<=]425S
M4&[@O/XTO+ W#D4^69A)]_?[QKOMU(VN1]L%R=*TZW*4D>% R'^!TB@<#0.I
M,EWTO7LM!'\:^,O@_M99LR1]JW= (15T."W6.)PZQ!)9ZGBZ:'X0FWT]T7W)
MY"G-(GF@,__N /SLVTO>CM<I>IOPVR]Q;3.@TLMD["-0.;U^ EO*!D%'I>FZ
MDU+YD6-Z:8VNNJR>M93S'@YX##HF_YH^1X?8$HTPD5PTA2EHC6)L!)=0[N\X
MJ:H,TW@N2:C(M2Q@J_DGX3U=H-K:-#0S(XQH[AMUH*_$D1\11_ZO)=H"[Y%S
M'%! :/.IDKX]RU+8#!?I>=<)L/&1@VU(875E6,/!&E,^C#V(21E3$,#Y5$9)
MG=4MI3>,P;(;.F%=OD[F<K!JX'5#4P&?BR/@E^23G4;)%:D0>^R:-=D#LEO'
M5ZW@GE5*> M4'!]S>@\'FLZ0/)$ 'MR__Q0CLG@C+EL&#!Z%S0QJ6=/T4WPF
M\ B)S12&0E <1,FD7##-^4!E"58=/NAND7MI'*U;<V=(^G'"NT99.#VFV=H3
MET@6G1*08\'VLT_OV7Q6H&#!C8/K;8Z#$S6M(>GXSHX"NQ46T* X/]ZQYR.S
M+TQY;CR<"894W:AX##3'Q <=D.2SFK.6:N(/?!H\N1Z!O6U+VL8=T@.EUZ&_
MC32-6E3(UD*%=LQZ<*E%A,Z.)M'3U%!/-K4W%9^I-2N&,N*& ^<="?133(\I
MEQ=,;Y@21Q<->$F"^E:&Q %S+?-HS^1'"IG8J=FKQC:N>8(I 5:7U?4RQ> B
MK802YDA#ZAE.0S=X>,@P[K&CWKZQ9BIOI2'X&R6VK[7.1\C[.("]BB[AWE.\
M?9MU5I3%/;@$TY0C3FIU4? ;-MZ3!;JOP*1&K3;GY!,?@S+19Y25O>O!F^9W
MSY";]8&XZT'>+XHRS=-&.2PQ5S2KUFPL7X>[VI.#Z%?TQRRK15FS0CL&EIC!
MQ3'Y@3@'O"I(B>AQNLZF@8J]=JLX[-B[7>O(,(Q7CL=IGK(35%DB^2?GY026
M@/Z4P K>&C@%84_A,G3@TP3"A:$Z ]N,0H%<^ANF,!RX.= ][?/%X5YR8EJ'
M?YJ;?"=>GT<'E+.&.6ZP54>AY,5KI(9I]#?D&>;9 [0B;CW'\A$[B<P\B I?
M)J"JMIQ$>(@N?V]3=HT>32 $W%L#_CM*0=O:AZ6?RT'J)(B!<P*D_;@G9+QM
MX&M2,FP(4;(3MDZ<H(.2"=,J_F@VN(P5N%X@. ,F#C.&I4Z$"] .'$2GWEG4
MMPZ8I$F4=#L7=QQV<").O&R*AEG1V-EEX1^5.#C$<:5<I?5T;.1 UWUE7$PN
M(.A<4>K&0]\!!@6-MA2.8!2;EA'C$PE5W=@AD/]03I0]YK$*,R?-G%H[TJM)
MNA/Z-5B&^"^8P*R.IO,+_3GJPL=WN% Z&F7FIWERQ9JW<Y"C!"$//ISI/9IA
M'":R'H_'%6@=T3NP0"_8%=@IH_D6'2D/OSM2OA@[Y_1BYXW\?!X^''A>Z@I#
M_  ][-QR:0[+[<;9/Y=Q/[@^X^XR;&#.!:M?G(+0(W%>&5]OA_W*^*YHR82P
M-W%HW) "]A W].?[FNR%KBJOZ(CJHS^O9V75<%* ]SX+H]1J'\UR%DL?!G':
ME9@^X4N' Q_'Y-/>(-I"OX&F[!O2\-GV01*WER#>VT)*X]I7!%9A]QC<;M=Q
MH"/N2NVA9=6S;)38FVY+*+#71YMZ20@)<2+*O<C$'D:OD1QO\AOW E?Z=6O?
MX(,L=&>JL@Q<;.-M>AR(S-U2-/:.5:1*]+T=V6V'DJSWTT64>W64<@RZ YPN
MR%),H>YFB,/CV7PYCVQ&@4MP$/?J<&#>&T?S9=YDL$'>MBB66,1*:<!X\^2&
MV%DZS86SI6UVH;H<[-PI%S+C$ R-@04\&K*NLT^8)$$[]_"GQ_O 2?UMVFJU
MOJ_*>V=(;FJO=I(H)/=A.,!C8*],A>SE8<!>Q&YJ[_@1W]07G^^[\,K>SGK\
M;I8]D/#7,>W%S]OKY8"I85FJ.'#5#8U>JJA<-L8WINXZG*RD9A)C2<94EFAM
M>V/DBM:])L''_DC*PEHEUG(N:EO+Y0X5Q-LT+BFL\RI-FEF8Z[6K\2:.+\_$
MPQHTIX],< A+5;ZN  6!Z.!:X2:RS&H#/2R%?>FLP.CE[A1;T+B!RO$%K5BK
M>EU;&WK(F>SD9NB?]N9LMAY;DW/GD)VY&JNTJG%!%<?>5E2W?<%BT&9K6&5K
MFN4=WRU6'65X,/)&D,BU>5>\_GR\!K9&<!Y9S^5V;V _7SUJ6XW6)VQNV^TG
MBC_B,)MUX%BZ_D-NP9=WZ%S9-Y-Q>Y%=!L7Y+=51?9/F)JRQ#JZAPM,;>8"6
MSKM<(-'TZ]0<K37WVKQ&K@RRC<UW5@,1/;MQ[<M*WM,[4@6W3"[0!$U9UR95
M\)F)>MS\ROE[6X,M5K'82U9<V>(+%'O50<X1[YA803GU%?QX!?K!LHKV'CR2
MH>B7L,53SIE, Z61Z264N1_<W'K,'9-(CR4WL&,\^ZSH*,.22 ^_J, J.K+,
M1LP;1XB2?A3-N30WCF9EO0 5)Y<$,9-NI*%:_@E.8BD;J?D[I8F4<@P\J3&!
M_ (S3V-3(;DA78@JLQP=3-)%2MRLMB*FO4^8SQKWEJLL6#\/^)3*G<XZK-)I
M\V@=&^N9E;I#D\*_:#C@9(MJK]Z/ZA3KJ[K<!HR%):Z>9]/)<"6PB2JY2(-<
M\-1]C 5J927&@.3[ZSJRNE5:BE<VJ31$NVZ<('782VH>E8LW6P,Q7VQ<LC3F
M$L,I7)7+?&+*O2C)UHIP[X?HSL-.HVI- ]/@ZYIFPTIWL=I7<7KI?+":N>T,
M//PIR!I*789%@&T9'1X\)B.D[ASRL4SCF%,YNCG&?4ZJ:C@ ^V;#6P-;DN?G
M;W3+J/IY%Z/JV_70/OKNH?UB^MKC]?I:ZO2(W[ P^XS"*:TJF4!KVQA&VJBV
MF0'Z;@=95H0A@)>7:@?Z5:FP9+OC):Q$G5*DG%#7"C&;0I9/L@&#+BH/?,18
M_+,N.6N===;2W\S6)&P7DEPCI>M2BS*892TR#R;$\^U9O+/!!>O'V $FW(X)
M.%1KFP9[WC$*K:@)M,E]P43IZ"'F?+?IEX^OXQKOUN'-X8IN(@+6EMJ"W)QY
MWW%C?!\U&SP6-1C9ZMUI-3OKZ5\^0OR8M?7-":AKE/>[L!!_VL1Q4"TVA'F
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MTTX_(< 7@5<A= PZ+85>VW9R*RBX+>I"%[.LFWL!+S4"SF:\4H9)4V]$.>-
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MX+?=IM9"2Y_O"[JVN#E'&D7:M&5SOK.\<Z^UZ\&4Z:HGP*6NMDNF;,LX?\U
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ME'UZIP[[Y%,!B=E4\SD<^*+/N59T8L32"8QM)9W4Y-%5=4YDXR785"!H*#(
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MV&( 20%B;^5'SZI0V1"EP6(D]+;*:*%:-\ZC[QP,F*WCR*6CE1"@2>\HNZC
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M_O<LJ=N0[USI;I'=VC]CG)AVRA(MW*4+]8(,76]?#]H98-8>,+J_U.;;D>H
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MZL>J%7/N:,->:V'[6E/?,ZUF5I5+D'O4DX/-H%JM <D2J)6^C^=IA<B0T;$
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M&*6(ALIM#=X#S1..4QQQJ/6-T*,$6O7CESF6D=K/@0;7!&<YK;OG0H)EGB.
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MB1R8*;.U24Q)X?;D$N"O7Q)I(("^#%RO'[@3S-%9M*-AK@]F0'C42@#8T*N
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M_S8/2:K% H=]%;;/[ZNL[UL'9[117+?T_/'GAOX0%G;0>AUH';]#:'6X J"
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M#)-O7?,SLA93ETSHC!')9IS-F8M%YXK0,(RICYM3(2,B0G(I9$#JE_WKX9+
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M6A^LPQ,VU736)JA#C6Z8@HD.GR*'[KCULMQR7B&W.C/JQV:+U[ACGH=2B<^
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MI!"$ $2C2%,"5KI@M%HU"#>!]<91&NP@FT71-@ PEP/+PF.0BZ=*7@\8LFF
MK6^5(< ?4L,<+$$##"U1I<BJRQ6%EDB!T&S%M@@_-J$M?W+8EH]+#H%=\94
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M0'F!'??3D4@4DEG@Z[15\-AJA4-0QHG5PFXS#Y-*Q-V-B R+1=ML>!@O%UP
M<S*+8DV!IEDA*N1P76[4O'8\9@?#);;,='HHY?5!&</K$3B S6!9ZC4(W'()
MD2KOM"2)JU!6-%1.#%.FB6!52.,J5VSF\KD>4VZ $%]@XQV\086 Q[,JFHA7
MI)"6<&E>5,_%0Z(.YEE'4E33WT)#9##NLB#%Q4"&.,R*H)6N!Z41-.O+M+)!
MJD1@A6+-C==LUE"*8D&*B5J]5NKR336152(UER'7=-H-U\E42Y'-=(WPN-BX
MV]/&,6/H]:R2-U[)V)5ZQA=I4VHP[Y.)1,\H,ZE0I)7.LFF#X_P6IUJ9H$H9
M-(F!N8X1@/OQS19/>M)Y?US(A[FNET:&5$1O)-+>E)>B/*;;W<11,:@VA%2\
MG1)3J)F36-T48[*GBZ:DHJ?A$BFK6(DAO! WG K2T:U*)I0(%$)X/1A A_%R
MCC02=:B8H+1N/WU;,J5&-%>,AW1;R%>0F)#K":5 7,JE1<V+BV21M[Q=6C9I
M*$>K62R5B&;X6AZ2FD8^S X4!AN@U1*4C[IJ"NLQE:;MRK?HB&E%H6:Y!J.R
MK<7X<$('=$HSU"R'9=HE5YFI6JXNY:V:*N!13LX3R!.=\>>E.+=9Y=M1N*PX
MX1)1#CJ0AP]QOCSG9!MT)HIW"W@(8X+)@HD"Q\3 IB/ED034I 007J24"'#]
MG@31U%S$>,HT[L)\HJ<9-[5."8E'3*GL<5LU+$JH7L()V<5(W,PKCL>(@&UG
M:QQ@]1!#4[0"93"C6(D[I.UN!CM-4HYSP^ QV"N;=I4.*Y)M. 0%!5..S3'B
M^"8C_'VNA*5 0-&L=9EZ-I6N)T)(2.@DPU8S$V;#,)'J@"D%!KDSO&O6PMDF
M::8SU6H\*M9$7L.!/A#?QOUDS@8^FT4UU=O5BF%+%) "WPL59 &OU6DHE.Q;
M_A+1@[J^>HHDVOS0I[0[>$+HRAB-9D2]S&5+P+"5(07- !:*6B#JS+MU&?'%
M7)HOVRH),9GG"KB**4XGJ/:0: PBX6B>9 UX2>J>+OJ*('QR66Y-:19I*]%E
M.@E:Y!ML24W)+:]NHU97*Y7CP2PMD6R1Q,!BA!3$9.NY5-"NQ&QW!.F9H1RA
M#.<0KU+=3I:+M@(9#\=DB*HH^AC(X^V/-)ECXXX3K]9AJ ["(BVC,F:E[A!V
MT&QJ4L/!XDZ<TP <6Y:3R^-#;E/.D:6&UA%$?Z;K0+;:<?A,QI65*+;(U8V4
MDXII[J(E)_/AJ@',/I\K _@$@+_1F$HLJ2LI)5CD?'05,JSA'$I,H17-P&Y/
MLA,S/!Y31S6EWD7$5J^5BMM>Q=6B!%1NT*AM@)6$ .9:!LL3E4ZQ"MEN$#>Z
M38@(!1*15JD]4-CAVH2#-@J&@$,F&X2Z-N*40WBNG,GU*4A*-KNE+)T*)=I0
M5M$J3)6H.MY"A#%EAY9EK<96Q!8@9 J2[P[Y81GEE'(&C2I6QM);83R(96W6
M))28%8T@%DUD\+H/0]IFITYH4(QOBFPIP2:DK$/S'=)#Y+HYW*%@HJUKW/ Y
MAVK54:@4W_)W PT\U8(YL0;IT7Q"D]B4J.F2D^'#+&>$&<)-=LJ 2T>2[3;5
MJA.JR'-*&$9D!TLW\1S:H\6!PJX%F=U\(MND]31E=$W3K''^8)7U1]I^L%%7
MD4Y952Q=Y75)&3ZF5\:]5J0N%CRI3-6&P.IT')3QLKTN "I7,M-$WM.CJIQ4
MH_I$7RK;="W A<4\W572LJM@23P--Y$.'D:M80^KA70@E6 LO@HB9[TH2F9/
MJ[N(,B75C"I7*_2=DNCC-"@EL:VDUU7 K C<+!I6.V7T4@%13[00CD_%LU%N
MJ)!FZKFR&*'<71R#XA3<C+G"J(KV$N5J1,]Z$=+0H5 EW7^2@&U!Z;2[YN3K
M(M,+^[Q-)-P+B]Y$/(S"U7I(&#XXT>Q!<=H7U90"2H3C42;&MBRIX)/JO$\$
MO,#C-HN2)TKT.FH+P04,@#M@::Q7:H0@N%$6I)QL1>@>39AB>:@00,%VBKP/
MK>2C>C41"EFBGK=KG,:F&>#L"*%;YN*"EG  Z!%7MJ*9347,^.@2"X(&PYW"
M,W@6+8<YTVX,PUNA&V;4;%(I644&K:?;9))+T"W"'\XK/MJ'^_*M"DWDS#"K
M-%J\YK;42%QLB4W*T H06W+12"+*YYL>"//$ASTT2-2'L!Z2H?%D \)* !)5
M\%,'1'AI@3\6IUU"LA_V@E]X,-F>Y0H(O])L2JY@#AHRV/@*=?]M97T]0R?U
M!2GK5QO> ?^"E/6K#:G(FBAC4HZ_P%(@8A,,J]N(Q5U\&P31NC3(F [SV"MD
M3*&Z+(#@AFB#7^-VP:R7N0P,(JL ;/33 *$0U*&  \FM%.'S>118T2'[DKHN
M1\3S@/'X!%G(1E*&/X>&&N6J5(Z2;%*B(EJG#F6L)F3S4;?$M!*U!LM91#+9
MZ[:!?XF%2!Z"<YA:&W+L4CY?3R%N) C7U"@L<3D0*;2CO;B%8KB;QJHX7>0C
MBMO7C[8T7Q(E$"OLKYMYVBIK:L,*XH:O6C8Y0E2IH5\FH$ZMD(FH)N]@1CS*
M64V_&I9PI.,O6F4I%Y=-P9W6<<DDFTZOD$]R:,GQ@3@):62@>",>H?3Z4M,V
M4/@IJ>&!X0,.*96!,&#X"'^?IQ<P3"'<*2P+)2IT,MCNY"#6DZ 5DJ:&<0I+
M=5MDN),P;4L*6HI)U>)&QJ^52#:DMS"C9=)J&_>[%"L<DG)\F4.C%:,<\'CT
M8KRA!CM&!\_ 2E[C8W9U.(?9K-\$D3465$%D72QF&3),UV2E4$K%42XGFRU7
M(T9C\9:+":-0*D(UH6PX2C10*":7(+7>3VH$0RX0A3>8U)+'8V P/E\L(W5S
M #)]N7&P9JI0HY]5^ARJH!X#(NSA+:1: (H#(,;4<70/U6!AH'WYEF30R0'6
ME^NP/]17,ZZA[1\2SCB8;- <:[2<,&'EG6ZI6<JIO(^&HKY @ Z4 1T,VF4=
M]#38X3(N7:@+,,2H3KYKMMPE$7+RK4*5]I7JH?+PT0Z\:',"U EAJM.W?U$P
ML(H@6@9J6C'&HP;Q+$FZ9"#$10D0 2@FFFT:V1S.BAXDZ-8<Q?($LTP@#(VS
M+SN2IAP7+_6"A"X*L3CF\[> F8]U^)Y+2\/))-1.M;(ZY??";CKCL[F<MMKY
M7I*#_=R3_EGS/<R*K,&DC\_WTI;\\7%55J87IXQAK)<!A(BN,X!>I<DTI>?S
MP-8!FU,#"MHP"FR.QW3@8E@"?HE#0@E?OIH*4K+.9-.M:IEC7)0N "-E]!]:
M&28Q/BV67>F+H[Q.2?0Z12N+U<..4X[!+)RK1)@V5\QYAV0I2O)1D:.[12BA
M=7NE7)OG&QD03<HY)-IH*3Q>KE1-)Q;JL"(*(QTN#58SD%>J$EIIQ%*FU(S'
M"Y66!+OSXRZ@Q-DN-D6A1EEHA#R0D6-S.3R4!I.7=Y'NO M#ZB#>@XB\%6]Y
MH%9#@0S9*L)1KM-LJ3DV*+;%1*X+)KK$#9]9<J4I.PRE<MV*J\P;;K=J8 S1
M59/MGNUS!YEBFF'$0+(1<Z7(F&"&*RX79:..-]'KVN%L%V\9O:Y9#0-#2Z6'
ML''%JP'6FS?KEC=$<I@,0G4VB,-N7F,@DR JDJ^.$PKM ML$\*L*A[I,H42E
M<8DO>OJ)]%:F 7GJLB4AK=[0T>>ANB*4<I"C]X! ,03&BF>!7?:UF!AO^"S8
M@E-YB,,Z#.(SX0Y7DS )4A.N0KHEJ0&K61,PK 0Q8ET8LJ]X2$ E0#3;Q7A&
MI@BKT<FZ]%K"WZE6TIX.AZ_*R/:3(?TR&NHG0_IE@R>4AE1$Z-\<Q%D(^M1D
MR.?[&F9%EL^A.&7(,TBM+L&T-]-WG\"W0O[D$M_:EKH(EB8@-ZUV,20(F%&4
MR2,\T1RF"*P$CI9[*1^K\H5X!"Z9L9;<:-0+%!5,,K(65\L>LU=UNX S+Q8;
MJLRG8(8+,7;'%6Y6\'2+<%.F9N *U!JW-C6PMQT(X< B#HI=4:B112$N3^9%
MS<R[@/&86.*17$Q"\G%E3BBF6(]6I_V\88>"P_O+5#_+@9)Y2C7+3%>KAEC4
M7Q,54*<)S-H$!15<-"0O<.X32X;=&BA<UC?"OZRW HOD$7\@%6CK(N.+XXA)
ME42+(+B5.KE4(S"#P\P26/95C69YP=7)\+IJ*KF>6@V8@I])5X;9.0ULFX1#
M)+G/,6>?=\A"5["ZN7K*G\D1Q63.&ZSA4DN*J)35RB$)2.IGB[OQ4C]##) $
M^[(0,+Y^B)!Y"%]6$AJGQ$E0W [V;QSX:+8%2)&?AF)*R[5<"< B*"'\IB6;
M1DG&_>5\*-;!I*:[SEJ<&,.KMANB6L,7#4B67A*Z+4F Y,>?_X/\Z26/_A44
MB\9*J,]7!JS/,2N.T.WB]83)AC%;;:B.N^'HUG .F2".AB42; ,SZ:/EN,YT
ML(#"IDJ00H9*0BV>$E [Y130<*/=K-!5)RO3I5RDQWE$R2)KO9I-YQH%!"MW
M,T/V!79.!TX0303NY1,ASD@T*4%HRRV] .6J8EQ6?)5N/I[S&$8!86B68YAT
MO@T) ,ZRE1RP5\XE.&% BA-#>ZCCZ4;7W4/A4,8JTU%<KR="19=?2!MYDY8C
MP)RF%8C*H'Y$SY,^0?(JQ4Y*<-4+"FUJ':K7K J>"J])<$P<)M.,")8U6"0=
M03AOB[ LU9/U^)%JIHG@I69;K3O=J,,UD(#752S4<81F&U8TVC-<[5 '!>%J
MH]6 N@2DH%VO,,RTIY&>K^0R7496JA9PD["RE!.$ZU(PXD&*[J+)Q>,@,._U
MR7E!PARBEA-\*;-N5-S]N]8%-R+#'%)4<2Y7&EKL7#;"5[4J%K;*96!.L_YV
M2I1-5E!<; 4IRQ2/(&JZBY"Q6 Q+9;*]1"Z;Z^0IE%5@;Z0<1:)*2!&BG@P6
M&(]3"B4NI4M=&%9ISN-M6R6GQ#M00.))NU0F/:3C)1-,H:$F[#8D9I@N40WX
M-#DC-@-\89 _" >J&8:-%JH^:MS $J@-=>M-73*[.:$.\)%J%3,\:Q=A%R-9
M442(6>%20_9"8BPNAK6@BOK]8:Y@ES@S2FAY&19QV*CD&6LXAUFW#X#*R@G!
M,L^U"@;-%!7,B48#\38>]6'-+,/6>-;%MR@)#R/YO!?"$=R#= D2P_,&06=C
MF7@'*VL85!QFB0-$LTG9U?Y##':%0%U<T9%259CK!/R(C+2A".:T++:L66Y8
M:9(5FJT%,JE8M)AC4QW@\B,<%(<E773;/#+D-B$<"13SCNHC%#5#:$C3+2#U
M0*C79,A .%:U):KEM:4(I07-EA7%^#P)D>6D6^^T*BB;A,M$K1HDL&*BBS9C
M X7Y!N:DK8Z;X/1&7K=K(<L%.V6NV#$4Q<? ;MAN<:*$6Z%H"(=KIM>EZOE&
MQVLCE.8?/M1A^UM2UU&;WB''[B50G^/C'%^F57(7<\5D$1 -5Q&+)YAXK1R"
M$8$J>C0Z7&MGQ)B>Y'BWAK&14+[@RZ;U#,31?-.2/;";@I/#G<+6T8#<J+-D
M4<XT6"+8\T<<WFH&G)K#11D)$+(N$C731DKJY))(7>J =@&M8&4LGXM38M!E
MI=IRIHUDDZ7AG4>M7(7(#&7CP.OV[W=J4/]^9__)'[53[=\861M'_REIKD^Q
ME< ]CC_I,IX87^,'9"9\]9_FZPS(S]#1C^?7$CH-DWA8TB4C!*=CO@0,P?6V
MAW5%ZSE!22M)RH+\=#G7SRPEH&81# #R1\.0#_SE3Z@\""+&WXT'<R9T(>^@
MJ!WHT!#XJQW$%,#_?> O?\1NN09_$7Z@SFV#GT-U*RL?6NSE6EA;Y4-'OYKN
M_SO*A]FYU73_WU$^I'.?8VX^K_+A''[*W-@:E,GK61%$]73&HR$2"V7I4"WG
M:7(5D\5!U )![LS<N<M>M1R^1[G2ZZ-K\![RJM]/_2+?0TXF/_V%8E5=Y<O(
MML.(TJ?7M/NOQ4)+WHH%XKNO6E&XY:R)HG!+U)S=)[[AG$R.QC3;$;2R& N-
M@8+9LEP9#: 8$<:]'AS#R7  07PDY@^'@UZ?F_!Z29]_,,$K5EU);6C\_?5Q
MM94U4+M<U974IBVY*FN"LIQ,LPET8R$W3/C<'A\:($-]W8C'3V ^.(0B&$P$
MB26Z5U%_I3884:O(?1P$%<&VQ\;/XEFB8<+5E0<N6G)+K)"6KG[.5YWG#% Q
M*J]B(=R?-6,K55V5YLHJUN)S:JZL:IZ6:=;_[>58;?U5-6.M9D56>76"(5AQ
M259>KZAL@W"@NXJ7V+.B^<6\Q#[8K*-">6!S; %TI=_UY<I67VD5H'"'0A@>
M" 9A#^8.^\'<XD$B$ X0&%A,PA] ENA>'2A6T-^NB5K_/ %X<)X D7/#HQ[?
M* 8O.4]@.:G5*[%UR6D+ENBO@B7\[(,%5E5I]<K'CT :@Y947%+P^1S$EV/-
M/MOT_1MKMKHS(";]F@U+5]Q^2_;RA.WZA?ET>=G85^U6EQ,8GC6R?.>6NSB:
M=03+:1JTI4NR(H[1_3.[YD"?(O'_@9[DZ,\X\,2!C.IJ&$I(5C\/L0!BHM8_
MQ\=>#4$AM<]%4$B]STM6<W#+9YW:,I'/@'&/1@6;DVVYI(CI)4>FC>6LICA
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MT,D$C;4+3R:Z@__TJR83D?WEA(9WV0/"V&3R*&N'C8F/_OS''Q">Z-*^=.#
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M-5CJ> #4"Y#$!K#H"ZH&> %</IP)@04%?&%YCF:UP/JY)<TU/<\/!F3QRC0
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M8)(_N^\<S451"&\(:PQAL+L +X $0?N0Z6:QN:9S71'9+_MI$^_%]ZR,. #
M2 YX@P'@V<<(X$$0J?991G#] QJ\O]!A0*8!+VIK&]I>XL7:CAB'$%]C(W[,
M%C&TF] \+N)52KT]-J WCQ'2JRRME#*"Q(8X7V9CSW7YBQ7+$ ^>Z22F&IB1
M7@U"MG)>:&LG%O$2QDQTCNJX08N=@$O.:OAA!/[*'KFJHXK"RV]U(X5;SC(/
MGV$0<.HN O8^/:J!5I_YLH.]T8MXUP\6W0_ ^T^+\#]&:7^@-"(Q]HTO]!G
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M">E_\J=K'QF7$[%4SU\F'K8LW#R1Z<I]$7&(96A0F93*=*_M)=+$V10W7$:
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MF._A6A0BEES%QY:TF0V7O.$>,^%EP\Z]_D^&(*O]9]FQ?DX3Q\L.*$7,+/D
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M-RLV4I+<F\?II5C%IOSBV>9([<D.?@P8MB)33AT\GMSLLE@RH>*$)"K)TL'
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M0%OG2@)&.N4%VHYQ_TTCU@+4>M#-['\ 4$L#!!0    ( !PX4E)\O"OR]QD
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M9S[W/?+,> A?/<^A*V:#?\:<HX^QI1K?&Z3Z0UZJ&@@KAF']X>#L[I>K\PG
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M"_]Y*D]8\&TE-6)7Q_A')T)"CCM!;2C1>R:_NM!"-_:R.1U)+_E7%_P>8;8
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M*27W<346B8_P![L(\SP+&G!*J_4 .RG_?*#^8!6H1X*6'M[LFM4("<J[#XV
M<3XF?[2*R4,Z1T1W<<$K[#X:/*[Y4/R7W7&,L4AW><DR3KSP"XFS):S PXP>
MP,"W?ARE.()]?>'5B"/=]6 SHNY#VT8ZO@G\M^414N!GAJ%=.E#*JCD HWB@
ME#'.1^@GJPAM7.42-+9%'-;\EDF^EG^VJN5;3/U8=WB%:@<2\IZ@JN@P(BK6
M!1OD"U>6#U_CR#=9053+.PR+@&,!&G;]%0;3H %FK:@ZC&PKN03XV_5U"%S?
M\B%35LEE]"1L"\!IZJ;8]_LO@M_*<T58M,# 31W6[(1Q0LD_3+\G2.A)OK\Q
MJ.T@ $;\"Y#@^"'.]PX4CO>,H7(,!?I[2F/_;_,X!,4D=/F;KB5]55WUT$-.
MA2,]OBW;M*[R]X>;'0D$5FW7DU/A4.T6X!5V!1<-"%2G1DT=.9R17AC\4V'G
M\VNQ>"A^JAQ2BZ& <;0KVJX@)_#6="BI &^[7AL3U#7J.(ZFA@0"E.QZ;JH+
ME3(82@V4O%I/L)(+(8#+K@N('[FG 9BJ8D\@4XDA.&NWZPZJB-?Q.49KRCV!
MO;6< KMHZICBK(CNXFCV#9$%#1%@02%+G'HA,].'YQ#/&#_;V7Q3''9P-/@,
MMNQ8L!SJA+ K.',609W()\#7KN/IW@N7Q/-3#'-,G"37S#QG*/+7;)7@A=^C
M@%HM+ %1H.5T;$S15?Q;"R8 WF[L3<T+5]& H=MQOZ;K0"H%$ !F-P:''6=4
M.=4^M1%4<ATF&>\"A"Q'Y/ 7?GI J>LZCY=:! %L=J-WFB[<M'#M@KCKP'<A
MH\ R[+J'ZD[F4J#'F# HTI3@YRREKK%O,14(I 3] BNS,:P#"$IDUM%5 ZY8
MB)%COBOA!:9CUV=E=#@D/ ZR!6FWAJ\&7@BB74]6?A^+L:N\,%(KZAB (C#J
MC MN"MCU3XT"V$,SCAX]#"OW8@M>X5[FLM>HW!.X=$01 &@WP@GVR-F"ZA86
M '1A3R]^$C1'48)7*-^)T5TU[+\>IK EDQ_ F%'J"[2F<@EPMNM0FM"KIA$*
M/GLD@KD@J4@%^V[L<UV()I5[@J:.* ( [3J&'DGA'M&:][BE>P(1EW<!)G9]
M/_<XB@E;A2FW%/6BCJ'1Y4JR+JP /HYCZ*!A:_Q4418N1>]=!)Z T@CV@</B
MHO#N%Y62CXC@F+I,"?7NW*#\WQ+,SZ_^W(MF+)M%GMI"ME@^,".'[J[T.B<P
MS7*<@,5<K?,L#>-H!4*Q,)D4KU21=R9$K'9Q.V:U/Q28J,O5C 4:S',=:3(S
M:DG7JF69]R->^H,6TKN8%D%?*?D)90;?:5E*6\(]-Y6VXKN88.'16[-%Q[=X
MY,.82]!5EL"F)$E0OHUDHW/^2R!;Y!N1Z8D=R'I';:=@I !E!H>A"Z:0JX1]
M9P+]3K53@'I'8&4B""O0DMA'*$AN044T%\R]E]+L+VN642P,:9HY$)@FW]-"
MO FU8S2$)GIP,3M%S:*9=U%X@=]D,%!1.D:S,-6!,EN%"T,&V/%F2AM-ISC$
M>5)**!9D+$NE,KU>8XK':"--=>%BW@R!BK8W25LX,[A$?C@SC-3E8A803>8[
M<688T'5QJ)'T(QUGAH'T3J8AT==*-]X,;<(]MY6VXKN9)04M"?(QXQ$^AX@!
M$P6C!3U*^@?[7AJXKE.])\";K$?T!'<R,4J5Q8=I?AL29&9/'K"$U_F%"VGB
M9VT21PB]OO =IU[I*(R29B^_@D44S8U.<W*J^KBHPA%"*Q)5/W/+08?NO3LW
M18K5*Q2AJ30F2%GS"*%5RNQD'A/F":$!'*"0G/.";=F]%W&=(\15(JTZ'XH-
M/U%]+UM/7BU!5Z_Z$0*M)[@Z)XH;F!=9L3>C4F&SL'RHI%@TL@(]@B=A%WJJ
M4.=E<<-2R@$NO]?5P#0$%$["%@2RJ[.\N &^3JJH1I.%G.!)F(:>*IQ,+<,5
M9B\!52&6J76(J)R*28CD[SB5S%O907E'_#8FUZ&'%]0E47P(_C_+3]6+&7&"
M$D169A;2B/Y)V$XCS3B9P$8PBVZ3$32<>R143L)")/([F<^&OIB*4WI!3AZD
M4!8Z0A2KXCF9PV9[BY&&1O /*C5N@)J1.4*@S12@3I9C,2"53D";3%HIO3*%
M@T*"<HXR"S5I2?<(K:6E1M1)>VR8CT!5Y0E7F[ D+I$?84E&ZG(RH8\F]YW$
M)1G0=7',D70DG;@D ^F=S-^CKY5NXI*T"??<5MJ*[V2>H&J\[QT-\Y5DR]6H
MTQ.(FT9$[TGK9+JA"5H6<?X/4UU$)76.$%&)M.K\0S86C#L,%PF:!8F<=4%6
M43EVV%7RJQ,4V;[[,DZ2C+ZO ,:KE4E,H^X1@JXAM9NIC I3A9TOV&U&8)^3
MZ$.M4?D8L=806YTCR9U^_80B')-J G_C[LTC<8S(:PNOGV3)$OR;O% L1+;(
M/J4).[_JD</-%UH LQ.WF36<F6:NP)9TC]% VFE$8#VV+SZ7J]?=NQ :"X%Z
ME>,%G2.L $]>".*;I]:K!]..H@ 4,D$K%&7HR9^C( MA]JH7A%(W-#5G>.CL
M>UQ6M)X;E%2SD,5WCYLOA+Z%TT",W8IVGTO6@(:3K5<JD(LYYD9A&+_091V,
MZ3=Q]IQ.L[ NAP:89G3ZAZV9?,HL<8<;&+_$<?""PQ"&PW&4>M$,T[&1Q1$_
M4861-4U8L_N#M1$19AC [@ZO4(U9^0M4JHH6'B@5\<,&A6:B%%6M]AX]B#B/
MEBJ$<G%TE'!=2=ZM>=>\";'C0EHHID/#Y>Z35<EVW<C^9@M?F +V2N6#Y<&S
M-Y<L2:RN4L;NXV<*/GF%[;YAM,^T_'&SO*2+@]@O'L%T<:*# J>LVR!P&.XV
M0R_GS=R]SE^\S,'W&-S?R(J[J5LYS]TFM>6IES969LN;\/<=E$=..7<5RF%6
MF136_J3'?\ 16YOQ! ]*:L\KE1J./ 6JWEJK*EJU>04@F@^".NTB.>8W7+N!
M3^/5SA^#FFP9#[LC)-#MQOM^(WUS29_$P9_2U>3L?Y!'OKW$'<A84K*\&# #
MM?:"KJFT+CXV8"0$--R%B5=HG8X!Y/)J+R@=-8';.",=64!.ZF0,(!=7^12!
MZ_ACZ6U^<U*G@S\6W\:W&YRC*\5HFB+2H1'LT3L)2]B36?G,@,/F\!66^]]>
M4+A"]W&4SF7G9<U)GH11U,76?E+@$$$[-%\-35( TC!^*MNQG9@=4;FUZ4$U
MQ^-X[X5+XODI]MD%^C*VS5^S4"K:X"T->*6/._%]D6846KE'2X+;K"PEZ0EB
MAVO?XL*A0L<"/L/F5*QT%F/5UAROYH)VZX-JBN CP3%IB5^%QC&C5Q'3'>^3
MC:&MHY>EA9#EV:#&N;,OD ?D&%$Y^./9FLR-HSQ10@=R;DE9774T +?VPK:Q
MQ"ZZI@RDH,-++HIL&=J4X F9PX[<[IQ^5M(EEA&1-']^'.5A[^7OY6QD9V V
M3Y0O3Y!_R$ Z1&^(A )^#/-E-"%FM9<I@*M%T#60S\6#TV)578AC8K?*FG;C
M(AL;<RU-CDI.%U\;W^0EEZM!@JXN@2,!65=<%U=)3VG^+N4=--'1Z-V<9)_&
M\.92NGB(5XQ3.T(U&,]5]:T"W-;4!6.[2F87S^PV(Y:.2C3&>3TR1P6^F>C:
MYW9OOA7*<WJP]\SIAVW&2)8&H.*VNMZV^C#-?\PO&U]Y"?;9,W)AEK*-8RXV
M[/M8,3M;IU^9(E$P6@%R,_0U6SPC\C MF,SY?\C2)/4BFO]28M3&E [=>04,
MUCAC0)D+*J)CM?LVA'>_UQJ*[.*>BZ5TI6YR+RSR\S#F1VE*\'.6TJL2W^+M
M,X'%.>&($)KNE1T9RMT)K8D?@YUTH0=W3BIH H\XQ $]3&'SU:+J]CKT2%U.
M&(J\_7OE?J2M?^N^PP7F+;+06Q] *Q+PUGQEENQ'>H454-CI]C06'BJ!:H&U
MV3A*$8P,:A]M]PWVS5BZD]Q%IYE:UBLTC0FJG$5\?DV)!\SCR"/K,:@[>0/;
M:M&J ^Z8M^JFYI;:0H\N^OW*L#*MN9A;VG'S:-W=A'>CJDIPT9E7,EJX(;20
MW99UX[Z:>G;AL*[TM9FEG^.&=N4GX4]>Z!&,Z!-JA9='$#@HK>"&JO?-9"<\
M2\)]M]'H,F5GRV68M[[[1)G$P*O,JZOW!PBU+"Y&A7\!HR$>35$U"A8XPDE*
MN5YI/!:OK.DV=-IB:,=L'_288$F0CYDBX'.(F'XCW7Q(>M7[@9^>+'P0[3Y4
MPIZ(ROPT(S2OY]PC,^F"@%^\'R#Q>1<X(6P_-L*REFX6KW1T_Q6G\^LL26'9
M0\J]#<VK!?\%<B]3(VIN8*I>YS423@"Z7=<3[#?B7;G5\Y^DSJEMP"2J$,!M
MVR6T0OF5AIQ;>3P]M[1='Y_*7.M>%(X( FCLNC\VIJ;N?[62?8-DCWT!');?
M\=@=36A40KJ^1^F</F&YL2G%P:5._;YAIR64 %&[$49=A[*[.\UU[X;6#B"Z
MY+W'>]#;%&6XT V>3D&TR$<P[Z<O"$7YL[*PQ9WD$5+?:=;8_/PYV8^4I=]F
M8(EK6M9. %');LD4Y<4P]-6$R*%[))^W"0+S]'&8[VQ'FTCU$I"=PL:2&U*W
MVM/-#6"_]W:B Q>/S'4$XP="2ET-[<B>@+&(A7?Q!%Q'(I@.8:K)H!C,CNK%
M=W.2)V =?,%=/&S6D8:=9FR3 +0=-^KD3L BZD*[>#RM(\GUG$92CJ--F#T4
MRE\8^,4+LQR^S7LM+0W%J*43L"$C?;AXMT6[HY1?P;Z,.B,?$?'ER7[;DSX!
M Y(KP,4,=B;=XG/D^2GK%1ULB$1$3\!*1**[&+S0=#&VO2! DTW -[GD\@<Z
MWJ*Q$[ G4Y6XDR*OZD[#LPA/L>_11U>WZ4DV4W%9LGAL"3:&^ZG-#^TUJZT2
MY&=<_.*V;K\V6U2ZOU"4@2*ZQ]I@F7=I]\BHQKGJV3U1A?YB)7U8SXT<(B6O
M\&'S73$\3U""R(J%,K(<>5Z8R![A-$&V@\;<LHH=VU;:10?BN^A&:B;GYJO.
M[6=+^.AM92NJBPXE#9FJ"\!*#'NC%?K;-'=<-M1  2[ZDFJ2/A(:PI&N'T-8
MHX-@Y8-O)O8B(=)G*Y"(Y:+7I\8_<UR9X%A4Z#-FA0@N>EWJO):9\&D64H^0
M]30F+QZ1)FTUHM)K)"5RN7FW9$^ :V^)4R]L!:Z81I^A%4O5[7T3S@T\B9G1
MYRCR[S@(W=_H5NT!,/K"Z%\U^>%6U!D<2M8J'&F,!_QJ%D>X"A]?XCAXP2&]
M"3B.4B^:48=UKOG]O_5&OJ:TG>AX,H EXV)3F3N^%20?,"M,;DZ["O\*#!MY
M'+=RY-2BT1LD&\CFY,4>OA &^X=ZK=Y@J"6-DW=^^!S3^9M>'M1+D&= XT@0
MY<JFOD1TL'6.T.NPO9NP*5+]U<ZZ1LBL_-A47NW0_4C(C>H 3E71:H_1@6:_
MQZ@$<C&6_RK#(;VM1-?YX\62Q*N\4ZO 4]1S$SOI/ELAD8NGJG=>)'NJ*O^Y
MAU#DC+MXYGB+7].,L,,P[7%.4J>'V$BD<?$P$+80V2)C#P?JY&QI<J#371-N
MFH-DQNM.=/U4;8=XR9%%/3QZ:WII=W/N71YF[C[F*"]J9UTI9*NZQ\Z?JY#;
MM3X5"_VZRIRQ-+N,V^IS#8#B=$&N7&_^JNWF(5-O36^S,\]RY6A?#,C]C6[5
MOD*C+Z&+BTKQ^XY%^,_W**!YOD$Y*%#WNV;D^@I].ZE=7/%N<E1H#[2B"GV'
M5"27BZO>_.9G@SE?5;'O(*KDZS;J3#QK5A+HCB-Z%0ZO=H+D=*9/;1I]!:V!
MJ*U>UCJGK3]["?KSOP%02P,$%     @ '#A24M;8H);Q/P  =;\# !,   !M
M9"TR,#(P,3(S,5]D968N>&UL[7UK<^.XDN7WC=C_4%OSN6Z5;*ML=TS/A/SJ
M]H3+\EBJ[KFQL:&@24C";8I4@Z1M]<;^]TV0>E 2GB0@0#4W8N:VRP; /'GP
MRD0B\:___CZ+/[PBDN$T^?ECYV]?/GY 29A&.)G\_+'(QY\N/O[[O_W/__&O
M_^O3IU]0@DB0H^C#R^+#S=W]XX?_NGI^^'"?9'F0A.C#31H6,Y3D'SY]F.;Y
M_*?/G]_>WOX6C7&2I7&1PP>ROX7I[#/\_;?J@Q^>3__V!?X)/W4N/MVA%U($
M9/'IY,M)Y\/__M+YZ4OWIY/3__/A__:^_;]/GZ@4,4[^> DR] &D3K*?/]:^
M\_Y"XK^E9/+YY,N7T\^K@A^KDC^]9WBK]-OIJFSG\W]]>QB$4S0+/N$EE'4M
MV@RK7N?R\O)S^5<HFN&?LK+^0QH&>:E'J5P?N"7HOSZMBGVBO_K4.?ETVOG;
M>Q:MY8(R4;[^3+V![N?JCQ^IND@:HV<T_E!*^E.^F*.?/V9X-H\IPO)W4X+&
M/W^<153G7SHGU6?^Y3JEE.&(DCW(X7\IK5E_?/MG@?/%QP^TW>_/]ULX9RA*
M@O>28/KGS[(V/K<3D*1)\(I)D3T%281F.+Q.7W'4N>Q%$:8<!/%],D[)K"3D
M!N4!CE7E;M1T*SB#8C:#CM\?#_ DP6,<!DG>"\.T2'(8AT^@QA"CK#4T Y\Y
M $PZ%J,B1OWQ(\J?T2M*"G2U&"#RBD/T@!-D'K+R)P\*_R[ Y+<@+E _Z3VC
ML" $BET%&<YL:D#^U<,J 2<P(V/:&;.<E.M+-IP&>8^@QS2_#D \%/7RM=16
M5=-0EE8*NT]>49:7W]I(4ONE#F#5MEH)O-1@!IT'X=?@)4:])-J,*]98T\'0
MHOF#P7J".1/TN9Q UA/*$#[6'S\%BY380JS^Y5;*>"+I')%\ 8+0]7Q.>T_K
MY4F[T580KHH,)O8LNTYG+S"NR^UI:PC:C;:"\$N:1F\XCD%A]PEL7">8]HTL
M0WE[)$W;M@5H/5?O_@$ZO2%<*I]H!>\&9V%*UY8"1?TYM:6,=+H&S;:"L?Q&
M,GE 8*+45I+M/SRCF.[]G_%DFO?'W[-5[TFBY5\></""8Q 2T:DM)1&(GPRG
M" ;//$@6@ZL@IL;88(I0#K7@+[\CVABLL6"P!A/XPBS R>I[0T1F4*S4!DR7
MS_")"FZFIL8CA&6'QO+?UVF69W<IV2EE1J-*7[ #;E#,H3)=6H+X.LBF=W'Z
M5AL@2PZ'J17<;3]^B&%;Z[XVA@^K^5:PJ'G6'U\3!-/=0YI,Z'BY02]T:%7[
M=51^M_\2XXFA"=?P)P\,OS8,:^7MXA=_\] *6*WSMUF.9W3$;6S>,1AR2,NF
MLOG]EH8CR(B&P;L!SY%J6^U< WD:_@%?@ND1OZ(G6"7IJEK^]JD@X12T6/VR
MM1_,Q(=:^B]GLS0IO_B,YJMODG1"@EE[?,U;;PD*]B]/L(%1E7)=O.5G-X[F
M^MXJ>PH(,#Q%.0X#9<VIM65,X+IGO!ID[;SKJS:L"+C:LBCN"!2:,>*$H&,U
MKSL--JL-RZ70Q"71\!.'<3CM%]2TB<U\R0C8IV"Q_#[\AH!!>_L^1\G6?E):
MM ETD]]MJPC:)O2J,<JR<IZN;9FWI.&56V@JP-CW+ )OO2:V:-Z:CVZ6DAS_
M57YKU8? 'KY]QQDUEW:+PY^&4QAP[_D=[%K^C@*BU=,/(HC=G3P&SKB&!;>(
MT<U\.Q%,[>?7%@3U*:5)?>F'OT,??\59\QV^9NO&0*WU>(/'8P3[K1!E5RA_
M0RBYA5^$=+-.W5] QO<$KS85V1V*$*$#=]D2_6V1IV2Q<97IJ\"F+,84MCFU
MK#-U@T!@Z,'KDFL'Y9[O15\O!C[9"OXS[,!)N9$T8PKJM-?.N$4Q]!H4_6<1
MD!R1>%$[3%Y_:6OD!<DB4ZJE9?K:%\/\?-"CPPWV&6O_Z"\DS;+O"4%A"OWQ
M+_A5\'Z%$C3&NN?AIKYFP!L HZ7Z@9H1KT%,K8PIF)TUT:Z#."SB4MO]<?7'
M[QD==C0^(RQ/">("9(9=>07M"9&RF+[WX!#2',1;M)'W&64YP6$Y64,I*N!R
MWJK^_1:02"^TQJX(!U;/JM]3YL&@#7#2SZ>(L,XGRF;Z<_J[0VC-A&3M-O%E
MY*OJ1GM5^ !Q4B;CG XBL W!#PI@2&U_H^*O6C05):8="F;NTSK*852SZ2XS
MX@FS*Z*.]A2;LNN3,^1BLRUF$[U*&[/HZS+AT+(JH*9"%5HZ\ FPK9/=@P/1
M8:)YZ_:..@V<9YIU*#3R&AC0$*Y6PM+J*G<'*%'?)@D;L.^U,.AY.(2X6CLX
MG0:-1U0W#YNV((R.VD3U;9VFZ,BGT(PI+Y:V(\K<I_5VXWO5;+JTC'BB[(JH
MHSW%I@[BT#'KA#F0T%ISLF:;=H*+6L83F8WE;12A:U8$'08Y52W<K6AS@<+"
M_:+FEXCLK9NM5TQK5[G;WM=>"A:0<"7;\L=ZD^N[\SC)/T=X]GE9YG,0QQ^E
M8#BW^%>7\.GU_6Z)LFRMC3CP,TJH_?PI0N.@B'.#PC':-B1J2F^RV)%TV70K
M0<LV/LW0[ 41DU)NM]M&Q"E(0\+B!7U:0S<H*+/U-N(F:=XS.FY6#99"0>_$
M27D^_P!-;7T$O><(!G^T^@R5IDUZBC+92!IN?2.FZ3U2PD12HA@'V4L)I<@^
M38)@_IE.=)]1G&>KWY13WZ<OG64^CW]9_GJTEH Z:>[AQVSUE3AX07'Y[1&_
M\.CR8JFB \K<B_Y1K!SXZ29PXBG L$1<!W.<!W&Y_Z6)3.C.F#I0EZ=UH.0,
MYVAY3?D)$9Q&S]7Y.BU0WH40:,#VIT>=SNE>G^N1;=5"GU^)N.S^#6><,4EG
M2@POOYZZ4$:1 ;QT7K7]\0.]UDA^_M@Y?+=;1Q,\I)EHE&R5&W6^?#T:0AF2
ML[5_<GCM5P;M?985F[F6-475B@&"[M'H?E]PMNI/':A^A:.TEU36A[+@Z/+2
MBO9K^^.V.M^7M]H&_$2M,EC9;ZL[L["50)/*N[GZ>YS"E/;SQYS0Y8+-U)E#
MIJK-Q"92LO>.E19V5KW1Y;D5'@4[3 &O-:K$G'*AL-GJ'IZM'0EOMFP6!DO,
M\J-+2^L+QY824,/5.)LI/APV0U^/EZ'1MGEKC:EM ]T^51M<;,K.#T]9[<CV
MV];ZS*!KKRPLO%]<[ACX0X+-"P< FPPM2VW763:+1L\TH#%!T6U :(Z0K I1
M*69%&0%9!D92R0F:TN[XBJJM))>$EBT"TI-CH,H(3#:AERY,;Z:5)QUIPGJ
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M#.B;,552-8(S^%,=Y"/*^^-A\"Y@W-8G1Z>7IR=G_AM+!],#IY<Y<':Q';,
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MQ"A3\'$S2I<+[9G3QVFU#5D1#'^.CA_3'&5/P4+B3:@7JU X];F)=,MF@PG
MGR/>&J!F!T-J#93(W3[RW&8<J2#SYQBWWN7TCB$D-2NLO@Q %5+D8U($4W)T
M:]G_73LRV3BY:[]TY+]>B])[A<^7*DP)34@TH ?@)3-*KFV==D8G3ES>:Q%_
M17$T3+\%.15LL1%0/<>CL 6 9\=Z%7O(]1G@>%AU4!ZW/WTS_!026.T7!A7X
MX#[7XHM).0^:-Z[T;0&O8>F?I 3_568JD08RR2L#6M=^=AX%*H3Q(7GC:C\
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MZP.[,$R^3LX1%;H_GQ06! X3#DSB9Q1D(,1+O'A*LPS#;#S DP3@A4&2KPS
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M#Z.L?+32\(]NI=M5G3^9(^VE.MC<YW&3P:+V_5+OEJY]>]%E#ZM%26Y-R_D
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M(H!.)8+H< PM,(2-H?H7!LQY')/V+.O_W"09?J<%B[2\5Z#(+5: I"ZU:GY
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M39^2M8U5]R[\!13V([VO^Q*E=*_?')_C:QZU0!V4=0A5  N)D9U.OVL=V>.
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M9EJZP"2J!WTABE"C2<SGT"A;)(FF97;F.=RFQ_0%UP2;GGDT8H?YFD?#-:3
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M_W<G G7P0;N0_KJQYQNVNN8FH<8F1(U"W"J8]TG!:YY&2R5-;2496C?5S'[
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M*/'(!B??!L\I#]^]I+<GNVV))@,0])[$)"\OV5.))7M]BAV@LSF4D- 1=./
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M[^O&W<5_N<R+/(M>DN) 9LQ9C'?)^O+VE^NKSTF&*XRSJW;UVWY9TO)C%7F
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MKC/5P<!3T"N\$W \N-H[ <0 5]X=V*D4@;CJ;L&R]GYX@"0:XT8@U]QM>6"
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MR/'$R9$TY*@8.6*1'#0>.Q(^,<>.J:P;_D3ZX-UA=\X''?:KG[,8%[S4^;;
M; -7WAE.4NBG_YOFLW30OAU,PE"M$8DJ$=/9%&VU K%_AK87"!]*PUMP? $
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M T9\\J1H"=!;?!)*&*_Q2?C@-R1P>-YW^R4C3?B<[#O;- QWT.$YC-#6,UF
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M+\0.B>K+('8P#& ;YL;BEH>-< C;,3>:VPD&[-U 7\?P[%00.S4#[%GOU@R
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M94_??Z/=GLL5WH6Z0%]7H=VN7<)4\<?DE5;5?ZHS>N=KTUX9"QI.;<A.KI2
M#:)6I.:6QT^#9^$V5+M%T#1,CFV9(1SIV)A:VT(6&$)]3VS U,9OXB 22ULW
MD W$I*TS]KK[R9&T+C.OO*2G2^IR*P<[A;V(!K <O#/;Z^L6O 8+X@7WI8%@
M<W?=M8)9T,0<IU;:LS8M?VP$?3U;9./#\,$7[6$O(-N\NN/M'2)KG)V\/.07
M9%9O#2W0.C,0^0KS.S55],K74(H)MKJH'[*J[!S>KN7E'J/7>CD--Y\V5:^
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MH@.U2E"C!=5J^(:,=ZK/XN:^#7TB;E;$S:)ULVS<W-5N;F5N>NH*QJ%5Z!@
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M8@E-1(7R%CHIRR3&'Y)%42T,M"P\=>@^V3Y7MYN?2WX?27<^IY?S>3QG\,!
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MEHF("3V^14#X?/.I2.@YI V )66]OMHTM'3X+!,O$P)ZG>P-!+M*- S??5)
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M]4MN"=U28=K S"">Z^AJ,0M;@UW;RLH7WV]?\.Z8,('W8Z@Z5[<%;#EF'YS
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MX7SU%'TMU&RSVKT5VI$Q@+*-$A93 EO_P)$J6T2OE<^2I#WJ!+O8E"WV].]
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M5-T1$&SY*RY?,DGU8-LQO$</F'%F:G*=E%WM*(@/X]OV7/#986+/VJ MZQQ
M>(&%2HKC#'SKHUW P4R]')R-J\]6)7+I?U*@BLBR&AOI-J?;,GH-<4PHF1^)
M IS3VLUI>8?S.*.M[^H,,XJ-@:L)/.X.G,EDJ!?2\C!TC\ '1\W@B)H<JH9'
M?'S6Z4Z6U\>/*W4QZ30C\)Q&U'PRM*WX?Z=E#LI0LAJYM9KACL.MR02*)7>$
MWGPY))$.'RJ.R.7A $78X&O%$'/)"!'DP'A?,7YH+&46>FC,!!P[/O%T*H2D
M'MG7T:' MT^;PR&)MQ$MC<ARQ).?KN-]S/=V$Z!DWFSPR#)36A9 T\PT1!HV
M%TW;T,Y6U7%@OW8FA'*"^)'=!19 45(+AQ=Y('\D_YTTXP2(2"[LSQ"@7!@?
M.%XUGWV9O8[E\/"(9"L/"PBJAX;8ZSA!G+FR$4+,BG8[DVS%$$PF&<I$!ZV&
MA!X%%_$K3=U+BY5*WG=-'\V/TW8&M\;&+;7M[H#>7X8YY%QHNCL%<YX<NW-5
MN>/B#4*/#9R]/O19OEC)%-K?1F:3EO$N3HXTM>4]WAYSYJF^?-LFQQW>,0]3
MMC\<N0AOGRZC/"74TPR[+!?$9D_=V(J=C*/Q/6YE7$ED=(O3&1>U Z-ZY,KA
MVXY-3P?UZ'1#PS.VG"$^ U3&!B_B*5KQI%E)2VAR$='4]B\8L7;DGS1%8%5>
M\T"S/F3[/1%;0>=!VRC9'A/P@Y53^QKN?IP:ES_,8;XHALO).?MDC)IB4Y9Y
M_$BH):>\AZQ--5.E738,!G,QN$>T<2(+H2.4#XKXJ!P["M0=EVXZ+FJ+X_F-
M*>1H,EX#N8P7D=/?<?S\0H$D(N 7/6.4'FDQ:BJ%!HIZH$)SSKU&"73::W<&
M-$04=];C#T[NMR]X=TSP[9,X/567N@_O8^)I1H\'RID"51S.X1%<7$IFE$2M
M&GL(&;U4<MT)T..[&%OH+.@+FP?H>=#ZY>03?9S;VQ"$G!N;Q^,4FYO,LGF+
M5;N403N?QYL!A:-].%,SV@!]H4V 3'(VF5XW^:*O/MJLBSZYQU5RLBFUA*<[
MFI3V)MKCBVP?Q2.72A<D%IG.Y]JYC+PDQ54J<.?-H%;!@#CVNIXM:!FCI6U!
ML_!8YFI_2+)WC%DBW=L#9>&OF)Z<%("@Z..SZ)2"\I&B5FT1:XQX:_2%MP>R
M41OZC<CV6JU)IS:CHDLZG9EX9?<)%^0\2XL\$V.JH[79)+^D<5E(==F\JY_+
M.%,^!)EWJGZ(=&P3$'&-87V!]-P-4Y$M4Y[NUZSTKG.9YE_I#&[.''VG)I%
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MB/8<W:1$U/M7B3QO@S$K;/Q:/9__H7X^?^!RCE.6@0STB3P,=$@?,'C%C1,
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M^)4IA%QQH6#V_OA8X-^/1'"7K^1_'LA\NKVWK(?/#8>4ZM$JW;1$K"FB;0,
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M 9I32M;7B: _A?.%@,)O4OC"S>>,Q)GI?F P3*-I+O#&DWL2&D]JIU-32C%
ML'C&(*Y ^C"ZI^$;C6ANO&WJQF@TP7M81W!RIF1$\_LDGKR2='I-WG)@QBVL
M+%"D2CH\OD5T8B-W=<9MN.\S#>HU_#0EZT:'AH?W=)K$@(S_P+;'CS""_?'E
M'=1/8Z5&,TBS8SQ/AK\#8AB/?I GT) S^%3YVZ<B';X#*\I?&A[DQJ,YH&LY
M[#.9+0=.DTD:3JVH*AVBT?2>X5:1EKJG!>EV.C6F$.6Z2RDYI2)%8G.53#E
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M&;8:09$PUU.[# ?VCR0J@/#I_)9&)%7OM5MM^5'3F4U6-GL)USPUS+RP-]J
M9G#X]DKS2*:M;C?C&U '+AC2B4O8Y*D1YC4-V=;P,I^^)9&$1QMM.,X.7"/$
MLY9PQU,+RU+(;CZ'[V$\(0H+BZ@I1]T!3ZIR\A*6>6UB85OW0S%]T]SPULWX
MV7S@/ZND$Y>PR5.CRE()'B8IW&5XX @+K;UBC]E24*-&:E.FLB>G20>\=C98
M)&YRKZTNK^'GW8A%O;%88C9S@S4IZ</IT $?D1D*"3>]MKI<C$9 ]FSQGWL:
MDX&2DX+V''\'7$5Z!!(.>FUL60"Y@A\?T]?D1VS"OW5KCKT#^HQN_A+>>6U=
M6: ISX?'M'Q/Q(L9:1FXU853H0,W"",0$E9Z;4M90'I*LCR,_A\ZTVH[H@Z<
M IVQJB@A2)CHJ6F%;2@7*0D5;*LVX2@[X"\23EK"&D_-*?<)"^QX3V+U[6^[
M&4?; :N7=.(2-GEJ5UE?8M,KV-8G2:J.@MAHR4,_.N,1$,]=PB^OC2HOTS"*
MENG/E/S::,D-29VYC8OG+N&7U]:5FRE))S2>?$V3'_G[XCF.DF_"'IP&G3&-
MJ3%(PM6]MJ*\O),H,F%?M2%'W &M0S%U";.\-I(\%6\1'=Y&2:@.8JBT8Q[&
M+]UAE6CF$DYY:@RY&X[3BV)$8;2+/"<9)[;B38B\0W V.!J<=\ D8@!!PL1&
M5I%?M]]RMO&^4U9$V$J*ED(T#K.W$E"1_3()PQF7)!+EV?(WVR*U^'6PJA=;
MR6D#]]WRU93B7:A-]^#PR'9U-,>UR/*A1[#9,#A$NE!9$W1SM2C0.'I<FI,T
M(_=UMCI7S%R$FQGS=*M]<(AD/E3P1L5$T?0=/3O%Y"7+%<DR1,!_UNE9LHNR
MY, <5. RUYB"MT;]@R.DTTW/0C'+S5$Y>KN*NIP_0AJQI+ZW2?H"2!>1'&4>
MIK=\_2]Y7&W-D8(C)--S7;&H@\_1^UG0T-X2/!$15;DPD =%M^ (R?Q6F_DZ
M,(X>W6)N!4\IF85TF=-;SV!A^^ 8R=!3E[-R%(X>XV*RM$SZM$$1!3]W&P=8
MF0OJ,E,"P=&K7'RUF^69S&9)%D9?TZ28W<7#J&!!LL*:!09;=.U!8<\[&9PA
MW\^L-_'F<!V]%D8^T TWA*V%A!0[UXS;U=D[>C6<)WD8(;'.0G07=6F2>*AE
M=(-1X:0\_W+NQ3%A<)MW =35ZV7</4!:&0ST6J7.)^\6''5%#+0H7+UIQM08
ME@6<%-Q<-@F.O-C;#3BW,6-7SY4QN71+65KP>_I!=LILJ5>BNF-PA!0C;<U1
M QRNWC+7X_-V+M7I*%B5GMDJWK!=O$G /HO>P=G@\.S,]SVU#B!7[Y<Q%ZXD
ME[UZT<H[!2<')T=^V$Y,]"@]#E>OG3TQGQCIT<+VP9$7UV0#KLJG[^I--+X%
M17O=#8ZZY9HLY^OJ533FU;9:_FR1W/X]B0!(QM3S?&[@:S8=(CA$=DDVC"RP
MPNGJ^37FVJT -H\\D'<*L+)OU6*@5@9$Z%R]YG:F,TMKR%: W'PN+#*+/U7J
MZLBME<[&#DZ0=6T-2W?T;H>P73T.1[Y*KZX>J]J1>BNWJEMP='XTP(Y?L1(+
M*U2N'I&CZNC",K &?%=WY#3RYY@PY[PA+E?/SU%5>HMC0MLGP,I W8C;:CBN
MWJE[HOLY=G\W')D[A;NX1;@"[NKM/*XK;)>$5I>* "N=MBL1J.)P]9#>$T."
ME70;F?B:#\X=R<@.-[<7T*:4<)4CH.X^(KBN;I6AO@IG--^M,+VZ72V;WU<J
M68OOJ@X&#H[]V7%LI<<A!5RE+, ]?23JNIF_0=>WU/:/_;F_UMUKS(&ZRHN
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MGV'V-AX+]HWD[\EH+;NJ;=>H?X!==J$.QTUQN2J;@JL_/21QLGGVZ->UM$^
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MJGI8*FP?G/N2^TK**HG.+473KW1WWP@[X!5LW6D;# Z0[:QRWHAY*8'0@P0
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MUS2X&8_)D#V#7A'@&4X?ED(Q'H*N;F9Q<C$LT!99&6LL3W5!]RAPDJFE?,J
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M0ZZ5)E!]GPFS90+BRR1-DQ_PPU4X@[_E<Y4T6 W$J8ALQ;67C7H8):DGK*V
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M391316*!&J, +1#S)6I8M+/_UD.'FX%$P.IO(0P%<[DE>1A] P!#JGX<H.@
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M G(9,W*]S !? K.^B6%*LY1F)&-6X/79:2 C]L,!+9&#F)M*3%W,J"DO'04
MD#0O@ZA@R3R.K\DLR:@\0:9!K^ 0VYC:3!JTT/Q+D5ECTWA-R^<9<ZNM0=8I
M.!L<GI]U_-30@O,O>V8#.\'%1TBCTL*4I"PS[!JUD4?,9AP@.[:GK/F=L@9B
MU"2=CJX<4JRJ"X>T$RREHZ-3[%PI]IR4W#ST.%O+WKD' ^TBI)J]W2/T@^$$
MC7I=9JA"QIV&T K'?+N>@HGY5M :3OASA&6V0\&O:9)E5T7*!%JUU)0=@\,3
M9$U,2F')BC* TP,;[444)3_">,@VCNND>,O'1;0+W8#[-N, ]9#M/+;"8(^N
MJ8'WG,M&3":@/8ZPI$.TG=;9"M;=@#K(CT\;;P3;8%R5'DKR,/+U8%W_#N<T
M74ZT=$C?)V',;&J+UU3Q9&N37BU7#L;DV;2#X4$84,L*FF(P=[]:C0CPD;5I
M=TS4WKOL">.?KK"?8B8GWMRW:S!M4P[4(/WSZ.Z[H,D)4CB&FB]2'LH@]*"2
MX-])&.7O5T"U)V "<R5PG%J[JKIC</@%26\W8)MXSS8!A%I#4/#^X^])-J.@
M"V:L #D[E)25:F2M 1N2HFW-+"V*'OA&%P19TZ.,%# M[2GL5CZ#.>T*DZT0
M^?<H:R>'0U5E4#HJS#L#V; S<+G3EFQA]\"5>4VS<#))F<D&4#R.%S=F@_NG
MIB=0""D6SI:+XC5O!*\'/LT%KEL@W_(<^XV"^E%D>3(EZ5T\C(H1T(^EU8'_
M&[V&GTJ?@/5H<%PBF]F-6"V6DMIXV_)N>F: V]1@%RUX^?3'\5,X3U(<V]Q:
MQWY,)V&\B'-8,CX>W7S.2)R9;(.6(P'W3S M;DLF)44*JH]X\N;6-N/1 #:R
MFE"+3SJCFB5^_PQJ;A?.@@Z:9Q.F0P#-L O]U&6T[F)O MP_XUPKPJ)-R&(^
M"- -V9QOQ^'Z4E+%BVK[$]PZEWH0&7T+XW!"1@R*RAJDZ! <GB)[W6VYL7.A
MU*)#->6Y6>?K^&^M<6B[:8!F#7+#836N'A@!7]]I.GH*TWQ>JNM:!@O; S60
M\U*ZX;("7 _>,KR0B-W)M"S>: ?HD9^\NF&M %0/S'LRVE1N[LL8F76^5I5E
MV,W P AO?.RMJO8VY$ U)@H4N75U9T-3CEB]LQX&%A^R0= %-W<4P9ITZ+"A
M\"E-9H2=E1%+,1Z/;OY5T%GY2G"U^)9-JG_%L0A*)VM@ ]3V#0[/#O:_^5\6
M(.4TGC WV-UTEH**6B;^*(/)%'"4_0 *\I7,D-KBC=H 6P^L=/=A/%(PF/T9
ML")?O!KQ<0VA!W:R6_J9EXGR*T30+5)IGP"]>FXCQFIP]2#234H>'<O5'0/T
M,KF-^&X"SI6I;/O5PGX?!133(F(/9*X)3'M(2R[!SQ$IV16/+J9)FB]T3BE5
MU \#G'PB0*^YVTB@W)*AJ27/B[=14HQP'ZFS[T WH [R3;Z=76<%S95=#^&E
ME.AR=3$:48[E+AXGZ72Q)NQN7")C@8R05V$9)$O_349W+"<,R?*K)%/FAVPR
M'##M##.^0CIQ\Z *]1#!X3F2WMZ<+;IP"A/D/;B=26%R\X\F?,*@-U#;FZ!<
M$YY:[LW;0'MP Y13";ZL#9$PZ V$]M5LL\U.2VG8QMCG&Z*)9T;?&>B$G>R]
MS>UA"V</XBNJ]Q=51'ZE&6#W]?*VQ1\Q=W>QM!5+L0=%_++( '.67273-QJ7
M@V9.%'%'(1X Z#)B1?_TKHZ=MBR?_CI0<Y\Z=_TJJ>C!R'(J2E1D,80_2Z-N
MU*I$]QM+V*3AJ13*'[XT*GKTIYY'8MXJX'2[-.KR)+L8PFF>E0>89L5*>G!Z
M8 <!V:Q7'9!N5TH5H6,_ID1__=3VY31"?LRAXY\YU\78/*JD^O0^SR@HS_'7
M-"EFJMA[44N."/DEA3G=-_FFPX0:IBL,LAO!)2>EPY?B+9NQ&T\$5R:F$JIR
MGYAU+%,O8U\#FS#2 B)JK*Z K]>+K^;A)Z@"))<]BI,UY<"PW[^9G(]:!%@%
M4DVX,DF2T0\:1=(S3M^)XT3:+K7$U_-*@L91W*D_ZHR)[535C>]3R*%53376
M732N<FPC,[IB6KM*XHP""AZYGX9QQF$,#!AO,@PG'7*LE1%OU6)AA;4?Y5._
M+O:ZA08RNBY2&D^>2$H35;RLJANGD']*EJDT&&%S52L5TXDB$/MG,DPF<1FT
M, (JTS$M7W?P4W1!CXMX5*U)G67%M(QQ".,)9<F$[#85%U_D7$&V8+O=?YR2
M12*L'2M7^!3.RX<)MTGZE)(/FA156JO\O\J.)97.D.WD#83'$)U$!CI6LM#E
M2JD32;R7[P<GI\=?COTS-V%L9WHB201[3RD%!%?JAX+981['FU:WI95F!5=\
MM3;L7.;8_-(]':L&0@E_K0V4+JPER[D_$)A,GD3)9&[)5U5/#AG9 ]2,J4;P
M)!RU-DVZY*C2LFJZ9HW&X&3PS_5CLW3M@$KXC6+O7$)X#D>TSOJ5]^-PNW=J
MVX&3\+(K5M"ELOR:+) M"4:T;\!U78/C\_-S[!?$#NX16GR2(!QK^ZC#O-X7
MPV%:@+)8I,/W,",;QCOQ>E;UX$B1[=KU5K(1+ D#NQ(EY_)ZL2@!QEONZ=ZW
M\<W@Y.1X@/T0P9.[GI@P$FFUMK0*MIL]!#JOC,EQQ3*WH(4_\<["<&Q]Z+.J
M6W!TB/KL4"#3V>6\\B_SYX=F0P5'1YX<_G)VB-=P/:0]>':X\ATO<;^02:D#
MF<9<B_H!=9 ]H?7X*9$-/=0>/#9<@-+&=6ZT _2^Q#[(F2/AZBZ.'CP2O*4Q
MS<D]_2 [9^WE_%OXSR0MH] UB]MB%-A4O7E5W'RI6P/OP3M"!>8UXH=PJ@_Y
MMAP)&('L<K1FM[74R'&C9H$6V \J6GI9R&P;R>HV)#8F&'<']-CO=QQL&/:(
M>Y *>HG8("@*,",Y<>PYHPZ!XDAZD/69[U*1:)=:FB14P9 FW8%62,J *ZZ;
MH^Q!E;=JIK/'\39>A2RH.P9'QT@[O"LI,,'7X13,"H/<2S&=ANE\%_0#04K!
MK)CL.L^V@:'.:AQ@\3&FY4ZA49K;['2# $AD5VT-GNC,=V:@>V"X0[CI'R,'
M6]ERV<$=_U@:?=4IXQ[B'?\8.<S'FMV.[OC'TJ@?O"ILJWA#V'"7A>HO)BGA
MV>Z-GH0K>@9')\C>GUI,VKG8FV-%M?X)^%MJO*]D^!Z7(4PJA@J;!F>#HV./
MC7(63%3CZT$)-@695*8ZF^Y 6NQ<+&V?^%M8>V"D4X#55X]0=P4:(?MZS#EI
M+0D5A+TQ]@F!5E+@5^T<]>1",A@<C_Z>(DTE18FYJ5G0BY( "O#JH@#JCD A
M9-=/BU*QPN?*,(A0&T 5J5>1])O/&8DSPIY;WL"U*:?Q9+LY_.GUG3S #&Z!
M6/])PC3[0YD/3Q!RGZJVK%WN,=Z\_B#1!_F6Q/E[3;W 8& @1K?,C"?2C*LN
M"-%OTZ. #&SQO_Y(G,G78CR@)K(RBB16&_C[;9N4H8?/JUP@-4<,CKX@*ZV8
M$K6F0+_#("7X;Y-"5=V\WH! 3V2%%U&BU@3H=Y"D##ZT=2M0T!;HB6QBQQ2H
M%0$Z7/6!$0FT01H79/0X6SQ+].D=E&2"\0C^,$NR,"IS59@\C;(<B;VO'JQJ
M,& \@;&L&7'\Y>SH!-E 7I?&DC *,4"LBA**7*VOX>>%80;=C:8EIC._,N@N
MR;SCPU(CP"H$8<(5D\RY6XTY+OR,N6)BZWFSA0*KHH,)=W;<J@H_L6'G$C=B
M#4H=._3\T^#RJI!#EN:5XPW^M7VTP:^"9X C*QNY\7?F%3\8^/*.3[4GBJ>-
M56.A(6NDJVZK!<>)])Y63'$)5[;FZ\B9OD>^? L_Z;28*CFST89C10J+E-%]
MESOB.?OGYC9C$EP<M4RJMN& D11U"R8)Y]R#9R8;5Y$R>HN.Z9 S0!V=K.E9
M$NF@"\J\+:!NUUE0H-3&%VO[<AHA>Q1-^6@M!5L8T>HPB-(&)FG^?C$E*4PU
M?@K3/(8]Y2Z^B$F6OY.,AJIKA&%GONTA>V',V;-SJ["%Z:J @KL*1?0#IDKS
M(B6/XV]D- IS)5_E[4N,A\CNCP:L-$"&6P!!P+U5\LH7DGZPW)4P;X ;:2N^
M&73DJ)&]#PWX:0/15;$ 9XQ=;2"UN&O:F^'_@NVQ;,!B:YRN"@)@:M>OX2>O
MRZ+1I3?:E13 ]EU8:<[BZ;M*?(^D**] :=7BK9:< ,@W'S%+-.S;FK]/F>UA
MCHO8JM?WI,C"F*7H?/T!E)@SU[-JAS7JRD$CWUQDC-C93.T@H>6S=^P"OC=X
M.K7;F.]=V'G0;+93!0:T5/6.DIHP[\W==!;2M*S1_AZF$V5!+G&'X'@ Y//%
MMK3+)3%;-5A<9:Y'M29N.^X4$4DJ.Y/%,(Q^IX.NR4(MA!XFMG\@^5.:# D9
M+5Z5*&]R$O.3U1C!V>'QV;$O#E$=O^O#<Y4$WQOGPD.2"P.BOH*F<Y]DV6.\
M;&YJ@38?L2S&U;D#HRE85YGIO1&ANW@8%2,:3X24>"8?!'YA*CU&@W%:8J?6
M:20X=C@E,M.I!P86\!<_L#>2PV1*[M5O\)L-S&GLBUVG!5E289;(5:>L>:MC
M'*BZX8%85R)2"(]!;VX]Q<[.;RLA-L D8H"767D1?;-1B.B9# G]D,2;:_MP
MK%TY,LSA2%BWI_PKXJ):21'G6;J::\H>9<2R$GGR]AQC5W9F,R@2=NTI@DS
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M2$4U'>?-YQ"::BM9U1JOK 7O::1?37G10FW\PNN<"T],)F6F.!^<@"OTQE[
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MDR(+X]'K#V@V+Q]2JQ:PN_&!?LA/C"T6N6O8OM5U?:&?#>"]D \2JZ3&V?!
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M,3<Y-&1E>#$P,C$N:'1M4$L! A0#%     @ '#A24LN9%B'T @  0A(  !
M             ( !$W0# &0U,3<Y-&1E>#(Q,2YH=&U02P$"% ,4    "  <
M.%)2<=K/.W@"  !Q!@  $               @ $U=P, 9#4Q-SDT9&5X,C,Q
M+FAT;5!+ 0(4 Q0    ( !PX4E(J(IW1^0<  /8L   0              "
M =MY P!D-3$W.31D97@S,3$N:'1M4$L! A0#%     @ '#A24A6UE+SY!P
M_RP  !               ( ! H(# &0U,3<Y-&1E>#,Q,BYH=&U02P$"% ,4
M    "  <.%)2X'$O=%,$  #3$   #P              @ $IB@, 9#4Q-SDT
M9&5X,S(N:'1M4$L! A0#%     @ '#A24@&M/)\_G   ZET! !
M     ( !J8X# &<U,3<Y-&<X-7DS-2YJ<&=02P$"% ,4    "  <.%)2?+PK
M\O<9  #<% $ #P              @ $6*P0 ;60M,C R,#$R,S$N>'-D4$L!
M A0#%     @ '#A24OV 4J)$%0  34,! !,              ( !.D4$ &UD
M+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  <.%)2UMB@EO$_  !UOP,
M$P              @ &O6@0 ;60M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( !PX4E(FDE&N<YP  %1<"0 3              "  =&:! !M9"TR,#(P
M,3(S,5]L86(N>&UL4$L! A0#%     @ '#A24N\'BR0$<   .#0' !,
M         ( !=3<% &UD+3(P,C Q,C,Q7W!R92YX;6Q02P4&      T #0 O
) P  JJ<%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
